{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "import urllib.request\n",
    "import ssl\n",
    "ssl._create_default_https_context = ssl._create_unverified_context\n",
    "response = urllib.request.urlopen('https://www.python.org')\n",
    "#print(response.read().decode('utf-8'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import json \n",
    "import xmltodict\n",
    "from Bio import Medline\n",
    "from Bio import Entrez\n",
    "Entrez.email = \"folooyi@outlook.com\" # replace it with your email"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  pubmed_id                                              title  \\\n",
      "0  33181813  [Why is it important to detect atrophic gastri...   \n",
      "1  33181754  18F-FDG PET/CT in a Rare Case of Poland Syndro...   \n",
      "2  33181006  Postgastrectomy gastric cancer patients are at...   \n",
      "3  33180314  Colonic interposition, a contemporary experien...   \n",
      "4  33179620  Precancerous lesions of the stomach, gastric c...   \n",
      "5  33179005  Voluminous abdominal gastrointestinal stromal ...   \n",
      "6  33178597  Crosstalk Between Cancer Associated Fibroblast...   \n",
      "7  33178590  Spectrum of Mesenchymal-Epithelial Transition ...   \n",
      "8  33177022  [Tubular gastric elongation surgery for high e...   \n",
      "9  33176054  Innovative marking method using novel endoscop...   \n",
      "\n",
      "                                            abstract  \\\n",
      "0  Gastric intestinal metaplasia and atrophic gas...   \n",
      "1  Poland syndrome is a rare congenital anomaly c...   \n",
      "2  Several studies have shown that colorectal neo...   \n",
      "3  Colonic interposition is rarely used as an oes...   \n",
      "4  Gastric cancer accounts for about 6% of cancer...   \n",
      "5  Gastrointestinal stromal tumors (GISTs) are ra...   \n",
      "6  Gastric cancer (GC) is the third leading cause...   \n",
      "7  The receptor tyrosine kinase mesenchymal-epith...   \n",
      "8  To summarize our experience with tubular gastr...   \n",
      "9  An asymptomatic 76-year-old man presented to o...   \n",
      "\n",
      "                                          copyrights publication_date  \\\n",
      "0                                               None       2020-11-13   \n",
      "1                                               None       2020-11-13   \n",
      "2                                               None       2020-11-13   \n",
      "3                                               None       2020-11-13   \n",
      "4  Copyright © 2020 Società Italiana di Anatomia ...       2020-11-13   \n",
      "5        2020 AME Case Reports. All rights reserved.       2020-11-13   \n",
      "6  Copyright © 2020 Miki, Yashiro, Moyano-Galcera...       2020-11-13   \n",
      "7  Copyright © 2020 Li, Hu, Zhou, Huang, Zeng, Xu...       2020-11-13   \n",
      "8                                               None       2018-01-30   \n",
      "9  © 2020 Japan Society for Endoscopic Surgery, A...       2020-11-12   \n",
      "\n",
      "                                             authors  \\\n",
      "0  [{'lastname': 'Sarem', 'firstname': 'Muhannad'...   \n",
      "1  [{'lastname': 'Loharkar', 'firstname': 'Sarves...   \n",
      "2  [{'lastname': 'Gweon', 'firstname': 'Tae-Geun'...   \n",
      "3  [{'lastname': 'Fearon', 'firstname': 'Naomi M'...   \n",
      "4  [{'lastname': 'Gullo', 'firstname': 'Irene', '...   \n",
      "5  [{'lastname': 'Ferro', 'firstname': 'Silvia', ...   \n",
      "6  [{'lastname': 'Miki', 'firstname': 'Yuichiro',...   \n",
      "7  [{'lastname': 'Li', 'firstname': 'Juanni', 'in...   \n",
      "8  [{'lastname': 'Zhong', 'firstname': 'Hai', 'in...   \n",
      "9  [{'lastname': 'Namikawa', 'firstname': 'Tsutom...   \n",
      "\n",
      "                                            keywords  \\\n",
      "0                                                 []   \n",
      "1                                                 []   \n",
      "2  [Colonoscopic surveillance, Colonoscopy, Color...   \n",
      "3  [Colon interposition, Oesophageal cancer, Surg...   \n",
      "4  [gastric adenocarcinoma, gastric cancer, gastr...   \n",
      "5  [Gastrointestinal stromal tumor (GIST), case r...   \n",
      "6  [cancer associated fibroblast, fibroblast grow...   \n",
      "7  [gene alteration, gene mutation, mesenchymal–e...   \n",
      "8  [esophageal cancer, gastric tube, high esophag...   \n",
      "9  [gastric cancer, indocyanine green, near-infra...   \n",
      "\n",
      "                                             journal conclusions methods  \\\n",
      "0  Revista de gastroenterologia del Peru : organo...        None    None   \n",
      "1                          Clinical nuclear medicine        None    None   \n",
      "2                                Intestinal research        None    None   \n",
      "3                                 Updates in surgery        None    None   \n",
      "4                                        Pathologica        None    None   \n",
      "5                                   AME case reports        None    None   \n",
      "6                              Frontiers in oncology        None    None   \n",
      "7                              Frontiers in oncology        None    None   \n",
      "8  Nan fang yi ke da xue xue bao = Journal of Sou...        None    None   \n",
      "9                Asian journal of endoscopic surgery        None    None   \n",
      "\n",
      "                                             results  \n",
      "0                                               None  \n",
      "1                                               None  \n",
      "2                                               None  \n",
      "3                                               None  \n",
      "4                                               None  \n",
      "5                                               None  \n",
      "6                                               None  \n",
      "7                                               None  \n",
      "8  All the patients recovered smoothly after the ...  \n",
      "9                                               None  \n"
     ]
    }
   ],
   "source": [
    "\n",
    "from pymed import PubMed\n",
    "from datetime import date\n",
    "\n",
    "pubmed = PubMed(tool=\"PubMedSearcher\", email=\"folooyi@outlook.com\")\n",
    "\n",
    "## PUT YOUR SEARCH TERM HERE ##\n",
    "search_term = \"Stomach Cancer\"\n",
    "results = pubmed.query(search_term, max_results=1500)\n",
    "\n",
    "articleList = []\n",
    "articleInfo = []\n",
    "\n",
    "for article in results:\n",
    "# Print the type of object we've found (can be either PubMedBookArticle or PubMedArticle).\n",
    "# We need to convert it to dictionary with available function\n",
    "    articleDict = article.toDict()\n",
    "    articleList.append(articleDict)\n",
    "\n",
    "# Generate list of dict records which will hold all article details that could be fetch from PUBMED API\n",
    "\n",
    "for article in articleList:\n",
    "#Sometimes article['pubmed_id'] contains list separated with comma - take first pubmedId in that list - thats article pubmedId\n",
    "    pubmedId = article['pubmed_id'].partition('\\n')[0]\n",
    "    info_dict = {u'pubmed_id':pubmedId,\n",
    "                   u'title':article['title'],\n",
    "                   u'abstract':article['abstract'],\n",
    "                   u'copyrights':article['copyrights'],\n",
    "                   #u'doi':article['doi'],\n",
    "                   u'publication_date':article['publication_date'], \n",
    "                   u'authors':article['authors']}\n",
    "    \n",
    "    info_dict[u'keywords'] = article['keywords'] if 'keywords' in article else \"none\"\n",
    "    info_dict[u'journal'] = article['journal'] if 'journal' in article else \"none\"\n",
    "    info_dict[u'conclusions'] = article['conclusions'] if 'conclusions' in article else \"none\"\n",
    "    info_dict[u'methods'] = article['methods'] if 'methods' in article else \"none\"\n",
    "    info_dict[u'results'] = article['results'] if 'results' in article else \"none\"\n",
    "    #info_dict[u'xml'] = article['xml'] if 'xml' in article else \"none\"\n",
    "    # Append article info to dictionary\n",
    "    articleInfo.append(info_dict)\n",
    "\n",
    "\n",
    "# Generate Pandas DataFrame from list of dictionaries\n",
    "articlesPD = pd.DataFrame.from_dict(articleInfo)\n",
    "export_csv = articlesPD.to_csv (r'search.csv', index = None, header=True) \n",
    "\n",
    "#Print first 10 rows of dataframe\n",
    "print(articlesPD.head(10))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>copyrights</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>authors</th>\n",
       "      <th>keywords</th>\n",
       "      <th>journal</th>\n",
       "      <th>conclusions</th>\n",
       "      <th>methods</th>\n",
       "      <th>results</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33181813</td>\n",
       "      <td>[Why is it important to detect atrophic gastri...</td>\n",
       "      <td>Gastric intestinal metaplasia and atrophic gas...</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Sarem', 'firstname': 'Muhannad'...</td>\n",
       "      <td>[]</td>\n",
       "      <td>Revista de gastroenterologia del Peru : organo...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>33181754</td>\n",
       "      <td>18F-FDG PET/CT in a Rare Case of Poland Syndro...</td>\n",
       "      <td>Poland syndrome is a rare congenital anomaly c...</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Loharkar', 'firstname': 'Sarves...</td>\n",
       "      <td>[]</td>\n",
       "      <td>Clinical nuclear medicine</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>33181006</td>\n",
       "      <td>Postgastrectomy gastric cancer patients are at...</td>\n",
       "      <td>Several studies have shown that colorectal neo...</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Gweon', 'firstname': 'Tae-Geun'...</td>\n",
       "      <td>[Colonoscopic surveillance, Colonoscopy, Color...</td>\n",
       "      <td>Intestinal research</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>33180314</td>\n",
       "      <td>Colonic interposition, a contemporary experien...</td>\n",
       "      <td>Colonic interposition is rarely used as an oes...</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Fearon', 'firstname': 'Naomi M'...</td>\n",
       "      <td>[Colon interposition, Oesophageal cancer, Surg...</td>\n",
       "      <td>Updates in surgery</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33179620</td>\n",
       "      <td>Precancerous lesions of the stomach, gastric c...</td>\n",
       "      <td>Gastric cancer accounts for about 6% of cancer...</td>\n",
       "      <td>Copyright © 2020 Società Italiana di Anatomia ...</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Gullo', 'firstname': 'Irene', '...</td>\n",
       "      <td>[gastric adenocarcinoma, gastric cancer, gastr...</td>\n",
       "      <td>Pathologica</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1494</th>\n",
       "      <td>32160618</td>\n",
       "      <td>The Potential Role of Radiotherapy in the Mana...</td>\n",
       "      <td>Hepatoid adenocarcinoma (AC) of the stomach (H...</td>\n",
       "      <td>© 2020 S. Karger AG, Basel.</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Ilyas', 'firstname': 'Waqas', '...</td>\n",
       "      <td>[Gastric cancer, Gastrointestinal cancer, Hepa...</td>\n",
       "      <td>Oncology research and treatment</td>\n",
       "      <td>RT may have a role in the multimodality manage...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1495</th>\n",
       "      <td>32160410</td>\n",
       "      <td>Inferior prognosis of gastric involvement in p...</td>\n",
       "      <td>Due to limited information reported on the cli...</td>\n",
       "      <td>© 2020 The Authors. Cancer Medicine published ...</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Xie', 'firstname': 'Yi', 'initi...</td>\n",
       "      <td>[SEER, gastric cancer, lymphoma, prognostic fa...</td>\n",
       "      <td>Cancer medicine</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1496</th>\n",
       "      <td>32159312</td>\n",
       "      <td>[Differential diagnostics of gastric cancer an...</td>\n",
       "      <td>The lack of specific symptoms for the early de...</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Titov', 'firstname': 'S E', 'in...</td>\n",
       "      <td>[dysplasia, gastric cancer, miRNA, molecular d...</td>\n",
       "      <td>Klinicheskaia laboratornaia diagnostika</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1497</th>\n",
       "      <td>32158613</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>© 2019 The Author(s). Published by Informa UK ...</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Lee', 'firstname': 'Hana', 'ini...</td>\n",
       "      <td>[Geranium thunbergii, apoptosis, cell cycle ar...</td>\n",
       "      <td>Animal cells and systems</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1498</th>\n",
       "      <td>32157635</td>\n",
       "      <td>Global updates in the treatment of gastric can...</td>\n",
       "      <td>Gastric cancer (GC) is the fifth malignancy an...</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Agnes', 'firstname': 'Annamaria...</td>\n",
       "      <td>[Biomarkers, Gastrectomy, Gastric cancer, Lymp...</td>\n",
       "      <td>Updates in surgery</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1499 rows × 11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     pubmed_id                                              title  \\\n",
       "0     33181813  [Why is it important to detect atrophic gastri...   \n",
       "1     33181754  18F-FDG PET/CT in a Rare Case of Poland Syndro...   \n",
       "2     33181006  Postgastrectomy gastric cancer patients are at...   \n",
       "3     33180314  Colonic interposition, a contemporary experien...   \n",
       "4     33179620  Precancerous lesions of the stomach, gastric c...   \n",
       "...        ...                                                ...   \n",
       "1494  32160618  The Potential Role of Radiotherapy in the Mana...   \n",
       "1495  32160410  Inferior prognosis of gastric involvement in p...   \n",
       "1496  32159312  [Differential diagnostics of gastric cancer an...   \n",
       "1497  32158613                                                      \n",
       "1498  32157635  Global updates in the treatment of gastric can...   \n",
       "\n",
       "                                               abstract  \\\n",
       "0     Gastric intestinal metaplasia and atrophic gas...   \n",
       "1     Poland syndrome is a rare congenital anomaly c...   \n",
       "2     Several studies have shown that colorectal neo...   \n",
       "3     Colonic interposition is rarely used as an oes...   \n",
       "4     Gastric cancer accounts for about 6% of cancer...   \n",
       "...                                                 ...   \n",
       "1494  Hepatoid adenocarcinoma (AC) of the stomach (H...   \n",
       "1495  Due to limited information reported on the cli...   \n",
       "1496  The lack of specific symptoms for the early de...   \n",
       "1497                                                      \n",
       "1498  Gastric cancer (GC) is the fifth malignancy an...   \n",
       "\n",
       "                                             copyrights publication_date  \\\n",
       "0                                                  None       2020-11-13   \n",
       "1                                                  None       2020-11-13   \n",
       "2                                                  None       2020-11-13   \n",
       "3                                                  None       2020-11-13   \n",
       "4     Copyright © 2020 Società Italiana di Anatomia ...       2020-11-13   \n",
       "...                                                 ...              ...   \n",
       "1494                        © 2020 S. Karger AG, Basel.       2020-03-12   \n",
       "1495  © 2020 The Authors. Cancer Medicine published ...       2020-03-12   \n",
       "1496                                               None       2020-03-12   \n",
       "1497  © 2019 The Author(s). Published by Informa UK ...       2020-03-12   \n",
       "1498                                               None       2020-03-12   \n",
       "\n",
       "                                                authors  \\\n",
       "0     [{'lastname': 'Sarem', 'firstname': 'Muhannad'...   \n",
       "1     [{'lastname': 'Loharkar', 'firstname': 'Sarves...   \n",
       "2     [{'lastname': 'Gweon', 'firstname': 'Tae-Geun'...   \n",
       "3     [{'lastname': 'Fearon', 'firstname': 'Naomi M'...   \n",
       "4     [{'lastname': 'Gullo', 'firstname': 'Irene', '...   \n",
       "...                                                 ...   \n",
       "1494  [{'lastname': 'Ilyas', 'firstname': 'Waqas', '...   \n",
       "1495  [{'lastname': 'Xie', 'firstname': 'Yi', 'initi...   \n",
       "1496  [{'lastname': 'Titov', 'firstname': 'S E', 'in...   \n",
       "1497  [{'lastname': 'Lee', 'firstname': 'Hana', 'ini...   \n",
       "1498  [{'lastname': 'Agnes', 'firstname': 'Annamaria...   \n",
       "\n",
       "                                               keywords  \\\n",
       "0                                                    []   \n",
       "1                                                    []   \n",
       "2     [Colonoscopic surveillance, Colonoscopy, Color...   \n",
       "3     [Colon interposition, Oesophageal cancer, Surg...   \n",
       "4     [gastric adenocarcinoma, gastric cancer, gastr...   \n",
       "...                                                 ...   \n",
       "1494  [Gastric cancer, Gastrointestinal cancer, Hepa...   \n",
       "1495  [SEER, gastric cancer, lymphoma, prognostic fa...   \n",
       "1496  [dysplasia, gastric cancer, miRNA, molecular d...   \n",
       "1497  [Geranium thunbergii, apoptosis, cell cycle ar...   \n",
       "1498  [Biomarkers, Gastrectomy, Gastric cancer, Lymp...   \n",
       "\n",
       "                                                journal  \\\n",
       "0     Revista de gastroenterologia del Peru : organo...   \n",
       "1                             Clinical nuclear medicine   \n",
       "2                                   Intestinal research   \n",
       "3                                    Updates in surgery   \n",
       "4                                           Pathologica   \n",
       "...                                                 ...   \n",
       "1494                    Oncology research and treatment   \n",
       "1495                                    Cancer medicine   \n",
       "1496            Klinicheskaia laboratornaia diagnostika   \n",
       "1497                           Animal cells and systems   \n",
       "1498                                 Updates in surgery   \n",
       "\n",
       "                                            conclusions methods results  \n",
       "0                                                  None    None    None  \n",
       "1                                                  None    None    None  \n",
       "2                                                  None    None    None  \n",
       "3                                                  None    None    None  \n",
       "4                                                  None    None    None  \n",
       "...                                                 ...     ...     ...  \n",
       "1494  RT may have a role in the multimodality manage...    None    None  \n",
       "1495                                               None    None    None  \n",
       "1496                                               None    None    None  \n",
       "1497                                               None    None    None  \n",
       "1498                                               None    None    None  \n",
       "\n",
       "[1499 rows x 11 columns]"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "articlesPD"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>copyrights</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>authors</th>\n",
       "      <th>keywords</th>\n",
       "      <th>journal</th>\n",
       "      <th>conclusions</th>\n",
       "      <th>methods</th>\n",
       "      <th>results</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Total Cites</th>\n",
       "      <th>Journal Impact Factor</th>\n",
       "      <th>Eigenfactor Score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33181813</td>\n",
       "      <td>[Why is it important to detect atrophic gastri...</td>\n",
       "      <td>Gastric intestinal metaplasia and atrophic gas...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Sarem', 'firstname': 'Muhannad'...</td>\n",
       "      <td>[]</td>\n",
       "      <td>revista de gastroenterologia del peru : organo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>33181754</td>\n",
       "      <td>18F-FDG PET/CT in a Rare Case of Poland Syndro...</td>\n",
       "      <td>Poland syndrome is a rare congenital anomaly c...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Loharkar', 'firstname': 'Sarves...</td>\n",
       "      <td>[]</td>\n",
       "      <td>clinical nuclear medicine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>671</td>\n",
       "      <td>5,042</td>\n",
       "      <td>6.587</td>\n",
       "      <td>0.00620</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>33181006</td>\n",
       "      <td>Postgastrectomy gastric cancer patients are at...</td>\n",
       "      <td>Several studies have shown that colorectal neo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Gweon', 'firstname': 'Tae-Geun'...</td>\n",
       "      <td>['Colonoscopic surveillance', 'Colonoscopy', '...</td>\n",
       "      <td>intestinal research</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>33180314</td>\n",
       "      <td>Colonic interposition, a contemporary experien...</td>\n",
       "      <td>Colonic interposition is rarely used as an oes...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Fearon', 'firstname': 'Naomi M'...</td>\n",
       "      <td>['Colon interposition', 'Oesophageal cancer', ...</td>\n",
       "      <td>updates in surgery</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4161</td>\n",
       "      <td>913</td>\n",
       "      <td>2.587</td>\n",
       "      <td>0.00200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33179620</td>\n",
       "      <td>Precancerous lesions of the stomach, gastric c...</td>\n",
       "      <td>Gastric cancer accounts for about 6% of cancer...</td>\n",
       "      <td>Copyright © 2020 Società Italiana di Anatomia ...</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>[{'lastname': 'Gullo', 'firstname': 'Irene', '...</td>\n",
       "      <td>['gastric adenocarcinoma', 'gastric cancer', '...</td>\n",
       "      <td>pathologica</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1509</th>\n",
       "      <td>32160618</td>\n",
       "      <td>The Potential Role of Radiotherapy in the Mana...</td>\n",
       "      <td>Hepatoid adenocarcinoma (AC) of the stomach (H...</td>\n",
       "      <td>© 2020 S. Karger AG, Basel.</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Ilyas', 'firstname': 'Waqas', '...</td>\n",
       "      <td>['Gastric cancer', 'Gastrointestinal cancer', ...</td>\n",
       "      <td>oncology research and treatment</td>\n",
       "      <td>RT may have a role in the multimodality manage...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5953</td>\n",
       "      <td>910</td>\n",
       "      <td>1.967</td>\n",
       "      <td>0.00266</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1510</th>\n",
       "      <td>32160410</td>\n",
       "      <td>Inferior prognosis of gastric involvement in p...</td>\n",
       "      <td>Due to limited information reported on the cli...</td>\n",
       "      <td>© 2020 The Authors. Cancer Medicine published ...</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Xie', 'firstname': 'Yi', 'initi...</td>\n",
       "      <td>['SEER', 'gastric cancer', 'lymphoma', 'progno...</td>\n",
       "      <td>cancer medicine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2485</td>\n",
       "      <td>6,732</td>\n",
       "      <td>3.491</td>\n",
       "      <td>0.01788</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1511</th>\n",
       "      <td>32159312</td>\n",
       "      <td>[Differential diagnostics of gastric cancer an...</td>\n",
       "      <td>The lack of specific symptoms for the early de...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Titov', 'firstname': 'S E', 'in...</td>\n",
       "      <td>['dysplasia', 'gastric cancer', 'miRNA', 'mole...</td>\n",
       "      <td>klinicheskaia laboratornaia diagnostika</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1512</th>\n",
       "      <td>32158613</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>© 2019 The Author(s). Published by Informa UK ...</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Lee', 'firstname': 'Hana', 'ini...</td>\n",
       "      <td>['Geranium thunbergii', 'apoptosis', 'cell cyc...</td>\n",
       "      <td>animal cells and systems</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10220</td>\n",
       "      <td>305</td>\n",
       "      <td>0.907</td>\n",
       "      <td>0.00049</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1513</th>\n",
       "      <td>32157635</td>\n",
       "      <td>Global updates in the treatment of gastric can...</td>\n",
       "      <td>Gastric cancer (GC) is the fifth malignancy an...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>[{'lastname': 'Agnes', 'firstname': 'Annamaria...</td>\n",
       "      <td>['Biomarkers', 'Gastrectomy', 'Gastric cancer'...</td>\n",
       "      <td>updates in surgery</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4161</td>\n",
       "      <td>913</td>\n",
       "      <td>2.587</td>\n",
       "      <td>0.00200</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1514 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      pubmed_id                                              title  \\\n",
       "0      33181813  [Why is it important to detect atrophic gastri...   \n",
       "1      33181754  18F-FDG PET/CT in a Rare Case of Poland Syndro...   \n",
       "2      33181006  Postgastrectomy gastric cancer patients are at...   \n",
       "3      33180314  Colonic interposition, a contemporary experien...   \n",
       "4      33179620  Precancerous lesions of the stomach, gastric c...   \n",
       "...         ...                                                ...   \n",
       "1509   32160618  The Potential Role of Radiotherapy in the Mana...   \n",
       "1510   32160410  Inferior prognosis of gastric involvement in p...   \n",
       "1511   32159312  [Differential diagnostics of gastric cancer an...   \n",
       "1512   32158613                                                NaN   \n",
       "1513   32157635  Global updates in the treatment of gastric can...   \n",
       "\n",
       "                                               abstract  \\\n",
       "0     Gastric intestinal metaplasia and atrophic gas...   \n",
       "1     Poland syndrome is a rare congenital anomaly c...   \n",
       "2     Several studies have shown that colorectal neo...   \n",
       "3     Colonic interposition is rarely used as an oes...   \n",
       "4     Gastric cancer accounts for about 6% of cancer...   \n",
       "...                                                 ...   \n",
       "1509  Hepatoid adenocarcinoma (AC) of the stomach (H...   \n",
       "1510  Due to limited information reported on the cli...   \n",
       "1511  The lack of specific symptoms for the early de...   \n",
       "1512                                                NaN   \n",
       "1513  Gastric cancer (GC) is the fifth malignancy an...   \n",
       "\n",
       "                                             copyrights publication_date  \\\n",
       "0                                                   NaN       2020-11-13   \n",
       "1                                                   NaN       2020-11-13   \n",
       "2                                                   NaN       2020-11-13   \n",
       "3                                                   NaN       2020-11-13   \n",
       "4     Copyright © 2020 Società Italiana di Anatomia ...       2020-11-13   \n",
       "...                                                 ...              ...   \n",
       "1509                        © 2020 S. Karger AG, Basel.       2020-03-12   \n",
       "1510  © 2020 The Authors. Cancer Medicine published ...       2020-03-12   \n",
       "1511                                                NaN       2020-03-12   \n",
       "1512  © 2019 The Author(s). Published by Informa UK ...       2020-03-12   \n",
       "1513                                                NaN       2020-03-12   \n",
       "\n",
       "                                                authors  \\\n",
       "0     [{'lastname': 'Sarem', 'firstname': 'Muhannad'...   \n",
       "1     [{'lastname': 'Loharkar', 'firstname': 'Sarves...   \n",
       "2     [{'lastname': 'Gweon', 'firstname': 'Tae-Geun'...   \n",
       "3     [{'lastname': 'Fearon', 'firstname': 'Naomi M'...   \n",
       "4     [{'lastname': 'Gullo', 'firstname': 'Irene', '...   \n",
       "...                                                 ...   \n",
       "1509  [{'lastname': 'Ilyas', 'firstname': 'Waqas', '...   \n",
       "1510  [{'lastname': 'Xie', 'firstname': 'Yi', 'initi...   \n",
       "1511  [{'lastname': 'Titov', 'firstname': 'S E', 'in...   \n",
       "1512  [{'lastname': 'Lee', 'firstname': 'Hana', 'ini...   \n",
       "1513  [{'lastname': 'Agnes', 'firstname': 'Annamaria...   \n",
       "\n",
       "                                               keywords  \\\n",
       "0                                                    []   \n",
       "1                                                    []   \n",
       "2     ['Colonoscopic surveillance', 'Colonoscopy', '...   \n",
       "3     ['Colon interposition', 'Oesophageal cancer', ...   \n",
       "4     ['gastric adenocarcinoma', 'gastric cancer', '...   \n",
       "...                                                 ...   \n",
       "1509  ['Gastric cancer', 'Gastrointestinal cancer', ...   \n",
       "1510  ['SEER', 'gastric cancer', 'lymphoma', 'progno...   \n",
       "1511  ['dysplasia', 'gastric cancer', 'miRNA', 'mole...   \n",
       "1512  ['Geranium thunbergii', 'apoptosis', 'cell cyc...   \n",
       "1513  ['Biomarkers', 'Gastrectomy', 'Gastric cancer'...   \n",
       "\n",
       "                                                journal  \\\n",
       "0     revista de gastroenterologia del peru : organo...   \n",
       "1                             clinical nuclear medicine   \n",
       "2                                   intestinal research   \n",
       "3                                    updates in surgery   \n",
       "4                                           pathologica   \n",
       "...                                                 ...   \n",
       "1509                    oncology research and treatment   \n",
       "1510                                    cancer medicine   \n",
       "1511            klinicheskaia laboratornaia diagnostika   \n",
       "1512                           animal cells and systems   \n",
       "1513                                 updates in surgery   \n",
       "\n",
       "                                            conclusions methods results  \\\n",
       "0                                                   NaN     NaN     NaN   \n",
       "1                                                   NaN     NaN     NaN   \n",
       "2                                                   NaN     NaN     NaN   \n",
       "3                                                   NaN     NaN     NaN   \n",
       "4                                                   NaN     NaN     NaN   \n",
       "...                                                 ...     ...     ...   \n",
       "1509  RT may have a role in the multimodality manage...     NaN     NaN   \n",
       "1510                                                NaN     NaN     NaN   \n",
       "1511                                                NaN     NaN     NaN   \n",
       "1512                                                NaN     NaN     NaN   \n",
       "1513                                                NaN     NaN     NaN   \n",
       "\n",
       "       Rank Total Cites Journal Impact Factor  Eigenfactor Score  \n",
       "0       NaN         NaN                   NaN                NaN  \n",
       "1       671       5,042                 6.587            0.00620  \n",
       "2       NaN         NaN                   NaN                NaN  \n",
       "3      4161         913                 2.587            0.00200  \n",
       "4       NaN         NaN                   NaN                NaN  \n",
       "...     ...         ...                   ...                ...  \n",
       "1509   5953         910                 1.967            0.00266  \n",
       "1510   2485       6,732                 3.491            0.01788  \n",
       "1511    NaN         NaN                   NaN                NaN  \n",
       "1512  10220         305                 0.907            0.00049  \n",
       "1513   4161         913                 2.587            0.00200  \n",
       "\n",
       "[1514 rows x 15 columns]"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df1 = pd.read_csv('search.csv', engine='python')\n",
    "df1[\"journal\"] = df1[\"journal\"].str.lower()\n",
    "df2 = pd.read_csv('journal.csv', engine='python')\n",
    "df2[\"journal\"] = df2[\"journal\"].str.lower()\n",
    "\n",
    "df = df1.merge(df2, on='journal',how = 'left')\n",
    "export_csv = df.to_csv (r'search_with_journal.csv', index = None, header=True) \n",
    "#df = df.sort_values(by=[\"Journal Impact Factor\"],ascending=False)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "#the above dealing with keyword, generate keywords count csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Colonoscopic surveillance', 'Colonoscopy', 'Colorectal neoplasm', 'Stomach neoplasms', 'Colon interposition', 'Oesophageal cancer', 'Surgical techniques', 'Upper gastrointestinal surgery', 'gastric adenocarcinoma', 'gastric cancer', 'gastric dysplasia', 'hereditary diffuse gastric cancer (HDGC)', 'hereditary gastric cancer syndromes', 'Gastrointestinal stromal tumor (GIST)', 'case report', 'embolization', 'emergency surgery', 'radiofrequency procedure', 'cancer associated fibroblast', 'fibroblast growth factor receptor', 'gastric cancer', 'scirrhous carcinoma of the stomach', 'transforming growth factor β1', 'tumor microenvironment', 'gene alteration', 'gene mutation', 'mesenchymal–epithelial transition factor', 'outcome', 'pancancer', 'esophageal cancer', 'gastric tube', 'high esophageal-gastric anastomosis', 'tubular gastric lengthening surgery', 'gastric cancer', 'indocyanine green', 'near-infrared fluorescence', 'alpha-fetoprotein-producing gastric cancer', 'gastric cancer', 'hepatoid adenocarcinoma of stomach', 'immunotherapy', 'Breast cancer', 'Case report', 'Ileal GIST', 'Neurofibromatosis type I', 'Immune-related adverse events', 'Muscle-invasive bladder cancer', 'Pembrolizumab', 'Positron emission tomography/computed tomography', 'Prognosis', 'clinical efficacy', 'laparoscopic-assisted radical gastrectomy', 'modified roux-en-y anastomosis', 'roux-en-y anastomosis', 'totally laparoscopic radical gastrectomy', 'cervix uteri', 'dogs', 'odorants', 'urine', 'volatile organic compounds', 'Early-stage gastric cancers', 'Endoscopy', 'Pathology', 'Stomach cancer', 'Tumor budding', 'HBV', 'HCV', 'NAFLD', 'adipokine', 'adiponectin', 'biliary', 'colon', 'esophagus', 'gallbladder', 'leptin', 'pancreas', 'small intestine', 'stomach', 'gastric cancer', 'natural medicine', 'phytocompounds', 'phytotherapy', 'Caveolin-1', 'MicroRNA-451a', 'stomach cancer', 'Double contrast study', 'Gastric arteries', 'Gastric veins', 'Submucosal gastric vessels', 'X-ray imaging', 'Gastrectomy', 'Quality of life', 'Stomach neoplasms', 'Endoscopic submucosal dissection (ESD)', 'Endoscopy', 'Gastrectomy', 'Gastric cancer', 'Undifferentiated type', 'Atrophic gastritis', 'Endoscopy', 'Gastric cancer', 'Mutation', 'Screening', 'Biopsy', 'Breast cancer', 'Lobular carcinoma', 'Metastasis', 'Polyps', 'Image reconstruction', 'Intraoperative imaging', 'Lymph node metastases', 'Positron emission tomography', 'Stomach cancer', 'cancer risk', 'digestive tract cancer', 'socioeconomic status', 'Early gastric cancer', 'Histopathology', 'Lymph node metastasis risk', 'Stomach', 'Endoscopic submucosal dissection', 'Gastric cancer', 'Ho:YAG laser', 'Laser ablation', 'cytoreduction surgical procedures', 'laparoscopes', 'ovarian cancer', 'CpG', 'SOX protein family', 'SOX17', 'SOX18', 'SOX30', 'SOX7', 'lung adenocarcinoma', 'lung squamous-cell carcinoma', 'miRNA', 'non-small cell lung carcinoma', 'Gene expression profiling', 'Microsatellite instability', 'PD-L1', 'Prognosis', 'Stomach neoplasms', \"Women's Health Initiative\", 'cancer', 'cardiometabolic risk factors', 'survival', 'Dumping symptoms', 'Esophagectomy', 'Health-related quality of life', 'Long-term follow-up', 'cancer pain', 'celiac plexus', 'chronic pain', 'pancreatic cancer', 'splanchnic nerves', 'YAP1', 'cell biology', 'miR-205', 'propofol', 'stomach cancer', 'Gastric cancer', 'cytotoxic chemotherapy', 'gastroesophageal junction cancer', 'immunotherapy', 'targeted therapy', 'Stomach', 'lymph node', 'metastasis', 'neoplasm', 'prognosis', 'Proximal gastric cancer', 'overall survival', 'postoperative complication', 'review', 'splenectomy', 'association rule', 'cancer', 'comorbidity', 'prevalence ratio', 'MiNEN', 'small (large) cell', 'Cholecystectomy', 'Colorectal Cancer', 'Stomach Cancer', 'CANCER EPIDEMIOLOGY', 'COLORECTAL CANCER', 'COLORECTAL CANCER SCREENING', 'GASTROINTESTINAL CANCER', 'Cancer', 'drinking water', 'meta-analysis', 'nitrates', 'nitrites', 'systematic review', 'Adenocarcinoma', 'Neuroendocrine neoplasms', 'Serum lipids', 'Stomach neoplasms', 'Allergenic genes', 'Anisakis pegreffii', 'Gastric juice', 'Transcriptomic analysis', 'cancer', 'methylation', 'overall survival', 'selenoprotein', 'selenoproteome', 'Amyloid', 'Heart failure', 'Transthyretin', 'Transthyretin amyloidosis', 'Val122Ile', 'convolutional neural network', 'deep learning', 'gastric cancer', 'histology', 'whole-slide imaging', 'Adenocarcinoma', 'Carcinoma', 'Esophageal cancer', 'Gastric cancer', 'Gastroesophageal junction', 'Histology', 'Metastases', 'Squamous cell', 'carcinoma', 'immunohistochemistry', 'viruses', 'Barrett', 'Epidemiology', 'adenoma', 'capsule endoscopy', 'diverticula', 'healthy population', 'immunosuppression', 'mouse model', 'resistance', 'stomach cancer', 'Adaptive radiotherapy', 'Kernel modeling', 'Multi-organ motion analysis', 'Statistical deformation library', 'electrical stimulation', 'electroceuticals', 'gastrointestinal tract', 'Gastrointestinal stromal tumors', 'Risk factors', 'Stomach neoplasms', 'Tomography, X-ray computed', 'ambulatory care', 'oncology', 'patient-reported outcome measures', 'quality of health care', 'LncRNA', 'SNHG12', 'cancer', 'prognosis', 'sarcoma', 'LncRNA FTX', 'cancer', 'cirrhosis', 'heart failure.', 'temporal lobe epilepsy', 'Bursa sac', 'Lymphadenectomy', 'Mesogastrium', 'Stomach neoplasms', 'Surgical procedures', 'Laparoscopic gastrectomy', 'Lung neoplasms', 'Nivolumab', 'Stomach neoplasms', 'CpG', 'Piwil1 gene', 'gastric cancer', 'single nucleotide polymorphisms', 'biliary tract', 'metastasis', 'neutrophil to lymphocyte ratio', 'nomogram', 'pancreas', 'stomach', 'metastasis', 'prognosis', 'site', 'stomach neoplasms', 'surgery', 'Billroth I reconstruction', 'gastric cancer', 'laparoscopic distal gastrectomy', 'Non-small-cell lung cancer', 'cancer stem cell', 'prognostic marker', 'GastroPanel', 'Helicobacter pylori', 'Hp IgG ELISA', 'biomarker test', 'biopsy', 'clinical validation', 'gastrin-17', 'gastroscopy', 'new-generation', 'non-invasive', 'pepsinogen I', 'pepsinogen II', 'Asian Americans', 'gastric cancer', 'survival outcomes', 'Gastric cancer', 'LITAF', 'miR-1', 'Cytoreductive surgery', 'Differentiation', 'Nongynecologic primary site', 'Ovarian metastasis', 'Prognosis', 'Residual lesion', 'COVID-19', 'Chemotherapy', 'Gastric cancer', 'SARS-CoV-2', 'treatment', 'LUCAT1', 'Long non-coding RNA', 'epigenetic modulation', 'gastric cancer', 'Breath Tests', 'Electronic Nose', 'Gastrointestinal Neoplasms', 'Stomach Neoplasms', 'Volatile Organic Compounds', 'COVID-19', 'SARS-CoV-2', 'fetus', 'pathogenesis', 'placenta', 'Gastric cancer', 'PD-1', 'biomarker', 'tumor-infiltrating lymphocytes', 'COMPREV software', 'Population-based cancer registry', 'complete cancer prevalence', 'phase of care prevalence', 'acute gastritis', 'immune checkpoint inhibitor', 'melanoma', 'Cancer', 'intermittent hypoxia', 'obesity', 'risk factors', 'sleep', 'sleep apnea', 'Thromboelastography', 'gastric cancer', 'lower extremity deep venous thrombosis', 'portal hypertension', 'prognosis', 'diet', 'epidemiology', 'flavonoids', 'gastric cancer', 'polyphenols', 'Breast neoplasms', 'Colorectal neoplasms', 'Early detection of cancer', 'Healthcare surveys', 'Liver neoplasms', 'Stomach neoplasms', 'Trends', 'Uterine cervical neoplasms', 'Lauren', 'cancer', 'epidemiology', 'gastrin', 'stomach', 'Education', 'Endoscopic Surgical Skill Qualification System', 'Gastrectomy', 'Minimally invasive surgical procedures', 'Postoperative complications', 'Stomach neoplasms', 'Endoscopy', 'gastric malignancy', 'red cell distribution width', 'stomach cancer', 'Digestive tract cancer', 'Immediate double primary cancer', 'Stomach neoplasms', 'Cell Biology', 'Immunology', 'A case series study', 'Case report', 'Different outcomes', 'Localized gastric amyloidosis', 'Mucosa-associated lymphoid tissue lymphoma', 'Rare disease', 'Case report', 'Differentiation', 'Gastric adenocarcinoma', 'Immunohistochemical staining', 'Protease inhibitor', 'Squamous cell carcinoma antigen', 'Krukenberg tumor', 'Nomograms', 'Ovarian metastasis', 'Risk factors', 'Stomach neoplasms', 'MMR proteins', 'MSI', 'head and neck cancer', 'immunotherapy', 'local recurrence', 'microsatellite instability', 'multiple primary tumors', 'progression', 'Wnt/β-catenin dependent pathway', 'Wnt/β-catenin independent pathway', 'breast cancer', 'colorectal cancer', 'extracellular vesicles', 'ovarian cancer', 'Apoptosis', 'FADD', 'Gastric Cancer', 'INDEL', 'Direct medical expenses', 'Risk factors', 'Smoking', 'Stomach cancer', 'Chinese herbs', 'recurrence', 'symptoms', 'type 1 gastric neuroendocrine tumors', 'Carcinoma–signet ring cell', 'Crohn disease', 'ileal neoplasms', 'inflammation', 'intestine–small', 'Calcification', 'Calcifying fibrous pseudotumor', 'Calcifying fibrous tumor', 'Gastrointestinal tract', 'Mesenchymal lesion', 'Pathology', 'B7-H1 antigen', 'Liquid biopsy', 'Progression-free survival', 'Stomach neoplasms', 'Prognosis', 'Stomach neoplasms', 'Trastuzumab', 'Treatment outcome', 'Claudin-2', 'Gastric Cancer', 'Genomic Profile', 'Paracellular Permeability', 'RNAseq', 'Ussing Chambers', 'Cancer pain', 'GI cancer', 'OIC-J', 'Observational study', 'Opioid-induced constipation', 'copy number', 'expression', 'immune cell', 'mutation', 'pan-cancer', 'pathways', 'pepsinogen', 'prognosis', 'risk', 'Ivor-Lewis procedure', 'anastomotic leak', 'confocal laser endomicroscopy', 'esophageal cancer', 'esophageal resection', 'fluorescence imaging', 'hyperspectral imaging', 'ischemic preconditioning', 'optical imaging', 'health communication', 'health literacy', 'neoplasms', 'quality of life', 'social support', 'cdh1', 'e-cadherin', 'hereditary gastric diffuse cancer', 'invasive lobular breast cancer', 'prophylactic gastrectomy', 'signet ring cell adenocarcinoma', 'Alternative splicing', 'ECT2', 'Gastric cancer', 'Prognosis', 'TCGA', 'Anti-reflux', 'Esophagogastric junction tumor', 'Proximal gastrectomy', 'Reconstruction of digestive tract', 'Adenocarcinoma of the esophagogastric junction, Siewert II', 'Digestive tract reconstruction', 'Lymphadenectomy', 'Carbon nanoparticles', 'Lymph node retrieval', 'Stomach neoplasms', 'Complications', 'Esophagojejunal anastomosis', 'Stomach neoplasms', 'Total gastrectomy', 'Pathology', 'Prognosis', 'Stomach neoplasms, adolescent', 'Biological behavior', 'Prognosis', 'Stomach neoplasms', 'TNM staging', 'Function preserving', 'Minimally invasive treatment', 'Submucosal tumors', 'Combined laparoscopy-endoscopy surgery', 'Local resection', 'Sentinel node navigation surgery', 'Stomach neoplasms, early', 'Function-preserving gastrectomy', 'Stomach neoplasms', 'Vagal nerve, celiac branch', 'Cardia', 'Function-preserving gastrectomy', 'Pylorus-preserving gastrectomy', 'Segmental gastrectomy', 'Stomach neoplasms, early', 'Anastomosis', 'Segmental gastrectomy', 'Stomach neoplasms, early', 'Function preserving', 'Function reconstruction', 'Stomach neoplasms', 'Helicobacter pylori infection', 'falls', 'fractures', 'management', 'medications', 'osteoporosis', 'gastric cancer', 'laparoscopy', 'lymphadenectomy', 'mesogastric excision', 'ER-phagy', 'autophagy', 'endoplasmic reticulum', 'gene expression', 'reticulophagy', 'CT image', 'application', 'gastric cancer', 'nursing intervention', 'Disease-free survival', 'laparoscopic', 'overall survival', 'robotic', 'stomach cancer', 'Helicobacter pylori', 'gastric mucosa homeostasis', 'gastric organoid', 'gastric stem cells', 'stem cell niche', 'stomach neoplasms', 'STAT family', 'Stomach adenocarcinoma', 'bioinformatics analysis', 'biomarker', 'immune checkpoint inhibitor', 'Gastric cancer', 'pathological features', 'prognosis', 'α-fetoprotein', 'Colon', 'Lung metastasis', 'Lymphangitic lung carcinomatosis', 'Metastatic cancer', 'Micropapillary colorectal carcinoma', 'acute vestibular syndrome', 'carcinomatous meningitis', 'epithelial mesenchymal transition', 'signet ring cell carcinoma', 'Gastrectomy', 'Gastric conduit', 'Thoracic esophageal cancer', 'Chemoresistance', 'GAC', 'GNEC', 'NeuroD1', 'Transcriptome analysis', 'Ovarian cancer', 'Prior malignancy', 'SEER', 'prognosis', 'Infiltrated macrophages', 'NF-kB and STAT3', 'PD-1/PD-L1', 'TNF-ɑ and IL-6', 'Biclonal gammopathy', 'Bone marrow', 'Marginal zone B-cell lymphoma', ' helicobacter pylori ', 'Caudal type homeoboxes', 'intestinal metaplasia', 'sonic hedgehog', 'sry- related high-mobility group box 2', 'Gastric glands', 'Glycoconjugates', 'Lectin histochemistry', 'Mucins', 'Zymogens', 'adenocarcinoma', 'fundic gland mucosa type', 'fundic gland type', 'oxyntic gland neoplasm', 'stomach', 'esophageal cancer', 'esophagectomy', 'intrapleural esophageal-gastric anastomosis', 'laparothoracoscopic esophagectomy', 'Azores', 'Cancer control', 'Cancer surveillance', 'Portugal', 'Trends', 'Gastrointestinal stromal tumor', 'Meckel’s diverticulum', 'Perforation', 'Autoimmune atrophic gastritis', 'Potassium-competitive acid blocker', 'Vonoprazan', 'White globe appearance', 'Abdominal pain', 'CT', 'Colon', 'Gastrointestinal tumors', 'Stomach', 'Gastrectomy', 'Lymphatic metastasis', 'Prognosis', 'Stomach neoplasm', 'Laparoscopy', 'Minimally invasive surgical procedures', 'Stomach neoplasms', 'Surgical anastomosis', 'Volumetric CT', 'Gastrectomy', 'Gastric cancer', 'Laparoscopic surgery', 'Patient outcome assessment', 'Postoperative complication', 'Endoscopy, gastrointestinal', 'Minimally invasive surgical procedures', 'Stomach neoplasms', 'Anastomotic leak', 'Gastrectomy', 'Self-expandable metallic stents', 'Stomach neoplasms', 'Vacuum assisted closure', 'Dendritic cell', 'H. Pylori', 'SOCS', 'Type IV secretion system', 'p38', 'antioxidants', 'coffee', 'mortality', 'observational study', 'stomach neoplasms', 'intestinal metaplasia', 'partial gastrectomy', 'pathogenesis', 'pyloric metaplasia', 'remnant gastric cancer', 'diagnostic techniques and procedures', 'gastrointestinal neoplasms', 'immunohistochemistry', 'molecular', 'pathology', 'stomach neoplasms', 'clinical trial', 'phase III', 'precision medicine', 'sentinel lymph node', 'stomach neoplasms', 'enhanced recovery after surgery', 'length of hospital stay', 'nausea and vomiting scores', 'oral carbohydrate loading', 'ovarian cancer', 'pain scores', 'post operative care', 'Hepatocellular carcinoma', 'biomarker', 'metabolism', 'prognosis', 'Gastrointestinal stromal tumour', 'Prognosis', 'Survival', 'Diffuse large B-cell lymphoma', 'Gallbladder', 'Literature review', 'Prognosis', 'Testis', 'COVID-19', 'Coronavirus disease 2019', 'Gastric cancer', 'Retrospective analysis', 'gastric cancer', 'proximal gastrectomy', 'reconstruction method', 'Cancer-associated thrombosis', 'Direct oral anticoagulants', 'Gastrointestinal cancer', 'Splanchnic vein thrombosis', 'Venous thromboembolism', 'breast cancer', 'computed tomography', 'gastric metastasis', 'Bioinformatic analysis', 'Differentially expressed genes', 'Gastric carcinoma', 'Overall survival', 'Prognosis', 'heterogeneity', 'multi-gene model', 'prediction', 'prognosis', 'stomach adenocarcinoma', 'gastric cancer', 'organoids', 'personalized medicine', 'spheroids', 'Case report', 'Epstein–Barr virus-associated gastric cancer', 'Multiple gastric cancer', 'Robot-assisted laparoscopic gastrectomy', 'Colitis', 'Colonic neoplasms', 'Heart failure', 'Intestinal polyposis', 'Malnutrition', 'Drug therapy', 'Huachansu injection', 'Meta-analysi', 'Randomized controlled trial', 'Stomach neoplasm', 'Early gastric cancer', 'Gastric fornix', 'Helicobacter pylori-uninfected', 'Poorly differentiated adenocarcinoma', 'Undifferentiated-type', 'Cardiovascular diseases', 'Chronic kidney diseases', 'Disability-adjusted life years', 'Future prediction', 'Japan', 'Salt intake', 'Stomach cancer', 'FES-PET', 'abdominal distribution', 'breast cancer', 'chocolate', 'fasting', 'Fluorescence-guided surgery', 'Fluorescent over the scope clip', 'Indocyanine green tattooing', 'Preoperative endoscopic marking', 'Preoperative endoscopic tattooing', 'Gastric cancer', 'S-1', 'adjuvant chemotherapy', 'glioma-associated oncogene 1', 'prognostic factor', 'Cell biology', 'margins of excision', 'stomach neoplasms', 'TAM', 'TYRO3', 'gastric cancer', 'prognostic factor', '5-fluorouracil', 'Gastric cancer', 'gemcitabine', 'liver metastasis', 'nude mice', 'oxaliplatinum', 'patient-derived orthotopic xenograft (PDOX)', '6 MV Linac', 'Cobalt-60 teletherapy machine', 'MLCs', 'ROPS planning system', 'gastric cancer', 'genetics', 'neuroendocrine carcinoma', 'targeted sequencing', 'Cancer cure', 'Europe', 'life expectancy', 'mixture cure models', 'population-based cancer registries', 'survival', 'time to cure', 'Liver', 'neuroendocrine neoplasm', 'primary', 'Carcinoma', 'diagnosis', 'management', 'primary care', 'stomach', 'Case report', 'GI', 'General surgery', 'Oncology', 'Pathology', 'CD44', 'breast cancer chemotherapy', 'doxorubicin', 'hyaluronic acid', 'pH-sensitive', 'CAR-T cell therapy', 'TCGA database', 'gastric cancer', 'radiosensitivity genes', 'Endoscopy', 'Gastric cancer', 'Gastritis', 'Helicobacter pylori', 'Kyoto classification', 'Neutrophil activity', 'Pathology', 'Updated Sydney System', 'Esophagogastric junction', 'Minimally invasive surgery', 'Para-aortic lymph node', 'Deep learning', 'Multi-detector computed tomography', 'Radiomics', 'Stomach neoplasms', 'Cancer of stomach', 'laparoscopic approach', 'robotic approach', 'Apoptosis', 'Cardiac adenocarcinoma', 'Epithelial–mesenchymal transition', 'NCAPG', 'Wnt/β-catenin signaling pathway', 'clinical staging', 'esophageal cancer', 'gastric cancer', 'pancreatic cancer', 'cancer incidence', 'case-control study', 'diabetes', 'occupational exposure', 'smoking', 'adenocarcinoma of esophagus', 'cardia', 'esophagogastric junction', 'stomach', 'stomach neoplasms', 'SEER', 'gastrointestinal stromal tumors', 'metastasis', 'primary tumor resection', 'survival', 'lamb model', 'monoclonal antibody', 'nebulization ', 'palivizumab', 'prophylactic', 'respiratory syncytial virus', 'AFP-positive', 'Adenocarcinomatous', 'Case report', 'Gastric carcinoma', 'Gastric carcinosarcoma', 'Metastasis', 'Recurrence', 'N6-methyladenosine', 'immune checkpoint', 'mRNA modification', 'prognosis', 'signature', 'stomach carcinoma', 'coats plus', 'dyskeratosis congenita', 'gastrointestinal hemorrhage', 'telomere biology disorder', 'vascular ectasia', 'Clinical T1N0', 'Gastric adenocarcinoma', 'Poor differentiation', 'Gastrectomy', 'Laparoscopy', 'Stomach Neoplasms', 'Hand-assisted laparoscopic surgery', 'Oesophageal cancer', 'oesophagectomy', 'robotic surgery', 'Endoscopic submucosal dissection', 'Gas chromatography', 'Stomach cancer', 'Volatile organic compounds', 'ADAMTS18', 'mRNA expression', 'prognosis', 'stomach adenocarcinoma', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'Esophageal cancer screening', 'liver cancer screening', 'stomach cancer screening', 'study protocol', 'Gastric polyp', 'Inflammatory fibroid polyps', 'Pólipo fibroideo inflamatorio', 'Pólipo gástrico', 'Tumor de Vanek', 'Vanek’s tumor', 'DNA damage', 'Salmonella\\n', 'gallbladder', 'gallbladder cancer', 'mucosoid cultures', 'organoid cultures', 'typhoid toxin', 'Roux-en-Y gastric bypass', 'acute gastric dilation', 'bariatric surgery', 'complication', 'image-guided surgery', 'percutaneous gastrostomy', 'Duodenum', 'Gastric cancer', 'Lymphoma', 'Mucosa-associated lymphoid tissue', 'Rituximab', 'Gastrectomy', 'Stomach neoplasms', 'Survival', 'Gastric cancer', 'REC8', 'Tumor angiogenesis', 'VEGF', 'development', 'hedgehog signaling', 'tGLI1', 'target therapy', 'tumor–stroma interaction', 'IFRD1', 'Regeneration', 'cyclical hit model', 'gamma-H2Ax', 'Helicobacter pylori', 'PCR', 'eosin', 'hematoxylin', 'histopathology', 'immunohistochemistry', 'stomach neoplasms', 'E2F3', 'Esophageal squamous cell carcinoma (ESCC)', 'RACGAP1', 'mitotic catastrophe', 'Stomach neoplasm', 'gastrectomy', 'prognosis', 'Robotic-assisted pancreatoduodenectomy (RAPD)', 'case report', 'complication', 'hemorrhage', 'intussusception', 'Height', 'meta-analysis', 'stomach cancer', 'Alternative splicing (AS)', 'gastric cancer (GC)', 'integrative bioinformatics', 'Adenocarcinoma', 'augmentation cystoplasty', 'bladder', 'poorly differentiated', 'signet-ring cells', 'Chinese medicine', 'Clinical trail', 'Cohort study', 'TCM formula', 'Triple-negative breast cancer', 'COVID-19', 'Lian Hua Qing Wen (LHQW)', 'Network pharmacology', 'Traditional Chinese Medicine', 'Analgesic', 'Network pharmacology', 'Pain', 'Radix angelicae dahuricae', 'Rhizoma Corydalis', 'Hematologic neoplasms', 'Liver neoplasms', 'Nationwide', 'Primary immune thrombocytopenia', 'Sweden', 'animal model', 'gastrointestinal stromal tumor', 'neoplasia', 'smooth muscle', 'stomach', 'Arteriovenous malformation', 'Colon cancer', 'Epistaxis', 'Extraintestinal manifestation', 'Telangiectasia', 'Ampullary', 'Computed tomography', 'Duodenum', 'Endoscopic ultrasound', 'Magnetic resonance ımaging', 'Schwannoma', 'Cell line', 'Primary culture', 'Stomach neoplasm', 'XGC-1', 'early gastric carcinoma', 'endoscopic submucosal dissection', 'long-term outcome', 'non-curative resection', 'stomach', 'PD-L1', 'gastric cancer', 'immuno-escape', 'lncRNA SNHG15', 'miR-141', 'Crawling-type adenocarcinoma', 'Early gastric cancer', 'Molecular analysis', 'TP53 mutation', 'Gastrointestinal cancer', 'Illness acceptance', 'Quality of life', 'Strategies for coping with the illness', 'Lynch syndrome', 'extracolonic manifestation', 'pheochromocytoma', 'Autophagic flux', 'CD44', 'Epithelial-to-mesenchymal transition', 'Tumorspheres', 'mTORC1', 'cost-effectiveness of miRNA test', 'gastric cancer screening', 'miRNA cancer screening', 'miRNA test', 'model-based cost-effectiveness', 'laparoscopy', 'minimally invasive surgical procedures', 'stomach neoplasm', 'immunohistochemistry', 'neuroendocrine tumours', 'pancreatic neoplasms', 'rectal neoplasms', 'Adolescent and young adult', 'Germ cell cancer', 'Risk factor', 'Second primary malignancy', 'Seminoma', 'Nasopharyngeal carcinoma', 'Pri-miRNA-encoded protein', 'Tumor suppressor', 'miPEP133', 'miR-34a', 'Chemoradiation therapy', 'Esophageal neoplasm', 'Locoregional recurrence', 'Palliative management', 'R1/R2 resection', 'Clinical curative effect', 'Gastrointestinal stromal tumor', 'Laparoscopic surgery', 'Open surgery', 'Propensity score matching', 'Gastrointestinal stromal tumor', 'Platelet-derived growth factor alpha (PDGFRA)', 'Prognosis', 'Diagnosis', 'Evidence-based medicine', 'Gastrointestinal stromal tumor, small', 'Treatment', 'Duodenogastric reflux', 'Gastric stump cancer', 'Mice, inbred C57BL', 'HSP60', 'TNFR2', 'gastric lymphoma', 'miR-17', 'Duodenal ulcer', 'Gastric cancer', 'Helicobacter pylori', 'Plasticity region', 'dupA gene', 'Gastric cancer (GC)', 'HER2', 'case report', 'targeted therapy', 'trastuzumab', 'tumor mutation burden (TMB)', 'Endoscopic resection', 'Resection margins', 'Residual tumor', 'Stomach cancer', 'Clinical decision rules', 'Diagnostic interval', 'Early detection of cancer', 'Health care reform', 'Neoplasms', 'Primary health care', 'Semiparametric varying-coefficient model', 'Time to diagnosis', 'aspirin', 'cancer', 'metformin', 'Barrett’s esophagus', 'Genome-Wide Association Study', 'Interaction', 'Sex Difference', 'Intraoperative perfusion imaging', 'Isoperistaltic colon interposition', 'Oesophagectomy', 'Supercharged colon conduit', 'Thoracoscopy', 'Chromogranin (CgA)', 'Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)', 'Heterogeneity', 'Ki-67 index', 'Metastasis', 'Synaptophysin (Syn)', 'esophagus', 'gastric neoplasm', 'quality indicators', 'stomach', 'tumor', 'National Health Insurance Research Database', 'eating disorders', 'esophageal cancer', 'stomach cancer', 'Brain', 'Case report', 'Colon', 'Extrahepatic metastasis', 'Hepatocellular carcinoma', 'Stomach', 'Body Composition', 'Prognosis', 'Spiral Computed', 'Stomach Neoplasms', 'Tomography', 'epidemiology', 'occupational & industrial medicine', 'public health', 'gastric cancer', 'gastrointestinal surgery', 'gastrointestinal system', 'orthopaedics', 'stomach and duodenum', 'gastric cancer', 'gastrointestinal surgery', 'radiology', 'gastric cancer', 'gastrointestinal surgery', 'malignant disease and immunosuppression', 'pathology', 'stomach and duodenum', 'Laparoscopy', 'Stomach neoplasms', 'Breast neoplasms', 'Neoplasms, multiple primary', 'Neoplasms, second primary', 'KLF2', 'gastric cancer', 'invasion', 'miR-92a-3p', 'proliferation', 'Apoptosis', 'Cancer', 'Cell cycle arrest', 'Epithelial-mesenchymal transition', 'Flavonoids', 'Hispidulin', 'Metastasis', 'Gastric cancer', 'H. pylori', 'carcinogenesis', 'microbiota', 'double tract reconstruction', 'gastric cancer', 'proximal gastrectomy', 'gastrectomy', 'neoplasm recurrence and metastasis', 'prognosis', 'stomach neoplasms', 'MMP2/MMP9', 'TCGA', 'USP19', 'gastric cancer', 'invasion', 'metastasis', 'prognosis', 'gastrointestinal stromal tumor', 'skin metastasis', 'tyrosine kinase inhibitors', 'Gastric cancer', 'Internal hernia', 'Laparoscopy distal gastrectomy', 'Roux limb syndrome', 'Roux-en-Y reconstruction', 'Epidemiology', 'Gastrointestinal Cancer', 'Markazi', 'Endoscopy', 'Gastrectomy', 'Gastrointestinal', 'Stomach neoplasms', 'Follow-up studies', 'Gastroscopy', 'Precancerous conditions', 'Risk factors', 'Stomach neoplasms', '\\n          Helicobacter pylori\\n        ', 'bacterial recovery', 'extracellular vesicles', 'free-living amphizoic amoebae', 'intracellular multiplication', 'phagosomal pH', 'BUB1 gene', 'bioinformatics', 'gastric cancer', 'survival', 'Mendelian randomization', 'cancer', 'single-nucleotide polymorphisms', 'sleep', 'Duodenum', 'Endoscopy', 'Fluorescein', 'Lower gastrointestinal tract', 'Stomach', 'DNA demethylation', 'NF-κB', 'PD-L1', 'gastric cancer', 'oleanolic acid', 'Gastric/gastroesophageal junction carcinoma', 'Lgr5', 'Stem/progenitor cell', 'active ingredient', 'gastric cancer', 'mechanism of action', 'traditional Chinese medicine', 'breast cancer', 'cancer survivorship', 'cancer-related fatigue', 'gastrointestinal cancer', 'prevalence', 'quality of life', 'Enteroblastic differentiation', 'Prognosis', 'Stomach neoplasms', 'alpha-Fetoproteins', 'Breast neoplasms', 'Colorectal neoplasms', 'Liver neoplasms', 'Lung neoplasms', 'Oesophageal neoplasms', 'Quality of life', 'Stomach neoplasms', 'Nutritional status', 'Stomach neoplasms', 'Survival analysis', 'Bariatric surgery', 'Gastric cancer', 'Gastrointestinal stromal tumor', 'Roux-en-Y gastric bypass', 'Interstitial cells of Cajal', 'Obesity', 'Self-expandable metallic stents', 'CTGF', 'Peritoneal metastasis', 'Stomach neoplasms', 'TGF-β1', 'arsenic poisoning', 'epidemiology', 'observational study', 'standardized incidence ratio', 'standardized mortality ratio', 'Anemia', 'Iron deficiency anemia', 'Leukopenia', 'Lymphopenia', '5-FU, 5-fluorouracyl', 'ACVR2A, activin A receptor type 2A', 'AKT, AKT serine/threonine kinase', 'AR, androgen receptor', 'ATG7, autophagy related 7', 'ATM, ATM serine/threonine kinase', 'BAX, BCL2 associated Xapoptosis regulator', 'BCL2, BCL2 apoptosis regulator', 'BCL2L10, BCL2 like 10', 'BDNF, brain derived neurotrophic factor', 'BLCA, bladder urothelial carcinoma', 'BRCA, breast cancer', 'Biomarker', 'Bp, base pair', 'C-myc (MYCBP), MYC binding protein', 'CASC2, cancer susceptibility 2', 'CD133 (PROM1), prominin 1', 'CDC42, cell division cycle 42', 'CDKN1, Bcyclin dependent kinase inhibitor 1B', 'COAD, colon adenocarcinoma', 'Cancer', 'Circulating miRNA', 'DDR, DNA damage repair', 'E2F family (E2F1, E2F2, E2F3), E2F transcription factors', 'EBV, Epstein-Barr virus', 'EMT, epithelial-to-mesenchymal transition', 'ER, estrogen receptor', 'ERBB (EGFR), epidermal growth factor receptor', 'ESCA, esophageal carcinoma', 'FENDRR, FOXF1 adjacent non-coding developmental regulatory RNA', 'FER1L4, fer-1 like family member 4 (pseudogene)', 'GAS5, growth arrest–specific 5', 'HIF-1α (HIF1A), hypoxia inducible factor 1 subunit alpha', 'HNRNPA1, heterogeneous nuclear ribonucleoprotein A1', 'HNSC, head and neck squamous cell carcinoma', 'HRR, homologous recombination-based DNA repair', 'IFN-γ (IFNG), interferon gamma', 'IGF1, insulin like growth factor 1', 'IL6, interleukin 6', 'IPMK, inositol phosphate multikinase', 'KIRC, clear cell kidney carcinoma', 'KIRP, kidney renal papillary cell carcinoma', 'KRAS, KRAS proto-oncogene, GTPase', 'LIHC, liver hepatocellular carcinoma', 'LMP1, latent membrane protein 1', 'LUAD, lung adenocarcinoma', 'LUSC, lung squamous cell carcinoma', 'Liquid biopsy', 'MAPK, mitogen-activated protein kinase', 'MCM7, minichromosome maintenance complex component 7', 'MET, mesenchymal-to-epithelial transition', 'MTOR, mechanistic target of rapamycin kinase', 'N-myc (MYCN), MYCN proto-oncogene, bHLH transcription factor', 'NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells', 'NOTCH2, notch receptor 2', 'Oncogene', 'PAAD, pancreatic adenocarcinoma', 'PERK (EIF2AK3), eukaryotic translation initiation factor 2 alpha kinase 3', 'PI3K (PIK3CA), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'PIAS3, protein inhibitor of activated STAT 3', 'PRAD, prostate adenocarcinoma', 'RISC, RNA-induced silencing complex', 'SMAD2, SMAD family member 2', 'SMG1, SMG1 nonsense mediated mRNA decay associated PI3K related kinase', 'SNHG1, small nucleolar RNA host gene 1', 'SOCS5, suppressor of cytokine signaling 5', 'STAD, stomach adenocarcinoma', 'STAT3, signal transducer and activator of transcription 3', 'STK4, serine/threonine kinase 4', 'Suppressor', 'TCGA', 'TCGA, The Cancer Genome Atlas', 'TGF-β (TGFB1), transforming growth factor beta 1', 'TGFBR2, transforming growth factor beta receptor 2', 'THCA, papillary thyroid carcinoma', 'TNM, Classification of Malignant Tumors: T - tumor / N - lymph nodes / M – metastasis', 'TP53, tumor protein p53', 'TP53TG1, TP53 target 1', 'TRIAP1, p53-regulating inhibitor of apoptosis gene', 'TSC1, TSC complex subunit 1', 'UCA1, urothelial cancer associated 1', 'UCEC, uterine corpus endometrial carcinoma', 'UTR, untranslated region', 'WDFY3-AS2, WDFY3 antisense RNA 2', 'WEE1, WEE1 G2 checkpoint kinase', 'WNT family, Wingless-type MMTV integration site family/Wnt family ligands', 'ZEB1/ZEB2, zinc finger E-box binding homeobox 1 and 2', 'ceRNA, competitive endogenous RNA', 'cncRNA, protein coding and non-coding RNA', 'lncRNA, long-non coding RNA', 'miR-17-92a', 'miR-18a', 'miRNA', 'CircPRRX1', 'Doxorubicin', 'Exosome', 'Gastric cancer', 'MiR-3064-5p', 'PTPN14', '80 and over', 'aged', 'centenarians', 'mortality', 'neoplasms', 'Bioactive compounds', 'Mechanism insights', 'Origanum majorana', 'Pharmacological actions', 'Traditional use', 'Early gastric cancer', 'Endoscopic resection', 'Lymph node metastasis', 'Stomach neoplasms', 'KLF5', 'cancer biology', 'cell cycle', 'chromatin', 'human', 'oesophageal cancer', 'transcription factors', 'oxygen consumption', 'paradoxical low-flow low-pressure gradient severe aortic stenosis', 'advanced gastric cancer', 'metastatic gastric cancer', 'progressive gastric cancer', 'Nomograms', 'Overall survival', 'Prognostic model', 'Risk score', 'Stomach neoplasms', 'CagA', 'Helicobacter pylori', 'HtrA', 'OMV', 'VacA', 'outer membrane vesicles', 'urease', 'laparoscopiccentralpancreatectomy', 'pancreatogastricanastomosis', 'serouscystadenomaofthepancreas', 'gastrectomy', 'metabolic', 'post-gastrectomysyndromes', 'reconstruction', 'reservoir', 'duplicate left gastric artery', 'laparoscopic gastrectomy', 'stomach cancer', 'Cancer', 'Gout', 'Incidence', 'Dialysis', 'Histiocyte', 'Lanthanum carbonate', 'Mucosal deposition', 'Stomach', 'Free flap', 'Hypopharyngeal neoplasms', 'Life quality', 'Surgery therapy', 'KDM6A', 'Prognosis', 'Stomach neoplasms', 'Gastrointestinal malignancies', 'Sarcopenia', 'Urinary titin', 'Adenocarcinoma', 'Adenosquamous carcinoma', 'Gastric cancer', 'Pembrolizumab', 'Stomach', 'Stomach cancer', 'Colon cancer', 'Early gastric cancer', 'Gastrointestinal stromal tumor', 'Synchronous tumor', 'Cancer', 'Gastrectomy', 'Laparoscopy', 'Perforation', 'Stomach', 'Ulcer', 'Gastric cancer', 'Immune', 'Mutation', 'Prognosis', 'TP53', 'Cancer', 'Colon', 'Gastrectomy', 'Right hemicolectomy', 'Robotic surgery', 'Stomach', 'Technique', 'abdomen', 'mass', 'pathology', 'plasma', 'plasmacytoma', 'surgery', 'Burden of disease study', 'Child maltreatment', 'Cost-of-illness', 'Disability-adjusted life year (DALY)', 'Lifelong health consequences', 'direct expenditure', 'financial burden', 'indirect expenditure', 'medical expenditure', 'non-medical expenditure', 'stomach cancer', 'X-ray computed', 'diagnosis', 'gastric cancer', 'sarcomatoid carcinoma', 'stomach', 'tomography', 'Genotype-Tissue Expression', 'RNA-seq', 'The Cancer Genome Atlas', 'differential expression', 'gastric cancer', 'gender differences', 'gene co-expression networks', 'thyroid cancer', 'CAR cells', 'biomarkers', 'cancer stem cells', 'precision therapy', 'senescence', 'targeted therapy', 'Octopus vulgaris', 'Sepia officinalis', 'digestive tract', 'motility', 'nutrition', 'regurgitation', 'vomiting', 'welfare', 'Gene Expression Omnibus', 'Genotype-Tissue Expression', 'The Cancer Genome Atlas', 'competing endogenous RNA', 'gastric cancer', 'risk score', 'weighted correlation network analysis', 'STAT3', 'Xiaoai Jiedu Recipe', 'cell behaviors', 'hepatocellular carcinoma', 'microRNA-29a', 'PIWI', 'gastric cancer', 'human', 'nonsense-mediated mRNA decay', 'piRNA', 'cancer', 'epidemiology', 'health surveillance', 'rubber', 'Biodegradation', 'DNMP', 'DNMP reductase', 'LC-MS/MS', 'Meat preservatives', 'Nitrite', 'Nitroreductase', 'Sorbate', 'Ivor Lewis', 'distal gastrectomy', 'esophageal carcinoma', 'esophagogastrostomy', 'remnant stomach', 'biliary intervention', 'cancer intervention', 'endocrine cancer', 'gastrointestinal system', 'pancreas and biliary tract', 'CRISPR/Cas9', 'cell survival', 'chemoresistance', 'exon skipping', 'morpholinos', 'stomach neoplasms', 'Gastrin', 'Gastroscopy', 'Helicobacter pylori', 'Magnetic capsule gastroscopy', 'Pepsinogen', 'Screening', 'Stomach neoplasms', 'Chemotherapy', 'Laparoscopy', 'Peritoneal metastasis', 'Stomach neoplasms', 'Case-control study', 'Drinking water', 'Gastric cancer', 'Carcinoma', 'Location', 'Prognosis', 'Stomach', 'TCGA', 'Bayesian network', 'Gastrointestinal cancer', 'Group LASSO', 'acute kidney injury', 'disease prediction', 'machine learning', 'Anticancer therapy', 'NF-kB modulator', 'Sesquiterpene', 'Sesquiterpene derivatives', 'Structure activity relationship', 'acetylcholine', 'cisplatin', 'curcumin', 'gastric emptying', 'interstitial cells of Cajal', 'Anastomotic leakage', 'Double-lumen feeding tube', 'Percutaneous transesophageal gastro-tubing', 'Transnasal drainage', 'Upper GI surgery', 'Endoscopic mucosal resection', 'Lymph node metastasis', 'Stomach neoplasms', 'Treatment outcome', 'Undifferentiated-type histology', 'PD1', 'PDL1', 'Pembrolizumab', 'bile tract cancer', 'lenvatinib', 'gastric cancer', 'neutrophil-lymphocyte ratio', 'postoperative cognitive dysfunction', 'risk factor', 'Helicobacter pylori', 'Lymphoma, B-Cell, Marginal zone', 'Prognosis', 'Stomach neoplasms', 'Microenvironment - feedback', 'Parasympathetic', 'Sensory', 'Sympathetic', 'Vagus nerve', 'Allergy', 'Anisakiasis', 'Anisakis', 'Control', 'Diagnosis', 'Seafood-borne disease', 'Adjuvant', 'Gastrointestinal stromal tumour', 'Imatinib', 'Características', 'Characteristics', 'Cáncer gástrico', 'Diagnóstico temprano', 'Early diagnosis', 'Endoscopic treatment', 'Gastric cancer', 'Tratamiento endoscópico', 'PD-L1', 'advanced GC', 'genetic alterations', 'meta-analysis', 'prognostic factor review', 'recurrence pattern', 'signet-ring cell', 'Helicobacter pylori', 'Lactobacillus casei', 'Lactobacillus fermentum', 'Lactobacillus rhamnosus', 'amino acids', 'fatty acids', 'biomarker', 'immunotherapy', 'microsatellite instability', 'tumor microenvironment', 'tumor-infiltrating immune cells', 'Distal pancreatectomy', 'Extended surgery', 'Left-sided pancreatic cancer', 'Lymph node ratio', 'Multivisceral resection', 'Pancreatic fistula', 'Autoencoders', 'Cancer', 'Classification', 'Deep learning', 'Gene expression analysis', 'Deleterious  Single  Nucleotide  Polymorphisms', 'Evolutionary conservation', 'Integrin  αV', 'Ligand binding site prediction', 'Post  translational  modifications', 'Three-dimensional modelling', 'Curative treatment', 'Esophageal cancer', 'Gastric cancer', 'Health-related quality of life', 'Patient-reported outcome', 'Quality-of-Life questionnaire', 'Cancer risk', 'China', 'Environmental tobacco smoke', 'Non-smokers', 'Prospective cohort study', 'Smoking-related cancers', 'immunocytochemistry', 'lung adenocarcinoma', 'pleural effusion cytology', 'reactive mesothelial cells', 'single-cell pattern', 'Colonic adenocarcinoma', 'Colonic neuroendocrine neoplasm', 'Descending colon', 'Large cell neuroendocrine carcinoma', 'gastroenterology', 'gastrointestinal neoplasms', 'stomach neoplasms', 'COVID-19', 'Cancer', 'Oesophageal Cancer', 'Oesophagectomy', 'Pandemic', 'Adenocarcinoma', 'Adjuvant treatment', 'Adénocarcinome', 'Cancer de l’estomac', 'Cancer du pancréas', 'Chemoradiation', 'Chimioradiothérapie', 'Gastric cancer', 'Neoadjuvant treatment', 'Pancreatic cancer', 'Radiothérapie stéréotaxique', 'Stereotactic body radiation therapy', 'Traitement adjuvant', 'Traitement néoadjuvant', 'CDH1', 'E-cadherin', 'hereditary diffuse gastric cancer', 'therapy', 'tumorigenesis', 'Enhanced recovery after surgery', 'Retrospective Cohort study', 'Stomach neoplasms', 'Digestive tract reconstruction', 'Perception', 'Proximal gastrectomy', 'Questionnaire survey', 'Treatment selection', 'gastrectomy', 'gastric outlet obstruction', 'palliative care', 'stomach neoplasms', 'AMPK', 'Glioma', 'Loss-of-function', 'Pan-cancer', 'Tumor metabolism', 'AXIN2', 'Gastric adenomas', 'Hereditary cancer syndrome', 'Hereditary colorectal cancer', 'Hereditary polyposis', 'Hypodontia', 'Olfactory neuroblastoma', 'Alpha-fetoproteins', 'Clear cell adenocarcinoma', 'Colonic neoplasms', 'Endoscopy', 'Enteroblastic differentiation', 'Chinese burden of cancer', 'Joinpoint analysis', 'age–period–cohort analysis', 'mortality and incidence', 'trend', 'STAD', 'ceRNA', 'lncRNA', 'mutation', 'prognostic marker', 'Dolichos lablab L.', 'HO-1', 'Nrf2', 'SRMD', 'cytoprotection', 'Anatomical classification', 'Artificial intelligence', 'Convolutional neural network (CNN)', 'Endoscopy', 'Upper gastrointestinal tract', 'Everolimus', 'Lanreotide', 'Neuroendocrine tumors', 'Randomized controlled trial', 'ECL cell', 'carcinogenesis', 'cell of origin', 'dormancy', 'gastric cancer', 'gastrin', 'hormones', 'Cancer epidemiology', 'Cancer incidence', 'Costa Rica', 'Latin America', 'Social gradient', 'Social inequalities', 'Helicobacter pylori', 'Iran', 'Peptic ulcer disease', 'vacA genotypes', 'Cre recombinase', 'Lgr5', 'clonality', 'field cancerization', 'metaplasia', 'stem cells', 'Gastritis', 'Incidence', 'Lynch syndrome', 'Stomach neoplasms', 'atrophic', 'Bioinformatical analysis', 'G2/miotic-specific cyclin B1 (CCNB1)', 'differentially expressed genes (DEGs)', 'gastric cancer (GC)', 'pituitary tumor-transforming gene-1 (PTTG1)', 'polo-like kinases 1 (PLK1)', 'survival', 'Borrmann type', 'Clinicopathological features', 'Gastric cancer', 'Prognosis', 'Endoscopic submucosal dissection', 'Gastric cancer', 'Lymphovascular invasion', 'Papillary adenocarcinoma', 'Bariatric surgery', 'Cancer', 'Colorectal', 'Early-onset', 'Obesity', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'n', 'o', 'n', 'e', 'Gastrointestinal cancers', 'Iran', 'Mortality rate', 'Projection', 'Trend', 'asbestos', 'epithelioid mesothelioma', 'esophagogastroduodenoscopy', 'neoplasm', 'retroperitoneal', 'The Cancer Genome Atlas', 'bioinformatics', 'biomarker candidates', 'limb-bud and heart', 'stomach neoplasms', 'European and Asian diversity', 'biomarkers', 'gastric cancer', 'gastric microbiome', 'miQTL', 'microbiome quantitative trait loci', 'awareness', 'cancer prevention knowledge', 'cohort study', 'risk of cancer', 'rural China', 'Endoscopic submucosal dissection', 'Function preserving gastrectomy', 'Metachronous gastric cancer', 'Proximal gastrectomy', 'Pylorus preserving gastrectomy', 'Neoadjuvant chemotherapy', 'Pathological assessment', 'Prognosis', 'Stomach neoplasms', 'Tumor regression grade', 'Atrial natriuretic peptide', 'Gastric cancer', 'Hedgehog (Hh) signaling pathway', 'Invasion', 'Matrix metalloproteinases-9 (MMp-9)', 'Migration', 'Binding pocket prediction', 'Conformational alteration', 'Domain characterization', 'Integrin αV subunit', 'Molecular modelling', 'Stability assay', 'AUC', 'cancer prognosis', 'mixture cure model', 'survival analysis', 'time-dependent ROC curve', 'Case report', 'Duodenoscopy', 'Endoscopic mucosal resection', 'Neoplasm', 'Pylorus', 'Stomach', 'Antimicrobial defense', 'Helicobacter pylori (H. pylori)', 'plasticity', 'stem cells', 'stomach', 'CTLA-4', 'Gastrointestinal cancer', 'Immunotherapy', 'MSI', 'PD-1', 'Alopecia neoplastica', 'Breast cancer', 'Gastrointestinal metastasis', 'Endoscopic resection', 'Gastric cancer', 'High-grade dysplasia', 'Low-grade dysplasia', 'Risk factors', 'Dysplasia', 'Gastric', 'Hereditary', 'Polyp', 'Polyposis', 'Stomach', 'Epidemiology', 'Healthcare Disparity', 'Helicobacter pylori', 'Stomach Cancer', 'Eradication Failure', 'Gastric cancer', 'Helicobacter pylori', 'New therapeutic strategies', 'Peptic ulcers', 'Refractory\\nHelicobacter pylori infection ', 'DNA methylation', 'DNA methyltransferase', 'Pacbio', 'SMRT', 'epigenetics', 'epigenome', 'gastric cancer', 'methylome', 'gastric cancer', 'nanoparticles', 'pharmacokinetics', 'polydopamine', 'target', 'xanthatin', 'cancer', 'dairy products', 'diet', 'gut microbiota', 'ketogenic diet', 'malnutrition', 'meat', 'mediterranean diet', 'milk', 'nuts', 'personalized medicine', 'short chain fatty acids', 'vegetarian diet', 'Cancer prevention', 'Education', 'Helicobacter pylori', 'Screening', 'Stomach cancer', 'Esophageal cancer', 'Gastric conduit', 'Gastric mucosa-associated lymphoma', 'Surgery', 'Acute abdomen', 'Anti-VEGF', 'Cancer chemotherapy', 'Chemotherapy', 'Emergency surgery', 'ACE2', 'COVID-19', 'cancer', 'immune infiltration', 'Bufothionine', 'ER stress', 'Gastric cancer', 'MiR-133a-3p', 'Krukenberg tumors', 'ovarian masses', 'ovarian metastasis', 'LA-ICP-MS', 'lanthanum', 'macrophage', 'mass spectrometry imaging', 'toxicology', 'Sherlock integrative analysis', 'eSNP', 'gastric cancer', 'gene-based analysis', 'genome-wide association study', 'D2 gastrectomy', 'chemoradiotherapy', 'gastric cancer', 'radiation therapy', 'stomach cancer', 'DNA repair', 'apoptosis', 'chemoresistance', 'epithelial-mesenchymal transition', 'gastric cancer', 'metabolism', 'refractoriness', 'stomach', 'transport', 'tumor environment', 'Epstein-Barr Virus', 'gastric inflammation', 'helicobacter pylori', 'nonatrophic gastritis', 'pediatric dyspepsia', 'SHIVA02 trial', 'core biopsy', 'fine-needle aspiration', 'next-generation sequencing', 'precision medicine', 'tumour molecular profiling', 'Laparoscopy', 'Minimally invasive surgical procedures', 'Stomach neoplasm', 'Three-dimensional', 'Agitation', 'Anesthesia', 'Desflurane', 'Recovery period', 'Sevoflurane', 'Aprepitant', 'Cancer', 'Gastrointestinal complaints', 'Rat', 'Lymphadenectomy', 'Neoplasm', 'Para-aortic lymph node', 'Stomach', 'Age-standardized rate', 'Cancer epidemiology', 'Esophageal cancer', 'Gastric cancer', 'Mongolia', 'Early death', 'Nomogram', 'SEER', 'Stage IV', 'Stomach neoplasm', 'Chronic atrophic gastritis', 'Computer-aided diagnosis', 'Convolutional neural network', 'Deep learning', 'Gastric X-ray images', 'Gastric cancer risk', 'Helicobacter pylori', 'activity of daily living', 'bone metastasis', 'cancer pain', 'pharmacist', 'topical non-steroidal anti-inflammatory drug', 'Case report', 'EWDA of the stomach', 'Endoscopic submucosal dissection', 'Preoperative biopsy', 'Submucosal tumor', 'Conversion surgery', 'Gastric cancer', 'Immune check point inhibitor', 'Immunotherapy', 'Cancer', 'Direct oral anticoagulant', 'Guidelines', 'Low molecular weight heparin', 'Risk factors', 'Thromboprophylaxis', 'Venous thromboembolism', 'COVID-19', 'Coronavirus', 'SARS-CoV-2 interacting proteins', 'USP13', 'Ubiquitin Specific Peptidase 13', 'Complications', 'Gastric ulcer', 'Oesophageal cancer', 'Oesophagectomy', 'Pseudoaneurysm', 'autonomic dysfunction', 'neuropathology', 'peripheral autonomic system disorder', 'pure autonomic failure', 'α-synucleinopathy', 'foot', 'glomangioma', 'glomus tumor', 'soft tissue', 'tumor', 'Connexins', 'gastric cancer', 'prognosis', 'Gastric cancer', 'gastrectomy', 'psoas muscle', 'survival rate', 'Helicobacter pylori', 'Next generation sequence', 'Signet ring cell carcinoma', 'Smoking', 'Uninfected', 'Antineoplastic combined chemotherapy protocols', 'Gastroscopy', 'Neoplasm staging', 'Stomach neoplasms', 'Tomography, X-ray computed', 'cancer survivors', 'colorectal neoplasms', 'diet', 'esophageal neoplasms', 'gastrointestinal neoplasms', 'stomach neoplasms', 'adjuvant chemotherapy', 'gastric cancer', 'perioperative chemotherapy', 'surgery', 'survival', 'anastomotic leakage', 'esophageal surgery', 'quality of life', 'reconstruction', 'subtotal stomach', 'C‐reactive protein', 'gastrectomy', 'intra‐abdominal fat', 'postoperative complications', 'stomach neoplasms', 'S-1', 'advanced stomach cancer', 'immune function', 'palliative care', 'quality of life', 'Operative Link for Gastritis Assessment', 'endoscopy', 'gastric cancer', 'neutrophil to lymphocyte ratio', 'numerical rating scale', 'pain', 'FBXW7', 'Siewert classification', 'esophageal adenocarcinoma', 'gastric cancer', 'gastroesophageal junction', 'genomic features', 'whole-exome', 'cancer', 'pulmonary embolism', 'registry', 'thrombosis', 'venous thromboembolism', '13C-urea breath test', 'Children', 'Gastrointestinal system', 'Health sciences', 'Helicobacter pylori', 'Infection', 'Infectious disease', 'Jordan', 'Laboratory medicine', 'Pediatrics', 'biomarker', 'neutrophil extracellular traps', 'peripheral blood', 'prognosis', 'stomach neoplasms', 'Average lifespan shortened', 'Average years of life lost', 'Premature mortality', 'Stomach cancer', 'Years of life lost', 'Image-enhanced endoscopy', 'Metastatic gastric tumor', 'Squamous-cell carcinoma of the cervix', 'Stomach cancer', 'circRNA', 'lncRNA', 'miRNA', 'piRNA', 'Fruit', 'Helicobacter pylori', 'Vegetable', 'stomach cancer', 'tobacco smoking', 'Cancer metastasis', 'Early diagnosis', 'Gastric cancer', 'Malignant transformation', 'MiR-135b', 'Poor prognosis', 'Gastrointestinal tract', 'Malakoplakia', 'Pathology', 'anamorelin', 'appetite loss', 'bladder neoplasm', 'chemotherapy', 'cisplatin', 'gemcitabine', 'mucositis', 'muscle atrophy', 'sarcopenia', 'urothelial cancer', 'ABVD protocol', \"Hodgkin's lymphoma\", 'Immunohistochemistry', 'Lymphadenopathy', 'Primary gastric lymphoma', 'Epidemiology', 'Gastric cancer', 'Tlemcen (Algeria)', 'Gastric gastrointestinal stromal tumor', 'Gender', 'Propensity score matching', 'Enhanced delivery', 'Formulation', 'Microencapsulation', 'Polymeric carriers', 'Probiotics', 'atrophic gastritis', 'diagnostic performance', 'gastropanel', 'noninvasive markers', 'Focus groups', 'Gastric cancer', 'Helicobacter pylori', 'Indigenous health', 'Qualitative research', 'Circular-stapled anastomosis', 'Double-tract reconstruction', 'Laparoscopic proximal gastrectomy', 'CCN1', 'Esophageal cancer', 'NFkB', 'TRAIL', 'esophageal cells', 'gastroesophageal reflux disease (GERD)', 'p53', 'Atrophy', 'Endoscopy', 'Helicobacter pylori', 'Stomach neoplasms', 'Dithiocarbamate derivative', 'Epithelial-mesenchymal transition (EMT)', 'Ferritinophagy', 'Iron chelator', 'ROS', 'p53/AKT/mTor', 'extracutaneous melanoma', 'gastrointestinal melanoma', 'melanoma', 'mucosal melanoma', 'stomach', 'age-related trends', 'gastric adenocarcinoma', 'young adults', 'benign anastomotic stricture', 'esophageal cancer', 'gastric conduit', 'Radical surgery for distal gastric cancer', 'Recanalization of closed point', 'Stomach neoplasms', 'Uncut Roux-en-Y anastomosis', 'D2 radical surgery', 'Membrane anatomy', 'Neoadjuvant chemotherapy', 'Stomach neoplasms', 'D2 procedure', 'Laparoscope', 'Mesogastrium', 'Stomach neoplasms', 'Gastric mesentery', 'Membrane anatomy', 'Stomach neoplasms', 'Cancer', 'DP-CAR', 'Pancreas', 'Surgery', 'ecological factors', 'environmental factor', 'review', 'stomach cancer', 'EDGE', 'ERCP', 'Endoscopic ultrasound', 'Gastric bypass', 'Gastrogastrostomy', 'Pancreatic cancer', 'Roux-en-Y', '99mTc', 'Molecular Imaging', 'Oncology: GU', 'PHC-102', 'SPECT/CT', 'Single-Photon Emission Computed Tomography', 'carbonic anhydrase IX', 'clear cell renal cell carcinoma', 'Hepatoid adenocarcinoma of the stomach', 'Non-hepatoid adenocarcinoma of the stomach', 'Overall survival', 'Prognosis', 'active cancer', 'cancer', 'cancer associated thrombosis (CAT)', 'low molecular weight heparins (LMWHs)', 'thromboprophylaxis', 'thrombosis', 'FAK', 'Gastric cancer', 'Nexrutine', 'STAT3/NF-κB pathway', 'Esophageal cancer', 'Gastric remnant', 'Pedicle jejunum', 'Postoperative', 'Reconstruction', 'Sunitinib', 'adenosine triphosphate', 'cutaneous side effects', 'oxidative stress', 'protective effect', 'Classification', 'Diagnostic imaging', 'Neuroendocrine cells', 'Neuroendocrine neoplasm', 'Phenotype', 'Somatostatin', 'Hepatocellular cancer', 'Intensity-modulated proton therapy', 'Machine learning', 'RapidArc', 'Volumetric modulated arc therapy', 'cervical carcinoma', 'lymphangitis carcinomatosis', 'pulmonary microvascular tumor embolism', 'pulmonary tumor thrombotic microangiopathy', 'ARN no codificante largo', 'Cáncer gástrico', 'Gastric cancer', 'Long non-coding RNA', 'Modelo predictivo', 'Predictive model', 'Anti-HER2 therapy', 'HER2', 'Metastatic gastric cancer', 'Review', 'Trastuzumab', 'Helicobacter pylori', 'gastric cancer', 'methylation', 'pepsinogen', 'screening', 'Biomarkers', 'Immunotherapy', 'Remnant\\xa0gastric cancer', 'Stomach neoplasms', 'Targeted therapy', 'colonic stricture', 'gastric cancer', 'signet ring cell type carcinoma', 'CLDN18', 'biological network', 'gastric cancer', 'gene expression', 'prognosis', 'FDG/PET-CT', 'head and neck metastasis', 'neck dissection', 'remote primary', 'survival analysis.', 'Macrophage: Infiltration', 'Ovarian Serous Cystadenocarcinoma', 'Stomach adenocarcinoma', 'TAMs', 'TP53', 'Antioxidant', 'Cytoprotective', 'Isothiocyanate', 'Nutrigenomics', 'Sequencing', 'esophageal cancer', 'fecal immunochemical test', 'gastric cancer', 'small intestine cancer', 'cancer survivor', 'employment', 'occupational therapy', 'pilot projects', 'return to work', 'work rehabilitation', 'circular RNA', 'gastric cancer', 'm6A modification', 'poorly differentiated adenocarcinoma', 'gastric cancer', 'individual detection', 'preoperative neutrophil-to-lymphocyte ratio', 'tumor markers', 'antitumor agents', 'metallodrug', 'nanoformulation', 'oral administration', 'titanium', 'Endoscopic gastric atrophy', 'Kimura-Takemoto classification', 'Risk stratification', 'Stomach neoplasmsMeta-analysis', 'carcinogenicity', 'meta-analysis', 'night-shift work', 'odds ratio', 'risk factor', 'Cell signalling', 'Stomach diseases', 'Atrophic gastritis', 'Gastric cancer', 'Intestinal metaplasia', 'Operative link for gastritis assessment', 'Operative link on gastric intestinal metaplasia assessment', 'TAIM', 'adenocarcinoma', 'hyperplastic polyp', 'neuroendocrine tumor', 'stomach', 'adaptive radiotherapy', 'multi-organ segmentation', 'pancreatic radiotherapy', 'treatment planning', 'Bowel', 'Computed tomography', 'Endoscopy', 'Inter-observer variability', 'Malignancy', 'Endosonography', 'Gastric bypass', 'Gastric outlet obstruction', 'Prostheses and implants', '5-Fluorouracil', 'Crosslinked dextran nanoparticles', 'Dextranase responsive delivery system', 'Telechelic oligoester', 'Chemotherapy', 'Drug resistance', 'Gastric cancer', 'Molecule-targeted therapy', 'Monoclonal antibodies', 'Small-molecule drugs', 'Targeted drugs', 'gastric cancer', 'signet ring', 'Aged', 'Comorbidity', 'Endoscopic mucosal resection', 'Stomach neoplasms', 'Bilingual', 'Cancer data', 'Cancer information', 'Cross language', 'HealthNLP', 'Medical parallel corpus', 'gastric cancer', 'lncRNA', 'nomogram', 'overall survival', 'signature', 'Deep inspiration breath-hold', 'Gastric lymphoma', 'Heart dose', 'NSAIDs', 'factorial design', 'formulation', 'peptic ulcer', 'pharmacokinetics', 'stomatitis', 'Biomarker', 'Gastric cancer', 'Therapeutic response', 'miRNA', 'Cancers', 'Occupational cohorts', 'Radon exposure', 'Uranium miners', 'Gene expression omnibus', 'Lung adenocarcinoma', 'Purinergic receptors', 'Pyrimidine metabolic rate–limiting enzymes', 'The Cancer genome atlas', 'Phase III', 'clinical trial', 'gastric cancer', 'omentectomy', 'omentum preservation', 'omentum preserving gastrectomy', 'CagA', 'Gastric adenocarcinoma', 'Interleukin-6', 'PKCδ', 'eEF1A1', 'p-STAT3S727', 'Cancer', 'Clinical translation', 'Gene delivery', 'Gene editing', 'Non-viral vectors', 'in vivo', 'Chemotherapy', 'Curcumin', 'Curcuminoids', 'Gastric cancer', 'Systematic review', 'esophagectomy', 'hand-assisted laparoscopic surgery', 'stomach', 'Proximal gastrectomy', 'Quality of life', 'Reconstruction', '3,3′-Diindolylmethane', 'MDM2', 'cancer prevention', 'colorectal cancer', 'p53', 'Acute abdomen', 'Gastrointestinal stromal tumor', 'Perforation', 'Bayesian networks', 'The Cancer Genome Atlas', 'genomic and epigenomic molecular data', 'methylation', 'mixed mutual information', 'multimodal big data', 'variable selection', 'Cancer', 'Direct oral anticoagulants', 'Venous thromboembolism', 'Lymph node Metastasis', 'Non-curative resection', 'Risk factors', 'Stomach neoplasms', 'Undifferentiated-type histology', 'Chronic laryngitis', 'Gastritis', 'H. pylori', 'Laryngeal carcinoma', 'Gastric cancer', 'postoperative infectious complications', 'prognostic factor', 'Avoidable deaths', 'Cohort studies', 'Coronary heart disease', 'Diabetes', 'Mortality', 'Gastrectomy', 'Linitis plastica', 'Lymphatic metastasis', 'Neoadjuvant chemotherapy', 'Stomach neoplasm', 'Stomach', 'left gastric artery', 'lymph node (LN)', 'neoplasm', 'prognosis', 'abdominoperineal resection', 'gastric outlet obstruction', 'internal hernia', 'stoma-associated complication', 'The Cancer Genome Atlas', 'gastric cancer', 'serine/arginine-rich splicing factor 10', 'splicing factor', 'Colorectal cancer', 'Esophageal neoplasms', 'Stomach neoplasms', 'GIST', 'Meckeldiverticulum', 'acuteabdomen', 'Artificial intelligence', 'Cancer management', 'Diagnosis', 'Gastric cancer', 'Treatment', 'R-CHOP', 'endoscopic ultrasonography', 'primary gastric diffuse large B-cell lymphoma', 'prognosis', 'Chinese cancer research', 'anatomical site', 'burden of disease', 'comparison with GDP', 'research type', 'angiogenesis inhibitor', 'gastric cancer', 'pulmonary tumor thrombotic microangiopathy', 'transbronchial lung biopsy', 'cancer epidemiology', 'gastrointestinal neoplasia', 'screening', 'Lynch syndrome', 'Microsatellite instability', 'Mismatch repair gene', 'Somatic mutation', 'Turcot’s syndrome type 1', 'Bibliometric Analysis', 'Cancer Epidemiology', 'Research Funding', 'Socio-Economic Influences', 'Stomach Cancer', 'Carcinoma, hepatocellular', 'Diagnosis, differential', 'Hepatoid adenocarcinoma', 'Liver neoplasms', 'Neoplasm metastasis', 'MIR100HG', 'bioinformatics analysis', 'gastric cancer', 'lncRNAs', 'Fluorescence-guided surgery', 'Gastric cancer', 'Indocyanine green', 'Lymphadenectomy', 'Navigation surgery', 'Gastrointestinal inflammation', 'National guidelines', 'Oral cancer', 'Routine panendoscopy', 'Synchronous second primary cancer', 'Endoscopic mucosal resection', 'Endoscopy', 'Recurrence', 'Stomach neoplasms', 'AGS gastric cancer', 'adzuki bean', 'digestion in vitro', 'mung bean', 'phenolics', 'probiotic', 'sprouts', 'body weight loss', 'calorie intake', 'diet therapy', 'gastrectomy', 'stomach neoplasm', 'Gastric cancer', 'Helicobacter pylori', 'Immunomodulation', 'Inflammation', 'Metabolization', 'stage IV gastric cancer', 'systemic inflammatory', 'systemic inflammatory response', 'atrophy', 'cyclooxygenase-2', 'dysplasia', 'metaplasia', 'Breast cancer', 'Germline mutation', 'Mongoloid race', 'JNK inhibitors', 'MAP2K7', 'MBNL1', 'alternative splicing', 'tumor cell dedifferentiation', 'Cáncer gástrico', 'Gastrectomy', 'Gastrectomía', 'Gastrectomía subtotal', 'Gastrectomía total', 'Gastric cancer', 'Subtotal gastrectomy', 'Total gastrectomy', 'Biomarker', 'Microsatellite instability', 'Prognosis', 'Recurrence', 'Stomach neoplasms', 'Adjuvant chemotherapy', 'Microsatellite instability', 'Stomach neoplasms', 'Cancer', 'Complication', 'Difference', 'Fear', 'Sex', 'inflammation', 'malnutrition', 'mortality', 'skeletal muscle', 'stomach cancer', 'Balloon enteroscope', 'Balloon puncturing method', 'Elevated jejunum', 'Percutaneous jejunal tube insertion', 'Helicobacter pylori', 'environmental factors', 'human genetic factors', 'peptic ulcer', 'stomach cancer', 'TLR 7', 'X chromosome', 'Yakuts', 'hepatocellular cancer', 'male gender', 'risk factors', 'single nucleotide polymorphisms', 'Epithelial-mesenchymal transition', 'Prognosis', 'Stomach neoplasms', 'miR-205', 'Cardia', 'Gastric cancer', 'Non-cardia', 'Tumor location', 'Tumor-infiltrating lymphocytes', 'Gastrectomy', 'Quality of life', 'Stomach neoplasms', 'Endoscopic submucosal dissection', 'Lymphovascular invasion', 'Stomach neoplasm', 'Submucosal invasion', 'LETM1 protein, human', 'Phosphatidylinositol 3 kinase', 'Protein kinase B', 'Stomach neoplasms', 'Endoscopic marking', 'Gastric cancer', 'India ink tattooing', 'Totally laparoscopic distal gastrectomy', 'Gastrectomy', 'Hypertension', 'Non-obese non-diabetic', 'Biomarker', 'FBXO47', 'Gastric cancer', 'tRNA-derived fragment', 'Cohort effects', 'cancer', 'mortality', 'vital statistics', 'CD44', 'Gastric cancer', 'HER-2/neu', 'Ki-67', 'p53', 'Carcinogenesis', 'Gastric cancer', 'Microbiota', 'Stomach', 'Antitumor', 'FB-15', 'HIF-1α', 'MGC-803', 'Tubulin', 'Food factor', 'HO-1', 'Keap-1', 'NSAID-Induced GI damages', 'Nrf-2', 'Walnut', '3D culture', 'Gastrointestinal tract', 'Intestine', 'Organoids', 'Stomach', 'Carcinomas', 'Clioquinol', 'Treatment', 'Zinc', 'Cancer', 'expression', 'methylation', 'mutation', 'spleen tyrosine kinase', 'survival rate', 'HER-2; docking', 'dynamic simulation', 'fragment-based', 'in vitro cytotoxic effect. ', 'virtual screening', 'esophageal neoplasm', 'gastrointestinal neoplasms', 'healthy diet', 'stomach neoplasms', 'Gastric cancer; Signet ring cell', 'Helicobacter pylori; Prognosis; Outcome; H.pylori', 'MALT lymphoma', 'MALToma', 'gastrointestinal bleed', 'COL5A1', 'Gastric cancer', 'HOTAIR', 'Immune infiltration', 'MiR-1277-5p', 'Bcl-2', 'chemotherapy', 'dihydropyrimidine dehydrogenase', 'emphysematous pancreatitis', 'gastric cancer', 'ESTIMATE algorithm', 'Prognosis', 'Stomach adenocarcinoma', 'TCGA', 'Tumour microenvironment', 'gastric cancer', 'neuroendocrine cell differentiation', 'prognosis', 'surgical treatment', 'carcinoid', 'endoscopic resection', 'neuroendocrine tumors', 'stomach neoplasms', 'Gastric neoplasms', 'Gastric outlet obstruction', 'Palliative operation', 'Stomach-partitioning gastrojejunostomy', 'Adenocarcinoma, esophagogastric junction', 'Disease attributes', 'Hemorrhage', 'Prognosis', 'Survival', 'cardia', 'esophageal neoplasms', 'ethnic groups', 'mortality', 'race', 'stomach neoplasms', 'neuroendocrine tumor', 'Carcinoid tumor', 'gastroenteropancreatic neuroendocrine tumor', 'Histopathological tumor regression', 'Locally advanced gastric cancer', 'Neoadjuvant chemotherapy', 'Overall survival', 'Posttherapy nodal status', 'Laparoscopic cancer surgery', 'Minimally invasive treatment', 'Robotic cancer surgery', 'Intensity-modulated proton therapy', 'Intensity-modulated radiotherapy', 'Normal tissue complication probability', 'Pancreatic cancer', 'Inflammation', 'Inhibitory Signal', 'Monocyte', 'Programmed Cell Death 1 Ligand 1', 'CLCA4', 'colorectal cancer', 'development', 'prognosis', 'survival', 'cancer', 'conflict', 'low-income countries', 'middle-income countries', 'systematic review', 'war', 'Extranodal lymphoma', 'lesion biopsy', \"non-Hodgkin's lymphoma\", 'periapical lesion', 'pulp vitality testing', 'Dysplasia', 'EGC', 'Endoscopic resection', 'Stomach cancer', 'C-kit', 'Epstein-Barr virus', 'Gastrointestinal stromal tumour', 'Leiomyosarcoma', 'Stomach', 'AIM2', 'CCL19/CCR7', 'Gastric cancer', 'Inflammation', 'Tumor growth', 'complication', 'gastric cancer', 'immune inflammation-based score', 'lymphocyte-c-reactive protein ratio', 'prognosis', 'FAM83H', 'SCRIB', 'cancer', 'stomach', 'β-catenin', 'Anti-oxidation', 'Autophagy', 'Natural bioactive compound', 'Preventive therapy', 'Toona sinensis', 'Cancer', 'Epidemiology', 'Liver metastasis', 'cancer', 'prevalence', 'risk', 'stroke', 'Aged 80', 'Elderly', 'Surgery', 'Helicobacter pylori', 'culture', 'gastric microbiota', 'microbiome', 'persistent', 'sequencing', 'transient', 'FDG', 'Ga-68 DOTA-peptides', 'MRI', 'NET', 'PET', 'chemotherapy', 'colon/rectal cancer', 'molecular genetics', 'Complete remission', 'Hepatocellular carcinoma', 'Lung metastases', 'Sorafenib', 'Adenocarcinoma', 'Heterotopic pancreas', 'SSPPD', 'polyps', 'stomach neoplasms', 'ulcerative colitis', 'Cancer', 'Golestan', 'Incidence', 'Iran', 'Prediction', 'FMNLs', 'gastric cancer', 'immune infiltrating', 'prognosis', 'LY6E', 'colorectal cancer', 'dendritic cell', 'dendritic cell tumor-associated antigen therapy', 'Immunocytochemistry', 'Scrape cellblock', 'Unknown primary', 'VEGFR2 inhibitor', 'apatinib', 'gastric cancer', 'non-intervention', 'adoptive cell transfer', 'gastric cancer', 'hydrogels', 'interferon-α2b', 'low-dose irradiation', 'BLADE and gastric cancer', 'FDG, PET/MR, PET/CT, HASTE', 'CDH1', 'E-cadherin', 'cancer', 'chemotherapy', 'diffuse type', 'histopathology', 'radiotherapy', 'surgery', 'Date of incidence', 'International variation', 'Registration practice', 'Survival', 'SEER database', 'nomogram', 'prognosis', 'stomach neoplasm', 'Lymph node metastasis', 'Occult gastric cancer', 'Skip lymphatic metastasis', 'ACC, adrenocortical carcinoma', 'BLCA, bladder urothelial carcinoma', 'BRCA, breast invasive carcinoma', 'CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma', 'CHOL, cholangiocarcinoma', 'COAD, colon adenocarcinoma', 'ESCA, esophageal carcinoma', 'Function', 'GBM, glioblastoma multiforme', 'HNSC, head and neck squamous cell carcinoma', 'IsomiR', 'KICH, kidney chromophobe', 'KIRC, kidney renal clear cell carcinoma', 'KIRP, kidney renal papillary cell carcinoma', 'LAML, acute myeloid leukemia', 'LGG, brain Lower grade glioma', 'LIHC, liver hepatocellular carcinoma', 'LUAD, lung adenocarcinoma', 'LUSC, lung squamous cell carcinoma', 'Let-7', 'MESO, mesothelioma', 'MicroRNA (miRNA)', 'Network', 'OV, ovarian serous cystadenocarcinoma', 'PAAD, pancreatic adenocarcinoma', 'PCPG, pheochromocytoma and paraganglioma', 'PRAD, prostate adenocarcinoma', 'READ, rectum adenocarcinoma', 'SARC, sarcoma', 'SKCM, skin cutaneous melanoma', 'STAD, stomach adenocarcinoma', 'TGCT, testicular germ cell tumors', 'THCA, thyroid carcinoma', 'THYM, thymoma', 'TSG, tumor suppressor gene', 'UCEC, uterine corpus endometrial carcinoma', 'UCS, uterine carcinosarcoma', 'UVM, uveal melanoma', 'miR-10', 'Cancer', 'longitudinal cohort study', 'mental disorders', 'suicide', 'Helicobacter pylori', 'gastric cancer', 'gastrokines', 'transcriptional regulation', 'Delayed gastric emptying', 'Endoscopic Botulinum toxin', 'Oesophagogastrectomy', 'Pylorus drainage procedures', 'Clinical features', 'Diagnosis', 'Digestive tract cancers', 'Expression', 'PTPN family members', 'Prognosis', 'Epidemiology', 'Iran', 'Stomach cancer', 'Exosome', 'Gastric cancer', 'Macrophage', 'Metastasis', 'miR-223', 'Advanced gastric cancer and hydro-distension', 'Early gastric cancer', 'Multi-detector computed tomography', 'Virtual gastroscopy', 'Centrosome', 'Gene regulation', 'Mutation', 'Stomach cancer', 'Gastric cancer', 'Kaplan–Meier plotter', 'Oncomine', 'Prognosis', 'Topoisomerases', 'GI bleeding', 'chemotherapy', 'end of life decisions (palliative care)', 'gynecological cancer', 'stomach and duodenum', 'Adénocarcinome gastrique', 'Dépistage', 'Epidemiology', 'Gastric adenocarcinoma', 'Maroc', 'Morocco', 'Prognosis', 'Pronostic', 'Screening', 'Épidémiologie', 'Epstein–Barr virus', 'PD-L1', 'immunotherapy', 'intestinal/solid', 'lymphoepithelioma-like', 'poorly cohesive', 'targeted therapy', 'EBV-miR-BART11', 'EMT', 'Epithelial-mesenchymal transition', 'FOXP1', 'Forkhead box protein P1', 'Gastric carcinoma', 'Metastasis', 'Delayed gastric emptying', 'Laparoscopy-assisted distal gastrectomy', 'Laparoscopy-assisted pylorus-preserving gastrectomy', 'Meta-analysis', 'Perioperative outcomes', 'Fluid cytology', 'Gastric cancer', 'Gastrointestinal cytology', 'Non-gynecologic cytopathology', 'Oncologic cytopathology', 'fruits', 'gastric cancer', 'nutrition', 'pooled analyses', 'vegetables', 'CT', 'Postoperative complications', 'Stomach', 'Stomach cancer', 'Surgical techniques', 'Apoptosis', 'Cancer treatment', 'Chemotherapeutic agent', 'Pancreatic cancer', 'Real-time PCR', 'Shigella flexneri', 'Clinicopathological features', 'Early gastric cancer', 'Endoscopic submucosal dissection', 'Helicobacter pylori', 'Mucins', 'Negative', 'Phenotype', 'Un-infection', 'D2 lymphadenectomy', 'Gastrectomy', 'Lymph node ratio', 'Stomach cancer', 'Gastric cancer', 'adjuvant therapy', 'class III β-tubulin', 'taxane', 'DNA damage; Repair pathway', 'Gastric cancer', 'Germline mutation', 'Microsatellite instability', 'Next-generation sequencing', 'DNA damage', 'DNA repair', 'Helicobacter pylori', 'Nei-like DNA glycosylase', 'Nei-like DNA glycosylase 2 (NEIL2)', 'bacterial infection', 'base excision repair', 'cytokine response', 'enteroids', 'gastric cancer', 'gastric organoid', 'infection', 'inflammation', 'oxidative stress', 'stem cells', 'BLU-285', 'D842V', 'GIST', 'PDGFRA', 'avapritinib', 'Combined modality treatment', 'Esophagogastric junction cancer', 'Neoadjuvant radiochemotherapy', 'Perioperative chemotherapy', 'Real-life population', 'Chemotherapy', 'Endoscopic resection', 'Esophageal cancer', 'Gastric cancer', 'Gastrointestinal metastasis', 'Epstein–Barr virus', 'Epstein–Barr virus infection', 'Gastric cancer', 'Oesophago-gastric cancer', 'Stomach cancer', 'DNA', 'colorectal neoplasms', 'molecular', 'pancreatic neoplasms', 'pathology', 'stomach neoplasms', 'amino acid supplementation in cancer', 'chemotherapy associated malnutrition', 'glutamine', 'glutathione', 'mucositis', 'radiation injury', 'trehalose', 'boosting', 'health record analysis', 'imbalanced data problem', 'over- and under-sampling', 'stomach cancer detection', 'Health Communication', 'Neoplasm Staging', 'Quality of Life', 'Stomach Neoplasms', 'Gastric cancer', 'Histology type', 'Prognostic factor', 'Signet ring cell carcinoma', 'Survival', 'Complication', 'Esophagogastrostomy', 'Gastric cancer', 'Laparoscopic proximal gastrectomy', 'SDH deficiency', 'gastrointestinal stromal tumor', 'next-generation sequencing', 'sarcoma', 'Artificial intelligence', 'capsule endoscopy', 'colon polyp', 'colonoscopy', 'esophageal squamous cell carcinoma', 'esophagogastroduodenoscopy', 'gastric cancer', 'helicobacter pylori', 'magnified endoscopy', 'narrow band imaging', 'Epstein-Barr virus', 'Microsatellite instability', 'PD-L1', 'Prognosis', 'Stomach cancer', 'Tumor-infiltrating lymphocytes', 'Kawasaki disease', 'airborne pollen exposure', 'breast cancer', 'cancer incidence', 'lung cancer', 'pancreatic cancer', 'pollen diseases', 'specific intractable diseases', 'bile acids', 'bile ducts', 'cholecystectomy', 'gallstone disease', 'gut', 'microbiota', 'oral cavity', 'Gastric cancer', 'Helicase', 'Immunohistochemistry', 'Methylation', 'RECQL5', 'Enhanced recovery after surgery', 'colorectal cancer', 'complication', 'inflammation', 'neutrophil–lymphocyte ratio', 'perioperative management', 'Colostomy', 'Internal hernia', 'Rectal cancer', 'Stomach', 'Advanced gastric cancer', 'Capecitabine', 'Cisplatin', 'Recurrent gastric cancer', 'S-1', 'Colonic varices', 'Embolization', 'Interventional radiology', 'Left-sided portal hypertension', 'Pancreatic cancer', 'Pancreatoduodenectomy', 'Portal vein resection', 'grade 3', 'neuroendocrine tumor', 'well-differentiated', 'extrusion', 'legume', 'lipid metabolism', 'obesity', 'rat', 'dehydro-metabolite', 'metabolic pathway in vivo', 'siphonaxanthin', 'white adipose tissue', 'Analgesic activity', 'Antimicrobial activity', 'Antiviral activity', 'Pharmacology', 'Phytochemicals', 'Zanthoxylum nitidum', 'CT, computed tomography', 'Diffuse ground-glass opacities', 'GGO, ground-glass opacity', 'Gastric cancer', 'HRCT, high resolution computed tomography', 'Metastatic lung tumor', 'Mucinous adenocarcinoma', 'Signet-ring cell carcinoma', 'Coptidis Rhizoma', 'Pinelliae Rhizoma', 'gastric cancer', 'mechanism of action', 'molecular docking', 'systemic pharmacology', 'Claudin 18.2', 'Claudiximab', 'Esophageal cancer', 'Gastric cancer', 'IMAB362', 'Distal gastrectomy', 'Jejunal pouch', 'Peptic ulcer', 'Pouch interposition', 'Truncal vagotomy', 'Stomach neoplasms', 'contrast media', 'echo-endoscopy', 'multidetector computed tomography', 'neoplasm staging', 'Epstein-Barr virus', 'Rta', 'cell migration', 'interleukin-6', 'nasopharyngeal carcinoma', '5-FU', 'Drug resistance', 'EMT', 'cell cycle', 'cyclin D1', 'gastric cancer', 'p57', 'ERCC1', 'Stomach', 'cisplatin', 'human gastric carcinoma', 'Ultrasonically-activated surgical device', 'dissemination', 'gastric cancer', 'Carcinoma, signet ring cell', 'Lymphangitis', 'Lymphatic metastasis', 'Database', 'Differentially expressed gene', 'Single nucleotide polymorphism', 'Stomach cancer', 'microRNA', 'EBV', 'Epstein-Barr virus', 'Gastric cancer', 'Gastric carcinoma', 'Meta-analysis', 'Stomach cancer', 'case report', 'heterotopic pancreas', 'jejunum', 'neuroendocrine tumor', 'small intestine', 'Genistein', 'anti-tumor mechanism', 'calcium-sensing receptor', 'gastric cancer', 'Lymph nodes', 'Radiomics', 'Spectral imaging', 'Stomach neoplasms', 'Intramuscular nodules', 'Myalgia', 'Neoplasm metastasis', 'Stomach neoplasms', 'Fzd', 'Fzd7', 'Wnt', 'cancer', 'gastric', 'signaling', 'stomach', 'CagPAI', 'Helicobacter pylori', 'Type IV secretion system', 'human conventional dendritic cell (cDC), Toll-like receptor 2/4/10', 'Chemotherapy', 'Gastric cancer', 'TAS-102', 'Third line', '\\nHelicobacter\\xa0pylori\\n', '5′-exonuclease', 'DNA polymerase I', 'DNA replication', 'Okazaki fragments', 'Clinical competence', 'Education measurement', 'Endoscopic submucosal dissection', 'Stomach neoplasms', 'Early gastric cancer', 'Endoscopic submucosal dissection', 'Gastrectomy', 'Western countries', 'Intestine', 'Neuroendocrine neoplasms', 'Pancreas', 'Pathological features', 'Prognosis', 'Stomach', 'cancer', 'case-control study', 'hepatitis B virus', 'meta-analysis', 'Helicobacter pylori', 'MyD88', 'cancer and inflammation', 'gastric cardia cancer', 'prognosis', 'gastric schwannoma', 'nausea', 'stomach mass', 'vomiting', 'diffuse reflectance', 'esophageal cancer', 'fiber optic probe', 'fluorescence spectroscopy', 'gastrointestinal', 'optical biopsy', 'time-resolved fluorescence', 'Gastrectomy', 'Margins of excision', 'Prognosis', 'Recurrence', 'Stomach neoplasms', 'Latin America', 'Neoplasms', 'Uruguay', 'breast neoplasms', 'carcinoma, transitional cell', 'incidence', 'noncommunicable diseases', 'stomach neoplasms', 'testicular germ cell tumor', 'testicular neoplasms', 'thyroid gland', 'tobacco', 'trends', 'urinary bladder neoplasms', 'uterine cervical neoplasms', 'Cheonwangbosim-dan', 'Helicobacter pylori', 'gastritis', 'ELPS', 'ESD', 'double cancer', 'esophageal cancer', 'pharyngeal cancer', 'Bacterial microbiota', 'Dysbiosis', 'Fungal microbiota', 'Gastric disorders', 'Helicobacter pylori', 'Microbial interactions', 'Microbiome', 'Microbiota', 'Mucosa', 'Stomach', 'Drug therapy', 'Her-2 antibody', 'poly (lactic-co-glycolic acid) nanoparticles', 'targeting', 'Advanced gastric cancer', 'carbon nanoparticles', 'para-aortic lymph nodes', 'tracer agents', '125 I seeds', 'brachytherapy', 'radiation injury', 'stomach', 'gastrointestinal tumours', 'oesophageal disease', 'oncology', 'pathology', 'surgery', 'Chromatography', 'Colorectal cancer', 'Diagnosis', 'Saliva', 'Stomach cancer', 'Cancer survivor', 'Gender difference', 'Qualitative research', 'Telephone consultation', 'Unmet needs', 'Cancer chemoprevention', 'Gastric cancer', 'PIM-1', 'Resveratrol', 'Gastrectomy', 'Intraoperative complications', 'Laparoscopy', 'Postoperative complications', 'Stomach neoplasms', 'Blind loop of Roun-en-Y anastomosis', 'Metastatic gastric and jejunal cancer', 'Primary colon cancer', 'Acyl-CoA thioesterase 7', 'gastric cancer', 'long non-coding RNA', 'methylation', 'Dysplasia', 'Fundic gland polyp', 'Helicobacter pylori-negative', 'Magnifying endoscopy', 'Chemotherapy', 'Pancreatic cancer', 'Splenic artery pseudoaneurysm', 'gastric cancer', 'inadequate oral intake', 'massive ascites', 'modified FOLFOX6', 'severe peritoneal metastases', 'CDH11', 'HEYL', 'gastric cancer', 'transcriptional factors', 'tumor microenvironment', 'anticancer drugs', 'cucurbituril', 'host-guest systems', 'nanoparticles', 'supra-pyramid', 'gastric cancer', 'neoadjuvant', 'radiation therapy', 'recurrence', 'tumor regression grade', 'Cancer', 'Disparities', 'Gastric', 'Race', 'Stomach', 'Survival', 'Air pollution', 'Cancer', 'Mortality', 'PM2.5', 'Smoking', 'Diabetes mellitus', 'Incidence', 'Metformin', 'Stomach neoplasm', 'Fluorescent clip', 'Gastric cancer', 'Intraoperative endoscopy', 'NIRF, Near-infrared fluorescent', 'Age distribution', 'Chemotherapy', 'Gastric cancer', 'Perioperative', 'Tumour localisation', 'Validity', 'Cancer', 'comorbidity', 'epidemiology', 'schizophrenia', 'FOXD1', 'FOXD1-AS1', 'PI3K/AKT/mTOR pathway', 'eIF4G-eIF4E-eIF4A translational complex', 'gastric cancer', 'blood plasma', 'gastric cancer', 'sPD-1', 'sPD-L1', 'Apoptosis', 'Drug Resistance, Multiple', 'Stomach neoplasms', 'Clinical feature', 'Colorectal cancer', 'Gastric cancer', 'Risk factor', 'Schistosomiasis', 'Wuhu area', 'BPDE-DNA adduct', 'Benzo[a]pyrene', 'myricetin', 'oxidative stress', 'phase detoxifying enzyme', 'Esophagogastric junction cancer', 'Gastric cancer', 'HER2', 'Stage IV', 'Trastuzumab', 'Gastric cancer', 'Peritoneal recurrence', 'Prognosis', 'Recurrence pattern', 'Young', 'bacterial nanomachines', 'bacterial protein secretion', 'cryo-electron microscopy', 'cryo-electron tomography', 'gastric adenocarcinoma', 'gastric cancer', 'macromolecular structures', 'peptic ulcer disease', 'type IV secretion system', 'Neoadjuvant therapy', 'Stomach neoplasms', 'Tomography, X-ray computed', 'dysplasia', 'fluorescein', 'fluorescence', 'oral cancer', 'oral potentially malignant disorders', 'photodetection', 'photodiagnosis', 'screening', 'Gastric cancer', 'PHF19', 'PRC2', 'cell growth', 'cell migration', 'Microbiome', 'gastric cancer', 'microbiome diversity', 'specific microbes', 'stomach cancer', 'Cancer risk', 'Familial colorectal cancer type X', 'Lynch syndrome', 'Lynch-like syndrome', 'Prospective surveillance study', 'Intensity-modulated proton therapy', 'Oesophagal cancer', 'RapidArc', 'Secondary cancer risk estimate', 'VMAT', 'Gastric carcinoma', 'USP44', 'circFOXO3', 'circRNA', 'miR-143-3p', '\\n          APC\\n        ', 'Jack Russell Terrier', 'dog', 'familial adenomatous polyposis', 'gastrointestinal tumor', 'hereditary disorder', 'BPC 157', 'NSAID induced gastroenteropathy', 'bile acids', 'epithelial permeability', 'gut permeability', 'leaky gut syndrome', 'GIST', 'Immunohistochemical', 'Surgical treatment', 'ankylosing spondylitis', 'cancer', 'osteoarthritis', 'adenocarcinoma', 'alpha-fetoprotein', 'gastric', 'hepatoid', 'β-catenin', 'hepatocellular carcinoma', 'conventional gastric adenocarcinoma', 'Early stage', 'Gastric cancer', 'Jejunal interposition', 'Laparoscopy', 'Proximal gastrectomy', 'Biopsy', 'Helicobacter', 'NGS', 'Next-generation sequencing', 'Pylori', 'Sequencing', 'Specimens', 'Stomach', 'activin A receptor type 2A', 'gene mutation', 'microsatellite instability', 'neoplasm metastasis', 'stomach neoplasms', 'GLUT1', 'Gastric cancer', 'Immunohistochemistry', 'Prognosis', 'TKTL1', 'Tumor marker', 'Gastric adenocarcinoma', 'Localized gastric adenocarcinoma', 'Preoperative chemotherapy', 'Three-drug induction', 'CD44 variant 9', 'SPEM', 'Tacstd2', 'dysplasia', 'gastric cancer', 'intestinal metaplasia', 'metaplasia', 'cystadenocarcinoma', 'digestive surgery', 'indications for surgery', 'liver metastasis', 'microcystic', 'pancreas', 'serous cystic neoplasm', 'sunitinib', 'cell proliferation', 'gastric adenocarcinoma', 'hypoxia', 'lactic acid', 'lncRNA', 'Device visualization', 'Endoscopic clip', 'Indwelling ureteral catheter', 'Near-infrared fluorescence', 'Solid resin material', 'Helicobacter pylori\\n', 'Toll-like receptor 2', 'lipoproteins', 'posttranslational protein modification', 'type IV secretion systems', 'Gastric cancer', 'Nivolumab', 'Salvage chemotherapy', 'coronary artery perforation', 'gastric ulceration', 'gastrointestinal bleeding', 'COVID-19 outbreak', 'Psychological barriers', 'Urgent endoscopy', 'ARIMA, autoregressive integrated moving average', 'CI, confidence interval', 'COVID-19, coronavirus disease 2019', 'Colonoscopy', 'Coronavirus', 'Gastroscopy', 'SARS-CoV', 'Staging', 'Early gastric cancer', 'Low-grade intraepithelial neoplasia (LGIN)', 'Risk model', 'early gastric cancer', 'endoscopic resection', 'papillary adenocarcinoma', 'Case report', 'Glomangiosarcoma', 'Hepatic neoplasm', 'Malignant glomus tumor', 'gastric cancer', 'radical surgery', 'radiotherapy', 'recurrence patterns', 'Antimicrobial peptides', 'Innate immunity', 'MOB kinase activator-like 1', 'Macrobrachium nipponense', 'RNA interference', 'Cyclin D1', 'Gastric cancer', 'Proliferation', 'SYF2', 'miR-621', 'endoscopic full-thickness resection', 'endoscopic submucosal dissection', 'laparoscopy endoscopy cooperative surgery', 'per-oral endoscopic myotomy', 'per-oral endoscopic tumor resection', 'Laparoscopy', 'Oncology', 'Overview', 'Robot', 'Stomach', 'Gastric cancer', 'Health-related quality of life', 'Patient-reported outcomes', 'Aspirin', 'Galactic cosmic rays', 'Medical countermeasures', 'Risk of exposure induced death', 'Solar particle events', 'Warfarin', 'AKR1B1', 'GC', 'prognosis', 'colorectal cancer', 'seaweed', 'soybean products', 'stomach cancer', 'survival', 'Body composition', 'Gastrectomy', 'Quality of life', 'Stomach neoplasms', 'Stomach neoplasms', 'bariatric surgery', 'diabetes mellitus', 'gastric bypass', 'metabolic syndrome', 'Cancer burden', 'China', 'comparison', 'trend', 'Angiogenesis', 'EMT', 'FAK', 'Gastric cancer', 'ITGB1', 'Maspin', 'Chemoradiation', 'Gastric adenocarcinoma', 'Positron emission tomography (PET)', 'Total lesion glycolysis (TLG)', 'Biomarker', 'CD40', 'DNA methylation', 'GEO', 'Gastric cancer', 'Immune checkpoint', 'TCGA', 'alcohol consumption', 'alcohol-related cancer', 'cancer mortality', 'physical activity', 'Diet', 'Exercise', 'Hepatobiliary cancer', 'Liver cancer', 'Multidisciplinary rehabilitation', 'Oesophagogastric cancer', 'Pancreatic cancer', 'Diagnostic imaging', 'Endoscopy', 'Gastric cancer', 'Laparoscopy', 'Multimodality treatment', 'Neoadjuvant chemotherapy', 'Radiation therapy', 'Staging', 'BRCA', 'Familial adenomatous polyposis', 'Genetic testing', 'Hereditary cancer syndromes', 'Lynch syndrome', 'gastric cancer', 'lymph nodes', 'neoadjuvant chemotherapy', 'tumour regression', 'CuS–NiS2', 'apoptosis', 'gastric cancer', 'nanomaterials', 'necroptosis', 'Stomach neoplasms', 'biomarkers', 'integrated bioinformatics', 'microarray analysis', 'colorectal cancer', 'genotype–phenotype correlation', 'hereditary\\xa0hemorrhagic telangiectasia', 'juvenile polyposis syndrome', 'polyposis', 'Circular stapler', 'Esophagojejunostomy', 'Laparoscopic total gastrectomy', 'Linear stapler', 'Stenosis', 'STAT4', 'TBC1D10B', 'miR-3619-5p', 'stomach adenocarcinoma', 'IKKα/β Src', 'NF-κB signaling pathway', 'Sorbaria kirilowii', 'anti-inflammatory effect', 'DNA repair', 'epigenomics', 'microRNAs', 'microsatellite instability (MSI)', 'stomach neoplasms', 'Gastric cancer', 'Gastric cancer simulating SMT', 'LECS', 'Gastroenterostomy', 'Laparoscopy', 'Stamoch neoplasms', 'Suture techniques', 'Cancer burden', 'Kenya', 'infectious agents', 'sub-Saharan Africa', 'Diabetes', 'Korean National Health Insurance Service system', 'Neoplasms', 'Comparison', 'Epidemiology', 'Risk of Death', 'SEER (Surveillance', 'Tumor', 'and End Results Program)', 'Bacterial peptide', 'Bacteriocins', 'Bacteriotherapy', 'Gastrointestinal cancer', 'Toxin', 'Capecitabine', 'S-1', 'meta-analysis', 'randomized controlled trials (RCTs)', 'stomach neoplasms', 'Chemoresistance', 'GDF15', 'Gastric cancer', 'HIF1α', 'HMGB1', 'Tumor-associated macrophages', 'Checkpoint inhibition', 'Chemotherapy', 'Gastroesophageal cancer', 'Immunotherapy', 'Microsatellite instability', 'Mismatch repair deficiency', 'Adaptive radiotherapy', 'Gastric cancer', 'Library of plans', 'Observer study', 'Plan selection', 'Helicobacter pylori', 'adverse pregnancy outcomes', 'pregnancy-related diseases', 'pregnant women', 'Cancer', 'Diagnosis', 'Iron oxide nanoparticles', 'Magnetic nanoparticles', 'Magnetic resonance imaging', 'Carbon ion', 'Pancreatic cancer', 'Radiotherapy', 'Gastrectomy', 'Gastric cancer', 'Intraoperative frozen section', 'Resection margins', 'Risk factors', 'Antitumor immune response', 'CD8', 'Gastric cancer', 'Immune-related gene', 'PD-1', 'PD-L1', 'Prognosis', 'Surgery', 'Advanced gastric cancer', 'Early relapse', 'Irinotecan-based chemotherapy', 'S-1 adjuvant therapy', 'Second-line chemotherapy', 'ALKBH1', 'Gastric cancer', 'Malignant development', 'MiRNA-339-5p', 'bioactivity', 'cyclodextrin', 'pancreatic cancer', 'reversible pegylation', 'targeting', 'tumor stroma', 'E2F1', 'cell proliferation', 'gastric cancer', 'miR-449a/b', 'Akt', 'aerobic glycolysis', 'gastric cancer', 'glucose transporter-1', 'phosphoinositide 3-kinase', 'recombinant methioninase', 'Gastric cancer', 'Hsa_circ_0017639', 'Sponge', 'USP3', 'miR-224-5p', 'Immune Regulation', 'Lymphocyte', 'Mouse Model', 'Transcription', 'HPLC-MS', 'Lycium', 'coumarins', 'endemic plants', 'metabolomic', 'orbitrap', 'secondary metabolites', 'Incidence', 'Occupation dust', 'Stomach neoplasms', 'MSH2 gene', 'Multiple gastric cancer', 'TCGA', 'clonal relationship', 'predisposing gene', 'whole-exome sequencing', \"Barrett's esophagus\", 'EMI-137 targeting c-Met.', 'Structured roadmap', 'standardized fluorescence molecular endoscopy methodology', 'Idiopathic inflammatory myositis', 'Malignancy', 'Mortality', 'Adenocarcinoma', 'Gastric cancer', 'Lymph node dissection', 'Stomach', 'Surgery', 'Cancer stem cells (CSC)', 'Gastric carcinoma', 'Octamer-binding transcription factor 4 (Oct4)', 'cirrhosis', 'digestivesurgery', 'emergencysurgery', 'gastro-duodenalsurgery', 'gastroenterology', 'gastric carcinogenesis', 'metabolic pathway', 'nuclear magnetic resonance', 'rat model', 'tissue metabolomics', 'A. coarctata Poir.', 'Achillea L.', 'HeLa cells', 'MCF-7 cells', 'cancer', 'cytotoxicity', 'sesquiterpene lactones ', 'Bronchogenic cyst', 'Case report', 'Endoscopic ultrasound-guided fine needle aspiration', 'Endosonography', 'Stomach', 'Submucosal lesion', 'Analytical validation', 'Genetic testing', 'Hereditary cancer', 'Multigene panel testing', 'Next generation sequencing', 'Gastrointestinal neoplasms', 'colorectal neoplasms', 'esophageal neoplasms', 'hepatocellular cancer', 'immunologic antineoplastic agents', 'microsatellite instability', 'monoclonal antibodies', 'stomach neoplasms', 'Advanced gastric cancer', 'hyperbaric oxygen therapy', 'hyperthermia', 'ketogenic diet', 'metabolically supported chemotherapy', 'Cytotoxic T lymphocyte', 'Gastric cancer', 'Immunotherapy', 'PD-L1', 'PD-L2', 'Gastric cancer', 'Trousseau’ syndrome', 'internal jugular vein', 'neoplastic venous thrombosis', 'ACE2', 'COVID-19', 'Expression', '\\nHelicobacter pylori', 'gastric cancer', 'genetic polymorphisms', 'pathogenicity island', 'premalignant gastric lesions', 'SOX3', 'biomarker', 'gastric cancer', 'prognosis', 'proteome profiling', 'cross-sectional studies', 'liver neoplasms', 'proton therapy', 'stomach neoplasms', 'Colorectal', 'diffuse large B-cell lymphoma', 'primary', 'Esophagus and esophagogastric cancer', 'OG25', 'quality of life questionnaire – OES18', 'translation questionnaire', 'Immunohistochemistry', 'T-cell lymphomas', \"non-Hodgkin's lymphoma\", 'Diagnosis', 'Gastric cancer', 'Signaling pathway', 'Transcription factor', 'miRNA', 'Gastric cancer', 'Invasion', 'LINC00619', 'Migration', 'OPCML', 'Proliferation', 'microRNA-224-5p', 'Atg12', 'Autophagy', 'Gastric cancer', 'Oxaliplatin', 'WASF3', 'esophagogastric junction cancer', 'lymphatic invasion', 'mediastinal lymph node metastases', 'survival outcomes', 'China', 'actions', 'burden', 'cancer epidemiology', 'incidence', 'mortality', 'cause of death', 'mortality', 'prognosis', 'stomach neoplasm', 'survival', 'Endoscopic resection', 'Gastric cancer', 'Laparoscopic distal gastrectomy', 'MCT1/MCT4 lactate transporter inhibitor', 'OLINDA', '[18F]FACH', 'image-based internal dosimetry', 'preclinical radiopharmaceutical dosimetry', 'radiation safety', 'Gastritis', 'Helicobacter pylori', 'Lactobacillus', 'Probiotic', 'gastrectomy', 'gastric cancer', 'lymphadenectomy', 'staging prognosis.', 'Atrophic gastritis', 'Controversy', 'Gastric intestinal metaplasia', 'Gastric precancerous lesions', 'Guidelines', 'Surveillance', 'Cancer survival', 'Excess mortality', 'Inequalities', 'Rural', 'Survival analysis', 'Urban', 'Cancer', 'Laparoscopic gastrectomy', 'Open conversion', 'Stomach', 'Extranodal soft tissue', 'metastasis', 'neoplasm', 'prognosis', 'stomach', 'Early gastric cancer (EGC)', 'lymph node metastasis (LNM)', 'poorly differentiated adenocarcinoma', 'signet ring cells', 'Gastric duplication cyst', 'laparoscopic resection', 'pancreatic mucinous cyst', 'pseudostratified columnar ciliated epithelium', 'esophagoenterostomy', 'laparoscopic gastrectomy', 'mechanical anastomotic devices', 'stomach cancer', '\\nHelicobacter pylori\\n', 'CagA', 'VacA', 'gastric cancer', 'outer inflammatory protein', 'colon cancer', 'gastrointestinal lymphomas', 'malt', 'rare cancers', 'Gall bladder', 'metachronous', 'positron emission tomography-computed tomography', 'stomach', 'synchronous', 'gastric cancer', 'neoadjuvant therapy', 'recurrence', 'Gastric cancer', 'Gastric-cancer-derived mesenchymal stem cells', 'Metastasis', 'Resveratrol', 'Wnt/β-catenin', 'HMGCS1', 'gastric cancer progression', 'integrated stress response', 'mevalonate pathway', 'pluripotency', 'Gastric cancer', 'Prognostic factor', 'RECIST', 'Tumor marker', 'Brain metastases', 'Esophageal adenocarcinoma', 'Esophageal squamous-cell carcinoma', 'Gastric adenocarcinoma', 'Gastroesophageal junction adenocarcinoma', 'cancer', 'epidemiology', 'young adults', 'Bhutan', 'alcohol', 'betel nut', 'epidemiology', 'head and neck cancer', 'histopathology', 'hypopharyngeal cancer', 'laryngeal cancer', 'nasopharyngeal cancer', 'oral cancer', 'salivary gland neoplasm', 'sinonasal malignancy', 'thyroid cancer', 'tobacco', 'Eosinophilia', 'Eosinophilic colitis', 'Eosinophilic gastritis', 'Eosinophilic gastroenteritis', 'Eosinophilic gastrointestinal disorders', 'Hypereosinophilic syndrome', 'body fat percentage', 'body surface area', 'cancer', 'cardiovascular disease', 'physical measurements', 'extrahepatic cancer', 'hepatitis B virus (HBV)', 'hepatitis C virus (HCV)', 'Epstein-Barr virus infection', 'carcinoma', 'neoplastic stem cell', 'signal transduction', 'stomach neoplasm', 'Blood flow', 'Esophageal cancer', 'Gastric tube cancer', 'Indocyanine green', 'Intraoperative', 'Krukenberg tumours', 'colorectal cancer', 'early pregnancy symptoms', 'exploratory laparotomy', 'foetal management', 'gastric cancer', 'ovarian metastasis', 'preoperative diagnosis', 'termination of pregnancy', 'BIA', 'Chemotherapy', 'Hs-CRP', 'IL-8', 'Inflammation', 'Sarcopenia', 'TNF-α', 'Colon cancer', 'Gastrointestinal reaction', 'Hyperthermic intraperitoneal chemotherapy', 'Warming needling technique', 'AGS Cells', 'Autophagosome', 'Cathepsin D', 'LAMP1', 'ROS', 'mTOR', 'GI-stomach-Med', 'clinical trials', 'molecular diagnosis', 'adjuvant chemotherapy', 'early gastric cancer', 'stage 1b gastric cancer', 'Chemotherapy', 'Gastric cancer', 'Lymph node', 'Prognosis', 'Stage IV', 'Surgery', 'AGS cells', 'adsorption', 'microplastics', 'nanoplastics', 'tetracycline', 'Barrett’s Esophagus', 'Carcinogenesis', 'Esophageal Adenocarcinoma', 'Goblet Cells', 'Amsterdam I criteria', 'Cancer syndrome', 'Hereditary cancer', 'Mismatch repair proficient', 'Tumour spectrum', 'Epithelium with low-grade atypia', 'Eradication therapy', 'Helicobacter pylori', 'Reddish depression', 'Stomach neoplasms', 'Drug therapy', 'Ramucirumab', 'Salvage therapy', 'Stomach neoplasms', 'Alcohol Drinking', 'Cancer Survivors', 'Cardiovascular Diseases', 'Risk', 'E-cadherin', 'Epstein-Barr virus', 'HER2', 'MLH1', 'p53', 'Colorectal cancer', 'Fine particulate matter', 'Mortality', 'Public health', 'Stomach cancer', 'Time-series', 'n', 'o', 'n', 'e', 'Aortocaval lymph node', 'Gastric cancer', 'Metastasis', 'Paraaortic lymph node', 'Spermatic cord', 'Testis', 'Backbone chemotherapy', 'Human epidermal growth receptor 2', 'Metastatic adenocarcinoma of the stomach or gastroesophageal junction', 'Noninterventional study', 'Real-world data', 'Trastuzumab', 'Acute subdural hematoma', 'Chronic subdural hematoma', 'Intratumoral hemorrhage', 'Metastatic tumor', 'Gastric cancer', 'Morbidity', 'Mortality', 'Octogenarian', 'POSSUM', 'esophageal cancer', 'esophagectomy', 'laparoscopy', 'thoracotomy', 'body composition', 'cioelectrical impedance', 'colorectal cancer', 'pancreatic cancer', 'stomach cancer', '3D reconstruction', 'Gastric endoscopy', 'monocular endoscope', 'stomach', 'structure-from-motion', 'Lung adenocarcinoma', 'Nonbacterial thrombotic endocarditis', 'Skin necrosis', 'cancer', 'epidemiology', 'incidence', 'second cancer', 'venous thromboembolism', 'c-Met', 'chemoresistance', 'exosomes', 'gastric cancer', 'siRNA', 'body weight', 'coaching', 'distress management', 'oncology', 'physical activity', 'Greater curvature', 'Splenectomy', 'Splenic hilar lymph node', 'Therapeutic index', 'Type 4 gastric cancer', 'claudin-3', 'gastric adenocarcinoma', 'gastric cancer', 'immunohistochemistry', 'nuclear expression', 'tight junctions', 'Gastric acid', 'Gastroduodenal ulcer', 'Intestinal perforation', 'Pancreatic juice', 'Pancreaticoduodenectomy', 'Peptic ulcer', 'Postoperative complication', 'Surgery', 'Assistant', 'Gastric neoplasms', 'Radical surgery', 'Robotic surgery', 'Lymphadenectomy', 'Multidisciplinary treatment', 'Standardized surgical treatment', 'Stomach neoplasms', 'Gastric neoplasms', 'Outcomes', 'Prognostic factors', 'Robotic surgery', 'Total gastrectomy', 'Curative effect, short-term', 'D2 radical gastrectomy', 'Gastric neoplasms, distal', 'Laparoscope, three-dimensional imaging system', 'Robotic surgery', 'Robotic', 'Stomach neoplasms', 'Surgery', 'Cancer', 'Coronavirus disease 2019 (COVID-19)', 'Endoscopy, selective', 'Artificial intelligence', 'Conversion surgery', 'ERAS', 'Gastric cancer', 'Indocyanine green', 'Neoadjuvant therapy', 'Cancer', 'Firefighting', 'Incidence', 'Mortality', 'Region-specific differences', 'Secular trend', 'Mixed adenoneuroendocrine carcinoma', 'Neoadjuvant chemotherapy', 'Neuroendocrine carcinoma', 'Stomach', 'Cell proliferation', 'Invasion', 'MIEN1', 'Migration', 'circRNA_100876', 'miRNA sponge', '(MeSH): tissue engineering', 'esophageal sphincter, lower', 'esophagogastric junction', 'esophagus', 'regenerative medicine', 'stomach', 'Pancreatectomy', 'Pancreatic intraductal neoplasms', 'Stomach volvulus', 'OA', 'inflammation', 'miR-124-3p', 'γ-MS', '2ccPA', 'Enterosoluble capsule', 'Mass spectrometry', 'Oral administration', 'Abiraterone acetate', 'Bioavailability', 'Food effect', 'Precipitation', 'Solid dispersion', 'Spray drying', 'Adenocarcinoma, papillary', 'Lymphatic metastasis', 'Risk factors', 'Stomach neoplasm', 'colonoscopy', 'esophagogastroduodenoscopy', 'kaposi’s sarcoma', 'second primary malignancy', 'upper endoscopy', 'visceral', 'Billroth-I reconstruction', 'gastric cancer', 'robotic distal gastrectomy', 'Gastric cancer', 'LINC00483', 'MAPK1', 'miR-490-3p', 'Children', 'Hematopoietic stem cell transplantation', 'Peptides regulating gastrointestinal tract functions', 'Cancer', 'GEO', 'KEGG pathway', 'Sepsis', 'Septic shock', 'TCGA', 'Exosome', 'GKN1', 'Gastric cancer', 'Ras signaling', 'Uptake', 'adjuvant therapy', 'gastrointestinal tract', 'genetic diagnosis', 'radiosensitivity', 'Lymph Nodes', 'Prognosis', 'Registries', 'Stomach Neoplasms', 'Survival', ' Helicobacter pylori ', ' cagA-motifs', ' homB ', 'EPIYA-motifs', 'antibiotic resistance', 'Complication', 'Jejunogastricintussuception', 'Whipple', 'ascites', 'endoscopy', 'infection', 'laparoscopy', 'transrectal approach', 'Gastric cancer', 'Heparanase', 'Immunotherapy', 'Invasion and metastasis', '18F-FDG PET/CT', 'Advanced gastric cancer', 'Heterogeneity', 'Primary gastric lymphoma', 'SUVmax', 'HER2 status', 'diffuse-type gastric cancer', 'platinum doublet chemotherapy', 'primary tumor location', 'combined zero- and first-order absorption', 'first-order absorption', 'transit compartment absorption model', 'zero-order absorption', 'aspirin', 'colorectal neoplasm', 'digestive tract neoplasm', 'dose', 'duration', 'meta-analysis', 'risk factor', 'Adenomatous polyps', 'Klebsiella pneumoniae', 'Pyogenic liver abscess', 'Stomach cancer', 'acupuncture', 'association rules', 'cancer pain', 'entropy clustering', 'rules of acupoint selection', 'Alginic acid', 'hydrogel', 'indocyanine green (ICG)', 'laparoscopy', 'surgical marker', 'Gastrectomy', 'Gastroesophageal reflux', 'Laparoscopic surgery', 'Minimally invasive surgery', 'Stomach cancer', 'Lymph node dissection', 'Prognosis', 'Spleen preservation', 'Splenectomy', 'Stomach neoplasms', 'biomarkers', 'peroxiredoxin IV', 'prognosis', 'stomach neoplasm', 'survival analysis', 'Diagnosis, differential', 'Natural orifice endoscopic surgery', 'Stomach neoplasms', 'IGF2BP3', 'gastric cancer', 'microRNA-125a-5p', 'prognosis', 'proliferation', 'Endoscopic submucosal dissection', 'Multiple primary neoplasms', 'Risk factors', 'Secondary neoplasms', 'Stomach neoplasms', 'IFNγ gradient', 'co-expression network', 'colorectal cancer', 'immune checkpoint genes', 'novel immune checkpoint related genes', 'Gastrointestinal stromal tumor', 'Imatinib mesylate', 'Preoperative treatment', 'Retrospective study', 'CCN2/CTGF', 'CRISPR', 'cellular communication network factor', 'extracellular vesicles', 'genome editing', 'matrix metalloproteinase', 'moonlighting metalloproteinase (MMP)', 'oncosome', 'protein moonlighting', 'transcription factor', 'Antibody', 'Epirubicin', 'HER2', 'Intratumor distribution', 'Polymeric micelle', 'Tissue factor', 'Billroth‐I', 'Roux‐en‐Y', 'gastric cancer', 'nutrition', 'survival', 'Function-preserving gastrectomy', 'esophagogastrostomy with double-flap technique (esophagogastrostomy with DFT)', 'gastric cancer (GC)', 'proximal gastrectomy (PG)', 'pylorus-preserving gastrectomy (PPG)', 'Endocytoscopy (EC)', 'diagnosis', 'endoscopy', 'ultra-high magnification endoscopy', 'Afghanistan', 'Cancer prevalence', 'Cancer research', 'Epidemiology', 'Kabul Jamhoriyat hospital', 'Oncology', 'Public health', \"Women's health\", 'Endometrial carcinoma', 'FISH amplification', 'Fixation and cold ischemia time', 'Her2/neu', 'Her2/neu testing', 'Papillary serous carcinoma', 'Endoscopic submucosal dissection', 'Multiple primary neoplasms', 'Second primary neoplasms', 'Stomach neoplasms', 'Alpha-fetoprotein', 'Case report', 'Hepatoid adenocarcinoma of the stomach', 'Stomach cancer', 'Helicobacter pylori', 'ICOS-L', 'IL-17', 'gastric cancer', 'programmed death-ligand 1', 'retinoid orphan receptor γt', 'vacA-m1', 'ACC, adrenocortical carcinoma', 'AUC, area under the curve', 'Algorithm', 'BLCA, bladder urothelial carcinoma', 'BRCA, breast invasive carcinoma', 'CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma', 'CHOL, cholangiocarcinoma', 'COAD, colon adenocarcinoma', 'CV, cross validation', 'Cancer', 'Classification', 'DLBC, lymphoid neoplasm diffuse large B-cell lymphoma', 'ESCA, esophageal carcinoma', 'GBM, glioblastoma multiforme', 'GEO, Gene Expression Omnibus', 'GO, gene ontology', 'Gene expression profiling', 'HNSC, head and neck squamous cell carcinoma', 'KICH, kidney chromophobe', 'KIRC, kidney renal clear cell carcinoma', 'KIRP, kidney renal papillary cell carcinoma', 'LAML, acute myeloid leukemia', 'LGG, brain lower grade glioma', 'LIHC, liver hepatocellular carcinoma', 'LUAD, lung adenocarcinoma', 'LUSC, lung squamous cell carcinoma', 'MESO, mesothelioma', 'MSI, microsatellite instability', 'MSS, microsatellite stability', 'Machine learning', 'Microsatellite instability', 'OV, ovarian serous cystadenocarcinoma', 'PAAD, pancreatic adenocarcinoma', 'PCPG, pheochromocytoma and paraganglioma', 'PPI, protein-protein interaction', 'PRAD, prostate adenocarcinoma', 'READ, rectum adenocarcinoma', 'RF, random forest', 'ROC, receiver operating characteristic', 'SARC, sarcoma', 'SKCM, skin cutaneous melanoma', 'STAD, stomach adenocarcinoma', 'SVM, support vector machine', 'TCGA, The Cancer Genome Atlas', 'TGCT, testicular germ cell tumors', 'THCA, thyroid carcinoma', 'THYM, thymoma', 'UCEC, uterine corpus endometrial carcinoma', 'UCS, uterine carcinosarcoma', 'UVM, uveal melanoma', 'XGBoost, extreme gradient boosting', 'k-NN, k-nearest neighbor', 'BLCA, bladder carcinoma', 'CESC, cervical & endocervical squamous cell carcinomas', 'COAD, colon adenocarcinoma', 'COREAD, colon and rectal adenocarcinoma TCGA cohorts', 'Cancer microbiome', 'Exome sequencing', 'HNSC, head & neck squamous cell carcinoma', 'L2FC, log 2 fold change', 'LIHC, liver hepatocellular carcinoma', 'LUAD, lung adenocarcinoma', 'LUSC, lung squamous cell carcinoma', 'Microbial landscape', 'READ, rectal adenocarcinoma', 'STAD, stomach adenocarcinoma', 'TCGA', 'TCGA, The Cancer Genome Atlas', 'nomograms', 'perioperative chemotherapy', 'stomach neoplasms', 'survival', 'Gastric cancer', 'Model validity tool', 'Orthotopic transplantation', 'PDOX', 'PDX', 'Stomach tumour', 'CD44 variants', 'apoptosis', 'cell population dynamics', 'chemotherapy', 'stomach cancer', 'Gastric cancer', 'Gastroenterology', 'Clinical outcome', 'Gastric cancer', 'Lymphovascular invasion', 'Radiomics', 'Gastric cancer', 'Survival', 'TP73-AS1', 'miR-223-5p', 'Angiogenesis', 'Gastric cancer', 'Tumor immune microenvironment', 'Tumor-associated macrophages', 'Cancer', 'Epidemiology', 'Global', 'Incidence', 'Mortality', 'Risk Factors', 'Computed tomography', 'Gastrointestinal neoplasms', 'Gastrointestinal stromal tumors', 'Intestine', 'Stomach', 'Gastric cancer', 'Indocyanine green', 'Laparoscopic surgery', 'Lymph node dissection', 'Near-infrared imaging', 'GIST', 'mutations', 'outcome', 'treatment', 'young-adult patients', 'ADM', 'SPEM', 'mTORC1', 'metaplasia', 'mitochondria', 'paligenosis', 'ribosomes', 'Histology', 'Neuropilin-1', 'Prognosis', 'Stomach neoplasms', 'Survival', 'CircRNA sequence similarity', 'CircRNA-disease associations', 'Disease semantic similarity', 'Inductive matrix completion', 'African', 'African Americans', 'Afro-Caribbeans', 'Cancer', 'Intra-racial', 'Mortality', 'Apoptosis', 'Gastric cancer', 'Proliferation', 'Rab1A', 'mTOR/p70S6K pathway', 'Adjuvant chemotherapy', 'Gastric cancer', 'S-1', '\\nHelicobacter pylori-naïve\\n', 'endoscopy', 'gastric gland', 'incisura angularis', 'normal mucosa', 'stomach', 'Trousseau syndrome', 'disseminated carcinomatosis of bone marrow', 'embolic strokes of undetermined source (ESUS)', 'gastric cancer', 'recurrent stroke', 'colonic malignant tumors', 'hospital information system', 'medication characteristics', 'real-world study', 'syndrome distribution', 'Neoadjuvant chemotherapy', 'para-aortic lymph node excision', 'stomach neoplasms', 'Muscle mass loss', 'esophagectomy', 'oesophageal cancer', 'Anti-PD-(L)1', 'chemotherapy', 'gastric cancer', 'immune checkpoint inhibitor', 'Gastric cancer', 'HIPEC', 'cytoreductive surgery', 'peritoneal carcinomatosis', '5-FU', 'Apex1-Jagged-1 cascade', 'Cisplatin', 'chemorefractory', 'chemoresistance', 'chemoresponsive', 'Clinical outcom', 'Enhanced Recovery After Surgery', 'Prognosis', 'Stomach, neoplasm', 'Dyspnea', 'mortality', 'neoplasms', 'palliative care', 'survival', 'Gastrectomy', 'Minimally invasive procedures', 'Morbidity', 'Pancreatic fistula', 'Robotic surgical procedure', 'Stomach neoplasms', 'DFMO', 'Helicobacter. pylori', 'IL-6', 'capsaicin', 'gastric cancer', 'gastric inflammation', 'Helicobacter pylori', 'Inflammasome', 'Interleukin-1β', 'NLRP3', 'AB0 blood system', 'H.рylori', 'blood groups', 'breast cancer', 'coronary artery disease', 'esophageal cancer', 'human diseases', 'malaria', 'oral diseases', 'review', 'schistosomiasis', 'stomach cancer', 'ITLPDGL', 'gastric cancer', 'involved field radiotherapy', 'lymphoproliferative disorder', 'treatment', 'Australia', 'Cancer', 'Life expectancy', 'Neoplasms', 'Prognosis', 'cardia', 'early gastric carcinoma', 'muscularis mucosa', 'submucosa', 'Cancer', 'Epidemiology', 'Gender', 'Levothyroxine', 'Beta-alanine', 'Biomarkers', 'Metabolomics', 'Recurrence', 'Stomach neoplasms', 'Biomarker', 'Differentially expressed genes', 'Gastric cancer', 'Microarray', 'SOX5', 'Wnt signaling', 'miR-338-3p', 'proliferation', '·gastric cancer', 'Frozen section', 'Gastric carcinoma', 'Intraoperative consultation', 'Poorly cohesive', 'Signet-ring cell', 'Gastric cancer', 'Helicobacter pylori', 'autoimmune gastritis', 'survival', 'symptoms', 'EOX', 'Efficacy', 'Gastric cancer', 'm-DCF', 'safety', 'Lung carcinoma', 'metastasis', 'squamous cell carcinoma', 'stomach', 'Scirrhous gastric cancer', 'Splenectomy', 'Therapeutic value index', 'companion diagnostics', 'expression analysis', 'gastric cancer', 'genomic test', 'immunotherapy', 'molecular pathway analysis', 'mutation', 'platform comparison', 'stomach adenocarcinoma', 'general surgery', 'surgery', 'Clinical classification', 'Neuroendocrine tumors', 'Pathology', 'Prognosis', 'Stomach', 'Clinicopathological features', 'Lung neoplasms', 'Lymphoepithelioma-like carcinoma', 'Prognosis', 'early gastric cancer', 'gastric precancerous lesions', 'gastric tumorigenesis', 'immune infiltration', 'prognosis', 'stemness', 'tumor hallmarks', 'GERD', 'Laparoscopic Sleeve Gastrectomy', 'Magnetic Resonance Imaging (MRI)', 'DNA methylation', 'Gastric cancer', 'Prognosis', 'SAMD14 gene', 'Early gastric cancer', 'Endoscopy', 'Magnifying endoscopy', 'Narrow band imaging', 'MIS', 'gastrectomy', 'gastric cancer', 'CD8+ T cells', 'Gastric cancer', 'Lauren classification', 'Prognosis', 'Gastric cancer', 'Metastasis', 'Multidrug resistance', 'microRNA-1323', 'β-Elemene', 'Gastric cancer', 'Morbidity', 'Mortality', 'Octogenarian', 'POSSUM', '13C-urea breath test', 'Helicobacter pylori', 'gastric cardia', 'gastric cardia adenocarcinoma', 'population-based studies', 'precursor lesions', 'PSMA', 'actinium', 'metastatic mouse model', 'prostate cancer', 'targeted alpha therapy', 'Stomach', 'lymphadenectomy', 'metastasis', 'neoplasm', 'prognosis', 'De Novo Malignancy', 'Hepatocellular Carcinoma', 'Living Donor Liver Transplantation', 'Recurrence', 'Surveillance', 'Elderly patients', 'Gastric cancer', 'Prognostic nutrition index', 'Blue toe syndrome', 'Case report', 'Cholesterol crystal embolization', 'Distal gastrectomy', 'Gastric remnant necrosis', 'Cancer', 'Cancer prevalence', 'Cost of illness', 'Socioeconomic burden', 'Immunotherapy', 'esophageal neoplasms', 'stomach neoplasms', 'Esophagojejunostomy', 'Gastric cancer', 'Laparoscopic-assisted', 'Meta-analysis', 'Total gastrectomy', 'Totally laparoscopic', 'AmBF3-TATE', 'Dosimetry', 'Fluorine-18', 'Neuroendocrine tumors', 'Positron emission tomography', 'Toxicology', '18F-FDG', 'Cancer', 'Dynamic acquisition', 'Whole-body PET', 'Sophora alopecuroides', 'computer simulation', 'cytisine-isoflavone derivative', 'druggability', 'pharmacokinetics', 'tissue distribution', 'ABC method', 'Helicobacter pylori', 'atrophic gastritis', 'cancer screening', 'gastric cancer', 'pepsinogens', 'Helicobacter pylori', 'atrophic', 'gastritis', 'pepsinogens', 'serological risk prediction system', 'stomach neoplasms', 'Early detection of cancer', 'Stomach neoplasms', 'Systematic review', 'China', 'Economics, medical', 'Neoplasms', 'Priority setting', 'Screening', 'Systematic review', 'Angiogenesis inhibitors', 'Apoptosis', 'Cell proliferation', 'Methylnitronitrosoguanidine', 'Stomach neoplasms', 'Weining granule', 'BGC823 cell', 'Epithelial- mesenchymal transition', 'Matrix metalloproteinases, secreted', 'Signal transduction', 'Smad proteins', 'Transforming growth factor beta1', 'Wulong Xiaozheng Wan', 'Decision trees', 'Endosonography', 'Neoplasm staging', 'Stomach neoplasm', 'GC/MS', 'Metabolomics', 'Sample treatment', 'Stomach cancer cells', 'folate', 'gene therapy', 'leucine-bearing PEI', 'siPLK1', 'targeted delivery', 'Bacteria', 'Risk of Death', 'Stomach Cancer', 'Thickened Gastric Wall', 'Advanced gastric Cancer', 'Intraperitoneal Hyperthermic chemotherapy', 'Neoadjuvant chemotherapy', 'Peritoneal Carcinomatosis', 'Progression-free survival', 'early gastric cancer', 'endoscopic submucosal dissection', 'precancerous lesions', 'stomach', 'Gastric cancer', 'Glasgow prognostic score', 'Prognostic value', 'Recurrence', 'Survival', 'Chemoprevention', 'Diagnosis', 'Epidemiology', 'Gastric cancer', 'Prevention', 'Screening', 'Surveillance', 'Early gastric cancer', 'Endoscopic submucosal dissection', 'Gastrectomy', 'Laparoscopy', 'Bevacizumab', 'Chemotherapy', 'Colon cancer', 'Gastric cancer', 'Liver metastasis', 'SOX', 'Synchronous double cancer', 'Gastrointestinal cancer mortality', 'Live cancer mortality', 'Long-term exposure', 'PM(2.5) air pollution', 'Taiwan', '2020', 'Forecasting', 'Incidence', 'Korea', 'Mortality', 'Neoplasms', 'endoscopic submucosal dissection', 'frailty', 'gastric cancer', 'malignancy', 'prognosis', 'Fentanyl', 'apoptosis, matrix metalloproteinase-9 (MMP-9)', 'cell proliferation', 'stomach neoplasm', 'A-kinase anchor protein 5 (AKAP5)', 'Stomach neoplasms', 'adenocarcinoma', 'survival analysis', 'EMCN', 'MUC family', 'MUC15', 'gastric cancer', 'prognostic', 'Esophagus cancer', 'chemoradiation', 'proton therapy', 'Incidence', 'Iran', 'Kurdistan', 'joinpoint', 'stomach neoplasms', 'trends', 'Cancer therapy', 'Gastric cancer', 'MicroRNAs', 'Signaling pathway', 'Wnt', 'DNA methylation', 'Epigenetics alterations', 'Gastric cancer', 'ATM', 'Case–control study', 'Gastric cancer', 'Birt-Hogg-Dubé syndrome', 'FLCN gene', 'Pneumothorax', 'Polyps', 'Skin neoplasms', 'Adenocarcinoma', 'Diffuse type', 'Gastric neoplasms', 'Histology', 'Intestinal type', 'Laurén classification', 'Oesophageal neoplasms', 'Prognosis', 'Survival', 'Diagnosis', 'Gastric cancer', 'Gastritis', 'Helicobacter pylori', 'Peptic ulcer disease', 'Treatment', 'immune checkpoint blockade', 'microsatellite instability-high', 'stomach adenocarcinoma', 'subtyping', '177Lu', '18F-FDG', '90Y', 'neuroendocrine neoplasms', 'peptide receptor radionuclide therapy', 'prognostic factor', 'Gastric cancer', 'clinical practice', 'outcome research', 'real-world', 'Helicobacter pylori', 'gastric carcinoma', 'immunohistochemistry', 'resistin-like molecule beta', 'Gastric cancer', 'Immune infiltration', 'SLC22A17', 'SUPV3L1', 'bone metastasis', 'gastrointestinal stromal tumor', 'prognosis', 'tyrosine kinase inhibitors', 'Gastric cancer', 'Gastrointestinal cancer', 'Hepatocellular cancer', 'Hepatoid adenocarcinoma', 'Radiation therapy', 'SEER', 'gastric cancer', 'lymphoma', 'prognostic factor', 'dysplasia', 'gastric cancer', 'miRNA', 'molecular diagnostics', 'Geranium thunbergii', 'apoptosis', 'cell cycle arrest', 'gastric cancer', 'Biomarkers', 'Gastrectomy', 'Gastric cancer', 'Lymphadenectomy', 'Minimally invasive surgery', 'Molecular classification']\n"
     ]
    }
   ],
   "source": [
    "col_keywords = articlesPD['keywords'].tolist()\n",
    "\n",
    "col_keywords = list(filter(None, col_keywords))\n",
    "#col_keywords\n",
    "#print((\",\").join(str(i) for i in col_keywords))\n",
    "keywords=[]\n",
    "for i in col_keywords:\n",
    "    keywords+=i\n",
    "print (keywords)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Colonoscopic surveillance, 1\n",
      "Colonoscopy, 2\n",
      "Colorectal neoplasm, 1\n",
      "Stomach neoplasms, 82\n",
      "Colon interposition, 1\n",
      "Oesophageal cancer, 3\n",
      "Surgical techniques, 2\n",
      "Upper gastrointestinal surgery, 1\n",
      "gastric adenocarcinoma, 5\n",
      "gastric cancer, 110\n",
      "gastric dysplasia, 1\n",
      "hereditary diffuse gastric cancer (HDGC), 1\n",
      "hereditary gastric cancer syndromes, 1\n",
      "Gastrointestinal stromal tumor (GIST), 1\n",
      "case report, 4\n",
      "embolization, 1\n",
      "emergency surgery, 1\n",
      "radiofrequency procedure, 1\n",
      "cancer associated fibroblast, 1\n",
      "fibroblast growth factor receptor, 1\n",
      "scirrhous carcinoma of the stomach, 1\n",
      "transforming growth factor β1, 1\n",
      "tumor microenvironment, 3\n",
      "gene alteration, 1\n",
      "gene mutation, 2\n",
      "mesenchymal–epithelial transition factor, 1\n",
      "outcome, 2\n",
      "pancancer, 1\n",
      "esophageal cancer, 11\n",
      "gastric tube, 1\n",
      "high esophageal-gastric anastomosis, 1\n",
      "tubular gastric lengthening surgery, 1\n",
      "indocyanine green, 1\n",
      "near-infrared fluorescence, 1\n",
      "alpha-fetoprotein-producing gastric cancer, 1\n",
      "hepatoid adenocarcinoma of stomach, 1\n",
      "immunotherapy, 6\n",
      "Breast cancer, 4\n",
      "Case report, 13\n",
      "Ileal GIST, 1\n",
      "Neurofibromatosis type I, 1\n",
      "Immune-related adverse events, 1\n",
      "Muscle-invasive bladder cancer, 1\n",
      "Pembrolizumab, 3\n",
      "Positron emission tomography/computed tomography, 1\n",
      "Prognosis, 45\n",
      "clinical efficacy, 1\n",
      "laparoscopic-assisted radical gastrectomy, 1\n",
      "modified roux-en-y anastomosis, 1\n",
      "roux-en-y anastomosis, 1\n",
      "totally laparoscopic radical gastrectomy, 1\n",
      "cervix uteri, 1\n",
      "dogs, 1\n",
      "odorants, 1\n",
      "urine, 1\n",
      "volatile organic compounds, 1\n",
      "Early-stage gastric cancers, 1\n",
      "Endoscopy, 14\n",
      "Pathology, 7\n",
      "Stomach cancer, 24\n",
      "Tumor budding, 1\n",
      "HBV, 1\n",
      "HCV, 1\n",
      "NAFLD, 1\n",
      "adipokine, 1\n",
      "adiponectin, 1\n",
      "biliary, 1\n",
      "colon, 1\n",
      "esophagus, 3\n",
      "gallbladder, 2\n",
      "leptin, 1\n",
      "pancreas, 3\n",
      "small intestine, 2\n",
      "stomach, 25\n",
      "natural medicine, 1\n",
      "phytocompounds, 1\n",
      "phytotherapy, 1\n",
      "Caveolin-1, 1\n",
      "MicroRNA-451a, 1\n",
      "stomach cancer, 20\n",
      "Double contrast study, 1\n",
      "Gastric arteries, 1\n",
      "Gastric veins, 1\n",
      "Submucosal gastric vessels, 1\n",
      "X-ray imaging, 1\n",
      "Gastrectomy, 26\n",
      "Quality of life, 6\n",
      "Endoscopic submucosal dissection (ESD), 1\n",
      "Gastric cancer, 139\n",
      "Undifferentiated type, 1\n",
      "Atrophic gastritis, 3\n",
      "Mutation, 3\n",
      "Screening, 6\n",
      "Biopsy, 2\n",
      "Lobular carcinoma, 1\n",
      "Metastasis, 9\n",
      "Polyps, 2\n",
      "Image reconstruction, 1\n",
      "Intraoperative imaging, 1\n",
      "Lymph node metastases, 1\n",
      "Positron emission tomography, 2\n",
      "cancer risk, 1\n",
      "digestive tract cancer, 1\n",
      "socioeconomic status, 1\n",
      "Early gastric cancer, 11\n",
      "Histopathology, 1\n",
      "Lymph node metastasis risk, 1\n",
      "Stomach, 32\n",
      "Endoscopic submucosal dissection, 12\n",
      "Ho:YAG laser, 1\n",
      "Laser ablation, 1\n",
      "cytoreduction surgical procedures, 1\n",
      "laparoscopes, 1\n",
      "ovarian cancer, 3\n",
      "CpG, 2\n",
      "SOX protein family, 1\n",
      "SOX17, 1\n",
      "SOX18, 1\n",
      "SOX30, 1\n",
      "SOX7, 1\n",
      "lung adenocarcinoma, 2\n",
      "lung squamous-cell carcinoma, 1\n",
      "miRNA, 6\n",
      "non-small cell lung carcinoma, 1\n",
      "Gene expression profiling, 2\n",
      "Microsatellite instability, 8\n",
      "PD-L1, 8\n",
      "Women's Health Initiative, 1\n",
      "cancer, 25\n",
      "cardiometabolic risk factors, 1\n",
      "survival, 13\n",
      "Dumping symptoms, 1\n",
      "Esophagectomy, 1\n",
      "Health-related quality of life, 3\n",
      "Long-term follow-up, 1\n",
      "cancer pain, 3\n",
      "celiac plexus, 1\n",
      "chronic pain, 1\n",
      "pancreatic cancer, 5\n",
      "splanchnic nerves, 1\n",
      "YAP1, 1\n",
      "cell biology, 1\n",
      "miR-205, 2\n",
      "propofol, 1\n",
      "cytotoxic chemotherapy, 1\n",
      "gastroesophageal junction cancer, 1\n",
      "targeted therapy, 4\n",
      "lymph node, 1\n",
      "metastasis, 8\n",
      "neoplasm, 5\n",
      "prognosis, 35\n",
      "Proximal gastric cancer, 1\n",
      "overall survival, 4\n",
      "postoperative complication, 1\n",
      "review, 3\n",
      "splenectomy, 1\n",
      "association rule, 1\n",
      "comorbidity, 2\n",
      "prevalence ratio, 1\n",
      "MiNEN, 1\n",
      "small (large) cell, 1\n",
      "Cholecystectomy, 1\n",
      "Colorectal Cancer, 1\n",
      "Stomach Cancer, 4\n",
      "CANCER EPIDEMIOLOGY, 1\n",
      "COLORECTAL CANCER, 1\n",
      "COLORECTAL CANCER SCREENING, 1\n",
      "GASTROINTESTINAL CANCER, 1\n",
      "Cancer, 35\n",
      "drinking water, 1\n",
      "meta-analysis, 7\n",
      "nitrates, 1\n",
      "nitrites, 1\n",
      "systematic review, 2\n",
      "Adenocarcinoma, 8\n",
      "Neuroendocrine neoplasms, 2\n",
      "Serum lipids, 1\n",
      "Allergenic genes, 1\n",
      "Anisakis pegreffii, 1\n",
      "Gastric juice, 1\n",
      "Transcriptomic analysis, 1\n",
      "methylation, 5\n",
      "selenoprotein, 1\n",
      "selenoproteome, 1\n",
      "Amyloid, 1\n",
      "Heart failure, 2\n",
      "Transthyretin, 1\n",
      "Transthyretin amyloidosis, 1\n",
      "Val122Ile, 1\n",
      "convolutional neural network, 1\n",
      "deep learning, 1\n",
      "histology, 1\n",
      "whole-slide imaging, 1\n",
      "Carcinoma, 3\n",
      "Esophageal cancer, 9\n",
      "Gastroesophageal junction, 1\n",
      "Histology, 3\n",
      "Metastases, 1\n",
      "Squamous cell, 1\n",
      "carcinoma, 2\n",
      "immunohistochemistry, 6\n",
      "viruses, 1\n",
      "Barrett, 1\n",
      "Epidemiology, 12\n",
      "adenoma, 1\n",
      "capsule endoscopy, 2\n",
      "diverticula, 1\n",
      "healthy population, 1\n",
      "immunosuppression, 1\n",
      "mouse model, 1\n",
      "resistance, 1\n",
      "Adaptive radiotherapy, 2\n",
      "Kernel modeling, 1\n",
      "Multi-organ motion analysis, 1\n",
      "Statistical deformation library, 1\n",
      "electrical stimulation, 1\n",
      "electroceuticals, 1\n",
      "gastrointestinal tract, 2\n",
      "Gastrointestinal stromal tumors, 2\n",
      "Risk factors, 10\n",
      "Tomography, X-ray computed, 3\n",
      "ambulatory care, 1\n",
      "oncology, 3\n",
      "patient-reported outcome measures, 1\n",
      "quality of health care, 1\n",
      "LncRNA, 1\n",
      "SNHG12, 1\n",
      "sarcoma, 2\n",
      "LncRNA FTX, 1\n",
      "cirrhosis, 2\n",
      "heart failure., 1\n",
      "temporal lobe epilepsy, 1\n",
      "Bursa sac, 1\n",
      "Lymphadenectomy, 6\n",
      "Mesogastrium, 2\n",
      "Surgical procedures, 1\n",
      "Laparoscopic gastrectomy, 2\n",
      "Lung neoplasms, 3\n",
      "Nivolumab, 2\n",
      "Piwil1 gene, 1\n",
      "single nucleotide polymorphisms, 2\n",
      "biliary tract, 1\n",
      "neutrophil to lymphocyte ratio, 2\n",
      "nomogram, 3\n",
      "site, 1\n",
      "stomach neoplasms, 32\n",
      "surgery, 6\n",
      "Billroth I reconstruction, 1\n",
      "laparoscopic distal gastrectomy, 1\n",
      "Non-small-cell lung cancer, 1\n",
      "cancer stem cell, 1\n",
      "prognostic marker, 2\n",
      "GastroPanel, 1\n",
      "Helicobacter pylori, 41\n",
      "Hp IgG ELISA, 1\n",
      "biomarker test, 1\n",
      "biopsy, 1\n",
      "clinical validation, 1\n",
      "gastrin-17, 1\n",
      "gastroscopy, 1\n",
      "new-generation, 1\n",
      "non-invasive, 1\n",
      "pepsinogen I, 1\n",
      "pepsinogen II, 1\n",
      "Asian Americans, 1\n",
      "survival outcomes, 2\n",
      "LITAF, 1\n",
      "miR-1, 1\n",
      "Cytoreductive surgery, 1\n",
      "Differentiation, 2\n",
      "Nongynecologic primary site, 1\n",
      "Ovarian metastasis, 2\n",
      "Residual lesion, 1\n",
      "COVID-19, 8\n",
      "Chemotherapy, 13\n",
      "SARS-CoV-2, 2\n",
      "treatment, 3\n",
      "LUCAT1, 1\n",
      "Long non-coding RNA, 2\n",
      "epigenetic modulation, 1\n",
      "Breath Tests, 1\n",
      "Electronic Nose, 1\n",
      "Gastrointestinal Neoplasms, 1\n",
      "Stomach Neoplasms, 5\n",
      "Volatile Organic Compounds, 1\n",
      "fetus, 1\n",
      "pathogenesis, 2\n",
      "placenta, 1\n",
      "PD-1, 3\n",
      "biomarker, 6\n",
      "tumor-infiltrating lymphocytes, 1\n",
      "COMPREV software, 1\n",
      "Population-based cancer registry, 1\n",
      "complete cancer prevalence, 1\n",
      "phase of care prevalence, 1\n",
      "acute gastritis, 1\n",
      "immune checkpoint inhibitor, 3\n",
      "melanoma, 2\n",
      "intermittent hypoxia, 1\n",
      "obesity, 2\n",
      "risk factors, 2\n",
      "sleep, 2\n",
      "sleep apnea, 1\n",
      "Thromboelastography, 1\n",
      "lower extremity deep venous thrombosis, 1\n",
      "portal hypertension, 1\n",
      "diet, 3\n",
      "epidemiology, 9\n",
      "flavonoids, 1\n",
      "polyphenols, 1\n",
      "Breast neoplasms, 3\n",
      "Colorectal neoplasms, 2\n",
      "Early detection of cancer, 3\n",
      "Healthcare surveys, 1\n",
      "Liver neoplasms, 4\n",
      "Trends, 2\n",
      "Uterine cervical neoplasms, 1\n",
      "Lauren, 1\n",
      "gastrin, 2\n",
      "Education, 2\n",
      "Endoscopic Surgical Skill Qualification System, 1\n",
      "Minimally invasive surgical procedures, 4\n",
      "Postoperative complications, 3\n",
      "gastric malignancy, 1\n",
      "red cell distribution width, 1\n",
      "Digestive tract cancer, 1\n",
      "Immediate double primary cancer, 1\n",
      "Cell Biology, 1\n",
      "Immunology, 1\n",
      "A case series study, 1\n",
      "Different outcomes, 1\n",
      "Localized gastric amyloidosis, 1\n",
      "Mucosa-associated lymphoid tissue lymphoma, 1\n",
      "Rare disease, 1\n",
      "Gastric adenocarcinoma, 7\n",
      "Immunohistochemical staining, 1\n",
      "Protease inhibitor, 1\n",
      "Squamous cell carcinoma antigen, 1\n",
      "Krukenberg tumor, 1\n",
      "Nomograms, 2\n",
      "MMR proteins, 1\n",
      "MSI, 2\n",
      "head and neck cancer, 2\n",
      "local recurrence, 1\n",
      "microsatellite instability, 4\n",
      "multiple primary tumors, 1\n",
      "progression, 1\n",
      "Wnt/β-catenin dependent pathway, 1\n",
      "Wnt/β-catenin independent pathway, 1\n",
      "breast cancer, 6\n",
      "colorectal cancer, 10\n",
      "extracellular vesicles, 3\n",
      "Apoptosis, 7\n",
      "FADD, 1\n",
      "Gastric Cancer, 2\n",
      "INDEL, 1\n",
      "Direct medical expenses, 1\n",
      "Smoking, 3\n",
      "Chinese herbs, 1\n",
      "recurrence, 3\n",
      "symptoms, 2\n",
      "type 1 gastric neuroendocrine tumors, 1\n",
      "Carcinoma–signet ring cell, 1\n",
      "Crohn disease, 1\n",
      "ileal neoplasms, 1\n",
      "inflammation, 5\n",
      "intestine–small, 1\n",
      "Calcification, 1\n",
      "Calcifying fibrous pseudotumor, 1\n",
      "Calcifying fibrous tumor, 1\n",
      "Gastrointestinal tract, 3\n",
      "Mesenchymal lesion, 1\n",
      "B7-H1 antigen, 1\n",
      "Liquid biopsy, 2\n",
      "Progression-free survival, 2\n",
      "Trastuzumab, 4\n",
      "Treatment outcome, 2\n",
      "Claudin-2, 1\n",
      "Genomic Profile, 1\n",
      "Paracellular Permeability, 1\n",
      "RNAseq, 1\n",
      "Ussing Chambers, 1\n",
      "Cancer pain, 1\n",
      "GI cancer, 1\n",
      "OIC-J, 1\n",
      "Observational study, 1\n",
      "Opioid-induced constipation, 1\n",
      "copy number, 1\n",
      "expression, 2\n",
      "immune cell, 1\n",
      "mutation, 4\n",
      "pan-cancer, 1\n",
      "pathways, 1\n",
      "pepsinogen, 2\n",
      "risk, 2\n",
      "Ivor-Lewis procedure, 1\n",
      "anastomotic leak, 1\n",
      "confocal laser endomicroscopy, 1\n",
      "esophageal resection, 1\n",
      "fluorescence imaging, 1\n",
      "hyperspectral imaging, 1\n",
      "ischemic preconditioning, 1\n",
      "optical imaging, 1\n",
      "health communication, 1\n",
      "health literacy, 1\n",
      "neoplasms, 3\n",
      "quality of life, 4\n",
      "social support, 1\n",
      "cdh1, 1\n",
      "e-cadherin, 1\n",
      "hereditary gastric diffuse cancer, 1\n",
      "invasive lobular breast cancer, 1\n",
      "prophylactic gastrectomy, 1\n",
      "signet ring cell adenocarcinoma, 1\n",
      "Alternative splicing, 1\n",
      "ECT2, 1\n",
      "TCGA, 9\n",
      "Anti-reflux, 1\n",
      "Esophagogastric junction tumor, 1\n",
      "Proximal gastrectomy, 5\n",
      "Reconstruction of digestive tract, 1\n",
      "Adenocarcinoma of the esophagogastric junction, Siewert II, 1\n",
      "Digestive tract reconstruction, 2\n",
      "Carbon nanoparticles, 1\n",
      "Lymph node retrieval, 1\n",
      "Complications, 2\n",
      "Esophagojejunal anastomosis, 1\n",
      "Total gastrectomy, 4\n",
      "Stomach neoplasms, adolescent, 1\n",
      "Biological behavior, 1\n",
      "TNM staging, 1\n",
      "Function preserving, 2\n",
      "Minimally invasive treatment, 2\n",
      "Submucosal tumors, 1\n",
      "Combined laparoscopy-endoscopy surgery, 1\n",
      "Local resection, 1\n",
      "Sentinel node navigation surgery, 1\n",
      "Stomach neoplasms, early, 3\n",
      "Function-preserving gastrectomy, 3\n",
      "Vagal nerve, celiac branch, 1\n",
      "Cardia, 2\n",
      "Pylorus-preserving gastrectomy, 1\n",
      "Segmental gastrectomy, 2\n",
      "Anastomosis, 1\n",
      "Function reconstruction, 1\n",
      "Helicobacter pylori infection, 1\n",
      "falls, 1\n",
      "fractures, 1\n",
      "management, 2\n",
      "medications, 1\n",
      "osteoporosis, 1\n",
      "laparoscopy, 5\n",
      "lymphadenectomy, 3\n",
      "mesogastric excision, 1\n",
      "ER-phagy, 1\n",
      "autophagy, 1\n",
      "endoplasmic reticulum, 1\n",
      "gene expression, 2\n",
      "reticulophagy, 1\n",
      "CT image, 1\n",
      "application, 1\n",
      "nursing intervention, 1\n",
      "Disease-free survival, 1\n",
      "laparoscopic, 1\n",
      "robotic, 1\n",
      "gastric mucosa homeostasis, 1\n",
      "gastric organoid, 2\n",
      "gastric stem cells, 1\n",
      "stem cell niche, 1\n",
      "STAT family, 1\n",
      "Stomach adenocarcinoma, 3\n",
      "bioinformatics analysis, 2\n",
      "pathological features, 1\n",
      "α-fetoprotein, 1\n",
      "Colon, 4\n",
      "Lung metastasis, 1\n",
      "Lymphangitic lung carcinomatosis, 1\n",
      "Metastatic cancer, 1\n",
      "Micropapillary colorectal carcinoma, 1\n",
      "acute vestibular syndrome, 1\n",
      "carcinomatous meningitis, 1\n",
      "epithelial mesenchymal transition, 1\n",
      "signet ring cell carcinoma, 1\n",
      "Gastric conduit, 2\n",
      "Thoracic esophageal cancer, 1\n",
      "Chemoresistance, 2\n",
      "GAC, 1\n",
      "GNEC, 1\n",
      "NeuroD1, 1\n",
      "Transcriptome analysis, 1\n",
      "Ovarian cancer, 1\n",
      "Prior malignancy, 1\n",
      "SEER, 4\n",
      "Infiltrated macrophages, 1\n",
      "NF-kB and STAT3, 1\n",
      "PD-1/PD-L1, 1\n",
      "TNF-ɑ and IL-6, 1\n",
      "Biclonal gammopathy, 1\n",
      "Bone marrow, 1\n",
      "Marginal zone B-cell lymphoma, 1\n",
      " helicobacter pylori , 1\n",
      "Caudal type homeoboxes, 1\n",
      "intestinal metaplasia, 3\n",
      "sonic hedgehog, 1\n",
      "sry- related high-mobility group box 2, 1\n",
      "Gastric glands, 1\n",
      "Glycoconjugates, 1\n",
      "Lectin histochemistry, 1\n",
      "Mucins, 2\n",
      "Zymogens, 1\n",
      "adenocarcinoma, 4\n",
      "fundic gland mucosa type, 1\n",
      "fundic gland type, 1\n",
      "oxyntic gland neoplasm, 1\n",
      "esophagectomy, 4\n",
      "intrapleural esophageal-gastric anastomosis, 1\n",
      "laparothoracoscopic esophagectomy, 1\n",
      "Azores, 1\n",
      "Cancer control, 1\n",
      "Cancer surveillance, 1\n",
      "Portugal, 1\n",
      "Gastrointestinal stromal tumor, 7\n",
      "Meckel’s diverticulum, 1\n",
      "Perforation, 3\n",
      "Autoimmune atrophic gastritis, 1\n",
      "Potassium-competitive acid blocker, 1\n",
      "Vonoprazan, 1\n",
      "White globe appearance, 1\n",
      "Abdominal pain, 1\n",
      "CT, 2\n",
      "Gastrointestinal tumors, 1\n",
      "Lymphatic metastasis, 4\n",
      "Stomach neoplasm, 11\n",
      "Laparoscopy, 12\n",
      "Surgical anastomosis, 1\n",
      "Volumetric CT, 1\n",
      "Laparoscopic surgery, 4\n",
      "Patient outcome assessment, 1\n",
      "Postoperative complication, 2\n",
      "Endoscopy, gastrointestinal, 1\n",
      "Anastomotic leak, 1\n",
      "Self-expandable metallic stents, 2\n",
      "Vacuum assisted closure, 1\n",
      "Dendritic cell, 1\n",
      "H. Pylori, 1\n",
      "SOCS, 1\n",
      "Type IV secretion system, 2\n",
      "p38, 1\n",
      "antioxidants, 1\n",
      "coffee, 1\n",
      "mortality, 8\n",
      "observational study, 2\n",
      "partial gastrectomy, 1\n",
      "pyloric metaplasia, 1\n",
      "remnant gastric cancer, 1\n",
      "diagnostic techniques and procedures, 1\n",
      "gastrointestinal neoplasms, 4\n",
      "molecular, 2\n",
      "pathology, 5\n",
      "clinical trial, 2\n",
      "phase III, 1\n",
      "precision medicine, 2\n",
      "sentinel lymph node, 1\n",
      "enhanced recovery after surgery, 1\n",
      "length of hospital stay, 1\n",
      "nausea and vomiting scores, 1\n",
      "oral carbohydrate loading, 1\n",
      "pain scores, 1\n",
      "post operative care, 1\n",
      "Hepatocellular carcinoma, 3\n",
      "metabolism, 2\n",
      "Gastrointestinal stromal tumour, 3\n",
      "Survival, 11\n",
      "Diffuse large B-cell lymphoma, 1\n",
      "Gallbladder, 1\n",
      "Literature review, 1\n",
      "Testis, 2\n",
      "Coronavirus disease 2019, 1\n",
      "Retrospective analysis, 1\n",
      "proximal gastrectomy, 2\n",
      "reconstruction method, 1\n",
      "Cancer-associated thrombosis, 1\n",
      "Direct oral anticoagulants, 2\n",
      "Gastrointestinal cancer, 6\n",
      "Splanchnic vein thrombosis, 1\n",
      "Venous thromboembolism, 3\n",
      "computed tomography, 1\n",
      "gastric metastasis, 1\n",
      "Bioinformatic analysis, 1\n",
      "Differentially expressed genes, 2\n",
      "Gastric carcinoma, 7\n",
      "Overall survival, 4\n",
      "heterogeneity, 1\n",
      "multi-gene model, 1\n",
      "prediction, 1\n",
      "stomach adenocarcinoma, 5\n",
      "organoids, 1\n",
      "personalized medicine, 2\n",
      "spheroids, 1\n",
      "Epstein–Barr virus-associated gastric cancer, 1\n",
      "Multiple gastric cancer, 2\n",
      "Robot-assisted laparoscopic gastrectomy, 1\n",
      "Colitis, 1\n",
      "Colonic neoplasms, 2\n",
      "Intestinal polyposis, 1\n",
      "Malnutrition, 1\n",
      "Drug therapy, 3\n",
      "Huachansu injection, 1\n",
      "Meta-analysi, 1\n",
      "Randomized controlled trial, 2\n",
      "Gastric fornix, 1\n",
      "Helicobacter pylori-uninfected, 1\n",
      "Poorly differentiated adenocarcinoma, 1\n",
      "Undifferentiated-type, 1\n",
      "Cardiovascular diseases, 1\n",
      "Chronic kidney diseases, 1\n",
      "Disability-adjusted life years, 1\n",
      "Future prediction, 1\n",
      "Japan, 1\n",
      "Salt intake, 1\n",
      "FES-PET, 1\n",
      "abdominal distribution, 1\n",
      "chocolate, 1\n",
      "fasting, 1\n",
      "Fluorescence-guided surgery, 2\n",
      "Fluorescent over the scope clip, 1\n",
      "Indocyanine green tattooing, 1\n",
      "Preoperative endoscopic marking, 1\n",
      "Preoperative endoscopic tattooing, 1\n",
      "S-1, 5\n",
      "adjuvant chemotherapy, 3\n",
      "glioma-associated oncogene 1, 1\n",
      "prognostic factor, 5\n",
      "Cell biology, 1\n",
      "margins of excision, 1\n",
      "TAM, 1\n",
      "TYRO3, 1\n",
      "5-fluorouracil, 1\n",
      "gemcitabine, 2\n",
      "liver metastasis, 2\n",
      "nude mice, 1\n",
      "oxaliplatinum, 1\n",
      "patient-derived orthotopic xenograft (PDOX), 1\n",
      "6 MV Linac, 1\n",
      "Cobalt-60 teletherapy machine, 1\n",
      "MLCs, 1\n",
      "ROPS planning system, 1\n",
      "genetics, 1\n",
      "neuroendocrine carcinoma, 1\n",
      "targeted sequencing, 1\n",
      "Cancer cure, 1\n",
      "Europe, 1\n",
      "life expectancy, 1\n",
      "mixture cure models, 1\n",
      "population-based cancer registries, 1\n",
      "time to cure, 1\n",
      "Liver, 1\n",
      "neuroendocrine neoplasm, 1\n",
      "primary, 2\n",
      "diagnosis, 3\n",
      "primary care, 1\n",
      "GI, 1\n",
      "General surgery, 1\n",
      "Oncology, 3\n",
      "CD44, 3\n",
      "breast cancer chemotherapy, 1\n",
      "doxorubicin, 1\n",
      "hyaluronic acid, 1\n",
      "pH-sensitive, 1\n",
      "CAR-T cell therapy, 1\n",
      "TCGA database, 1\n",
      "radiosensitivity genes, 1\n",
      "Gastritis, 5\n",
      "Kyoto classification, 1\n",
      "Neutrophil activity, 1\n",
      "Updated Sydney System, 1\n",
      "Esophagogastric junction, 1\n",
      "Minimally invasive surgery, 3\n",
      "Para-aortic lymph node, 2\n",
      "Deep learning, 3\n",
      "Multi-detector computed tomography, 2\n",
      "Radiomics, 3\n",
      "Cancer of stomach, 1\n",
      "laparoscopic approach, 1\n",
      "robotic approach, 1\n",
      "Cardiac adenocarcinoma, 1\n",
      "Epithelial–mesenchymal transition, 1\n",
      "NCAPG, 1\n",
      "Wnt/β-catenin signaling pathway, 1\n",
      "clinical staging, 1\n",
      "cancer incidence, 2\n",
      "case-control study, 2\n",
      "diabetes, 1\n",
      "occupational exposure, 1\n",
      "smoking, 1\n",
      "adenocarcinoma of esophagus, 1\n",
      "cardia, 3\n",
      "esophagogastric junction, 2\n",
      "gastrointestinal stromal tumors, 1\n",
      "primary tumor resection, 1\n",
      "lamb model, 1\n",
      "monoclonal antibody, 1\n",
      "nebulization , 1\n",
      "palivizumab, 1\n",
      "prophylactic, 1\n",
      "respiratory syncytial virus, 1\n",
      "AFP-positive, 1\n",
      "Adenocarcinomatous, 1\n",
      "Gastric carcinosarcoma, 1\n",
      "Recurrence, 7\n",
      "N6-methyladenosine, 1\n",
      "immune checkpoint, 1\n",
      "mRNA modification, 1\n",
      "signature, 2\n",
      "stomach carcinoma, 1\n",
      "coats plus, 1\n",
      "dyskeratosis congenita, 1\n",
      "gastrointestinal hemorrhage, 1\n",
      "telomere biology disorder, 1\n",
      "vascular ectasia, 1\n",
      "Clinical T1N0, 1\n",
      "Poor differentiation, 1\n",
      "Hand-assisted laparoscopic surgery, 1\n",
      "oesophagectomy, 1\n",
      "robotic surgery, 1\n",
      "Gas chromatography, 1\n",
      "Volatile organic compounds, 1\n",
      "ADAMTS18, 1\n",
      "mRNA expression, 1\n",
      "n, 28\n",
      "o, 14\n",
      "e, 14\n",
      "Esophageal cancer screening, 1\n",
      "liver cancer screening, 1\n",
      "stomach cancer screening, 1\n",
      "study protocol, 1\n",
      "Gastric polyp, 1\n",
      "Inflammatory fibroid polyps, 1\n",
      "Pólipo fibroideo inflamatorio, 1\n",
      "Pólipo gástrico, 1\n",
      "Tumor de Vanek, 1\n",
      "Vanek’s tumor, 1\n",
      "DNA damage, 2\n",
      "Salmonella\n",
      ", 1\n",
      "gallbladder cancer, 1\n",
      "mucosoid cultures, 1\n",
      "organoid cultures, 1\n",
      "typhoid toxin, 1\n",
      "Roux-en-Y gastric bypass, 2\n",
      "acute gastric dilation, 1\n",
      "bariatric surgery, 2\n",
      "complication, 4\n",
      "image-guided surgery, 1\n",
      "percutaneous gastrostomy, 1\n",
      "Duodenum, 3\n",
      "Lymphoma, 1\n",
      "Mucosa-associated lymphoid tissue, 1\n",
      "Rituximab, 1\n",
      "REC8, 1\n",
      "Tumor angiogenesis, 1\n",
      "VEGF, 1\n",
      "development, 2\n",
      "hedgehog signaling, 1\n",
      "tGLI1, 1\n",
      "target therapy, 1\n",
      "tumor–stroma interaction, 1\n",
      "IFRD1, 1\n",
      "Regeneration, 1\n",
      "cyclical hit model, 1\n",
      "gamma-H2Ax, 1\n",
      "PCR, 1\n",
      "eosin, 1\n",
      "hematoxylin, 1\n",
      "histopathology, 3\n",
      "E2F3, 1\n",
      "Esophageal squamous cell carcinoma (ESCC), 1\n",
      "RACGAP1, 1\n",
      "mitotic catastrophe, 1\n",
      "gastrectomy, 9\n",
      "Robotic-assisted pancreatoduodenectomy (RAPD), 1\n",
      "hemorrhage, 1\n",
      "intussusception, 1\n",
      "Height, 1\n",
      "Alternative splicing (AS), 1\n",
      "gastric cancer (GC), 3\n",
      "integrative bioinformatics, 1\n",
      "augmentation cystoplasty, 1\n",
      "bladder, 1\n",
      "poorly differentiated, 1\n",
      "signet-ring cells, 1\n",
      "Chinese medicine, 1\n",
      "Clinical trail, 1\n",
      "Cohort study, 1\n",
      "TCM formula, 1\n",
      "Triple-negative breast cancer, 1\n",
      "Lian Hua Qing Wen (LHQW), 1\n",
      "Network pharmacology, 2\n",
      "Traditional Chinese Medicine, 1\n",
      "Analgesic, 1\n",
      "Pain, 1\n",
      "Radix angelicae dahuricae, 1\n",
      "Rhizoma Corydalis, 1\n",
      "Hematologic neoplasms, 1\n",
      "Nationwide, 1\n",
      "Primary immune thrombocytopenia, 1\n",
      "Sweden, 1\n",
      "animal model, 1\n",
      "gastrointestinal stromal tumor, 4\n",
      "neoplasia, 1\n",
      "smooth muscle, 1\n",
      "Arteriovenous malformation, 1\n",
      "Colon cancer, 4\n",
      "Epistaxis, 1\n",
      "Extraintestinal manifestation, 1\n",
      "Telangiectasia, 1\n",
      "Ampullary, 1\n",
      "Computed tomography, 3\n",
      "Endoscopic ultrasound, 2\n",
      "Magnetic resonance ımaging, 1\n",
      "Schwannoma, 1\n",
      "Cell line, 1\n",
      "Primary culture, 1\n",
      "XGC-1, 1\n",
      "early gastric carcinoma, 2\n",
      "endoscopic submucosal dissection, 4\n",
      "long-term outcome, 1\n",
      "non-curative resection, 1\n",
      "immuno-escape, 1\n",
      "lncRNA SNHG15, 1\n",
      "miR-141, 1\n",
      "Crawling-type adenocarcinoma, 1\n",
      "Molecular analysis, 1\n",
      "TP53 mutation, 1\n",
      "Illness acceptance, 1\n",
      "Strategies for coping with the illness, 1\n",
      "Lynch syndrome, 5\n",
      "extracolonic manifestation, 1\n",
      "pheochromocytoma, 1\n",
      "Autophagic flux, 1\n",
      "Epithelial-to-mesenchymal transition, 1\n",
      "Tumorspheres, 1\n",
      "mTORC1, 2\n",
      "cost-effectiveness of miRNA test, 1\n",
      "gastric cancer screening, 1\n",
      "miRNA cancer screening, 1\n",
      "miRNA test, 1\n",
      "model-based cost-effectiveness, 1\n",
      "minimally invasive surgical procedures, 1\n",
      "stomach neoplasm, 7\n",
      "neuroendocrine tumours, 1\n",
      "pancreatic neoplasms, 2\n",
      "rectal neoplasms, 1\n",
      "Adolescent and young adult, 1\n",
      "Germ cell cancer, 1\n",
      "Risk factor, 2\n",
      "Second primary malignancy, 1\n",
      "Seminoma, 1\n",
      "Nasopharyngeal carcinoma, 1\n",
      "Pri-miRNA-encoded protein, 1\n",
      "Tumor suppressor, 1\n",
      "miPEP133, 1\n",
      "miR-34a, 1\n",
      "Chemoradiation therapy, 1\n",
      "Esophageal neoplasm, 1\n",
      "Locoregional recurrence, 1\n",
      "Palliative management, 1\n",
      "R1/R2 resection, 1\n",
      "Clinical curative effect, 1\n",
      "Open surgery, 1\n",
      "Propensity score matching, 2\n",
      "Platelet-derived growth factor alpha (PDGFRA), 1\n",
      "Diagnosis, 9\n",
      "Evidence-based medicine, 1\n",
      "Gastrointestinal stromal tumor, small, 1\n",
      "Treatment, 4\n",
      "Duodenogastric reflux, 1\n",
      "Gastric stump cancer, 1\n",
      "Mice, inbred C57BL, 1\n",
      "HSP60, 1\n",
      "TNFR2, 1\n",
      "gastric lymphoma, 1\n",
      "miR-17, 1\n",
      "Duodenal ulcer, 1\n",
      "Plasticity region, 1\n",
      "dupA gene, 1\n",
      "Gastric cancer (GC), 1\n",
      "HER2, 5\n",
      "trastuzumab, 1\n",
      "tumor mutation burden (TMB), 1\n",
      "Endoscopic resection, 6\n",
      "Resection margins, 2\n",
      "Residual tumor, 1\n",
      "Clinical decision rules, 1\n",
      "Diagnostic interval, 1\n",
      "Health care reform, 1\n",
      "Neoplasms, 6\n",
      "Primary health care, 1\n",
      "Semiparametric varying-coefficient model, 1\n",
      "Time to diagnosis, 1\n",
      "aspirin, 2\n",
      "metformin, 1\n",
      "Barrett’s esophagus, 1\n",
      "Genome-Wide Association Study, 1\n",
      "Interaction, 1\n",
      "Sex Difference, 1\n",
      "Intraoperative perfusion imaging, 1\n",
      "Isoperistaltic colon interposition, 1\n",
      "Oesophagectomy, 3\n",
      "Supercharged colon conduit, 1\n",
      "Thoracoscopy, 1\n",
      "Chromogranin (CgA), 1\n",
      "Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), 1\n",
      "Heterogeneity, 2\n",
      "Ki-67 index, 1\n",
      "Synaptophysin (Syn), 1\n",
      "gastric neoplasm, 1\n",
      "quality indicators, 1\n",
      "tumor, 2\n",
      "National Health Insurance Research Database, 1\n",
      "eating disorders, 1\n",
      "Brain, 1\n",
      "Extrahepatic metastasis, 1\n",
      "Body Composition, 1\n",
      "Spiral Computed, 1\n",
      "Tomography, 1\n",
      "occupational & industrial medicine, 1\n",
      "public health, 1\n",
      "gastrointestinal surgery, 3\n",
      "gastrointestinal system, 2\n",
      "orthopaedics, 1\n",
      "stomach and duodenum, 3\n",
      "radiology, 1\n",
      "malignant disease and immunosuppression, 1\n",
      "Neoplasms, multiple primary, 1\n",
      "Neoplasms, second primary, 1\n",
      "KLF2, 1\n",
      "invasion, 2\n",
      "miR-92a-3p, 1\n",
      "proliferation, 3\n",
      "Cell cycle arrest, 1\n",
      "Epithelial-mesenchymal transition, 3\n",
      "Flavonoids, 1\n",
      "Hispidulin, 1\n",
      "H. pylori, 2\n",
      "carcinogenesis, 2\n",
      "microbiota, 2\n",
      "double tract reconstruction, 1\n",
      "neoplasm recurrence and metastasis, 1\n",
      "MMP2/MMP9, 1\n",
      "USP19, 1\n",
      "skin metastasis, 1\n",
      "tyrosine kinase inhibitors, 2\n",
      "Internal hernia, 2\n",
      "Laparoscopy distal gastrectomy, 1\n",
      "Roux limb syndrome, 1\n",
      "Roux-en-Y reconstruction, 1\n",
      "Gastrointestinal Cancer, 1\n",
      "Markazi, 1\n",
      "Gastrointestinal, 1\n",
      "Follow-up studies, 1\n",
      "Gastroscopy, 4\n",
      "Precancerous conditions, 1\n",
      "\n",
      "          Helicobacter pylori\n",
      "        , 1\n",
      "bacterial recovery, 1\n",
      "free-living amphizoic amoebae, 1\n",
      "intracellular multiplication, 1\n",
      "phagosomal pH, 1\n",
      "BUB1 gene, 1\n",
      "bioinformatics, 2\n",
      "Mendelian randomization, 1\n",
      "single-nucleotide polymorphisms, 1\n",
      "Fluorescein, 1\n",
      "Lower gastrointestinal tract, 1\n",
      "DNA demethylation, 1\n",
      "NF-κB, 1\n",
      "oleanolic acid, 1\n",
      "Gastric/gastroesophageal junction carcinoma, 1\n",
      "Lgr5, 2\n",
      "Stem/progenitor cell, 1\n",
      "active ingredient, 1\n",
      "mechanism of action, 2\n",
      "traditional Chinese medicine, 1\n",
      "cancer survivorship, 1\n",
      "cancer-related fatigue, 1\n",
      "gastrointestinal cancer, 1\n",
      "prevalence, 2\n",
      "Enteroblastic differentiation, 2\n",
      "alpha-Fetoproteins, 1\n",
      "Oesophageal neoplasms, 2\n",
      "Nutritional status, 1\n",
      "Survival analysis, 2\n",
      "Bariatric surgery, 2\n",
      "Interstitial cells of Cajal, 1\n",
      "Obesity, 2\n",
      "CTGF, 1\n",
      "Peritoneal metastasis, 2\n",
      "TGF-β1, 1\n",
      "arsenic poisoning, 1\n",
      "standardized incidence ratio, 1\n",
      "standardized mortality ratio, 1\n",
      "Anemia, 1\n",
      "Iron deficiency anemia, 1\n",
      "Leukopenia, 1\n",
      "Lymphopenia, 1\n",
      "5-FU, 5-fluorouracyl, 1\n",
      "ACVR2A, activin A receptor type 2A, 1\n",
      "AKT, AKT serine/threonine kinase, 1\n",
      "AR, androgen receptor, 1\n",
      "ATG7, autophagy related 7, 1\n",
      "ATM, ATM serine/threonine kinase, 1\n",
      "BAX, BCL2 associated Xapoptosis regulator, 1\n",
      "BCL2, BCL2 apoptosis regulator, 1\n",
      "BCL2L10, BCL2 like 10, 1\n",
      "BDNF, brain derived neurotrophic factor, 1\n",
      "BLCA, bladder urothelial carcinoma, 3\n",
      "BRCA, breast cancer, 1\n",
      "Biomarker, 6\n",
      "Bp, base pair, 1\n",
      "C-myc (MYCBP), MYC binding protein, 1\n",
      "CASC2, cancer susceptibility 2, 1\n",
      "CD133 (PROM1), prominin 1, 1\n",
      "CDC42, cell division cycle 42, 1\n",
      "CDKN1, Bcyclin dependent kinase inhibitor 1B, 1\n",
      "COAD, colon adenocarcinoma, 4\n",
      "Circulating miRNA, 1\n",
      "DDR, DNA damage repair, 1\n",
      "E2F family (E2F1, E2F2, E2F3), E2F transcription factors, 1\n",
      "EBV, Epstein-Barr virus, 1\n",
      "EMT, epithelial-to-mesenchymal transition, 1\n",
      "ER, estrogen receptor, 1\n",
      "ERBB (EGFR), epidermal growth factor receptor, 1\n",
      "ESCA, esophageal carcinoma, 3\n",
      "FENDRR, FOXF1 adjacent non-coding developmental regulatory RNA, 1\n",
      "FER1L4, fer-1 like family member 4 (pseudogene), 1\n",
      "GAS5, growth arrest–specific 5, 1\n",
      "HIF-1α (HIF1A), hypoxia inducible factor 1 subunit alpha, 1\n",
      "HNRNPA1, heterogeneous nuclear ribonucleoprotein A1, 1\n",
      "HNSC, head and neck squamous cell carcinoma, 3\n",
      "HRR, homologous recombination-based DNA repair, 1\n",
      "IFN-γ (IFNG), interferon gamma, 1\n",
      "IGF1, insulin like growth factor 1, 1\n",
      "IL6, interleukin 6, 1\n",
      "IPMK, inositol phosphate multikinase, 1\n",
      "KIRC, clear cell kidney carcinoma, 1\n",
      "KIRP, kidney renal papillary cell carcinoma, 3\n",
      "KRAS, KRAS proto-oncogene, GTPase, 1\n",
      "LIHC, liver hepatocellular carcinoma, 4\n",
      "LMP1, latent membrane protein 1, 1\n",
      "LUAD, lung adenocarcinoma, 4\n",
      "LUSC, lung squamous cell carcinoma, 4\n",
      "MAPK, mitogen-activated protein kinase, 1\n",
      "MCM7, minichromosome maintenance complex component 7, 1\n",
      "MET, mesenchymal-to-epithelial transition, 1\n",
      "MTOR, mechanistic target of rapamycin kinase, 1\n",
      "N-myc (MYCN), MYCN proto-oncogene, bHLH transcription factor, 1\n",
      "NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells, 1\n",
      "NOTCH2, notch receptor 2, 1\n",
      "Oncogene, 1\n",
      "PAAD, pancreatic adenocarcinoma, 3\n",
      "PERK (EIF2AK3), eukaryotic translation initiation factor 2 alpha kinase 3, 1\n",
      "PI3K (PIK3CA), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, 1\n",
      "PIAS3, protein inhibitor of activated STAT 3, 1\n",
      "PRAD, prostate adenocarcinoma, 3\n",
      "RISC, RNA-induced silencing complex, 1\n",
      "SMAD2, SMAD family member 2, 1\n",
      "SMG1, SMG1 nonsense mediated mRNA decay associated PI3K related kinase, 1\n",
      "SNHG1, small nucleolar RNA host gene 1, 1\n",
      "SOCS5, suppressor of cytokine signaling 5, 1\n",
      "STAD, stomach adenocarcinoma, 4\n",
      "STAT3, signal transducer and activator of transcription 3, 1\n",
      "STK4, serine/threonine kinase 4, 1\n",
      "Suppressor, 1\n",
      "TCGA, The Cancer Genome Atlas, 3\n",
      "TGF-β (TGFB1), transforming growth factor beta 1, 1\n",
      "TGFBR2, transforming growth factor beta receptor 2, 1\n",
      "THCA, papillary thyroid carcinoma, 1\n",
      "TNM, Classification of Malignant Tumors: T - tumor / N - lymph nodes / M – metastasis, 1\n",
      "TP53, tumor protein p53, 1\n",
      "TP53TG1, TP53 target 1, 1\n",
      "TRIAP1, p53-regulating inhibitor of apoptosis gene, 1\n",
      "TSC1, TSC complex subunit 1, 1\n",
      "UCA1, urothelial cancer associated 1, 1\n",
      "UCEC, uterine corpus endometrial carcinoma, 3\n",
      "UTR, untranslated region, 1\n",
      "WDFY3-AS2, WDFY3 antisense RNA 2, 1\n",
      "WEE1, WEE1 G2 checkpoint kinase, 1\n",
      "WNT family, Wingless-type MMTV integration site family/Wnt family ligands, 1\n",
      "ZEB1/ZEB2, zinc finger E-box binding homeobox 1 and 2, 1\n",
      "ceRNA, competitive endogenous RNA, 1\n",
      "cncRNA, protein coding and non-coding RNA, 1\n",
      "lncRNA, long-non coding RNA, 1\n",
      "miR-17-92a, 1\n",
      "miR-18a, 1\n",
      "CircPRRX1, 1\n",
      "Doxorubicin, 1\n",
      "Exosome, 3\n",
      "MiR-3064-5p, 1\n",
      "PTPN14, 1\n",
      "80 and over, 1\n",
      "aged, 1\n",
      "centenarians, 1\n",
      "Bioactive compounds, 1\n",
      "Mechanism insights, 1\n",
      "Origanum majorana, 1\n",
      "Pharmacological actions, 1\n",
      "Traditional use, 1\n",
      "Lymph node metastasis, 3\n",
      "KLF5, 1\n",
      "cancer biology, 1\n",
      "cell cycle, 2\n",
      "chromatin, 1\n",
      "human, 2\n",
      "oesophageal cancer, 2\n",
      "transcription factors, 1\n",
      "oxygen consumption, 1\n",
      "paradoxical low-flow low-pressure gradient severe aortic stenosis, 1\n",
      "advanced gastric cancer, 1\n",
      "metastatic gastric cancer, 1\n",
      "progressive gastric cancer, 1\n",
      "Prognostic model, 1\n",
      "Risk score, 1\n",
      "CagA, 3\n",
      "HtrA, 1\n",
      "OMV, 1\n",
      "VacA, 2\n",
      "outer membrane vesicles, 1\n",
      "urease, 1\n",
      "laparoscopiccentralpancreatectomy, 1\n",
      "pancreatogastricanastomosis, 1\n",
      "serouscystadenomaofthepancreas, 1\n",
      "metabolic, 1\n",
      "post-gastrectomysyndromes, 1\n",
      "reconstruction, 2\n",
      "reservoir, 1\n",
      "duplicate left gastric artery, 1\n",
      "laparoscopic gastrectomy, 2\n",
      "Gout, 1\n",
      "Incidence, 9\n",
      "Dialysis, 1\n",
      "Histiocyte, 1\n",
      "Lanthanum carbonate, 1\n",
      "Mucosal deposition, 1\n",
      "Free flap, 1\n",
      "Hypopharyngeal neoplasms, 1\n",
      "Life quality, 1\n",
      "Surgery therapy, 1\n",
      "KDM6A, 1\n",
      "Gastrointestinal malignancies, 1\n",
      "Sarcopenia, 2\n",
      "Urinary titin, 1\n",
      "Adenosquamous carcinoma, 1\n",
      "Synchronous tumor, 1\n",
      "Ulcer, 1\n",
      "Immune, 1\n",
      "TP53, 2\n",
      "Right hemicolectomy, 1\n",
      "Robotic surgery, 4\n",
      "Technique, 1\n",
      "abdomen, 1\n",
      "mass, 1\n",
      "plasma, 1\n",
      "plasmacytoma, 1\n",
      "Burden of disease study, 1\n",
      "Child maltreatment, 1\n",
      "Cost-of-illness, 1\n",
      "Disability-adjusted life year (DALY), 1\n",
      "Lifelong health consequences, 1\n",
      "direct expenditure, 1\n",
      "financial burden, 1\n",
      "indirect expenditure, 1\n",
      "medical expenditure, 1\n",
      "non-medical expenditure, 1\n",
      "X-ray computed, 1\n",
      "sarcomatoid carcinoma, 1\n",
      "tomography, 1\n",
      "Genotype-Tissue Expression, 2\n",
      "RNA-seq, 1\n",
      "The Cancer Genome Atlas, 5\n",
      "differential expression, 1\n",
      "gender differences, 1\n",
      "gene co-expression networks, 1\n",
      "thyroid cancer, 2\n",
      "CAR cells, 1\n",
      "biomarkers, 4\n",
      "cancer stem cells, 1\n",
      "precision therapy, 1\n",
      "senescence, 1\n",
      "Octopus vulgaris, 1\n",
      "Sepia officinalis, 1\n",
      "digestive tract, 1\n",
      "motility, 1\n",
      "nutrition, 3\n",
      "regurgitation, 1\n",
      "vomiting, 2\n",
      "welfare, 1\n",
      "Gene Expression Omnibus, 1\n",
      "competing endogenous RNA, 1\n",
      "risk score, 1\n",
      "weighted correlation network analysis, 1\n",
      "STAT3, 1\n",
      "Xiaoai Jiedu Recipe, 1\n",
      "cell behaviors, 1\n",
      "hepatocellular carcinoma, 2\n",
      "microRNA-29a, 1\n",
      "PIWI, 1\n",
      "nonsense-mediated mRNA decay, 1\n",
      "piRNA, 2\n",
      "health surveillance, 1\n",
      "rubber, 1\n",
      "Biodegradation, 1\n",
      "DNMP, 1\n",
      "DNMP reductase, 1\n",
      "LC-MS/MS, 1\n",
      "Meat preservatives, 1\n",
      "Nitrite, 1\n",
      "Nitroreductase, 1\n",
      "Sorbate, 1\n",
      "Ivor Lewis, 1\n",
      "distal gastrectomy, 1\n",
      "esophageal carcinoma, 1\n",
      "esophagogastrostomy, 1\n",
      "remnant stomach, 1\n",
      "biliary intervention, 1\n",
      "cancer intervention, 1\n",
      "endocrine cancer, 1\n",
      "pancreas and biliary tract, 1\n",
      "CRISPR/Cas9, 1\n",
      "cell survival, 1\n",
      "chemoresistance, 4\n",
      "exon skipping, 1\n",
      "morpholinos, 1\n",
      "Gastrin, 1\n",
      "Magnetic capsule gastroscopy, 1\n",
      "Pepsinogen, 1\n",
      "Case-control study, 1\n",
      "Drinking water, 1\n",
      "Location, 1\n",
      "Bayesian network, 1\n",
      "Group LASSO, 1\n",
      "acute kidney injury, 1\n",
      "disease prediction, 1\n",
      "machine learning, 1\n",
      "Anticancer therapy, 1\n",
      "NF-kB modulator, 1\n",
      "Sesquiterpene, 1\n",
      "Sesquiterpene derivatives, 1\n",
      "Structure activity relationship, 1\n",
      "acetylcholine, 1\n",
      "cisplatin, 3\n",
      "curcumin, 1\n",
      "gastric emptying, 1\n",
      "interstitial cells of Cajal, 1\n",
      "Anastomotic leakage, 1\n",
      "Double-lumen feeding tube, 1\n",
      "Percutaneous transesophageal gastro-tubing, 1\n",
      "Transnasal drainage, 1\n",
      "Upper GI surgery, 1\n",
      "Endoscopic mucosal resection, 4\n",
      "Undifferentiated-type histology, 2\n",
      "PD1, 1\n",
      "PDL1, 1\n",
      "bile tract cancer, 1\n",
      "lenvatinib, 1\n",
      "neutrophil-lymphocyte ratio, 1\n",
      "postoperative cognitive dysfunction, 1\n",
      "risk factor, 3\n",
      "Lymphoma, B-Cell, Marginal zone, 1\n",
      "Microenvironment - feedback, 1\n",
      "Parasympathetic, 1\n",
      "Sensory, 1\n",
      "Sympathetic, 1\n",
      "Vagus nerve, 1\n",
      "Allergy, 1\n",
      "Anisakiasis, 1\n",
      "Anisakis, 1\n",
      "Control, 1\n",
      "Seafood-borne disease, 1\n",
      "Adjuvant, 1\n",
      "Imatinib, 1\n",
      "Características, 1\n",
      "Characteristics, 1\n",
      "Cáncer gástrico, 3\n",
      "Diagnóstico temprano, 1\n",
      "Early diagnosis, 2\n",
      "Endoscopic treatment, 1\n",
      "Tratamiento endoscópico, 1\n",
      "advanced GC, 1\n",
      "genetic alterations, 1\n",
      "prognostic factor review, 1\n",
      "recurrence pattern, 1\n",
      "signet-ring cell, 1\n",
      "Lactobacillus casei, 1\n",
      "Lactobacillus fermentum, 1\n",
      "Lactobacillus rhamnosus, 1\n",
      "amino acids, 1\n",
      "fatty acids, 1\n",
      "tumor-infiltrating immune cells, 1\n",
      "Distal pancreatectomy, 1\n",
      "Extended surgery, 1\n",
      "Left-sided pancreatic cancer, 1\n",
      "Lymph node ratio, 2\n",
      "Multivisceral resection, 1\n",
      "Pancreatic fistula, 2\n",
      "Autoencoders, 1\n",
      "Classification, 3\n",
      "Gene expression analysis, 1\n",
      "Deleterious  Single  Nucleotide  Polymorphisms, 1\n",
      "Evolutionary conservation, 1\n",
      "Integrin  αV, 1\n",
      "Ligand binding site prediction, 1\n",
      "Post  translational  modifications, 1\n",
      "Three-dimensional modelling, 1\n",
      "Curative treatment, 1\n",
      "Patient-reported outcome, 1\n",
      "Quality-of-Life questionnaire, 1\n",
      "Cancer risk, 2\n",
      "China, 4\n",
      "Environmental tobacco smoke, 1\n",
      "Non-smokers, 1\n",
      "Prospective cohort study, 1\n",
      "Smoking-related cancers, 1\n",
      "immunocytochemistry, 1\n",
      "pleural effusion cytology, 1\n",
      "reactive mesothelial cells, 1\n",
      "single-cell pattern, 1\n",
      "Colonic adenocarcinoma, 1\n",
      "Colonic neuroendocrine neoplasm, 1\n",
      "Descending colon, 1\n",
      "Large cell neuroendocrine carcinoma, 1\n",
      "gastroenterology, 2\n",
      "Oesophageal Cancer, 1\n",
      "Pandemic, 1\n",
      "Adjuvant treatment, 1\n",
      "Adénocarcinome, 1\n",
      "Cancer de l’estomac, 1\n",
      "Cancer du pancréas, 1\n",
      "Chemoradiation, 2\n",
      "Chimioradiothérapie, 1\n",
      "Neoadjuvant treatment, 1\n",
      "Pancreatic cancer, 8\n",
      "Radiothérapie stéréotaxique, 1\n",
      "Stereotactic body radiation therapy, 1\n",
      "Traitement adjuvant, 1\n",
      "Traitement néoadjuvant, 1\n",
      "CDH1, 2\n",
      "E-cadherin, 3\n",
      "hereditary diffuse gastric cancer, 1\n",
      "therapy, 1\n",
      "tumorigenesis, 1\n",
      "Enhanced recovery after surgery, 2\n",
      "Retrospective Cohort study, 1\n",
      "Perception, 1\n",
      "Questionnaire survey, 1\n",
      "Treatment selection, 1\n",
      "gastric outlet obstruction, 2\n",
      "palliative care, 3\n",
      "AMPK, 1\n",
      "Glioma, 1\n",
      "Loss-of-function, 1\n",
      "Pan-cancer, 1\n",
      "Tumor metabolism, 1\n",
      "AXIN2, 1\n",
      "Gastric adenomas, 1\n",
      "Hereditary cancer syndrome, 1\n",
      "Hereditary colorectal cancer, 1\n",
      "Hereditary polyposis, 1\n",
      "Hypodontia, 1\n",
      "Olfactory neuroblastoma, 1\n",
      "Alpha-fetoproteins, 1\n",
      "Clear cell adenocarcinoma, 1\n",
      "Chinese burden of cancer, 1\n",
      "Joinpoint analysis, 1\n",
      "age–period–cohort analysis, 1\n",
      "mortality and incidence, 1\n",
      "trend, 2\n",
      "STAD, 1\n",
      "ceRNA, 1\n",
      "lncRNA, 4\n",
      "Dolichos lablab L., 1\n",
      "HO-1, 2\n",
      "Nrf2, 1\n",
      "SRMD, 1\n",
      "cytoprotection, 1\n",
      "Anatomical classification, 1\n",
      "Artificial intelligence, 4\n",
      "Convolutional neural network (CNN), 1\n",
      "Upper gastrointestinal tract, 1\n",
      "Everolimus, 1\n",
      "Lanreotide, 1\n",
      "Neuroendocrine tumors, 3\n",
      "ECL cell, 1\n",
      "cell of origin, 1\n",
      "dormancy, 1\n",
      "hormones, 1\n",
      "Cancer epidemiology, 2\n",
      "Cancer incidence, 1\n",
      "Costa Rica, 1\n",
      "Latin America, 2\n",
      "Social gradient, 1\n",
      "Social inequalities, 1\n",
      "Iran, 5\n",
      "Peptic ulcer disease, 2\n",
      "vacA genotypes, 1\n",
      "Cre recombinase, 1\n",
      "clonality, 1\n",
      "field cancerization, 1\n",
      "metaplasia, 4\n",
      "stem cells, 3\n",
      "atrophic, 2\n",
      "Bioinformatical analysis, 1\n",
      "G2/miotic-specific cyclin B1 (CCNB1), 1\n",
      "differentially expressed genes (DEGs), 1\n",
      "pituitary tumor-transforming gene-1 (PTTG1), 1\n",
      "polo-like kinases 1 (PLK1), 1\n",
      "Borrmann type, 1\n",
      "Clinicopathological features, 3\n",
      "Lymphovascular invasion, 3\n",
      "Papillary adenocarcinoma, 1\n",
      "Colorectal, 2\n",
      "Early-onset, 1\n",
      "Gastrointestinal cancers, 1\n",
      "Mortality rate, 1\n",
      "Projection, 1\n",
      "Trend, 1\n",
      "asbestos, 1\n",
      "epithelioid mesothelioma, 1\n",
      "esophagogastroduodenoscopy, 3\n",
      "retroperitoneal, 1\n",
      "biomarker candidates, 1\n",
      "limb-bud and heart, 1\n",
      "European and Asian diversity, 1\n",
      "gastric microbiome, 1\n",
      "miQTL, 1\n",
      "microbiome quantitative trait loci, 1\n",
      "awareness, 1\n",
      "cancer prevention knowledge, 1\n",
      "cohort study, 1\n",
      "risk of cancer, 1\n",
      "rural China, 1\n",
      "Function preserving gastrectomy, 1\n",
      "Metachronous gastric cancer, 1\n",
      "Pylorus preserving gastrectomy, 1\n",
      "Neoadjuvant chemotherapy, 8\n",
      "Pathological assessment, 1\n",
      "Tumor regression grade, 1\n",
      "Atrial natriuretic peptide, 1\n",
      "Hedgehog (Hh) signaling pathway, 1\n",
      "Invasion, 3\n",
      "Matrix metalloproteinases-9 (MMp-9), 1\n",
      "Migration, 3\n",
      "Binding pocket prediction, 1\n",
      "Conformational alteration, 1\n",
      "Domain characterization, 1\n",
      "Integrin αV subunit, 1\n",
      "Molecular modelling, 1\n",
      "Stability assay, 1\n",
      "AUC, 1\n",
      "cancer prognosis, 1\n",
      "mixture cure model, 1\n",
      "survival analysis, 3\n",
      "time-dependent ROC curve, 1\n",
      "Duodenoscopy, 1\n",
      "Neoplasm, 2\n",
      "Pylorus, 1\n",
      "Antimicrobial defense, 1\n",
      "Helicobacter pylori (H. pylori), 1\n",
      "plasticity, 1\n",
      "CTLA-4, 1\n",
      "Immunotherapy, 7\n",
      "Alopecia neoplastica, 1\n",
      "Gastrointestinal metastasis, 2\n",
      "High-grade dysplasia, 1\n",
      "Low-grade dysplasia, 1\n",
      "Dysplasia, 3\n",
      "Gastric, 2\n",
      "Hereditary, 1\n",
      "Polyp, 1\n",
      "Polyposis, 1\n",
      "Healthcare Disparity, 1\n",
      "Eradication Failure, 1\n",
      "New therapeutic strategies, 1\n",
      "Peptic ulcers, 1\n",
      "Refractory\n",
      "Helicobacter pylori infection , 1\n",
      "DNA methylation, 4\n",
      "DNA methyltransferase, 1\n",
      "Pacbio, 1\n",
      "SMRT, 1\n",
      "epigenetics, 1\n",
      "epigenome, 1\n",
      "methylome, 1\n",
      "nanoparticles, 2\n",
      "pharmacokinetics, 3\n",
      "polydopamine, 1\n",
      "target, 1\n",
      "xanthatin, 1\n",
      "dairy products, 1\n",
      "gut microbiota, 1\n",
      "ketogenic diet, 2\n",
      "malnutrition, 2\n",
      "meat, 1\n",
      "mediterranean diet, 1\n",
      "milk, 1\n",
      "nuts, 1\n",
      "short chain fatty acids, 1\n",
      "vegetarian diet, 1\n",
      "Cancer prevention, 1\n",
      "Gastric mucosa-associated lymphoma, 1\n",
      "Surgery, 8\n",
      "Acute abdomen, 2\n",
      "Anti-VEGF, 1\n",
      "Cancer chemotherapy, 1\n",
      "Emergency surgery, 1\n",
      "ACE2, 2\n",
      "immune infiltration, 2\n",
      "Bufothionine, 1\n",
      "ER stress, 1\n",
      "MiR-133a-3p, 1\n",
      "Krukenberg tumors, 1\n",
      "ovarian masses, 1\n",
      "ovarian metastasis, 2\n",
      "LA-ICP-MS, 1\n",
      "lanthanum, 1\n",
      "macrophage, 1\n",
      "mass spectrometry imaging, 1\n",
      "toxicology, 1\n",
      "Sherlock integrative analysis, 1\n",
      "eSNP, 1\n",
      "gene-based analysis, 1\n",
      "genome-wide association study, 1\n",
      "D2 gastrectomy, 1\n",
      "chemoradiotherapy, 1\n",
      "radiation therapy, 2\n",
      "DNA repair, 3\n",
      "apoptosis, 4\n",
      "epithelial-mesenchymal transition, 1\n",
      "refractoriness, 1\n",
      "transport, 1\n",
      "tumor environment, 1\n",
      "Epstein-Barr Virus, 1\n",
      "gastric inflammation, 2\n",
      "helicobacter pylori, 2\n",
      "nonatrophic gastritis, 1\n",
      "pediatric dyspepsia, 1\n",
      "SHIVA02 trial, 1\n",
      "core biopsy, 1\n",
      "fine-needle aspiration, 1\n",
      "next-generation sequencing, 2\n",
      "tumour molecular profiling, 1\n",
      "Three-dimensional, 1\n",
      "Agitation, 1\n",
      "Anesthesia, 1\n",
      "Desflurane, 1\n",
      "Recovery period, 1\n",
      "Sevoflurane, 1\n",
      "Aprepitant, 1\n",
      "Gastrointestinal complaints, 1\n",
      "Rat, 1\n",
      "Age-standardized rate, 1\n",
      "Mongolia, 1\n",
      "Early death, 1\n",
      "Nomogram, 1\n",
      "Stage IV, 3\n",
      "Chronic atrophic gastritis, 1\n",
      "Computer-aided diagnosis, 1\n",
      "Convolutional neural network, 1\n",
      "Gastric X-ray images, 1\n",
      "Gastric cancer risk, 1\n",
      "activity of daily living, 1\n",
      "bone metastasis, 2\n",
      "pharmacist, 1\n",
      "topical non-steroidal anti-inflammatory drug, 1\n",
      "EWDA of the stomach, 1\n",
      "Preoperative biopsy, 1\n",
      "Submucosal tumor, 1\n",
      "Conversion surgery, 2\n",
      "Immune check point inhibitor, 1\n",
      "Direct oral anticoagulant, 1\n",
      "Guidelines, 2\n",
      "Low molecular weight heparin, 1\n",
      "Thromboprophylaxis, 1\n",
      "Coronavirus, 2\n",
      "SARS-CoV-2 interacting proteins, 1\n",
      "USP13, 1\n",
      "Ubiquitin Specific Peptidase 13, 1\n",
      "Gastric ulcer, 1\n",
      "Pseudoaneurysm, 1\n",
      "autonomic dysfunction, 1\n",
      "neuropathology, 1\n",
      "peripheral autonomic system disorder, 1\n",
      "pure autonomic failure, 1\n",
      "α-synucleinopathy, 1\n",
      "foot, 1\n",
      "glomangioma, 1\n",
      "glomus tumor, 1\n",
      "soft tissue, 1\n",
      "Connexins, 1\n",
      "psoas muscle, 1\n",
      "survival rate, 2\n",
      "Next generation sequence, 1\n",
      "Signet ring cell carcinoma, 2\n",
      "Uninfected, 1\n",
      "Antineoplastic combined chemotherapy protocols, 1\n",
      "Neoplasm staging, 2\n",
      "cancer survivors, 1\n",
      "colorectal neoplasms, 3\n",
      "esophageal neoplasms, 4\n",
      "perioperative chemotherapy, 2\n",
      "anastomotic leakage, 1\n",
      "esophageal surgery, 1\n",
      "subtotal stomach, 1\n",
      "C‐reactive protein, 1\n",
      "intra‐abdominal fat, 1\n",
      "postoperative complications, 1\n",
      "advanced stomach cancer, 1\n",
      "immune function, 1\n",
      "Operative Link for Gastritis Assessment, 1\n",
      "endoscopy, 4\n",
      "numerical rating scale, 1\n",
      "pain, 1\n",
      "FBXW7, 1\n",
      "Siewert classification, 1\n",
      "esophageal adenocarcinoma, 1\n",
      "gastroesophageal junction, 1\n",
      "genomic features, 1\n",
      "whole-exome, 1\n",
      "pulmonary embolism, 1\n",
      "registry, 1\n",
      "thrombosis, 2\n",
      "venous thromboembolism, 2\n",
      "13C-urea breath test, 2\n",
      "Children, 2\n",
      "Gastrointestinal system, 1\n",
      "Health sciences, 1\n",
      "Infection, 1\n",
      "Infectious disease, 1\n",
      "Jordan, 1\n",
      "Laboratory medicine, 1\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Pediatrics, 1\n",
      "neutrophil extracellular traps, 1\n",
      "peripheral blood, 1\n",
      "Average lifespan shortened, 1\n",
      "Average years of life lost, 1\n",
      "Premature mortality, 1\n",
      "Years of life lost, 1\n",
      "Image-enhanced endoscopy, 1\n",
      "Metastatic gastric tumor, 1\n",
      "Squamous-cell carcinoma of the cervix, 1\n",
      "circRNA, 2\n",
      "Fruit, 1\n",
      "Vegetable, 1\n",
      "tobacco smoking, 1\n",
      "Cancer metastasis, 1\n",
      "Malignant transformation, 1\n",
      "MiR-135b, 1\n",
      "Poor prognosis, 1\n",
      "Malakoplakia, 1\n",
      "anamorelin, 1\n",
      "appetite loss, 1\n",
      "bladder neoplasm, 1\n",
      "chemotherapy, 7\n",
      "mucositis, 2\n",
      "muscle atrophy, 1\n",
      "sarcopenia, 1\n",
      "urothelial cancer, 1\n",
      "ABVD protocol, 1\n",
      "Hodgkin's lymphoma, 1\n",
      "Immunohistochemistry, 4\n",
      "Lymphadenopathy, 1\n",
      "Primary gastric lymphoma, 2\n",
      "Tlemcen (Algeria), 1\n",
      "Gastric gastrointestinal stromal tumor, 1\n",
      "Gender, 2\n",
      "Enhanced delivery, 1\n",
      "Formulation, 1\n",
      "Microencapsulation, 1\n",
      "Polymeric carriers, 1\n",
      "Probiotics, 1\n",
      "atrophic gastritis, 2\n",
      "diagnostic performance, 1\n",
      "gastropanel, 1\n",
      "noninvasive markers, 1\n",
      "Focus groups, 1\n",
      "Indigenous health, 1\n",
      "Qualitative research, 2\n",
      "Circular-stapled anastomosis, 1\n",
      "Double-tract reconstruction, 1\n",
      "Laparoscopic proximal gastrectomy, 2\n",
      "CCN1, 1\n",
      "NFkB, 1\n",
      "TRAIL, 1\n",
      "esophageal cells, 1\n",
      "gastroesophageal reflux disease (GERD), 1\n",
      "p53, 4\n",
      "Atrophy, 1\n",
      "Dithiocarbamate derivative, 1\n",
      "Epithelial-mesenchymal transition (EMT), 1\n",
      "Ferritinophagy, 1\n",
      "Iron chelator, 1\n",
      "ROS, 2\n",
      "p53/AKT/mTor, 1\n",
      "extracutaneous melanoma, 1\n",
      "gastrointestinal melanoma, 1\n",
      "mucosal melanoma, 1\n",
      "age-related trends, 1\n",
      "young adults, 2\n",
      "benign anastomotic stricture, 1\n",
      "gastric conduit, 1\n",
      "Radical surgery for distal gastric cancer, 1\n",
      "Recanalization of closed point, 1\n",
      "Uncut Roux-en-Y anastomosis, 1\n",
      "D2 radical surgery, 1\n",
      "Membrane anatomy, 2\n",
      "D2 procedure, 1\n",
      "Laparoscope, 1\n",
      "Gastric mesentery, 1\n",
      "DP-CAR, 1\n",
      "Pancreas, 2\n",
      "ecological factors, 1\n",
      "environmental factor, 1\n",
      "EDGE, 1\n",
      "ERCP, 1\n",
      "Gastric bypass, 2\n",
      "Gastrogastrostomy, 1\n",
      "Roux-en-Y, 1\n",
      "99mTc, 1\n",
      "Molecular Imaging, 1\n",
      "Oncology: GU, 1\n",
      "PHC-102, 1\n",
      "SPECT/CT, 1\n",
      "Single-Photon Emission Computed Tomography, 1\n",
      "carbonic anhydrase IX, 1\n",
      "clear cell renal cell carcinoma, 1\n",
      "Hepatoid adenocarcinoma of the stomach, 2\n",
      "Non-hepatoid adenocarcinoma of the stomach, 1\n",
      "active cancer, 1\n",
      "cancer associated thrombosis (CAT), 1\n",
      "low molecular weight heparins (LMWHs), 1\n",
      "thromboprophylaxis, 1\n",
      "FAK, 2\n",
      "Nexrutine, 1\n",
      "STAT3/NF-κB pathway, 1\n",
      "Gastric remnant, 1\n",
      "Pedicle jejunum, 1\n",
      "Postoperative, 1\n",
      "Reconstruction, 2\n",
      "Sunitinib, 1\n",
      "adenosine triphosphate, 1\n",
      "cutaneous side effects, 1\n",
      "oxidative stress, 3\n",
      "protective effect, 1\n",
      "Diagnostic imaging, 2\n",
      "Neuroendocrine cells, 1\n",
      "Neuroendocrine neoplasm, 1\n",
      "Phenotype, 2\n",
      "Somatostatin, 1\n",
      "Hepatocellular cancer, 2\n",
      "Intensity-modulated proton therapy, 3\n",
      "Machine learning, 2\n",
      "RapidArc, 2\n",
      "Volumetric modulated arc therapy, 1\n",
      "cervical carcinoma, 1\n",
      "lymphangitis carcinomatosis, 1\n",
      "pulmonary microvascular tumor embolism, 1\n",
      "pulmonary tumor thrombotic microangiopathy, 2\n",
      "ARN no codificante largo, 1\n",
      "Modelo predictivo, 1\n",
      "Predictive model, 1\n",
      "Anti-HER2 therapy, 1\n",
      "Metastatic gastric cancer, 1\n",
      "Review, 1\n",
      "screening, 3\n",
      "Biomarkers, 3\n",
      "Remnant gastric cancer, 1\n",
      "Targeted therapy, 1\n",
      "colonic stricture, 1\n",
      "signet ring cell type carcinoma, 1\n",
      "CLDN18, 1\n",
      "biological network, 1\n",
      "FDG/PET-CT, 1\n",
      "head and neck metastasis, 1\n",
      "neck dissection, 1\n",
      "remote primary, 1\n",
      "survival analysis., 1\n",
      "Macrophage: Infiltration, 1\n",
      "Ovarian Serous Cystadenocarcinoma, 1\n",
      "TAMs, 1\n",
      "Antioxidant, 1\n",
      "Cytoprotective, 1\n",
      "Isothiocyanate, 1\n",
      "Nutrigenomics, 1\n",
      "Sequencing, 2\n",
      "fecal immunochemical test, 1\n",
      "small intestine cancer, 1\n",
      "cancer survivor, 1\n",
      "employment, 1\n",
      "occupational therapy, 1\n",
      "pilot projects, 1\n",
      "return to work, 1\n",
      "work rehabilitation, 1\n",
      "circular RNA, 1\n",
      "m6A modification, 1\n",
      "poorly differentiated adenocarcinoma, 2\n",
      "individual detection, 1\n",
      "preoperative neutrophil-to-lymphocyte ratio, 1\n",
      "tumor markers, 1\n",
      "antitumor agents, 1\n",
      "metallodrug, 1\n",
      "nanoformulation, 1\n",
      "oral administration, 1\n",
      "titanium, 1\n",
      "Endoscopic gastric atrophy, 1\n",
      "Kimura-Takemoto classification, 1\n",
      "Risk stratification, 1\n",
      "Stomach neoplasmsMeta-analysis, 1\n",
      "carcinogenicity, 1\n",
      "night-shift work, 1\n",
      "odds ratio, 1\n",
      "Cell signalling, 1\n",
      "Stomach diseases, 1\n",
      "Intestinal metaplasia, 1\n",
      "Operative link for gastritis assessment, 1\n",
      "Operative link on gastric intestinal metaplasia assessment, 1\n",
      "TAIM, 1\n",
      "hyperplastic polyp, 1\n",
      "neuroendocrine tumor, 4\n",
      "adaptive radiotherapy, 1\n",
      "multi-organ segmentation, 1\n",
      "pancreatic radiotherapy, 1\n",
      "treatment planning, 1\n",
      "Bowel, 1\n",
      "Inter-observer variability, 1\n",
      "Malignancy, 2\n",
      "Endosonography, 3\n",
      "Gastric outlet obstruction, 2\n",
      "Prostheses and implants, 1\n",
      "5-Fluorouracil, 1\n",
      "Crosslinked dextran nanoparticles, 1\n",
      "Dextranase responsive delivery system, 1\n",
      "Telechelic oligoester, 1\n",
      "Drug resistance, 2\n",
      "Molecule-targeted therapy, 1\n",
      "Monoclonal antibodies, 1\n",
      "Small-molecule drugs, 1\n",
      "Targeted drugs, 1\n",
      "signet ring, 1\n",
      "Aged, 1\n",
      "Comorbidity, 1\n",
      "Bilingual, 1\n",
      "Cancer data, 1\n",
      "Cancer information, 1\n",
      "Cross language, 1\n",
      "HealthNLP, 1\n",
      "Medical parallel corpus, 1\n",
      "Deep inspiration breath-hold, 1\n",
      "Gastric lymphoma, 1\n",
      "Heart dose, 1\n",
      "NSAIDs, 1\n",
      "factorial design, 1\n",
      "formulation, 1\n",
      "peptic ulcer, 2\n",
      "stomatitis, 1\n",
      "Therapeutic response, 1\n",
      "Cancers, 1\n",
      "Occupational cohorts, 1\n",
      "Radon exposure, 1\n",
      "Uranium miners, 1\n",
      "Gene expression omnibus, 1\n",
      "Lung adenocarcinoma, 2\n",
      "Purinergic receptors, 1\n",
      "Pyrimidine metabolic rate–limiting enzymes, 1\n",
      "The Cancer genome atlas, 1\n",
      "Phase III, 1\n",
      "omentectomy, 1\n",
      "omentum preservation, 1\n",
      "omentum preserving gastrectomy, 1\n",
      "Interleukin-6, 1\n",
      "PKCδ, 1\n",
      "eEF1A1, 1\n",
      "p-STAT3S727, 1\n",
      "Clinical translation, 1\n",
      "Gene delivery, 1\n",
      "Gene editing, 1\n",
      "Non-viral vectors, 1\n",
      "in vivo, 1\n",
      "Curcumin, 1\n",
      "Curcuminoids, 1\n",
      "Systematic review, 3\n",
      "hand-assisted laparoscopic surgery, 1\n",
      "3,3′-Diindolylmethane, 1\n",
      "MDM2, 1\n",
      "cancer prevention, 1\n",
      "Bayesian networks, 1\n",
      "genomic and epigenomic molecular data, 1\n",
      "mixed mutual information, 1\n",
      "multimodal big data, 1\n",
      "variable selection, 1\n",
      "Lymph node Metastasis, 1\n",
      "Non-curative resection, 1\n",
      "Chronic laryngitis, 1\n",
      "Laryngeal carcinoma, 1\n",
      "postoperative infectious complications, 1\n",
      "Avoidable deaths, 1\n",
      "Cohort studies, 1\n",
      "Coronary heart disease, 1\n",
      "Diabetes, 2\n",
      "Mortality, 10\n",
      "Linitis plastica, 1\n",
      "left gastric artery, 1\n",
      "lymph node (LN), 1\n",
      "abdominoperineal resection, 1\n",
      "internal hernia, 1\n",
      "stoma-associated complication, 1\n",
      "serine/arginine-rich splicing factor 10, 1\n",
      "splicing factor, 1\n",
      "Colorectal cancer, 4\n",
      "Esophageal neoplasms, 1\n",
      "GIST, 4\n",
      "Meckeldiverticulum, 1\n",
      "acuteabdomen, 1\n",
      "Cancer management, 1\n",
      "R-CHOP, 1\n",
      "endoscopic ultrasonography, 1\n",
      "primary gastric diffuse large B-cell lymphoma, 1\n",
      "Chinese cancer research, 1\n",
      "anatomical site, 1\n",
      "burden of disease, 1\n",
      "comparison with GDP, 1\n",
      "research type, 1\n",
      "angiogenesis inhibitor, 1\n",
      "transbronchial lung biopsy, 1\n",
      "cancer epidemiology, 2\n",
      "gastrointestinal neoplasia, 1\n",
      "Mismatch repair gene, 1\n",
      "Somatic mutation, 1\n",
      "Turcot’s syndrome type 1, 1\n",
      "Bibliometric Analysis, 1\n",
      "Cancer Epidemiology, 1\n",
      "Research Funding, 1\n",
      "Socio-Economic Influences, 1\n",
      "Carcinoma, hepatocellular, 1\n",
      "Diagnosis, differential, 2\n",
      "Hepatoid adenocarcinoma, 2\n",
      "Neoplasm metastasis, 2\n",
      "MIR100HG, 1\n",
      "lncRNAs, 1\n",
      "Indocyanine green, 4\n",
      "Navigation surgery, 1\n",
      "Gastrointestinal inflammation, 1\n",
      "National guidelines, 1\n",
      "Oral cancer, 1\n",
      "Routine panendoscopy, 1\n",
      "Synchronous second primary cancer, 1\n",
      "AGS gastric cancer, 1\n",
      "adzuki bean, 1\n",
      "digestion in vitro, 1\n",
      "mung bean, 1\n",
      "phenolics, 1\n",
      "probiotic, 1\n",
      "sprouts, 1\n",
      "body weight loss, 1\n",
      "calorie intake, 1\n",
      "diet therapy, 1\n",
      "Immunomodulation, 1\n",
      "Inflammation, 4\n",
      "Metabolization, 1\n",
      "stage IV gastric cancer, 1\n",
      "systemic inflammatory, 1\n",
      "systemic inflammatory response, 1\n",
      "atrophy, 1\n",
      "cyclooxygenase-2, 1\n",
      "dysplasia, 4\n",
      "Germline mutation, 2\n",
      "Mongoloid race, 1\n",
      "JNK inhibitors, 1\n",
      "MAP2K7, 1\n",
      "MBNL1, 1\n",
      "alternative splicing, 1\n",
      "tumor cell dedifferentiation, 1\n",
      "Gastrectomía, 1\n",
      "Gastrectomía subtotal, 1\n",
      "Gastrectomía total, 1\n",
      "Subtotal gastrectomy, 1\n",
      "Adjuvant chemotherapy, 2\n",
      "Complication, 3\n",
      "Difference, 1\n",
      "Fear, 1\n",
      "Sex, 1\n",
      "skeletal muscle, 1\n",
      "Balloon enteroscope, 1\n",
      "Balloon puncturing method, 1\n",
      "Elevated jejunum, 1\n",
      "Percutaneous jejunal tube insertion, 1\n",
      "environmental factors, 1\n",
      "human genetic factors, 1\n",
      "TLR 7, 1\n",
      "X chromosome, 1\n",
      "Yakuts, 1\n",
      "hepatocellular cancer, 2\n",
      "male gender, 1\n",
      "Non-cardia, 1\n",
      "Tumor location, 1\n",
      "Tumor-infiltrating lymphocytes, 2\n",
      "Submucosal invasion, 1\n",
      "LETM1 protein, human, 1\n",
      "Phosphatidylinositol 3 kinase, 1\n",
      "Protein kinase B, 1\n",
      "Endoscopic marking, 1\n",
      "India ink tattooing, 1\n",
      "Totally laparoscopic distal gastrectomy, 1\n",
      "Hypertension, 1\n",
      "Non-obese non-diabetic, 1\n",
      "FBXO47, 1\n",
      "tRNA-derived fragment, 1\n",
      "Cohort effects, 1\n",
      "vital statistics, 1\n",
      "HER-2/neu, 1\n",
      "Ki-67, 1\n",
      "Carcinogenesis, 2\n",
      "Microbiota, 2\n",
      "Antitumor, 1\n",
      "FB-15, 1\n",
      "HIF-1α, 1\n",
      "MGC-803, 1\n",
      "Tubulin, 1\n",
      "Food factor, 1\n",
      "Keap-1, 1\n",
      "NSAID-Induced GI damages, 1\n",
      "Nrf-2, 1\n",
      "Walnut, 1\n",
      "3D culture, 1\n",
      "Intestine, 3\n",
      "Organoids, 1\n",
      "Carcinomas, 1\n",
      "Clioquinol, 1\n",
      "Zinc, 1\n",
      "spleen tyrosine kinase, 1\n",
      "HER-2; docking, 1\n",
      "dynamic simulation, 1\n",
      "fragment-based, 1\n",
      "in vitro cytotoxic effect. , 1\n",
      "virtual screening, 1\n",
      "esophageal neoplasm, 1\n",
      "healthy diet, 1\n",
      "Gastric cancer; Signet ring cell, 1\n",
      "Helicobacter pylori; Prognosis; Outcome; H.pylori, 1\n",
      "MALT lymphoma, 1\n",
      "MALToma, 1\n",
      "gastrointestinal bleed, 1\n",
      "COL5A1, 1\n",
      "HOTAIR, 1\n",
      "Immune infiltration, 2\n",
      "MiR-1277-5p, 1\n",
      "Bcl-2, 1\n",
      "dihydropyrimidine dehydrogenase, 1\n",
      "emphysematous pancreatitis, 1\n",
      "ESTIMATE algorithm, 1\n",
      "Tumour microenvironment, 1\n",
      "neuroendocrine cell differentiation, 1\n",
      "surgical treatment, 1\n",
      "carcinoid, 1\n",
      "endoscopic resection, 2\n",
      "neuroendocrine tumors, 1\n",
      "Gastric neoplasms, 4\n",
      "Palliative operation, 1\n",
      "Stomach-partitioning gastrojejunostomy, 1\n",
      "Adenocarcinoma, esophagogastric junction, 1\n",
      "Disease attributes, 1\n",
      "Hemorrhage, 1\n",
      "ethnic groups, 1\n",
      "race, 1\n",
      "Carcinoid tumor, 1\n",
      "gastroenteropancreatic neuroendocrine tumor, 1\n",
      "Histopathological tumor regression, 1\n",
      "Locally advanced gastric cancer, 1\n",
      "Posttherapy nodal status, 1\n",
      "Laparoscopic cancer surgery, 1\n",
      "Robotic cancer surgery, 1\n",
      "Intensity-modulated radiotherapy, 1\n",
      "Normal tissue complication probability, 1\n",
      "Inhibitory Signal, 1\n",
      "Monocyte, 1\n",
      "Programmed Cell Death 1 Ligand 1, 1\n",
      "CLCA4, 1\n",
      "conflict, 1\n",
      "low-income countries, 1\n",
      "middle-income countries, 1\n",
      "war, 1\n",
      "Extranodal lymphoma, 1\n",
      "lesion biopsy, 1\n",
      "non-Hodgkin's lymphoma, 2\n",
      "periapical lesion, 1\n",
      "pulp vitality testing, 1\n",
      "EGC, 1\n",
      "C-kit, 1\n",
      "Epstein-Barr virus, 5\n",
      "Leiomyosarcoma, 1\n",
      "AIM2, 1\n",
      "CCL19/CCR7, 1\n",
      "Tumor growth, 1\n",
      "immune inflammation-based score, 1\n",
      "lymphocyte-c-reactive protein ratio, 1\n",
      "FAM83H, 1\n",
      "SCRIB, 1\n",
      "β-catenin, 2\n",
      "Anti-oxidation, 1\n",
      "Autophagy, 2\n",
      "Natural bioactive compound, 1\n",
      "Preventive therapy, 1\n",
      "Toona sinensis, 1\n",
      "Liver metastasis, 2\n",
      "stroke, 1\n",
      "Aged 80, 1\n",
      "Elderly, 1\n",
      "culture, 1\n",
      "gastric microbiota, 1\n",
      "microbiome, 1\n",
      "persistent, 1\n",
      "sequencing, 1\n",
      "transient, 1\n",
      "FDG, 1\n",
      "Ga-68 DOTA-peptides, 1\n",
      "MRI, 1\n",
      "NET, 1\n",
      "PET, 1\n",
      "colon/rectal cancer, 1\n",
      "molecular genetics, 1\n",
      "Complete remission, 1\n",
      "Lung metastases, 1\n",
      "Sorafenib, 1\n",
      "Heterotopic pancreas, 1\n",
      "SSPPD, 1\n",
      "polyps, 1\n",
      "ulcerative colitis, 1\n",
      "Golestan, 1\n",
      "Prediction, 1\n",
      "FMNLs, 1\n",
      "immune infiltrating, 1\n",
      "LY6E, 1\n",
      "dendritic cell, 1\n",
      "dendritic cell tumor-associated antigen therapy, 1\n",
      "Immunocytochemistry, 1\n",
      "Scrape cellblock, 1\n",
      "Unknown primary, 1\n",
      "VEGFR2 inhibitor, 1\n",
      "apatinib, 1\n",
      "non-intervention, 1\n",
      "adoptive cell transfer, 1\n",
      "hydrogels, 1\n",
      "interferon-α2b, 1\n",
      "low-dose irradiation, 1\n",
      "BLADE and gastric cancer, 1\n",
      "FDG, PET/MR, PET/CT, HASTE, 1\n",
      "diffuse type, 1\n",
      "radiotherapy, 2\n",
      "Date of incidence, 1\n",
      "International variation, 1\n",
      "Registration practice, 1\n",
      "SEER database, 1\n",
      "Occult gastric cancer, 1\n",
      "Skip lymphatic metastasis, 1\n",
      "ACC, adrenocortical carcinoma, 2\n",
      "BRCA, breast invasive carcinoma, 2\n",
      "CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma, 2\n",
      "CHOL, cholangiocarcinoma, 2\n",
      "Function, 1\n",
      "GBM, glioblastoma multiforme, 2\n",
      "IsomiR, 1\n",
      "KICH, kidney chromophobe, 2\n",
      "KIRC, kidney renal clear cell carcinoma, 2\n",
      "LAML, acute myeloid leukemia, 2\n",
      "LGG, brain Lower grade glioma, 1\n",
      "Let-7, 1\n",
      "MESO, mesothelioma, 2\n",
      "MicroRNA (miRNA), 1\n",
      "Network, 1\n",
      "OV, ovarian serous cystadenocarcinoma, 2\n",
      "PCPG, pheochromocytoma and paraganglioma, 2\n",
      "READ, rectum adenocarcinoma, 2\n",
      "SARC, sarcoma, 2\n",
      "SKCM, skin cutaneous melanoma, 2\n",
      "TGCT, testicular germ cell tumors, 2\n",
      "THCA, thyroid carcinoma, 2\n",
      "THYM, thymoma, 2\n",
      "TSG, tumor suppressor gene, 1\n",
      "UCS, uterine carcinosarcoma, 2\n",
      "UVM, uveal melanoma, 2\n",
      "miR-10, 1\n",
      "longitudinal cohort study, 1\n",
      "mental disorders, 1\n",
      "suicide, 1\n",
      "gastrokines, 1\n",
      "transcriptional regulation, 1\n",
      "Delayed gastric emptying, 2\n",
      "Endoscopic Botulinum toxin, 1\n",
      "Oesophagogastrectomy, 1\n",
      "Pylorus drainage procedures, 1\n",
      "Clinical features, 1\n",
      "Digestive tract cancers, 1\n",
      "Expression, 2\n",
      "PTPN family members, 1\n",
      "Macrophage, 1\n",
      "miR-223, 1\n",
      "Advanced gastric cancer and hydro-distension, 1\n",
      "Virtual gastroscopy, 1\n",
      "Centrosome, 1\n",
      "Gene regulation, 1\n",
      "Kaplan–Meier plotter, 1\n",
      "Oncomine, 1\n",
      "Topoisomerases, 1\n",
      "GI bleeding, 1\n",
      "end of life decisions (palliative care), 1\n",
      "gynecological cancer, 1\n",
      "Adénocarcinome gastrique, 1\n",
      "Dépistage, 1\n",
      "Maroc, 1\n",
      "Morocco, 1\n",
      "Pronostic, 1\n",
      "Épidémiologie, 1\n",
      "Epstein–Barr virus, 2\n",
      "intestinal/solid, 1\n",
      "lymphoepithelioma-like, 1\n",
      "poorly cohesive, 1\n",
      "EBV-miR-BART11, 1\n",
      "EMT, 3\n",
      "FOXP1, 1\n",
      "Forkhead box protein P1, 1\n",
      "Laparoscopy-assisted distal gastrectomy, 1\n",
      "Laparoscopy-assisted pylorus-preserving gastrectomy, 1\n",
      "Meta-analysis, 3\n",
      "Perioperative outcomes, 1\n",
      "Fluid cytology, 1\n",
      "Gastrointestinal cytology, 1\n",
      "Non-gynecologic cytopathology, 1\n",
      "Oncologic cytopathology, 1\n",
      "fruits, 1\n",
      "pooled analyses, 1\n",
      "vegetables, 1\n",
      "Cancer treatment, 1\n",
      "Chemotherapeutic agent, 1\n",
      "Real-time PCR, 1\n",
      "Shigella flexneri, 1\n",
      "Negative, 1\n",
      "Un-infection, 1\n",
      "D2 lymphadenectomy, 1\n",
      "adjuvant therapy, 2\n",
      "class III β-tubulin, 1\n",
      "taxane, 1\n",
      "DNA damage; Repair pathway, 1\n",
      "Next-generation sequencing, 2\n",
      "Nei-like DNA glycosylase, 1\n",
      "Nei-like DNA glycosylase 2 (NEIL2), 1\n",
      "bacterial infection, 1\n",
      "base excision repair, 1\n",
      "cytokine response, 1\n",
      "enteroids, 1\n",
      "infection, 2\n",
      "BLU-285, 1\n",
      "D842V, 1\n",
      "PDGFRA, 1\n",
      "avapritinib, 1\n",
      "Combined modality treatment, 1\n",
      "Esophagogastric junction cancer, 2\n",
      "Neoadjuvant radiochemotherapy, 1\n",
      "Perioperative chemotherapy, 1\n",
      "Real-life population, 1\n",
      "Epstein–Barr virus infection, 1\n",
      "Oesophago-gastric cancer, 1\n",
      "DNA, 1\n",
      "amino acid supplementation in cancer, 1\n",
      "chemotherapy associated malnutrition, 1\n",
      "glutamine, 1\n",
      "glutathione, 1\n",
      "radiation injury, 2\n",
      "trehalose, 1\n",
      "boosting, 1\n",
      "health record analysis, 1\n",
      "imbalanced data problem, 1\n",
      "over- and under-sampling, 1\n",
      "stomach cancer detection, 1\n",
      "Health Communication, 1\n",
      "Neoplasm Staging, 1\n",
      "Quality of Life, 1\n",
      "Histology type, 1\n",
      "Prognostic factor, 2\n",
      "Esophagogastrostomy, 1\n",
      "SDH deficiency, 1\n",
      "colon polyp, 1\n",
      "colonoscopy, 2\n",
      "esophageal squamous cell carcinoma, 1\n",
      "magnified endoscopy, 1\n",
      "narrow band imaging, 1\n",
      "Kawasaki disease, 1\n",
      "airborne pollen exposure, 1\n",
      "lung cancer, 1\n",
      "pollen diseases, 1\n",
      "specific intractable diseases, 1\n",
      "bile acids, 2\n",
      "bile ducts, 1\n",
      "cholecystectomy, 1\n",
      "gallstone disease, 1\n",
      "gut, 1\n",
      "oral cavity, 1\n",
      "Helicase, 1\n",
      "Methylation, 1\n",
      "RECQL5, 1\n",
      "neutrophil–lymphocyte ratio, 1\n",
      "perioperative management, 1\n",
      "Colostomy, 1\n",
      "Rectal cancer, 1\n",
      "Advanced gastric cancer, 5\n",
      "Capecitabine, 2\n",
      "Cisplatin, 2\n",
      "Recurrent gastric cancer, 1\n",
      "Colonic varices, 1\n",
      "Embolization, 1\n",
      "Interventional radiology, 1\n",
      "Left-sided portal hypertension, 1\n",
      "Pancreatoduodenectomy, 1\n",
      "Portal vein resection, 1\n",
      "grade 3, 1\n",
      "well-differentiated, 1\n",
      "extrusion, 1\n",
      "legume, 1\n",
      "lipid metabolism, 1\n",
      "rat, 1\n",
      "dehydro-metabolite, 1\n",
      "metabolic pathway in vivo, 1\n",
      "siphonaxanthin, 1\n",
      "white adipose tissue, 1\n",
      "Analgesic activity, 1\n",
      "Antimicrobial activity, 1\n",
      "Antiviral activity, 1\n",
      "Pharmacology, 1\n",
      "Phytochemicals, 1\n",
      "Zanthoxylum nitidum, 1\n",
      "CT, computed tomography, 1\n",
      "Diffuse ground-glass opacities, 1\n",
      "GGO, ground-glass opacity, 1\n",
      "HRCT, high resolution computed tomography, 1\n",
      "Metastatic lung tumor, 1\n",
      "Mucinous adenocarcinoma, 1\n",
      "Signet-ring cell carcinoma, 1\n",
      "Coptidis Rhizoma, 1\n",
      "Pinelliae Rhizoma, 1\n",
      "molecular docking, 1\n",
      "systemic pharmacology, 1\n",
      "Claudin 18.2, 1\n",
      "Claudiximab, 1\n",
      "IMAB362, 1\n",
      "Distal gastrectomy, 2\n",
      "Jejunal pouch, 1\n",
      "Peptic ulcer, 2\n",
      "Pouch interposition, 1\n",
      "Truncal vagotomy, 1\n",
      "contrast media, 1\n",
      "echo-endoscopy, 1\n",
      "multidetector computed tomography, 1\n",
      "neoplasm staging, 1\n",
      "Rta, 1\n",
      "cell migration, 2\n",
      "interleukin-6, 1\n",
      "nasopharyngeal carcinoma, 1\n",
      "5-FU, 2\n",
      "cyclin D1, 1\n",
      "p57, 1\n",
      "ERCC1, 1\n",
      "human gastric carcinoma, 1\n",
      "Ultrasonically-activated surgical device, 1\n",
      "dissemination, 1\n",
      "Carcinoma, signet ring cell, 1\n",
      "Lymphangitis, 1\n",
      "Database, 1\n",
      "Differentially expressed gene, 1\n",
      "Single nucleotide polymorphism, 1\n",
      "microRNA, 1\n",
      "EBV, 1\n",
      "heterotopic pancreas, 1\n",
      "jejunum, 1\n",
      "Genistein, 1\n",
      "anti-tumor mechanism, 1\n",
      "calcium-sensing receptor, 1\n",
      "Lymph nodes, 1\n",
      "Spectral imaging, 1\n",
      "Intramuscular nodules, 1\n",
      "Myalgia, 1\n",
      "Fzd, 1\n",
      "Fzd7, 1\n",
      "Wnt, 2\n",
      "gastric, 2\n",
      "signaling, 1\n",
      "CagPAI, 1\n",
      "human conventional dendritic cell (cDC), Toll-like receptor 2/4/10, 1\n",
      "TAS-102, 1\n",
      "Third line, 1\n",
      "\n",
      "Helicobacter pylori\n",
      ", 1\n",
      "5′-exonuclease, 1\n",
      "DNA polymerase I, 1\n",
      "DNA replication, 1\n",
      "Okazaki fragments, 1\n",
      "Clinical competence, 1\n",
      "Education measurement, 1\n",
      "Western countries, 1\n",
      "Pathological features, 1\n",
      "hepatitis B virus, 1\n",
      "MyD88, 1\n",
      "cancer and inflammation, 1\n",
      "gastric cardia cancer, 1\n",
      "gastric schwannoma, 1\n",
      "nausea, 1\n",
      "stomach mass, 1\n",
      "diffuse reflectance, 1\n",
      "fiber optic probe, 1\n",
      "fluorescence spectroscopy, 1\n",
      "gastrointestinal, 1\n",
      "optical biopsy, 1\n",
      "time-resolved fluorescence, 1\n",
      "Margins of excision, 1\n",
      "Uruguay, 1\n",
      "breast neoplasms, 1\n",
      "carcinoma, transitional cell, 1\n",
      "incidence, 3\n",
      "noncommunicable diseases, 1\n",
      "testicular germ cell tumor, 1\n",
      "testicular neoplasms, 1\n",
      "thyroid gland, 1\n",
      "tobacco, 2\n",
      "trends, 2\n",
      "urinary bladder neoplasms, 1\n",
      "uterine cervical neoplasms, 1\n",
      "Cheonwangbosim-dan, 1\n",
      "gastritis, 2\n",
      "ELPS, 1\n",
      "ESD, 1\n",
      "double cancer, 1\n",
      "pharyngeal cancer, 1\n",
      "Bacterial microbiota, 1\n",
      "Dysbiosis, 1\n",
      "Fungal microbiota, 1\n",
      "Gastric disorders, 1\n",
      "Microbial interactions, 1\n",
      "Microbiome, 2\n",
      "Mucosa, 1\n",
      "Her-2 antibody, 1\n",
      "poly (lactic-co-glycolic acid) nanoparticles, 1\n",
      "targeting, 2\n",
      "carbon nanoparticles, 1\n",
      "para-aortic lymph nodes, 1\n",
      "tracer agents, 1\n",
      "125 I seeds, 1\n",
      "brachytherapy, 1\n",
      "gastrointestinal tumours, 1\n",
      "oesophageal disease, 1\n",
      "Chromatography, 1\n",
      "Saliva, 1\n",
      "Cancer survivor, 1\n",
      "Gender difference, 1\n",
      "Telephone consultation, 1\n",
      "Unmet needs, 1\n",
      "Cancer chemoprevention, 1\n",
      "PIM-1, 1\n",
      "Resveratrol, 2\n",
      "Intraoperative complications, 1\n",
      "Blind loop of Roun-en-Y anastomosis, 1\n",
      "Metastatic gastric and jejunal cancer, 1\n",
      "Primary colon cancer, 1\n",
      "Acyl-CoA thioesterase 7, 1\n",
      "long non-coding RNA, 1\n",
      "Fundic gland polyp, 1\n",
      "Helicobacter pylori-negative, 1\n",
      "Magnifying endoscopy, 2\n",
      "Splenic artery pseudoaneurysm, 1\n",
      "inadequate oral intake, 1\n",
      "massive ascites, 1\n",
      "modified FOLFOX6, 1\n",
      "severe peritoneal metastases, 1\n",
      "CDH11, 1\n",
      "HEYL, 1\n",
      "transcriptional factors, 1\n",
      "anticancer drugs, 1\n",
      "cucurbituril, 1\n",
      "host-guest systems, 1\n",
      "supra-pyramid, 1\n",
      "neoadjuvant, 1\n",
      "tumor regression grade, 1\n",
      "Disparities, 1\n",
      "Race, 1\n",
      "Air pollution, 1\n",
      "PM2.5, 1\n",
      "Diabetes mellitus, 1\n",
      "Metformin, 1\n",
      "Fluorescent clip, 1\n",
      "Intraoperative endoscopy, 1\n",
      "NIRF, Near-infrared fluorescent, 1\n",
      "Age distribution, 1\n",
      "Perioperative, 1\n",
      "Tumour localisation, 1\n",
      "Validity, 1\n",
      "schizophrenia, 1\n",
      "FOXD1, 1\n",
      "FOXD1-AS1, 1\n",
      "PI3K/AKT/mTOR pathway, 1\n",
      "eIF4G-eIF4E-eIF4A translational complex, 1\n",
      "blood plasma, 1\n",
      "sPD-1, 1\n",
      "sPD-L1, 1\n",
      "Drug Resistance, Multiple, 1\n",
      "Clinical feature, 1\n",
      "Schistosomiasis, 1\n",
      "Wuhu area, 1\n",
      "BPDE-DNA adduct, 1\n",
      "Benzo[a]pyrene, 1\n",
      "myricetin, 1\n",
      "phase detoxifying enzyme, 1\n",
      "Peritoneal recurrence, 1\n",
      "Recurrence pattern, 1\n",
      "Young, 1\n",
      "bacterial nanomachines, 1\n",
      "bacterial protein secretion, 1\n",
      "cryo-electron microscopy, 1\n",
      "cryo-electron tomography, 1\n",
      "macromolecular structures, 1\n",
      "peptic ulcer disease, 1\n",
      "type IV secretion system, 1\n",
      "Neoadjuvant therapy, 2\n",
      "fluorescein, 1\n",
      "fluorescence, 1\n",
      "oral cancer, 2\n",
      "oral potentially malignant disorders, 1\n",
      "photodetection, 1\n",
      "photodiagnosis, 1\n",
      "PHF19, 1\n",
      "PRC2, 1\n",
      "cell growth, 1\n",
      "microbiome diversity, 1\n",
      "specific microbes, 1\n",
      "Familial colorectal cancer type X, 1\n",
      "Lynch-like syndrome, 1\n",
      "Prospective surveillance study, 1\n",
      "Oesophagal cancer, 1\n",
      "Secondary cancer risk estimate, 1\n",
      "VMAT, 1\n",
      "USP44, 1\n",
      "circFOXO3, 1\n",
      "miR-143-3p, 1\n",
      "\n",
      "          APC\n",
      "        , 1\n",
      "Jack Russell Terrier, 1\n",
      "dog, 1\n",
      "familial adenomatous polyposis, 1\n",
      "gastrointestinal tumor, 1\n",
      "hereditary disorder, 1\n",
      "BPC 157, 1\n",
      "NSAID induced gastroenteropathy, 1\n",
      "epithelial permeability, 1\n",
      "gut permeability, 1\n",
      "leaky gut syndrome, 1\n",
      "Immunohistochemical, 1\n",
      "Surgical treatment, 1\n",
      "ankylosing spondylitis, 1\n",
      "osteoarthritis, 1\n",
      "alpha-fetoprotein, 1\n",
      "hepatoid, 1\n",
      "conventional gastric adenocarcinoma, 1\n",
      "Early stage, 1\n",
      "Jejunal interposition, 1\n",
      "Helicobacter, 1\n",
      "NGS, 1\n",
      "Pylori, 1\n",
      "Specimens, 1\n",
      "activin A receptor type 2A, 1\n",
      "neoplasm metastasis, 1\n",
      "GLUT1, 1\n",
      "TKTL1, 1\n",
      "Tumor marker, 2\n",
      "Localized gastric adenocarcinoma, 1\n",
      "Preoperative chemotherapy, 1\n",
      "Three-drug induction, 1\n",
      "CD44 variant 9, 1\n",
      "SPEM, 2\n",
      "Tacstd2, 1\n",
      "cystadenocarcinoma, 1\n",
      "digestive surgery, 1\n",
      "indications for surgery, 1\n",
      "microcystic, 1\n",
      "serous cystic neoplasm, 1\n",
      "sunitinib, 1\n",
      "cell proliferation, 3\n",
      "hypoxia, 1\n",
      "lactic acid, 1\n",
      "Device visualization, 1\n",
      "Endoscopic clip, 1\n",
      "Indwelling ureteral catheter, 1\n",
      "Near-infrared fluorescence, 1\n",
      "Solid resin material, 1\n",
      "Helicobacter pylori\n",
      ", 1\n",
      "Toll-like receptor 2, 1\n",
      "lipoproteins, 1\n",
      "posttranslational protein modification, 1\n",
      "type IV secretion systems, 1\n",
      "Salvage chemotherapy, 1\n",
      "coronary artery perforation, 1\n",
      "gastric ulceration, 1\n",
      "gastrointestinal bleeding, 1\n",
      "COVID-19 outbreak, 1\n",
      "Psychological barriers, 1\n",
      "Urgent endoscopy, 1\n",
      "ARIMA, autoregressive integrated moving average, 1\n",
      "CI, confidence interval, 1\n",
      "COVID-19, coronavirus disease 2019, 1\n",
      "SARS-CoV, 1\n",
      "Staging, 2\n",
      "Low-grade intraepithelial neoplasia (LGIN), 1\n",
      "Risk model, 1\n",
      "early gastric cancer, 4\n",
      "papillary adenocarcinoma, 1\n",
      "Glomangiosarcoma, 1\n",
      "Hepatic neoplasm, 1\n",
      "Malignant glomus tumor, 1\n",
      "radical surgery, 1\n",
      "recurrence patterns, 1\n",
      "Antimicrobial peptides, 1\n",
      "Innate immunity, 1\n",
      "MOB kinase activator-like 1, 1\n",
      "Macrobrachium nipponense, 1\n",
      "RNA interference, 1\n",
      "Cyclin D1, 1\n",
      "Proliferation, 3\n",
      "SYF2, 1\n",
      "miR-621, 1\n",
      "endoscopic full-thickness resection, 1\n",
      "laparoscopy endoscopy cooperative surgery, 1\n",
      "per-oral endoscopic myotomy, 1\n",
      "per-oral endoscopic tumor resection, 1\n",
      "Overview, 1\n",
      "Robot, 1\n",
      "Patient-reported outcomes, 1\n",
      "Aspirin, 1\n",
      "Galactic cosmic rays, 1\n",
      "Medical countermeasures, 1\n",
      "Risk of exposure induced death, 1\n",
      "Solar particle events, 1\n",
      "Warfarin, 1\n",
      "AKR1B1, 1\n",
      "GC, 1\n",
      "seaweed, 1\n",
      "soybean products, 1\n",
      "Body composition, 1\n",
      "diabetes mellitus, 1\n",
      "gastric bypass, 1\n",
      "metabolic syndrome, 1\n",
      "Cancer burden, 2\n",
      "comparison, 1\n",
      "Angiogenesis, 2\n",
      "ITGB1, 1\n",
      "Maspin, 1\n",
      "Positron emission tomography (PET), 1\n",
      "Total lesion glycolysis (TLG), 1\n",
      "CD40, 1\n",
      "GEO, 2\n",
      "Immune checkpoint, 1\n",
      "alcohol consumption, 1\n",
      "alcohol-related cancer, 1\n",
      "cancer mortality, 1\n",
      "physical activity, 2\n",
      "Diet, 1\n",
      "Exercise, 1\n",
      "Hepatobiliary cancer, 1\n",
      "Liver cancer, 1\n",
      "Multidisciplinary rehabilitation, 1\n",
      "Oesophagogastric cancer, 1\n",
      "Multimodality treatment, 1\n",
      "Radiation therapy, 2\n",
      "BRCA, 1\n",
      "Familial adenomatous polyposis, 1\n",
      "Genetic testing, 2\n",
      "Hereditary cancer syndromes, 1\n",
      "lymph nodes, 1\n",
      "neoadjuvant chemotherapy, 1\n",
      "tumour regression, 1\n",
      "CuS–NiS2, 1\n",
      "nanomaterials, 1\n",
      "necroptosis, 1\n",
      "integrated bioinformatics, 1\n",
      "microarray analysis, 1\n",
      "genotype–phenotype correlation, 1\n",
      "hereditary hemorrhagic telangiectasia, 1\n",
      "juvenile polyposis syndrome, 1\n",
      "polyposis, 1\n",
      "Circular stapler, 1\n",
      "Esophagojejunostomy, 2\n",
      "Laparoscopic total gastrectomy, 1\n",
      "Linear stapler, 1\n",
      "Stenosis, 1\n",
      "STAT4, 1\n",
      "TBC1D10B, 1\n",
      "miR-3619-5p, 1\n",
      "IKKα/β Src, 1\n",
      "NF-κB signaling pathway, 1\n",
      "Sorbaria kirilowii, 1\n",
      "anti-inflammatory effect, 1\n",
      "epigenomics, 1\n",
      "microRNAs, 1\n",
      "microsatellite instability (MSI), 1\n",
      "Gastric cancer simulating SMT, 1\n",
      "LECS, 1\n",
      "Gastroenterostomy, 1\n",
      "Stamoch neoplasms, 1\n",
      "Suture techniques, 1\n",
      "Kenya, 1\n",
      "infectious agents, 1\n",
      "sub-Saharan Africa, 1\n",
      "Korean National Health Insurance Service system, 1\n",
      "Comparison, 1\n",
      "Risk of Death, 2\n",
      "SEER (Surveillance, 1\n",
      "Tumor, 1\n",
      "and End Results Program), 1\n",
      "Bacterial peptide, 1\n",
      "Bacteriocins, 1\n",
      "Bacteriotherapy, 1\n",
      "Toxin, 1\n",
      "randomized controlled trials (RCTs), 1\n",
      "GDF15, 1\n",
      "HIF1α, 1\n",
      "HMGB1, 1\n",
      "Tumor-associated macrophages, 2\n",
      "Checkpoint inhibition, 1\n",
      "Gastroesophageal cancer, 1\n",
      "Mismatch repair deficiency, 1\n",
      "Library of plans, 1\n",
      "Observer study, 1\n",
      "Plan selection, 1\n",
      "adverse pregnancy outcomes, 1\n",
      "pregnancy-related diseases, 1\n",
      "pregnant women, 1\n",
      "Iron oxide nanoparticles, 1\n",
      "Magnetic nanoparticles, 1\n",
      "Magnetic resonance imaging, 1\n",
      "Carbon ion, 1\n",
      "Radiotherapy, 1\n",
      "Intraoperative frozen section, 1\n",
      "Antitumor immune response, 1\n",
      "CD8, 1\n",
      "Immune-related gene, 1\n",
      "Early relapse, 1\n",
      "Irinotecan-based chemotherapy, 1\n",
      "S-1 adjuvant therapy, 1\n",
      "Second-line chemotherapy, 1\n",
      "ALKBH1, 1\n",
      "Malignant development, 1\n",
      "MiRNA-339-5p, 1\n",
      "bioactivity, 1\n",
      "cyclodextrin, 1\n",
      "reversible pegylation, 1\n",
      "tumor stroma, 1\n",
      "E2F1, 1\n",
      "miR-449a/b, 1\n",
      "Akt, 1\n",
      "aerobic glycolysis, 1\n",
      "glucose transporter-1, 1\n",
      "phosphoinositide 3-kinase, 1\n",
      "recombinant methioninase, 1\n",
      "Hsa_circ_0017639, 1\n",
      "Sponge, 1\n",
      "USP3, 1\n",
      "miR-224-5p, 1\n",
      "Immune Regulation, 1\n",
      "Lymphocyte, 1\n",
      "Mouse Model, 1\n",
      "Transcription, 1\n",
      "HPLC-MS, 1\n",
      "Lycium, 1\n",
      "coumarins, 1\n",
      "endemic plants, 1\n",
      "metabolomic, 1\n",
      "orbitrap, 1\n",
      "secondary metabolites, 1\n",
      "Occupation dust, 1\n",
      "MSH2 gene, 1\n",
      "clonal relationship, 1\n",
      "predisposing gene, 1\n",
      "whole-exome sequencing, 1\n",
      "Barrett's esophagus, 1\n",
      "EMI-137 targeting c-Met., 1\n",
      "Structured roadmap, 1\n",
      "standardized fluorescence molecular endoscopy methodology, 1\n",
      "Idiopathic inflammatory myositis, 1\n",
      "Lymph node dissection, 3\n",
      "Cancer stem cells (CSC), 1\n",
      "Octamer-binding transcription factor 4 (Oct4), 1\n",
      "digestivesurgery, 1\n",
      "emergencysurgery, 1\n",
      "gastro-duodenalsurgery, 1\n",
      "gastric carcinogenesis, 1\n",
      "metabolic pathway, 1\n",
      "nuclear magnetic resonance, 1\n",
      "rat model, 1\n",
      "tissue metabolomics, 1\n",
      "A. coarctata Poir., 1\n",
      "Achillea L., 1\n",
      "HeLa cells, 1\n",
      "MCF-7 cells, 1\n",
      "cytotoxicity, 1\n",
      "sesquiterpene lactones , 1\n",
      "Bronchogenic cyst, 1\n",
      "Endoscopic ultrasound-guided fine needle aspiration, 1\n",
      "Submucosal lesion, 1\n",
      "Analytical validation, 1\n",
      "Hereditary cancer, 2\n",
      "Multigene panel testing, 1\n",
      "Next generation sequencing, 1\n",
      "Gastrointestinal neoplasms, 2\n",
      "immunologic antineoplastic agents, 1\n",
      "monoclonal antibodies, 1\n",
      "hyperbaric oxygen therapy, 1\n",
      "hyperthermia, 1\n",
      "metabolically supported chemotherapy, 1\n",
      "Cytotoxic T lymphocyte, 1\n",
      "PD-L2, 1\n",
      "Trousseau’ syndrome, 1\n",
      "internal jugular vein, 1\n",
      "neoplastic venous thrombosis, 1\n",
      "\n",
      "Helicobacter pylori, 1\n",
      "genetic polymorphisms, 1\n",
      "pathogenicity island, 1\n",
      "premalignant gastric lesions, 1\n",
      "SOX3, 1\n",
      "proteome profiling, 1\n",
      "cross-sectional studies, 1\n",
      "liver neoplasms, 1\n",
      "proton therapy, 2\n",
      "diffuse large B-cell lymphoma, 1\n",
      "Esophagus and esophagogastric cancer, 1\n",
      "OG25, 1\n",
      "quality of life questionnaire – OES18, 1\n",
      "translation questionnaire, 1\n",
      "T-cell lymphomas, 1\n",
      "Signaling pathway, 2\n",
      "Transcription factor, 1\n",
      "LINC00619, 1\n",
      "OPCML, 1\n",
      "microRNA-224-5p, 1\n",
      "Atg12, 1\n",
      "Oxaliplatin, 1\n",
      "WASF3, 1\n",
      "esophagogastric junction cancer, 1\n",
      "lymphatic invasion, 1\n",
      "mediastinal lymph node metastases, 1\n",
      "actions, 1\n",
      "burden, 1\n",
      "cause of death, 1\n",
      "Laparoscopic distal gastrectomy, 1\n",
      "MCT1/MCT4 lactate transporter inhibitor, 1\n",
      "OLINDA, 1\n",
      "[18F]FACH, 1\n",
      "image-based internal dosimetry, 1\n",
      "preclinical radiopharmaceutical dosimetry, 1\n",
      "radiation safety, 1\n",
      "Lactobacillus, 1\n",
      "Probiotic, 1\n",
      "staging prognosis., 1\n",
      "Controversy, 1\n",
      "Gastric intestinal metaplasia, 1\n",
      "Gastric precancerous lesions, 1\n",
      "Surveillance, 3\n",
      "Cancer survival, 1\n",
      "Excess mortality, 1\n",
      "Inequalities, 1\n",
      "Rural, 1\n",
      "Urban, 1\n",
      "Open conversion, 1\n",
      "Extranodal soft tissue, 1\n",
      "Early gastric cancer (EGC), 1\n",
      "lymph node metastasis (LNM), 1\n",
      "signet ring cells, 1\n",
      "Gastric duplication cyst, 1\n",
      "laparoscopic resection, 1\n",
      "pancreatic mucinous cyst, 1\n",
      "pseudostratified columnar ciliated epithelium, 1\n",
      "esophagoenterostomy, 1\n",
      "mechanical anastomotic devices, 1\n",
      "\n",
      "Helicobacter pylori\n",
      ", 1\n",
      "outer inflammatory protein, 1\n",
      "colon cancer, 1\n",
      "gastrointestinal lymphomas, 1\n",
      "malt, 1\n",
      "rare cancers, 1\n",
      "Gall bladder, 1\n",
      "metachronous, 1\n",
      "positron emission tomography-computed tomography, 1\n",
      "synchronous, 1\n",
      "neoadjuvant therapy, 1\n",
      "Gastric-cancer-derived mesenchymal stem cells, 1\n",
      "Wnt/β-catenin, 1\n",
      "HMGCS1, 1\n",
      "gastric cancer progression, 1\n",
      "integrated stress response, 1\n",
      "mevalonate pathway, 1\n",
      "pluripotency, 1\n",
      "RECIST, 1\n",
      "Brain metastases, 1\n",
      "Esophageal adenocarcinoma, 1\n",
      "Esophageal squamous-cell carcinoma, 1\n",
      "Gastroesophageal junction adenocarcinoma, 1\n",
      "Bhutan, 1\n",
      "alcohol, 1\n",
      "betel nut, 1\n",
      "hypopharyngeal cancer, 1\n",
      "laryngeal cancer, 1\n",
      "nasopharyngeal cancer, 1\n",
      "salivary gland neoplasm, 1\n",
      "sinonasal malignancy, 1\n",
      "Eosinophilia, 1\n",
      "Eosinophilic colitis, 1\n",
      "Eosinophilic gastritis, 1\n",
      "Eosinophilic gastroenteritis, 1\n",
      "Eosinophilic gastrointestinal disorders, 1\n",
      "Hypereosinophilic syndrome, 1\n",
      "body fat percentage, 1\n",
      "body surface area, 1\n",
      "cardiovascular disease, 1\n",
      "physical measurements, 1\n",
      "extrahepatic cancer, 1\n",
      "hepatitis B virus (HBV), 1\n",
      "hepatitis C virus (HCV), 1\n",
      "Epstein-Barr virus infection, 1\n",
      "neoplastic stem cell, 1\n",
      "signal transduction, 1\n",
      "Blood flow, 1\n",
      "Gastric tube cancer, 1\n",
      "Intraoperative, 1\n",
      "Krukenberg tumours, 1\n",
      "early pregnancy symptoms, 1\n",
      "exploratory laparotomy, 1\n",
      "foetal management, 1\n",
      "preoperative diagnosis, 1\n",
      "termination of pregnancy, 1\n",
      "BIA, 1\n",
      "Hs-CRP, 1\n",
      "IL-8, 1\n",
      "TNF-α, 1\n",
      "Gastrointestinal reaction, 1\n",
      "Hyperthermic intraperitoneal chemotherapy, 1\n",
      "Warming needling technique, 1\n",
      "AGS Cells, 1\n",
      "Autophagosome, 1\n",
      "Cathepsin D, 1\n",
      "LAMP1, 1\n",
      "mTOR, 1\n",
      "GI-stomach-Med, 1\n",
      "clinical trials, 1\n",
      "molecular diagnosis, 1\n",
      "stage 1b gastric cancer, 1\n",
      "Lymph node, 1\n",
      "AGS cells, 1\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "adsorption, 1\n",
      "microplastics, 1\n",
      "nanoplastics, 1\n",
      "tetracycline, 1\n",
      "Barrett’s Esophagus, 1\n",
      "Esophageal Adenocarcinoma, 1\n",
      "Goblet Cells, 1\n",
      "Amsterdam I criteria, 1\n",
      "Cancer syndrome, 1\n",
      "Mismatch repair proficient, 1\n",
      "Tumour spectrum, 1\n",
      "Epithelium with low-grade atypia, 1\n",
      "Eradication therapy, 1\n",
      "Reddish depression, 1\n",
      "Ramucirumab, 1\n",
      "Salvage therapy, 1\n",
      "Alcohol Drinking, 1\n",
      "Cancer Survivors, 1\n",
      "Cardiovascular Diseases, 1\n",
      "Risk, 1\n",
      "MLH1, 1\n",
      "Fine particulate matter, 1\n",
      "Public health, 2\n",
      "Time-series, 1\n",
      "Aortocaval lymph node, 1\n",
      "Paraaortic lymph node, 1\n",
      "Spermatic cord, 1\n",
      "Backbone chemotherapy, 1\n",
      "Human epidermal growth receptor 2, 1\n",
      "Metastatic adenocarcinoma of the stomach or gastroesophageal junction, 1\n",
      "Noninterventional study, 1\n",
      "Real-world data, 1\n",
      "Acute subdural hematoma, 1\n",
      "Chronic subdural hematoma, 1\n",
      "Intratumoral hemorrhage, 1\n",
      "Metastatic tumor, 1\n",
      "Morbidity, 3\n",
      "Octogenarian, 2\n",
      "POSSUM, 2\n",
      "thoracotomy, 1\n",
      "body composition, 1\n",
      "cioelectrical impedance, 1\n",
      "3D reconstruction, 1\n",
      "Gastric endoscopy, 1\n",
      "monocular endoscope, 1\n",
      "structure-from-motion, 1\n",
      "Nonbacterial thrombotic endocarditis, 1\n",
      "Skin necrosis, 1\n",
      "second cancer, 1\n",
      "c-Met, 1\n",
      "exosomes, 1\n",
      "siRNA, 1\n",
      "body weight, 1\n",
      "coaching, 1\n",
      "distress management, 1\n",
      "Greater curvature, 1\n",
      "Splenectomy, 3\n",
      "Splenic hilar lymph node, 1\n",
      "Therapeutic index, 1\n",
      "Type 4 gastric cancer, 1\n",
      "claudin-3, 1\n",
      "nuclear expression, 1\n",
      "tight junctions, 1\n",
      "Gastric acid, 1\n",
      "Gastroduodenal ulcer, 1\n",
      "Intestinal perforation, 1\n",
      "Pancreatic juice, 1\n",
      "Pancreaticoduodenectomy, 1\n",
      "Assistant, 1\n",
      "Radical surgery, 1\n",
      "Multidisciplinary treatment, 1\n",
      "Standardized surgical treatment, 1\n",
      "Outcomes, 1\n",
      "Prognostic factors, 1\n",
      "Curative effect, short-term, 1\n",
      "D2 radical gastrectomy, 1\n",
      "Gastric neoplasms, distal, 1\n",
      "Laparoscope, three-dimensional imaging system, 1\n",
      "Robotic, 1\n",
      "Coronavirus disease 2019 (COVID-19), 1\n",
      "Endoscopy, selective, 1\n",
      "ERAS, 1\n",
      "Firefighting, 1\n",
      "Region-specific differences, 1\n",
      "Secular trend, 1\n",
      "Mixed adenoneuroendocrine carcinoma, 1\n",
      "Neuroendocrine carcinoma, 1\n",
      "Cell proliferation, 2\n",
      "MIEN1, 1\n",
      "circRNA_100876, 1\n",
      "miRNA sponge, 1\n",
      "(MeSH): tissue engineering, 1\n",
      "esophageal sphincter, lower, 1\n",
      "regenerative medicine, 1\n",
      "Pancreatectomy, 1\n",
      "Pancreatic intraductal neoplasms, 1\n",
      "Stomach volvulus, 1\n",
      "OA, 1\n",
      "miR-124-3p, 1\n",
      "γ-MS, 1\n",
      "2ccPA, 1\n",
      "Enterosoluble capsule, 1\n",
      "Mass spectrometry, 1\n",
      "Oral administration, 1\n",
      "Abiraterone acetate, 1\n",
      "Bioavailability, 1\n",
      "Food effect, 1\n",
      "Precipitation, 1\n",
      "Solid dispersion, 1\n",
      "Spray drying, 1\n",
      "Adenocarcinoma, papillary, 1\n",
      "kaposi’s sarcoma, 1\n",
      "second primary malignancy, 1\n",
      "upper endoscopy, 1\n",
      "visceral, 1\n",
      "Billroth-I reconstruction, 1\n",
      "robotic distal gastrectomy, 1\n",
      "LINC00483, 1\n",
      "MAPK1, 1\n",
      "miR-490-3p, 1\n",
      "Hematopoietic stem cell transplantation, 1\n",
      "Peptides regulating gastrointestinal tract functions, 1\n",
      "KEGG pathway, 1\n",
      "Sepsis, 1\n",
      "Septic shock, 1\n",
      "GKN1, 1\n",
      "Ras signaling, 1\n",
      "Uptake, 1\n",
      "genetic diagnosis, 1\n",
      "radiosensitivity, 1\n",
      "Lymph Nodes, 1\n",
      "Registries, 1\n",
      " Helicobacter pylori , 1\n",
      " cagA-motifs, 1\n",
      " homB , 1\n",
      "EPIYA-motifs, 1\n",
      "antibiotic resistance, 1\n",
      "Jejunogastricintussuception, 1\n",
      "Whipple, 1\n",
      "ascites, 1\n",
      "transrectal approach, 1\n",
      "Heparanase, 1\n",
      "Invasion and metastasis, 1\n",
      "18F-FDG PET/CT, 1\n",
      "SUVmax, 1\n",
      "HER2 status, 1\n",
      "diffuse-type gastric cancer, 1\n",
      "platinum doublet chemotherapy, 1\n",
      "primary tumor location, 1\n",
      "combined zero- and first-order absorption, 1\n",
      "first-order absorption, 1\n",
      "transit compartment absorption model, 1\n",
      "zero-order absorption, 1\n",
      "colorectal neoplasm, 1\n",
      "digestive tract neoplasm, 1\n",
      "dose, 1\n",
      "duration, 1\n",
      "Adenomatous polyps, 1\n",
      "Klebsiella pneumoniae, 1\n",
      "Pyogenic liver abscess, 1\n",
      "acupuncture, 1\n",
      "association rules, 1\n",
      "entropy clustering, 1\n",
      "rules of acupoint selection, 1\n",
      "Alginic acid, 1\n",
      "hydrogel, 1\n",
      "indocyanine green (ICG), 1\n",
      "surgical marker, 1\n",
      "Gastroesophageal reflux, 1\n",
      "Spleen preservation, 1\n",
      "peroxiredoxin IV, 1\n",
      "Natural orifice endoscopic surgery, 1\n",
      "IGF2BP3, 1\n",
      "microRNA-125a-5p, 1\n",
      "Multiple primary neoplasms, 2\n",
      "Secondary neoplasms, 1\n",
      "IFNγ gradient, 1\n",
      "co-expression network, 1\n",
      "immune checkpoint genes, 1\n",
      "novel immune checkpoint related genes, 1\n",
      "Imatinib mesylate, 1\n",
      "Preoperative treatment, 1\n",
      "Retrospective study, 1\n",
      "CCN2/CTGF, 1\n",
      "CRISPR, 1\n",
      "cellular communication network factor, 1\n",
      "genome editing, 1\n",
      "matrix metalloproteinase, 1\n",
      "moonlighting metalloproteinase (MMP), 1\n",
      "oncosome, 1\n",
      "protein moonlighting, 1\n",
      "transcription factor, 1\n",
      "Antibody, 1\n",
      "Epirubicin, 1\n",
      "Intratumor distribution, 1\n",
      "Polymeric micelle, 1\n",
      "Tissue factor, 1\n",
      "Billroth‐I, 1\n",
      "Roux‐en‐Y, 1\n",
      "esophagogastrostomy with double-flap technique (esophagogastrostomy with DFT), 1\n",
      "proximal gastrectomy (PG), 1\n",
      "pylorus-preserving gastrectomy (PPG), 1\n",
      "Endocytoscopy (EC), 1\n",
      "ultra-high magnification endoscopy, 1\n",
      "Afghanistan, 1\n",
      "Cancer prevalence, 2\n",
      "Cancer research, 1\n",
      "Kabul Jamhoriyat hospital, 1\n",
      "Women's health, 1\n",
      "Endometrial carcinoma, 1\n",
      "FISH amplification, 1\n",
      "Fixation and cold ischemia time, 1\n",
      "Her2/neu, 1\n",
      "Her2/neu testing, 1\n",
      "Papillary serous carcinoma, 1\n",
      "Second primary neoplasms, 1\n",
      "Alpha-fetoprotein, 1\n",
      "ICOS-L, 1\n",
      "IL-17, 1\n",
      "programmed death-ligand 1, 1\n",
      "retinoid orphan receptor γt, 1\n",
      "vacA-m1, 1\n",
      "AUC, area under the curve, 1\n",
      "Algorithm, 1\n",
      "CV, cross validation, 1\n",
      "DLBC, lymphoid neoplasm diffuse large B-cell lymphoma, 1\n",
      "GEO, Gene Expression Omnibus, 1\n",
      "GO, gene ontology, 1\n",
      "LGG, brain lower grade glioma, 1\n",
      "MSI, microsatellite instability, 1\n",
      "MSS, microsatellite stability, 1\n",
      "PPI, protein-protein interaction, 1\n",
      "RF, random forest, 1\n",
      "ROC, receiver operating characteristic, 1\n",
      "SVM, support vector machine, 1\n",
      "XGBoost, extreme gradient boosting, 1\n",
      "k-NN, k-nearest neighbor, 1\n",
      "BLCA, bladder carcinoma, 1\n",
      "CESC, cervical & endocervical squamous cell carcinomas, 1\n",
      "COREAD, colon and rectal adenocarcinoma TCGA cohorts, 1\n",
      "Cancer microbiome, 1\n",
      "Exome sequencing, 1\n",
      "HNSC, head & neck squamous cell carcinoma, 1\n",
      "L2FC, log 2 fold change, 1\n",
      "Microbial landscape, 1\n",
      "READ, rectal adenocarcinoma, 1\n",
      "nomograms, 1\n",
      "Model validity tool, 1\n",
      "Orthotopic transplantation, 1\n",
      "PDOX, 1\n",
      "PDX, 1\n",
      "Stomach tumour, 1\n",
      "CD44 variants, 1\n",
      "cell population dynamics, 1\n",
      "Gastroenterology, 1\n",
      "Clinical outcome, 1\n",
      "TP73-AS1, 1\n",
      "miR-223-5p, 1\n",
      "Tumor immune microenvironment, 1\n",
      "Global, 1\n",
      "Risk Factors, 1\n",
      "Near-infrared imaging, 1\n",
      "mutations, 1\n",
      "young-adult patients, 1\n",
      "ADM, 1\n",
      "mitochondria, 1\n",
      "paligenosis, 1\n",
      "ribosomes, 1\n",
      "Neuropilin-1, 1\n",
      "CircRNA sequence similarity, 1\n",
      "CircRNA-disease associations, 1\n",
      "Disease semantic similarity, 1\n",
      "Inductive matrix completion, 1\n",
      "African, 1\n",
      "African Americans, 1\n",
      "Afro-Caribbeans, 1\n",
      "Intra-racial, 1\n",
      "Rab1A, 1\n",
      "mTOR/p70S6K pathway, 1\n",
      "\n",
      "Helicobacter pylori-naïve\n",
      ", 1\n",
      "gastric gland, 1\n",
      "incisura angularis, 1\n",
      "normal mucosa, 1\n",
      "Trousseau syndrome, 1\n",
      "disseminated carcinomatosis of bone marrow, 1\n",
      "embolic strokes of undetermined source (ESUS), 1\n",
      "recurrent stroke, 1\n",
      "colonic malignant tumors, 1\n",
      "hospital information system, 1\n",
      "medication characteristics, 1\n",
      "real-world study, 1\n",
      "syndrome distribution, 1\n",
      "para-aortic lymph node excision, 1\n",
      "Muscle mass loss, 1\n",
      "Anti-PD-(L)1, 1\n",
      "HIPEC, 1\n",
      "cytoreductive surgery, 1\n",
      "peritoneal carcinomatosis, 1\n",
      "Apex1-Jagged-1 cascade, 1\n",
      "chemorefractory, 1\n",
      "chemoresponsive, 1\n",
      "Clinical outcom, 1\n",
      "Enhanced Recovery After Surgery, 1\n",
      "Stomach, neoplasm, 1\n",
      "Dyspnea, 1\n",
      "Minimally invasive procedures, 1\n",
      "Robotic surgical procedure, 1\n",
      "DFMO, 1\n",
      "Helicobacter. pylori, 1\n",
      "IL-6, 1\n",
      "capsaicin, 1\n",
      "Inflammasome, 1\n",
      "Interleukin-1β, 1\n",
      "NLRP3, 1\n",
      "AB0 blood system, 1\n",
      "H.рylori, 1\n",
      "blood groups, 1\n",
      "coronary artery disease, 1\n",
      "human diseases, 1\n",
      "malaria, 1\n",
      "oral diseases, 1\n",
      "schistosomiasis, 1\n",
      "ITLPDGL, 1\n",
      "involved field radiotherapy, 1\n",
      "lymphoproliferative disorder, 1\n",
      "Australia, 1\n",
      "Life expectancy, 1\n",
      "muscularis mucosa, 1\n",
      "submucosa, 1\n",
      "Levothyroxine, 1\n",
      "Beta-alanine, 1\n",
      "Metabolomics, 2\n",
      "Microarray, 1\n",
      "SOX5, 1\n",
      "Wnt signaling, 1\n",
      "miR-338-3p, 1\n",
      "·gastric cancer, 1\n",
      "Frozen section, 1\n",
      "Intraoperative consultation, 1\n",
      "Poorly cohesive, 1\n",
      "Signet-ring cell, 1\n",
      "autoimmune gastritis, 1\n",
      "EOX, 1\n",
      "Efficacy, 1\n",
      "m-DCF, 1\n",
      "safety, 1\n",
      "Lung carcinoma, 1\n",
      "squamous cell carcinoma, 1\n",
      "Scirrhous gastric cancer, 1\n",
      "Therapeutic value index, 1\n",
      "companion diagnostics, 1\n",
      "expression analysis, 1\n",
      "genomic test, 1\n",
      "molecular pathway analysis, 1\n",
      "platform comparison, 1\n",
      "general surgery, 1\n",
      "Clinical classification, 1\n",
      "Lymphoepithelioma-like carcinoma, 1\n",
      "gastric precancerous lesions, 1\n",
      "gastric tumorigenesis, 1\n",
      "stemness, 1\n",
      "tumor hallmarks, 1\n",
      "GERD, 1\n",
      "Laparoscopic Sleeve Gastrectomy, 1\n",
      "Magnetic Resonance Imaging (MRI), 1\n",
      "SAMD14 gene, 1\n",
      "Narrow band imaging, 1\n",
      "MIS, 1\n",
      "CD8+ T cells, 1\n",
      "Lauren classification, 1\n",
      "Multidrug resistance, 1\n",
      "microRNA-1323, 1\n",
      "β-Elemene, 1\n",
      "gastric cardia, 1\n",
      "gastric cardia adenocarcinoma, 1\n",
      "population-based studies, 1\n",
      "precursor lesions, 1\n",
      "PSMA, 1\n",
      "actinium, 1\n",
      "metastatic mouse model, 1\n",
      "prostate cancer, 1\n",
      "targeted alpha therapy, 1\n",
      "De Novo Malignancy, 1\n",
      "Hepatocellular Carcinoma, 1\n",
      "Living Donor Liver Transplantation, 1\n",
      "Elderly patients, 1\n",
      "Prognostic nutrition index, 1\n",
      "Blue toe syndrome, 1\n",
      "Cholesterol crystal embolization, 1\n",
      "Gastric remnant necrosis, 1\n",
      "Cost of illness, 1\n",
      "Socioeconomic burden, 1\n",
      "Laparoscopic-assisted, 1\n",
      "Totally laparoscopic, 1\n",
      "AmBF3-TATE, 1\n",
      "Dosimetry, 1\n",
      "Fluorine-18, 1\n",
      "Toxicology, 1\n",
      "18F-FDG, 2\n",
      "Dynamic acquisition, 1\n",
      "Whole-body PET, 1\n",
      "Sophora alopecuroides, 1\n",
      "computer simulation, 1\n",
      "cytisine-isoflavone derivative, 1\n",
      "druggability, 1\n",
      "tissue distribution, 1\n",
      "ABC method, 1\n",
      "cancer screening, 1\n",
      "pepsinogens, 2\n",
      "serological risk prediction system, 1\n",
      "Economics, medical, 1\n",
      "Priority setting, 1\n",
      "Angiogenesis inhibitors, 1\n",
      "Methylnitronitrosoguanidine, 1\n",
      "Weining granule, 1\n",
      "BGC823 cell, 1\n",
      "Epithelial- mesenchymal transition, 1\n",
      "Matrix metalloproteinases, secreted, 1\n",
      "Signal transduction, 1\n",
      "Smad proteins, 1\n",
      "Transforming growth factor beta1, 1\n",
      "Wulong Xiaozheng Wan, 1\n",
      "Decision trees, 1\n",
      "GC/MS, 1\n",
      "Sample treatment, 1\n",
      "Stomach cancer cells, 1\n",
      "folate, 1\n",
      "gene therapy, 1\n",
      "leucine-bearing PEI, 1\n",
      "siPLK1, 1\n",
      "targeted delivery, 1\n",
      "Bacteria, 1\n",
      "Thickened Gastric Wall, 1\n",
      "Advanced gastric Cancer, 1\n",
      "Intraperitoneal Hyperthermic chemotherapy, 1\n",
      "Peritoneal Carcinomatosis, 1\n",
      "precancerous lesions, 1\n",
      "Glasgow prognostic score, 1\n",
      "Prognostic value, 1\n",
      "Chemoprevention, 1\n",
      "Prevention, 1\n",
      "Bevacizumab, 1\n",
      "SOX, 1\n",
      "Synchronous double cancer, 1\n",
      "Gastrointestinal cancer mortality, 1\n",
      "Live cancer mortality, 1\n",
      "Long-term exposure, 1\n",
      "PM(2.5) air pollution, 1\n",
      "Taiwan, 1\n",
      "2020, 1\n",
      "Forecasting, 1\n",
      "Korea, 1\n",
      "frailty, 1\n",
      "malignancy, 1\n",
      "Fentanyl, 1\n",
      "apoptosis, matrix metalloproteinase-9 (MMP-9), 1\n",
      "A-kinase anchor protein 5 (AKAP5), 1\n",
      "EMCN, 1\n",
      "MUC family, 1\n",
      "MUC15, 1\n",
      "prognostic, 1\n",
      "Esophagus cancer, 1\n",
      "chemoradiation, 1\n",
      "Kurdistan, 1\n",
      "joinpoint, 1\n",
      "Cancer therapy, 1\n",
      "MicroRNAs, 1\n",
      "Epigenetics alterations, 1\n",
      "ATM, 1\n",
      "Case–control study, 1\n",
      "Birt-Hogg-Dubé syndrome, 1\n",
      "FLCN gene, 1\n",
      "Pneumothorax, 1\n",
      "Skin neoplasms, 1\n",
      "Diffuse type, 1\n",
      "Intestinal type, 1\n",
      "Laurén classification, 1\n",
      "immune checkpoint blockade, 1\n",
      "microsatellite instability-high, 1\n",
      "subtyping, 1\n",
      "177Lu, 1\n",
      "90Y, 1\n",
      "neuroendocrine neoplasms, 1\n",
      "peptide receptor radionuclide therapy, 1\n",
      "clinical practice, 1\n",
      "outcome research, 1\n",
      "real-world, 1\n",
      "gastric carcinoma, 1\n",
      "resistin-like molecule beta, 1\n",
      "SLC22A17, 1\n",
      "SUPV3L1, 1\n",
      "lymphoma, 1\n",
      "molecular diagnostics, 1\n",
      "Geranium thunbergii, 1\n",
      "cell cycle arrest, 1\n",
      "Molecular classification, 1\n"
     ]
    }
   ],
   "source": [
    "from wordcloud import WordCloud, STOPWORDS \n",
    "import collections\n",
    "stopwords = set(STOPWORDS)\n",
    "\n",
    "filtered_words = [word for word in keywords if word not in stopwords]\n",
    "counted_words = collections.Counter(filtered_words)\n",
    "\n",
    "word_count = {}\n",
    "word_frequency = []\n",
    "for letter, count in counted_words.most_common(30):\n",
    "    counted_words[letter] = count\n",
    "    \n",
    "for i,j in counted_words.items():\n",
    "        #print('Word: {0}, frequency count: {1}'.format(i,j))\n",
    "        print('{0}, {1}'.format(i,j))\n",
    "        #word_frequency.append('Word: {0}, frequency count: {1}'.format(i,j))\n",
    "        word_frequency.append('{0},{1}'.format(i,j))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Colonoscopic surveillance</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Colonoscopy</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Colorectal neoplasm</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Stomach neoplasms</td>\n",
       "      <td>82</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Colon interposition</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3445</th>\n",
       "      <td>lymphoma</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3446</th>\n",
       "      <td>molecular diagnostics</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3447</th>\n",
       "      <td>Geranium thunbergii</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3448</th>\n",
       "      <td>cell cycle arrest</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3449</th>\n",
       "      <td>Molecular classification</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3450 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                              0   1\n",
       "0     Colonoscopic surveillance   1\n",
       "1                   Colonoscopy   2\n",
       "2           Colorectal neoplasm   1\n",
       "3             Stomach neoplasms  82\n",
       "4           Colon interposition   1\n",
       "...                         ...  ..\n",
       "3445                   lymphoma   1\n",
       "3446      molecular diagnostics   1\n",
       "3447        Geranium thunbergii   1\n",
       "3448          cell cycle arrest   1\n",
       "3449   Molecular classification   1\n",
       "\n",
       "[3450 rows x 2 columns]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_wordcount = pd.DataFrame([sub.split(\",\") for sub in word_frequency])\n",
    "#search_wordcount = search_wordcount.drop(columns=[2,3,4,5,6,7,8,9,10])\n",
    "search_wordcount = search_wordcount[[0,1]]\n",
    "\n",
    "export_csv = search_wordcount.to_csv (r'search_wordcount.csv', index = None, header=True) \n",
    "search_wordcount"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1080x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "from wordcloud import WordCloud, STOPWORDS \n",
    "import matplotlib.pyplot as plt \n",
    "import pandas as pd \n",
    "  \n",
    "#convert list to string and generate\n",
    "unique_string=(\" \").join(keywords)\n",
    "wordcloud = WordCloud(background_color=\"white\", width = 1200, height = 650,collocations=False).generate(unique_string)\n",
    "plt.figure(figsize=(15,8))\n",
    "plt.imshow(wordcloud)\n",
    "#plt.imshow(wordcloud_spam, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "#plt.savefig(\"your_file_name\"+\".png\", bbox_inches='tight')\n",
    "plt.show()\n",
    "plt.close() "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "#dealing with author information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "col_authors = articlesPD['authors'].tolist()\n",
    "#print (col_authors)\n",
    "affiliation_list=[]\n",
    "for i in range(len(col_authors)):\n",
    "    for j in col_authors[i]:\n",
    "        if 'affiliation' in j.keys():\n",
    "            affiliation_list.append(j['affiliation'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'Color Genomics, 831 Mitten Road, Suite 100, Burlingame, CA, 94010, USA.',\n",
       " 'From the Departments of Medical Oncology.',\n",
       " 'From the Departments of Medical Oncology.',\n",
       " 'From the Departments of Medical Oncology.',\n",
       " 'Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.',\n",
       " 'Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.',\n",
       " 'From the Department of Nuclear Medicine.',\n",
       " 'Kuwait Cancer Control Center, Jack Brignall PET/CT Centre, Castle Hill Hospital, Cottingham, United Kingdom.',\n",
       " 'From the Department of Nuclear Medicine.',\n",
       " 'Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center.\\nDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai.',\n",
       " 'Department of Emergency, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang.',\n",
       " 'Division of Breast Surgery, Department of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning.',\n",
       " 'Department of General Surgery, Zhejiang Hospital, Hangzhou, Zhejiang, China.',\n",
       " 'Department of General Surgery, Zhejiang Hospital, Hangzhou, Zhejiang, China.',\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " 'Department of Surgery.',\n",
       " 'Department of Surgery.',\n",
       " 'Department of Pathology, Kosin University Gospel Hospital, Busan, Republic of Korea.',\n",
       " 'Department of Surgery.',\n",
       " \"Department of Oncology, The Second People's Hospital of Hefei, Hefei, Anhui, China.\",\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " 'From the Cardiovascular Division, Department of Medicine and Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine.\\nDepartments of Biomedical Engineering.\\nRadiology, University of Virginia, Charlottesville, VA.',\n",
       " 'Department of Radiation Oncology Cancer Hospital and Department of Oncology Shanghai Medical College, Fudan University, Shanghai, 200433, CHINA.',\n",
       " 'Department of Radiation Oncology, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, California, CA94305-5847, Stanford, California, 94305-5847, UNITED STATES.',\n",
       " 'Department of Radiation Oncology, Stanford University, Stanford, California, UNITED STATES.',\n",
       " 'Department of Radiation Oncology Cancer Hospital and Department of Oncology Shanghai Medical College, Fudan University, Shanghai, Shanghai, CHINA.',\n",
       " 'Department of Radiation Oncology Cancer Hospital and Department of Oncology Shanghai Medical College, Fudan University, Shanghai, Shanghai, Outside North America, 200032, CHINA.',\n",
       " 'Radiation Oncology, Stanford University, Stanford, California, UNITED STATES.',\n",
       " 'Institute of Translational & Precision Medicine, Nantong University, 19 Qi Xiu Road, Nantong, JS 226019, China; Department of Pharmacology and Biochemistry, Fudan University School of Pharmacy, 826 Zhangheng Road, Pu Dong, Shanghai 201203, China.',\n",
       " 'School of Biomedical Sciences and Gerald Choa Neuroscience Centre, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.',\n",
       " 'Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200000, China.',\n",
       " 'Institute of Translational & Precision Medicine, Nantong University, 19 Qi Xiu Road, Nantong, JS 226019, China.',\n",
       " 'School of Biomedical Sciences and Gerald Choa Neuroscience Centre, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.',\n",
       " 'Institute of Translational & Precision Medicine, Nantong University, 19 Qi Xiu Road, Nantong, JS 226019, China; Department of Pharmacology and Biochemistry, Fudan University School of Pharmacy, 826 Zhangheng Road, Pu Dong, Shanghai 201203, China. Electronic address: qianzhongming@fudan.edu.cn.',\n",
       " 'Department of Pathology, Molecular Biology Laboratory, Cancer Institute of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Pathology, Molecular Biology Laboratory, Cancer Institute of Ceará, Fortaleza, Brazil; Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceara, Fortaleza, Brazil.',\n",
       " 'Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.',\n",
       " 'Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. Electronic address: robertocesar@ufc.br.',\n",
       " 'Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. Electronic address: paulo.almeida@ufc.br.',\n",
       " 'Professor of Medicine, Director, Breast Cancer Translational Research; Co-Director, Yale Cancer Center Genetics and Genomics Program. Electronic address: lajos.pusztai@yale.edu.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China.',\n",
       " 'Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China. Electronic address: tingmeichen@cqmu.edu.cn.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " \"Institute of Pediatrics, Children's Hospital, Fudan University, Shanghai 201102, P.R. China.\",\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.',\n",
       " 'Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.',\n",
       " 'Laboratory Animal Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China; Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.',\n",
       " 'Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing 100871, P.R. China.',\n",
       " 'Predictive Oncology Laboratory and Department of Medical Oncology, CRCM, Institut Paoli-Calmettes, INSERM, CNRS, Aix-Marseille Université, Marseille, France.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China; Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China. Electronic address: xinhu@fudan.edu.cn.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China; Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China. Electronic address: yizhoujiang@fudan.edu.cn.',\n",
       " 'Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China; Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China. Electronic address: zhimingshao@yahoo.com.',\n",
       " 'Department of Obstetrics and Gynecology, Faculty of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand.',\n",
       " 'National Cancer Institute, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand.',\n",
       " 'Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.',\n",
       " 'Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.',\n",
       " 'Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.',\n",
       " 'Department of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " 'Department of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " 'Department of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " 'Department of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " 'Department of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " 'Department of Public Health, School of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " 'Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.',\n",
       " 'Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.',\n",
       " 'Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.',\n",
       " 'Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.',\n",
       " 'Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.',\n",
       " 'Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.',\n",
       " 'Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.',\n",
       " 'Department of Pathology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang Tumor Hospital , Anyang, Henan, China.',\n",
       " 'Department of Pathology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang Tumor Hospital , Anyang, Henan, China.',\n",
       " 'Department of Medical Microbiology & Immunology, Faculty of Medicine, South Valley University, Qena, Egypt.',\n",
       " 'Department of Oncology, Faculty of Medicine, South Valley University, Qena, Egypt.',\n",
       " 'Department of Medical Microbiology & Immunology, Faculty of Medicine, South Valley University, Qena, Egypt.',\n",
       " 'Department of Medical Microbiology & Immunology, Faculty of Medicine, South Valley University, Qena, Egypt.\\nDepartment of Microbiology & Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.',\n",
       " 'SAMRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.\\nNon communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, Gauteng, South Africa.',\n",
       " 'SAMRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.\\nNon communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, Gauteng, South Africa.',\n",
       " 'SAMRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.\\nNon communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, Gauteng, South Africa.',\n",
       " 'Non communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, Gauteng, South Africa.\\nDepartment of Surgery, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa.',\n",
       " 'Makerere University, Kampala, Uganda.',\n",
       " 'Windhoek Central Hospital, Windhoek, Namibia.',\n",
       " 'University of North Carolina, Chapel Hill, USA.',\n",
       " 'Abia State University Teaching Hospital, Aba, Nigeria.',\n",
       " 'Federal Medical Centre, Owerri, Nigeria.',\n",
       " 'Section of Environment and Radiation, International Agency for Research on Cancer, (IARC/WHO), Lyon, France.',\n",
       " 'Fred Hutchinson Cancer Research Center and University of Washington, Seattle, US.',\n",
       " 'Section of Environment and Radiation, International Agency for Research on Cancer, (IARC/WHO), Lyon, France.',\n",
       " 'Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.',\n",
       " 'Section of Environment and Radiation, International Agency for Research on Cancer, (IARC/WHO), Lyon, France.',\n",
       " 'Department of Surgery, Cancer Centre, University Medical Centre Utrecht, PO Box 85500, 3508, GA, Utrecht, The Netherlands. m.d.filipe-2@umcutrecht.nl.',\n",
       " 'Department of Surgery, Cancer Centre, University Medical Centre Utrecht, PO Box 85500, 3508, GA, Utrecht, The Netherlands.',\n",
       " 'Department of Surgery, Cancer Centre, University Medical Centre Utrecht, PO Box 85500, 3508, GA, Utrecht, The Netherlands.',\n",
       " 'Department of Surgery, Cancer Centre, University Medical Centre Utrecht, PO Box 85500, 3508, GA, Utrecht, The Netherlands.',\n",
       " 'Department of Surgery, Cancer Centre, University Medical Centre Utrecht, PO Box 85500, 3508, GA, Utrecht, The Netherlands.',\n",
       " 'Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands.',\n",
       " 'Department of Surgery, Cancer Centre, University Medical Centre Utrecht, PO Box 85500, 3508, GA, Utrecht, The Netherlands.',\n",
       " 'Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. aknarayan@mgh.harvard.edu.',\n",
       " 'Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.',\n",
       " 'Mount Auburn Hospital, 330 Mt Auburn Street, Cambridge, MA, 02138, USA.',\n",
       " 'Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.',\n",
       " 'Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.',\n",
       " 'Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.',\n",
       " 'Department of Surgery, University of California San Diego, 9300 Campus Point Drive, #7220, La Jolla, CA, 92037, USA.',\n",
       " 'Department of Surgery, University of California San Diego, 9300 Campus Point Drive, #7220, La Jolla, CA, 92037, USA.',\n",
       " 'Division of Breast Surgery and The Comprehensive Breast Health Center, University of California San Diego, Mailbox 0819, 3855 Health Sciences Dr, La Jolla, CA, 92037, USA.',\n",
       " 'Division of Breast Surgery and The Comprehensive Breast Health Center, University of California San Diego, Mailbox 0819, 3855 Health Sciences Dr, La Jolla, CA, 92037, USA. slblair@health.ucsd.edu.',\n",
       " 'Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA.',\n",
       " 'Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA.',\n",
       " 'Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA.',\n",
       " 'Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA.',\n",
       " 'Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA. gblanck@usf.edu.\\nDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA. gblanck@usf.edu.',\n",
       " 'IHBI, Queensland University of Technology, Brisbane, QLD, Australia.',\n",
       " 'IHBI, Queensland University of Technology, Brisbane, QLD, Australia.\\nDepartment of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.\\nMays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, TX, USA.',\n",
       " 'Cancer Pathology Research Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD, 4102, Australia.\\nMater Pathology, Mater Hospital Brisbane, Mater Misericordiae Limited, South Brisbane, QLD, 4101, Australia.',\n",
       " 'Cancer Pathology Research Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD, 4102, Australia.\\nMater Pathology, Mater Hospital Brisbane, Mater Misericordiae Limited, South Brisbane, QLD, 4101, Australia.',\n",
       " 'IHBI, Queensland University of Technology, Brisbane, QLD, Australia.\\nUniversity of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.',\n",
       " 'IHBI, Queensland University of Technology, Brisbane, QLD, Australia. dray@uthscsa.edu.\\nDepartment of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. dray@uthscsa.edu.\\nCancer Pathology Research Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD, 4102, Australia. dray@uthscsa.edu.\\nMays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, TX, USA. dray@uthscsa.edu.',\n",
       " 'Department of Biomedical Engineering, Sogang University, Seoul, Korea.',\n",
       " 'Department of Mechanical Engineering, Sogang University, Seoul, Korea.',\n",
       " 'Department of Biomedical Engineering, Sogang University, Seoul, Korea.',\n",
       " 'Department of Biomedical Engineering, Sogang University, Seoul, Korea.',\n",
       " 'Department of Mechanical Engineering, Sogang University, Seoul, Korea. bchung@sogang.ac.kr.',\n",
       " 'Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. m.ferioli88@gmail.com.',\n",
       " 'Oncologic Gynaecology Unit, Department Medical and Surgical Sciences (DIMEC), University of Bologna S. Orsola-Malpighi Hospital, Bologna, Italy.',\n",
       " 'Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy.',\n",
       " 'Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy.',\n",
       " 'Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy.',\n",
       " 'Radiotherapy Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Campobasso, Italy.',\n",
       " 'Radiotherapy Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Campobasso, Italy.',\n",
       " 'Medical Physic Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Campobasso, Italy.',\n",
       " 'Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy.',\n",
       " 'Scientific & Medical Department IGEA S.p.A., Carpi, MO, Italy.',\n",
       " 'Oncologic Gynaecology Unit, Department Medical and Surgical Sciences (DIMEC), University of Bologna S. Orsola-Malpighi Hospital, Bologna, Italy.',\n",
       " 'Department of Hematology and Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.',\n",
       " 'Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy.',\n",
       " 'Section for Breast Cancer Screening, Cancer Registry of Norway, PO Box 5313, Majorstuen, 0304, Oslo, Norway.\\nOslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, PO Box 1122, Blindern, 0317, Oslo, Norway.',\n",
       " 'Department of Radiology, Vestre Viken Hospital Trust, PO Box 800, 3004, Drammen, Norway.\\nInstitute of Clinical Medicine, University of Oslo, PO Box 1171, Blindern, 0318, Oslo, Norway.',\n",
       " 'Division of Oncology, Department of Medicine, Bærum Hospital, Vestre Viken Hospital Trust, PO Box 800, 3004, Drammen, Norway.',\n",
       " 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, PO Box 1122, Blindern, 0317, Oslo, Norway.',\n",
       " 'Section for Breast Cancer Screening, Cancer Registry of Norway, PO Box 5313, Majorstuen, 0304, Oslo, Norway. Solveig.Hofvind@kreftregisteret.no.\\nFaculty of Health Sciences, Oslo Metropolitan University, Pilestredet Campus, PO Box 4 St. Olavs plass, N-0130, Oslo, Norway. Solveig.Hofvind@kreftregisteret.no.',\n",
       " 'Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.',\n",
       " 'Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.',\n",
       " 'Center for Preventive Ophthalmology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.',\n",
       " 'Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.\\nCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.\\nLeonard Davis Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.',\n",
       " 'Department of Radiology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.\\nDepartment of Neurosurgery, Baylor Scott & White Health, Temple, Texas 76502, United States.\\nNeuroscience Institute, Baylor Scott & White Health, Temple, Texas 76502, United States.',\n",
       " \"Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China.\",\n",
       " 'Department of Radiology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.',\n",
       " 'Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas 76502, United States.\\nNeuroscience Institute, Baylor Scott & White Health, Temple, Texas 76502, United States.\\nLaboratory of Molecular Pathology, Shantou University Medical College, Shantou 515031, China.',\n",
       " 'Department of Radiology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.',\n",
       " 'Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas 76502, United States.\\nNeuroscience Institute, Baylor Scott & White Health, Temple, Texas 76502, United States.',\n",
       " 'Department of Radiology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.',\n",
       " 'Department of Radiology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.',\n",
       " 'Department of Breast Surgery, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.',\n",
       " 'Department of Computer Science, Shantou University, Shantou 515041, China.',\n",
       " 'Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas 76502, United States.\\nNeuroscience Institute, Baylor Scott & White Health, Temple, Texas 76502, United States.\\nDepartment of Surgery, Texas A & M University Health Science Center College of Medicine, Temple 76508, Texas United States.\\nDepartment of Pharmaceutical Sciences, College of Pharmacy, Texas A & M University Health Science Center, College Station, Texas 77843, United States.\\nLIVESTRONG Cancer Institutes, Dell Medical School, the University of Texas at Austin, Austin, Texas 78712, United States.',\n",
       " 'Department of Radiology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.',\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " 'GE Healthcare, MR Research, Beijing, China.',\n",
       " 'GE Healthcare, MR Research, Beijing, China.',\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " \"Department of Radiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.\",\n",
       " 'Fujian Medical University Provincial Clinical Medical College; Fujian Provincial Hospital, Fuzhou, China.',\n",
       " 'Fujian Medical University Provincial Clinical Medical College; Fujian Provincial Hospital, Fuzhou, China.',\n",
       " 'Fujian Medical University, Fuzhou, China.',\n",
       " 'Fujian Medical University Provincial Clinical Medical College; Fujian Provincial Hospital, Fuzhou, China.',\n",
       " 'Fujian Medical University Provincial Clinical Medical College; Fujian Provincial Hospital, Fuzhou, China.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Department of Biomedical Engineering, School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, PR China. sunwei19801208@163.com.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. chenggang63@hotmail.com.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.',\n",
       " 'Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos\\xa06627, Belo Horizonte, Minas Gerais\\xa031270 901, Brazil.',\n",
       " 'Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos\\xa06627, Belo Horizonte, Minas Gerais\\xa031270 901, Brazil.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.\\nLaboratory of Nanoscience & Immunology, Faculty of Ceilandia, University of Brasília, Brasília/DF 72220 900, Brazil.',\n",
       " 'Soft Matter Nanotechnology Group, CIC biomaGUNE, Paseo Miramón 182, 20014, Donostia-San Sebastián, Spain.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.',\n",
       " 'Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos\\xa06627, Belo Horizonte, Minas Gerais\\xa031270 901, Brazil.',\n",
       " 'Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, Brasília/DF 70910 900, Brazil.',\n",
       " 'Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.',\n",
       " 'Division of Gland Sugery, The Third Hospital of Xingtai, Xingtai, China.',\n",
       " 'Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'Department of Pathology, Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo,01246-903,São Paulo, Brazil.',\n",
       " 'Department of Pathology, Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo,01246-903,São Paulo, Brazil.',\n",
       " 'Department of Pathological Anatomy, A. C. Camargo Cancer Center, 01509-020, Sao Paulo, Brazil.',\n",
       " 'Department of Pathological Anatomy, A. C. Camargo Cancer Center, 01509-020, Sao Paulo, Brazil.',\n",
       " 'Discipline of Oncology, Department of Radiology & Oncology, Faculty of Medicine, University of Sao Paulo, 01246-903, Sao Paulo, Brazil.\\nLaboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of Sao Paulo, 01246-000, Sao Paulo, Brazil.',\n",
       " 'University of Illinois at Urbana-Champaign, Beckman Institute for Advanced Science and Technology, U, United States.',\n",
       " 'University of Illinois at Urbana-Champaign, Beckman Institute for Advanced Science and Technology, U, United States.\\nUniversity of Illinois at Urbana-Champaign, Department of Statistics, Champaign, Illinois, United States.',\n",
       " 'University of Illinois at Urbana-Champaign, Beckman Institute for Advanced Science and Technology, U, United States.\\nUniversity of Illinois at Urbana-Champaign, Department of Electrical and Computer Engineering, Urban, United States.\\nUniversity of Illinois at Urbana-Champaign, Department of Bioengineering, Urbana, Illinois, United States.',\n",
       " 'Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Medical Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Medical Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Medical Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Division of Medical Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.',\n",
       " 'Federal Institute of Education Science and Technology of Triângulo Mineiro (IFTM), Patrocínio, Minas Gerais, Brazil. osmando@iftm.edu.br.',\n",
       " 'São Carlos School of Engineering, University of São Paulo (EESC/USP), São Carlos, São Paulo, Brazil.',\n",
       " 'University Center Campo Limpo Paulista (UNIFACCAMP), Campo Limpo Paulista (SP), São Paulo, Brazil.',\n",
       " 'University Center Campo Limpo Paulista (UNIFACCAMP), Campo Limpo Paulista (SP), São Paulo, Brazil.',\n",
       " 'São Carlos School of Engineering, University of São Paulo (EESC/USP), São Carlos, São Paulo, Brazil.',\n",
       " 'São Carlos School of Engineering, University of São Paulo (EESC/USP), São Carlos, São Paulo, Brazil.',\n",
       " 'Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Psychology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Psychology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Oncology, Medical Center Leeuwarden, P.O. Box 888, 8901 NR, Leeuwarden, The Netherlands.',\n",
       " 'Department of Medical Oncology, Amphia, P.O. Box 90157, 4800 RL, Breda, The Netherlands.',\n",
       " 'Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.\\nDepartment of Medical Oncology, Haga Hospital, Den Haag, P.O. Box 40551, 2504 LN, The Hague, The Netherlands.',\n",
       " 'Department of Medical Oncology, Viecuri, 5912 BL, Venlo, The Netherlands.',\n",
       " 'Department of Medical Oncology, Deventer Hospital, P.O. Box 5001, 7416 SE, Deventer, The Netherlands.',\n",
       " 'Department of Medical Oncology, Deventer Hospital, P.O. Box 5001, 7416 SE, Deventer, The Netherlands.',\n",
       " 'Department of Medical Oncology, Noordwest Hospital Group, Location Alkmaar, P.O. Box 501, 1815 JD, Alkmaar, The Netherlands.',\n",
       " 'Department of Medical Oncology, Hospital Gelderse Vallei, 6710 HN, Ede, The Netherlands.',\n",
       " 'Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, P.O. Box 9600, 2300RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Biological Sciences, Longevity Institute, School of Gerontology, University of Southern California, Los Angeles, CA, 90089, USA.\\nIFOM FIRC Institute of Molecular Oncology, Via Adamello 16, Milan, Italy.',\n",
       " 'Department of Endocrinology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.',\n",
       " 'Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. j.r.kroep@lumc.nl.',\n",
       " None,\n",
       " 'Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.',\n",
       " 'Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.',\n",
       " 'Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.\\nCenter of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Düsseldorf, Kerpener Str. 62, 50937, Cologne, Germany.\\nDivision of Molecular PET-Imaging and Theranostics , Paracelsus Medical University , Salzburg, 5020, Austria.',\n",
       " 'Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.',\n",
       " \"Nanomab Technology Limited, Shanghai, People's Republic of China.\",\n",
       " \"Nanomab Technology Limited, Shanghai, People's Republic of China.\",\n",
       " 'Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.',\n",
       " 'Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Düsseldorf, Kerpener Str. 62, 50937, Cologne, Germany.\\nDepartment of Gynecology and Obstetrics, RWTH Aachen, Aachen, Germany.',\n",
       " 'Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany. fmottaghy@ukaachen.de.\\nCenter of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Düsseldorf, Kerpener Str. 62, 50937, Cologne, Germany. fmottaghy@ukaachen.de.\\nDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), 6202, Maastricht, The Netherlands. fmottaghy@ukaachen.de.',\n",
       " \"Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.\",\n",
       " \"Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.\",\n",
       " 'Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.',\n",
       " \"Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.\",\n",
       " \"Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.\",\n",
       " \"Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.\",\n",
       " \"Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China.\",\n",
       " \"Department of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R.\\xa0China.\",\n",
       " \"Department of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R.\\xa0China.\",\n",
       " \"Department of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R.\\xa0China.\",\n",
       " \"Department of Clinical Laboratory, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R.\\xa0China.\",\n",
       " 'Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.',\n",
       " 'Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.',\n",
       " 'Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.',\n",
       " 'Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.',\n",
       " 'Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.',\n",
       " 'Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Ferrara, Italy.',\n",
       " 'Unit of General Surgery, Azienda USL di Ferrara, Ferrara, Italy.',\n",
       " 'Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Ferrara, Italy.',\n",
       " 'Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Ferrara, Italy.',\n",
       " 'Department of Radiation Oncology, S. Anna University Hospital, Ferrara, Italy.',\n",
       " 'Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Ferrara, Italy.',\n",
       " 'Department of Radiation Oncology Fox Chase Cancer Center, Temple University, Philadelphia, USA.',\n",
       " 'Department of Radiation Oncology Fox Chase Cancer Center, Temple University, Philadelphia, USA.',\n",
       " None,\n",
       " 'Department of Radiology, Breast Imaging Service, Memorial Sloan-Kettering Cancer Center, New York, USA.',\n",
       " None,\n",
       " 'Department of Radiology, Breast Imaging Service, Memorial Sloan-Kettering Cancer Center, New York, USA.',\n",
       " 'Department of Radiology, Breast Imaging Service, Memorial Sloan-Kettering Cancer Center, New York, USA.',\n",
       " 'Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.',\n",
       " None,\n",
       " None,\n",
       " 'Department of NMR & MRI Facility, All India Institute of Medical Sciences , New Delhi, India.',\n",
       " 'Department of NMR & MRI Facility, All India Institute of Medical Sciences , New Delhi, India.',\n",
       " 'WeiHai Central Hospital, Weihai City, ShanDong, China.',\n",
       " 'WeiHai Central Hospital, Weihai City, ShanDong, China.',\n",
       " 'WeiHai Central Hospital, Weihai City, ShanDong, China.',\n",
       " 'GE Healthcare, Shanghai, China.',\n",
       " 'Jersey General Hospital.',\n",
       " 'Jersey General Hospital.',\n",
       " 'Jersey General Hospital.',\n",
       " 'Jersey General Hospital.',\n",
       " 'Jersey General Hospital.',\n",
       " 'Department of Biosciences, Manipal University Jaipur, Rajasthan, India.',\n",
       " 'Department of Physiology, Government Medical College, Kannauj, Uttar Pradesh, India.',\n",
       " 'Department of Neurology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.',\n",
       " 'Department of Biosciences, Manipal University Jaipur, Rajasthan, India.',\n",
       " 'Recombinant antibody laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.',\n",
       " 'Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.\\nShiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.',\n",
       " 'Nusing Care Research Center, Department of Pediatrics, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.',\n",
       " 'Department of Pediatrics, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.',\n",
       " 'Mental Health Research Center, Tehran Institute of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.',\n",
       " 'Biostatistics, School of Management and Information Technology, Iran university of Medical Sciences, Tehran, Iran.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.\\nDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.',\n",
       " 'Department of Physiological Sciences, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa.',\n",
       " 'Department of Physiological Sciences, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa.',\n",
       " 'Department of Physiological Sciences, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa.',\n",
       " 'Department of Physiological Sciences, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa.',\n",
       " 'Department of Physiological Sciences, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa.\\nAfrican Cancer Institute (ACI), Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.',\n",
       " 'University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.',\n",
       " 'University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.',\n",
       " 'University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.',\n",
       " 'University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.',\n",
       " 'University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.',\n",
       " 'University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.',\n",
       " 'Department of Computer Science, UiT The Arctic University of Norway, Tromsø, Norway.',\n",
       " 'Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.',\n",
       " 'Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.\\nDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " 'Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " 'Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.',\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " 'State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.',\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " \"Health Promotion Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.\",\n",
       " 'Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China.',\n",
       " 'Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China.',\n",
       " 'Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.',\n",
       " 'Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.',\n",
       " 'Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.',\n",
       " 'Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.',\n",
       " 'Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.',\n",
       " 'Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nCancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine,\\xa0Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nCancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine,\\xa0Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nCancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Gynecology, The Second Affiliated Hospital, Zhejiang University School of\\xa0Medicine, Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nCancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine,\\xa0Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nCancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine,\\xa0Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine,\\xa0Hangzhou, China.',\n",
       " 'Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.',\n",
       " 'Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nCancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine,\\xa0Hangzhou, China.',\n",
       " 'Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, United States.\\nDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Medicine, Case Western Reserve University, Cleveland, OH, United States.',\n",
       " 'Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI, United States.',\n",
       " 'Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, United States.',\n",
       " 'Department of Radiation Oncology, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.',\n",
       " 'Cardiology, St. Ekaterina University Hospital, Medical University of Sofia, Sofia, BGR.',\n",
       " 'Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.n.d.), Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " 'Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " 'Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " \"Department of Biomedical Sciences and Human Oncology, University of Bari 'A.moro' and Division of Oncology, Policlinico Consorziale, Bari, Italy.\",\n",
       " 'Team Immunity and Cancer, Centre De Recherche En Cancérologie De Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France.',\n",
       " 'Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " 'Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " 'Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy.',\n",
       " 'Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.',\n",
       " \"Breast Cancer Translational Research Laboratory, Jules Bordet Institut, L'Université Libre De Brussels, Belgium.\",\n",
       " 'Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " 'Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.n.d.), Section of Medical Oncology, University of Palermo, Palermo, Italy.',\n",
       " 'Team Pancreatic Cancer, Centre De Recherche En Cancérologie De Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc Scientifique Et Technologique De Luminy, Marseille, France.',\n",
       " 'School of Rehabilitation Science, McMaster University, Hamilton, Canada.',\n",
       " 'Department of Oncology, McMaster University, Hamilton, Canada.\\nJuravinski Cancer Centre, Hamilton, Canada.',\n",
       " 'School of Rehabilitation Science, McMaster University, Hamilton, Canada.',\n",
       " 'Medical Sciences, McMaster University, Hamilton, Canada.',\n",
       " 'Department of Oncology, McMaster University, Hamilton, Canada.\\nJuravinski Cancer Centre, Hamilton, Canada.\\nHealth Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.',\n",
       " 'School of Nursing, McMaster University, Hamilton, Canada.',\n",
       " 'Department of Oncology, McMaster University, Hamilton, Canada.\\nJuravinski Cancer Centre, Hamilton, Canada.',\n",
       " 'Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.',\n",
       " 'Department of Oncology, McMaster University, Hamilton, Canada.\\nJuravinski Cancer Centre, Hamilton, Canada.',\n",
       " 'Kinesiology and Physical Education, University of Toronto, Toronto, Canada.',\n",
       " 'School of Information Technology, Deakin University, 75 Pigdons Rd, Waurn Ponds, VIC 3216 Australia.',\n",
       " 'School of Information Technology, Deakin University, 75 Pigdons Rd, Waurn Ponds, VIC 3216 Australia.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " 'School of Science and Health, Western Sydney University, Narellan Road, Campbelltown NSW 2560, Australia.',\n",
       " 'Department of Occupational Health and Occupational Medicine, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Shandong, Jinan, 250012, China.',\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Radiotherapy, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of Breast Cancer Medicine, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China.\",\n",
       " \"Department of General Surgery, The Second People's Hospital of Yunnan Province, Kunming, Yunnan 650021, China.\",\n",
       " 'Department of Breast and Thyroid, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou City, Henan Province 450000, China.',\n",
       " 'Department of Biochemistry, Dharmapuram Gnanambigai Government Arts and Science College for Women, Mayiladuthurai, Tamilnadu, India.',\n",
       " 'School of Computing, SASTRA Deemed University, Tirumalaisamudram, Thanjavur 613401, Tamilnadu, India.',\n",
       " \"Department of General Surgery, The Fourth People's Hospital of Shaanxi, No. 512 Xianning East Road, Xi'an, Shaanxi 710043, China.\",\n",
       " 'Department of Medicine, Princefield University, P.O. Box MA128, Ho, Ghana.',\n",
       " 'Department of Anesthesia and Critical Care, School of Medicine, University of Health and Allied Sciences, Ho, Ghana.',\n",
       " 'Department of Pharmacy, Ho Teaching Hospital, P.O. Box MA-374, Ho, Ghana.',\n",
       " 'Department of Anesthesia and Critical Care, School of Medicine, University of Health and Allied Sciences, Ho, Ghana.',\n",
       " 'Department of Surgery, School of Medicine and Health Science, University for Development Studies, Tamale, Ghana.',\n",
       " 'Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, USA.',\n",
       " 'Department of Quantitative Health Sciences & Taussig Cancer Institute, Cleveland Clinic, USA.',\n",
       " 'Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, USA.',\n",
       " 'Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, USA.',\n",
       " 'Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, USA.',\n",
       " 'College of Computer Science and Technology, Jilin University, Changchun, China.',\n",
       " 'College of Computer Science and Technology, Jilin University, Changchun, China.',\n",
       " 'College of Computer Science and Technology, Jilin University, Changchun, China.\\nSchool of Information Engineering, Jiangxi University of Science and Technology, Ganzhou, China.',\n",
       " 'College of Computer Science and Technology, Jilin University, Changchun, China.',\n",
       " 'Department of The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China.',\n",
       " \"Department of The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China.\\nDepartment of Breast Surgery, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, China.\",\n",
       " 'İnönü University Faculty of Pharmacy, Department of Pharmaceutical Technology, Malatya, Turkey.',\n",
       " 'Hitit University Sungurlu Vocational High School, Department of Medical Services and Techniques, Çorum, Turkey.',\n",
       " 'Hacettepe University Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey.',\n",
       " \"Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province 215006, People's Republic of China.\",\n",
       " \"Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province 215006, People's Republic of China.\",\n",
       " \"Third Ward of Breast and Thyoid Surgery Department, Affiliated Zhongshan Hospital of Dalian University, Dalian City, Liaoning Province, People's Republic of China.\",\n",
       " \"Third Ward of Breast and Thyoid Surgery Department, Affiliated Zhongshan Hospital of Dalian University, Dalian City, Liaoning Province, People's Republic of China.\",\n",
       " \"Third Ward of Breast and Thyoid Surgery Department, Affiliated Zhongshan Hospital of Dalian University, Dalian City, Liaoning Province, People's Republic of China.\",\n",
       " \"Third Ward of Breast and Thyoid Surgery Department, Affiliated Zhongshan Hospital of Dalian University, Dalian City, Liaoning Province, People's Republic of China.\",\n",
       " \"Third Ward of Breast and Thyoid Surgery Department, Affiliated Zhongshan Hospital of Dalian University, Dalian City, Liaoning Province, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " \"Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.\",\n",
       " 'School of Nursing & Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.',\n",
       " \"Department of Public Health, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.\",\n",
       " 'School of Nursing & Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.',\n",
       " 'Department of Biology, Yarmouk University, Irbid, Jordan.',\n",
       " 'Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.',\n",
       " 'Department of Medical Science, Irbid Faculty, Al-Balqa Applied University (BAU), Irbid, Jordan.',\n",
       " 'Department of Basic Medical Sciences, Yarmouk University, Irbid, Jordan.',\n",
       " 'Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.',\n",
       " 'Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.\\nDepartment of Pharmacology and Therapeutics, United Arab Emirates University, Al Ain, United Arab Emirates.',\n",
       " 'Kantar, Health Division, New York, NY, USA.',\n",
       " 'Pfizer Oncology, Pfizer Inc, New York, NY, USA.',\n",
       " 'Kantar, Health Division, Horsham, PA, USA.',\n",
       " 'Kantar, Health Division, St. Louis, MO, USA.',\n",
       " 'Pfizer Oncology, Pfizer Inc, New York, NY, USA.',\n",
       " 'Kantar, Health Division, New York, NY, USA.',\n",
       " 'Kantar, Health Division, Horsham, PA, USA.',\n",
       " 'Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD USA.',\n",
       " 'Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD USA.',\n",
       " 'Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD USA.',\n",
       " 'Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD USA.',\n",
       " 'Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD USA.',\n",
       " 'Fischer Imaging, West Hills, CA USA.',\n",
       " 'Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD USA.',\n",
       " 'Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.',\n",
       " 'Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.',\n",
       " 'MSD K.K., Tokyo, Japan.',\n",
       " 'Department of Breast Surgery, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.',\n",
       " 'Department of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, 260-8670, Japan.',\n",
       " 'Department of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, 260-8670, Japan.',\n",
       " 'Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.',\n",
       " 'Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.',\n",
       " 'Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.',\n",
       " 'Department of Breast Surgery, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.',\n",
       " 'Department of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, 260-8670, Japan. naoseki@faculty.chiba-u.jp.',\n",
       " 'Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan. tago-mg@pha.keio.ac.jp.',\n",
       " 'Division of Structural Biochemistry, Department of Biochemistry, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ktago@jichi.ac.jp.',\n",
       " 'Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.',\n",
       " 'Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.',\n",
       " 'Division of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.',\n",
       " 'Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Madrid. España.\\nDepartamento de Medicina Preventiva y Salud Pública. Universidad Autónoma de Madrid/IdiPAZ. Madrid. España.',\n",
       " 'Sub-direcció General de Drogodependències. Agència de Salut Pública de Catalunya. Departament de Salut. Generalitat de Catalunya. Barcelona, España.',\n",
       " 'Departamento de Farmacología. Facultad de Medicina. Universidad de Valladolid. Valladolid. España.\\nCEIm. Hospital Clínico Universitario de Valladolid. Valladolid. España.',\n",
       " 'Estudios de Ciencias de la Salud. Universitat Oberta de Catalunya. Barcelona. España.\\nDepartament de Psicobiologia i Metodologia en Ciències de la Salut. Universitat Autònoma de Barcelona (UAB). Barcelona. España.',\n",
       " 'Graduate Program of Dentistry, Universidade Federal da Paraíba, João Pessoa.',\n",
       " 'Graduate Program of Dentistry, Universidade Federal da Paraíba, João Pessoa.\\nCleft Lip and palate center, Lauro Wanderley University Hospital, Universidade Federal da Paraiba, João Pessoa, Brasil.',\n",
       " 'Graduate Program of Dentistry, Universidade Federal da Paraíba, João Pessoa.',\n",
       " 'Department of Oral Biology.',\n",
       " 'Department of Pediatric Dentistry, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA.',\n",
       " 'Graduate Program of Dentistry, Universidade Federal da Paraíba, João Pessoa.\\nDepartment of Oral Biology.',\n",
       " 'Memorial Sloan Kettering Cancer Center, New York, NY.',\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " 'Breast Medical Oncology, The University of Texas MD Anderson Cancer Center.',\n",
       " 'Breast Medical Oncology, The University of Texas MD Anderson Cancer Center.',\n",
       " 'Chemistry, Romanian Academy.',\n",
       " 'Ben May Department for Cancer Research, University of Chicago.',\n",
       " 'Breast Medical Oncology, The University of Texas MD Anderson Cancer Center.',\n",
       " 'Breast Medical Oncology, The University of Texas MD Anderson Cancer Center.',\n",
       " 'Molecular and Cellular Biology and Center for Precision Environmental Health, Baylor College of Medicine.',\n",
       " 'Department of Biochemistry and Molecular Biology, Baylor College of Medicine.',\n",
       " 'Verna & Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine.',\n",
       " 'Mass Spectrometry Proteomics Core, Baylor College of Medicine.',\n",
       " 'Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago.',\n",
       " 'Ben May Department for Cancer Research, University of Chicago.',\n",
       " 'Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago.',\n",
       " 'Pharmacology & Toxicology, University of Arizona.',\n",
       " 'Breast Medical Oncology, The University of Texas MD Anderson Cancer Center VCJordan@mdanderson.org.',\n",
       " 'Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden anthony.matthews@ki.se.\\nDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.\\nDepartment of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.',\n",
       " 'Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.',\n",
       " 'Departmnet of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.',\n",
       " 'National Heart and Lung Institute, Imperial College, London, UK.\\nRoyal Brompton and Harefield NHS Trust, London, UK.',\n",
       " 'Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.',\n",
       " 'Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.\\nLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.',\n",
       " 'Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.',\n",
       " 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou.',\n",
       " 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkuo & Chang Gung University, Taoyuan, Taiwan.',\n",
       " 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital.',\n",
       " 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou, Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou.',\n",
       " 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital.',\n",
       " 'Institute of Biological Chemistry, Academia Sinica.',\n",
       " 'Institute of Biological Chemistry, Academia Sinica.',\n",
       " 'Graduate Institute of Biochemistry, Chang Gung University.',\n",
       " 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko.',\n",
       " 'Pediatrics, University of California in San Diego a1yu@health.ucsd.edu.',\n",
       " 'Pharmacology, Vanderbilt University Ann.Richmond@vanderbilt.edu.',\n",
       " 'Pharmacology, Vanderbilt University.',\n",
       " 'Pharmacology, Vanderbilt University.',\n",
       " 'Pathology, Ohio State University.',\n",
       " 'Biostatistics, Vanderbilt University Medical Center.',\n",
       " 'Biostatistics, Vanderbilt University School of Medicine.',\n",
       " 'Pharmacology, Vanderbilt University Medical Center.',\n",
       " 'Department of Hematology/Oncology, Geisinger Health System vgvogel@geisinger.edu.',\n",
       " 'Breast Oncology Division, Foshan hospital affiliated to Sun Yat-Sen University, Foshan 528100, China.',\n",
       " 'Department of Histology and Embryology, State Key Laboratory, Southern Medical University, Guangzhou 510515, China.',\n",
       " 'Department of Histology and Embryology, State Key Laboratory, Southern Medical University, Guangzhou 510515, China.',\n",
       " 'Department of Histology and Embryology, State Key Laboratory, Southern Medical University, Guangzhou 510515, China.',\n",
       " 'Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.',\n",
       " 'Department of Oncology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.',\n",
       " 'Department of Oncology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.',\n",
       " 'Department of Oncology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.',\n",
       " \"Department of Pharmacy, Puning Peoples' Hospital, Southern Medical University, Puning 515300, China.\",\n",
       " 'Department of Oncology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.',\n",
       " 'Department of Oncology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.',\n",
       " 'Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.',\n",
       " 'Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY.',\n",
       " 'Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY. Electronic address: kk2693@cumc.columbia.edu.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China. Electronic address: lykong@cpu.edu.cn.',\n",
       " 'State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China. Electronic address: luojg@cpu.edu.cn.',\n",
       " 'Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain. mquintela@cnio.es.\\nMedical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. mquintela@cnio.es.\\nMedical Oncology Department, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain. mquintela@cnio.es.',\n",
       " 'Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.',\n",
       " 'Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.',\n",
       " 'Medical Oncology Department, Hospital Universitari Arnau Vilanova, Lleida, Spain.',\n",
       " 'Medical Oncology Department, Hospital Clínico Universitario, Valencia, Spain.\\nINCLIVA, Valencia, Spain.\\nCIBERONC, Instituto Carlos III, Madrid, Spain.',\n",
       " 'Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.\\nMedical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.\\nFacultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.',\n",
       " 'Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.\\nMedical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.',\n",
       " 'Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin, 3, 28049, Madrid, Spain.',\n",
       " 'Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.',\n",
       " 'Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center, Madrid, Spain.',\n",
       " 'CIBERONC, Instituto Carlos III, Madrid, Spain.\\nMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.\\nMedicine Department, Universitat de Valencia, Valencia, Spain.',\n",
       " 'Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.',\n",
       " 'Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center, Madrid, Spain.',\n",
       " 'Medical Oncology Department, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain.',\n",
       " 'Medical Oncology Department, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain.',\n",
       " \"ION Institute of Oncology, Quironsalud Group - Madrid & Barcelona, Barcelona, Spain.\\nVall d'Hebron Institute of Oncology, Barcelona, Spain.\",\n",
       " 'Medical Oncology Department, Hospital Universitari Arnau Vilanova, Lleida, Spain.',\n",
       " 'Medical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.',\n",
       " 'Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.',\n",
       " 'Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin, 3, 28049, Madrid, Spain.',\n",
       " 'Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.',\n",
       " 'Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin, 3, 28049, Madrid, Spain. smanes@cnb.csic.es.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden. siker.kimbung@med.lu.se.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.\\nDepartment of Reconstructive Plastic Surgery, Skåne University Hospital, Malmö, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Surgery, Lund University, Lund, Sweden.\\nDepartment of Surgery, Central Hospital, Kristianstad, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.',\n",
       " 'Department of Clinical Sciences Lund, Division of Oncology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden. signe.borgquist@auh.rm.dk.\\nDepartment of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. signe.borgquist@auh.rm.dk.',\n",
       " 'Institute of Hospital Management, West China Hospital, Sichuan University, 37 Guo Xue Alley, Chengdu, 610040, Sichuan, China.',\n",
       " 'West China Biomedical Big Data Center, West China Hospital, Sichuan University, 37 Guo Xue Alley, Chengdu, 610040, Sichuan, China.',\n",
       " 'West China Biomedical Big Data Center, West China Hospital, Sichuan University, 37 Guo Xue Alley, Chengdu, 610040, Sichuan, China. weizhanghx@163.com.',\n",
       " 'Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Avenue career 45 number 103-34, Building Logic 2, Office 802, 110111, Bogotá, Colombia. jhernandez@cuentadealtocosto.org.',\n",
       " 'Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Avenue career 45 number 103-34, Building Logic 2, Office 802, 110111, Bogotá, Colombia.',\n",
       " 'Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Avenue career 45 number 103-34, Building Logic 2, Office 802, 110111, Bogotá, Colombia.',\n",
       " 'Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Avenue career 45 number 103-34, Building Logic 2, Office 802, 110111, Bogotá, Colombia.',\n",
       " 'Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Avenue career 45 number 103-34, Building Logic 2, Office 802, 110111, Bogotá, Colombia.',\n",
       " 'Asociación Colombiana de Hematología y Oncología, Bogotá, Colombia.',\n",
       " 'Biology Department, Pennsylvania State University, Beaver Campus, Monaca, PA, USA.',\n",
       " 'Department of Biological Sciences, Fordham University, Bronx, NY, USA.',\n",
       " \"Department of Biological Sciences, St. John's University, Queens, NY, USA. schramml@stjohns.edu.\",\n",
       " 'Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.',\n",
       " 'Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany.',\n",
       " 'Merrimack Pharmaceuticals, Cambridge, MA, USA.',\n",
       " 'Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.',\n",
       " 'Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Kooperatives Brustzentrum, Paderborn, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.',\n",
       " 'Ansbach University of Applied Sciences, Ansbach, Germany.',\n",
       " 'Department of Gynecology, Zurich University Hospital, Zurich, Switzerland.',\n",
       " 'Oncologianova GmbH, Recklinghausen, Germany.',\n",
       " 'Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.\\nBiostatistics Unit, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.',\n",
       " 'Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany.',\n",
       " 'Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.',\n",
       " 'Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.',\n",
       " 'ClinSol GmbH & Co KG, Würzburg, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany. peter.fasching@fau.de.',\n",
       " 'Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.',\n",
       " 'Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.',\n",
       " 'Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.',\n",
       " 'Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.',\n",
       " 'National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.',\n",
       " 'Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.',\n",
       " 'King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589. Saudi Arabia.',\n",
       " 'Department of Surgery, Sylvester Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136. United States.',\n",
       " 'Department of Radiation Oncology, Washington University in St Louis Saint Louis, MO 63108. United States.',\n",
       " 'Department of Anesthesiology, University of Miami, Miami, 33125. United States.',\n",
       " 'Glocal School of Pharmacy, Glocal University, Mirzapur Pole, Saharanpur, 247121 Uttar Pradesh. India.',\n",
       " 'King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589. Saudi Arabia.',\n",
       " 'King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589. Saudi Arabia.',\n",
       " 'King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589. Saudi Arabia.',\n",
       " 'Department of Anatomy, Fukuoka University School of Medicine, Fukuoka City. Japan.',\n",
       " 'Department of Radiology, Ospital ng Makati, Makati City. Philippines.',\n",
       " 'Department of Anatomy, Fukuoka University School of Medicine, Fukuoka City. Japan.',\n",
       " \"Pathology Department, 117926The People's Hospital of Lishui, Zhejiang, China.\",\n",
       " 'External Liaison Office, The Central Hospital of Lishui City, Zhejiang, China.',\n",
       " \"The Oncology Department, 117926The People's Hospital of Lishui, Zhejiang, China.\",\n",
       " \"Pathology Department, 117926The People's Hospital of Lishui, Zhejiang, China.\",\n",
       " \"Department of Clinical laboratory, 117926The People's Hospital of Lishui, Zhejiang, China.\",\n",
       " 'Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.\\nDepartment of Experimental Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.',\n",
       " 'Department of Pharmacy, International Islamic University Chittagong, Chittagong, Bangladesh.\\nDepartment of Biochemistry and Molecular Biology, University of Chittagong, Chittagong, Bangladesh.',\n",
       " 'Department of Pharmacy, International Islamic University Chittagong, Chittagong, Bangladesh.\\nDepartment of Biochemistry and Molecular Biology, University of Chittagong, Chittagong, Bangladesh.',\n",
       " 'Department of Biochemistry and Molecular Biology, University of Chittagong, Chittagong, Bangladesh.',\n",
       " 'Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, The University of Hong Kong, Pokfulam, Hong Kong.\\nDepartment of Anaesthesiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.',\n",
       " 'Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, The University of Hong Kong, Pokfulam, Hong Kong.\\nDepartment of Anaesthesiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.',\n",
       " 'Department of Anaesthesiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.',\n",
       " 'Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, The University of Hong Kong, Pokfulam, Hong Kong.\\nDepartment of Anaesthesiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.',\n",
       " 'University College Cork, Cork, Ireland.',\n",
       " 'Cork Breast Research Centre, University College Cork, Cork, Ireland.',\n",
       " 'Cork Breast Research Centre, University College Cork, Cork, Ireland.',\n",
       " 'Cork University Hospital, Wilton, Ireland.',\n",
       " 'University College Cork, Cork, Ireland.',\n",
       " 'Cork University Hospital, Wilton, Ireland.',\n",
       " 'Cork University Hospital, Wilton, Ireland.',\n",
       " 'Cork Breast Research Centre, University College Cork, Cork, Ireland.',\n",
       " 'Cork Breast Research Centre, University College Cork, Cork, Ireland.',\n",
       " 'Medical Oncology Department, Institut Curie, 26 rue Ulm, 75005, Paris, France. Electronic address: paul.cottu@curie.fr.',\n",
       " 'Medical Oncology Department, Georges François Leclerc Comprehensive Cancer Center, 1 rue du Professeur Marion, 21000, Dijon, France. Electronic address: bcoudert@cgfl.fr.',\n",
       " 'Medical Oncology Department, Centre Léon Bérard Comprehensive Cancer Center, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France. Electronic address: david.perol@lyon.unicancer.fr.',\n",
       " 'Medical Biophysics, Auvergne University, 49 boulevard François Mitterrand, 63000 Clermont-Ferrand, France. Electronic address: anne.doly@gmail.com.',\n",
       " \"Pharmacy department, Centre Hospitalier René-Dubos, 6 avenue de l'Ile de France, CS, 95303, Cergy Pontoise, France. Electronic address: julien.manson@ght-novo.fr.\",\n",
       " \"Pharmacy department, South Alsace Hospital Group, 87 avenue d'Altkirch, 68051, Mulhouse, France. Electronic address: dr.barletta@orange.fr.\",\n",
       " 'Medical Oncology, Ramsay Générale de Santé, Hôpital Privé Drome Ardèche, 294 boulevard Charles de Gaulle, 07500, Valence, France. Electronic address: aujoulato@ghrmsa.fr.',\n",
       " \"Medical affairs, Roche SAS, 30 cours de l'île Seguin, 92650, Boulogne-Billancourt, France. Electronic address: nassera.chalabi@roche.com.\",\n",
       " \"Market access, Roche SAS, 30 cours de l'île Seguin, 92650, Boulogne-Billancourt, France. Electronic address: laurence.samelon@roche.com.\",\n",
       " \"Medical Oncology Department, Paul Strauss Comprehensive Cancer Center, 3 rue de la Porte de l'Hôpital, 67000, Strasbourg, France. Electronic address: XPivot@strasbourg.unicancer.fr.\",\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'Metabolomics Core Facility of RHLCCC, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States.',\n",
       " 'School of Medical Devices, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.',\n",
       " 'School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China. Electronic address: lqyxm@hotmail.com.',\n",
       " 'School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China.',\n",
       " 'Pharmaceutical Materials Science and Engineering Laboratory, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.',\n",
       " 'School of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300071, China.',\n",
       " 'School of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300071, China.',\n",
       " 'School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China.',\n",
       " 'School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China.',\n",
       " 'Aikedao Biotechnology Co. Ltd., Changde, Hunan, 415000, China. Electronic address: liuergang@hotmail.com.',\n",
       " 'School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China. Electronic address: junbo_gong@tju.edu.cn.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Graduate Program in Genetics and Development, UConn Health, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Graduate Program in Genetics and Development, UConn Health, Farmington, CT, USA.',\n",
       " 'Graduate Program in Genetics and Development, UConn Health, Farmington, CT, USA; Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Institute for Systems Genomics, UConn Health, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA; Institute for Systems Genomics, UConn Health, Farmington, CT, USA.',\n",
       " 'Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA; Institute for Systems Genomics, UConn Health, Farmington, CT, USA.',\n",
       " 'The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA; Institute for Systems Genomics, UConn Health, Farmington, CT, USA. Electronic address: olga.anczukow@jax.org.',\n",
       " 'Computational Biology Laboratory, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.',\n",
       " 'Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SE-171 21, Sweden.',\n",
       " 'Breast Cancer Biology Group, Genome Integrity Unit, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.',\n",
       " 'Department of Cancer Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.',\n",
       " 'Department of Computer Science and Department of Biology, University of Copenhagen, Copenhagen, Denmark.',\n",
       " 'Department of Cancer Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.',\n",
       " 'Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SE-171 21, Sweden.',\n",
       " 'Computational Biology Laboratory, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.\\nTranslational Disease System Biology, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.',\n",
       " 'Breast Cancer Biology Group, Genome Integrity Unit, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.',\n",
       " 'Directorate for Nursing Services, Naval Hospital Rota, 11520 Cádiz, Spain.',\n",
       " 'Department of Family Medicine, Naval Hospital Rota, 11520 Cádiz, Spain.',\n",
       " 'Department of Psychology, Eastern Kentucky University, Richmond, Kentucky, KY 40475, USA.',\n",
       " 'Penn State College of Medicine, Department of Family and Community Medicine, Hershey, PA 17033, USA.',\n",
       " 'Department of Medical Oncology, International Oncology Services, Fortis Hospital, UP, India.',\n",
       " 'Department of Research, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.',\n",
       " \"Department of Molecular Medicine, St John's Research Institute, Karnataka, India.\",\n",
       " \"Department of Molecular Medicine, St John's Research Institute, Karnataka, India.\",\n",
       " 'Department of Medical Oncology, International Oncology Services, Fortis Hospital, UP, India.',\n",
       " 'Department of Molecular Diagnostics and Cell Biology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.',\n",
       " 'Department of Pathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.',\n",
       " 'Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.',\n",
       " 'Department of Parasitology, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey. esra.atalay.sahar@gmail.com.',\n",
       " 'Department of Parasitology, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey. mert.doskaya@ege.edu.tr.',\n",
       " 'Ödemiş Vocational School, Ege University, Ödemiş, İzmir, Turkey. mkarakavuk@gmail.com.',\n",
       " 'Molecular Biology Section, Department of Biology, Faculty of Science, Ege University, Bornova, İzmir, Turkey. huseyin.can@ege.edu.tr.',\n",
       " 'Department of Bioengineering, Faculty of Engineering, Ege University, Bornova, İzmir, Turkey. aytul.gul.89@gmail.com.',\n",
       " 'Department of Parasitology, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey. yuksel.guruz@ege.edu.tr.',\n",
       " 'Department of Parasitology, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey. aysu.degirmenci.doskaya@ege.edu.tr.',\n",
       " 'Breast Cancer Unit, Department of General Surgery, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey. levent.yeniay@ege.edu.tr.',\n",
       " 'Clinical Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Research Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Research Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Medical Affair Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Clinical Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Clinical Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Research Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Clinical Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Clinical Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Clinical Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Research Laboratory Department, Benxi Central Hospital, Benxi 117000, China.',\n",
       " 'Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.',\n",
       " 'Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.',\n",
       " 'Department of Biomedical Engineering, University of California, Davis, CA, 95616, United States.',\n",
       " 'Department of Biomedical Engineering, University of California, Davis, CA, 95616, United States.',\n",
       " 'Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.',\n",
       " 'Institute for Biomedical Engineering, Science and Technology (iBEST), Li Ka-Shing Knowledge Institute, 209 Victoria Street, Toronto, ON, Canada M5B 1T8.\\nUltrashort Laser Nanomanufacturing Research Facility, Department of Mechanical and Industrial Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nBioNanoInterface Facility, Department of Mechanical and Industrial Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nNanocharacterization Laboratory, Department of Aerospace Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nDepartment of Biomedical Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.',\n",
       " 'Institute for Biomedical Engineering, Science and Technology (iBEST), Li Ka-Shing Knowledge Institute, 209 Victoria Street, Toronto, ON, Canada M5B 1T8.\\nUltrashort Laser Nanomanufacturing Research Facility, Department of Mechanical and Industrial Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nBioNanoInterface Facility, Department of Mechanical and Industrial Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nNanocharacterization Laboratory, Department of Aerospace Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.',\n",
       " \"Keenan Research Center for Biomedical Science, St. Michael's Hospital, 30 Bond Street, Toronto, ON, Canada M5B 1W8.\\nUltrashort Laser Nanomanufacturing Research Facility, Department of Mechanical and Industrial Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nBioNanoInterface Facility, Department of Mechanical and Industrial Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\\nNanocharacterization Laboratory, Department of Aerospace Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\",\n",
       " \"Keenan Research Center for Biomedical Science, St. Michael's Hospital, 30 Bond Street, Toronto, ON, Canada M5B 1W8.\\nNanocharacterization Laboratory, Department of Aerospace Engineering, Ryerson University, 350 Victoria Street, Toronto, ON, Canada M5B 2K3.\",\n",
       " 'CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.\\nUniversity of Chinese Academy of Sciences, Beijing 100049, China.',\n",
       " 'CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.\\nUniversity of Chinese Academy of Sciences, Beijing 100049, China.',\n",
       " 'CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.\\nUniversity of Chinese Academy of Sciences, Beijing 100049, China.',\n",
       " 'CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.\\nUniversity of Chinese Academy of Sciences, Beijing 100049, China.',\n",
       " 'CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.\\nUniversity of Chinese Academy of Sciences, Beijing 100049, China.',\n",
       " 'Department of Ultrasound, Peking University Third Hospital, Beijing 100191, P.R. China.\\nKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P.R. China.\\nUniversity of Chinese Academy of Sciences, Beijing 100049, P.R. China.',\n",
       " 'Medical Isotopes Research Center and Department of Radiation Medicine, State Key Laboratory of Natural and Biomimetic Drugs, School of Basic Medical Sciences, Peking University, Beijing 100191, P.R. China.',\n",
       " 'Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P.R. China.',\n",
       " 'Medical and Health Analysis Center, Peking University, Beijing 100191, P.R. China.',\n",
       " 'Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P.R. China.',\n",
       " 'Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P.R. China.\\nBioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou 510005, P.R. China.',\n",
       " 'Medical Isotopes Research Center and Department of Radiation Medicine, State Key Laboratory of Natural and Biomimetic Drugs, School of Basic Medical Sciences, Peking University, Beijing 100191, P.R. China.',\n",
       " 'Department of Ultrasound, Peking University Third Hospital, Beijing 100191, P.R. China.',\n",
       " 'Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P.R. China.\\nMedical Isotopes Research Center and Department of Radiation Medicine, State Key Laboratory of Natural and Biomimetic Drugs, School of Basic Medical Sciences, Peking University, Beijing 100191, P.R. China.\\nBioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou 510005, P.R. China.',\n",
       " 'School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.',\n",
       " 'The College at Brockport, State University of New York, Brockport, NY, USA.',\n",
       " 'Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.',\n",
       " 'Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.',\n",
       " 'Department of Mathematics and Applied Mathematics, University of Science and Technology Beijing, Beijing, China.',\n",
       " 'Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.\\nDepartment of Psychology, University of Houston, Houston, TX, USA.',\n",
       " \"Department of Surgery, Duke University Medical Center, Durham, North Carolina.\\nWomen's Cancer Program, Duke Cancer Institute, Durham, North Carolina.\\nDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.\\nDuke Forge, Duke University, Durham, North Carolina.\\nDepartment of Surgery, Durham VA Medical Center, Durham, North Carolina.\",\n",
       " 'Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina.',\n",
       " 'Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina.',\n",
       " 'Department of Quality and Outcomes, Duke Cancer Institute, Durham, North Carolina.',\n",
       " 'Department of Surgery, Duke University Medical Center, Durham, North Carolina.',\n",
       " \"Women's Cancer Program, Duke Cancer Institute, Durham, North Carolina.\\nDepartment of Medicine, Duke University Medical Center, Durham, North Carolina.\",\n",
       " 'Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina.\\nDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.',\n",
       " \"Department of Surgery, Duke University Medical Center, Durham, North Carolina.\\nWomen's Cancer Program, Duke Cancer Institute, Durham, North Carolina.\",\n",
       " 'National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100021, China.',\n",
       " 'National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100021, China. bhxu@hotmail.com.',\n",
       " 'Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.',\n",
       " 'Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.',\n",
       " 'Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.',\n",
       " 'School of Social Work, College of Health and Human Sciences, Colorado State University, Fort Collins, CO, USA.',\n",
       " 'Department of Oncology, Georgetown University, Washington, DC, USA.',\n",
       " 'Department of Oncology, Georgetown University, Washington, DC, USA.',\n",
       " 'Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.\\nDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.',\n",
       " 'Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. tomi.akinyemiju@duke.edu.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan. ginaguma@fujita-hu.ac.jp.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan.',\n",
       " 'Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-8521, Japan.',\n",
       " 'Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.\\nInstitute of Medical Science, University of Toronto, Toronto, Ontario, Canada.\\nResearch Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Research Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Biostatistics Division, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Biostatistics Division, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " \"Department of Diagnostic Radiology, School of Medicine, Queen's University, Kingston, Ontario, Canada.\",\n",
       " 'Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Research Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.\\nInstitute of Medical Science, University of Toronto, Toronto, Ontario, Canada.\\nResearch Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.\\nDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.\\nRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.',\n",
       " 'Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles.',\n",
       " 'Instituto do Cancer do Estado de Sao Paulo (ICESP), Instituto de Radiologia (InRad), Serviço de Radioterapia, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, SP, BR.',\n",
       " 'Instituto do Cancer do Estado de Sao Paulo (ICESP), Instituto de Radiologia (InRad), Serviço de Radioterapia, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, SP, BR.',\n",
       " 'Instituto do Cancer do Estado de Sao Paulo (ICESP), Instituto de Radiologia (InRad), Serviço de Radioterapia, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, SP, BR.',\n",
       " 'Instituto do Cancer do Estado de Sao Paulo (ICESP), Instituto de Radiologia (InRad), Serviço de Radioterapia, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, SP, BR.',\n",
       " 'Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul, Campus Porto Alegre, Coronel Vicente, 281, Centro, 90030-041 Porto Alegre, RS, Brazil.',\n",
       " 'Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul, Campus Porto Alegre, Coronel Vicente, 281, Centro, 90030-041 Porto Alegre, RS, Brazil.',\n",
       " 'Faculdade de Farmácia da Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, 90610-000 Santana, Porto Alegre, RS, Brazil.',\n",
       " 'Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul, Campus Porto Alegre, Coronel Vicente, 281, Centro, 90030-041 Porto Alegre, RS, Brazil.',\n",
       " 'Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul, Campus Porto Alegre, Coronel Vicente, 281, Centro, 90030-041 Porto Alegre, RS, Brazil.',\n",
       " 'Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite, 245, Centro Histórico, 90050-170, Porto Alegre, RS, Brazil.',\n",
       " 'Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul, Campus Porto Alegre, Coronel Vicente, 281, Centro, 90030-041 Porto Alegre, RS, Brazil.',\n",
       " 'Irmandade da Santa Casa de Misericórdia de Porto Alegre, Departamento de Neurologia, Porto Alegre RS, Brazil.',\n",
       " 'Irmandade da Santa Casa de Misericórdia de Porto Alegre, Departamento de Neurologia, Porto Alegre RS, Brazil.',\n",
       " 'Irmandade da Santa Casa de Misericórdia de Porto Alegre, Departamento de Radiologia, Porto Alegre RS, Brazil.',\n",
       " 'Irmandade da Santa Casa de Misericórdia de Porto Alegre, Departamento de Oncologia Clínica, Porto Alegre RS, Brazil.',\n",
       " 'Irmandade da Santa Casa de Misericórdia de Porto Alegre, Departamento de Psiquiatria, Porto Alegre RS, Brazil.',\n",
       " 'Irmandade da Santa Casa de Misericórdia de Porto Alegre, Departamento de Neurologia, Porto Alegre RS, Brazil.',\n",
       " 'Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.',\n",
       " 'Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.\\nFaculty of Health, University of Copenhagen, Copenhagen, Denmark.',\n",
       " 'Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.',\n",
       " 'Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, P. R. China.',\n",
       " 'Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, P. R. China.',\n",
       " 'Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, P. R. China.',\n",
       " 'Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, P. R. China.',\n",
       " 'BrightGene Bio-Medical Technology Company, Ltd., Suzhou 215123, P. R. China.',\n",
       " 'Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, P. R. China.',\n",
       " 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.\\nCenter of Excellence for Natural Product Drug Interaction Research, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.',\n",
       " 'SOLVO Biotechnology, SZTE Biológiai Epület, University of Szeged, Szeged, Hungary.',\n",
       " 'SOLVO Biotechnology, SZTE Biológiai Epület, University of Szeged, Szeged, Hungary.',\n",
       " 'Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, USA.',\n",
       " 'Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.',\n",
       " 'Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.',\n",
       " 'Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, USA.\\nCenter of Excellence for Natural Product Drug Interaction Research, Spokane, WA, USA.',\n",
       " 'Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.\\nCenter of Excellence for Natural Product Drug Interaction Research, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.\\nCenter of Excellence for Natural Product Drug Interaction Research, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.\\nCenter of Excellence for Natural Product Drug Interaction Research, Spokane, WA, USA.',\n",
       " 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.\\nCenter of Excellence for Natural Product Drug Interaction Research, Spokane, WA, USA.',\n",
       " 'Medical Center of Cervical Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Medical Center of Cervical Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Medical Center of Cervical Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Medical Center of Cervical Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Medical Center of Cervical Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Medical Center of Cervical Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " 'Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China.',\n",
       " \"Department of Clinical Laboratory, Shanghai No. 8 People's Hospital, Shanghai 200235, P.R. China.\",\n",
       " 'Department of Radiation Oncology, The Fourth Hospital, Harbin Medical University, Harbin, China.',\n",
       " 'Department of Radiation Oncology, The Fourth Hospital, Harbin Medical University, Harbin, China.',\n",
       " 'Department of Radiation Oncology, The Fourth Hospital, Harbin Medical University, Harbin, China.',\n",
       " 'Griffith University, Institute for Glycomics, Gold Coast Campus, 4222, Gold Coast, AUSTRALIA.',\n",
       " 'Griffith University, Institute for Glycomics, Griffith University, Gold Coast Campus, 4222, Southport, AUSTRALIA.',\n",
       " 'Griffith University, Institute for Glycomics, Griffith University, Gold Coast Campus, 4222, Southport, AUSTRALIA.',\n",
       " 'Minnesota State University Mankato, Biochemistry, Chemistry and Geology, Mankato, USA, UNITED STATES.',\n",
       " 'Griffith University, Institute for Glycomics, Griffith University, Gold Coast Campus, 4222, Southport, AUSTRALIA.',\n",
       " 'Virginia Commonwealth University, Department of Chemistry, 23284-2006, Richmond, UNITED STATES.',\n",
       " 'Virginia Commonwealth University, Department of Chemistry, 23284-2006, Richmond, UNITED STATES.',\n",
       " 'Virginia Commonwealth University, Massey Cancer Centre, 23298-0037, Richmond, UNITED STATES.',\n",
       " 'University at Buffalo, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center,, University at Buffalo, 14203, Buffalo, UNITED STATES.',\n",
       " 'University at Buffalo, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, University at Buffalo, 14203, Buffalo, UNITED STATES.',\n",
       " 'Griffith University, Institute for Glycomics, Griffith University, Gold Coast Campus, 4222, Southport, AUSTRALIA.',\n",
       " 'Virginia Commonwealth University, Department of Chemistry, 23284, Richmond, UNITED STATES.',\n",
       " 'College of Public Health, University of South Florida, Tampa, FL, USA.',\n",
       " 'Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.',\n",
       " 'Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.',\n",
       " 'Vanderbilt Institute for Global Health, Vanderbilt University School of Nursing, Nashville, TN, USA.',\n",
       " 'Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.',\n",
       " \"Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada.\\nWomen's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.\",\n",
       " \"Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.\",\n",
       " \"Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.\",\n",
       " 'Sunnybrook Health Sciences Centre, Toronto, ON, Canada.',\n",
       " \"Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.\",\n",
       " 'Princess Margaret Cancer Centre, Toronto, ON, Canada.',\n",
       " 'Princess Margaret Cancer Centre, Toronto, ON, Canada.',\n",
       " 'Sunnybrook Health Sciences Centre, Toronto, ON, Canada.',\n",
       " 'Princess Margaret Cancer Centre, Toronto, ON, Canada.',\n",
       " 'Sunnybrook Health Sciences Centre, Toronto, ON, Canada.',\n",
       " \"Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.\",\n",
       " \"Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada. steven.narod@wchospital.ca.\",\n",
       " 'Department of Gynecology, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany. maria-margarete.karsten@charite.de.',\n",
       " 'Department of Gynecology, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.',\n",
       " 'Department of Gynecology, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.',\n",
       " 'ConsultantCA, Moraga, CA 94556, USA.',\n",
       " 'Tumor Initiation and Maintenance Program, NCI‑Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'School of Basic Medical Sciences, Ningxia Medical University, Ministry of Education, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " 'Department of Oncology, General Hospital of The Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China.',\n",
       " \"Department of Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.\",\n",
       " \"Department of Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.\",\n",
       " \"Department of Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.\",\n",
       " \"Department of Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.\",\n",
       " \"Department of Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.\",\n",
       " 'Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R.\\xa0China.',\n",
       " 'Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R.\\xa0China.',\n",
       " 'Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R.\\xa0China.',\n",
       " 'Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R.\\xa0China.',\n",
       " \"Frontier Institute of Science and Technology, State Key Laboratory for Mechanical Behavior of Materials, Xi'an Jiaotong University, Xi'an, Shaanxi 710054, P.R. China.\",\n",
       " 'Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.',\n",
       " \"Institute of Hematological Research, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710000, P.R. China.\",\n",
       " 'Jiangxi Province Key Laboratory of Tumor Pathogens and Molecular Pathology and Department of Pathophysiology, School of Basic Medical Sciences, Nanchang University Medical College, Nanchang, Jiangxi 330006, P.R. China.',\n",
       " ...]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "def remove_none_elements_from_list(list):\n",
    "     return [e for e in affiliation_list if(pd.notnull(e))]\n",
    "\n",
    "affiliation_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "#import re\n",
    "#affiliation_list_re=[]\n",
    "#count = 0\n",
    "#for i in affiliation_list:\n",
    "#    count = count+1\n",
    "#    line = re.sub(r\"[\\w\\W]* ((Institute|Hospital|University|Center|Law School|School|Academy|Department)[\\w -]*)[\\w\\W]*$\", r\"\\1\", i)\n",
    "#    affiliation_list_re.append(line)\n",
    "#    print (line)\n",
    "#    print (i)\n",
    "#    if count == 100:\n",
    "#        break\n",
    "#print (affiliation_list_re)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 261,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>{'lastname': 'Berger', 'firstname': 'Mark J', ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>{'lastname': 'Boers', 'firstname': 'Jorianne',...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>{'lastname': 'Usmani', 'firstname': 'Sharjeel'...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>{'lastname': 'Hou', 'firstname': 'Jianjing', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>{'lastname': 'Wang', 'firstname': 'Jian Ming',...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>995</th>\n",
       "      <td>{'lastname': 'Ke', 'firstname': 'Qiwei', 'init...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>996</th>\n",
       "      <td>{'lastname': 'Zhang', 'firstname': 'Wei', 'ini...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>997</th>\n",
       "      <td>{'lastname': 'Chen', 'firstname': 'Yuanyuan', ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>998</th>\n",
       "      <td>{'lastname': 'Chan', 'firstname': 'Pi-Wei', 'i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>999</th>\n",
       "      <td>{'collective': None, 'lastname': 'Pratt', 'fir...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1000 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                     0\n",
       "0    {'lastname': 'Berger', 'firstname': 'Mark J', ...\n",
       "1    {'lastname': 'Boers', 'firstname': 'Jorianne',...\n",
       "2    {'lastname': 'Usmani', 'firstname': 'Sharjeel'...\n",
       "3    {'lastname': 'Hou', 'firstname': 'Jianjing', '...\n",
       "4    {'lastname': 'Wang', 'firstname': 'Jian Ming',...\n",
       "..                                                 ...\n",
       "995  {'lastname': 'Ke', 'firstname': 'Qiwei', 'init...\n",
       "996  {'lastname': 'Zhang', 'firstname': 'Wei', 'ini...\n",
       "997  {'lastname': 'Chen', 'firstname': 'Yuanyuan', ...\n",
       "998  {'lastname': 'Chan', 'firstname': 'Pi-Wei', 'i...\n",
       "999  {'collective': None, 'lastname': 'Pratt', 'fir...\n",
       "\n",
       "[1000 rows x 1 columns]"
      ]
     },
     "execution_count": 261,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "authors = pd.DataFrame(col_authors)  \n",
    "authors_1 = authors[[0]]\n",
    "authors_2 = authors[[1]]\n",
    "authors_3 = authors[[2]]\n",
    "authors_1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "col_authors_1 = authors_1.tolist()\n",
    "#print (col_authors)\n",
    "affiliation_list_1=[]\n",
    "for i in range(len(col_authors_1)):\n",
    "    for j in col_authors[i]:\n",
    "        if 'affiliation' in j.keys():\n",
    "            affiliation_list.append(j['affiliation'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 279,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Angola\n",
      "United Arab Emirates\n",
      "Argentina\n",
      "Australia\n",
      "Austria\n",
      "Belgium\n",
      "Bangladesh\n",
      "Bulgaria\n",
      "Bahrain\n",
      "Brazil\n",
      "Canada\n",
      "Switzerland\n",
      "Chile\n",
      "China\n",
      "Cameroon\n",
      "Colombia\n",
      "Cuba\n",
      "Cyprus\n",
      "Germany\n",
      "Denmark\n",
      "Egypt\n",
      "Eritrea\n",
      "Spain\n",
      "Ethiopia\n",
      "Finland\n",
      "Fiji\n",
      "France\n",
      "United Kingdom\n",
      "Georgia\n",
      "Ghana\n",
      "Greece\n",
      "Hong Kong\n",
      "Croatia\n",
      "Haiti\n",
      "Hungary\n",
      "Indonesia\n",
      "India\n",
      "Ireland\n",
      "Israel\n",
      "Italy\n",
      "Jersey\n",
      "Jordan\n",
      "Japan\n",
      "Kuwait\n",
      "Lebanon\n",
      "Sri Lanka\n",
      "Latvia\n",
      "Morocco\n",
      "Mexico\n",
      "Mali\n",
      "Mozambique\n",
      "Malaysia\n",
      "Namibia\n",
      "Niger\n",
      "Nigeria\n",
      "Netherlands\n",
      "Norway\n",
      "New Zealand\n",
      "Pakistan\n",
      "Peru\n",
      "Philippines\n",
      "Poland\n",
      "Portugal\n",
      "Qatar\n",
      "Romania\n",
      "Russian Federation\n",
      "Saudi Arabia\n",
      "Sudan\n",
      "Singapore\n",
      "Serbia\n",
      "Slovakia\n",
      "Slovenia\n",
      "Sweden\n",
      "Thailand\n",
      "Tunisia\n",
      "Turkey\n",
      "Uganda\n",
      "Uruguay\n",
      "United States\n",
      "Viet Nam\n",
      "South Africa\n"
     ]
    }
   ],
   "source": [
    "#note: it's best to get country count, rather than just country\n",
    "#using list comprehension \n",
    "Country = ' '.join(map(str, affiliation_list)) \n",
    "  \n",
    "\n",
    "import pycountry\n",
    "country_list = []\n",
    "for country in pycountry.countries:\n",
    "    if country.name in Country:\n",
    "        country_list.append(country.name)\n",
    "        print(country.name)\n",
    "  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#below draw interactive node and edge"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "#for interactive node and edge\n",
    "#how to draw graph by tableau https://www.youtube.com/watch?v=mV-AgEmBNss\n",
    "import csv\n",
    "import itertools\n",
    "\n",
    "from pymed import PubMed\n",
    "\n",
    "\n",
    "# Create a PubMed object that GraphQL can use to query\n",
    "# Note that the parameters are not required but kindly requested by PubMed Central\n",
    "# https://www.ncbi.nlm.nih.gov/pmc/tools/developers/\n",
    "pubmed = PubMed(tool=\"Author co-occurence analysis\", email=\"folooyi@outlook.com\")\n",
    "\n",
    "# Create a GraphQL query in plain text\n",
    "query = \"Breast Cancer[keywords]\"\n",
    "\n",
    "\n",
    "# Execute the query against the API\n",
    "results = list(pubmed.query(query, max_results=18))\n",
    "\n",
    "\n",
    "# Create a node for each unique author\n",
    "nodes = {\n",
    "    author: index\n",
    "    for index, author in enumerate(\n",
    "        set(\n",
    "            itertools.chain.from_iterable(\n",
    "                [\n",
    "                    [\n",
    "                        f'{author[\"lastname\"]} {author[\"firstname\"]}'\n",
    "                        for author in article.authors\n",
    "                    ]\n",
    "                    for article in results\n",
    "                ]\n",
    "            )\n",
    "        )\n",
    "    )\n",
    "}\n",
    "\n",
    "# Create an edge for each combination of authors (co-authorship)\n",
    "edges = list(\n",
    "    itertools.chain.from_iterable(\n",
    "        [\n",
    "            [combination for combination in itertools.combinations(co_author_list, 3)]\n",
    "            for co_author_list in [\n",
    "                [\n",
    "                    nodes[f'{author[\"lastname\"]} {author[\"firstname\"]}']\n",
    "                    for author in article.authors\n",
    "                ]\n",
    "                for article in results\n",
    "            ]\n",
    "        ]\n",
    "    )\n",
    ")\n",
    "\n",
    "# De-duplicate the list of edges by adding a weight\n",
    "edges = set([(edge[0], edge[1], edges.count(edge)) for edge in edges])\n",
    "\n",
    "\n",
    "# Open the nodes file\n",
    "with open(\"./nodes.csv\", \"w\", encoding=\"utf8\", newline=\"\") as nodes_file:\n",
    "\n",
    "    # Create a CSV writer\n",
    "    writer = csv.writer(nodes_file, delimiter=\",\")\n",
    "\n",
    "    # Write the header\n",
    "    writer.writerow([\"id\", \"label\"])\n",
    "\n",
    "    # Loop over the authors and create rows\n",
    "    for name, index in nodes.items():\n",
    "        writer.writerow([index, name])\n",
    "\n",
    "\n",
    "with open(\"./edges.csv\", \"w\", encoding=\"utf8\", newline=\"\") as edge_file:\n",
    "\n",
    "    # Create a CSV writer\n",
    "    writer = csv.writer(edge_file, delimiter=\",\")\n",
    "\n",
    "    # Write the header\n",
    "    writer.writerow([\"source\", \"target\", \"weight\"])\n",
    "\n",
    "    # Loop over the edges and put them in the file\n",
    "    for edge in edges:\n",
    "        writer.writerow(edge)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#below dealing with abstract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 287,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Publicly available genetic databases promote data sharing and fuel scientific discoveries for the prevention, treatment and management of disease. In 2018, we built Color Data, a user-friendly, open access database containing genotypic and self-reported phenotypic information from 50\\u2009000 individuals who were sequenced for 30 genes associated with hereditary cancer. In a continued effort to promote access to these types of data, we launched Color Data v2, an updated version of the Color Data database. This new release includes additional clinical genetic testing results from more than 18\\u2009000 individuals who were sequenced for 30 genes associated with hereditary cardiovascular conditions as well as polygenic risk scores for breast cancer, coronary artery disease and atrial fibrillation. In addition, we used self-reported phenotypic information to implement the following four clinical risk models: Gail Model for 5-year risk of breast cancer, Claus Model for lifetime risk of breast cancer, simple office-based Framingham Coronary Heart Disease Risk Score for 10-year risk of coronary heart disease and CHARGE-AF simple score for 5-year risk of atrial fibrillation. These new features and capabilities are highlighted through two sample queries in the database. We hope that the broad dissemination of these data will help researchers continue to explore genotype-phenotype correlations and identify novel variants for functional analysis, enabling scientific discoveries in the field of population genomics. Database URL: https://data.color.com/. We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16α-[F]fluoro-17β-estradiol ([F]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F]-FDG PET because of physiological [F]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F]-FES PET imaging. [F]-FES PET could be used to prove the presence of ER-positive metastases in the brain. Osteitis condensans ilii (OCI) is a benign cause of low back pain for which no clear etiology has been identified. We report cases of 2 women with breast cancer referred for F-NaF PET/CT for skeletal staging. Both cases show characteristic findings of OCI on CT images, with F-NaF PET uptake in symptomatic patient and no uptake in asymptomatic. F-NaF PET CT can be useful in evaluating back pain and may be used as an adjunctive biological maker for assessing OCI as a potential cause of pain. Amplified in breast cancer 1 (AIB1) expression is known to be involved in the initiation and progression of malignant breast cancer (BC), but its prognostic role remains uncertain. This meta-analysis assessed reported studies to evaluate this relationship.\\nElectronic databases were systematically reviewed to collect eligible studies using pre-established criteria. Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (CIs) were pooled to estimate the impact of AIB1 protein expression on overall survival (OS) and clinicopathologic properties of BC cases.\\nNine eligible studies, including 6774 patients, were finally assessed by the current clinical meta-analysis. AIB1 positivity correlated with reduced OS (pooled HR\\u200a=\\u200a1.409, 95% CI 1.159-1.714, P\\u200a=\\u200a.001). AIB1 overexpression also impacted prognosis as shown by univariate (pooled HR\\u200a=\\u200a1.420, 95% CI 1.154-1.747, P\\u200a=\\u200a.001) and multivariate (pooled HR\\u200a=\\u200a1.446, 95% CI 1.099-1.956; P\\u200a=\\u200a.009) analyses. Notably, subgroup analyses also revealed that AIB1 overexpression was associated with poor OS in some subgroups, such as ER-positive group (pooled HR\\u200a=\\u200a1.511, 95% CI 1.138-2.006, P\\u200a=\\u200a.004), ER-positive without tamoxifen administration group (pooled HR\\u200a=\\u200a2.338, 95% CI 1.489-3.627, P\\u200a<\\u200a.001), and premenopausal women group (pooled HR\\u200a=\\u200a1.715, 95% CI 1.231-2.390, P\\u200a=\\u200a.001). Additionally, high AIB1 protein levels were associated with HER2 positivity (pooled OR\\u200a=\\u200a0.331, 95% CI 0.245-0.448; P\\u200a<\\u200a.001), poorly differentiated histological grade (pooled OR\\u200a=\\u200a0.377, 95% CI 0.317-0.448; P\\u200a<\\u200a.001), high Ki67 (pooled OR\\u200a=\\u200a0.501, 95% CI 0.410-0.612; P\\u200a<\\u200a.001), presence of lymph node metastases (pooled OR\\u200a=\\u200a0.866, 95% CI 0.752-0.997; P\\u200a=\\u200a.045), and absence of progesterone receptor (pooled OR\\u200a=\\u200a1.447, 95% CI 1.190-1.759; P\\u200a<\\u200a.001).\\nThis analysis demonstrated that AIB1 overexpression is related to aggressive phenotypes and unfavorable clinical outcomes in BC, and might involve in tamoxifen resistance. AIB1 may be a new prognostic biomarker and therapeutic target in BC. To determine the association between mammographic density (MD) and the risk of breast cancer (BC) in Chinese women and to investigate the role of fertility risk factors in regulating the relationship between MD and BC.We used Quantra software and the BI-RADS classification to assess MD in 466 patients and 932 controls. Conditional matched logistic multiple regression analysis was used to determine the relationship between MD and BC, and risk was evaluated with the odds ratio (OR) and 95% confidence interval (CI).The ORs for category 4 versus category 2 were 1.95 (95% confidence interval [95% CI] (1.42∼2.66)) and 1.76 (95% CI (1.28∼2.42)) for the BI-RADS and Quantra classifications, respectively. The ORs for category 5 volumetric breast density (VBD) versus category 2 VBD and 5 fibroglandular tissue volume (FGV) versus category 2 FGV were 1.63 (95% CI (1.20∼2.23)) and 1.92 (95% CI (1.40∼2.63)), respectively. Females with category 5 VBD whose age at menarche was ≤13 years had the highest risk of BC (OR\\u200a=\\u200a2.16, 95% CI (1.24∼3.79)), and females with category 5 FGV whose age at menarche was\\u200a=\\u200a15 years had the lowest risk of BC (OR\\u200a=\\u200a1.65, 95% CI (1.05∼2.62)). Females with categories 3-5 VBD and categories 3-5 FGV had reduced risks of BC with increasing number of births. Females with category 5 VBD had an increased risk of BC with increasing age at first childbirth (the OR increased from 1.49 to 1.95). Those with category 5 VBD had a reduced risk of BC with increasing breastfeeding duration (the OR decreased from 2.08 to 1.55). Females with category 5 FGV had a reduced risk of BC with increasing breastfeeding duration (the OR decreased from 4.12 to 1.62).Both the BI-RADS density classification and Quantra measures indicated that MD is positively associated with the risk of BC in Chinese women and that associations between MD and BC risk differ by age at menarche, parity, age at first childbirth and breastfeeding duration. The human epidermal growth factor receptor 2 (HER2) is amplified in approximately 20% of breast cancers, and HER2 receptor targeting therapy is associated with a significant improvement in disease-free and overall survival. In several clinical trials, the pathologic complete response (pCR) rate was significantly increased with combined pertuzumab and trastuzumab treatment in HER2-amplified breast cancer. Although the efficacy and safety of anti-HER2 dual blockade therapy has been reported, the markers that predict the response are still unclear. This study aimed to investigate the relationship between the level of HER2 amplification and the pCR in trastuzumab and pertuzumab neoadjuvant therapy.Twenty-two HER2-amplified early breast cancer patients who had received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) therapy were included in this study. HER2/CEP17 ratio and average HER2 copy number were measured by fluorescence in situ hybridization analysis. The relationship between level of HER2 amplification and tumor pCR status was investigated.The median age was 47.5 years (range, 36-62). 31.8% of the patients were hormone receptor (HR) positive and 68.2%% of the patients were HR negative. The pCR (ypN0/is ypN0) rate in the breast and axilla was 68.2%. The patients who experienced a pCR had a median HER2/CEP17 ratio of 7.08 (range, 3.16-10.40) and average HER2 copy number of 17.00 (range, 5.85-37.50). The patients who did not experience a pCR had a median ratio of 4.70 (range, 1.06-9.00) and median HER2 copy number of 12.00 (range, 5.85-20.95) (P\\u200a=\\u200a.030, P\\u200a=\\u200a.174), respectively.pCR was highly correlated with HER2/CEP17 ratio in neoadjuvant anti-HER2 dual blockade. This suggests that the HER2/CEP17 ratio can be used as a predictive marker for pCR in neoadjuvant trastuzumab and pertuzumab therapy. Several studies have explored the prognostic value of MicroRNA-153 (miR-153) in various cancers, but obtained inconsistent results. Thus, we conducted a meta-analysis to assess the prognostic significance of miR-153 for patients with cancer.\\nEligible studies were identified by searching the online databases Pubmed, Embase, Web of Science, Medline,and the China National Knowledge Infrastructure (CNKI) up to March 2020. Hazard ratios (HRs) with 95% CIs and were calculated to clarify the correlation between miR-153 expression and prognosis of different cancers. Odds ratios (ORs) with 95% CI were selected to appraise the correlation between miR-153 with clinicopathological characteristics of cancer patients.\\nIn total, 933 patients from 11 articles were enrolled in our meta-analysis. The results revealed that low miR-153 expression was significantly correlated with poor overall survival (OS) (HR\\u200a=\\u200a2.45, 95% CI\\u200a=\\u200a1.66-3.63, P\\u200a<\\u200a.001), but not with disease-free survival (DFS) (HR\\u200a=\\u200a1.67, 95% CI\\u200a=\\u200a0.45-6.19, P\\u200a=\\u200a.442). Subgroup analysis found that low miR-153 expression was associated with worse OS in the reported directly from articles group (HR\\u200a=\\u200a2.67, 95% CI: 1.32-5.37, P\\u200a=\\u200a.006), survival curves group (HR\\u200a=\\u200a2.10, 95% CI: 1.56-2.84, P\\u200a<\\u200a.001), digestive system tumor (HR\\u200a=\\u200a2.76, 95% CI: 1.73-4.41, P\\u200a<\\u200a.001), and breast cancer (HR\\u200a=\\u200a4.01, 95% CI: 1.46-11.04, P\\u200a=\\u200a.007).Moreover, cancer patients with low miR-153 expression were prone to poor tumor differentiation(poor vs well+moderate, OR\\u200a=\\u200a2.41, 95% CI\\u200a=\\u200a1.52-3.82, P\\u200a<\\u200a.001), earlier lymph node metastasis (present vs absent, OR\\u200a=\\u200a2.19, 95% CI\\u200a=\\u200a1.12-4.25, P\\u200a=\\u200a.021) and earlier distant metastasis (present vs absent,OR\\u200a=\\u200a8.24, 95% CI\\u200a=\\u200a2.93-23.21, P\\u200a<\\u200a.001), but not associated with age,gender and TNM stage.\\nThis meta-analysis indicated that low miR-153 expression is associated with poor prognosis. miR-153 may serve as an effective predictive biomarker for tumor prognosis, especially for digestive system tumor and breast cancer. Gas-filled microbubbles are currently in clinical use as blood pool contrast agents for ultrasound imaging. The goal of this review is to discuss the trends and issues related to these relatively unusual intravascular materials, which are not small molecules per se, not polymers, not even nanoparticles, but larger micrometer size structures, compressible, flexible, elastic, and deformable. The intent is to connect current research and initial studies from 2 to 3 decades ago, tied to gas exchange between the bubbles and surrounding biological medium, in the following areas of focus: (1) parameters of microbubble movement in relation to vasculature specifics; (2) gas uptake and loss from the bubbles in the vasculature; (3) adhesion of microbubbles to target receptors in the vasculature; and (4) microbubble interaction with the surrounding vessels and tissues during insonation.Microbubbles are generally safe and require orders of magnitude lower material doses than x-ray and magnetic resonance imaging contrast agents. Application of microbubbles will soon extend beyond blood pool contrast and tissue perfusion imaging. Microbubbles can probe molecular and cellular biomarkers of disease by targeted contrast ultrasound imaging. This approach is now in clinical trials, for example, with the aim to detect and delineate tumor nodes in prostate, breast, and ovarian cancer. Imaging of inflammation, ischemia-reperfusion injury, and ischemic memory is also feasible. More importantly, intravascular microbubbles can be used for local deposition of focused ultrasound energy to enhance drug and gene delivery to cells and tissues, across endothelial barrier, especially blood-brain barrier.Overall, microbubble behavior, stability and in vivo lifetime, bioeffects upon the action of ultrasound and resulting enhancement of drug and gene delivery, as well as targeted imaging are critically dependent on the events of gas exchange between the bubbles and surrounding media, as outlined in this review. Accurate and efficient dose calculation is an important prerequisite to ensure the success of radiation therapy. However, all the dose calculation algorithms commonly used in current clinical practice have to compromise between calculation accuracy and efficiency, which may result in unsatisfactory dose accuracy or highly intensive computation time in many clinical situations. The purpose of this work is to develop a novel dose calculation algorithm based on the deep learning method for radiation therapy. In this study we performed a feasibility investigation on implementing a fast and accurate dose calculation based on a deep learning technique. A two dimensional (2D) fluence map was first converted into a three dimensional (3D) volume using ray traversal algorithm. A 3D U-Net like deep residual network was then established to learn a mapping between this converted 3D volume, CT and 3D dose distribution. Therefore an indirect relationship was built between a fluence map and its corresponding 3D dose distribution without using significantly complex neural networks. 200 patients, including nasopharyngeal, lung, rectum and breast cancer cases, were collected and applied to train the proposed network. Additional 47 patients were randomly selected to evaluate the accuracy of the proposed method through comparing dose distributions, dose volume histograms (DVH) and clinical indices with the results from a treatment planning system (TPS), which was used as the ground truth in this study. The proposed deep learning based dose calculation algorithm achieved good predictive performance. For 47 tested patients, the average per-voxel bias of the deep learning calculated value and standard deviation (normalized to the prescription), relative to the TPS calculation, is 0.17%±2.28%. The average deep learning calculated values and standard deviations for relevant clinical indices were compared with the TPS calculated results and the t-test p-values demonstrated the consistency between them. None Triple-negative breast cancer (TNBC) is a subtype of cancer, which tests negative for estrogen receptors, progesterone receptors, and lacks overexpression of the human epidermal growth factor 2 (C-erbB2, HER2/neu) gene. The expression of chemokines and their receptors, including CCR7, has been described in several types of cancer, contributing to tumor progression.\\nThis study investigated the association between the membrane and cytoplasmic CCR7 expression and the prognosis of TNBC.\\nSurgical paraffin histopathology blocks and clinico-pathological data were assessed from 133 patients. Samples were analyzed by immunohistochemistry and immunofluorescence using the Tissue Microarray technique for scoring the intensity of CCR7 expression.\\nTNBC patients in which the CCR7 labeling was predominantly in the cytoplasm of tumor cells presented increased local tumor recurrence (P = 0.033). Conversely, there was no statistical difference in five-year overall survival between the patients with low (77%) versus high (80%) cytoplasmic CCR7 expression (P = 0.7104). Additionally, the risk of death between these groups was 1.19 (95% CI = 0.48-2.91).\\nThe cytoplasmic CCR7 expression associates with an increased incidence of tumor relapse in TNBC, not affecting patients survival. Consequently, the cell compartment in which the CCR7 localizes could serve as a prognostic marker in this cancer subtype. None Breast cancer is one of the most malignant diseases world-wide and ranks the first among female cancers. Progranulin (PGRN) plays a carcinogenic role in breast cancer, but its mechanisms are not clear. In addition, there are few reports on the relationship between PGRN and tumor-associated macrophages (TAMs).\\nTo investigate the effects of exosomes derived from PGRN\\nMouse breast cancer xenograft model was constructed to explore the effect of PGRN\\nThe lung metastasis of breast cancer of PGRN\\nOur study elucidates a new molecular mechanism of lung metastasis of breast cancer, so it may contribute to efficient prevention and therapeutic strategies. Triple-negative breast cancer (TNBC) remains an unmet medical challenge. We investigated metabolic dysregulation in TNBCs by using our multi-omics database (n\\xa0= 465, the largest to date). TNBC samples were classified into three heterogeneous metabolic-pathway-based subtypes (MPSs) with distinct metabolic features: MPS1, the lipogenic subtype with upregulated lipid metabolism; MPS2, the glycolytic subtype with upregulated carbohydrate and nucleotide metabolism; and MPS3, the mixed subtype with partial pathway dysregulation. These subtypes were validated by metabolomic profiling of 72 samples. These three subtypes had distinct prognoses, molecular subtype distributions, and genomic alterations. Moreover, MPS1 TNBCs were more sensitive to metabolic inhibitors targeting fatty acid synthesis, whereas MPS2 TNBCs showed higher sensitivity to inhibitors targeting glycolysis. Importantly, inhibition of lactate dehydrogenase could enhance tumor response to anti-PD-1 immunotherapy in MPS2 TNBCs. Collectively, our analysis demonstrated the metabolic heterogeneity of TNBCs and enabled the development of personalized therapies targeting unique tumor metabolic profiles. Cervical cancer is the third most common cancer among Thai women, after breast and colon cancer, with an age-standardized incidence rate (ASR) of 11.7/100\\u2009000 women each year, as of 2015. Over decades, comprehensive national cervical cancer screening programs, research, and the HPV vaccination policy have gradually helped decrease the incidence of cervical cancer in Thailand. In 2017, the Thai Ministry of Public Health signed a memorandum of understanding with the Royal Thai College of Obstetricians and Gynecologists to eliminate invasive cervical cancer from Thailand. This is a tremendous challenge for Thailand as a whole. The present paper reviews and discusses the experiences in the prevention and screening of cervical cancer in Thailand. High mammographic density in postmenopausal women is an independent risk factor for breast cancer by undetermined mechanisms. No preventive therapy for this risk group is available. Activated platelets release growth factors that modulate the microenvironment into a pro-tumorigenic state. Estrogens may affect the risk of breast cancer and platelet function. Whether platelets are activated in situ in breast cancer or in normal breast tissue at high risk of breast cancer and the association to estradiol remains elusive.\\nTo investigate whether platelets are activated in situ in breast cancers and in dense breast tissue of postmenopausal women and explore correlations between estradiol, released platelet factors, and inflammatory proteins.\\nSampling of in vivo proteins was performed using microdialysis in a total of 71 women; 10 with breast cancer, 42 healthy postmenopausal women with different breast densities, and 19 premenopausal women.\\nOur data demonstrate increased levels of coagulation factors in dense breast tissue similar to that found in breast cancers, indicating excessive platelet activation. Premenopausal breasts exhibited similar levels of coagulation factors as postmenopausal dense breasts. Out of 13 coagulations factors that were upregulated in dense breasts, 5 exhibited significant correlations with estradiol both locally in the breast and systemically. In breast tissue, positive correlations between coagulation factors and key inflammatory proteins and matrix metalloproteinases were detected.\\nBreast density, not estradiol, is the major determinant of local platelet activation. Inactivation of platelets may be a therapeutic strategy for cancer prevention in postmenopausal women with dense breasts. C-peptide is usually considered as a marker of insulin secretion and has no physiological function. This study aimed to assess the association between serum C-peptide level as independent risk factor and breast cancer and explored the possible underlying mechanisms. This was a population-based cohort study. All the data was collected according to a standard protocol. The C-peptide and insulin-like growth factor binding proteins-3(IGFBP-3) concentrations were measured in blood. The breast cancer deaths were confirmed by National Death Index records. Cox proportional hazard regression analysis was conducted to determine the hazard ratio of serum C-peptide level for breast cancer deaths. Analysis of covariance was used to assess the association between serum C-peptide and IGFBP-3 level, and the linear trend was tested by using a linear model. A total of 8,373 women 17 years of age or older were included in the study, and 57 breast cancer deaths were observed over the study period. The result of survival analysis showed that breast cancer deaths increased with increasing levels of serum C-peptide. The hazard ratio was 1.69 (95% confidence interval, 1.17-2.45). The levels of circulating IGFBP-3 were positively associated with changes in serum C-peptide levels and showed a strong linear trend in the covariance analysis. Serum C-peptide level was associated with increased risk of breast cancer death. Our results suggest that the increased risk of breast cancer death can be via a pathway that serum C-peptide level positive associated with the change in serum IGFBP-3 level. The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification of cases with HER2-equivocal results by FISH. The impact of such reclassification is unclear. We sought to determine the proportion of HER2-equivocal cases that are reclassified as HER2-negative and the impact of anti-HER2 therapy on survival in HER2-equivocal cases.\\nWe reviewed medical records of breast cancer patients who had HER2 testing by fluorescence in stitu hybridization (FISH) and immunohistochemistry (IHC) performed or verified at The University of Texas MD Anderson Cancer Center during April 2014 through March 2018 and had equivocal results according to the 2013 ASCO/CAP guideline. The population was divided into 2 cohorts according to whether the biopsy specimen analyzed came from primary or from recurrent or metastatic disease. HER2 status was reclassified according to the 2018 ASCO/CAP guideline. Overall survival (OS) and event-free survival (EFS) were calculated using the Kaplan-Meier method, and the relationship between anti-HER2 therapy and clinical outcomes was assessed.\\nWe identified 139 cases with HER2-equivocal results according to the 2013 ASCO/CAP guideline: 90 cases of primary disease and 49 cases of recurrent/metastatic disease. Per the 2018 ASCO/CAP guideline, these cases were classified as follows: overall, HER2-negative 112 cases (80%), HER2-positive 1 (1%), and unknown 26 (19%); primary cohort, HER2-negative 85 (94%), HER2-positive 1 (1%), unknown 4 (4%); and recurrent/metastatic, HER2-negative 27 (55%) and unknown 22 (45%). Five patients in the primary-disease cohort and 1 patient in the recurrent/metastatic-disease cohort received anti-HER2 therapy. There was no significant association between anti-HER2 therapy and OS or EFS in either cohort (primary disease: OS, p = 0.67; EFS, p = 0.49; recurrent/metastatic-disease, OS, p = 0.61; EFS, p = 0.78.\\nThe majority of HER2-equivocal breast cancer cases were reclassified as HER2-negative per the 2018 ASCO/CAP guideline. No association between anti-HER2 therapy and OS or EFS was observed. HER2-equivocal cases seem to have clinical behavior similar to that of HER2-negative breast cancers. This study examines the protective effects of omega-3 fatty acids (OMG), a frequently used nutritional therapy in cancer patients, against doxorubicin (DOX)-induced acute cardiorenal toxicity in rats, and evaluates the cytotoxic activity of DOX when used with OMG against breast cancer cell line. Five groups of rats were treated for 4 consecutive weeks with vehicle (groups I & II), or OMG (25, 50 or 100 mg/kg/day, po; groups III, IV & V, respectively). After twenty-four hours, the last four groups were injected with DOX (200 mg/kg, ip). In DOX-treated rats, the altered ECG, serum cardiac and renal function biomarkers, and histopathological features indicated the induction of cardiorenal toxicity. Increased oxidative and apoptotic markers in both organs was observed, with elevated renal contents of NADPH-oxidase-4 (Nox4) and renin. OMG pretreatment improved those DOX-induced impairments in a dose-dependent manner, and showed antioxidant and antiapoptotic effects with regulation of renal Nox4 expression. The in-vitro study showed preservation of the cytotoxic activity of DOX on MCF7 cell line in the presence of OMG. The data suggests OMG for protection against acute DOX-induced cardiorenal damage without affecting the latter antitumor activity. It proposes regulation of oxidative stress, Nox4 activity and apoptosis as contributing protective mechanisms. To investigate the clinicopathologic features and immunophenotype of primary squamous cell carcinoma of the breast (PSCCB) with HER2 overexpression.  This study was performed to determine the role of autophagy-related 16-like 1 (ATG16L1, rs2241880) and IL10 (rs1800872) polymorphisms in the susceptibility to and early prediction of breast cancer in Egyptians. The study included 50 breast cancer patients and 50 apparently healthy controls. The PCR-RFLP technique was used to detect ATG16L1 (rs2241880) and IL10 (rs1800872) genotypes. IL10 level was determined in serum by ELISA. The mean age of the patients was 54.2 years. Among the patients, 80% had no family history for breast cancer, 70% were postmenopausal, and 72% exhibited grade II tumors. Metastasis was detected in 18% of the patients, and 6% of the cases exhibited triple-negative receptor (TNR) status. In the ATG16LI (rs2241880) gene, the GG genotype frequency was significantly higher in patients than in controls (14% in patients versus 2% in controls, P =0.02), and no metastasis was observed in patients with the AA genotype (P=0.03). In the IL10 (rs1800872) gene, the A allele was observed in 30% of patients and 23% of controls, but the difference was insignificant (P=0.26). Also, the prevalence of the AA genotype was 8% in patients and 4% in controls (P=0.54). Serum IL10 levels were higher in patients than in controls (P < 0.001). Within the patient group, individuals with the IL10 (rs1800872) AA genotype showed significantly higher serum IL10 levels than those with the CC and CA+CC genotypes (P =0.03 and 0.04, respectively). In conclusion, in Egyptian breast cancer patients, the GG genotype of ATG16LI (rs2241880) may be associated with increased disease risk, and the AA genotype could be protective against metastasis. The presence of pre-existing morbidities poses a challenge to cancer patient care. There is little information on the profile and prevalence of multi-morbidities in breast cancer patients across middle to lower income countries (MIC and LIC) in Sub-Saharan Africa (SSA). The African Breast Cancer-Disparities in Outcomes breast cancer cohort spans upper MICs South Africa and Namibia, lower MICs Zambia and Nigeria and LIC Uganda. At cancer diagnosis 7 morbidities were assessed: obesity, hypertension, diabetes, asthma/chronic obstructive pulmonary disease, heart disease, tuberculosis and HIV. Logistic regression models were used to assess determinants of morbidities and the influence of morbidities on advanced stage (stage III/IV) breast cancer diagnosis. Among 2189 women, morbidity prevalence was highest for obesity (35%, country-specific range 15-57%), hypertension (32%, 15-51%) and HIV (16%, 2-26%) then for diabetes (7%, 4-10%), asthma (4%, 2-10%), tuberculosis (4%, 0-8%) and heart disease (3%, 1-7%). Obesity and hypertension were more common in upper MICs and in higher socio-economic groups. Overall, 27% of women had at least 2 pre-existing morbidities. Older women were more likely to have obesity (odds ratio: 1.09 per 10\\u2009years, 95% CI 1.01-1.18), hypertension (1.98, 1.81-2.17), diabetes (1.51, 1.32-1.74) and heart disease (1.69, 1.37-2.09) and were less likely to be HIV positive (0.64, 0.58-0.71). Multi-morbidity was not associated with stage-at-diagnosis, with the exception of earlier stage in obese and hypertensive women. Breast cancer patients in higher income countries and higher social groups in SSA face the additional burden of pre-existing non-communicable diseases, particularly obesity and hypertension, exacerbated by HIV in Southern/Eastern Africa. Pathologic nipple discharge (PND) is a common complaint often associated with breast cancer. However, when ultrasound and mammography are negative, the chances of malignancy are lower than 5%. Currently, major duct excision and microdochectomy are often recommended to alleviate symptoms and definitely rule out malignancy, but can cause infections and breastfeeding problems. Ductoscopy is a minimally invasive endoscopy technique that allows visualization of the mammary ducts and may not only obviate surgery but also detect malignancy. The aim of this study was to determine quality of life (QOL) after ductoscopy in patients with PND.\\nAll PND patients referred for ductoscopy between 2014 and 2015 to our hospital were included. Ductoscopy procedures were performed under local anaesthesia in the outpatient clinic. Patients were asked to fill out questionnaires (Breast-Q, EQ-5D-5L and SF-36) on the day of ductoscopy, and after 2 weeks, 3 and 6 months. Additionally, we performed reliability analysis to determine if these questionnaires were suitable for PND patients.\\nFifty consecutive patients underwent ductoscopy of whom 47 patients participated in this study. One domain of SF-36 (vitality) varied significantly over time. Breast-Q, SF-36 and EQ-5D-5L showed that QOL after ductoscopy for PND was unaffected by ductoscopy. Success of the ductoscopy procedure was a significant predictor for satisfaction with the result domain.\\nDuctoscopy is a minimally invasive technique that does not seem to impact QoL of PND patients over time. Breast-Q, SF-36 and EQ-5D-5L seem to be suitable existing QOL tests for PND patients undergoing ductoscopy, whereas SF-36 would require modifications. Mammography screening encounters may represent ideal opportunities to identify high-risk women for risk-based screening. During mammography appointments, radiology practices evaluate breast density and ascertain known breast cancer risk factors. Our purpose was to evaluate the potential for mammographic screening encounters to identify high-risk women by estimating the (1) proportion of high-risk women who report that they have undergone mammographic screening and the (2) proportion of high-risk women who receive recommendations for breast MRI screening.\\nWomen ages 30-85 without breast cancer histories were included from the 2015 National Health Interview Survey, a nationally representative cross-sectional household survey (response rate 80%). Breast Cancer Risk Assessment Tool was used to determine high-risk (lifetime risk>20%). Among high-risk women, primary outcome was proportion reporting mammography screening, secondary outcome was receipt of a breast MRI recommendation after recent mammogram, accounting for complex survey design.\\n14,958 women were included. 1.0% were high-risk of whom: 91.9% ever had a mammogram, 68.0% had a mammogram within the last year, 81.5% had a mammogram within the last 2\\xa0years. 6.4% were recommended to undergo breast MRI. Among high-risk women, women with dense breast tissue were more likely (OR 496.0, 95%CI 52.6,4674.0) and older women were less likely (OR 0.91, 95%CI 0.84,0.99) to receive recommendations for breast MRI.\\nAmong high-risk women, 92% reported undergoing at least one mammogram in their lives. 94% did not receive recommendations for breast MRI screening and 32% did not have a mammogram within the last year. To identify high-risk women, breast imaging centers should consider determining lifetime breast cancer risk during mammography screening visits. To use the National Cancer Database to assess treatment patterns in very young women with ductal carcinoma in situ (DCIS) given their propensity for higher risk features and increased risk of recurrence.\\nWe used the NCDB to identify female patients who underwent surgery for a first cancer diagnosis of DCIS within three different age groups: ≤30, 31-50, and >50. Demographic information, tumor characteristics, and initial treatment patterns were characterized and compared. Univariable and multivariable logistic regression of individuals with hormone-receptor-positive disease who underwent breast-conserving surgery (BCS) was conducted to assess for group differences in adjuvant endocrine therapy utilization. Survival analysis was conducted via Kaplan-Meier method and Cox regression.\\nWe identified 236,832 patients meeting inclusion criteria. Individuals in the youngest group were more likely to be a minority, had better Charlson-Deyo scores, lived further from their treatment facility, and were less often insured. This group also had more unfavorable tumor features and were more likely to undergo bilateral mastectomy. In subgroup analysis of patients with hormone-receptor-positive disease who underwent BCS, the youngest group was significantly less likely to have received endocrine therapy. There was also a trend toward worse overall survival in the youngest group.\\nWe report differences in demographics, tumor characteristics, and treatment of very young women with DCIS. Given the known reduction in recurrence with use of adjuvant endocrine therapy, there may be room for increasing therapy rates or otherwise altering guidelines for treatment of young women with hormone-receptor-positive DCIS who undergo BCS. Immunogenomics and earlier, pioneering studies, particularly by Whiteside and colleagues, have indicated a positive role for B-cells in breast cancer, as well as a positive role for gamma-delta T-cells. However, these studies have been completely limited to assessing breast cancer tumor tissue.\\nOur analyses here has shown that blood-borne T-cell receptor gamma (TRG) chain sequences were associated with greater overall survival, of particular note due to the comparative longevity of primary breast cancer patients, whereby assessments of disease-free, but rarely overall survival parameters are possible. Additional immunogenomics approaches narrowed the overall survival correlations to specific, TRG complementarity determining region-3, amino acid (AA) sequence chemical features, independently of many common, confounding variables in the breast cancer setting, such as estrogen or progesterone receptor status.\\nThese results are discussed in the context of patient age and with regard to potential antigenic targets, based on the chemistry of the TRG CDR3 AA sequences associated with the higher survival rates. Chromatin remodeling plays an essential role in regulating transcriptional networks and timing of gene expression. Chromatin remodelers such as SWItch/Sucrose Non-Fermentable (SWI/SNF) harbor many protein components, with the catalytic subunit providing ATPase activity to displace histones along or from the DNA molecules, and associated subunits ensuring tissue specificity and transcriptional or co-transcriptional activities. Mutations in several of the SWI/SNF subunits have been linked to cancer. Here, we investigate between\\xa0SMARCD3/Baf60c expression and hormone-positive (ER+) breast cancer.\\n\\xa0The level of SMARCD3 was detected by immunohistochemistry in breast cancer patient samples, and expression levels of\\xa0SMARCD1,\\xa0SMARCD2, and\\xa0SMARCD3\\xa0were investigated using publicly available datasets from large cohorts of breast cancer patients. Using molecular biology and microscopy, we interrogated the cellular consequences of lower\\xa0SMARCD3\\xa0expression.\\n\\xa0Lower proliferation rates were observed in SMARCD3-depleted cells, which reflects a failure of the cell cycle progression and an increase in endoreplication. In the absence of SMARCD3, p21 accumulates in cells, but does not halt the cell cycle, and DNA damage accumulates and remains unrepaired.\\n\\xa0Taken together, our data begin to explain why ER+ breast cancer patients with low-SMARCD3 expressing tumors exhibit reduced survival rates compared to patients expressing normal or higher levels of SMARCD3. SMARCD3 might act as a tumor suppressor through regulation of cell cycle checkpoints and could be a reliable and specific breast cancer prognostic biomarker. The combination therapy based on multifunctional nanocomposites has been considered as a promising approach to improve cancer therapeutic efficacy. Herein, we report targeted multi-functional poly(N-isopropylacrylamide) (PNIPAM)-based nanocomposites for synergistic chemo-photothermal therapy toward breast cancer cells. To increase the transition temperature, acrylic acid (AAc) was added in synthetic process of PNIPAM, showing that the intrinsic lower critical solution temperature was changed to 42\\xa0°C . To generate the photothermal effect under near-infrared (NIR) laser irradiation (808\\xa0nm), polypyrrole (ppy) nanoparticles were uniformly decorated in PNIPAM-AAc. Folic acid (FA), as a cancer targeting ligand, was successfully conjugated on the surplus carboxyl groups in PNIPAM network. The drug release of PNIPAM-ppy-FA nanocomposites was efficiently triggered in response to the temperature change by NIR laser irradiation. We also confirmed that PNIPAM-ppy-FA was internalized to MDA-MB-231 breast cancer cells by folate-receptor-mediated endocytosis and significantly enhanced cancer therapeutic efficacy with combination treatment of chemo-photothermal effects. Therefore, our work encourages further exploration of multi-functional nanocarrier agents for synergistic therapeutic approaches to different types of cancer cells. Skin metastases occur in 5-30% of breast cancer (BC) patients. Standard treatments include systemic therapies (chemotherapy, endocrine therapy, and immunotherapy) and local treatments (surgery and radiotherapy). Electrochemotherapy (ECT) could be another option in this setting based on preclinical and clinical studies. Aim of this review was to analyze the available evidence on ECT in skin metastases from BC. Studies reporting on ECT in skin metastases from BC were included in this review. Studies not reporting toxicity or tumor response or not reporting results separately from other primary cancers were excluded. The search was based on Medline, Scopus, and The Cochrane Library databases. Eleven studies including 464 patients were analyzed. ECT was performed using intravenous/intratumoral bleomycin (10 studies) or intratumoral cisplatin (one study). Complete and overall pooled response rates were 46.2% ( \"True\" breast cancers, defined as not being visible on prior screening mammograms, are expected to be more aggressive than \"missed\" cancers, which are visible in retrospect. However, the evidence to support this hypothesis is limited. We compared the risk of death from any cause for women with true, minimal signs, and missed invasive screen-detected (SDC) and interval breast cancers (IC).\\nThis nation-wide study included 1022 SDC and 788 IC diagnosed through BreastScreen Norway during 2005-2016. Cancers were classified as true, minimal signs, or missed by five breast radiologists in a consensus-based informed review of prior screening and diagnostic images. We used multivariable Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of death from any cause associated with true, minimal signs, and missed breast cancers, adjusting for age at diagnosis, histopathologic tumour diameter and grade, and subtype. Separate models were created for SDC and IC.\\nAmong SDC, 463 (44%) were classified as true and 242 (23%) as missed; among IC, 325 (39%) were classified as true and 235 (32%) missed. Missed SDC were associated with a similar risk of death as true SDC (HR = 1.20, 95% CI (0.49, 2.46)). Similar results were observed for missed versus true IC (HR = 1.31, 95% CI (0.77, 2.23)).\\nWe did not observe a statistical difference in the risk of death for women diagnosed with true or missed SDC or IC; however, the number of cases reviewed and follow-up time limited the precision of our estimates.\\n• An informed radiological review classified screen-detected and interval cancers as true, minimal signs, or missed based on prior screening and diagnostic mammograms. • It has been hypothesised that true cancers, not visible on the prior screening examination, may be more aggressive than missed cancers. • We did not observe a statistical difference in the risk of death from any cause for women with missed versus true screen-detected or interval breast cancers. Oral contraceptives have been associated with cardiovascular disease, ischemic stroke, venous thromboembolic disease, and breast cancer. Retinal vascular occlusions share the same risk factors as cardiovascular and cerebrovascular disease.\\nTo determine whether filling a prescription of female hormone therapy (FHT) is associated with an increased risk of retinal artery occlusion (RAO) or retinal vein occlusions (RVO).\\nA multiple-cohort study was conducted using an administrative claims insurance database comparing women who filled a prescription for FHT with matched control individuals. Exclusion occurred for those enrolled for less than 2 years in the plan, with no prior ophthalmologic examination, with a history of a RAO/RVO, with systemic diseases/medications that affected estrogen levels, or a disease associated with an increased risk for thromboembolism.\\nThe primary outcome was the incidence of a new diagnosis of RAO or RVO. Cox proportional hazard regression modeling with inverse probability of treatment weight was used to assess the hazard ratio (HR) for a new diagnosis of RAO or RVO relative to filling prescription for FHT. Subanalyses were conducted to stratify by age, race/ethnicity, diabetes, and hypertension.\\nA total of 205\\u202f304 women who filled a prescription for FHT were matched to 755\\u202f462 control individuals. After inverse probability of treatment weight, the study cohort was a mean age of 47.2 years, 71% were White, 7% were Black, 6% were Hispanic, 3% were Asian, and 3% were unknown. There were 41 cases (0.01%) of RAO and 68 cases of RVO (0.02%) in the FHT cohort. In comparison, there were 373 cases of RAO (0.05%) and 617 cases of RVO (0.08%) in the control cohort. After inverse probability of treatment weight, Cox regression analysis showed no difference in hazard for RAO, RVO, or combined outcomes in the FHT cohort relative to the control cohort (RAO HR, 1.17; 95% CI, 0.83-1.65; P\\u2009=\\u2009.36; RVO HR, 1.07; 95% CI, 0.82-1.39; P\\u2009=\\u2009.65; combined HR, 1.10; 95% CI, 0.89-1.36; P\\u2009=\\u2009.37). Subanalyses that stratified by age, diabetes, and hypertension similarly showed no significant associations between the FHT prescription cohort and all outcomes.\\nThese findings suggest that filling a prescription for FHT, and presumably taking FHT, does not increase the risk of RAO or RVO. Such history may not be relevant in the evaluation of an individual with an RAO or RVO nor do our results support stopping FHT in an individual who develops an RAO or RVO. Early life stress (ELS) is associated with an increased risk of developing depression and anxiety disorders. Disturbances of the neurobiological glutamatergic system are implicated in depression; however, the long-term effects of ELS on glutamate (Glu) metabolites remain unclear. Our study used 7T proton magnetic resonance spectroscopy (7T  Breast cancer is the most common malignant tumor in women and a quantitative contrast-free method is highly desirable for its diagnosis.\\nTo investigate the performance of quantitative MRI in differentiating malignant from benign breast lesions and to compare with the Breast Imaging Reporting and Data System (BI-RADS).\\nRetrospective.\\nEighty patients (56 with malignant lesions and 24 with benign lesions).\\nDiffusion-weighted imaging (DWI) with a single-shot echo planar sequence and synthetic MRI with magnetic resonance image compilation (MAGiC) were performed at 3T.\\nT\\nThe diagnostic performance was evaluated using multivariate logistic regression analysis and area under the receiver operating characteristic (ROC) curves (AUC).\\nT\\nThe approach that combined synthetic MRI and DWI outperformed BI-RADS in the differential diagnosis of malignant and benign breast lesions and was achieved without contrast agents. This approach may serve as an alternative and effective strategy for the improvement of breast lesion differentiation.\\n3.\\n3. Breast cancer (BRCA) represents the most common malignancy among women worldwide with high mortality. Radiotherapy is a prevalent therapeutic for BRCA that with heterogeneous effectiveness among patients. Here, we proposed to develop a gene expression-based signature for BRCA radiotherapy sensitivity estimation. Gene expression profiles of BRCA samples from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were obtained and used as training and independent testing dataset, respectively. Differential expression genes (DEGs) in BRCA samples compared with their paracancerous samples in the training set were identified by using the edgeR Bioconductor package. Univariate Cox regression analysis and LASSO Cox regression method were applied to screen optimal genes for constructing a radiotherapy sensitivity estimation signature. Nomogram combining independent prognostic factors was used to predict 1-, 3-, and 5-year OS of radiation-treated BRCA patients. Relative proportions of tumor infiltrating immune cells (TIICs) calculated by CIBERSORT and mRNA levels of key immune checkpoint receptors was adopted to explore the relation between the signature and tumor immune response. As a result, 603 DEGs were obtained in BRCA tumor samples, 6 of which were retained and used to construct the radiotherapy sensitivity prediction model. The signature was proved to be robust in both training and testing sets. In addition, the signature was closely related to the immune microenvironment of BRCA in the context of TIICs and immune checkpoint receptors\\' mRNA levels. In conclusion, this study obtained a radiotherapy sensitivity estimation signature for BRCA, which should shed new light in clinical and experimental research. Chemotherapy and surgery are commonly used clinical treatments for breast cancer. However, unsatisfactory therapeutic effects, unavoidable side effects, and the removal of breast tissue during surgery are still major obstacles to be overcome during breast-cancer treatment. To overcome the aforementioned issues, a biomimetic and thermosensitive hydrogel encapsulating reactive oxygen species (ROS)-sensitive tegafur (TF)-protoporphyrin IX (PpIX) heterodimers (TTP) was prepared aimed at the strategy of synergizing chemotherapy and photodynamic therapy. TF was grafted onto the photosensitizer PpIX through ROS-sensitive thioether bonds. Under 630 nm laser irradiation, the ROS concentration in tumors was increased to help drug release. The \"on-demand\" drug release maximized the therapeutic effects of TF and effectively reduced its toxicity. Particularly, the ROS concentration was increased, and it was expected that the tumor-cell-killing abilities of ROS could be exploited. A hydrogel formed from temperature-sensitive chitosan and silk sericin was selected as a drug carrier, which formed a drug reservoir intratumorally after intratumoral injection. Intratumoral injection gave the drug precise and long-term release behavior, which allowed for the clever avoidance of various physical and biological barriers in vivo. In vivo and in vitro studies prove that the use of this TTP hydrogel provides a new attempt to overcome the many difficulties related to breast-cancer treatment simultaneously, and this study opens up new paths for breast-cancer treatment.  Ductal carcinoma in situ (DCIS) with microinvasion (DCIS-MI) is defined as the extension of cancer cells beyond the basement membrane into adjacent tissue with no focus larger than 1 mm or a maximum diameter of less than 1\\u2009mm for multiple invasive foci. DCIS-MI constitutes approximately 1% of all breast cancer cases and 5% to 10% of cases of DCIS. The current literature is controversial concerning the clinical prognostic features and management of DCIS-MI. This narrative review described recently reported literature regarding the characteristics, diagnosis, treatment, and prognosis of DCIS-MI.  Optical coherence tomography (OCT) is widely used as a potential diagnostic tool for a variety of diseases including various types of cancer. However, sensitivity and specificity analyses of OCT in different cancers yield results varying from 11% to 100%. Hence, there is a need for more detailed statistical analysis of blinded reader studies.\\nExtensive statistical analysis is performed on results from a blinded study involving OCT of breast tumor margins to assess the impact of reader variability on sensitivity and specificity.\\nFive readers with varying levels of experience reading OCT images assessed 50 OCT images of breast tumor margins collected using an intraoperative OCT system. Statistical modeling and analysis was performed using the R language to analyze reader experience and variability.\\nStatistical analysis showed that the readers\\' prior experience with OCT images was directly related to the probability of the readers\\' assessment agreeing with histology. Additionally, results from readers with prior experience specific to OCT in breast cancer had a higher probability of agreement with histology compared to readers with experience with OCT in other (noncancer) diseases.\\nThe results from this study demonstrate the potential impact of reader training and experience in the assessment of sensitivity and specificity. They also demonstrate even greater potential improvement in diagnostic performance by combining results from multiple readers. These preliminary findings suggest valuable directions for further study. This study was undertaken to investigate the role of postoperative radiotherapy (PORT) including post-breast conserving radiotherapy (PBCRT) and post-mastectomy radiotherapy (PMRT) in stage IV breast cancer patients who underwent planned primary tumor resection (PTR).\\nThis study enrolled 112 patients diagnosed with de novo stage IV breast cancer who were treated with potentially curative PTR with or without PORT. The primary outcome was overall survival (OS), and the secondary outcomes were locoregional recurrence-free survival (LRRFS) and distant progression-free survival (DPFS).\\nAt a median follow-up of 48.9 months (range, 3.5-183.4 months), the median OS was 54.9 months (range, 5.3-185.9 months) with a 5 year OS rate of 59.6%. Lower clinical T stage, Luminal A or B type tumors and PBCRT were significantly predictive of longer OS. The 5 year LRRFS and DMFS rates were 79.0% and 34.3%, respectively. In multivariate analysis for LRRFS, the PBCRT arm demonstrated significant superiority compared to the No PORT arm. A comparison of patients who did and did not receive PORT showed that patients with disseminated metastasis more likely did not receive PORT and were excluded from the analysis. PBCRT arm demonstrated significantly superior LRRFS of 100% while PMRT and No PORT arm demonstrated 81.5% and 84.0%, respectively CONCLUSIONS: De novo stage IV breast cancer patients who received planned PTR showed favorable survival outcomes compared with historical cohorts. PTR may be predictive of a good prognosis, especially in patients with luminal A or B type tumors. PORT, especially PBCRT was predictive of LRRFS, suggesting that patients may benefit from this treatment. Architectural distortion (AD) is the earliest sign of breast cancer that can be detected on a mammogram, and it is usually associated with malignant tumors. Breast cancer is one of the major causes of death among women, and the chance of cure can increase significantly when detected early. Computer-aided detection (CAD) systems have been used in clinical practice to assist radiologists with the task of detecting breast lesions. However, due to the complexity and subtlety of AD, its detection is still a challenge, even with the assistance of CAD. Recently, the fusion of descriptors has become a trend for improving the performance of computer vision algorithms. In this work, we evaluated some local texture descriptors and their possible combinations, considering different fusion approaches, for application in CAD systems to improve AD detection. In addition, we present a novel fusion-based texture descriptor, the Completed Mean Local Mapped Pattern (CMLMP), which is based on complementary information between three LMP operators (signal, magnitude and center) and the local differences between pixel values and the mean value of a neighborhood. We compared the performance of the proposed descriptor with two other well-known descriptors: the Completed Local Binary Pattern (CLBP) and the Completed Local Mapped Pattern (CLMP), for the task of detecting AD in 350 digital mammography clinical images. The results showed that the descriptor proposed in this work outperforms the others, for both individual and fused approaches. Moreover, the choice of the fusion operator is crucial because it results in different detection performances. In the phase II DIRECT study a fasting mimicking diet (FMD) improved the clinical response to neoadjuvant chemotherapy as compared to a regular diet. Quality of Life (QoL) and illness perceptions regarding the possible side effects of chemotherapy and the FMD were secondary outcomes of the trial.\\n131 patients with HER2-negative stage II/III breast cancer were recruited, of whom 129 were randomly assigned (1:1) to receive either a fasting mimicking diet (FMD) or their regular diet for 3\\xa0days prior to and the day of neoadjuvant chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires EORTC-QLQ-C30 and EORTC-QLQ-BR23; the Brief Illness Perception Questionnaire (BIPQ) and the Distress Thermometer were used to assess these outcomes at baseline, halfway chemotherapy, before the last cycle of chemotherapy and 6\\xa0months after surgery.\\nOverall QoL and distress scores declined during treatment in both arms and returned to baseline values 6\\xa0months after surgery. However, patients\\' perceptions differed slightly over time. In particular, patients receiving the FMD were less concerned and had better understanding of the possible adverse effects of their treatment in comparison with patients on a regular diet. Per-protocol analyses yielded better emotional, physical, role, cognitive and social functioning scores as well as lower fatigue, nausea and insomnia symptom scores for patients adherent to the FMD in comparison with non-adherent patients and patients on their regular diet.\\nFMD as an adjunct to neoadjuvant chemotherapy appears to improve certain QoL and illness perception domains in patients with HER2-negative breast cancer. Trialregister ClinicalTrials.gov Identifier: NCT02126449. The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development.\\nClinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential. Antibody fragments, such as nanobodies, on the other hand, can be radiolabelled with short-lived radioisotopes and provide high-contrast images within a few hours after injection, allowing early diagnosis and reduced radiation exposure of patients. Even in therapy, the small radioactively labeled nanobodies prove to be superior to radioactively labeled monoclonal antibodies due to their higher specificity and their ability to penetrate the tumor.\\nWhile monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach. Triple‑negative breast cancer (TNBC) is characterized by strong invasiveness, frequent local recurrence and distant metastasis, with poor prognosis. According to tumor angiogenesis theory, tumor cells can obtain blood supply not only by fusing with host blood vessels, but also by constructing a new vascular system through angiogenesis, so as to continuously obtain nutrients and oxygen supply; this is called vasculogenic mimicry (VM). In our previous study, differential expression profiles of miRNAs were examined with gene chip in TNBC and corresponding paracancer tissues, which demonstrated significant up‑regulation of microRNA (miR)‑93. Bioinformatics found that the target genes of miR‑93 were associated with cell proliferation, invasion and migration. The present study investigated the association between miR‑93, epithelial‑to‑mesenchymal transition (EMT) and VM formation in TNBC cell lines. The results indicated that miR‑93 depletion suppressed MDA‑MB‑231 cell viability, invasion and migration (P<0.001). In addition, knockdown of miR‑93 significantly upregulated the expression levels of EMT‑associated genes such as E‑cadherin and occludin, but downregulated the expression levels of vimentin and N‑cadherin in MDA‑MB‑231 cells. VM formation assay showed a significant decrease in microtubule‑forming ability of cells following miR‑93 knockdown, which was associated with the occurrence of EMT, suggesting that miR‑93 may promote the formation of VM via EMT and may be a therapeutic target for the treatment of TNBC. Increasing evidence has demonstrated that long non‑coding RNAs\\xa0(lncRNAs) serve important roles in numerous malignancies, including triple‑negative breast cancer (TNBC). The lncRNA titin‑antisense RNA1\\xa0(TTN‑AS1) has previously been reported to promote tumorigenesis in various types of cancer. The present study aimed to investigate the potential role of TTN‑AS1 in breast cancer and the associated underlying mechanisms. Following prediction by Starbase and confirmation by dual‑luciferase reporter assay, TINCR was demonstrated to be a target gene for microRNA (miR)‑211‑5p. The expression levels of TTN‑AS1 and miR‑211‑5p, which was predicted to be targeted by TTN‑AS1, in TNBC tissues and in the breast cancer cell lines MDA‑MB‑453 and MDA‑MB‑231 were measured using reverse transcription‑quantitative PCR. Following TTN‑AS1‑knockdown, cell proliferation was measured using a Cell Counting Kit‑8 assay and colony formation assay, whereas cell invasion and migration were measured using Transwell and wound healing assays, respectively. Luciferase reporter assay was performed to verify the potential interaction between TTN‑AS1 and miR‑211‑5p. In addition, rescue assays were conducted to investigate the effects of TTN‑AS1 and miR‑211‑5p on TNBC development. The results demonstrated that TTN‑AS1 expression was significantly upregulated, whereas that of miR‑211‑5p was found to be downregulated in TNBC tissues and cell lines compared with the matched adjacent normal tissues and normal breast epithelial cell line MCF‑10A, respectively. Furthermore, TTN‑AS1‑knockdown inhibited the proliferation and invasive and migratory abilities of MDA‑MB‑453 and MDA‑MB‑231 cells, which was reversed following co‑transfection with the miR‑211‑5p inhibitor. The results from luciferase reporter assay confirmed that miR‑211‑5p was a direct target of TTN‑AS1, suggesting that TTN‑AS1 may bind directly to miR‑211‑5p to negatively regulate its expression. In conclusion, the findings from the present study demonstrated that TTN‑AS1 regulated the proliferation and invasive and migratory abilities of TNBC by targeting miR‑211‑5p. This study may provide some insights into the regulatory mechanism of TNBC and help the development of novel therapeutic interventions for TNBC. The H19 long non‑coding RNA is involved in the development of tamoxifen resistance in breast cancer. However, the relationship between H19 and the metastatic potential and treatment options for tamoxifen‑resistant (TAMR) breast cancer is not completely understood. Curcumin inhibits cellular proliferation, migration and invasiveness in several cancer types, including pancreatic cancer, breast cancer and chronic myeloid leukemia. The present study aimed to investigate the role of H19 in MCF‑7/TAMR cell epithelial‑mesenchymal transition (EMT), migration and invasiveness, and to assess the ability of curcumin to inhibit H19‑mediated effects. Reverse transcription‑quantitative PCR and western blot analysis were conducted to detect the gene or protein expression. Cell Counting Kit‑8, wound healing and Transwell invasion assays were performed to estimate the capabilities of cell viability, invasion and migration. H19 overexpression enhanced MCF‑7/TAMR cell EMT, invasion and migration by upregulating Snail. Furthermore, curcumin notably decreased the expression levels of epithelial marker E‑cadherin and markedly increased the expression levels of mesenchymal marker N‑cadherin in MCF‑7/TAMR cells compared with the control group. In addition, following treatment with curcumin for 48\\xa0h, H19 expression was decreased in a dose‑dependent manner. Moreover, curcumin treatment for 48\\xa0h significantly attenuated H19‑induced alterations in N‑cadherin and E‑cadherin expression levels. Curcumin also prevented H19‑induced invasion and migration. The present study indicated that H19 may serve as a promoting factor of EMT, invasion and migration in MCF‑7/TAMR cells, suggesting that curcumin may prevent H19‑associated metastasis. Therefore, curcumin may serve as a promising therapeutic drug for patients with TAMR breast cancer. The hedgehog pathway (HH) is one of the key regulators involved in many biological events. Malfunction of this pathway is associated with a variety of diseases including several types of cancers.\\nWe collected data from public databases and conducted a comprehensive search linking the HH pathway with female cancers. In addition, we overviewed clinical trials of targeting HH pathway in female cancers.\\nThe activation of HH pathway and its role in female cancers, including breast cancer, ovarian cancer, cervical cancer, endometrial cancer, and uterine leiomyosarcoma were summarized. Treatment options targeting SMO and GLI in HH pathway were reviewed and discussed.\\nThe hedgehog pathway was shown to be activated in several types of female cancers. Therefore, targeting HH pathway may be considered as a therapeutic option to be acknowledged in the treatment of female cancers. Breast cancer is the most common cause of chest wall recurrence, skin, and subcutaneous tissue metastases which mainly occur as multiple nodes in the skin and subcutaneous tissue. When it occurs, surgery (re-excision or totalization) is the treatment of choice. Unfortunately, it is not possible in rare cases for example after multiple plastic reconstructions and particular anatomical sites not eligible for resection. Moreover, in some cases where radiation therapy has already been used, and systemic therapy is ineffective or contraindicated, electrochemotherapy could represent a choice of palliation treatment. The principle of electrochemotherapy is based on a physical approach to permeabilize cells in the tissue exposed to electric pulses with increased cellular uptake of hydrophilic chemotherapeutics as bleomycin. We present a case of a 62-year-old woman suffering from chest wall recurrence of triple-negative breast cancer, previously treated with chemotherapy, surgery, and radiotherapy. The persistence of the tumor disease with abundant losses of blood serum material led the patient to a progressive decay of the general physical conditions. For this reason, we performed an electrochemotherapy session with an improvement in pain management and partial necrosis of the tumor tissue and devascularization that reduced bleeding and serum production leading to a better quality of life. To investigate motion artifacts on kV CBCT and MV CBCT images with metal localization devices for image-guided radiation therapy.\\nThe 8 μ pelvis CBCT template for the Siemens Artiste MVision and Pelvis template for the Varian IX on-board Exact Arms kV were used to acquire CBCT images in this study. Images from both CBCT modalities were compared in CNRs, metal landmark absolute positions, and image volume distortion on three different planes of view. The images were taken on a breathing-simulated thoracic phantom in which several typical metal localization devices were implanted, including clips and wires for breast patients, gold seeds for prostate patients, and BBs as skin markers. To magnify the artifacts, a 4 cm diameter metal ball was also implanted into the thoracic phantom to mimic the metal artifacts.\\nFor MV CBCT, the CNR at a 4 sec breathing cycle with 1 cm breathing amplitude was 5.0, 3.4 and 4.6 for clips, gold seeds and BBs, respectively while it was 1.5, 2.0 and 1.6 for the kV CBCT. On the images, the kV CBCT showed symmetric streaking artifacts both in the transverse and longitudinal directions relative to the motion direction. The kV CBCT images predicted 89 % of the expected volume, while the MV CBCT images predicted 95 % of the expected volume. The simulated soft tissue observed in the MVCT could not be detected in the kV CBCT.\\nThe MV CBCT images showed better volume prediction, less streaking effects and better CNRs of a moving metal target, \\nThis study would benefit clinicians to prescribe MV CBCT as localization modality for radiation treatment with moving target when metal markers are implanted. To investigate differences in the degree of enhancement on contrast-enhanced mammography (CEM) between patients with invasive lobular (ILC) and infiltrating ductal carcinoma (IDC) not otherwise specified.\\nBetween 2010 and 2017, all patients diagnosed with ILC and who underwent CEM were included for this dual center study. Twenty-two patients with IDC, matched by size, were identified for comparison. Three independent readers, blinded for histopathology results, re-evaluated all CEM exams to determine degree of lesion enhancement according to a previously defined scoring scale ranging from minimal to strong enhancement. Interobserver agreement among the three readers was calculated by quadratic weighted κ coefficient.\\n44 patients were included: 22 patients with ILC and 22 patients with IDC. There were no significant differences in age, mean tumor size, tumor grade or receptor status between the two subgroups. Degree of lesion enhancement on CEM was more often considered weak in case of ILC compared to IDC according to two out of three readers (31.8% \\nIn patients with ILC, degree of lesion enhancement on CEM appears to be more often weak than in infiltrating ductal carcinoma not otherwise specified. Radiologists should be aware that weakly enhancing lesions may in fact be malignant and particularly invasive lobular cancers.\\nThree independent readers evaluated 44 CEM cases with ILC or IDC. Degree of lesion enhancement seems more often weak in case of ILC. Radiologists should be aware of ILC in case of weak CEM enhancement. Breast cancer is a significant health concern in females, worldwide.  Lymph node metastasis is an important trait of breast cancer, and tumors with different lymph node statuses require various clinical treatments. This study was designed to evaluate the lymph node metastasis of breast cancer through pharmacokinetic and histogram analysis via dynamic contrast-enhanced (DCE) MRI.\\nA retrospective analysis was conducted to quantitatively evaluate the lymph node statuses of patients with breast cancer. A total of 75 patients, i.e. 34 patients with lymph node metastasis and 41 patients without lymph node metastasis, were involved in this research. Of the patients with lymph node metastases, 19 had sentinel lymph node metastasis, and 15 had axillary lymph node metastasis. MRI was conducted using a 3.0 T imaging device. Segmentation was carried out on the regions of interest (ROIs) in breast tumors under DCE-MRI, and pharmacokinetic and histogram parameters were calculated from the same ROIs. Mann-Whitney \\nPharmacokinetic parameters, including Ktrans, Kep, area under the curve of time-concentration, and time to peak, which were derived from the extended Tofts linear model for DCE-MRI, could highlight the tumor areas in the breast and reveal the increased perfusion. Conversely, the pharmacokinetic parameters showed no significant difference between the patients with and without lymph node metastases. By contrast, the parameters from the histogram analysis yielded promising results. The entropy of the ROIs exhibited the best diagnostic ability between patients with and without lymph node metastases (\\nIn comparison with the pharmacokinetic parameters, the histogram analysis of the MR images could reveal the differences between patients with and without lymph node metastases. The entropy from the histogram indicated that the diagnostic ability was highly sensitive and specific.\\nThis research gave out a promising result on the differentiating lymph node metastases through histogram analysis on tumors in DCE-MR images. Histogram could reveal the tumors heterogenicity between patients with different lymph node status. To evaluate mammography screening quality on the Island of Jersey over a 25-year period from Jan 1990 to end March 2015 from females invited between ages 50 to 75 using a 2 yearly screening interval. Jersey had a population of only around 67,000 at onset, rising to around 100,000 at the end of the 25 years.\\nAn analysis was performed of key routinely collected measures that are important to determining if a screening programme is on course to reduce breast cancer mortality such as uptake, recall rates, screen detected cancer and interval cancer rates. Further supporting indicators including grade, stage and comparative deaths from breast cancer in screen detected and not screen detected females were also assessed.\\nOver the 25-year period 19,768 females were invited to screening and 16,866 attended, giving an uptake of 85.2%. There were 501 screen detected cancers of which 400 were invasive, and 101 DCIS. 125 interval cancers presented outside screening over the 25 years. The annual recall rate over the last 20 years was <6% for prevalent round and 4% for incident round screening. Based on the standardized detection ratio (SDR) and uptake, the estimated reduction in mortality from breast cancer was calculated as 40.2%.\\nRecommended population sizes for breast units range from a quarter to half a million people. For very small units like Jersey serving smaller populations, rigorous quality control is essential to maintain credibility. Despite the small size of the programme evidence shows a similar detection rate to the UK NHS Breast screening programme was achieved. In small programmes careful monitoring of rates of uptake, recall, cancer detection and interval rates are required over adequate time periods together with supporting information to show that small units can achieve national standards and detection rates necessary to reduce breast cancer mortality.\\nRunning a small breast cancer screening programme is challenging for quality control. The impact on mortality can be predicted for small screening programmes despite their size. 10-year group survival in screen detected invasive breast cancer >90%. Interval cancers are more advanced than screen detected invasive cancers, so high suspicion is still required in breast symptoms after \"normal\" screen result. Mortality in lapsed/ceased attenders suggest that extending age range could be beneficial. The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely. The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake by the host cell is a necessary step for infection. ACE2 has garnered widespread therapeutic possibility as it is entry/interactive point for SARS-CoV-2, responsible for coronavirus disease 2019 (COVID-19) pandemic and providing a critical regulator for immune modulation in various disease. Patients with suffering from cancer always being on the verge of being immune compromised therefore gaining knowledge about how SARS-CoV-2 viruses affecting immune cells in human cancers will provides us new opportunities for preventing or treating virus-associated cancers. Despite COVID-19 pandemic got center stage at present time, however very little research being explores, which increase our knowledge in context with how SARS-CoV-2 infection affect cancer a cellular level. Therefore, in light of the ACE-2 as an important contributor of COVID-19 global, we analyzed correlation between ACE2 and tumor immune infiltration (TIL) level and the type markers of immune cells were investigated in breast cancer subtypes by using TIMER database. Our findings shed light on the immunomodulatory role of ACE2 in the luminal A subtype which may play crucial role in imparting therapeutic resistance in this cancer subtype. Targeted therapy is an important treatment strategy that is widely used for cancer therapy. Epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of Triple-negative breast cancer (TNBC) patients. Although Cetuximab, which targets EGFR, has shown some inhibitory effects on TNBC cells, Cetuximab resistance cases due to ligand-independent activating mutations in the EGFR gene limit its application. Due to various benefits of single chain antibodies (scFvs), the use of these antibodies in cancer targeted therapy is increasing. In this study, a specific anti-EGFR antibody was isolated and evaluated.\\nPanning procedure was used against an immunodominant epitope of EGFR in its dimerization arm using a diverse phage library. Polymerase Chain Reaction (PCR) and fingerprinting were applied to identify the specific clones. The MTT tetrazolium assay was performed to evaluate the inhibitory effects of selected anti- EGFR scFv phage antibody on MDA-MB-468, a TNBC cell line.\\nAfter four round of panning, one dominant pattern was observed in DNA fingerprinting with frequency of 85%. The growth of MDA-MB-468 cells was decreased dose-dependently after treatment with anti-EGFR scFv phage antibody. No significant inhibitory effect of M13KO7 helper phage as negative control on the cell growth of MDA-MB-468 was observed (p> 0.05).\\nThe selected anti-EGFR scFv with high anti proliferative effect on TNBC cells offers an effective alternative for TNBC targeted therapy. The antibody, which binds to the dimerization arm of EGFR and inhibits EGFR dimerization, could also overcome TNBC cases with Cetuximab resistance due to ligandindependent activating mutations. Cancer affects the quality of life (QoL) of patients and their families. The purpose of this study was to determine the effect of coping skills training on the QoL among daughters of mothers with breast cancer.\\nIn this quasi-experimental pre-test/post-test design, data were collected from 70 participants (35 in each of the control and education groups) from January 2016 to July 2017 in Imam Khomeini and Rasole-e-Akram Hospitals in Tehran. The education group participated in a workshop and group discussion (groups of 5 to 8 participants) with the presence of a pediatric psychiatrist and two pediatric nurses, and then a follow up program was performed. The Pediatric Quality of Life Inventory version 4.0 was used in this study in two stages of pre-test (before education) and post-test (four weeks later). Data were analyzed through SPSS, version 21 using independent t-test and paired t-test for comparison of the mean scores of the two groups, with the significance level of 0.05.\\nAfter the education, there were significantly improved scores of the QoL in the dimensions of physical functioning (P<0.001), emotional functioning (P<0.001), and school functioning (P<0.001) in the study group compared to the control group. The social functioning did not show a significant change (P<0.083).\\nThe findings of the study confirm that coping skills training can lead to the improvement of QoL in adolescent daughters of mothers with breast cancer. Healthcare professionals must provide the mothers and daughters with information about breast cancer and instruments to handle their situation to promote the daughters\\' QoL. Cyclin-dependent kinase-like 2 (CDKL2) is a member of the CDKL family and recognized as a novel regulator of epithelial-mesenchymal transition of breast cancer cells, but its role has not been explored in gastric cancer (GC). This study was to characterize the CDKL2 protein expression and gene copy number in relation to human epidermal growth factor receptor 2 (HER2) status, clinicopathological features, and overall survival (OS) in GC.\\nThis study detected the CDKL2 protein expression and gene copy number by immunochemistry (IHC) and fluorescent in situ hybridization (FISH), respectively, in 334 GC samples. HER2 status was determined according to established criteria. Associations of the CDKL2 protein expression and gene copy number with OS in GC were evaluated, and the association between CDKL2 mRNA expression and OS in GC was also analyzed using TCGA data.\\nThe detection results suggested that 34.1% cases showed high CDKL2 protein expression; 11.4% cases had ≥5 copies of CDKL2 gene or a ratio of CDKL2 to chromosome of ≥2. The CDKL2 protein expression was markedly correlated with its gene copy number. High protein expression and high gene copy number were both significantly associated with positive HER2 status, and they both could predicted a shorter OS, although not as independent markers suggested by the multivariate Cox proportional hazard regression analysis. The TCGA data indicated that higher CDKL2 mRNA level also predicted a shorter OS in GC.\\nThe combined detection of the CDKL2 protein level and gene copy number could be of important value in predicting HER2 status and prognosis of patients with GC. Rap1GAP is a tumor suppressor and is downregulated in human malignancies including papillary thyroid cancer (PTC). The mechanism of its suppression in PTC remains unclear.\\nBioinformatic analyses were carried out to evaluate clinical significance and to predict upstream miRNA bindings of Rap1GAP. Three PTC cell lines, TPC-1, B-CPAP, and K1, were employed for functional verification and further experiments. We used dual-luciferase reporter gene assay to confirm the miRNA binding prediction, Western blotting and quantitative polymerase chain reaction (qPCR) to explore miRNA and Rap1GAP regulation, Transwell and wound healing assays to compare cell migration and invasion after protein knockout or overexpression, and Cell Counting Kit-8 (CCK-8) assay to evaluate cell proliferation.\\nRap1GAP expression was suppressed in thyroid cancer compared to adjacent normal tissues and was a potential diagnostic marker of PTC. Rap1GAP suppression was correlated to younger age, advanced T stage, N stage, extrathyroidal extension, BRAF-like tumors, and higher risk of recurrence. Combined analysis of bioinformatic prediction and dual-luciferase assay revealed binding between miR-3121-3p with 3\\'UTR of Rap1GAP promoter. MiR-3121-3p promoted cell migration, invasion, and proliferation via inhibiting Rap1GAP and thus upregulating MAPK pathway. Overexpression and knockdown of Rap1GAP could counteract the influence on cell migration and invasion carried out by miR-3121-3p mimic and inhibitor, respectively. Rap1GAP partially impaired the effect of miR-3121-3p in cell growth in the CCK-8 assay.\\nRap1GAP expression is suppressed in PTC and is a potential diagnostic marker. Its upstream regulator, miR-3121-3p, affects tumor metastasis and proliferation via regulating Rap1GAP expression. MAPK signaling pathway may be involved in this effect. Many clinical trials are beginning to assess the effectiveness of compounds known to regulate autophagy in patients receiving anti-cancer chemotherapy. However, autophagy inhibition, through exogenous inhibitors, or activation, through starvation, has revealed conflicting roles in cancer management and chemotherapeutic outcome. This study aimed to assess the effect of amino acid starvation on doxorubicin-treated breast cancer cells by assessing the roles of autophagy and apoptosis. An  Curcumin, very rightly referred to as \"a wonder drug\" is proven to be efficacious in a variety of inflammatory disorders including cancers. Antiaging, anti-inflammatory, antioxidant, antitumor, chemosensitizing, P-gp efflux inhibiting, and antiproliferative activity are some of the striking features of curcumin, highlighting its importance in chemotherapy. Curcumin inhibits Bcl-2, Bcl-XL, VEGF, c-My Breast cancer patients with metastatic disease have a higher incidence of deaths from breast cancer than patients with early-stage cancers. Recent findings suggest that there are differences in immune cell function between metastatic and non-metastatic cases, even years before diagnosis. We have analyzed whole blood gene expression by Illumina bead chips in blood samples taken using the PAXgene blood collection system up to two years before diagnosis. The final study sample included 197 breast cancer cases and 197 age-matched controls. We defined a causal directed acyclic graph to guide a Bayesian data analysis to estimate the risk of metastasis associated with the expression of all genes and with relevant sets of genes. We ranked genes and gene sets according to the sign probability for excess risk. Among the screening detected cancers, 82% were without metastasis, compared to 53% of between-screening detected cancers. Among the highest ranking genes and gene sets associated with metastasis risk, we identified plasmacytiod dentritic cell function, the SLC22 family of transporters, and glutamine metabolism as potential links between the immune system and metastasis. We conclude that there may be potentially wide-reaching differences in blood gene expression profiles between metastatic and non-metastatic breast cancer cases up to two years before diagnosis, which warrants future study. Monocarboxylate transporter 1 (MCT1) participates in the transport of lactate to facilitate metabolic reprogramming during tumor progression. Tumor-associated macrophages (TAMs) are also involved in the inflammatory adaptation of the tumor microenvironment (TME). This study aimed to determine the correlation between metabolite changes and the polarization of macrophages in the TME. We demonstrated that the expression of CD163 on macrophages was significantly higher in breast cancer tissues than in normal tissues, especially in the HER2 subtype, although it was not statistically associated with recurrence-free survival (RFS). The presence of MCT1   Lung metastasis is one of the leading causes of death in patients with breast cancer. The mechanism of tumor metastasis remains controversial. Recently, the formation of a pre-metastatic niche has been considered a key factor contributing to breast cancer metastasis, which might also explain the tendency of organ metastasis. Our study initially re-examined the critical time of the niche formation and simultaneously detected a novel subset of neutrophils, CD62L Node-positive breast cancer patients often receive chemotherapy and regional nodal irradiation. The cardiotoxic effects of these treatments, however, may offset some of the survival benefit. Cardiac magnetic resonance (CMR) is an emerging modality to assess cardiac injury. This is a pilot trial assessing cardiac damage using CMR in patients who received anthracycline-based chemotherapy and three-dimensional conformal radiotherapy (3DCRT) regional nodal irradiation using heart constraints.\\nNode-positive breast cancer patients (2000-2008) treated with anthracycline-based chemotherapy and 3DCRT regional nodal irradiation (including the internal mammary chain nodes) with heart ventricular constraints (V25 < 10%) were invited to participate. Cardiac tissues were contoured and analyzed separately for whole heart (pericardium) and for combined ventricles and left atrium (myocardium). CMR obtained ventricular function/dimensions, late gadolinium enhancement (LGE), global longitudinal strain (GLS), and extracellular volume fraction (ECV) as measures of cardiac injury and/or early fibrosis. CMR parameters were correlated with dose-volume constraints using Spearman correlations.\\nFifteen left-sided and five right-sided patients underwent CMR. Median diagnosis age was 50 (32-77). No patients had baseline cardiac disease before regional nodal irradiation. Median time after 3DCRT was 8.3 years (5.2-14.4). Median left-sided mean heart dose (MHD) was 4.8 Gy (1.1-11.2) and V25 was 5.7% (0-12%). Median left ventricular ejection fraction (LVEF) was 63%. No abnormal LGE was observed. No correlations were seen between whole heart doses and LVEF, LV mass, GLS, or LV dimensions. Increasing ECV did not correlate with increased heart or ventricular doses. However, correlations between higher LV mass and ventricular mean dose, V10, and V25 were seen.\\nAt a median follow-up of 8.3 years, this cohort of node-positive breast cancer patients who received anthracycline-based chemotherapy and regional nodal irradiation had no clinically abnormal CMR findings. However, correlations between ventricular mean dose, V10, and V25 and LV mass were seen. Larger corroborating studies that include advanced techniques for measuring regional heart mechanics are warranted. 5-Fluorouracil (5-FU), a pyrimidine analogue, is widely used in different chemotherapy regimens with established indications for the treatment of gastrointestinal, breast, head, and neck tumors. Various prospective studies including randomized controlled trials and retrospective reviews have shown a wide range of reported incidence of cardiotoxicity related to 5-FU use. This incidence is dependent on drug regimen, doses, concomitant therapy, patients\\' clinical characteristics, and risk factors. Herein, we present a clinical case of coronary vasospasm mimicking ST-elevation myocardial infarction during a 5-FU infusion for salivary gland cancer. Cardiologists and oncologists must keep in mind the potential life-threatening side effects of 5-FU on the heart and they must be familiar with the risk factors for their occurrence and their management strategies. Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if soluble forms of the immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, and BTN2A1, could be candidate to predict the response to immune-checkpoint blockade therapy. We evaluated the plasma levels in a learning cohort of metastatic clear cell renal carcinoma (mccRCC) patients treated with the anti-PD-1 agent nivolumab by  The burden of breast cancer in Canada is steadily growing. More women are surviving breast cancer, yet, survivors live with side effects for years after treatments have ended. The benefits of exercise for women with breast cancer are well established and include improvement in treatment-related physical and emotional side effects. Despite these benefits, few survivors meet exercise guidelines. Exercise programmes are needed within the cancer institution in Canada to bridge the current knowledge to practice gap. The purpose of this study is to test the effects of a novel implementation strategy that includes institution-based exercise plus self-management (SM) or SM alone versus usual care in improving exercise level, quality of life, aerobic capacity, muscle strength and use of healthcare services over 12\\xa0months for women with breast cancer receiving chemotherapy.\\nThis study addresses a long-standing need to help women with breast cancer undergoing chemotherapy \\nThe study protocol (v1: July 2020) has been registered on ClinicalTrials.gov (NCT04109274). Nowadays Computer-Aided Diagnosis (CAD) models, particularly those based on deep learning, have been widely used to analyze histopathological images in breast cancer diagnosis. However, due to the limited availability of such images, it is always tedious to train deep learning models that require a huge amount of training data. In this paper, we propose a new deep learning-based CAD framework that can work with less amount of training data.\\nWe use pre-trained models to extract image features that can then be used with any classifier. Our proposed features are extracted by the fusion of two different types of features (foreground and background) at two levels (whole-level and part-level). Foreground and background feature to capture information about different structures and their layout in microscopic images of breast tissues. Similarly, part-level and whole-level features capture are useful in detecting interesting regions scattered in high-resolution histopathological images at local and whole image levels. At each level, we use VGG16 models pre-trained on ImageNet and Places datasets to extract foreground and background features, respectively. All features are extracted from mid-level pooling layers of such models.\\nWe show that proposed fused features with a Support Vector Classifier (SVM) produce better classification accuracy than recent methods on BACH dataset and our approach is orders of magnitude faster than the best performing recent method (EMS-Net).\\nWe believe that our method would be another alternative in the diagnosis of breast cancer because of performance and prediction time. This study investigated whether valproic acid (VPA, a histone deacetylase inhibitor) can interfere with the carcinogenicity of polycyclic aromatic hydrocarbons (PAHs). A typical representative compound of PAHs, 7,12-Dimethylbenz[a]anthracene (DMBA), was used to induce rat breast cancer. The results showed that therapeutic concentration of VPA (50 and 100\\xa0mg/kg) delayed the occurrence of tumors, reduced tumor formation rate and attenuated tumors growth, and have a protective effect on normal tissues. The macrophage-mediated inflammatory response was found to be associated with the observed effect of VPA. In addition, we screened and validated a possible gene,  In the present study, differences in the expression of target genes between chromatin immunoprecipitation sequencing (ChIP-seq) datasets of breast cancer MCF-7 cells treated with antibodies to E74-like factor 1 (ELF1) and cold-shock domain-containing E1 (CSDE1) were analyzed and gene regulatory networks were established. The datasets were downloaded from the Gene Expression Omnibus (GEO) database. ELF1-associated target genes and CSDE1-associated target genes were analyzed for functional prediction and protein-protein interaction (PPI) networks. The ELF1 ChIP-seq dataset contained 95 ELF1-associated target genes, while the CSDE1 ChIP-seq dataset contained 826 CSDE1-associated target genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated that the ELF1- and CSDE1-associated target genes had different potential functions and signaling pathways. The ELF1-associated target genes were mainly enriched in the GO terms of molecular transducer activity, catalytic activity, cellular processes and response to sensitivity, and in the KEGG pathways of olfactory transduction, the chemokine signaling pathway, carbohydrate digestion and absorption, and starch and sucrose metabolism. The CSDE1-associated target genes were mainly enriched in the GO terms of binding, transcription regulator activity, cellular processes and metabolic processes, and in the KEGG pathways of ribosome, metabolic pathways, endocytosis, oxidative phosphorylation and transcriptional misregulation in cancer. PPI network analysis revealed that the ELF1 regulatory network primarily regulated chemokine-mediated malignant tumor cells, while the CSDE1 regulatory network mainly regulated ribosomes, metabolic pathways and oxidative phosphorylation. Reverse transcription-quantitative PCR indicated that ELF1 overexpression led to significant downregulation of C-X-C motif chemokine-8 and -6 expression levels in MCF-7 cells, while overexpression of CSDE1 significantly induced the mRNA expression of CSDE1-associated target genes, which included mitochondrial ribosomal protein L4, NADH: ubiquinone oxidoreductase subunit B7, small nuclear ribonucleoprotein polypeptide E, ribosomal protein S26 (RPS26), RPS11 and RPS6, in the MCF-7 cells. In breast cancer MCF-7 cells, the target genes and regulatory pathways of ELF1 and CSDE1 were different. Understanding these regulatory pathways may help to develop strategies for personalized breast cancer treatment. The objective of this study is to investigate the anticancer potential of ginsenoside Rg1 using  Scorpion  Breast cancer remains the most commonly diagnosed malignancy in women. It encompasses considerable heterogeneity in pathology, patient clinical characteristics, and outcome. This study describes factors associated with overall survival (OS) of breast cancer in an updated national database.\\nWe conducted a retrospective analysis of patients with breast cancer diagnosed between 2004 and 2016 based on the National Cancer Database. Categorical variables were summarized using frequencies/percentages, whereas continuous variables were summarized using the median/interquartile range (IQR). OS was explored using the Kaplan-Meier method.\\nData from \\nThis large database provides a recent and comprehensive overview of breast cancer over 12 years. Molecular subtype, histologic subtype, stage, race, and facility type were correlated with OS. In addition to the educational perspective of this overview, significant factors impacting the outcome identified here should be considered in future cancer research on disparities. Breast invasive carcinoma (BRCA) is not a single disease as each subtype has a distinct morphology structure. Although several computational methods have been proposed to conduct breast cancer subtype identification, the specific interaction mechanisms of genes involved in the subtypes are still incomplete. To identify and explore the corresponding interaction mechanisms of genes for each subtype of breast cancer can impose an important impact on the personalized treatment for different patients.\\nWe integrate the biological importance of genes from the gene regulatory networks to the differential expression analysis and then obtain the weighted differentially expressed genes (weighted DEGs). A gene with a high weight means it regulates more target genes and thus holds more biological importance. Besides, we constructed gene coexpression networks for control and experiment groups, and the significantly differentially interacting structures encouraged us to design the corresponding Gene Ontology (GO) enrichment based on gene coexpression networks (GOEGCN). The GOEGCN considers the two-side distinction analysis between gene coexpression networks for control and experiment groups. The method allows us to study how the modulated coexpressed gene couples impact biological functions at a GO level.\\nWe modeled the binary classification with weighted DEGs for each subtype. The binary classifier could make a good prediction for an unseen sample, and the experimental results validated the effectiveness of our proposed approaches. The novel enriched GO terms based on GOEGCN for control and experiment groups of each subtype explain the specific biological function changes according to the two-side distinction of coexpression network structures to some extent.\\nThe weighted DEGs contain biological importance derived from the gene regulatory network. Based on the weighted DEGs, five binary classifiers were learned and showed good performance concerning the \"Sensitivity,\" \"Specificity,\" \"Accuracy,\" \" Verteporfin (VP) has long been clinically used to treat age-related macular degeneration (AMD) through photodynamic therapy (PDT). Recent studies have reported a significant anti-tumor effect of VP as well. Yes-associated protein (YAP) is a pro-tumorigenic factor that is aberrantly expressed in various cancers and is a central effector of the Hippo signaling pathway that regulates organ size and tumorigenesis. VP can inhibit YAP without photoactivation, along with suppressing autophagy, and downregulating germinal center kinase-like kinase (GLK) and STE20/SPS1-related proline/alanine-rich kinase (SPAK). In addition, VP can induce mitochondrial damage and increase the production of reactive oxygen species (ROS) upon photoactivation, and is an effective photosensitizer (PS) in anti-tumor PDT. We have reviewed the direct and adjuvant therapeutic action of VP as a PS, and its YAP/TEA domain (TEAD)-dependent and independent pharmacological effects in the absence of light activation against cancer cells and solid tumors. Based on the present evidence, VP may be repositioned as a promising anti-cancer chemotherapeutic and adjuvant drug. Telmisartan (TLM) is an antihypertensive drug that has been shown to have antiproliferative effects on cancer cells. It has low solubility and suboptimal oral bioavailability. To investigate the potential anticancer effect of TLM on breast cancer cells, poly (D, L-lactide) (PLA) nanoparticles were formulated with the benefit of improving its solubility.\\nTLM-loaded PLA nanoparticles were prepared by emulsion solvent evaporation. The effects of sonication time and polymer:drug ratio on nanoparticle size and drug encapsulation were investigated. TLM-loaded nanoparticles were tested against MCF-7 and MD-AMB-231 breast cancer cell lines for antiproliferative effects.\\nNanoparticles with mean particle size 272 nm and 79% encapsulation efficiency were obtained. Sustained release TLM nanoparticles (40% in 24 h) decreased cell viability to 45% for MCF-7 cells at 72 h, even at the lowest TLM concentration, indicating better anticancer efficiency than TLM solution.\\nTLM nanoparticles could be potential anticancer agents for breast cancer and deserve further studies. It is known that Lnc712 plays an important role in the pathogenesis of breast cancer. However, whether it is involved in hepatocellular carcinoma (HCC) remains unknown. In this study, we aimed to investigate the role and underlying mechanism of Lnc712 in HCC.\\nSixty-four HCC patients were enrolled and followed up for 5 years to analyze the prognostic value of Lnc712 for HCC. HCC cells were transfected with Lnc712 expression vector, Bach-1 expression vector (or siRNA) and miR-142-3p mimic (or inhibitor) to explore the interactions among Lnc712, miR-142-3p and Bach-1. Cell proliferation, migration, invasion and cell cycle were analyzed by CCK-8 assay, transwell assay, wound healing assay and flow cytometry assay, respectively.\\nThe expression of Lnc712 was upregulated in HCC, and the upregulated Lnc712 expression was significantly related to poor overall survival in HCC patients. In HCC cells, Lnc712 interacted with miR-142-3p and upregulated Bach-1, a target of miR-142-3p. In addition, Lnc712 promoted HCC cell proliferation, migration, invasion and cell cycle, while its effects were abolished by miR-142-3p mimic. Moreover, miR-142-3p mimic enhanced HCC cell proliferation, migration, invasion and cell cycle, while its effects were abolished by Bach-1 overexpression. miR-142-3p inhibitor repressed cell proliferation, migration, invasion and cell cycle in HCC cells, while its effects were abolished by Bach-1 knockdown. Furthermore, Lnc712 knockdown remarkably inhibited HCC tumor growth in nude mice.\\nLnc712 may promote the development of HCC by targeting the miR-142-3p/Bach-1 axis. Breast cancer (BC) remains the most common malignancy among women. Circular RNAs (circRNAs) have been demonstrated to play important roles in human cancers, including BC. In this study, we sought to identify the precise parts of circ_0061825 (circRNA trefoil factor 1, circ_TFF1) in BC pathogenesis.\\nThe expression levels of circ_0061825, miR-593-3p and fibroblast growth factor receptor 3 (FGFR3) were detected by quantitative real-time polymerase chain reaction (qRT-PCR) or Western blot. Circ_0061825 was characterized using ribonuclease (RNase) R digestion, actinomycin D and subcellular fractionation assays. Cell viability, colony formation, migration, invasion, cell cycle progression and apoptosis were evaluated using Cell Counting Kit-8 (CCK-8), colony formation, wound-healing, transwell and flow cytometry assays, respectively. Targeted relationships among circ_0061825, miR-593-3p and FGFR3 were determined by a dual-luciferase reporter assay. Animal studies were used to assess the impact of circ_0061825 in tumor growth in vivo.\\nOur data indicated that circ_0061825 was overexpressed in BC tissues and cells, and it was mainly localized in the cytoplasm of BC cells. Circ_0061825 knockdown hampered BC cell viability, colony formation, migration, invasion, cell cycle progression and enhanced cell apoptosis in vitro and weakened tumor growth in vivo. Mechanistically, circ_0061825 functioned as a molecular sponge of miR-593-3p, and circ_0061825 knockdown repressed BC cell malignant progression in vitro by miR-593-3p. FGFR3 was a direct target of miR-593-3p, and circ_0061825 modulated FGFR3 expression through sponging miR-593-3p. Moreover, miR-593-3p overexpression hindered BC cell malignant progression in vitro by down-regulating FGFR3.\\nOur current work provided evidence that circ_0061825, an up-regulated circRNA in BC, regulated BC malignant progression at least in part through targeting the miR-593-3p/FGFR3 axis, illuminating a novel therapeutic target for BC management. Nipple discharge is a common symptom of breast disease. We aimed to perform a descriptive statistical analysis of the cases we evaluated and establish a model to predict intraductal tumors.\\nWe conducted a retrospective study of patients from 2007 to 2019. In total, 1333 patients who completed the fiberoptic ductoscopy (FDS) were evaluated. The variables were analyzed by \\nPatients with spontaneous, single-duct, bloody discharge and a smooth ductal wall were more likely to be diagnosed with tumors by ductoscopy. A model was established based on five variables: age, side of discharge, spontaneous discharge status, duration of discharge, and color of discharge. The model was subsequently validated in 183 patients with complete data on the variables in the validation cohort. The area under the ROC curve (AUC) was calculated to be 0.716, indicating good predictive ability.\\nPatients with the clinical characteristics of unilateral, bloody, single-duct, spontaneous discharge and a smooth ductal wall were more likely to have intraductal tumors by ductoscopy. Our nomogram can effectively predict intraductal tumors in patients with nipple discharge. Breast cancer is the top cancer among women both in the developed and the developing world. Many deaths can be avoided if breast cancer can be detected and treated early. The practice of breast self-examination (BSE) is a convenient, no-cost tool that can be used regularly for detecting breast cancer at an early stage. Therefore, this study sought to assess the knowledge and practice of breast self-examination among young females in Addis Ababa, Ethiopia.\\nInstitutional-based cross-sectional study was conducted among 358 females using a pre-tested and self-administered questionnaire. The data were cleaned and analyzed using SPSS version 23, and the descriptive statistics, linear and logistic regression were used for analysis. The possible predictors were identified using the odds ratio with a 95% confidence interval and a P-value of 0.05.\\nAlmost half of 188 (52.5%) respondents had heard about breast cancer self-examination, while the media were the main source of information. The study revealed that only as little as 47 (13.1%) respondents did appropriate BSE. While confounding factors were controlled for, the linear multivariate regression analysis indicated that the healthcare providers as information sources about BSE (\\nThis study showed that a few females implemented regular BSE. Further implementations are needed in addressing young females, making awareness and advocacy campaigns about BSE to increase early diagnosis of breast cancer that raises the chances for successful treatment in Ethiopia. The objectives of the current study are to evaluate the prevalence of depression symptoms among breast cancer patients in Jordan and impact of the disease on patient\\'s quality-of-life.\\nA cross-sectional survey-based study was conducted over a 6-month period among breast cancer patients attending two major hospitals in Jordan. A validated questionnaire was used to evaluate the prevalence of depression symptoms and quality-of-life aspects among those patients utilizing Beck\\'s Depression Inventory-II score and 36-Item Survey Form (SF-36) score, respectively.\\nThe mean age±SD of patients (n=169) was 49.12±6.48 years. Depression symptoms were reported in 30.2% of patients. As for quality-of-life, the physical functioning (PF) subscale was significantly associated with the patient\\'s age (\\nAbout one-third of breast cancer patients reported depression symptoms. Quality-of-life subscales among those patients were associated with multiple social and health determinants, such as age, marital status, number of siblings, occupation, and number of sleeping hours. There is urgent need to support this group of patients to help them to cope with depression symptoms and to improve their quality-of-life. To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 kinase inhibitors regimens among US oncologists and patients.\\nOncologists and patients with mBC participated in an internet-based survey that included a discrete choice experiment (DCE) and a best-worst scaling (BWS) exercise. For the DCE, participants chose between two hypothetical treatment profiles, each with seven attributes: risk of dose reduction due to adverse events (AEs), risk of diarrhea, risk of abdominal pain, need for electrocardiogram (ECG) monitoring to assess heart function, risk of Grade 3/4 neutropenia, dosing regimen, and dosing schedule. The BWS exercise assessed the relative prioritization of a larger set of 16 attributes. Hierarchical Bayesian models were used to estimate preference weights for each attribute level.\\nOncologists (N=209) and patients (N=304) rated risks of diarrhea (25% each) and Grade 3/4 neutropenia (20% and 24%, respectively) as the most important attributes for treatment choice. The risks of diarrhea and Grade 3/4 neutropenia were 1.8 to 2.3 times (oncologists: 25% and 20%, respectively vs 11%) and 2.4 to 2.5 times (patients: 25% and 24%, respectively vs 10%) higher in relative importance than the risk of dose reduction due to AEs. Oncologists placed greater importance on the risk of dose reduction due to AEs and the need for ECG monitoring, whereas patients placed greater importance on the risk of Grade 3/4 neutropenia (all, p<0.05). The BWS exercise results were largely consistent with those from the DCE.\\nThe risks of diarrhea and Grade 3/4 neutropenia were key drivers of both oncologist and patient preferences. Overall, the palbociclib + aromatase inhibitor (AI) profile was most preferred, due to its association with a lower risk of diarrhea and no ECG monitoring, compared with abemaciclib + AI and ribociclib + AI profiles, respectively. Mammography and breast CT are important tools for breast cancer screening and diagnosis. Current implementations are limited by scattered radiation and/or spatial resolution. In this work, we propose and develop a slot scan-based system to be used in both mammography and CT mode that can limit scatter and collect sparse CT data for improved image quality at low radiation exposures. Monte Carlo simulations of an anthropomorphic breast phantom show a factor of 10 reduction in scattering amplitude with our slot scan-based system compared to that of a full-field detector mammography system (area mode). Similarly, slot-scan improved the MTF (particularly the low-frequency response) compared to an area detector. Investigation of sparse CT sampling with doubly sparse acquisition data return better quality reconstruction, for which our slot-scanning system is capable, over angle-only projection. Thus, a system with the combined ability for slot-scanning mammography and slot-scanning breast CT has the potential to deliver improved dose-efficient imaging performance and become viable breast cancer screening and diagnostic tools. Our recent research has revealed that passenger strands of certain microRNAs (miRNAs) function as tumor-suppressive miRNAs in cancer cells, e.g., miR-101-5p, miR-143-5p, miR-144-5p, miR-145-3p, and miR-150-3p. Thus, they are important in cancer pathogenesis. Analysis of the miRNA expression signature of breast cancer (BrCa) showed that the expression levels of two miRNAs derived from pre-miR-99a (miR-99a-5p and miR-99a-3p) were suppressed in cancerous tissues. The aim of this study was to identify oncogenic genes controlled by pre-miR-99a that are closely involved in the molecular pathogenesis of BrCa. A total of 113 genes were identified as targets of pre-miR-99a regulation (19 genes modulated by miR-99a-5p, and 95 genes regulated by miR-99a-3p) in BrCa cells. Notably, FAM64A was targeted by both of the miRNAs. Among these targets, high expression of 16 genes (C5orf22, YOD1, SLBP, F11R, C12orf49, SRPK1, ZNF250, ZNF695, CDK1, DNMT3B, TRIM25, MCM4, CDKN3, PRPS, FAM64A, and DESI2) significantly predicted reduced survival of BrCa patients based upon The Cancer Genome Atlas (TCGA) database. In this study, we focused on FAM64A and investigated the relationship between FAM64A expression and molecular pathogenesis of BrCa subtypes. The upregulation of FAM64A was confirmed in BrCa clinical specimens. Importantly, the expression of FAM64A significantly differed between patients with Luminal-A and Luminal-B subtypes. Our data strongly suggest that the aberrant expression of FAM64A is involved in the malignant transformation of BrCa. Our miRNA-based approaches (identification of tumor-suppressive miRNAs and their controlled targets) will provide novel information regarding the molecular pathogenesis of BrCa. The consumption of coffee has been suggested to effectively enhance the therapeutic effects of tamoxifen against breast cancer; however, the underlying molecular mechanisms remain unclear. We herein attempted to clarify how coffee decoction exerts anti-cancer effects in cooperation with tamoxifen using the estrogen receptor α (ERα)-positive breast cancer cell line, MCF-7. The results obtained showed that coffee decoction down-regulated the expression of ERα, which was attributed to caffeine inhibiting its transcription. Coffee decoction cooperated with tamoxifen to induce cell-cycle arrest and apoptotic cell death, which may have been mediated by decreases in cyclin D1 expression and the activation of p53 tumor suppressor. The inclusion of caffeine in coffee decoction was essential, but not sufficient, to induce cell-cycle arrest and apoptotic cell death, suggesting the requirement of unknown compound(s) in coffee decoction to decrease cyclin D1 expression and activate apoptotic signaling cascades including p53. The activation of p53 through the cooperative effects of these unidentified component(s), caffeine, and tamoxifen appeared to be due to the suppression of the ERK and Akt pathways. Although the mechanisms by which the suppression of these pathways induces p53-mediated apoptotic cell death remain unclear, the combination of decaffeinated coffee, caffeine, and tamoxifen also caused cell-cycle arrest and apoptotic cell death, suggesting that unknown compound(s) present in decaffeinated coffee cooperate with caffeine and tamoxifen. There is great controversy about whether the consumption of different types of alcoholic beverages has different effects on health. The objective was to carry out an umbrella review of the studies that described the association between the consumption of different types of alcoholic beverages and various health indicators.\\nSearch through PubMed (from January 2000 to February 2019) of systematic reviews and meta-analysis that reported quantitative results of the association between the consumption of different types of alcoholic beverages and health effects. 26 studies were identified: 21 related to cancer, three to cardiometabolic diseases, two to neurodegenerative diseases, and one to general mortality.\\nThe results were heterogeneous. The great methodological differences in the estimation of alcohol intake, control of confounding variables, and the evaluation of statistical difference between types of beverages, made it very difficult to conclude whether they cause an unequal effect on health. In general mortality and cardiometabolic diseases, it was suggested that beer and spirits appear to have a greater negative effect than wine, but the differences were not statistically significant. Regarding cancer, in those types where the causal evidence is totally consistent: oropharynx, colorectal and breast (women), the reviews did not show a differentiated effect according to the type of alcoholic beverages. Regarding neurodegenerative diseases, the available information did not allow clear conclusions to be drawn.\\nThe reviewed evidence does not allow to conclude that the consumption of wine, beer or spirits, has a differential effect on cardiometabolic, cancer or neurodegenerative diseases.\\nExiste gran controversia sobre si el consumo de diversos tipos de bebidas alcohólicas tiene efectos diferenciados en la salud. El objetivo de este estudio fue realizar una revisión paraguas de los estudios que describían la asociación del consumo de diferentes tipos de bebidas alcohólicas con diversos indicadores de salud.\\nSe realizó una búsqueda a través de PubMed (entre enero de 2000 y febrero de 2019) de revisiones sistemáticas y metaanálisis que reportaban resultados cuantitativos de la asociación entre el consumo de diferentes tipos de bebidas alcohólicas y efectos en salud. Se identificaron 26 estudios: veintiuno estaban relacionados con cáncer, tres con enfermedades cardiometabólicas, dos con neurodegenerativas y uno con mortalidad general.\\nLos resultados fueron heterogéneos. Las grandes diferencias metodológicas en la estimación de la ingesta de alcohol, el control de las variables confusoras y el contraste de las estimaciones entre el tipo de bebidas hacían muy difícil concluir sobre si provocaban un efecto desigual en la salud. En la mortalidad general y las enfermedades cardiometabólicas, aunque parece que la cerveza y los licores tenían un mayor efecto negativo que el vino, las diferencias entre tipos de bebidas no eran estadísticamente significativas. Respecto al cáncer, en aquellos tipos cuya evidencia causal era totalmente consistente (orofaringe, colorrectal y de mama [mujeres]), las revisiones no mostraban un efecto diferenciado según los tipos de bebidas alcohólicas. Respecto a las enfermedades neurodegenerativas, la información disponible tampoco permitía establecer claras conclusiones.\\nLa evidencia revisada no permite afirmar que el consumo de vino, cerveza o licores tenga un efecto diferencial en las enfermedades cardiometabólicas, las neurodegenerativas o el cáncer. The aim of this study was to test if the marker rs196929 in IRE1 associated with cleft lip and palate depending on the family history for cancer. A consecutive sample of 836 individuals were recruited between April and October of 2019 (303 born with cleft lip and palate, 256 relatives mostly of the maternal side of individuals born with cleft lip and palate, and 277 unaffected unrelated individuals). Parents or guardians of the children answered a questionnaire with basic demographic information about their children and their family history of cleft lip and palate and cancer. DNA was obtained from whole saliva and IRE1 rs196929 was genotyped using TaqMan chemistry and end-point analysis. Over-representation of alleles was determined using chi-square as implemented in PLINK using an alpha of 0.05. There was an excess of less common homozygotes of IRE1 rs196929 among relatives of individuals born with cleft lip and palate when they had positive family history of cancer in comparison with individuals born with cleft lip and palate or with unrelated unaffected individuals (P\\u200a=\\u200a0.0006 and P\\u200a<\\u200a0.001, respectively). This pattern was similar when families reported one type of cancer or multiple ones, or when cancer affecting females (breast or reproductive tract) or the structures of the gastro-intestinal tract were considered. These results provide support for a role of the ER stress IRE1-XPB1 pathway in the higher frequency of cancer in families of individuals born with cleft lip and palate. Assessment of the Ki67 index is critical for grading well-differentiated neuroendocrine tumors (WD-NETs), which can show a broad range of labeling that defines the WHO grade (G1-G3). Poorly differentiated neuroendocrine carcinomas (PD-NECs) have a relatively high Ki67 index, >20% in all cases and commonly exceeding 50%. After anecdotally observing PD-NECs with an unexpectedly low and heterogeneous Ki67 index following chemotherapy in 5 cases, we identified 15 additional cases of treated high-grade neuroendocrine neoplasms (HG-NENs). The study cohort comprised 20 cases; 11 PD-NECs, 8 mixed adenoneuroendocrine carcinomas, and 1 WD-NET, G3 from various anatomic sites (gastrointestinal tract, pancreas, larynx, lung, and breast). The Ki67 index was evaluated on pretreatment (when available) and posttreatment samples. Topographic heterogeneity in the Ki67 index was expressed using a semi-quantitative score of 0 (no heterogeneity) to 5 (>80% difference between maximal Ki67 and minimal Ki67 indices). Relative to the pretreatment group (n=9, mean Ki67 of 86.3%, range 80% to 100%), the neoplasms in the posttreatment group (n=20, mean Ki67 of 47.7%, range 1% to 90%) showed a significantly lower Ki67 index (18/20 cases). Of the 18 cases with a relatively low Ki67 index, 15 showed heterogeneous labeling (mean heterogeneity score of 2.3, range 1 to 5) and in 3 cases it was a homogeneously low. This phenomenon was observed in all subtypes of HG-NENs. In 6 cases, the alterations in Ki67 index following treatment were sufficient to place these HG-NENs in the WHO G1 or G2 grade, erroneously suggesting a diagnosis of WD-NET, and in 9 cases there was sufficient heterogeneity in the Ki67 index to suggest that a limited biopsy may sample an area of low Ki67, even though hotspot regions with a Ki67 index of >20% persisted. In 7 cases, the alterations in the Ki67 index were accompanied by morphologic features resembling a WD-NET. These observations suggest that there is a potential for misinterpretation of previously treated PD-NECs as WD-NETs, or for assigning a lower grade in G3 WD-NETs. While the prognostic significance of treatment-associated alterations in Ki67 index is unknown, awareness of this phenomenon is important to avoid this diagnostic pitfall when evaluating treated NENs. Patients with long-term estrogen-deprived breast cancer (BC), after resistance to tamoxifen or aromatase inhibitors develops, can experience tumor regression when treated with estrogens. Estrogen\\'s anti-tumor effect is attributed to apoptosis via the estrogen receptor (ER). Estrogen treatment can have unpleasant gynecological and non-gynecological adverse events thus the development of safer estrogenic agents remains a clinical priority. Here, we study synthetic selective estrogen mimics (SEMs) BMI-135 and TTC-352, and the naturally-occurring estrogen estetrol (E4), which are proposed as safer estrogenic agents compared to 17β-estradiol (E2), for the treatment of endocrine-resistant BC. TTC-352 and E4 are being evaluated in BC clinical trials. Cell viability assays, real-time polymerase chain reaction, immunoblotting, ERE DNA pull downs, Mass spectrometry, X-ray crystallography, docking and molecular dynamic simulations, live cell imaging, and annexin V staining were conducted in 11 biologically-different BC models. Results were compared with the potent full agonist E2, less potent full agonist E4, the benchmark partial agonist triphenylethylene bisphenol (BPTPE), and antagonists 4-hydroxytamoxifen and endoxifen. We report ERα\\'s regulation and coregulators\\' binding profiles with SEMs and E4. We describe TTC-352\\'s pharmacology as a weak full agonist and anti-tumor molecular mechanisms. This study highlights TTC-352\\'s benzothiophene scaffold that yields an H-bond with Glu353, which allows Asp351-to-helix 12 (H12) interaction; sealing ERα\\'s ligand binding domain, recruiting E2-enriched coactivators, and triggering rapid ERα-induced unfolded protein response (UPR) and apoptosis, as the basis of its anti-cancer properties. BPTPE\\'s phenolic OH yields an H-Bond with Thr347, which disrupts Asp351-to-H12 interaction; delaying UPR and apoptosis, and increasing clonal evolution risk. Examine the effect of tamoxifen and aromatase inhibitors (AIs) on the risk of 12 clinically relevant cardiovascular outcomes in postmenopausal female breast cancer survivors.\\nWe carried out two prospective cohort studies among postmenopausal women with breast cancer in UK primary care and hospital data (2002-2016) and US Surveillance, Epidemiology and End Results-Medicare data (2008-2013). Using Cox adjusted proportional hazards models, we compared cardiovascular risks between AI and tamoxifen users; and in the USA, between users of both drug classes and women receiving no endocrine therapy.\\n10\\u2009005 (UK) and 22\\u2009027 (USA) women with postmenopausal breast cancer were included. In both countries, there were higher coronary artery disease risks in AI compared with tamoxifen users (UK age-standardised incidence rate: 10.17 vs 7.51 per 1000 person-years, HR: 1.29, 95% CI 0.94 to 1.76; US age-standardised incidence rate: 36.82 vs 26.02 per 1000 person-years, HR: 1.29, 95% C I1.06 to 1.55). However, comparisons with those receiving no endocrine therapy (US data) showed no higher risk for either drug class and a lower risk in tamoxifen users (age-standardised incidence rate tamoxifen vs unexposed: 26.02 vs 35.19 per 1000 person-years, HR: 0.74, 95% 0.60 to 0.92; age-standardised incidence rate AI vs unexposed: 36.82 vs 35.19, HR: 0.96, 95% CI 0.83 to 1.10). Similar patterns were seen for other cardiovascular outcomes (arrhythmia, heart failure and valvular heart disease). As expected, there was more venous thromboembolism in tamoxifen compared with both AI users and those unexposed.\\nHigher risks of several cardiovascular outcomes among AI compared with tamoxifen users appeared to be driven by protective effects of tamoxifen, rather than cardiotoxic effects of AIs. Altered glycosylations, which are associated with expression and activities of glycosyltransferases, can dramatically affect the function of glycoproteins and modify the behavior of tumor cells. ST3GAL1 is a sialyltransferase that adds sialic acid to core 1 glycans, thereby terminating glycan chain extension. In breast carcinomas, overexpression of ST3GAL1 promotes tumorigenesis and correlates with increased tumor grade. In pursuing the role of ST3GAL1 in breast cancer using ST3GAL1-siRNA to knockdown ST3GAL1, we identified CD55 to be one of the potential target proteins of ST3GAL1. CD55 is an important complement regulatory protein, preventing cells from complement-mediated cytotoxicity. CD55 had one N-linked glycosylation site in addition to a Ser/Thr-rich domain, which was expected to be heavily O-glycosylated. Detailed analyses of N- and O-linked oligosaccharides of CD55 released from scramble or ST3GAL1 siRNA-treated breast cancer cells by tandem mass spectrometry revealed that the N-glycan profile was not affected by ST3GAL1 silencing. The O-glycan profile of CD55 demonstrated a shift in abundance to non-sialylated core 1 and monosialylated core 2, at the expenses of disialylated core 2 structure after ST3GAL1 silencing. We also demonstrated that O-linked desialylation of CD55 by ST3GAL1 silencing resulted in increased C3 deposition and complement-mediated lysis of breast cancer cells and enhanced sensitivity to antibody-dependent cell-mediated cytotoxicity. These data demonstrated that ST3GAL1-mediated O-linked sialylation of CD55 acts like an immune checkpoint molecule for cancer cells to evade immune attack and that inhibition of ST3GAL1 is a potential strategy to block CD55-mediated immune evasion. Recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the pre-metastatic niche. Here we compared the growth and metastasis of melanoma and breast cancer xenografts in mice exhibiting or not exhibiting targeted deletion of Cxcr2 in myeloid cells (CXCR2myeΔ/Δ vs. CXCR2 myeWT). Detailed analysis of leukocyte populations in peripheral blood and in tumors from CXCR2myeΔ/Δ mice revealed that loss of CXCR2 signaling in myeloid cells resulted in reduced intratumoral MDSCs and increased intratumoral CXCL11. The increase in intratumoral CXCL11 was derived in part from tumor-infiltrating B1b cells. The reduction in intratumoral MDSCs coupled with an increase in intratumoral B1b cells expressing CXCL11 resulted in enhanced infiltration and activation of effector CD8+ T cells in the TME of CXCR2myeΔ/Δ mice, accompanied by inhibition of tumor growth in CXCR2myeΔ/Δ mice compared to CXCR2myeWT littermates. Treatment of tumor-bearing mice with a CXCR2 antagonist (SX-682) also inhibited tumor growth, reduced intratumoral MDSCs, and increased intratumoral B1b cells expressing CXCL11, leading to an increase in activated CD8+ T cells in the tumor. Depletion of B220+ cells or depletion of CD8+ T cells reversed the tumor inhibitory properties in CXCR2myeΔ/Δ mice. These data revealed a mechanism by which loss of CXCR2 signaling in myeloid cells modulates antitumor immunity through decreasing MDSCs and enriching CXCL11-producing B1b cells in the TME, which in turn increases CD8+ T-cell recruitment and activation in tumors. Despite strong evidence that it is efficacious, chemoprevention has been underused in eligible women. Reasons offered not to adopt and initiate strategies to reduce the risk of breast cancer include the fear of adverse effects, medication costs, lack of reasonably accurate and feasible methods for assessing an individual\\'s personal risk, and lack of established risk thresholds that maximize benefit and minimize harms. The article by Macdonald and colleagues remind us that the problem of lack of uptake of risk-reducing medications for breast cancer remains a worldwide clinical challenge despite endorsements from national and international organizations that recommend the use of risk reducing medications for breast cancer with Level I evidence. Several strategies are suggested to improve uptake and utilization of safe and effective chemoprevention medications with high therapeutic indices. To investigate whether pigment epithelium-derived factor (PEDF) inhibits invasion and metastasis of breast cancer through regulation of epithelial-mesenchymal transition.\\nThe expressions of PEDF, vimentin, and E-cadherin were detected in 119 breast cancer tissues using immunohistochemistry. SK-BR-3 breast cancer cell models of PEDF knockdown and PEDF overexpression were established by transfecting the cells with a PEDF-siRNA vector and a lentivirusPEDF vector, respectively. Western blotting was used to detect the changes in the expressions of PEDF, vimentin, and E-cadherin in the cells, and the cell invasion and migration ability was assessed using scratch wound healing assay and transwell migration assay.\\nPEDF positivity rate was significantly lowered in breast cancer tissues compared with the adjacent tissues. PEDF was positively correlated with the tumor size and the expression level of E-cadherin (\\nPEDF is closely related with the metastasis of breast cancer cells through regulation of epithelial-mesenchy. To investigate whether soluble PD-1 overexpression in 4T1 senescence tumor cells enhances the antitumor effect of senescence tumor cell vaccine (STCV) against breast tumor cells in a tumor-bearing mouse model.\\n4T1 cells were treated with interferon-γ (IFN-γ) and the expression of PD-L1 was detected by flow cytometry. CCK8 assay was used to compare the cell proliferation activity between 4T1 cells and 4T1 cells infected by a lentiviral vector of sPD-1 (4T1/sPD-1 cells), and the expressions of sPD-1 mRNA and protein in 4T1/sPD-1 cells were detected using qPCR and Western blotting. The culture supernatant of 4T1/sPD-1 cells was added in 4T1 cells pre-treated with IFN-γ, and PD-1-positive 4T1 cells were detected with flow cytometry. Senescence β-galactosidase staining kit was used to detect the senescent 4T1 and 4T1/sPD-1 cells following exposure to X-ray radiation and Veliparib. Balb/c mice bearing subcutaneous 4T1 tumor xenografts were treated with injections of PBS, 4T1 STCV, or 4T1/sPD-1 STCV, and tumor growth was observed.\\nStimulation with IFN-γ concentration-dependently up-regulated PD-L1 expression by as much as (84.80 ± 1.03)% in 4T1 cells (\\nSenescence tumor cells vaccine has antitumor effect against breast cancer in mice, and sPD-1 overexpression can enhance this effect of the vaccine. None To develop novel GLS1 inhibitors as effective therapeutic agents for triple-negative breast cancer (TNBC), 25 derivatives were synthesized from the natural inhibitor withangulatin A (IC Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer.\\nPatients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10\\u2009mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4\\u2009weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as \"non-progressors\" if they had clinical benefit (SD/PR/CR) at 4\\u2009months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time.\\nTwenty-six patients were accrued. Median PFS and OS were 3.5 and 11\\u2009months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4\\u2009months in triple-negatives; P\\u2009=\\u20090.11). Clinical benefit rate at 2 and 4\\u2009months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P\\u2009=\\u20090.73). Non-progressors\\' tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased T\\nThis study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing T\\n(www.clinicaltrials.gov): NCT02802098 . Registered on June 16, 2020. 27-Hydroxycholesterol (27HC) stimulates estrogen receptor-positive (ER+) breast cancer (BC) progression. Inhibiting the sterol 27-hydroxylase (CYP27A1) abrogates these growth-promoting effects of 27HC in mice. However, the significance of CYP27A1 expression on BC biology and prognosis is unclear.\\nIntratumoral CYP27A1 expression in invasive BC was measured by immunohistochemistry in two Swedish population-based cohorts (n\\u2009=\\u2009645 and n\\u2009=\\u2009813, respectively). Cox proportional hazards models were used to evaluate the association between CYP27A1 expression and prognosis.\\nCYP27A1 was highly expressed in less than 1/3 of the tumors. High CYP27A1 expression was more frequent among high-grade tumors lacking hormone receptor expression and with larger tumor sizes. Over a median of 12.2\\u2009years follow-up in cohort 1, high CYP27A1 expression was associated with impaired survival, specifically after 5\\xa0years from diagnosis among all patients [overall survival (OS), HR\\nCYP27A1 demonstrated great potentials as a biomarker of aggressive tumor biology and late lethal disease in postmenopausal patients with ER+ BC. Future studies should investigate if the benefits of prolonged endocrine therapy and cholesterol-lowering medication in BC are modified by CYP27A1 expression. This study aimed to obtain health utility parameters among Chinese breast cancer patients in different disease states for subsequent health economics model. In addition, we aimed to explore the feasibility of establishing a breast cancer health utility mapping model in China.\\nMultiple patient-reported health attributes were assessed, including quality of life, which was measured by the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument; health utility and self-rated health, which were measured by the EuroQol-5 Dimension-5 Level (EQ-5D-5L) questionnaire. Multivariate regression models, including a linear regression model, an ordinal logistic regression model and a Tobit model, were employed to analyze health differences among 446 breast cancer patients. Subgroup analyses were performed to examine differences in multiple dimensions of health derived from the FACT-B and EQ-5D-5L instruments. A mapping function was used to estimate health utility from quality of life. Rank correlation analyses were employed to examine the correlation between estimated and observed health utility values.\\nA total of 446 breast cancer patients with different disease states were analyzed. The health utility values of breast cancer patients in the P state (without cancer recurrence and metastasis), R state (with cancer recurrence within a year), S state (with primary and recurrent breast cancer for the second year and above), and M state (metastatic cancer) were 0.81 (SD\\u2009±\\u20090.23), 0.90 (SD\\u2009±\\u20090.12), 0.78 (SD\\u2009±\\u20090.31), and 0.74 (SD\\u2009±\\u20090.27), respectively. There were positive correlations between all scores, including every domain of the FACT-B instrument (p\\u2009<\\u20090.001). Results from multivariate analysis suggested that patients in the R and M states had lower scores for overall quality of life (R, β\\u2009=\\u2009-\\u20099.45, p\\u2009<\\u20090.01; M, β\\u2009=\\u2009-\\u20096.72, p\\u2009<\\u20090.05). Patients in the M state had lower health utility values than patients in the P state (β\\u2009=\\u2009-\\u20090.11, p\\u2009<\\u20090.05). Estimated health utility values, which were derived from quality of life by using a mapping function, were significantly correlated with directly measured health utility values (p\\u2009<\\u20090.001).\\nWe obtained the health utility and health-related quality of life (HRQoL) scores of Chinese breast cancer patients in different disease states. Mapping health utility values from quality of life using four disease states could be feasible in health economic modelling, but the mapping function may need further revision. Cancer is widely recognized as a global public health problem. Breast, prostate, and cervical cancer are among the most frequent types in developing countries. Assessing their incidence and mortality by regions and municipalities is important to guide evidence-based health policy. Our aim was to describe the incidence and mortality trends for breast, cervical, and prostate cancer across regions and municipalities in Colombia during 2018.\\nWe performed a cross-sectional analysis with data from people with breast, prostate, or cervical cancer, reported to the National Administrative Cancer Registry during 2018. A descriptive analysis was performed. Age-standardized incidence and mortality rates were estimated at national, regional, and municipal levels. Finally, we identify the regions and municipalities with significantly higher or lower incidence and mortality rates compared to national estimations.\\nBreast cancer was the most frequent type among all new cases and deaths in Colombia. Breast, prostate and cervical cancer incidence and mortality rates per 100,000 were: 18.69 (CI 95%: 18.15-19.25) and 10.48 (CI 95%: 10.07-10.91); 11.34 (CI 95%: 10.90-11.78) and 7.58 (CI 95%: 7.22-7.96); 5.93 (CI 95%: 5.62-6.25) and 4.31 (CI 95%: 4.05-4.58), respectively. Eastern region had both, incidence and mortality rates, significantly lower than national for all types of cancer. By municipalities, there was a heterogeneous pattern. Nonetheless, Agua de Dios (Cundinamarca), had one of the highest incidence rates for all types.\\nWe observed clear differences in cancer incidence and mortality across regions and municipalities, depending on each type of cancer. Our findings are important to improve screening coverage, early detection, and treatment in the country. Deregulation of the RNA polymerase III specific TFIIIB subunit BRF2 occurs in subtypes of human cancers. However, correlations between BRF2 alterations and clinical outcomes in breast cancer are limited. We conducted this review to analyze BRF2 alterations in genomic data sets housed in Oncomine and cBioPortal to identify potential correlations between BRF2 alterations and clinical outcomes.\\nThe authors queried both Oncomine and cBioPortal for alterations in BRF2 in human cancers and performed meta-analyses identifying significant correlations between BRF2 and clinical outcomes in invasive breast cancer (IBC).\\nA meta cancer outlier profile analysis (COPA) of 715 data sets (86,733 samples) in Oncomine identified BRF2 as overexpressed in 60% of breast cancer data sets. COPA scores in IBC data sets (3594 patients) are comparable for HER2 (24.211, median gene rank 60) and BRF2 (29.656, median gene rank 36.5). Overall survival in IBC patients with BRF2 alterations (21%) is significantly decreased (p\\u2009=\\u20099.332e-3). IBC patients with BRF2 alterations aged 46 to 50 have a significantly poor survival outcome (p\\u2009=\\u20097.093e-3). Strikingly, in metastatic breast cancer, BRF2 is altered in 33% of women aged 45-50. BRF2 deletions are predominant in this age group.\\nThis study suggests BRF2 may be an prognostic biomarker in invasive breast carcinoma. Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry.\\nHeregulin (HRG) has been reported to identify patients with better responses to therapy with the anti-HER3 monoclonal antibody seribantumab (MM-121). The SHERBOC trial investigated adding seribantumab (MM-121) to standard therapy in patients with advanced HER2-negative, hormone receptor-positive (HR-positive) breast cancer and HRG overexpression. The PRAEGNANT registry was used for identification and tumor testing, helping to link potential HRG positive patients to the trial. Patients enrolled in PRAEGNANT have invasive and metastatic or locally advanced, inoperable breast cancer. Patients eligible for SHERBOC were identified by using the registry. Study aims were to describe the HRG positivity rate, screening procedures, and patient characteristics associated with inclusion and exclusion criteria.\\nAmong 2769 unselected advanced breast cancer patients, 650 were HER2-negative, HR-positive and currently receiving first- or second-line treatment, thus potentially eligible for SHERBOC at the end of current treatment; 125 patients also met further clinical eligibility criteria (e.g. menopausal status, ECOG). In the first/second treatment lines, patients selected for SHERBOC based on further eligibility criteria had a more favorable prognosis than those not selected. HRG status was tested in 38 patients, 14 of whom (36.8%) proved to be HRG-positive.\\nUsing a real-world breast cancer registry allowed identification of potentially eligible patients for SHERBOC focusing on patients with HER3 overexpressing, HR-positive, HER2-negative metastatic breast cancer. This approach may provide insights into differences between patients eligible or non-eligible for clinical trials.\\nClinicaltrials, NCT02338167 , Registered 14 January 2015 - retrospectively registered. Nuclear Factor-κappa B (NF-κB) is a family of critical transcription factors of inflammatory pathway and plays an imperative role in the progression of various cancers such as breast, lung, liver, pancreatic, prostate and multiple types of lymphoma. NF-κB develops an inherent relationship between inflammation and cancer. It is a crucial factor which controls the ability of malignant and pre-neoplastic cells to prevent programmed cell death-based tumor-surveillance channels. Due to its high significance in the onset and progression of various cancers, it has become an excellent target for cancer therapy. The emerging targeted therapies provide a lot of hope, whereby a single protein or generally the target enzyme is completely blocked. Several natural compounds have shown anticancer and anti-inflammatory activities by inhibiting NF-κB pathway in various cancer types. About 750 natural and synthetic inhibitors of the NF-κB have been reported. These inhibitors include microbial and viral proteins, small RNA/DNA, antioxidants, small molecules, peptides, and engineered constitutively active polypeptides, all of which may inhibit canonical and alternative NF-κB pathways. Thus, blocking or targeting the NFκB-signaling pathways by using natural and synthetic compounds could be a potential mechanism to cure the NF-κB induced tumors. High-intensity focused ultrasound (HIFU) is a noninvasive method of ablating malignant tumors. This paper will review the current clinical application of HIFU specially in the treatment of breast cancer. In addition to clinical studies, this review will also look into some basic studies that could address the technical issues related to this modality. In general, HIFU is considered to be safe being noninvasive and non-ionizing. Complication occurrence rate is low and repeated treatment is possible, making it an attractive option for some patients. However, for more than two decades since it was first used to treat breast cancer, clinical studies on HIFU still remain at the investigative stage and are only available in several centers. Reasons contributing to such few studies on HIFU include lack of specialized medical team and bioengineering technical staff, and breast cancer-dedicated imaging-HIFU platform to attain positive outcome. Despite these circumstances, we believe that HIFU will eventually become the treatment of choice for most breast cancer patients in the near future. Invasive breast cancer (BRCA) is one of the prevalent types of invasive tumors with high mortality worldwide. Due to the lack of effective treatment to control the recurrence of distant metastases, the prognosis of BRCA is still very unsatisfactory. We aimed to find some biomarkers by bioinformatics analysis for survival prediction.\\nDifferentially expressed genes (DEGs) were screened out based on tumor group and normal group. Then, the weighted gene correlation network analysis (WGCNA) was employed to identify the clinically associated gene sets. Meanwhile, the enrichment analyses were performed for the functional annotation of the critical genes. The Kaplan Meier analysis calculated the essential genes\\' prognostic value.\\nAfter threshold screening, 1655 DEGs were obtained for subsequent analysis. 51 out of 1655 DEGs were significantly associated with BRCA patients\\' estrogen receptor status via WGCNA. Three genes (FABP7, CXCL3, and LOC284578) out of the 51 genes were associated with overall survival, and 3 genes were relapse-free survival associated. Finally, we obtained 5 essential prognostic associated genes (FABP7, CXCL3, LOC284578, CAPN6, and NRG2), which could be used as prognostic factors for BRCA.\\nOur findings obtained a gene module associated with BRCA clinical trait and several key genes that acted as essential components in the prognostic of cancer, which may improve its treatment. In this study, we evaluated the antiproliferative and antimetastatic effects of the  Total intravenous anesthesia (TIVA) with propofol may improve acute postoperative pain control compared to inhalational anesthesia. The objective of this review was to comprehensively update and evaluate the existing literature on the analgesic efficacy of propofol TIVA. A systemized literature search for randomized controlled trials in adult patients was conducted in the PubMed and Cochrane CENTRAL (EMBASE source) databases up to August 2019. Clinical trials included compared propofol TIVA against inhalational isoflurane, sevoflurane, or desflurane. Only clinical trials that studied acute postoperative pain scores or analgesic consumption as a primary outcome were included. Sixteen randomized controlled trials were included. Surgical procedures evaluated included: radical gastrectomy, open vein stripping, breast cancer surgery, laparoscopic cholecystectomy, inguinal herniotomy, abdominoplasty, bariatric surgery, lumbar spine surgery, emergency neurosurgical operations, open and laparoscopic gynecological surgeries, and dental surgery. Propofol TIVA was associated with reduced postoperative pain scores and/or decreased opioid consumption in 9 out of 16 clinical trials. There was no difference in 5 clinical trials, and propofol TIVA was associated with worse analgesic outcomes in 2 trials. Propofol TIVA may improve acute postoperative analgesia after surgery, but different factors such as surgical procedures and anesthetic/analgesic techniques may influence its effectiveness. Management of the axilla in the era of neoadjuvant chemotherapy for breast cancer is evolving. The aim of this study is to determine if conventional gadolinium-enhanced breast MRI can aid in evaluation of the response to neoadjuvant chemotherapy in the axilla. A retrospective review of a prospectively maintained database of patients undergoing neoadjuvant chemotherapy for breast cancer was performed. Pre and post-neoadjuvant chemotherapy MRI reports for node-positive patients were examined in conjunction with demographic data, treatment type, and final histopathology reports. One-hundred and fourteen patients with breast cancer undergoing neoadjuvant chemotherapy were included in the study. The sensitivity of magnetic resonance imaging in detecting nodal response post-neoadjuvant chemotherapy was 33.93% and the specificity was 82.76%. Magnetic resonance imaging had a positive predictive value of 65.52% and a negative predictive value of 56.47%. MRI was found to be most specific in the detection of triple-negative cancer response. Specificity was 100% in this group and sensitivity was 75%. Magnetic resonance imaging has a relatively high specificity in detecting nodal response post-neoadjuvant chemotherapy but has a low sensitivity. Alone it cannot be relied upon to identify active axillary malignancy post-neoadjuvant chemotherapy. However, given its increased specificity among certain subgroups, it may have a role in super-selecting patients suitable for sentinel lymph node biopsy post-neoadjuvant chemotherapy. There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project using hospital data to analyse evolution in the therapeutic strategies implemented in patients with human epidermal growth factor receptor 2 (HER2)-overexpressed (HER2+) breast cancer (BC) and exposed to injectable HER2-targeted therapies, i.e. trastuzumab, pertuzumab or trastuzumab emtansine (T-DM1).\\nData from 26,350 women with BC were extracted in September 2018 from the Electronic Pharmacy Record systems of 120 French randomly recruited hospitals. Evolution in the treatments used, and combination regimens were described from 2011, in accordance with the BC stage and treatment line.\\nOverall, 21,119 patients treated since 2011 were analysed: 16,398 patients with early BC (eBC) and 6030 patients with metastatic BC (mBC) including patients treated at both stages. In eBC, 89.2% of patients received trastuzumab combined with at least taxanes (trastuzumab-taxane-anthracycline: 62.6%). Patients with mBC were\\xa0treated in the first line (80.3%) and/or the second line (40.1%) and/or\\xa0≥\\xa0the third line (28.3%). After its approval in 2014, pertuzumab was first used in first-line therapy combinations in 67.4% of the total cases, while trastuzumab-taxane decreased from 47.2% to 9.2%. Similarly, T-DM1 was used as the second-line treatment in 53.8% of cases.\\nGiven recent changes in available treatments for patients with HER2+ BC, this large French project provides robust information on real-world evolution in therapeutic strategies. Our data suggest there is room for significant improvement in optimal drug utilisation. Such data will be useful to build drug-related indicators for future value-based pricing solutions. Lysophosphatidic acids (LPAs) are important bioactive phospholipids consisting of various species involved in a wide array of physiological and pathological processes. However, LPAs were rarely identified in untargeted lipidomics studies because of the incompatibility with analytical methods. Moreover, in targeted studies, the coverages of LPAs remained unsatisfactorily low due to the limitation of reference standards. Herein, a \"modeling-prediction\" workflow for deep profiling of LPAs by liquid chromatography-mass spectrometry was developed. Multiple linear regression models of qualitative and quantitative parameters were established according to features of fatty acyl tails of the commercial standards to predict the corresponding parameters for unknown LPAs. Then 72 multiple reaction monitoring (MRM) transitions were monitored simultaneously and species of LPA 14:0, LPA 16:1, LPA 18:3, LPA 20:3 and LPA 20:5 were firstly characterized and quantified in plasma. Finally, the workflow was applied to explore the changes of LPAs in plasma of breast cancer patients compared with healthy volunteers. Multi-LPAs indexes with strong diagnostic ability for breast cancer were identified successfully using Student\\'s t- test, orthogona partial least-squares discrimination analysis (OPLS-DA) and logistic regression- receiver operating characteristic (ROC) curve analysis. The proposed workflow with high sensitivity, high accuracy, high coverage and reliable identification would be a powerful complement to untargeted lipidomics and shed a light on the analysis of other lipids. Macrophages are sentinels of the immune system, which are often hijacked by tumor cells to assist tumor growth and metastasis. Herein our results showed that low dose salinomycin (SAL) in the range of 10-50 nM could efficiently induce M1 macrophage polarization in a dose- and time- dependent manner in vitro, with 30 nM SAL being optimal to generate M1-type macrophages from RAW246.7 cells. In animal study, intratumorally injected SAL (50 µg/kg) increased proportion of CD86 cells (by 28.9%), and decreased CD206 cells (by 14.2%) in transplant 4T1 tumors, in comparison with PBS group. Thus it resulted in significant regression in tumor growth (20% tumor inhibition) and pulmonary metastasis (reduced the number of metastatic nodes by 58%) in SAL group, whereas lipopolysaccharide (LPS) and paclitaxel (PTX) groups showed comparable number of metastatic lesions and volume of tumor. LPS treatment could as well lead to inflammatory reactions in tumor with SAL group, but resulted in systemic inflammation (elevated levels of IL-1α, IL-1β and TNF-α in serum), and PTX (10 μg/kg) treatment increased both types of macrophages. For the first time, we employed salinomycin below the dose of direct antitumor activity could effectively prime M1 type macrophage stimulation and regress tumor growth and metastasis. The RNA isoform repertoire is regulated by splicing factor (SF) expression, and alterations in SF levels are associated with disease. SFs contain ultraconserved poison exon (PE) sequences that exhibit greater identity across species than nearby coding exons, but their physiological role and molecular regulation is incompletely understood. We show that PEs in serine-arginine-rich (SR) proteins, a family of 14 essential SFs, are differentially spliced during induced pluripotent stem cell (iPSC) differentiation and in tumors versus normal tissues. We uncover an extensive cross-regulatory network of SR proteins controlling their expression via alternative splicing coupled to nonsense-mediated decay. We define sequences that regulate PE inclusion and protein expression of the oncogenic SF TRA2β using an RNA-targeting CRISPR screen. We demonstrate location dependency of RS domain activity on regulation of TRA2β-PE using CRISPR artificial SFs. Finally, we develop splice-switching antisense oligonucleotides to reverse the increased skipping of TRA2β-PE detected in breast tumors, altering breast cancer cell viability, proliferation, and migration. Despite significant advancements in breast cancer (BC) research, clinicians lack robust serological protein markers for accurate diagnostics and tumor stratification. Tumor interstitial fluid (TIF) accumulates aberrantly externalized proteins within the local tumor space, which can potentially gain access to the circulatory system. As such, TIF may represent a valuable starting point for identifying relevant tumor-specific serological biomarkers. The aim of the study was to perform comprehensive proteomic profiling of TIF to identify proteins associated with BC tumor status and subtype. A liquid chromatography tandem mass spectrometry (LC MS/MS) analysis of 35 TIFs of three main subtypes: luminal (19), Her2 (4), and triple-negative (TNBC) (12) resulted in the identification of > 8800 proteins. Unsupervised hierarchical clustering segregated the TIF proteome into two major clusters, luminal and TNBC/Her2 subgroups. High-grade tumors enriched with tumor infiltrating lymphocytes (TILs) were also stratified from low-grade tumors. A consensus analysis approach, including differential abundance analysis, selection operator regression, and random forest returned a minimal set of 24 proteins associated with BC subtypes, receptor status, and TIL scoring. Among them, a panel of ten proteins, AGR3, BCAM, CELSR1, MIEN1, NAT1, PIP4K2B, SEC23B, THTPA, TMEM51, and ULBP2, was found to stratify the tumor subtype-specific TIFs. In particular, up-regulation of BCAM and CELSR1 differentiates luminal subtypes, while up-regulation of MIEN1 differentiates Her2 subtypes. Immunohistochemistry analysis showed a direct correlation between protein abundance in TIFs and intra-tumor expression levels for all ten proteins. Sensitivity and specificity were estimated for this protein panel by using an independent, comprehensive breast tumor proteome dataset. The results of this analysis strongly support our data, with eight of the proteins potentially representing biomarkers for stratification of BC subtypes. Five of the most representative proteomics databases currently available were also used to estimate the potential for these selected proteins to serve as putative serological markers. Screening for breast cancer (BC) and cervical cancer (CC) decreases morbidity and mortality. Most interventions to improve screening rely on automated modalities or nonphysician patient contact. There is limited data on direct patient contact by a physician to encourage BC and CC screening. This non-randomized pilot study sought to evaluate the potential of direct physician contact to improve BC and CC screening rates.\\nA Family Medicine physician telephoned patients on his panel who were due or overdue for BC and CC screening. If the patient did not answer her phone, a voicemail was left; if unable to leave a voicemail, a letter was mailed. The completion rate of recommended screening tests was measured 3 months after contact and compared to a retrospectively identified control population. The change in compliance of the patient panel over 3 months was also calculated.\\nDirect physician conversation by telephone yielded higher completion rates for BC and CC screening versus control patients, but only the CC completion rate increase was statistically significant. Direct conversation BC screening completion rate: 41.2% versus 22.7% (P\\u2009=\\u2009.22, n\\u2009=\\u200948). Direct conversation CC screening completion rate: 45% versus 13.9% (P\\u2009=\\u2009.01, n\\u2009=\\u200944). The intervention patient panel compliance with screening recommendations increased 20.5% for BC and 10.5% for CC.\\nDirect physician contact may be beneficial to increase compliance for more invasive screening tests. The study assessed the epigenetic regulation and the role of microRNA (miR) expression in locally advanced triple negative breast cancers (TNBC) and comparison with the clinico-pathological variables and survival.\\nFifty patients of locally advanced TNBC during the period 2011-2013 were included. Expression level of test microRNA (miR-182 and miR-18a) was determined using Taqman quantitative Real time polymerase chain reaction (qRT-PCR) from formalin fixed paraffin embedded biopsy blocks. Clinical and demographic information and survival data was retrieved from the Hospital medical records.\\nAn improved clinical complete response (cCR) was observed in patients with age ≥ 45 years (80%), premenopausal status (70%), tumor size < 6 cms (80%), nodal status N0-N1 (95%) and grade II-III tumor (80%). A statistically significant correlation was observed on comparison of cCR with menopausal status (p-value 0.020), T category (p-value 0.018) and the clinical nodal status (p-value 0.003). pCR also correlated with clinical nodal status (p-value 0.008). Epigenetically, miR-18a under expression (< 8.84) was most commonly associated with tumor size < 6 cms (76.7%), clinical nodal status N0-N1 (90%), cCR (60%) and pCR (53.3%). A similar trend was observed with miR-182. Statistical significance was observed with T category (p-values 0.003 and 0.004), clinical nodal status (p-values 0.001 and 0.001), clinical response (p-values 0.002 and 0.002) and pathological response (p-values 0.007 and 0.006) with respect to miR-18a and miR-182, respectively. Also, the menopausal status significantly correlated with the miR-182 expression (p-value 0.009). miR-182 overexpression (≥ 6.32) was not observed in any of the postmenopausal patients. A univariate cox proportional hazard regression model also showed statistical interactions (p-values <0.004).\\nmiR-182 and miR-18a overexpression correlates with worse clinical and pathological tumor characteristics in locally advanced TNBC and hence could be used to predict the outcomes and prognosis in these patients. Toxoplasma gondii is an opportunistic protozoan and can be grown using several human cell lines. Breast cancer is the second leading cause of cancer death in women. Her2/Neu-expressing mammary cancer cell lines called TUBO can be grown in vitro. In recent years, protozoan parasites have become popular means of use in cancer therapy research. In this study, we analyzed whether T. gondii tachyzoites can destroy TUBO cells using a novel continuous feed medium approach.\\nTwo sets of flasks (each containing four groups) containing TUBO cells were inoculated with T. gondii Ankara strain tachyzoites. First set containing 5×106 TUBO cells were inoculated with TUBO-tachyzoite ratios of 1:2, 1:1, 2:1, and 4:1 and second set containing 1×106 TUBO cells were inoculated with TUBO-tachyzoite ratios of 10:1, 100:1, 1000:1, and 2000:1. Thereafter, culture supernatants were harvested at various days until TUBO cells were destroyed and tachyzoites were counted.\\nIn the first and second sets of flasks, TUBO cells were destroyed between days 8 to 12 and 12 to 25, respectively. In addition, the amount of tachyzoites increased 7- 43 and 595 to 112500 times in the first and second set of flasks, respectively.\\nThese results show that T. gondii tachyzoites successfully destroy Her2/Neu-expressing mammary cancer cells using a continuous feed medium approach. Although this idea may be too premature for the moment, the approach defined herein may support future researchers investigating the relationship between cancer and parasites which can make important progress toward saving cancer patient lives. Long non-coding RNAs are a kind of endogenous ncRNAs with a length of more than 200\\u2009bp. Accumulating evidence suggests that long non-coding RNAs function as pivotal regulators in tumorigenesis and progression. However, their biological roles in breast cancer remain largely unknown. Here, we found that IGF2 antisense RNA (IGF2-AS) was significantly decreased in breast cancer tissues, cell lines, and plasma. Patients with low IGF2-AS were more likely to develop larger tumor size and later clinical stage. Overexpression of IGF2-AS evidently inhibited the proliferation and induced apoptosis of MCF-7 and T47D cells  Aquaporins (AQPs) are water channels that facilitate transport of water across cellular membranes. AQPs are overexpressed in several cancers. Especially in breast cancer, AQP5 overexpression correlates with spread to lymph nodes and poor prognosis. Previously, we showed that AQP5 expression reduced cell-cell adhesion by reducing levels of adherens and tight junction proteins (e.g., ZO1, plakoglobin and β-catenin) at the actual junctions. Here, we show that when targeted to the plasma membrane, the AQP5 C-terminal tail domain regulated junctional proteins. Moreover, that AQP5 interacted with ZO1, plakoglobin, β-catenin and desmoglein-2, which were all reduced at junctions upon AQP5 overexpression. Thus, our data suggest that AQP5 mediates the effect on cell-cell adhesion via interactions with junctional protein independently of AQP5 mediated water transport. AQP5 overexpression in cancers may thus contribute to carcinogenesis and cancer spread by two independent mechanisms: reduced cell-cell adhesion, a characteristic of epithelial-mesenchymal transition, and increased cell migration capacity via water transport. Cancer stem cells (CSCs) are the fundamental building blocks of cancer dissemination, so it is desirable to develop a technique to predict the behavior of CSCs during tumor initiation and relapse. It will provide a powerful tool for pathological prognosis. Currently, there exists no method of such prediction. Here, we introduce nickel-based functionalized nanoprobe facilitated surface enhanced Raman scattering (SERS) for prediction of cancer dissemination by undertaking CSC-based surveillance. SERS profiling of CSCs of various cell lines (breast cancer, cervical cancer, and lung cancer) was compared with their cancer counterparts for the prediction of prognosis, with statistical significance of single-cell sensitivity. The single-cell sensitivity is critical as even a few CSCs are capable of initiating a tumor. Intermediate states of CSC transmutation to cancer cells and its reverse were monitored, and nanoprobe-assisted SERS profiling was undertaken. We experimentally demonstrated that the  Exosomes, which are phospholipid bilayer nanovesicles, can transfer their content to recipient cells, playing a crucial role in intercellular communication. Exosomes have emerged as promising cancer biomarkers. However, a convenient, efficient, and economical approach for their isolation and comprehensive analysis is still technically challenging. In this study, aptamer-based immunoaffinitive magnetic composites, MagG@PEI@DSP@aptamer, were prepared to achieve the convenient capture, efficient enrichment, and mild release of exosomes. The constructed composites contain three segments: a PEI-modified magnetic graphene scaffold, an aptamer CD63 sequence, and a cleavable cross-linker in between. Notably, the binding capacity of MagG@PEI@DSP for an aptamer is 93 nmol/mg, and per milligram MagG@PEI@DSP@aptamer could capture 450 μg exosomes. Moreover, the released exosomes from MagG@PEI@DSP@aptamer composites were intact and well-dispersed. The prepared composites were then applied to profile the metabolite composition of exosomes secreted by breast cancer cells MCF-7, and the number of detected features was obviously increased when compared to that obtained by the traditional ultracentrifugation method (4528 vs 3710 and 3967 vs 3785 in the positive and negative ionization modes). Besides, the exosomes secreted by MCF-7 and normal breast cells MCF-10A were isolated from cell culture medium with MagG@PEI@DSP@aptamer, and their metabolic profiles were then comprehensively analyzed; in total, 119 metabolites in MCF-7 and MCF-10A were identified. Compared with exosomes from MCF-10A, 43 and 42 metabolites were upregulated and downregulated, respectively, in those from MCF-7. These data showed that the prepared MagG@PEI@DSP@aptamer composites can be used to effectively capture exosomes and further for metabolomics analysis. Hypoxia is a hostile hallmark of most solid tumors, which often leads to multidrug resistance (MDR) and causes the failure of chemotherapy. Hypoxia also promotes epithelial-mesenchymal transition (EMT), leading to acceleration of tumor metastasis. Many chemotherapeutic drugs can further exacerbate hypoxia and thus promote metastasis. Therefore, relieving hypoxia is necessary for chemotherapy to inhibit both MDR and EMT. Herein, highly stable cerasomal perfluorocarbon nanodroplets with an atomic layer of polyorganosiloxane surface and pH-sensitive tumor-targeting peptide (D-vPCs-O Despite the increasing scholarly attention toward self-stigma among Asian breast cancer survivors, research is limited about the underlying psychological mechanisms by which self-stigma may influence quality of life for this population. The present study investigated how self-stigma is associated with quality of life among Chinese American breast cancer survivors by examining the serial mediating effects of concerns about breast cancer, self-efficacy for coping with cancer, and depressive symptoms.\\nChinese American breast cancer survivors (n = 112) completed a questionnaire packet assessing self-stigma related to breast cancer, concerns about breast cancer, self-efficacy for coping with cancer, depressive symptoms, and quality of life. Path analysis was conducted to test the hypothesized serial multiple mediation model.\\nThe hypothesized model was supported: Self-stigma was negatively associated with quality of life through concerns about breast cancer, self-efficacy, and depressive symptoms. After the mediators were controlled for, the direct effect of self-stigma on quality of life was no longer significant.\\nOur findings suggest that concerns about breast cancer, self-efficacy for coping and depressive symptoms are important pathways through which self-stigma may influence quality of life among Chinese American breast cancer survivors. Healthcare practitioners should be aware of survivors\\' self-stigma and make efforts to alleviate survivors\\' excessive cancer concerns, facilitate their self-efficacy, and offer emotional support to improve quality of life for this population. This article is protected by copyright. All rights reserved. We examined whether the National Comprehensive Cancer Network distress thermometer (DT), a patient-reported outcome measure, could be used to identify levels and causes of distress associated with racial/ethnic disparities in time to care among patients with breast cancer.\\nWe identified women aged ≥18 years with stage 0-IV breast cancer who were diagnosed in a single health system between January 2014 and July 2016. The baseline visit was defined as the first postdiagnosis, pretreatment clinical evaluation. Zero-inflated negative binomial (ZINB) regression (modeling non-zero DT scores and DT scores\\xa0=\\xa00) and logistic regression (modeling DT score ≥ 4, threshold for social services referral) were used to examine associations between baseline score (0\\xa0=\\xa0none to 10\\xa0=\\xa0extreme) and types of stressors (emotional, familial, practical, physical, spiritual) after adjustment for race/ethnicity and other characteristics. Linear regression with log transformation was used to identify predictors of time to evaluation and time to treatment.\\nA total of 1029 women were included (median baseline DT score\\xa0=\\xa04). Emotional, physical, and practical stressors were associated with distress in both the ZINB and logistic models (all P < .05). Black patients (n\\xa0=\\xa0258) were more likely to report no distress than Whites (n\\xa0=\\xa0675; ZINB zero model odds ratio, 2.72; 95% CI, 1.68-4.40; P < .001) despite reporting a similar number of stressors (P\\xa0=\\xa0.07). Higher DT scores were associated with shorter time to evaluation and time to treatment while being Black and having physical or practical stressors were associated with delays in both (all P < .05).\\nPatient-reported stressors predicted delays in time to care, but patient-reported levels of distress did not, with Black patients having delayed time to care despite reporting low levels of distress. We describe anticipatory, culturally responsive strategies for using patient-reported outcomes to address observed disparities. New targeted therapies have been developed to overcome resistance to endocrine therapy (ET) and improve the outcome of HR To examine patterns of de-novo metastases (mets) and association with breast cancer-specific mortality across subtypes and racial groups.\\nNon-Hispanic (NH) Black and NH-White patients ages 40\\xa0years and older with primary breast cancer (BC) between 2010 and 2015 were examined. Multilevel logistic regression and Cox proportional hazards models were used to assess (1) odds of de-novo mets to specific sites by subtype, and (2) association of subtype with risk of BC mortality among patients with de-novo mets by race.\\nA total of 204,941 BC patients were included in analysis. The most common de-novo mets site was to the bone, and overall prevalence of de-novo mets was higher among NH-Black (6.4%) versus NH-White (4.1%) patients. The odds of de-novo mets to any site were lower for TNBC (OR 0.68, 95% CI 0.62-0.73) and HR+/HER2-\\u2009(OR 0.50, 95% CI 0.47-0.53) subtypes, but higher for HR-/HER2+\\u2009(OR 1.16, 95% CI 1.06-1.28) relative to HR+/HER2+\\u2009. De-novo mets to the brain only was associated with the highest mortality risk across all subtypes, ranging from a 13-fold increase (hazard ratio 13.45, 95% CI 5.03-35.96) for HR-/HER2+\\u2009to a 39-fold increase (hazard ratio 39.04, 95% CI 26.2-58.14) for HR+/HER2-.\\nSite and fatality of de-novo mets vary by subtype and by race. This information may help improve risk stratification and post-diagnostic surveillance to ultimately reduce BC mortality. Dermatomyositis is associated with malignant tumors including breast cancer, and inflammatory breast cancer is considered to have a poorer prognosis than most breast cancers.\\nA 74-year-old Asian woman, developed erythema on her face, back, and the back of her hands, 3\\xa0weeks before attending our department. At the same time, she had noticed a right breast mass and redness of the skin of the breast. The clinical findings and vacuum aspiration biopsy diagnosed inflammatory breast cancer and neoadjuvant chemotherapy was performed. The mass and enlarged axillary lymph nodes had shrunk, therefore a total mastectomy was performed. The sentinel lymph node biopsy was negative. She was discharged 7\\xa0days after surgery without any complications. She has received a postoperative aromatase inhibitor and is alive without recurrence. The dermatomyositis also began to improve with the start of her chemotherapy and has not recurred since the surgery.\\nNeoadjuvant chemotherapy was performed for inflammatory breast cancer with dermatomyositis, and tumor shrinkage was confirmed. A total mastectomy without axillary lymph node dissection was performed. Dermatomyositis and breast cancer have not recurred. Dermatomyositis may have been a paraneoplastic syndrome due to breast cancer. Approximately 1 in 5 patients with breast cancer who undergo axillary lymph node dissection will develop lymphedema. To appropriately triage and monitor these patients for timely diagnosis and treatment, robust risk models are required.\\nTo evaluate the prognostic value of mammographic breast density in estimating lymphedema severity.\\nThis prognostic study collected data from July 16, 2018, to March 3, 2020, from the electronic health records of patients of the Cancer Rehabilitation and Survivorship Program at the Princess Margaret Cancer Centre in Toronto, Ontario, Canada. Participants included women who had completed curative treatment for a first diagnosis of breast cancer and who were referred to the program. Also included were a sample of patients in the general breast oncology population who were receiving follow-up care at the center during the same period but who were not referred to the program. All patients attended follow-up appointments at the Princess Margaret Cancer Centre from January 1, 2016, to May 1, 2018. The cohort was randomly split 2:1 to group patients into a training cohort and a validation cohort.\\nParticipant demographic and clinical characteristics included age, sex, body mass index (BMI), medical history, cancer characteristics, and cancer treatment.\\nSpearman correlation coefficient between measured and predicted volume of lymphedema was calculated. Area under the curve (AUC) values were generated for predicting the occurrence of at least mild lymphedema (volume, >200 mL) and severe lymphedema (volume, >500 mL) at the time of initial lymphedema diagnosis.\\nA total of 373 female patients (median [interquartile range] age, 52.3 [45.9-60.1] years) were eligible for this analysis. Multivariate linear regression identified 3 patient factors (age, BMI, and mammographic breast density), 1 cancer factor (number of pathological lymph nodes), and 1 treatment factor (axillary lymph node dissection) as independent prognostic variables. In validation testing, Spearman correlation revealed a statistically significant moderate correlation (coefficient, 0.42; 95% CI, 0.26-0.56; P\\u2009<\\u2009.001) between measured volume and predicted volume of lymphedema. The AUC values were 0.72 (95% CI, 0.60-0.83) for predicting the occurrence of mild lymphedema and 0.83 (95% CI, 0.74-0.93) for severe lymphedema.\\nThis prognostic study found that patients with low breast density appeared to be at a higher risk of developing severe lymphedema. The finding suggests that by combining breast density with established risk factors a multivariate linear regression model could be used to predict the development of lymphedema and provide volumetric estimates of lymphedema severity in patients with breast cancer. None To report the impact of the COVID-19 pandemic on patient attendance at a radiotherapy department two months after the implementation of specific policies regarding the pandemic.\\nThe proposed treatment schemes, favoring hypofractionated schedules, and COVID-19 management strategies regarding irradiation are presented. Attendance after two months of implementation of these policies was measured and compared with that during the same period in 2019.\\nA 10% reduction in the number of treated patients and a 26% reduction in the number of sessions was observed. The main impact was a decrease in the treatment of benign diseases and gastrointestinal tumors, with a general increase in breast cancer treatments. Eighteen (1.7%) patients were confirmed as having COVID-19 during radiotherapy in April and May 2020, three of whom were hospitalized, and one patient died because of COVID-19. Among the 18 patients, 12 had their treatments interrupted for at least 15 days from symptom appearance.\\nThere was a decrease in the number of treated patients in our radiotherapy department, with a greater decrease in the total number of sessions. This indicated, overall, a smaller number of fractions/patients treated, despite our efforts to maintain the treatment routine. We had several patients who were infected with COVID-19 and one related death during treatment in the first few months of the pandemic in São Paulo Brazil. Breast and cervical cancer represent a major problem of women\\'s global public health. Here, we investigated the chemical composition of essential oils from leaves and flowers of T. ostenii and the antineoplastic potential in a cervical cancer and breast cancer cell line, SiHa and MCF-7; and non-tumoral cells, HaCat. The chemical analysis revealed a predominance of oxygenated monoterpenes in both essential oils. The IC50 after 24 h of treatment was 72 ng/mL for EO 1 and 83 ng/mL for EO 2 in SiHa cells. For MCF-7 the IC50 was 174.3 ng/mL for EO 1. For HaCat cells it was 54.45 ng/mL for EO 1 and 20.83 ng/mL for EO 2. A synergistic effect with both essential oils and cisplatin was also verified. SiHa cells had their wound healing capacity reduced after 48 h of treatment with EO 2 and both essential oils were able to significantly inhibit the adhesion process and clonogenic ability after 24 h of treatment. Our results suggest a long-lasting inhibitory activity in SiHa cells because of the low recovery capacity of cells after treatment withdrawal. Flow cytometer with annexin V/propidium iodide demonstrated a majority cell death through late apoptosis after 24, 48 and 72 hours of treatment. None Interest in the use of wearables in medical care is increasing. Wearables can be used to monitor different variables, such as vital signs and physical activity. A crucial point for using wearables in oncology is if patients already under the burden of severe disease and oncological treatment can accept and adhere to the device. At present, there are no specific recommendations for the use of wearables in oncology, and little research has examined the purpose of using wearables in oncology.\\nThe purpose of this review is to explore the use of wearables in clinical trials during cancer treatment, with a special focus on adherence.\\nPubMed and EMBASE databases were searched prior and up to October 3, 2019, with no limitation in the date of publication. The search strategy was aimed at studies using wearables for monitoring adult patients with cancer during active antineoplastic treatment. Studies were screened independently by 2 reviewers by title and abstract, selected for inclusion and exclusion, and the full-text was assessed for eligibility. Data on study design, type of wearable used, primary outcome, adherence, and device outcome were extracted. Results were presented descriptively.\\nOur systematic search identified 1269 studies, of which 25 studies met our inclusion criteria. The types of cancer represented in the studies were breast (7/25), gastrointestinal (4/25), lung (4/25), and gynecologic (1/25); 9 studies had multiple types of cancer. Oncologic treatment was primarily chemotherapy (17/25). The study-type distribution was pilot/feasibility study (12/25), observational study (10/25), and randomized controlled trial (3/25). The median sample size was 40 patients (range 7-180). All studies used a wearable with an accelerometer. Adherence varied across studies, from 60%-100% for patients wearing the wearable/evaluable sensor data and 45%-94% for evaluable days, but was differently measured and reported. Of the 25 studies, the most frequent duration for planned monitoring with a wearable was 8-30 days (13/25). Topics for wearable outcomes were physical activity (19/25), circadian rhythm (8/25), sleep (6/25), and skin temperature (1/25). Patient-reported outcomes (PRO) were used in 17 studies; of the 17 PRO studies, only 9 studies reported correlations between the wearable outcome and the PRO.\\nWe found that definitions of outcome measures and adherence varied across studies, and limited consensus among studies existed on which variables to monitor during treatment. Less heterogeneity, better consensus in terms of the use of wearables, and established standards for the definitions of wearable outcomes and adherence would improve comparisons of outcomes from studies using wearables. Adherence, and the definition of such, seems crucial to conclude on data from wearable studies in oncology. Additionally, research using advanced wearable devices and active use of the data are encouraged to further explore the potential of wearables in oncology during treatment. Particularly, randomized clinical studies are warranted to create consensus on when and how to implement in oncological practice. Antiangiogenic therapy with bevacizumab while being interesting for metastatic triple-negative breast cancer (mTNBC) is restrained by tumor hypoxia elevation and cancer stem cell enrichment. Here, we find that neuropilin-1 (NRP-1)-targeted delivery of nucleus accumbens-associated protein-1 (NAC-1) siRNA mediated by tLyP-1 peptide-functionalized chimaeric polymersomes (tLyP-1-Ps) effectively sensitizes antiangiogenic therapy of mTNBC  The botanical natural product goldenseal can precipitate clinical drug interactions by inhibiting cytochrome P450 (CYP) 3A and CYP2D6. Besides P-glycoprotein, effects of goldenseal on other clinically relevant transporters remain unknown. Established transporter-expressing cell systems were used to determine the inhibitory effects of a goldenseal extract, standardized to the major alkaloid berberine, on transporter activity. Using recommended basic models, the extract was predicted to inhibit the efflux transporter breast cancer resistance protein (BCRP) and uptake transporters organic anion transporting polypeptide (OATP) 1B1/3. Using a cocktail approach, effects of the goldenseal product on BCRP, OATP1B1/3, organic anion transporters (OATs), organic cation transporters (OCTs), multidrug and toxin extrusion (MATE) proteins, and CYP3A were next evaluated in 16 healthy volunteers. As expected, goldenseal increased the area under the plasma concentration-time curve (AUC Tripartite motif‑containing (TRIM)\\xa014 is a protein of the TRIM family. Studies have indicated that TRIM14 may be used as an oncogene in tumor cells, such as osteosarcoma, non‑small cell lung cancer and breast cancer through different pathways. However, the functions of TRIM14 in cervical cancer cells remain unclear. Therefore, this study aimed to investigate the functions of TRIM14 in cervical cancer cells and its underlying mechanism. Caski cells stably expressing TRIM14 and SiHa, and HeLa cells stably expressing TRIM14 short hairpin RNA were constructed by lentivirus‑mediated overexpression or knockdown systems. The effects of TRIM14 on proliferation and apoptosis of cervical cancer cells were detected by Cell Counting Kit‑8\\xa0(CCK‑8) assay and flow cytometry, respectively. In addition, reverse transcription‑quantitative\\xa0(RT‑q) PCR and western blotting were used to investigate the expression levels of TRIM14 and of signaling pathway marker protein including P21, caspase‑3, cleaved caspase‑3, Akt and phosphorylated Akt. The results of RT‑qPCR and western blotting revealed that TRIM14 was highly expressed in human cervical cancer tissues and cell lines compared with adjacent normal tissues and normal cervical epithelial cells. TRIM14 also regulated cell proliferation and apoptosis of human SiHa, HeLa and Caski cervical cancer cell lines through the Akt signaling pathway. Additionally, TRIM14 protein levels were related to the clinical and pathological features of cervical cancer. CCK‑8 assay and flow cytometry demonstrated that TRIM14 expression could promote cervical cancer cell proliferation and autophagy suppression. Taken together, TRIM14‑induced cell proliferation and apoptosis inhibition may by evoked by the activation of the Akt pathway. This study demonstrated the role of TRIM14 in cervical cancer, and reveals its mechanism of action as a potential therapeutic target for cervical cancer. To examine the accuracy and efficiency of breast radiotherapy after breast-conserving surgery of a novel 3-dimensional (3D) printing tissue compensator technology, the 3D-precise breast conformer, compared with a usual compensator and an unstructured compensator.\\nThis novel device is patented in China (patent No.: ZL2015 2 0259472.9). Thirty patients with breast cancer after breast-conserving surgery were randomly divided into 2 control groups (no compensator, NST group, and usual compensator, ST group) and 1 study group (3D-precise breast conformer, 3D-BCT group) (n = 10/group). Before radiotherapy, all patients were scanned in the same CT positioning conditions to prepare the treatment plans.\\nThe 3D-BCT showed the best homogeneity index (HI) (0.08 ± 0.03) and conformity index (CI) (0.95 ± 0.03), while the NST group showed the worst HI (0.34 ± 0.07) and CI (0.78 ± 0.06), with the ST group between the 2 (HI: 0.15 ± 0.05; CI: 0.87 ± 0.04) (all P < 0.01). The common tissue compensation membrane could lead to 95-100% of the prescription dose covering 85-95% of the target volume, and the uniformity and conformability of the target dose were improved overall compared with the NST group. In the 3D-BCT group, 100% of the prescription dose covered the target volume of 95-100%.\\nThe 3D-precision breast conformal device had the highest individualization, uniformity, and conformity. The V 1 H NMR spectroscopic studies on the 1:1 adduct of the pentasaccharide Fondaparinux (FPX) and the substitution-inert polynuclear platinum complex TriplatinNC show significant modulation of geometry around the glycosidic linkages of the FPX constituent monosaccharides. FPX is a valid model for the highly sulfated cell signalling molecule heparan sulfate (HS). The conformational ratio of the 1 C 4 : 2 S 0 forms of the FPX residue IdoA(2S) is altered from ≈ 35:65 (free FPX) to ≈ 75:25 in the adduct; the first demonstration of a small molecule affecting conformational changes on a HS oligosaccharide. Functional consequences of such binding are suggested to be inhibition of HS cleavage in MDA-MB-231 triple-negative breast cancer (TNBC) cells. We further describe inhibition of metastasis by TriplatinNC in the TNBC 4T1 syngeneic tumour model. Our work provides insight into a novel approach for design of platinum drugs (and coordination compounds in general) with intrinsic anti-metastatic potential. Identification of inherited breast cancer may guide care. These benefits can be amplified through communication of genetic test results with at-risk family members and subsequent family testing (FT). Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about family communication (FC) of genetic test results and FT. Comparisons were made across genes. The 235 participants with P/LP variants (186 BRCA1/2, 28 PALB2, 15 CHEK2, and 6 ATM) had a median age of 54 and most were non-Hispanic whites (89%) with a prior breast cancer diagnosis (61%). When controlling for other variables, FC was higher among younger participants (p<.0001), those with high FC self-efficacy (p=.019), and those with P/LP variants in BRCA1/2 compared to PALB2 (p =.040) and ATM/CHEK2 (p =.032). Higher rates of FC and FT were also observed among female relatives and relatives of closer kinship. Overall 94% of participants would find one or more resources helpful with FC and 70% reported using FC resources when telling family members about their genetic test result. The three most commonly used resources included the following: (a) a family sharing letter (38%); (b) printed materials (30%); and (c) web-based information (23%). Among the 86% who spoke with a genetic counselor (GC), 93% were given at least one FC resource and the three most common resources GCs provided to participants overlapped with the resources participants would find helpful and those that were used. Our results suggest lower FC and FT rates among women with P/LP variants in genes other than BRCA1/2, the reasons for which should be evaluated in future studies. As more data to refine cancer risks and management are generated across these other inherited breast cancer genes, strategies to improve FC and FT are needed to amplify the benefits of genetic testing. Many women with early-onset breast cancer experience adverse psychological sequelae which impact on their quality of life. We sought to correlate levels of anxiety and cancer-related distress in women with breast cancer shortly after surgery and one year after treatment with the estimated risk of death.\\nWe studied 596 women with Stage I to III breast cancer. For each woman we estimated the five-year risk of death based on SEER data from 2010 to 2019. For each woman we measured anxiety and cancer-related distress levels shortly after surgery and one year later.\\nThe mean estimated five-year survival was 95%. At one week post-surgery, 59% of women had a clinically significant level of anxiety and 74% had a clinically significant level of cancer-related distress. There was no correlation between the objective risk of death and the level of anxiety or distress, at one week or at one year.\\nMany women diagnosed with early-stage breast cancers experience significant levels of anxiety and distress. The emotional response to a breast cancer diagnosis is not related to the risk of death per se and other factors should be explored. None Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases. TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and therefore do not respond to hormonal or anti‑HER2 therapies. TNBC is a particularly aggressive form of breast cancer that generally displays poorer prognosis compared to other breast cancer subtypes. TNBC is chemotherapy sensitive, and this treatment remains the standard of care despite its limited benefit. Recent advances with novel agents have been made for specific subgroups with PD‑L1+ tumors or germline Brca‑mutated tumors. However, only a fraction of these patients responds to immune checkpoint or PARP inhibitors and even those who do respond often develop resistance and relapse. Various new agents and combination strategies have been explored to further understand molecular and immunological aspects of TNBC. In this review, we discuss clinical trials in the management of TNBC as well as perspectives for potential future treatments. Treatment of human estrogen receptor (ER)‑positive breast cancer (ER+ BC) using conventional chemotherapy remains a challenge and is often ineffective as a result of tumor metastasis. The present study aimed to investigate the ability of narasin, an ionophore antibiotic, to potentially inhibit tumor metastasis and growth in human ER+ BC. Narasin was found to have significant inhibitory abilities on cell proliferation, migration and invasion in ER+ BC cell lines MCF‑7 and T47D compared with the triple‑negative BC cell MDA‑MB‑231. For the in\\xa0vivo studies, narasin effectively decreased the number of tumor metastasis nodules, tumor volume and weight without apparent toxicity in human MCF‑7 nude mouse left ventricle injection tumor metastasis and xenograft models. Mechanistically, it demonstrated that exposure to TGF‑β or IL‑6 induced the expression of epithelial‑mesenchymal transition (EMT) markers in ER+ BC cell lines. On the contrary, narasin dose‑dependently reversed EMT by increasing the expression of E‑cadherin and decreasing the expression of N‑cadherin, vimentin, β‑catenin and zinc finger E‑box‑binding homeobox\\xa01 at the protein and gene expression levels. Gene microarray, molecular docking and western blotting were performed to demonstrate that those protein and gene expression levels are regulated by the inactivation of the TGF‑β/phosphorylated (p)‑SMAD3 and IL‑6/p‑STAT3 signaling pathways. Taken together, these findings indicated that narasin may be a promising candidate that can be further optimized for the treatment of human ER+ BC. Breast cancer (BC) is the most frequently diagnosed type of cancer, and the leading cause of cancer‑associated mortality in females worldwide. The aim of the present study was to investigate the prognostic and therapeutic potential of NUF2 in BC. The expression levels of NUF2 in BC tissues and cell lines were evaluated via bioinformatics, reverse transcription‑quantitative PCR, western blot analysis and immunohistochemistry (IHC). In addition, the effect of NUF2 knockdown on BC cell proliferation and apoptosis was investigated using small interfering RNA (siRNA) technology. Bioinformatics and IHC analysis showed that NUF2 was overexpressed in BC tissues. Furthermore, western blot and RT‑qPCR analyses demonstrated that NUF2 was upregulated in BC cells. In addition, BC cells transfected with NUF2 siRNA exhibited significantly decreased proliferation and colony formation, and increased apoptosis, compared with the control. Additionally, cell cycle analysis revealed that NUF2 induced G0/G1 cell cycle arrest by inhibiting cyclin B1 expression. Collectively, the present study suggested that NUF2 may represent a promising prognostic biomarker and a potential therapeutic target for BC. Breast cancer displays high morbidity and mortality. Despite exerting certain effects, traditional treatments cannot eliminate every cancer cell and may kill normal cells due to inaccurate targeting. However, as a traditional Chinese medicine, capsaicin, an active compound extracted from chili peppers, has displayed potent anticarcinogenic activities in\\xa0vitro and in\\xa0vivo, but the underlying mechanism is not completely understood. The pharmacological effects of capsaicin on tumors was evaluated in MDA MB 231 breast cancer cells. The MTT, cell scratch assay, cell cycle analysis, cell transfection, reverse transcription‑quantitative PCR and western blotting were performed to investigate the potential antitumor mechanisms of capsaicin. In the present study, the potential anticancer mechanism underlying capsaicin in MDA‑MB‑231 cells in\\xa0vitro was investigated. Capsaicin significantly inhibited MDA‑MB‑231 breast cancer cell viability and migration compared with the control group. The flow cytometry results indicated that capsaicin induced G2/M cell cycle arrest in MDA‑MB‑231 cells. In addition, capsaicin significantly reduced the expression of cyclin‑dependent kinase 8 (CDK8) in breast cancer cells compared with the control group. Moreover, LV‑CDK8 small interfering RNA‑transduced MDA‑MB‑231 cells displayed lower CDK8 mRNA and protein expression levels compared with LV‑negative control‑shRNA‑transduced cells. Furthermore, capsaicin significantly reduced the expression levels of phosphorylated (p)‑PI3K, p‑Akt, Wnt and β‑catenin in\\xa0vitro compared with the control group. Collectively, the results of the present study suggested that capsaicin inhibited breast cancer cell viability, induced G2/M cell cycle arrest, reduced CDK8 expression levels, decreased the phosphorylation of PI3K and Akt and downregulated Wnt and β‑catenin expression levels in MDA‑MB‑231 cells. Paclitaxel is a potent antineoplastic agent, but poor solubility and resistance have limited its use. Gold nanoparticles (AuNPs) are widely studied as drug carriers because they can be engineered to prevent drug insolubility, carry nucleic acid payloads for gene therapy, target specific tumor cell lines, modulate drug release and amplify photothermal therapy. Consequently, the conjugation of paclitaxel with AuNPs to improve antiproliferative and pro‑apoptotic potency may enable improved clinical outcomes. There are currently a number of different AuNPs under development, including simple drug or nucleic acid carriers and targeted AuNPs that are designed to deliver therapeutic payloads to specific cells. The current study reviewed previous research on AuNPs and the development of AuNP‑based paclitaxel delivery. Accumulating evidence suggests that inflammation is linked to multiple pathological processes and induces cellular and molecular damage through the activation of inflammatory signaling pathways, including the NF‑κB pathway. The aim of the present study was to identify natural anti‑inflammatory products that can target NF‑κB activity, in order to establish a novel therapeutic approach for inflammatory diseases. Using a 4T1 breast cancer cell line that expresses the firefly luciferase gene under the control of an NF‑κB response element, 112 natural products were tested for their anti‑inflammatory properties. Sohakuhi (Morus alba Linn. bark) extract was observed to strongly suppress NF‑κB activity without affecting cell viability. To further examine the anti‑inflammatory effect of Sohakuhi, tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL)‑induced cellular damage of human HaCaT keratinocytes was evaluated. While TRAIL triggered the phosphorylation of the p65 subunit of NF‑κB, leading to cellular damage in HaCaT cells, treatment with Sohakuhi extract protected HaCaT cells against TRAIL‑induced cellular damage. Moreover, Sohakuhi treatment also upregulated the anti‑apoptotic proteins Bcl‑xL and Bcl‑2. Importantly, through chemical fractionation of Sohakuhi extract, moracin O and\\xa0P were confirmed to mediate its anti‑inflammatory effects. Collectively, the present results indicated that Sohakuhi and moracin may represent potential candidates for the development of novel anti‑inflammatory drugs. Anti-Müllerian hormone (AMH) is expressed by antral stage ovarian follicles in women. Consequently, circulating AMH levels are detectable until menopause. Variation in age-specific AMH levels has been associated with breast cancer and polycystic ovary syndrome (PCOS), amongst other diseases. Identification of genetic variants underlying variation in AMH levels could provide clues about the physiological mechanisms that explain these AMH-disease associations. To date, only one variant in  Tamoxifen remains the most effective treatment for estrogen receptor α (ERα)-positive breast cancer. However, many patients still develop resistance to tamoxifen in association with metastatic recurrence, which presents a tremendous clinical challenge. To better understand tamoxifen resistance from the perspective of the tumor microenvironment, the whole microenvironment landscape is charted by single-cell RNA sequencing and a new cancer-associated fibroblast (CAF) subset, CD63 There is little consensus about the relative determinative value of each individual factor in female breast aesthetics. When performing breast surgery with an aesthetic goal, certain factors will be more important than others. The purpose of this study was to make an aesthetic factor rank list to determine the relative contributions to overall breast aesthetics.\\nVolunteers were scanned using the 3-dimensional Vectra system. Ten Scandinavian plastic surgeons rated 37 subjects, using a validated scoring system with 49 scoring items. The correlation between specific aesthetic factors and overall breast aesthetic scores of the subjects were calculated using Pearson\\'s r, Spearman\\'s ρ, and Kendall\\'s τ.\\nA very strong correlation was found between overall breast aesthetic score and lower pole shape (0.876, \\nAesthetic factors of the female breast can be ranked in a priority list. Shape of the lower pole and upper pole and breast height are primary factors of female breast aesthetics. These should be prioritized in any aesthetic breast surgery. Vertical dimensional factors seem to be more determinative than horizontal factors. A deep inferior epigastric perforator (DIEP) flap is one of the gold standards for autologous breast reconstructions. However, this flap cannot be chosen again if asynchronous contralateral breast cancer occurs in the future. To solve this problem, we propose an idea and design for a hemi-abdominal DIEP flap. The patient was a 50-year-old woman who was suffering from right invasive ductal carcinoma. In using a hemi-abdominal DIEP flap, the poor postoperative appearance of the donor site might be a problem. To obtain a good donor site shape, we use a specific design to make the appearance of the donor site as good as possible. Specifically, we make an oblique spindle-shaped flap that can cover the deep inferior epigastric perforators, the superficial circumflex iliac artery, and the superficial inferior epigastric artery and avoid dog-ears, without passing over the median line. The flap weight was 800\\u2009g, the operating time was 6 hours and 22 minutes, and the bleeding amount was 110\\u2009ml. The patient had a minor wound infection in the donor site, and it was treated with a local wound treatment. The patient is satisfied with the result. We believe our flap design could minimize the unfavorable appearance of the donor site. This method might be suited to cases where the patients present with excess skin and fat on the abdomen, and half the abdominal tissue is enough to create the necessary volume of the breast. Although more cases and studies will be required to justify our technique, this case may show the possibility of a new option for breast reconstructions. The profunda artery perforator (PAP) flap has become an alternative option for breast reconstruction. Reliable perforators arise through the adductor magnus muscle, and dissection of the perforator is straightforward. Recently, we have found that the PAP flap with the sensory nerves can be harvested as an innervated flap. We discuss the feasibility of PAP flap neurotization. We reviewed 13 patients for whom innervated PAP flap harvesting was considered. The average age was 50.7 years. There are 3 different patterns of innervated PAP flap harvesting, Type 1: including a sensory nerve that can be found in the adipose tissue around the PAP flap, Type 2: including a sensory nerve that runs along the medial femoral circumflex system, and Type 3: including a sensory nerve that runs along the profunda artery perforators. The average flap harvest time was 2:11 ± 0:31, and a sensory nerve was identified in 10 of 13 cases (77%). No sensory nerves were found in the other 3 cases. The length of the included sensory nerve was 5.5 ± 1.6\\u2009mm on average. Types 1 and 2 were found in 3 patients (30%), Type 3 was found in 2 patients (20%), and combined Types 1 and 3, 2 and 3 were found in one patient each (10%). As sensory nerves run around the PAP flap or close to the perforators, it is easy to perform flap neurotization with the PAP flap. We believe that the PAP flap could be an alternative option to achieve sensate breast reconstruction. Autologous breast reconstruction with deep inferior epigastric perforator flaps is considered a standard of care in the treatment after mastectomy, yet vascular anatomy is highly variable and perforator selection remains challenging. The use of preoperative imaging can influence surgical planning and assist intraoperative decision-making. However, this imaging can inevitably uncover incidental findings. The purpose of this study was to analyze incidental findings, evaluate correlation with patient factors, and examine effects on overall care.\\nA retrospective review was performed on 350 consecutive patients who received magnetic resonance angiography (MRA) or computed tomographic angiography (CTA) as a preoperative evaluation for deep inferior epigastric perforator flap breast reconstructions done between August 2015 and June 2019. Radiology reports were analyzed for incidental findings. Patient charts were reviewed for patient history, genetic history, cancer treatment, and type of reconstruction.\\nOf the 350 patients meeting the criteria, 56.9% were noted to have incidental findings on preoperative imaging, 12.9% received additional imaging, and 4.0% underwent additional interventions. There was no difference in the percentage of patients with incidental findings between immediate and delayed reconstructions or between CTA and MRA. Five patients were found to have malignancies.\\nPreoperative CTA and MRA is a valuable tool to optimize outcomes and efficiency in breast reconstruction with abdominal perforator flaps. However, this imaging can also be beneficial to the overall wellness of the patient. With the high prevalence of incidental findings on preoperative imaging, it is important to counsel patients and adjust surgical plans, if necessary. Breast conserving surgery followed by radiation therapy represents the standard of care for early stage breast cancer. Oncoplastic breast surgery includes several reconstructive techniques essentially summarized in 2 categories: volume displacement and volume replacement procedures. These latest procedures have evolved over time from the use of the entire latissimus dorsi muscle to the use of pedicled perforator flaps, namely the thoracodorsal artery perforator (TDAP) flap. The aim of this article is to provide a comprehensive review of the literature regarding the use of the TDAP flap in partial breast defects.\\nA literature search was performed via PubMed, Medline, and Cochrane. Studies reporting the use of the TDAP flap after breast conserving surgery were included. Patient characteristics, topography and size of breast defect, flap size and design, number of perforators, and operative time were analyzed. Moreover, aesthetic and functional (shoulder morbidity) results, patient satisfaction, postoperative complications, and donor site morbidity were registered.\\nTwelve articles fulfilled inclusion criteria, and 337 patients were included. All articles except 1 described the use of the TDAP flap for defects in every breast quadrant. The mean weight of resected breast tissue was 97.28\\u2009g, and patients with over 20% of volume deficiency were considered eligible for TDAP flap volume replacement. The ellipse-shaped skin paddle (oriented oblique downward, transversal or oblique upward in most cases) was extended over the anterior border of the latissimus dorsi muscle to include possible septocutaneous perforator vessels. Most authors began the dissection from the anterior and caudal border of the flap to reserve the possibility to convert the TDAP to a musculocutaneous flap and check for septocutaneous perforators. Flap size ranged from 4 × 12 to 21 × 9\\u2009cm. The mean procedure time was 192.21 minutes. Mean follow-up was 17.42 months. Evaluation by way of a 5-point Likert scale reported overall mean values of over 4 points. Satisfactory outcomes were reported in 92.85%-100% of cases. Patient satisfaction ranged from 80% to 94% of cases. The incidence of seroma (1 case) and \"shoulder-related\" donor site morbidity was very low.\\nDespite the heterogeneity of the evaluation methods, our review suggested that the use of the TDAP flap in oncoplastic surgery allows for satisfactory aesthetic outcomes and quite high levels of patient satisfaction. The TDAP flap represents an effective and versatile tool that amplifies the oncoplastic surgeon\\'s arsenal, which allows for satisfactory outcomes. Stiff person syndrome (SPS) is a rare neurologic disorder, characterized by muscle rigidity and spasms. Anti-glutamic acid decarboxylase (anti-GAD) antibodies are associated with the classic form of SPS, while antibodies against amphiphysin are associated with the paraneoplastic form of the disease. We present the case of a patient with paraneoplastic SPS, presenting with muscle cramps of lower extremities that progressed to severe muscle rigidity and spasms, associated with a right breast tumor and positive anti-amphiphysin antibodies. Paraneoplastic SPS is a rare neurological disorder, challenging for the physicians both to diagnose and treat. In the absence of clear interstitial invasion, encapsulated papillary carcinoma (EPC) of the breast may be attributed to an extremely good prognosis if handled similarly to ductal carcinoma in situ (DCIS) with suitable local treatment. Here, we report our experience with a case of EPC of the breast that presented with carcinomatous pleuritis and lymphangitis carcinomatosa postoperatively, which rapidly resulted in a poor outcome. A 67-year-old woman was diagnosed with DCIS of the left breast and underwent left partial mastectomy and sentinel lymph node biopsy. EPC was diagnosed because the pathological examination showed no sign of interstitial infiltration. Postoperative radiation therapy was performed. Five years and 9 months postoperatively, the patient began experiencing cough and shortness of breath on exertion. Imaging showed right pleural effusion and consolidation of the lung field, but nothing suggesting local recurrence in the preserved left breast, local lymph nodes, or opposite breast was observed. Postoperative recurrence of breast cancer, carcinomatous pleuritis, and lymphangitis carcinomatosa were diagnosed based on the results of pleural fluid cytology. One month later, multiple brain metastases were found, and the patient died of the primary disease 5 months after recurrence. After surgery for EPC without clear interstitial infiltration, there was a small possibility of a poor outcome from distant metastasis. Therefore, although distant metastasis is uncommon, regular examination and testing should be performed. Carcinoma of unknown primary (CUP) syndrome occurs when metastases from an unknown primary site spread to multiple organs. Occult breast cancer (OBC) is defined as a clinically recognizable metastatic carcinoma from an undetectable primary breast tumor. It accounts for 0.3-1% of all breast cancers, often presenting with lymph node, bone, and skin metastases. Clinical and radiological examinations represent the first steps in the diagnostic algorithm for CUP syndrome from OBC. However, histological and immunohistochemical analyses, multidisciplinary team evaluation, and a multidisciplinary therapy are essential in the diagnosis and treatment of CUP syndrome from OBC. We report the case of a 52-year-old woman who underwent the removal of a parietal skin lesion. The histological and immunohistochemical analyses suggested a breast cancer origin. Clinical assessment and laboratory and radiological examinations did not locate the primary tumor. Hormone therapy was offered to the patient; however, she refused it. After 28 months, the patient reported a right cervical lump, and a total-body positron emission tomography showed dissemination of the disease to the lymph nodes and bone. A CUP syndrome from OBC was diagnosed. A multimodality approach with radiotherapy and hormone and biological therapy was started. At present, 5 years from the first presentation, the patient is asymptomatic despite the disseminated disease. A 68-year-old woman with a breast mass was referred to our hospital. Imaging studies showed an oval well-defined mass, 1.3 cm in size, in her left lower outer quadrant of the breast. Core needle biopsy with immunohistochemical staining showed atypical spindle cells forming solid nests with necrosis and papillary lesions, leading to the tentative and pre-operative diagnosis of invasive ductal carcinoma. Due to the absence of daughter nodules, extensive ductal spread, and lymphadenopathy on imaging evaluation, the patient underwent breast-conserving surgery and sentinel node biopsy, resulting in negative surgical margins and no lymph node involvement. Post-operative pathological examination showed triple negative atypical cells with squamous differentiation, squamous cell carcinoma (SCC), with cystic parts and a small amount of low-grade adenosquamous cell carcinoma (LGASC), both encompassing the cystic parts in a contiguous fashion. No cases with synchronous SCC and LGASC in the breast have been reported to date. An etiologic correlation between SCC and LGASC should be further evaluated. Breast cancer is the most common cancer type in females, and exploring the mechanisms of disease progression is playing a crucial role in the development of potential therapeutics. Pituitary tumor-transforming gene (PTTG) family members are well documented to be involved in cell-cycle regulation and mitosis, and contribute to cancer development by their involvement in cellular transformation in several tumor types. The critical roles of PTTG family members as crucial transcription factors in diverse types of cancers are recognized, but how they regulate breast cancer development still remains mostly unknown. Meanwhile, a holistic genetic analysis exploring whether PTTG family members regulate breast cancer progression via the cell cycle as well as the energy metabolism-related network is lacking. To comprehensively understand the messenger RNA expression profiles of PTTG proteins in breast cancer, we herein conducted a high-throughput screening approach by integrating information from various databases such as Oncomine, Kaplan-Meier Plotter, Metacore, ClueGo, and CluePedia. These useful databases and tools provide expression profiles and functional analyses. The present findings revealed that PTTG1 and PTTG3 are two important genes with high expressions in breast cancer relative to normal breast cells, implying their unique roles in breast cancer progression. Results of our coexpression analysis demonstrated that PTTG family genes were positively correlated with thiamine triphosphate (TTP), deoxycytidine triphosphate (dCTP) metabolic, glycolysis, gluconeogenesis, and cell-cycle related pathways. Meanwhile, through Cytoscape analyzed indicated that in addition to the metastasis markers AURKA, AURKB, and NDC80, many of the kinesin superfamily (KIF) members including KIFC1, KIF2C, KIF4A, KIF14, KIF20A, KIF23, were also correlated with PTTG family transcript expression. Finally, we revealed that high levels of PTTG1 and PTTG3 transcription predicted poor survival, which provided useful insights into prospective research of cancer associated with the PTTG family. Therefore, these members of the PTTG family would serve as distinct and essential prognostic biomarkers in breast cancer.  The understanding of the biology and epidemiology of, and the optimal therapeutic strategies for, breast cancer (bca) in younger women is limited. We present the rationale, design, and initial recruitment of Reducing the Burden of Breast Cancer in Young Women (ruby), a unique national prospective cohort study designed to examine the diagnosis, treatment, quality of life, and outcomes from the time of diagnosis for young women with bca.\\nOver a 4-year period at 33 sites across Canada, the ruby study will use a local and virtual recruitment model to enrol 1200 women with bca who are 40 years of age or younger at the time of diagnosis, before initiation of any treatment. At a minimum, comprehensive patient, tumour, and treatment data will be collected to evaluate recurrence and survival. Patients may opt to complete patient-reported questionnaires, to provide blood and tumour samples, and to be contacted for future research, forming the core dataset from which 4 subprojects evaluating genetics, lifestyle factors, fertility, and local management or delivery of care will be performed.\\nThe ruby study will be the most comprehensive repository of data, biospecimens, and patient-reported outcomes ever collected with respect to young women with bca from the time of diagnosis, enabling research unique to that population now and into the future. This research model could be used for other oncology settings in Canada. Cancer initiation typically occurs when a proto-oncogene\\'s coding region undergoes mutation, resulting in uncontrollable cell growth and division, or when a tumour suppressor gene\\'s coding region is affected by a mutation that inhibits activity of the resulting gene product. The pathophysiologic result is, respectively, exaggerated cell-cycle growth or deficient programmed cell death. Osteopontin (opn) is an integrin-binding phosphoprotein that is expressed on the surface of normal cells. Osteopontin has a major role in diverse tumour components, especially those implicated in invasion and metastasis. In the present study, we aimed to illustrate the value of opn as a possible contributor in breast cancer (bca).\\nThis prospective study included 115 patients newly diagnosed with bca and distant metastasis who were recruited from the Oncology Center, Mansoura University, and the Department of Clinical Oncology and Nuclear Medicine, Mansoura University Hospital, Egypt. The patients recruited had been diagnosed with disseminated visceral metastasis (visceral crisis), with or without bone metastasis; patients with cranial metastasis were excluded from the study. All patients received first-line chemotherapy with docetaxel 75 mg/m\\nMean serum opn was highest in her2-amplified bca (64.4 ± 42.3 ng/dL), and then in triple-negative bca (55.9 ± 34.7 ng/dL), followed by the luminal B and A subtypes (38.4 ± 33.1 ng/dL and 36.3 ± 32.2 ng/dL respectively, \\nThe current prospective work helps to highlight opn as a valid prognostic biomarker for patients with metastatic bca and reveals that high pretreatment serum opn and opn gene mutation are both strongly linked with poor response and survival. Concordance between elisa and pcr results indicates that either method can be used for the evaluation of opn. Increased opn gene mutation in triple-negative bca could assist in tailoring the treatment response in this very aggressive tumour subtype and could be considered a targetable molecule in future studies. In response to Choosing Wisely recommendations that sentinel lymph node biopsy (slnb) should not be routinely performed in elderly patients with node-negative (cN0), estrogen receptor-positive (er+) breast cancer, we sought to evaluate how nodal staging affects adjuvant treatment in this population.\\nFrom a prospective database, we identified patients 70 or more years of age with cN0 breast cancer treated with surgery for er+ her2-negative invasive disease during 2012-2016. We determined rates of, and factors associated with, nodal positivity (pN+), and compared the use of adjuvant radiation (rt) and systemic therapy by nodal status.\\nOf 364 patients who met the inclusion criteria, 331 (91%) underwent slnb, with 75 (23%) being pN+. Axillary node dissection was performed in 11 patients (3%). On multivariate analysis, tumour size was the only factor associated with pN+ (\\nOf elderly patients with cN0 er+ breast cancer, 23% were pN+ on slnb. Size was the primary predictor of nodal status, and yet significant rates of nodal positivity were observed even in tumours preoperatively sized at 1 cm or less. The use of rt and systemic adjuvant therapies differed by nodal status, although the long-term oncologic implications require further investigation. Multidisciplinary input on a case-by-case basis should be considered before omission of slnb. Circ_0072995 is a novel identified circRNA and has been identified to involve in the metastasis of breast cancer. However, the detailed function and mechanism of circ_0072995 in the biological property of breast cancer cell remain vague.\\nThe expression of circ_0072995, microRNA (miR)-149-5p and \\nCirc_0072995 and \\nThis study demonstrated that circ_0072995 promoted cell malignant phenotypes and anaerobic glycolysis in breast cancer via up-regulating  The expression of \\nWe found that \\nTaken together, our results demonstrated that high  This study aimed to investigate the effect of long-chain non-coding SOX21-AS1 on the proliferation and migration of breast cancer (BC) cells through the PI3K/AKT signaling pathway.\\nEighty-eight BC and adjacent tissues were collected, and BC cells and normal breast epithelial cells were purchased. LncRNA SOX21-AS1 expression in tissues and cells was detected by RT-PCR. miR-NC, si-SOX21-AS1, and Sh-SOX21-AS1 were transfected into BC cells. The PI3K/AKT signaling pathway was interfered with L740Y-P (activator of the PI3K/AKT pathway) and LY294002 (inhibitor of the PI3K/AKT pathway) in BC cells. The SOX21-AS1 expression in BC tissues and cells was tested by qRT-PCR, and the expression levels of p-PI3K, p-AKT, N-cadherin, E-cadherin, and vimentin were detected by WB.\\nSOX21-AS1 was highly expressed in BC, and the p-PI3K and p-AKT levels were also high. Cell experiments showed that inhibiting SOX21-AS1 expression could inhibit the proliferation, invasion, migration, and EMT of BC cells, and up-regulating its expression could promote the proliferation, invasion, migration, and EMT of ovarian cancer cells. The tumor-forming experiment in nude mice was consistent with the results in vitro. 740Y-P intervention could reverse the inhibition effect of Si-SOX21-AS1 on BC cell proliferation, invasion, migration, and EMT, while LY294002 intervention could reverse the promotion effect of Sh-SOX21-AS1 on BC cell proliferation, invasion, migration, and EMT.\\nSOX21-AS1 is highly expressed in BC tissues. Silencing BC expression can inhibit the proliferation, invasion, migration, and EMT of cells by inhibiting the PI3K/AKT signaling pathway, which may be a new target for diagnosis and treatment. The deregulation of the Hippo pathway results in translocation ofYes-associated protein-1 \\nWe evaluated the expression of YAP1 protein and gene using immunohistochemistry (IHC) and RT-qPCR in FFPE tissue from normal and breast cancer cases. We also studied its association with CSC expression (\\nOur results imply that  Unlike developed countries, there is high mortality of breast cancer in low- and middle-income countries associated with prolonged patient delays and advanced stage presentations. However, evidence-based information about patient delay in presentation and contributing factors to diagnosis of breast cancer in Ethiopia is scarce.\\nInstitution-based cross-sectional study was conducted at oncology units of the University of Gondar and Felege Hiwot specialized hospitals. A total of 371 female breast cancer patients who were newly diagnosed from September 2019 to April 30, 2020 were included. Data were entered using EPI info version 7.2 and analyzed in SPSS version 23. Descriptive statistics was used to summarize socio-demographic and clinical characteristic of the patients. Multivariable logistic regression at a \\nA total of 281 (75.7%) patients had long patient delay of ≥90 days (3 months) with the average patient delay time of 8 months, and advanced stage diagnosis was found on 264 (71.2%) of patients. The median age of patients was 40 years. Rural residence (AOR=3.72; 95% CI=1.82-7.61), illiterate (AOR=3.8; 95% CI=1.71-8.64), having a painless wound (AOR=3.32; 95% CI=1.93, 5.72), travel distance ≥5 km (AOR=1.66; 95% CI=1.09-3.00), having no lump/swelling in the armpit (AOR=6.16; 95% CI=2.80-13.54), and no history of any breast problem before (AOR=2.46; 95% CI=(1.43-4.22) were predictors for long patient delay.\\nLong patient delay and advanced stage diagnosis of breast cancer are higher in our study. Travel distance ≥5 km, rural residence, no history of any breast problem before, having no lump/swelling in the arm pit, a painless lump in the breast, and being illiterate were important predictors for patient delay. Therefore, public awareness programs about breast cancer should be designed to prevent patient delay in presentation and to promote early detection of cases before advancement.  The human leukocyte antigen (HLA) genes are cell-surface proteins, essential for immune cell interaction. HLA-G is known for their high immunosuppressive effect and its potential as predictive marker in breast cancer. However, nothing is known about the HLA-J and its immunosuppressive, prognostic and predictive features, as it is assumed to be a \"pseudogene\" by in silico sequence interpretation. HLA-J, ESR1, ERBB2, KRT5 and KRT20 mRNA expression were analysed in 29 fresh frozen breast cancer biopsies and their corresponding resectates obtained from patients treated with neoadjuvant chemotherapy (NACT). mRNA was analysed with gene specific TaqMan-based Primer/Probe sets and normalized to Calmodulin 2. All breast cancer samples did express HLA-J and frequently increased HLA-J mRNA levels after NACT. HLA-J mRNA was significantly associated with overexpression of the ESR1 mRNA status (Spearman ρ 0,5679; p\\u2009=\\u20090.0090) and KRT5 mRNA (Spearman ρ 0,6121; p\\u2009=\\u20090.0041) in breast cancer core biopsies and dominated in luminal B subtype. Kaplan Meier analysis revealed that an increase of HLA-J mRNA expression after NACT had worse progression free survival (p\\u2009=\\u20090,0096), indicating a counterreaction of tumor tissues presumably to prevent elimination by enhanced immune infiltration induced by NACT. This counterreaction is associated with worse prognosis. To our knowledge this is the first study identifying HLA-J as a new predictive marker in breast cancer being involved in immune evasion mechanisms.\\nHumane Leukozyten-Antigene (HLA) sind Proteine auf der Zelloberfläche, die essenziell für die Immunzellinteraktion sind. HLA-G ist für seine hohe immunosuppressive Wirkung sowie als potenzieller prädikativer Marker für Brustkrebs bekannt. Dagegen ist kaum etwas über HLA-J und seine immunosuppressiven, prognostischen und prädiktiven Eigenschaften bekannt, da es basierend auf In-silico-Sequenzanalysen als „Pseudogen“ interpretiert wurde. Die Expression von HLA-J, ESR1, ERBB2, KRT5 und KRT20 mRNA wurde in 29\\xa0frisch gefrorenen Brustkrebsbiopsien analysiert und mit den klinisch-pathologischen Daten von Patientinnen, welche mit neoadjuvanter Chemotherapie behandelt wurden, verglichen. Die mRNA-Expression wurde mit genspezifischen TaqMan-basierten Primer/Probe-Sets analysiert und auf Calmodulin 2 normalisiert. Alle Gewebeproben von Patientinnen mit Brustkrebs exprimierten HLA-J, und der HLA-J-mRNA-Spiegel war nach NACT oft erhöht. In den Brustkrebsstanzbiopsien war die HLA-J-mRNA-Expression signifikant mit der Überexpression von ESR1-mRNA (Spearmans ρ 0,5679; p\\u2009=\\u20090,0090) und KRT5-mRNA (Spearmans ρ 0,6121; p\\u2009=\\u20090,0041) assoziiert und dominierte im Luminal-B-Subtyp. Die Kaplan-Meier-Analyse zeigte, dass ein Anstieg der HLA-J-mRNA-Expression nach NACT mit einem schlechteren progressionsfreien Überleben einhergeht (p\\u2009=\\u20090,0096), womöglich als Gegenreaktion des Tumorgewebes, um eine Eliminierung durch tumorinfiltrierende Lymphozyten, welche durch eine NACT induziert wurden, zu verhindern. Diese Gegenreaktion ist mit einer schlechteren Prognose assoziiert. Soweit uns bekannt, handelt es sich hierbei um die erste Studie, die HLA-J als neuen prädiktiven Marker im Brustkrebs identifiziert hat und möglicherweise zur Immunevasion beiträgt. Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a  The treatment of patients with early breast cancer has always been characterised by escalation by new therapies and de-escalation through identification of better treatment regimens or introduction of better tools to estimate prognosis. Efforts in some of these areas in the last few years have led to solid data. The results of the large studies of de-escalation through use of multi-gene tests are available, as are the results of some studies that investigated the new anti-HER2 substances T-DM1 and pertuzumab in the early treatment situation. Several large-scale studies examining the role of CDK4/6 inhibitors will soon be concluded so innovations can be anticipated in this area also. This review article will summarise and classify the results of the latest publications. In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA. To verify whether omitting radiotherapy from breast cancer treatment for patients\\u2009≥\\u200970\\xa0years old following breast-conserving surgery (BCS) without axillary lymph node dissection is safe. Previous studies have shown that omitting breast radiotherapy after BCS and axillary lymph node dissection is safe for elderly breast cancer patients. We aimed to evaluate the safety of BCS without axillary surgery or breast radiotherapy (BCSNR) in elderly patients with breast cancer and clinically negative axillary lymph nodes. We performed a retrospective analysis of 481 patients with breast cancer, aged\\u2009≥\\u200970\\xa0years, between 2010 and 2016. Of these, 302 patients underwent BCSNR and 179 underwent other, larger scope operations. Local recurrence rate, ipsilateral breast tumor recurrence (IBTR) rate, distant metastasis rate, breast-related death, disease-free survival (DFS), and overall survival (OS) were compared between the two groups. After a median follow-up of 60\\xa0months, no significant differences in local recurrence, distant metastasis rate, breast-related death, and DFS were noted. The OS was similar (P\\u2009=\\u20090.56) between the BCSNR group (91.7%) and other operations group (93.0%). The IBTR rate was considered low in both groups, however resulted greater (P\\u2009=\\u20090.005) in the BCSNR group (5.3%) than in other operations group (1.6%). BCSNR did not affect the survival of elderly patients with breast cancer with clinically negative axillary lymph nodes. IBTR was infrequent in both groups; however, there was a significant difference between the two groups. BCSNR is a feasible treatment modality for patients with breast cancer\\u2009≥\\u200970\\xa0years old with clinically negative axillary lymph nodes. The remarkable advances in next-generation sequencing technology have enabled the wide usage of sequencing as a clinical tool. To promote the advance of precision oncology for breast cancer in China, here we report a large-scale prospective clinical sequencing program using the Fudan-BC panel, and comprehensively analyze the clinical and genomic characteristics of Chinese breast cancer. The mutational landscape of 1,134 breast cancers reveals that the most significant differences between Chinese and Western patients occurred in the hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer subtype. Mutations in p53 and Hippo signaling pathways are more prevalent, and 2 mutually exclusive and 9 co-occurring patterns exist among 9 oncogenic pathways in our cohort. Further preclinical investigation partially suggests that NF2 loss-of-function mutations can be sensitive to a Hippo-targeted strategy. We establish a public database (Fudan Portal) and a precision medicine knowledge base for data exchange and interpretation. Collectively, our study presents a leading approach to Chinese precision oncology treatment and reveals potentially actionable mutations in breast cancer. Poorly immunogenic tumors, including triple negative breast cancers (TNBCs), remain resistant to current immunotherapies, due in part to the difficulty of reprogramming the highly immunosuppressive tumor microenvironment (TME). Here we show that peritumorally injected, macroporous alginate gels loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) for concentrating dendritic cells (DCs), CpG oligonucleotides, and a doxorubicin-iRGD conjugate enhance the immunogenic death of tumor cells, increase systemic tumor-specific CD8\\u2009+\\u2009T cells, repolarize tumor-associated macrophages towards an inflammatory M1-like phenotype, and significantly improve antitumor efficacy against poorly immunogenic TNBCs. This system also prevents tumor recurrence after surgical resection and results in 100% metastasis-free survival upon re-challenge. This chemo-immunotherapy that concentrates DCs to present endogenous tumor antigens generated in situ may broadly serve as a facile platform to modulate the suppressive TME, and enable in situ personalized cancer vaccination. Protein tyrosine kinase 6 (PTK6; also called Brk) is overexpressed in 86% of breast cancer patients; high PTK6 expression predicts poor outcome. We reported PTK6 induction by HIF/GR complexes in response to either cellular or host stress. However, PTK6-driven signaling events in the context of TNBC remain undefined. In a mouse model of TNBC, manipulation of PTK6 levels (i.e. via knock-out or add-back) had little effect on primary tumor volume but altered lung metastasis. To delineate the mechanisms of PTK6 downstream signaling, we created kinase-dead (KM) and kinase-intact domain structure mutants of PTK6 via in frame deletions of the N-terminal SH3 or SH2 domains. While the PTK6 kinase domain contributed to soft-agar colony formation, PTK6 kinase activity was entirely dispensable for cell migration. Specifically, TNBC models expressing a PTK6 variant lacking the SH2 domain (SH2-del PTK6) were unresponsive to growth factor-stimulated cell motility relative to SH3-del, KM or wild-type PTK6 controls. Reverse phase protein array (RPPA) revealed that while intact PTK6 mediates spheroid formation via p38 MAPK signaling, the SH2 domain of PTK6 limits this biology, and instead mediates TNBC cell motility via activation of the RhoA and/or AhR signaling pathways. Inhibition of RhoA and/or AhR blocked TNBC cell migration as well as the branching/invasive morphology of PTK6+/AhR+ primary breast tumor tissue organoids. Inhibition of RhoA also enhanced paclitaxel cytotoxicity in TNBC cells, including in a taxane-refractory TNBC model. Implications: The SH2-domain of PTK6 is a potent effector of advanced cancer phenotypes in TNBC via RhoA and AhR, identified herein as novel therapeutic targets in PTK6+ breast tumors. Lysosomes act as a cellular drug sink for weakly basic, lipophilic (lysosomotropic) xenobiotics, with many instances of lysosomal trapping associated with MDR. Lysosomotropic agents have also been shown to activate master lysosomal biogenesis transcription factor EB (TFEB), and ultimately lysosomal biogenesis. We investigated the role of lysosomal biogenesis in the disposition of hydroxychloroquine (HCQ), a hallmark lysosomotropic agent, and observed that modulating the lysosomal volume of human breast cancer cell lines can account for differences in disposition of HCQ. Through use of an  Cold-inducible RNA binding protein (CIRBP) is a stress-responsive protein that promotes cancer development and inflammation. Critical to most CIRBP functions is its capacity to bind and post-transcriptionally modulate mRNA. However, a transcriptome-wide analysis of CIRBP mRNA targets in cancer has not yet been performed. Here, we use an ex vivo breast cancer model to identify CIRBP targets and mechanisms. We find that CIRBP transcript levels correlate with breast cancer subtype and are an indicator of luminal A/B prognosis. Accordingly, over-expression of CIRBP in non-tumoral MCF-10A cells promotes cell growth and clonogenicity, while depletion of CIRBP from luminal A MCF-7 cells has opposite effects. We use RNA immunoprecipitation followed by high-throughput sequencing (RIP-Seq) to identify a set of 204 high confident CIRBP targets in MCF-7 cells. About 10% of these showed complementary changes after CIRBP manipulation in MCF-10 and MCF-7 cells, and were highly interconnected with known breast cancer genes. To test the potential of CIRBP-mediated regulation of these targets in breast cancer development, we focused on Cystatin C (CST3), one of the most highly interconnected genes and a protein that displays tumor suppressive capacities. CST3 depletion restored the effects of CIRBP depletion in MCF-7 cells, indicating that CIRBP functions, at least in part, by downregulating CST3 levels. Our data provide a resource of CIRBP targets in breast cancer, and identify CST3 as a novel downstream mediator of CIRBP function. There is a paucity of data on the prognostic value of programmed cell death protein 1 (PD-1) protein and gene expression in early breast cancer (BC) and the present study\\'s aim was to comprehensively investigate it.\\nThe study consisted of three parts: a correlative analysis of PD-1 protein and gene expression from an original patient cohort of 564 patients with early BC; a systematic review and trial-level meta-analysis on the association between PD-1 protein expression and disease-free survival/overall survival (OS) in early BC; and a pooled gene expression analysis from publicly available transcriptomic datasets regarding \\nIn the study cohort, PD-1 protein, but not gene expression, was associated with improved OS (HR\\nPD-1 protein and gene expression seem to be promising prognostic factors in early BC. Standardisation of detection and assessment methods is of utmost importance. Many breast cancer (BC) survivors are employed at diagnosis and are expected to return to work after treatment. Among them, around 50% are overweight or obese. There are limited data about the impact of body weight on their ability to return to work.\\nWe used data from CANcer TOxicity (NCT01993498), a prospective, multicentre cohort of women with stage I-III BC. Professionally active women who were ≥5 years younger than retirement age were identified. Multivariable logistic regression models examined associations of body mass index (BMI) at diagnosis and subsequent weight changes with non-return to work 2\\u2009years after diagnosis, adjusting for psychosocial, treatment and behavioural characteristics.\\nAmong 1869 women, 689 were overweight or obese. Overall, 398 patients (21.3%) had not returned to work 2\\u2009years after diagnosis. Non-return to work was more likely for overweight or obese than underweight or normal weight patients (adjusted OR (aOR) 1.32; 95%\\u2009CI, 1.01 to 1.75; p=0.045). Weight loss (≥5%) was observed in 15.7% overweight or obese and 8.7% underweight or normal weight patients and was associated with significant increases in physical activity only among overweight or obese patients (mean change, +4.7 metabolic-equivalent-of-task-hour/week; 95%\\u2009CI +1.9\\u2009to +7.5). Overweight or obese patients who lost weight were more likely to return to work compared with those who did not lose weight (aOR of non-return-to-work, 0.48; 95%\\u2009CI 0.24 to 0.97, p=0.0418), whereas weight loss was associated with increased odds of non-return to work among underweight or normal weight women (aOR 2.07; 95%\\u2009CI 1.20 to 3.56, p=0.0086) (p\\nExcess weight may be a barrier to return to work. Among overweight or obese BC survivors, weight loss was associated with higher rates of return to work, whereas further weight gain was associated with lower likelihood of return to work. Employment outcomes should be evaluated in randomised studies of weight management. In many tumors, cells transition reversibly between slow-proliferating tumor-initiating cells (TIC) and their differentiated, faster-growing progeny. Yet how transcriptional regulation of cell cycle and self-renewal genes is orchestrated during these conversions remains unclear. In this study, we show that as breast TIC form, a decrease in cell-cycle and increase in self-renewal gene expression is coregulated by SOX2 and EZH2, which colocalize at CpG islands. This pattern was negatively controlled by a novel long non-coding RNA (lncRNA) that we name SCIRT, which was markedly upregulated in tumorspheres but colocalized with and counteracted EZH2 and SOX2 during cell cycle and self-renewal regulation to restrain tumorigenesis. SCIRT specifically interacted with EZH2 to increase EZH2 affinity to FOXM1 without binding the latter. In this manner, SCIRT induced transcription at cell cycle gene promoters by recruiting FOXM1 through EZH2 to antagonize EZH2-mediated effects at target genes. Conversely, on stemness genes, FOXM1 was absent and SCIRT antagonized EZH2 and SOX2 activity, balancing towards repression. These data suggest that the interaction of a lncRNA with EZH2 can alter the affinity of EZH2 for its protein binding partners to regulate cancer cell state transitions. Luminal B breast tumors are more aggressive estrogen receptor positive breast cancers characterized by aggressive clinical behavior and a high risk of metastatic dissemination. The underlying pathological molecular events remain poorly understood with a paucity of actionable genetic drivers, which hinders the development of new treatment strategies.\\nWe performed large-scale RNAseq analysis to identify chimerical transcripts preferentially expressed in luminal B breast cancer. The lead candidate was validated by Reverse Transcription PCR in breast cancer tissues. The effects of inducible ectopic expression or genetic silencing were assessed by phenotypic assays such as MTS, transwell and transendothelial migration assays, and by clonogenic assays to assess MEK inhibitor sensitivity. Subcellular fractionation, western blots, and immunoprecipitation were performed to characterize the protein products and elucidate the engaged mechanisms.\\nHere we report a novel tumor-specific chimeric transcript RAD51AP1-DYRK4 preferentially expressed in luminal B tumors. Analysis of 200 ER-positive breast tumors detected RAD51AP1-DYRK4 overexpression in 19 tumors (9.5%), which is markedly enriched in the luminal B tumors (17.5%). Ectopic expression of RAD51AP1-DYRK4, but not wild-type RAD51AP1, leads to marked activation of MEK/ERK signaling, and endows increased cell motility and transendothelial migration. More importantly, RAD51AP1-DYRK4 appears to endow increased sensitivity to the MEK inhibitor Trametinib through attenuating compensatory activation of HER2/PI3K/AKT under MEK inhibition.\\nThis discovery sheds light on a new area of molecular pathobiology of luminal B tumors and implies potential new therapeutic opportunities for more aggressive breast tumors overexpressing this fusion. The Neurofibromatosis type I (NF1) is an autosomal dominant syndrome that affects 1/3000-1/4000 individuals. Patients with this condition are predisposed to different tumors, like neurofibromas, optic nerve gliomas, gastrointestinal stromal tumors (GIST) and breast cancers.\\nA 78-year-old female patient affected by NF1 in May 2018 during follow-up for a carcinoma of the right breast had persistent anemia requiring regular blood transfusions. She presented with NF 1 with disseminated cutaneous neurofibromas, asthma, hypothyroidism, arterial hypertension and uterine prolapse. She had performed gastroscopy and colonoscopy both negative for neoplastic lesions. She was subjected to chest and abdomen CT which revealed the presence of an ileal lesion of 6.5 × 4 cm suspected of GIST. The patient underwent laparoscopic ileal resection in 120 min and was discharged on the sixth postoperative day.\\nNF1 is caused by biallelic loss of a tumor suppressor gene. Most GISTs are localized in the stomach and small intestine. Surgery is the first line of treatment for localized disease. The main goal of surgery is complete excision with negative margins. The association between breast cancer and intestinal GIST in NF1 is reported only from two previous studies.\\nIt is a rare case of association of breast cancer and ileal GIST in NF1. Laparoscopic resection of intestinal GIST has shown in some studies to have oncological outcomes comparable to laparotomy. Furthermore, laparoscopy is associated with better perioperative outcomes and shorter hospital stays. Further studies with a higher level of evidence are needed. Most adults with cancer are over 65\\xa0years of age, and this cohort is expected to grow exponentially. Older adults have an increased burden of comorbidities and risk of experiencing adverse events on anticancer treatments, including functional decline. Functional impairment is a predictor of increased risk of chemotherapy toxicity and shorter survival in this population. Healthcare professionals caring for older adults with cancer should be familiar with the concept of functional status and its implications because of the significant interplay between function, cancer, anticancer treatments, and patient-reported outcomes. In this narrative review, we provide an overview of functional status among older patients with cancer including predictors, screening, and assessment tools. We also discuss the impact of functional impairment on patient outcomes, and describe the role of individual members of an interprofessional team in addressing functional impairment in this population, including the use of a collaborative approach aiming to preserve function. To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).\\nThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.\\nA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.\\nThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.\\nUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. By studying the effect of environmental factors on health, it is clear that geographical, climatic and environmental factors have a significant impact on human health. This study, based on the data of the patients with breast cancer in Iran since 2010 to 2014 and using the statistical methods has determined the effect of geographical features of Iran (solar radiation status, radiation angle) on the frequency and distribution of this disease.\\nThe maximum amount of total solar radiation occurs in the vicinity (surrounding) of the tropic of cancer, which covers some parts of the south of Iran and in the atmosphere of the northern latitudes of Iran. The amount of humidity and cloudiness is more than the southern latitudes, which causes more reflection of short waves of the sun during the day. Findings showed that the rate of breast cancer in low latitudes is higher than high latitudes. It was also found that with increasing longitude, the rate of cancer increases significantly due to the high thickness of the atmosphere and receiving more sunlight in the electromagnetic spectrum, as well as dry air and low water vapor in low altitude areas of eastern and southeastern Iran. Fine needle aspiration cytology is a simple, relatively accurate, non-invasive, and cost-effective method of diagnosing most breast pathologies. To date, there is no sufficient data depicting the distribution of breast lesions detected by fine needle aspiration cytology in our healthcare setting. The aim of this study was to elucidate the general distribution of breast lesions diagnosed by cytology test at Eritrean National Health Laboratory.\\nThis retrospective study was carried out on 905 symptomatic patients between the years 2013 and 2017 at Eritrean National Health Laboratory. Diagnosis was made by fine needle aspiration cytology in patients with palpable breast lump and in some patients direct smear was prepared from a nipple discharge. Statistical analysis was carried out using Statistical Package for the Social Sciences version 23.\\nA total of 905 patients were included in the study, of whom 871 (96.24%) were females. The age range of patients was from 13 to 93\\xa0years with mean and standard deviation of 33\\u2009±\\u200914.9\\xa0years. Breast lump, occurring in 892 (98.56%), was the most frequent presenting symptom. Fibroadenoma and fibrocystic breast lesions were the most prevalent lesions accounting for approximately 40% and 15%, respectively. Malignant breast lesions were seen predominantly in females above the age of 40\\xa0years with the highest frequency observed in the age range between 51 and 60\\xa0years. Pearson Chi-squared test showed significant association between patients\\' age above 40\\xa0years and the risk of having a malignant breast lesion (p\\u2009<\\u20090.001). The highest number of benign and malignant breast lesions was documented in 2014 with little fluctuation elsewhere in the study period.\\nFine needle aspiration cytology is a procedure of choice for preoperative diagnosis in breast lesions mainly in a resource-limited settings. Our study identified the occurrence of malignant breast lesions in young women, which is of a paramount public health concern. Of note, significant proportion of patients were late to seek medical attention. Therefore, enhancement of community awareness regarding breast disease and implementation of screening programs are necessary to ameliorate the morbidity and mortality associated with the disease. The ability to detect tumor-specific biomarkers in real-time using optical imaging plays a critical role in preclinical studies aimed at evaluating drug safety and treatment response. In this study, we engineered an imaging platform capable of targeting different tumor biomarkers using a multi-colored library of nanoprobes. These probes contain rare-earth elements that emit light in the short-wave infrared (SWIR) wavelength region (900-1700\\u2009nm), which exhibits reduced absorption and scattering compared to visible and NIR, and are rendered biocompatible by encapsulation in human serum albumin. The spectrally distinct emissions of the holmium (Ho), erbium (Er), and thulium (Tm) cations that constitute the cores of these nanoprobes make them attractive candidates for optical molecular imaging of multiple disease biomarkers.\\nSWIR-emitting rare-earth-doped albumin nanocomposites (ReANCs) were synthesized using controlled coacervation, with visible light-emitting fluorophores additionally incorporated during the crosslinking phase for validation purposes. Specifically, HoANCs, ErANCs, and TmANCs were co-labeled with rhodamine-B, FITC, and Alexa Fluor 647 dyes respectively. These Rh-HoANCs, FITC-ErANCs, and 647-TmANCs were further conjugated with the targeting ligands daidzein, AMD3100, and folic acid respectively. Binding specificities of each nanoprobe to distinct cellular subsets were established by in vitro uptake studies. Quantitative whole-body SWIR imaging of subcutaneous tumor bearing mice was used to validate the in vivo targeting ability of these nanoprobes.\\nEach of the three ligand-functionalized nanoprobes showed significantly higher uptake in the targeted cell line compared to untargeted probes. Increased accumulation of tumor-specific nanoprobes was also measured relative to untargeted probes in subcutaneous tumor models of breast (4175 and MCF-7) and ovarian cancer (SKOV3). Preferential accumulation of tumor-specific nanoprobes was also observed in tumors overexpressing targeted biomarkers in mice bearing molecularly-distinct bilateral subcutaneous tumors, as evidenced by significantly higher signal intensities on SWIR imaging.\\nThe results from this study show that tumors can be detected in vivo using a set of targeted multispectral SWIR-emitting nanoprobes. Significantly, these nanoprobes enabled imaging of biomarkers in mice bearing bilateral tumors with distinct molecular phenotypes. The findings from this study provide a foundation for optical molecular imaging of heterogeneous tumors and for studying the response of these complex lesions to targeted therapy. Breast cancer is the leading form of cancer in women, which is also hormone-dependent. Depend-ing on the receptor expression these cancers are subdivided to different forms; among the receptors, estrogen, progesterone, and Her2 are important. Targeting breast cancer (BC) has been difficult due to their varied nature; however, various Phyto-compounds, especially those are having estrogen-like properties, has been proven to be effective.\\nThe present review is aimed to provide a detailed description of various Phytocompounds inhibiting breast cancer proliferation and progression; emphasize has been given to the role of phytoestrogens with their molecular mechanism of action.\\nThe data were collected from reputed databases such as PubMed/Medline, Web of Science, Science Direct, Eu-rekaselect etc. Data on the phytoestrogens were collected using individual names and \"phytoestrogens\" as keywords. Arti-cles published in journals, which are not indexed by Thomson Reuters (SCI/SCIE/ESCI) are omitted.\\nNatural products are important drug candidates against multiple forms of breast cancer. In addition to the initiation and proliferation events, these molecules inhibit epithelial to mesenchymal transition (EMT) and metastasis of BC. Phy-toestrogens are an important class of compounds which has known estrogenic potential; studies have also indicated the anticancer potentials of these molecules in cell culture and animal models of BC.\\nNatural plant compounds, especially, phytoestrogens are promising anti-breast cancer agents by inducing cell cycle arrest, apoptosis and autophagy-mediated cell death. However, more clinical studies are necessary to up these mole-cules are commercial drug molecules. While cell fusion demonstrates an important pathway during tissue development and regeneration of distinct organs, this process can also contribute to pathophysiological phenotypes during tumor progression. Hybrid cell formation after heterofusion between cancer cells and various other cell types within the tumor microenvironment is observed in vitro and in vivo. In particular, mesenchymal stroma/stem-like cells (MSC) perform diverse levels of communication with cancer cells by exhibiting anti- and pro-tumorigenic effects. During these cellular interactions, MSC can eventually fuse with cancer cells. Thereby, the newly generated disparate hybrid populations display aneuploidy associated with chromosomal instability. Based upon a subsequent post-hybrid selection process (PHSP), fused cancer cells can undergo apoptosis/necroptosis, senescence, dormancy, or a proliferative state by acquisition of new properties. Consequently, PHSP-surviving hybrid cancer cells demonstrate altered functionalities within the tumor tissue. This is accompanied by changes in therapeutic responsiveness and a different metastatic behavior. Accordingly, enhanced tumor plasticity interferes with successful therapeutic interventions and aggravates patient prognoses. The present review article focusses on fusion of MSC with different human cancer cells, in particular breast cancer populations and resulting characteristics of various cancer hybrid cells. Moreover, some mechanisms of cancer cell fusion are discussed together with multiple PHSP pathways. To analyze if the prometastatic activity of calcitriol (active vitamin D Pyrimidine is a privileged scaffold in many synthetic compounds exhibiting diverse pharmacological activities, and is used for therapeutic applications in a broad spectrum of human diseases. In this study, we prepared a small set of pyrimidine libraries based on the structure of two hit compounds that were identified through the screening of an in-house library in order to identify an inhibitor of anoctamin 1 (ANO1). ANO1 is amplified in various types of human malignant tumors, such as head and neck, parathyroid, and gastrointestinal stromal tumors, as well as in breast, lung, and prostate cancers. After initial screening and further structure optimization, we identified  Mammography plays an important role in screening breast cancer among females, and artificial intelligence has enabled the automated detection of diseases on medical images. This study aimed to develop a deep learning model detecting breast cancer in digital mammograms of various densities and to evaluate the model performance compared to previous studies. From 1501 subjects who underwent digital mammography between February 2007 and May 2015, craniocaudal and mediolateral view mammograms were included and concatenated for each breast, ultimately producing 3002 merged images. Two convolutional neural networks were trained to detect any malignant lesion on the merged images. The performances were tested using 301 merged images from 284 subjects and compared to a meta-analysis including 12 previous deep learning studies. The mean area under the receiver-operating characteristic curve (AUC) for detecting breast cancer in each merged mammogram was 0.952 ± 0.005 by DenseNet-169 and 0.954 ± 0.020 by EfficientNet-B5, respectively. The performance for malignancy detection decreased as breast density increased (density A, mean AUC = 0.984 vs. density D, mean AUC = 0.902 by DenseNet-169). When patients\\' age was used as a covariate for malignancy detection, the performance showed little change (mean AUC, 0.953 ± 0.005). The mean sensitivity and specificity of the DenseNet-169 (87 and 88%, respectively) surpassed the mean values (81 and 82%, respectively) obtained in a meta-analysis. Deep learning would work efficiently in screening breast cancer in digital mammograms of various densities, which could be maximized in breasts with lower parenchyma density. TRAF6-BECN1 signaling axis is critical for autophagy induction and functionally implicated in cancer progression. Here, we report that AMP-activated protein kinase alpha 1 ( Although conserved throughout animal kingdoms, the protein encoded by the gene Mediator of ERBB2 Driven Cell Motility 1 or  Breast cancer is the most frequent neoplasm in the female population [...]. Development of new research, classification, and therapeutic options are urgently required due to the fact that TNBC is a heterogeneous malignancy. The expression of high molecular weight cytokeratins identifies a biologically and clinically distinct subgroup of TNBCs with a basal-like phenotype, representing about 75% of TNBCs, while the remaining 25% includes all other intrinsic subtypes. The triple negative phenotype in basal-like breast cancer (BLBC) makes it unresponsive to endocrine therapy, i.e., tamoxifen, aromatase inhibitors, and/or anti-HER2-targeted therapies; for this reason, only chemotherapy can be considered an approach available for systemic treatment even if it shows poor prognosis. Therefore, treatment for these subgroups of patients is a strong challenge for oncologists due to disease heterogeneity and the absence of unambiguous molecular targets. Dysregulation of the cellular miRNAome has been related to huge cellular process deregulations underlying human malignancy. Consequently, epigenetics is a field of great promise in cancer research. Increasing evidence suggests that specific miRNA clusters/signatures might be of clinical utility in TNBCs with basal-like phenotype. The epigenetic mechanisms behind tumorigenesis enable progress in the treatment, diagnosis, and prevention of cancer. This review intends to summarize the epigenetic findings related to miRNAome in TNBCs with basal-like phenotype. Xenobiotic transport proteins play an important role in determining drug disposition and pharmacokinetics. Our understanding of the role of these important proteins in humans and pre-clinical animal species has increased substantially over the past few decades, and has had an important impact on human medicine; however, veterinary medicine has not benefitted from the same quantity of research into drug transporters in species of veterinary interest. Differences in transporter expression cause difficulties in extrapolation of drug pharmacokinetic parameters between species, and lack of knowledge of species-specific transporter distribution and function can lead to drug-drug interactions and adverse effects. Horses are one species in which little is known about drug transport and transporter protein expression. The purpose of this mini-review is to stimulate interest in equine drug transport proteins and comparative transporter physiology. Extensive use of triclosan (2,4,4\\'-trichloro-2\\'-hydroxydiphenyl ether) as an antimicrobial agent in household and personal care products has resulted in global exposure of the human population. Its presence in human tissues, including milk, and its oestrogen-disrupting properties raise concerns for an involvement in breast cancer. Because metastatic tumour spread is the main cause of breast cancer mortality, we have investigated the effects of triclosan on cell migration and invasion using three human breast epithelial cell lines and using concentrations comparable with those in human tissues. Long-term exposure to 10 This European consensus statement on essential colposcopy provides standards for the general colposcopist seeing women referred for colposcopy with an abnormal cervical screening test (including cytology and HPV tests) or with a clinically suspicious cervix. The article gives guidance regarding the aims and conduct of colposcopy. Recommendations are provided on colposcopy technique, the management of common colposcopy issues, treatment and follow-up of after treatment of CIN or early stage cervical. Colposcopists should make an informed decision on the management of each individual that is referred and organize appropriate follow-up. Cervical cancer is still a major health issue and the quality of care can only improve if there is a structured guidance for women with an abnormal smear or suspicious cervix. A novel series of thiazolopyrimidines and fused thiazolopyrimidines was designed and synthesized as topoisomerase II alpha inhibitors. All synthesized compounds were screened by the National Cancer Institute (NCI), Bethesda, USA for anticancer activity against 60 human cancer cell lines representing the following cancer types: leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancers. Compound 3a was found to be the most potent inhibitor on renal cell line (A-498) causing 83.03% inhibition (IC Breast cancer (BC) remains a major health problem, despite the remarkable advances in cancer research setting. BC is the most common cancer affecting women worldwide. In the context of triple negative breast cancer (TNBC) treatment, major obstacles include late diagnoses and detrimental side effects of chemotherapy and radiotherapy. Research effort was rewarded with the discovery of mesothelin (MSLN), an oncogenic Glycosyl-Phosphatidyl-Inositol (GPI) anchored protein, over-expressed in TNBC. GPI pathway is a post-translational modification that attaches proteins to cellular membrane. MSLN targeted therapy succeeded in early clinical trials, nevertheless, to date, the epigenetic regulation of MSLN and GPI pathway by non-coding RNAs (nc-RNAs) in BC remains an untouched area. Accordingly, our aim is to investigate-for the first time- the impact of simultaneous targeting of MSLN and its associated GPI pathway member, PIG-C, by non-coding-RNAs. Expression profiling of PIG-C, MSLN in BC was performed. Using bioinformatics tools, MALAT-1 and miR-182 were found to target MSLN and PIG-C. MDA-MB-231 cells were transfected with synthetic nc-RNAs. Expression profiling of MSLN, miR-182 and MALAT-1 showed a dramatic over-expression in BC samples. MiR-182 ectopic expression and MALAT-1 silencing increased MSLN and PIG-C transcript levels. However, miR-182 inhibition and miR-182/si-MALAT-1 co-transfection lowered MSLN and PIG-C levels. Finally, si-PIG-C decreased MSLN and PIG-C levels. To conclude, our investigation unravels a new axis in TNBC, where miR-182 can manipulate MSLN and PIG-C. Meanwhile, MALAT-1 is the culprit lncRNA in this novel axis, possibly a sponge for miR-182. Altogether, this sheds light on new targets for BC immune-therapy. Breast cancer is a globally widespread disease whose detection has already been significantly improved by the introduction of screening programs. Nevertheless, mammography suffers from low soft tissue contrast and the superposition of diagnostically relevant anatomical structures as well as from low values for sensitivity and specificity especially for dense breast tissue. In recent years, two techniques for X-ray breast imaging have been developed that bring advances for the early detection of breast cancer. Grating-based phase-contrast mammography is a new imaging technique that is able to provide three image modalities simultaneously (absorption-contrast, phase-contrast and dark-field signal). Thus, an enhanced detection and delineation of cancerous structures in the phase-contrast image and an improved visualization and characterization of microcalcifications in the dark-field image is possible. Furthermore, latest studies about this approach show that dose-compatible imaging with polychromatic X-ray sources is feasible. In order to additionally overcome the limitations of projection-based imaging, efforts were also made towards the development of breast computed tomography (BCT), which recently led to the first clinical installation of an absorption-based BCT system. Further research combining the benefits of both imaging technologies is currently in progress. This review article summarizes the latest advances in phase-contrast imaging for the female breast (projection-based and three-dimensional view) with special focus on possible clinical implementations in the future. Neoadjuvant therapy (NAT) is increasingly used in breast cancer (BC), yet, the recommended time interval between NAT completion, preoperative imaging assessment, and breast surgery is not clearly defined. This single-center retrospective study investigated tumor growth between NAT completion and surgery. The analysis included 106 BC patients who received NAT (69% chemotherapy alone, 31% chemotherapy plus anti-HER2 therapy), had post-NAT breast MRI, and definitive surgery between 2012 and 2019. The median time interval between end-of-treatment and surgery was 6\\xa0weeks; 90% had surgery within 8\\xa0weeks of NAT completion, and 10% had surgery 8-12\\xa0weeks after NAT completion. No significant correlation was found between any of the time intervals (i.e., NAT completion-to-surgery, NAT completion-to-MRI, post-NAT MRI to surgery) and the tumor size as captured in the pathology report. The only parameter that was significantly correlated with pathological tumor size was tumor size as measured on the post NAT MRI (P\\xa0<\\xa0.0001). The difference in tumor size between post NAT MRI and surgical pathology did not correlate with the time interval between end-of-treatment and surgery. The ratio between residual tumor size on post-NAT MRI and the time interval from the end-of-treatment to surgery, significantly correlated with the tumor size on surgical pathology (P\\xa0<\\xa0.0001) suggesting that NAT has a beneficial effect weeks after end-of-treatment. In conclusion, our results suggest that for patients undergoing neoadjuvant chemotherapy, surgery within 4-8\\xa0weeks of completing NAT is reasonable, and is unlikely to result in a clinically significant change in residual tumor size. Bone is a common site of metastases, particularly in advanced breast and prostate cancer. Skeletal related events associated with bone metastases include pathologic fracture, need for surgery/radiation to bone and cord compression. These events cause significant morbidity and mortality. Bisphosphonates as well as denosumab act on the bone microenvironment and reduce the rate of skeletal related events by approximately 25%-40%. Hence, these therapies are an important adjunctive therapy in cancer care. Despite the established efficacy and recommendations for their use in many international guidelines, these bone modifying agents are underutilized. This review examines the currently available guidelines on bone modifying agents in metastatic bone disease and summarizes their efficacy, risk and comparative benefits. Translation of ribosomal protein-coding mRNAs (RP-mRNAs) constitutes a key step in ribosome biogenesis, but the mechanisms that modulate RP-mRNA translation in coordination with other cellular processes are poorly defined. Here, we show that subcellular localization of RP-mRNAs acts as a key regulator of their translation during cell migration. As cells migrate into their surroundings, RP-mRNAs localize to the actin-rich cell protrusions. This localization is mediated by La-related protein 6 (LARP6), an RNA-binding protein that is enriched in protrusions. Protrusions act as hotspots of translation for RP-mRNAs, enhancing RP synthesis, ribosome biogenesis, and the overall protein synthesis in migratory cells. In human breast carcinomas, epithelial-to-mesenchymal transition (EMT) upregulates LARP6 expression to enhance protein synthesis and support invasive growth. Our findings reveal LARP6-mediated mRNA localization as a key regulator of ribosome biogenesis during cell migration and demonstrate a role for this process in cancer progression downstream of EMT. Mastectomy patients\\' satisfaction with reconstructive options has not been examined.\\nA national study measured 18-month satisfaction with reconstructive options and collected case-mix and reconstructive offer and uptake data on breast cancer patients having mastectomy with or without immediate reconstruction (IR) in England between January 2008 and March 2009. Multivariable logistic regression examined the relationship between satisfaction, age, IR offer and uptake, and clinical suitability.\\nOf 4796 patients, 1889 were not offered IR, 1489 declined an offer and 1418 underwent it. Women not offered IR were more likely older, obese or smokers and had higher ASA grades, ECOG scores, tumour burdens and adjuvant chemotherapy and radiotherapy likelihoods (9% of lowest suitability group offered IR; 81% in highest suitability group). 83.7% were satisfied with their reconstructive options, varying significantly by IR offer and uptake (76.1% for those not offered IR; 85.8% for those who declined IR; 91.7% following IR). Older women and women deemed more suitable for IR were more often satisfied (p-values <0.001).\\nSatisfaction varied by offer and uptake status, age and suitability score. Clinicians should target equity for women deemed unsuitable by exploring their needs and desired outcomes, standardising operative fitness assessments and utilising shared decision-making aids. Venous congestion is the most common vascular complication of the deep inferior epigastric artery perforator (DIEP) flaps. Adding a second venous drainage by anastomosing a flap vein and a recipient vein (super-drainage) is considered the solution of choice. Evidence to support this procedure, had not yet been confirmed by an analysis of the literature. We aimed to provide this evidence.\\nWe searched the literature (MedLine, Scopus, EMBASE, Cochrane Library, and Google Scholar), for studies discussing venous congestion and venous super-drainage in DIEP flap for breast reconstruction. Thirteen of the 35 articles compared results between one or two venous anastomoses. Meta-analysis was performed following PRISMA guidelines. Pooled risk ratio (RRs) for congestion, fat necrosis, partial necrosis, and total necrosis with corresponding 95% confidence intervals (CI) were calculated using a fixed-effect model with the Mantel-Haenszel method. The need to return to surgery (95% CI) was estimated with a random effect model using the DerSimonian and Liard method.\\nWe showed a statistically significant advantage of super-drainage to reduce the venous congestion of the flap (RR: 0.12, 95% CI: 0.04-0.34, p-value <.001), partial flap necrosis (RR: 0.50, 95% CI: 0.30-0.84, p-value .008), total flap necrosis (RR: 0.31, 95% CI: 0.11-0.85, p-value .023), and the need to take the patient back to surgery for perfusion-related complications (RR: 0.45, 95% CI: 0.21-0.99, p value .048).\\nPerforming a second venous anastomosis between the SIEV and a recipient vein (venous superdrainage) reduces venous congestion and related complications in DIEP flaps for breast reconstruction. To identify a gene signature for the prognosis of breast cancer using high-throughput analysis.\\nRNASeq, single nucleotide polymorphism (SNP), copy number variation (CNV) data and clinical follow-up information were downloaded from The Cancer Genome Atlas (TCGA), and randomly divided into training set or verification set. Genes related to breast cancer prognosis and differentially expressed genes (DEGs) with CNV or SNP were screened from training set, then integrated together for feature selection of identify robust biomarkers using RandomForest. Finally, a gene-related prognostic model was established and its performance was verified in TCGA test set, Gene Expression Omnibus (GEO) validation set and breast cancer subtypes.\\nA total of 2287 prognosis-related genes, 131 genes with amplified copy numbers, 724 gens with copy number deletions, and 280 genes with significant mutations screened from Genomic Variants were closely correlated with the development of breast cancer. A total of 120 candidate genes were obtained by integrating genes from Genomic Variants and those related to prognosis, then 6 characteristic genes (CD24, PRRG1, IQSEC3, MRGPRX, RCC2, and CASP8) were top-ranked by RandomForest for feature selection, noticeably, several of these have been previously reported to be associated with the progression of breast cancer. Cox regression analysis was performed to establish a 6-gene signature, which can stratify the risk of samples from training set, test set and external validation set, moreover, the five-year survival AUC of the model in the training set and validation set was both higher than 0.65. Thus, the 6-gene signature developed in the current study could serve as an independent prognostic factor for breast cancer patients.\\nThis study constructed a 6-gene signature as a novel prognostic marker for predicting the survival of breast cancer patients, providing new diagnostic/prognostic biomarkers and therapeutic targets for breast cancer patients. For patients initially diagnosed with metastatic Her2-positive breast cancer (MHBC), we intended to construct a nomogram with risk stratification to predict prognosis and to explore the role of local surgery.\\nWe retrieved data from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier (KM) method and log-rank test were used for the selection of significant variables. Cox regression analysis and Fine-Gray test were utilized to confirm independent prognostic factors of overall survival (OS) and breast cancer-specific survival (BCSS). A nomogram predicting 1-year, 3-year, and 5-year OS was developed and validated. Patients were stratified based on the optimal cut-off values of total personal score. KM method and log-rank test were used to estimate OS prognosis and benefit from local surgery and chemotherapy.\\nThere were 1680 and 717 patients in the training and validation cohort. Age, race, marriage, T stage, estrogen receptor (ER) status, visceral metastasis (bone, brain, liver and lung) were identified as independent prognostic factors for OS and BCSS, while histology was also corelated with OS. C-indexes in the training and validation cohort were 0.70 and 0.68, respectively. Calibration plots indicated precise predictive ability. The total population was divided into low- (<141 points), intermediate- (142-208 points), and high-risk (>208 points) prognostic groups. Local surgery and chemotherapy brought various degrees of survival benefit for patients with diverse-risk prognosis.\\nWe constructed a model with accurate prediction and discrimination. It would provide a reference for clinicians\\' decision-making. Surgery on the primary lesion was recommended for patients with good physical performance status, while further study on optimal surgical opportunity was needed. Breast cancer is common global public health problem. It is the principal cause of cancer related death. In Ethiopia, study findings regarding prevalence and associated factors of BSE among female healthcare workers have been inconsistently reported and highly variable. Thus, this systematic review and meta-analysis aimed to determine the pooled prevalence of breast self-examination practice and determinants in Ethiopia.\\nA systematic search of PubMed, Medline, EMBASE, Global Health, Google Scholar, CINAHL and Scopus from April 2, 2020 to April 24, 2020. Data were extracted from articles included in the review using a data extraction tool which was adapted from the Joanna Briggs Institute. the quality of each included article was evaluated using the Newcastle-Ottawa scale. Data analysis was done using STATA 11. The Cochrane Q and I2 test were used to assess heterogeneity between the studies; and publication bias was assessed using funnel plots and Egger\\'s test. A random effects meta-analysis was computed to determine the pooled prevalence of breast self-examination. The determinants for breast self-examination were examined. Forest plots were used to present the prevalence and odds ratio with 95% confidence interval.\\nAfter reviewing 9605 studies, 12 studies involving 4129 female healthcare workers were included for this review and meta-analysis. The pooled prevalence of breast self-examination practice among healthcare workers in Ethiopia was 56.31% (95% CI: 44.37, 68.25). The subgroup analysis further revealed that the higher breast self-examination practice was observed among other healthcare workers, 58.60% (95% CI: 43.31, 73.90). Good knowledge (AOR = 3.02; 95% CI: 1.24, 7.35), positive attitude (AOR = 2.73; 95% CI: 1.95, 4.13) and family history of breast cancer (AOR = 3.21; 95% CI: 1.22, 6.52) were significantly associated with breast self-examination practice among healthcare workers.\\nThis meta-analysis found that nearly half of the female healthcare workers were not performed breast self-examination. The finding of this study suggests the need of strengthening early diagnosis of breast cancer and control strategies with a collaborative effort of policymakers and other concerned stakeholders. There is limited evidence on the intensity of end-of-life (EOL) care for women < 65 years old, who account for about 40% of breast cancer deaths in the United States. Using established indicators, we estimated the intensity of EOL care among these women.\\nWe used 2000-2014 claims data from a large US insurer to identify women with metastatic breast cancer who, in the last month of their lives, had more than one hospital admission, emergency department visit, or an intensive care unit (ICU) admission and/or used antineoplastic therapy in the last 14 days of life. Using multivariate logistic regression, we assessed whether intensity of EOL care differed by demographic characteristics, socioeconomic factors, or regions.\\nAdjusted estimates show an increase in EOL ICU admissions between 2000-2003 and 2010-2014 from 14% (95% CI, 10% to 17%) to 23% (95% CI, 20% to 26%) and a small increase in emergency department visits from 10% (95% CI, 7% to 13%) to 12% (95% CI, 9% to 15%), both statistically significant. There was no statistically significant change in the proportions of women experiencing more than one EOL hospitalization (14% in 2010-2014; 95% CI, 11% to 17%) and of those receiving EOL antineoplastic treatment (24% in 2010-2014; 95% CI, 21% to 27%). Living in predominantly mixed, Hispanic, Black, or Asian neighborhoods correlated with more intense care (odds ratio, 1.39; 95% CI, 1.10 to 1.77 for ICU).\\nConsistent with findings in the Medicare population, our results suggest an overall increase in the number of ICU admissions at the EOL over time. They also suggest that patients from non-White neighborhoods receive more intense acute care. The lungs are major sites of metastases for several cancer types, including breast cancer (BC). Prognosis and quality of life of BC patients that develop pulmonary metastases are negatively impacted. The development of strategies to slow the growth and relieve the symptoms of BC lung metastases (BCLM) is thus an important goal in the management of BC. However, systemically administered first line small molecule chemotherapeutics have poor pharmacokinetic profiles and biodistribution to the lungs and significant off-target toxicity, severely compromising their effectiveness. In this work, we propose the local delivery of add-on immunotherapy to the lungs to support first line chemotherapy treatment of advanced BC. In a syngeneic murine model of BCLM, we show that local pulmonary administration (p.a.) of PLX-3397 (PLX), a colony-stimulating factor 1 receptor inhibitor (CSF-1Ri), is capable of overcoming physiological barriers of the lung epithelium, penetrating the tumor microenvironment (TME), and decreasing phosphorylation of CSF-1 receptors, as shown by the Western blot of lung tumor nodules. That inhibition is accompanied by an overall decrease in the abundance of protumorigenic (M2-like) macrophages in the TME, with a concomitant increase in the amount of antitumor (M1-like) macrophages when compared to the vehicle-treated control. These effects with PLX (p.a.) were achieved using a much smaller dose (1 mg/kg, every other day) compared to the systemic doses typically used in preclinical studies (40-800 mg/kg/day). As an additive in combination with intravenous (i.v.) administration of paclitaxel (PTX), PLX (p.a.) leads to a decrease in tumor burden without additional toxicity. These results suggested that the proposed immunochemotherapy, with regional pulmonary delivery of PLX along with the i.v. standard of care chemotherapy, may lead to new opportunities to improve treatment, quality of life, and survival of patients with BCLM. In diffusion-weighted imaging (DWI) of breast MRI, simultaneous multislice acceleration techniques can be used for readout-segmented echo planar imaging (rs-EPI) to shorten the scan time.\\nTo compare the image quality, apparent diffusion coefficient (ADC) value, and scan time of rs-EPI and simultaneous multislice rs-EPI (SMS rs-EPI) sequences.\\nRetrospective.\\nIn all, 134 consecutive women (mean age: 55.3\\u2009years) with invasive breast cancer who underwent preoperative MRI.\\n3.0T; rs-EPI sequence, prototypic SMS rs-EPI sequence and dynamic contrast-enhanced MRI (DCE-MRI) sequence ASSESSMENT: For quantitative comparison, two radiologists independently measured the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), lesion contrast, and apparent diffusion coefficient (ADC). For qualitative comparison, image quality, lesion conspicuity, and reader preference were assessed with a reference of DCE-MRI.\\nPaired t-tests and Mann-Whitney tests were used.\\nFor SNR and CNR, there were no differences between the sequences (P = 0.342 and 0.665 for reader 1; P = 0.606 and P = 0.116 for reader 2). Lesion contrast of SMS rs-EPI was higher than that of rs-EPI (P\\u2009<\\u20090.05 for both reader 1 and reader 2). Mean tumor ADC was similar in rs-EPI and SMS rs-EPI sequences (0.98\\u2009±\\u20090.22 vs. 1.00\\u2009±\\u20090.22; P = 0.291 for reader 1, 0.98\\u2009±\\u20090.21 vs. 1.00\\u2009±\\u20090.22; P = 0.418 for reader 2). Regarding qualitative comparison, image quality and lesion conspicuity were higher in SMS rs-EPI than in rs-EPI (both P\\u2009<\\u20090.05 for both readers). The two readers regarded SMS rs-EPI as superior or equal to rs-EPI in over 90% of cases. The acquisition time was 4:30\\u2009minutes for rs-EPI and 2:31\\u2009minutes for SMS rs-EPI.\\nThe SMS rs-EPI sequence resulted in a similar ADC value and better image quality than the rs-EPI sequence in a 44.1% reduced scan time.\\n4 TECHNICAL EFFICACY: 3. During the coronavirus disease 2019 (COVID-19) pandemic, cancer screening decreased precipitously; home screening for colorectal cancer diminished less than that for colonoscopy and breast and cervical cancer screening. The authors have highlighted approaches for home cancer screening in addition to telemedicine. Women of lower socioeconomic status (SES) with early-stage breast cancer are more likely to report poorer physician-patient communication, lower satisfaction with surgery, lower involvement in decision making, and higher decision regret compared to women of higher SES. The objective of this study was to understand how to support women across socioeconomic strata in making breast cancer surgery choices.\\nWe conducted a 3-arm (Option Grid, Picture Option Grid, and usual care), multisite, randomized controlled superiority trial with surgeon-level randomization. The Option Grid (text only) and Picture Option Grid (pictures plus text) conversation aids were evidence-based summaries of available breast cancer surgery options on paper. Decision quality (primary outcome), treatment choice, treatment intention, shared decision making (SDM), anxiety, quality of life, decision regret, and coordination of care were measured from T0 (pre-consultation) to T5 (1-year after surgery.\\nSixteen surgeons saw 571 of 622 consented patients. Patients in the Picture Option Grid arm (n = 248) had higher knowledge (immediately after the visit [T2] and 1 week after surgery or within 2 weeks of the first postoperative visit [T3]), an improved decision process (T2 and T3), lower decision regret (T3), and more SDM (observed and self-reported) compared to usual care (n = 257). Patients in the Option Grid arm (n = 66) had higher decision process scores (T2 and T3), better coordination of care (12 weeks after surgery or within 2 weeks of the second postoperative visit [T4]), and more observed SDM (during the surgical visit [T1]) compared to usual care arm. Subgroup analyses suggested that the Picture Option Grid had more impact among women of lower SES and health literacy. Neither intervention affected concordance, treatment choice, or anxiety.\\nPaper-based conversation aids improved key outcomes over usual care. The Picture Option Grid had more impact among disadvantaged patients.\\nThe objective of this study was to understand how to help women with lower incomes or less formal education to make breast cancer surgery choices. Compared with usual care, a conversation aid with pictures and text led to higher knowledge. It improved the decision process and shared decision making (SDM) and lowered decision regret. A text-only conversation aid led to an improved decision process, more coordinated care, and higher SDM compared to usual care. The conversation aid with pictures was more helpful for women with lower income or less formal education. Conversation aids with pictures and text helped women make better breast cancer surgery choices. None As an alternative to traditional wire localization, an inducible magnetic seed system can be used to identify and remove nonpalpable breast lesions and axillary lymph nodes intraoperatively. We report the largest single-institution experience of magnetic seed placement for operative localization to date, including feasibility and short-term outcomes.\\nPatients who underwent placement of a magnetic seed in the breast or lymph node were identified from July 2017 to March 2019. Imaging findings, core needle biopsy, surgical pathology results, and type of surgery were collected. Outcomes included procedural complications, magnetic seed and biopsy clip retrieval rates, and need for additional surgery.\\nA total of 842 magnetic seeds were placed by nine radiologists in 673 patients and retrieved by six surgeons at six operative locations. The majority of breast lesions were malignant (395/659, 59.9%); 136 seeds were placed for lymph node localization. The overall magnetic seed retrieval rate was 98.6%, whereas the biopsy clip retrieval rate was 90.9%. Only six patients (0.7%) experienced a complication from magnetic seed placement. Reexcision was performed in 15.2% of patients with breast cancer; 9.6% of benign/high risk lesions were upgraded to malignancy at surgical excision.\\nThe magnetic seed technique is safe, effective, and accurate for localization of breast lesions and lymph nodes, and importantly uncouples surgery from the localization procedure. The high magnetic seed retrieval rate and low reexcision rate may reflect the accuracy of magnetic marker placement as a \"second chance\" localization procedure, especially in cases with biopsy clip migration. None Matrix metallopeptidases (MMPs) 1 and 3 have been shown to contribute to the initiation, and progression of different cancers, including breast cancer (BC). In this study, we aimed to examine the relations between polymorphisms of MMP1 (rs1799750) and MMP3 (rs632478) and their circulating levels with BC. The polymorphisms were genotyped by PCR-based Restriction Fragment Length Polymorphism (RFLP) and Allele-Specific PCR (AS-PCR) among 100 patients and 100 controls. MMP1 and MMP3 serum levels were measured by enzyme-linked immunosorbent assay (ELISA). Genotype distributions of MMP1 and MMP3 genes showed significant difference between patients and controls. The distribution of 2G/2G, 1G/2G and 1G/1G genotypes for MMP1 was 74%, 2% and 24% in the patients and 38%, 2% and 60% in the controls, respectively (P\\u2009=\\u20090.0001). For MMP3 the distribution of C/C, A/C and A/A genotypes was 28%, 54% and 18% in patients and 48%, 40% and 12% in controls, respectively (P\\u2009=\\u20090.01). For MMP1, the 2G/2G genotype was linked with a higher risk of BC when compared with that of the 1G/1G genotype (OR\\u2009=\\u20094.86; 95% CI\\u2009=\\u20092.63-8.99; P\\u2009=\\u20090.0001). For MMP3, in co-dominant model, there was a higher risk of BC in A/A and A/C genotype carriers (A/A: OR\\u2009=\\u20092.57; 95% CI\\u2009=\\u20091.08-6.11; P\\u2009=\\u20090.03) (A/C: OR\\u2009=\\u20092.31 95% CI\\u2009=\\u20091.24-4.30; P\\u2009=\\u20090.008). We also showed that MMP1 and MMP3 serum level was significantly increased in BC patients compared to controls. MMP1 and MMP3 genetic variations and their circulating levels are both significantly related to BC. Background Palbociclib and ribociclib are novel oral agents in hormone receptor-positive metastatic breast cancer. Neutropenia is a common adverse event associated with these treatments and its clinical management often requires regimen changes, such as cycle delays and dose adjustments. Objective To provide a real-world experience of the effectiveness and toxicities associated with these drugs and to evaluate the impact of regimen changes in disease progression. Setting This study was performed at Hospital Universitario La Paz, in Spain. Methods Observational, retrospective study which included hormone receptor-positive metastatic breast cancer patients who initiated treatment with palbociclib or ribociclib between March 1st, 2018 and March 1st, 2019. Main outcome measure The primary effectiveness variable was progression-free survival. Safety evaluation was performed to determine neutropenia-incidence and severity, as well as its clinical management, including dose adjustments and treatment interruptions. Correlations between these regimen changes and effectiveness were also evaluated. Results Sixty-one patients were included, 33 treated with palbociclib and 28 with ribociclib. Palbociclib was mainly used as second line of treatment in the metastatic setting (81.8%) and ribociclib as first line (67.9%). The median progression-free survival was 12.76\\xa0months (95% CI 7.5 to not estimable) in palbociclib and not reached in ribociclib. After 12\\xa0months, the progression-free survival rate was 51.5% (95% CI 34-69) in palbociclib and 78.6% (95% CI 63-94.1) in ribociclib. Neutropenia was the most common adverse event with an incidence rate of 87.9% in palbociclib and 82.1% in ribociclib. Cycle delays were needed in more than half of the patients treated with palbociclib and ribociclib (63.6% and 64.3%). Dose adjustments were seen in 42.4% and 53.6% of the patients receiving palbociclib and ribociclib, respectively. Regimen changes did not involve statistically significant differences in 12-month PFS rates in the cohort investigated. Conclusion Palbociclib and ribociclib outcomes are comparable to those reached in the phase III trials, PALOMA-3 and MONALEESA-2, respectively, and cannot be compared as they were used in different treatment settings. The toxicity profile is favourable, being neutropenia the most common adverse event, easily managed with regimen changes. Further studies are needed to confirm the observed tendency of no detrimental impact on effectiveness of these regimen changes. To identify physical activity level, exercise behavior, barriers, and preferences in female patients with breast cancer-related lymphedema (BCRL).\\nPatients with BCRL consulted to physical therapy to receive lymphedema treatment were included. Age, gender, body mass index matched healthy controls (HC) were included to identify differences. The transtheoretical model was used to determine exercise behavior. Physical activity level was assessed by the International Physical Activity Questionnaire-Short Form (IPAQ-SF). The exercise barriers and preferences of patients with BCRL were recorded using a checklist based on the previous studies.\\nA total of 48 female patients with BCRL and 38 female HC participated in the study. Physical activity level was significantly lower in patients with BCRL when compared to HC (p ˂ 0.05). However, the number of participants who engaged in regular exercise was significantly higher in patients with BCRL than HC (33.2% vs 7.9%, p ˂ 0.05). The most common exercise barriers were fatigue (64.5%), having other responsibilities (60.4%), and weather-related factors (56.2%). Majority of the participants preferred to participate in a supervised (79.1%), structured (66.6%), combined-type (77.1%), and moderate intensity (79.1%) exercise program, and they preferred to be informed at the time of the cancer diagnosis (45.8%) by a physiotherapist (66.6%). Moreover, the most preferred exercise type was walking/jogging (66.6%).\\nThe present study showed inadequate physical activity and exercise behavior in patients with BCRL. Supportive care interventions are needed to overcome barriers for patients with BCRL. Preferences of patients and exercise enjoyment should also be taken into consideration to increase the participation in exercises. Background Due to the rarity of primary bone tumors, precise radiologic diagnosis often requires an experienced musculoskeletal radiologist. In order to make the diagnosis more precise and to prevent the overlooking of potentially dangerous conditions, artificial intelligence has been continuously incorporated into medical practice in recent decades. This paper reviews some of the most promising systems developed, including those for diagnosis of primary and secondary bone tumors, breast, lung and colon neoplasms. Conclusions Although there is still a shortage of long-term studies confirming its benefits, there is probably a considerable potential for further development of computer-based expert systems aiming at a more efficient diagnosis of bone and soft tissue tumors. Background Few results are available about subsequent outcomes after screening with digital breast tomosynthesis (DBT). Purpose To compare the diagnostic accuracy of a screening round with DBT plus synthetic mammography (SM) (hereafter, DBT+SM) and the repeat screening round with DBT with SM (hereafter, DBT+SM) or full-field digital mammography (FFDM) with FFDM screening. Materials and Methods This prospective study (Verona Pilot Study, clinical trial identification: 2015/1238) included women screened with DBT+SM between April 2015 and March 2017 and rescreened with DBT+SM or FFDM between April 2017 and March 2019. Screening performance (recall rate, cancer detection rate [CDR], and positive predictive value of recall [PPV1]) was compared with that obtained from 28\\u2009680 women screened with FFDM between 2013 and 2014 (control group). Cancer stages were compared between modalities and screening rounds. A χ In this study, some novel cyanine dyes, 1, 3, and 5-15, were synthesized by a one-pot step reaction of pyridinium salts 2 and/or 4 with benzenaminium salt 1. N-{[1-Chloro-3,4-dihydronaphthalen-2-yl)methylene]benzenaminium} chloride 1 was obtained by the reaction of α-tetralone with Vilsmeier-Haack reagent, followed by a mixture of an equimolar ratio of anilin/ethanol (1:1). All new cyanine dyes were evaluated in vitro for their anticancer activity against two cell lines, that is, HepG2 (human hepatocellular liver carcinoma) and MCF-7 (breast cancer). The obtained results were compared with human lung fibroblasts (WI-38) and Vero cells (derived from the kidney of an African green monkey) as normal cells. In particular, some of these compounds, 6, 9, 13, and 14, were found to be the most potent derivatives against all the cancer cell lines, without effect on the normal cells. According to the structure-activity relationship, compound 13 (IC Advanced breast cancer is an outcome used to evaluate screening effectiveness. The advanced cancer definition resulting in the best discrimination of breast cancer death has not been studied in a breast imaging population.\\n52,496 women aged 40-79\\u2009years participating in the Breast Cancer Surveillance Consortium diagnosed with invasive cancer were staged using the eighth edition of American Joint Committee on Cancer (AJCC) anatomic and prognostic pathologic systems and Tomosynthesis Mammographic Imaging Screening Trial (TMIST) tumor categories. We calculated the area under the receiver operating characteristic curve (AUC) for predicting 5-year breast cancer death and the sensitivity and specificity for predicting 5-year breast cancer death for three advanced cancer classifications; anatomic stage IIB or higher, prognostic pathologic stage IIA or higher, and TMIST advanced cancer.\\nThe AUCs for predicting 5-year breast cancer death for AJCC anatomic stage, AJCC prognostic pathologic stage, and TMIST tumor categories were 0.826 (95% confidence interval [CI]=0.817, 0.835), 0.856 (95%CI\\u2009=\\u20090.846, 0.866), and 0.789 (95%CI\\u2009=\\u20090.780, 0.797), respectively. AJCC prognostic pathologic stage had statistically significantly better discrimination than AJCC anatomic stage (difference\\u2009=\\u20090.030, bootstrap 95%CI\\u2009=\\u20090.024, 0.037) and TMIST tumor categories (difference\\u2009=\\u20090.067, bootstrap 95%CI\\u2009=\\u20090.059, 0.075). The sensitivity and specificity for predicting 5-year breast cancer death for AJCC anatomic stage IIB or higher, AJCC prognostic pathologic stage IIA or higher, and TMIST advanced cancer were (72.6%, 76.7%, 96.1%) and (78.9%, 81.6%, 41.1%), respectively.\\nDefining advanced cancer as AJCC prognostic pathologic stage IIA or higher most accurately predicts breast cancer death. Use of this definition by investigators will facilitate comparing breast cancer screening effectiveness studies. PALB2 has been identified as a breast and pancreatic cancer susceptibility gene. Utilizing a targeted sequencing approach, we discovered two novel germline missense PALB2 variants c.191C>T and c.311C>T, encoding p.Ser64Leu and p.Pro104Leu, respectively, in individuals in a pancreatic cancer registry. No missense PALB2 variants from familial pancreatic cancer patients, and few PALB2 variants overall, have been functionally characterized. Given the known role of PALB2, we tested the impact of p.Ser64Leu and p.Pro104Leu variants on DNA damage responses. Neither p.Ser64Leu nor p.Pro104Leu had clear effects on interactions with BRCA1 and KEAP1, which are mediated by adjacent motifs in PALB2. However, both variants are associated with defective recruitment of PALB2, and the RAD51 recombinase downstream, to DNA damage foci. Further, p.Ser64Leu and p.Pro104Leu both largely compromise DNA double-strand break-initiated homologous recombination, and confer increased cellular sensitivity to ionizing radiation (IR) and the poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib. Taken together, our results represent the first demonstration of functionally deleterious PALB2 missense variants associated with familial pancreatic cancer and of deleterious variants in the N-terminus outside of the coiled-coil domain. Further, our results suggest the possibility of personalized treatments, using IR or PARP inhibitor, of pancreatic and other cancers that carry a deleterious PALB2 variant. This article is protected by copyright. All rights reserved. In the analysis of censored survival data, to avoid a biased inference of treatment effects on the hazard function of the survival time, it is important to consider the treatment heterogeneity. Without requiring any prior knowledge about the subgroup structure, we propose a data driven subgroup analysis procedure for the heterogeneous Cox model by constructing a pairwise fusion penalized partial likelihood-based objective function. The proposed method can determine the number of subgroups, identify the group structure, and estimate the treatment effect simultaneously and automatically. A majorized alternating direction method of multipliers algorithm is then developed to deal with the numerically challenging high-dimensional problems. We also establish the oracle properties and the model selection consistency for the proposed penalized estimator. Our proposed method is evaluated by simulation studies and further illustrated by the analysis of the breast cancer data. Although the PIG-A gene mutation frequency (MF) is considered a good proxy to evaluate the somatic MF in animals, evidence remains scarce in humans. In this study, a granulocyte PIG-A-mutant assay was evaluated in patients undergoing radiation therapy (RT) for breast cancer. Breast cancer patients undergoing adjuvant RT were prospectively enrolled. RT involved the whole breast, with (WBNRT) or without (WBRT) nodal area irradiation. Blood samples were obtained from participants before (T0) RT, and T1, T2 and T3 samples were collected 3\\u2009weeks after the initiation of RT, at the end of RT, and at least 10\\u2009weeks after RT discontinuation, respectively. The MF was assessed using a flow cytometry protocol identifying PIG-A-mutant granulocytes. Cytokinesis-blocked micronucleated lymphocyte (CBML) frequencies were also evaluated. Thirty patients were included, and five of them had received chemotherapy prior to RT. The mean (±SD) PIG-A MFs were 7.7 (±12.1) per million at T0, 5.2 (±8.6) at T1, 6.4 (±8.0) at T2 and 3.8 (±36.0) at T3. No statistically significant increases were observed between the PIG-A MF at T0 and the MFs at other times. RT significantly increased the CBML frequencies: 7.9 ‰ (±3.1‰) vs. 33.6‰ (±17.2‰) (p<0.0001). By multivariate analysis, the CBML frequency was correlated with age at RT initiation (p=0.043) and irradiation volume at RT discontinuation (p=0.0001) but not with chemotherapy. RT for breast cancer therapy failed to induce an increase in the PIG-A MF. The PIG-A assay in humans needs further evaluation, in various genotoxic exposures and including various circulating human cells. This article is protected by copyright. All rights reserved. This study examines the relationship between language preference and screening mammogram adherence in medically underserved women in New York City. A survey was conducted with 518 women age 40 and over attending breast health education programs in English, Spanish, Chinese (Mandarin/Cantonese), and French. Women who preferred Chinese were 53% less likely to have had a mammogram within the past year compared to women who preferred English (p < .01). Women age 75 and older (p < .0001) and those without insurance (p < .05) were also found to be significantly less likely to have had a screening mammogram compared to women ages 55-74 and those with private insurance, respectively. This research indicates medically underserved women who prefer a non-English language may benefit from linguistically appropriate interventions to improve screening mammogram adherence. Future research should examine appropriateness of breast cancer screening for women age 75 and older and explore ways to improve screening mammogram use in the uninsured population. None None High plasma vitamin D (VitD) level and regular exercise (Ex) are known to have anti-cancer and immunomodulatory effects. This study aimed to evaluate the impact of VitD supplementation and imposed physical Ex on mammary tumour growth and immune response in ovariectomised mice fed high-fat (HF) diet.\\nOvariectomised 33-week-old mice C57BL/6 (n\\u2009=\\u200960), housed in enriched environment (EE), were fed HF diet (450\\xa0kcal/100\\xa0g) supplemented or not with VitD (HF/HF\\u2009+\\u2009D: 125/1225\\xa0IU/100\\xa0g) for 12\\xa0weeks and submitted or not to Ex (HF\\u2009+\\u2009Ex; HF\\u2009+\\u2009D\\u2009+\\u2009Ex) on treadmill (45\\xa0min/day, 5\\xa0days/week). At w8, syngeneic tumour cells EO771 were orthotopically injected into the 4th mammary gland. Spontaneous activity (SPA), maximal speed (MS) and forelimb grip strength (GS) were measured. Tumour immune cells infiltrate was phenotyped by FACS. Data (mean\\u2009±\\u2009SEM) were analysed by two-way ANOVA\\u2009+\\u2009Tukey post-test.\\nEx (p\\u2009=\\u20090.01) and VitD (p\\u2009=\\u20090.05) reduced body weight gain. Exercise decreased visceral fat mass [g: 1.5\\u2009±\\u20090.8 (HF); 1.2\\u2009±\\u20090.65 (HF\\u2009+\\u2009Ex); 0.9\\u2009±\\u20090.6 (HF\\u2009+\\u2009D\\u2009+\\u2009Ex); p\\u2009=\\u20090.03]. SPA (p\\u2009<\\u20090.0001) and GS (p\\u2009=\\u20090.01) were higher in HF\\u2009+\\u2009D\\u2009+\\u2009Ex mice vs others. No effect of Ex or VitD on tumour growth was detected. In tumour, VitD decreased the proportion of NK (p\\u2009=\\u20090.03), while Ex increased it (p\\u2009=\\u20090.03). The Th1/Th2 ratio is lowered by VitD (p\\u2009=\\u20090.05), while Tc/Treg ratio was not affected either by Exercise or VitD.\\nIn our experimental conditions, VitD supplementation and physical exercise have synergetic effects reducing the weight gain under HF diet and improving the physical capacities of mice. VitD coupled with exercise induces an immunosuppressive response without effect on tumour growth. Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplastic proliferations showing different morphological features, immunophenotype, molecular background, clinical presentation, and outcome. They can virtually originate in every organ of the human body and their classification is not uniform among different sites. Indeed, as they have historically been classified according to the organ in which they primarily arise, the different nomenclature that has resulted have created some confusion among pathologists and clinicians. Although a uniform terminology to classify neuroendocrine neoplasms arising in different systems has recently been proposed by WHO/IARC, some issues remain unsolved or need to be clarified. In this review, we discuss the lights and shadows of the current WHO classifications used to define and characterize NENs of the pituitary gland, lung, breast and those of the head and neck region, and digestive and urogenital systems. To investigate whether health literacy (HL) among informal caregivers of breast cancer (BC) survivors is associated with patient psychological outcomes.\\nWe used data (n = 340 pairs) from baseline questionnaires administered in the MyHealth trial investigating nurse-led BC follow-up. All BC survivors and their invited caregivers were included immediately after completion of primary treatment. We performed multivariate regression analyses to examine the association between caregiver HL (nine dimensions as measured by the Health Literacy Questionnaire) as exposure and patient depression, anxiety, and health-related quality of life (HQoL) as outcomes. We further examined whether any association differed according to type of caregiver, patient HL, and patient activation (skill in managing one\\'s health).\\nThree dimensions, \"ability to engage with providers\" (β = - 0.2), \"navigating the system\" (β = - 0.2), and \"understand health information\" (β = - 0.2), were significantly associated with lower patient depression (p < 0.05), while four dimensions, \"having sufficient information\" (β = 0.3), \"navigating the system\" (β = 0.2), \"find health information\" (β = 0.2), and \"understand health information\" (β = 0.2), were significantly associated with better patient HQoL (p < 0.05). No significant associations were found for anxiety. Patient HL and activation did not significantly modify the associations, while certain associations for depression were stronger in patients with non-partner caregivers.\\nThe HL of informal caregivers may play an important role in optimizing psychological outcomes in cancer survivors.\\nInvolving informal caregivers, who can provide support related to health information and services, may be beneficial for the psychological well-being of cancer survivors. This study evaluated the bioequivalence of China-manufactured biosimilar, HLX02, to reference China (CN)- and European Union (EU)-sourced trastuzumab.\\nThis was a two-part Phase 1 study conducted in healthy Chinese males. Part 1 evaluated the safety of different doses of HLX02 (2, 4, 6 or 8\\xa0mg/kg; intravenous infusion over 90\\xa0min, n\\u2009=\\u20093 per group). Part 2, a randomized, double-blind study, investigated the pharmacokinetics (PK), safety and immunogenicity of study drugs (HLX02 [n\\u2009=\\u200937], CN-trastuzumab [n\\u2009=\\u200935] or EU-trastuzumab [n\\u2009=\\u200937] at the dose suggested by Part 1 results). The primary PK endpoint was the area under the serum concentration-time curve from time 0 to infinity (AUC\\nIn Part 1, all doses of HLX02 were well tolerated and 6\\xa0mg/kg was suggested for Part 2. The GLSMRs and 90% CIs for AUC\\nThis study demonstrated comparable safety profiles and PK bioequivalence among HLX02, CN-trastuzumab and EU-trastuzumab in healthy Chinese male subjects.\\nClinicalTrials.gov, NCT02581748, registered at October 19, 2015. Prenatal exposure to maternal smoking is detrimental to child health but its association with risk of cancer has seldom been investigated. Maternal smoking induces widespread and long-lasting DNA methylation changes, which we study here for association with risk of cancer in adulthood.\\nEight prospective case-control studies nested within the Melbourne Collaborative Cohort Study were used to assess associations between maternal-smoking-associated methylation marks in blood and risk of several cancers: breast (n\\u2009=\\u2009406 cases), colorectal (n\\u2009=\\u2009814), gastric (n\\u2009=\\u2009166), kidney (n\\u2009=\\u2009139), lung (n\\u2009=\\u2009327), prostate (n\\u2009=\\u2009847) and urothelial (n\\u2009=\\u2009404) cancer and B-cell lymphoma (n\\u2009=\\u2009426). We used conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between cancer and five methylation scores calculated as weighted averages for 568, 19, 15, 28 and 17 CpG sites. Models were adjusted for confounders, including personal smoking history (smoking status, pack-years, age at starting and quitting) and methylation scores for personal smoking.\\nAll methylation scores for maternal smoking were strongly positively associated with risk of urothelial cancer. Risk estimates were only slightly attenuated after adjustment for smoking history, other potential confounders and methylation scores for personal smoking. Potential negative associations were observed with risk of lung cancer and B-cell lymphoma. No associations were observed for other cancers.\\nWe found that methylation marks of prenatal exposure to maternal smoking are associated with increased risk of urothelial cancer. Our study demonstrates the potential for using DNA methylation to investigate the impact of early-life, unmeasured exposures on later-life cancer risk. Breast cancer (BC) is a genetically heterogeneous disease with high prevalence in Northern Europe. However, there has been no detailed investigation into the Scandinavian somatic landscape. Here, in a homogeneous Swedish cohort, we describe the somatic events underlying BC, leveraging a targeted next-generation sequencing approach. We designed a 20.5\\xa0Mb array targeting coding and regulatory regions of genes with a known role in BC (n\\u2009=\\u2009765). The selected genes were either from human BC studies (n\\u2009=\\u2009294) or from within canine mammary tumor associated regions (n\\u2009=\\u2009471). A set of predominantly estrogen receptor positive tumors (ER\\u2009+\\u2009 85%) and their normal tissue counterparts (n = 61) were sequenced to\\u2009~\\u2009140\\u2009×\\u2009and 85\\u2009×\\u2009mean target coverage, respectively. MuTect2 and VarScan2 were employed to detect single nucleotide variants (SNVs) and copy number aberrations (CNAs), while MutSigCV (SNVs) and GISTIC (CNAs) algorithms estimated the significance of recurrent somatic events. The significantly mutated genes (q\\u2009≤\\u20090.01) were PIK3CA (28% of patients), TP53 (21%) and CDH1 (11%). However, histone modifying genes contained the largest number of variants (KMT2C and ARID1A, together 28%). Mutations in KMT2C were mutually exclusive with PI3KCA mutations (p\\u2009≤\\u20090. 001) and half of these affect the formation of a functional PHD domain. The tumor suppressor CDK10 was deleted in 80% of the cohort while the oncogene MDM4 was amplified. Mutational signature analyses pointed towards APOBEC deaminase activity (COSMIC signature 2) and DNA mismatch repair (COSMIC signature 6). We noticed two significantly distinct patterns related to patient age; TP53 being more mutated in the younger group (29% vs 9% of patients) and CDH23 mutations were absent from the older group. The increased somatic mutation prevalence in the histone modifying genes KMT2C and ARID1A distinguishes the Swedish cohort from previous studies. KMT2C regulates enhancer activation and assists tumor proliferation in a hormone-rich environment, possibly pointing to a role in ER\\u2009+\\u2009BC, especially in older cases. Finally, age of onset appears to affect the mutational landscape suggesting that a larger age-diverse population incorporating more molecular subtypes should be studied to elucidate the underlying mechanisms. I have been a nurse for 40 years and I now have metastatic breast cancer. I have learned a lot, especially about giving bad news, disclosing the diagnosis to others, and using the hospital\\'s patient portal. First, how bad news is given to patients is important and should provide clear next steps for follow-up and treatment. Second, telling family, friends, and colleagues about a new cancer diagnosis is more challenging than you might expect. It is emotionally draining and time consuming, and support by primary care clinicians (PCCs) could make a difference. Finally, patient portals can be very beneficial, but their use in a complex diagnostic process like metastatic cancer can be problematic. Primary care clinicians should explicitly discuss use of portals with patients so that they receive the information they need in the way they want. On May 24, 2019, the FDA granted regular approval to alpelisib in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, HER2-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Approval was based on the SOLAR-1 study, a randomized, double-blind, placebo-controlled trial of alpelisib plus fulvestrant versus placebo plus fulvestrant. The primary endpoint was investigator-assessed progression-free survival (PFS) per RECIST v1.1 in the cohort of trial participants whose tumors had a PIK3CA mutation. The estimated median PFS by investigator assessment in the alpelisib plus fulvestrant arm was 11.0 months (95% CI: 7.5, 14.5) compared with 5.7 months (95% CI: 3.7, 7.4) in the placebo plus fulvestrant arm (HR 0.65; 95% CI: 0.50, 0.85; two-sided p=0.001). The median overall survival (OS) was not yet reached for the alpelisib plus fulvestrant arm (95% CI: 28.1, NE) and was 26.9 months (95% CI: 21.9, NE) for the fulvestrant control arm. No PFS benefit was observed in trial participants whose tumors did not have a PIK3CA mutation (HR = 0.85; 95% CI: 0.58, 1.25).The most common adverse reactions, including laboratory abnormalities, on the alpelisib plus fulvestrant arm were increased glucose, increased creatinine, diarrhea, rash, decreased lymphocyte count, increased gamma glutamyl transferase, nausea, increased alanine aminotransferase, fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, decreased weight, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time, and alopecia. On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Approval was based on data from the IMMU-132-01 trial, a single-arm, multicohort, multicenter, Phase 1/2 trial of sacituzumab govitecan. The assessment of efficacy was based on 108 patients with mTNBC who had previously received at least two prior lines of therapy in the metastatic setting and who received sacituzumab govitecan 10 mg/kg intravenously (IV). The assessment of safety was based on 408 patients with advanced solid tumors who had received sacituzumab govitecan at doses up to 10 mg/kg IV. The primary efficacy endpoint was investigator-assessed objective response rate (ORR) and duration of response (DoR) was a key secondary endpoint. The ORR was 33.3% [36/108, 95% CI: 24.6, 43.1], and median DoR among responders was 7.7 months (95% CI: 4.9, 10.8). The most common adverse reactions occurring in ≥25% of patients were nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain. This article summarizes the FDA review process and data supporting the approval of sacituzumab govitecan. The novel erector spinae plane block (ESPB) has been reported to provide important postoperative analgesic benefits following a variety of truncal and abdominal surgical procedures. However, evidence of its analgesic efficacy following breast cancer surgery, compared with parenteral analgesia, is unclear. This meta-analysis evaluates the analgesic benefits of adding ESPB to parenteral analgesia following breast cancer surgery.Databases were searched for breast tumor resection trials comparing ESPB to parenteral analgesia. The two co-primary outcomes examined were 24-hour postoperative oral morphine equivalent consumption and area-under-curve of rest pain scores. We considered reductions equivalent to 3.3 cm.h and 30 mg oral morphine in the first 24 hours postoperatively for the two co-primary outcomes, respectively, to be clinically important. We also assessed opioid-related side effects and long-term outcomes, including health-related quality of life, persistent postsurgical pain and opioid dependence. Results were pooled using random effects modeling.Twelve trials (699 patients) were analyzed. Moderate quality evidence suggested that ESPB decreased 24-hour morphine consumption and area-under-curve of rest pain by a mean difference (95% CI) of -17.60 mg (-24.27 to -10.93) and -2.74 cm.h (-3.09 to -2.39), respectively; but these differences were not clinically important. High-quality evidence suggested that ESPB decreased opioid-related side effects compared with parenteral analgesia by an OR (95% CI) of 0.43 (0.28 to 0.66). None of the studies evaluated long-term block benefits.Adding ESPB to parenteral analgesia provides statistically significant but clinically unimportant short-term benefits following breast cancer surgery. Current evidence does not support routine use of ESPB. Given the very modest short-term benefits and risk of complications, the block should be considered on a case-by-case basis. Our  To observe the effect of functional modulation of gap junctions (GJ) on the antitumor effect of adriamycin in breast cancer cells positive for estrogen receptor (ER).\\nThe inhibitory effect of 0 to 24.0 μmol/L adriamycin on the surviving fraction of ER-positive human breast cancer MCF-7 cells and ER-negative MDA-MB-231 cells was assessed with MTT assay; Western blotting and immunofluorescence assay were used to detect the expressions of Cx43 total protein and membrane protein in the cells. A parachute assay was used to evaluate the function of the GJ in MCF-7 cells. The cytotoxic effect of adriamycin was observed in the cells treated with retinoic acid (RA) for enhancing GJ function, in cells treated with oleamide and 18-\\nER-positive MCF-7 cells expressed a significantly higher level of Cx43 with stronger GJ function than ER-negative MDA- MB-231 cells. Adriamycin significantly inhibited the proliferation of MCF-7 cells (\\nER-positive breast cancer cells have stronger Cx43 expressions and GJ function than the ERnegative cells. The cytotoxicity of adriamycin against the breast cancer cells can be strengthened by enhancing GJ function and attenuated by inhibiting GJ function. Cx43 silencing inhibits the function of GJ to lower the cytotoxicity of adriamycin in human breast cancer MCF-7 cells. To explore the value of urinary long non-coding RNA(lncRNA) H19 in the differential diagnosis of acute intestinal necrosis against other abdominal emergencies.\\nSurgical specimens of necrotic intestinal tissues, adjacent normal intestinal tissues, and serum and urine samples were collected from 51 patients with acute intestinal necrosis, and analyzed along with the serum and urine samples from 51 healthy controls, patients with 10 different acute abdominal conditions(35 cases for each condition), and patients with breast cancer, gastric cancer, bladder cancer, acute myeloid leukemia, and lung cancer(10 cases for each malignancy). The expression levels of H19 were measured with quantitative PCR in the collected samples. Receiver-operating characteristic(ROC)curves were used to determine the diagnostic value of serum and urine H19 levels for acute intestinal necrosis.\\nThe 51 patients with acute intestinal necrosis included 35 women and 26 men(mean age of 74.4 years) with arterial thrombosis as the dominant etiology(26 cases). Compared with that in normal intestinal tissues, H19 was significantly overexpressed by 11.2 times in necrotic intestinal tissues(\\nIn patients with acute intestinal necrosis, H19 is overexpressed in necrotic intestinal tissues, from which it is released into the blood circulation and urine. Urinary H19 may serve as a novel and non-invasive biomarker that assists in early diagnosis of acute intestinal necrosis. To investigate the role of miR- 433 in chemoresistance to docetaxel in breast cancer cells.\\nA docetaxel-resistant MCF-7 breast cancer cell line (MCF-7/DOX) was established by exposure of parental MCF-7 cells to progressively increased docetaxel concentrations. The functional role of miR-433 was investigated by assessing the changes in viability and apoptosis of the cells transfected with a miR-433 inhibitor or a miR-433 mimics. The downstream targets of miR- 433 were determined by bioinformatics analysis, cell transfection and luciferase reporter assay.\\nQuantitative real-time PCR analysis showed that miR- 433 was down-regulated in MCF-7/DOX cells. Transfection of the cells with the miR-433 inhibitor obviously enhanced chemoresistance to docetaxel and attenuated cell apoptosis in MCF-7 cells; miR-433 overexpression significantly increased the sensitivity to docetaxel and promoted apoptosis in MCF- 7/DOX cells. Luciferase reporter assay showed that the down-regulation miR-433 expression was associated with significantly increased expressions of Notch1 at both mRNA and protein levels in MCF-7 cells. Compared with the control cells, McF-7/DOX cells transfected with miR-433 mimics exhibited significantly decreased mRNA and protein expressions of Notch1.\\nmiR-433 may reverse chemoresistance to docetaxel by targeting Notch1 in breast cancer cells. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the genetics of breast and gynecologic cancers. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Cancer Genetics Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). To analyze the characteristics of abnormal granulocytic differentiation in breast cancer patients and explore the role of TGF-β1 in granulocytic differentiation of hematopoietic stem cells (HSCs) and tumor development.\\nBlood samples were collected from 52 patients with invasive ductal carcinoma and 47 healthy donors. The distribution of granulocytes was compared between the two groups and the effects of surgery and radiotherapy on granulocytes were analyzed. The relationship between granulocyte abnormalities and the clinicopathological characteristics of the patients was analyzed. Spleen hematopoietic stem cells isolated from normal and tumor-bearing mice were cultured and treated with TGF-β1, and colony formation of the myeloid cells was compared and the proportion of granulocytes was analyzed with flow cytometry.\\nThe white blood cell (WBC) count, neutrophils, total granulocytes, granulocyte ratio in the total WBCs, and neutrophil/lymphocyte ratio (NLR) were significantly increased (\\nBreast cancer patients have obvious abnormalities in granulocytic differentiation possibly as a result of hematopoietic stem cell differentiation imbalance induced by TGF-β1 and other growth factors produced by the tumor cells. TGF-β1 highlights a paradoxical shift in the regulation of clone formation and granulocytic differentiation of spleen hematopoietic stem cells. Experimental studies have found that clinician-expressed empathy improves patients\\' information recall in (advanced) cancer consultations. It remains unclear, however, whether these results are generalizable to clinical care and, if so, what the underlying mechanism is. We aimed to i) determine the relationship between clinician-expressed empathy and patients\\' information recall in clinical advanced breast cancer consultations; and ii) test whether the relationship between clinician-expressed empathy and recall is mediated by a decrease in patients\\' anxiety.\\nForty-one consultations between oncologists and female patients with advanced breast cancer were audio recorded. Patients\\' post-consultation information recall and pre- and post-consultation anxiety (0-100) were assessed. Recall was scored according to a self-created questionnaire. Clinician-expressed empathy (0-100) was assessed by observers. Structural Equation Modelling was used for all analyses.\\nParticipants remembered 61% of the information discussed. Clinician-expressed empathy significantly increased patients\\' total information recall (p = .041) and recall of treatment aims/positive effects (p = .028). The mediating role of anxiety could not be established.\\nAlthough the underlying mechanism remains unclear, clinicians have a powerful tool to improve seriously ill breast cancer patients\\' recall of information: empathy.\\nThese insights should encourage clinicians to express empathy; practical communication training might prove helpful. Metastasis to different organs is the major cause of death in breast cancer patients. The poor clinical prognosis and lack of successful treatments for metastatic breast cancer patients demand the development of new tumor-selective therapies. Thus, it is necessary to develop treatments capable of releasing therapeutic agents to both primary tumors and metastases that avoid toxic side effects in normal tissue, and neural stem cells are an attractive vehicle for tracking tumor cells and delivering anti-cancer agents. The authorspreviously demonstrated that a soluble form of growth arrest specific 1 (GAS1) inhibits the growth of triple-negative breast tumors and glioblastoma.\\nIn this study, the authors engineered ReNcell CX (EMD Millipore, Temecula, CA, USA) neural progenitor cells to express truncated GAS1 (tGAS1) under a tetracycline/on inducible system using lentiviral vectors.\\nHere the authors show that treatment with ReNcell-tGAS1 in combination with tetracycline decreased primary tumor growth and inhibited the formation of metastases in tumor-bearing mice by diminishing the phosphorylation of AKT and ERK1/2 in orthotopic mammary gland tumors. Moreover, the authors observed that ReNcell-tGAS1 prolonged the survival of 4T1 tumor-bearing mice.\\nThese data suggest that the delivery of tGAS1 by ReNcell cells could be an effective adjuvant for the treatment of triple-negative breast cancer. Breast cancer (BCa) remains the most common cancer in women worldwide. It has been shown that microRNAs (miRs) play essential roles in tumorigenesis and progression in many types of cancers, including BCa. We assessed the role of miR-766 on the proliferation, chemosensitivity, migration, and invasion of BCa cells.\\nThe effect of miR-766 on the proliferation of MCF-7 and T47D BCa cells was evaluated using the MTT assay. The function of miR-766 on the migration and invasion of MCF-7 and T47D cells was examined using Transwell migration and Matrigel invasion assays. Protein expression was evaluated by Western blot. The role of miR-766 on 5-fluorouracil-induced apoptosis in MCF-7 and T47D cells was determined using the Caspase-Glo3/7 assay. A subcutaneous tumor xenograft was performed to examine the effect of miR-766 on tumor growth in\\xa0vivo.\\nUpregulation of miR-766 improved the proliferation, invasion, and migration of BCa cells. Furthermore, miR-766 reduced the sensitivity of MCF-7 and T47D cells to 5-fluorouracil treatment. The tumor xenograft experiment showed that miR-766 promoted BCa growth in\\xa0vivo. miR-766 decreased 5-flurouracil-induced apoptosis by regulation of BAX and Bcl-2 expression. miR-766 also affected the epithelial-mesenchymal transition by altering E-cadherin, N-cadherin, SNAIL, and vimentin expression in MCF-7 and T47D cells. Further study showed that the expression of phosphatase and tensin homolog and phosphorylated AKT in MCF-7 and T47D cells had changed after aberrant expression of miR-766.\\nmiR-766 displayed important roles in tumorigenesis and progression in BCa cells and might act as a potential biomarker to predict the chemotherapy response and progression in BCa. Genomic medicine has led to significant advancements in the prevention and treatment of cancer. The National Comprehensive Cancer Network (NCCN) guidelines recommend BRCA1/2 screening in high-risk individuals; however, the guidelines have not incorporated differences within ethnic cohorts beyond Ashkenazi Jewish ethnicity. We analyzed the prevalence of BRCA1/2 mutations in various ethnicities and identified high-risk personal characteristics and family history incorporating differences within ethnic cohorts beyond Ashkenazi Jewish ethnicity.\\nWe reviewed data collected by a Michigan medical genetic clinic in a community-based hospital from 2008 to 2018. A retrospective chart analysis was conducted of 1090 patients who received genetic counseling regarding hereditary cancer syndromes.\\nWe found a statistically significant higher rate of pathogenic BRCA1/2 mutation prevalence in African American patients, at 8.1%, compared to non-Ashkenazi Jewish white patients, at 3.6% (P\\xa0= .02). African Americans have a mutational prevalence nearing that of the Ashkenazi Jewish population.\\nRevision of the NCCN guidelines regarding hereditary cancer syndrome testing in various ethnic groups is imperative and overdue. Future studies are needed to identify health care disparities in and socioeconomic barriers to genetic testing. Physical sciences are often overlooked in the field of cancer research. The Physical Sciences in Oncology Initiative was launched to integrate physics, mathematics, chemistry, and engineering with cancer research and clinical oncology through education, outreach, and collaboration. Here, we provide a framework for education and outreach in emerging transdisciplinary fields. This systematic review aims to (1) characterize strategies used to identify individuals at increased risk for hereditary breast and ovarian cancer syndrome and Lynch syndrome outside of oncology and clinical genetic settings, (2) describe the extent to which these strategies have extended the reach of genetic services to underserved target populations, and (3) summarize indicators of the potential scalability of these strategies.\\nInvestigators searched PubMed, EMBASE, and PsycINFO for manuscripts published from October 2005 to August 2019. Eligible manuscripts were those published in English, those that described strategies to identify those at risk for hereditary breast and ovarian cancer syndrome or Lynch syndrome, those implemented outside of an oncology or genetic specialty clinic, and those that included measures of cancer genetic services uptake. This study assessed strategies used to increase the reach of genetic risk screening and counseling services. Each study was evaluated using the 16-item quality assessment tool, and results were reported according to the PRISMA guidelines.\\nOf the 16 eligible studies, 11 were conducted in clinical settings and 5 in public health settings. Regardless of setting, most (63%, 10/16) used brief screening tools to identify people with a family history suggestive of hereditary breast and ovarian cancer syndrome or Lynch syndrome. When reported, genetic risk screening reach (range =11%-100%) and genetic counseling reach (range =11%-100%) varied widely across studies. Strategies implemented in public health settings appeared to be more successful (median counseling reach=65%) than those implemented in clinical settings (median counseling reach=26%). Most studies did not describe fundamental components relevant for broad scalability.\\nEfforts to expand cancer genomic services are limited outside of traditional oncology and genetic clinics. This is a missed opportunity because evidence thus far suggests that these efforts can be successful in expanding the reach of genetic services with the potential to reduce health inequities in access. This review highlights the need for accelerating research that applies evidence-based implementation strategies and frameworks along with process evaluation to understand barriers and facilitators to scalability of strategies with high reach. We describe the case of a 49-year-old woman who, after surgical treatment of breast cancer, developed axillary web syndrome (AWS) followed, 3 weeks later, by the appearance of soft and painless subcutaneous nodules along the cords and close to the flexure of the elbow. After tests (soft tissue and Doppler ultrasound), a dermal/subcutaneous or neoplastic cause was ruled out, although a cephalic and ulnar venous thrombosis was revealed. Anticoagulant medication was prescribed, with disappearance of the nodules 3-4 weeks later and improvement of AWS. The symptoms, clinical course, diagnostic tests, as well as the published evidence, helped to establish a diagnosis of AWS with subcutaneous nodules. AWS is an early complication after axillary surgery, which is well known among breast cancer professionals and whose diagnosis is based on clinical presentation. Its association with subcutaneous nodules is one of its rare variants and requires compulsory complementary studies to exclude other causes. Like AWS, nodules are believed to be due to lymphatic vessel thrombosis. To evaluate the impact of insulin-like growth factor 1 receptor variant rs2016347 on the risk for breast and nonbreast cancers and cardiovascular disease in women with a history of hypertensive disorders of pregnancy (HDP).\\nThis retrospective cohort study included all parous women in the UK Biobank with prior rs2016347 genotyping (N=204,155), with enrollment taking place from March 2006 to July 2010. History of HDP was self-reported, and outcomes included breast and all nonbreast cancers, hospital diagnoses of hypertension and cardiovascular disease, and direct blood pressure measurements.\\nWomen with previous HDP had a higher risk for future hypertension and cardiovascular diagnoses, increased blood pressures, and lower risk for breast cancer compared with women without HDP, consistent with prior studies. Hazard ratios for all nonbreast cancers were unchanged. However, when taking genotype into account, HDP-positive women carrying at least 1 thymine (T) allele of rs2016347 had a lower risk for nonbreast cancer (hazard ratio, 0.59; 95% CI, 0.37 to 0.92; P=.02) and lower systolic blood pressure (-2.08±0.98 mm Hg; P=.03) compared with women with the guanine/guanine (GG) genotype with positive evidence of interaction (HDP:T allele) for both outcomes; P=.04 and P=.03, respectively.\\nWomen who experience HDP and carry a T allele of rs2016347 have 41% lower risk for developing nonbreast cancer and a lower systolic blood pressure of 2.08 mm Hg when compared with those with the GG genotype, suggesting a possible role of the insulin-like growth factor 1 axis for both cardiovascular and cancer risk in women with HDP. The aim of this study was to assess body shape trajectories in childhood and midlife in relation to subsequent risk of breast cancer in a Mediterranean cohort.\\nThe SUN Project is a dynamic prospective cohort study of university graduates initiated in 1999. With a group-based modelling approach, we assessed body shape trajectories from age 5 to 40 years. Multivariable Cox regression models were used to estimate the hazard ratio (HR) for breast cancer after the age of 40 years according to the body shape trajectory.\\nCity of Pamplona, in the North of Spain.\\n6498 women with a mean age of 40 years (standard deviation: 9 years).\\nWe identified four distinct body shape trajectories [\\'childhood lean-midlife increase\\' (19.9%), \\'childhood medium-midlife stable\\' (53%), \\'childhood heavy-midlife stable\\' (21%), and \\'childhood heavy-midlife increase\\' (6.1%)]. Among 54,978 women-years of follow-up, we confirmed 82 incident cases of breast cancer. Women in the \\'childhood lean-midlife increase\\' group showed a higher risk of breast cancer (HR=1.84, 95%CI 1.11, 3.04) compared to women in the \\'childhood medium-midlife stable\\' category. This association was stronger for postmenopausal breast cancer (HR=2.42, 95%CI 1.07, 5.48). Granulomatous mastitis (GM) is a rare benign chronic inflammatory breast disease. GM presents as a heterogeneous illness with variable clinical presentations, and its diagnosis is usually made by exclusion. There are no guidelines for the treatment of GM. This manuscript describes the management of a patient with GM, initially unsuccessfully treated outside our clinic under a diagnosis of mastitis. The patient\\'s history, physical examination, and needle biopsy flagged the patient\\'s findings as nonmalignant; however, imaging studies indicated a tumor. Differential diagnosis became a critical element of her care. This case report represents a valuable resource to foster more assertive clinical practice in managing patients with GM. The case coordination and its course were led by a team from an outreach clinic that provides health care services to underserved communities in the state of Michigan.\\nA 41-year-old G1P1 Hispanic female immigrant from Central America presented with a rare breast disease, granulomatous mastitis. A similar presentation occurred 5 years before pregnancy when she had an episode of pain and swelling in the left breast, which resolved spontaneously. She sought our services after being diagnosed with mastitis that was unsuccessfully treated. Physical examination revealed a nodular mass in the outer quadrants of the left breast without regional lymphadenopathy. Needle biopsy showed fibrohistiocytic and florid inflammatory reactions, with no evidence of invasive carcinoma. However, this result was inconsistent with the degree of abnormality revealed by the mammogram (BI-RADS grade 5), ultrasound, and physical examination. Full incisional biopsy revealed cystic neutrophilic GM. The surgical procedure, antibiotics, and corticosteroids resulted in a successful combination to secure the stable control of the symptoms and progression of this rare benign breast disease to date.\\nThis patient\\'s case highlights the importance of integrated communication among front-line primary care and other health care professionals to reduce the risk of invasive procedures and avoid institutional costs. GM is a rare disease. We raised the manifold red flags in which the multiple professional chains recruited to care for this patient were concerning for advanced breast cancer. The lack of experience and evidence-based medicine contributed to the contradictory interpretation of the findings on GM\\'s diagnosis. Complex genomic changes that arise in tumors are a consequence of chromosomal instability. In tumor cells genomic aberrations disrupt core signaling pathways involving various genes, thus delineating of signaling pathways can help understand the pathogenesis of cancer. The bioinformatics tools can further help in identifying networks of interactions between the genes to get a greater biological context of all genes affected by chromosomal instability.\\nKaryotypic analyses was done in 150 clinically confirmed breast cancer patients and 150 age and gender matched healthy controls after 72\\xa0h Peripheral lymphocyte culturing and GTG-banding. Reactome database from Cytoscape software version 3.7.1 was used to perform in-silico analysis (functional interaction and gene enrichment).\\nFrequency of chromosomal aberrations (structural and numerical) was found to be significantly higher in patients as compared to controls. The genes harbored by chromosomal regions showing increased aberration frequency in patients were further analyzed in-silico. Pathway analysis on a set of genes that were not linked together revealed that genes HDAC3, NCOA1, NLRC4, COL1A1, RARA, WWTR1, and BRCA1 were enriched in the RNA Polymerase II Transcription pathway which is involved in recruitment, initiation, elongation and dissociation during transcription.\\nThe current study employs the information inferred from chromosomal instability analysis in a non-target tissue for determining the genes and the pathways associated with breast cancer. These results can be further extrapolated by performing either mutation analysis in the genes/pathways deduced or expression analysis which can pinpoint the relevant functional impact of chromosomal instability. There is uncertainty about the effectiveness of clinical breast examination (CBE) and conflicting recommendations regarding its usefulness as a screening tool for breast cancer. This paper provides an overview of systematic reviews that assessed the effectiveness of CBE as a \\'stand-alone\\' screening modality for breast cancer compared to no screening and focused on its value in low- and middle-income countries (LMICs).\\nWe searched MEDLINE, EMBASE, Scopus, Web of Science, and the Cochrane Database of Systematic Reviews for systematic reviews reporting the effectiveness of CBE published prior to October 29, 2019. The main outcomes assessed were mortality and down staging. The AMSTAR 2 checklist was used to assess the methodological quality of the reviews including risk of bias.\\nEleven systematic reviews published between 1993 and 2019 were identified. There was no direct evidence that CBE reduced breast cancer mortality. Indirect evidence suggested that a well-performed CBE achieved the same effect as mammography regarding mortality despite its apparently lower sensitivity (40-69% for CBE vs 77-95% for mammography). Greater sensitivity was recorded among younger and Asian women. Moreover, CBE contributed between 17 and 47% of the shift from advanced to early stage cancer.\\nCBE merits attention from health system and service planners in LMICs where a national screening programme based on mammography would be prohibitively expensive. In particular, it is likely that considerable value would be gained from conducting implementation scientific research in countries with large numbers of Asian women and/or where younger women are at higher risk.\\nPROSPERO, registration number CRD42019126798 . Little is known about the presentation, help seeking behaviour for breast cancer in Singapore. Nor was there a study exploring the experience of patients in their breast cancer journey.\\nA qualitative interview study with thematic analysis, conducted with 36 patients.\\nThere is no clear pattern of presentation for breast cancer by cancer stage at diagnosis, age and ethnicity in the cancer journey of this group of patients. Patients were diagnosed with early to advanced stages cancer regardless of when they presented or took up treatment in their cancer journey. The reasons patients sought medical attention also did not appear to differ between the stages of cancer diagnosed, ethnic and age. Without setting a measure to define early and late presentation, we found that women shared similar experience in their breast cancer journey, regardless of age, ethnicity and stage of cancer at diagnosis. Poor knowledge of breast cancer (symptoms and causes); few practised regular BSE; denial of symptom; fear of hospitalisation, diagnosis and treatment; worries and stress over financial burden of treatment; misinformation in magazine and online sources; diet; stress; caring responsibility; support network; and use of alternative medicine before and after diagnosis were identified in patients\\' narratives. Strong social support; fear of being an emotional and financial burden for the family; and financial worries during treatment were also the recurring themes after diagnosis.\\nA measure of breast cancer presentation - that accounts for the patient\\'s experience in the cancer journey, the time interval and tumour biology - that is meaningful to patients, clinicians and researchers is needed. For research on late and delayed presentation, details on BSE practice - how often, when and was it done correctly - will improve the accuracy of time delay interval. For the public, concerted efforts to improve knowledge of breast cancer, survival and prognosis for early-diagnosed cancer, and the importance of regular and correct technique to perform BSE, are critical and urgent to address the rising breast cancer incidence in the country. In low-income countries breast cancer awareness (BCA) is essential to reduce the proportion of advanced stage presentations of breast cancer. There is a lack of studies using multivariable techniques to explore factors related to BCA in low-income countries. The objective of this study was to identify to what extent women in Fiji and Kashmir, India have BCA and practice breast self-examination (BSE) as well as factors associated with BCA and BSE.\\nA survey of women aged ≥18\\u2009years was conducted in Fiji and Kashmir, India to assess BCA and rates of BSE. Comparison between Fiji and Kashmir was done using student\\'s t-test for continuous data and chi-square for binary data. Factors associated with BCA and BSE were analysed using a multivariable logistic regression for Fiji and Kashmir separately.\\nData were collected from 399 and 1982 women in Kashmir and Fiji, respectively. Of 1968 women in Fiji 57% were deemed to have an acceptable BCA compared to only 7.3% of 395 women in Kashmir. Having some education was associated with having BCA with an odds ratio of 4.7 (1.7-13) in Fiji and 10 (1.7-59) in Kashmir. Of 1976 women in Fiji 40% had tertiary education while 40% of 392 women in Kashmir had no education at all. The marital status was similar in both samples (n\\u2009=\\u20091973 and 395) with 68-69% being married and 21-26% being single. The lack of female doctors or nurses with whom to discuss issues, was perceived as a problem in both countries.\\nThe key finding is an association between having any level of education and BCA. This correlation was much stronger than for a family history of breast cancer and BCA. Hence, general education to illiterate women may reduce the proportion of women in low-income countries presenting with advanced-stage breast cancer. Breast cancer (BC) is a major public health issue. More than one out of five women treated for breast cancer will develop lymphedema in an upper extremity. Current evidence advocates transdisciplinary oncological rehabilitation. Therefore, research in this area is necessary since limited consensus having been reached with regard to the basic essential components of this rehabilitation. Consensus has, however, been reached on the use of decongestive lymphedema therapy (DLT), but due to a lack of tests, the necessary dosages are unknown and its level is moderately strong. This study attempts to verify both the efficacy of activity-oriented proprioceptive antiedema therapy (TAPA), as compared to conventional treatments such as DLT or Complex Physical Therapy (CPT), as well as its efficiency in terms of cost-effectiveness, for patients affected by breast cancer-related arm lymphedema.\\nControlled, randomized clinical trial with dual stratification, two parallel arms, longitudinal and single blind. 64 women with breast cancer-related arm lymphedema will take part in the study. The experimental group intervention will be the same for stage I and II, and will consist of neuro-dynamic exercises oriented to the activity, proprioceptive neuromuscular facilitation activities and proprioceptive anti-edema bandaging. The control group intervention, depending on the stage, will consist of preventive measures, skin care and exercise-prescribed training in the lymphedema workshop as well as compression garments (Stage I) or conservative Complex Decongestive Therapy treatment (skin care, multi-layer bandaging, manual lymphatic drainage and massage therapy) (Stage II).\\nSociodemographic and clinical variables will be collected for the measurement of edema volume and ADL performance. Statistical analysis will be performed on intent to treat.\\nIt has been recommended that patient training be added to DLT, as well as a re-designing of patient lifestyles and the promotion of health-related aspects. In addition, clinical trials should be undertaken to assess neural mobilization techniques and proprioceptive neuromuscular facilitation should be included in the therapy. Cohesive bandaging will also be performed as an early form of pressotherapy. The proposed study combines all of these aspects in order to increased comfort and promote the participation of individuals with lymphedema in everyday situations.\\nThe authors have proposed the assessment of the experimental treatment for stages I and II. One possible limitation is the lack of awareness of whether or not this treatment would be effective for other stages as well as the concern for proper hand cleansing during use of bandages, given the current COVID-19 pandemic situation.\\nThis trial was registered in ClinicalTrials.gov ( NCT03762044 ). Date of registration: 23 November 2018. Prospectively Registered. Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with basal features, lacking the expression of receptors targeted successfully in other breast cancer subtypes. Treatment response to adjuvant and neoadjuvant chemotherapy is often short-lived and metastatic spread occurs at higher rates than other subtypes within the first five years after diagnosis. TNBCs exhibit stem cell features and are enriched for cancer stem cell (CSC) populations. E1A Binding Protein P300 (EP300) is a large protein with multiple cellular functions, including as an effector in stem cell biology.\\nWe used a genetic knockdown (KD) model of EP300 in TNBC cell lines to investigate the effect on CSC phenotype, tumor growth and metastasis. Side population assay and tumorsphere suspension culture were used in vitro. Xenograft mouse models were used for in vivo studies. We performed in silico analysis of publicly available gene expression data sets to investigate CSC gene expression and molecular pathways as well as survival outcomes associated with EP300 expression in patients with TNBC and basal-like BC.\\nEP300 KD abolished the CSC phenotype by reducing ABCG2 expression, side population cells and tumorsphere formation capacity in vitro as well as tumor formation in a xenograft mouse model in vivo. Metastatic capacity was markedly reduced in EP300 KD cells in vivo, with no detection of circulating tumor cells. TCGA data analysis demonstrated that genes positively correlated with EP300 expression in TNBC and basal-like BC were associated with CSC biology. Survival analysis demonstrated that EP300 expression predicts poor recurrence free survival in TNBC and basal BC.\\nWe report a novel oncogenic role for EP300 in driving CSC phenotype representing a potential target to address tumor initiation and metastatic spread in TNBC and basal-like BC. EP300 might serve as a prognostic marker and potential therapeutic target in TNBC. In recent years, the identification of genetic and phenotypic biomarkers of cancer for prevention, early diagnosis and patient stratification has been a main objective of research in the field. Different multivariable models that use biomarkers have been proposed for the evaluation of individual risk of developing breast cancer.\\nThis is a case control study based on a population-based cohort. We describe and evaluate a multivariable model that incorporates 92 Single-nucleotide polymorphisms (SNPs) (Supplementary Table S1) and five different phenotypic variables and which was employed in a Spanish population of 642 healthy women and 455 breast cancer patients.\\nOur model allowed us to stratify two groups: high and low risk of developing breast cancer. The 9th decile included 1% of controls vs 9% of cases, with an odds ratio (OR) of 12.9 and a p-value of 3.43E-07. The first decile presented an inverse proportion: 1% of cases and 9% of controls, with an OR of 0.097 and a p-value of 1.86E-08.\\nThese results indicate the capacity of our multivariable model to stratify women according to their risk of developing breast cancer. The major limitation of our analysis is the small cohort size. However, despite the limitations, the results of our analysis provide proof of concept in a poorly studied population, and opens up the possibility of using this method in the routine screening of the Spanish population. Resistance to chemotherapy is the most common cause of treatment failure in acute myeloid leukemia (AML) and the drug efflux pump ABCB1 is a critical mediator. Recent studies have identified promoter translocations as common drivers of high ABCB1 expression in recurrent, chemotherapy-treated high-grade serous ovarian cancer (HGSC) and breast cancer. These fusions place ABCB1 under the control of a strong promoter while leaving its open reading frame intact. The mechanisms controlling high ABCB1 expression in AML are largely unknown. We therefore established an experimental system and analysis pipeline to determine whether promoter translocations account for high ABCB1 expression in cases of relapsed human AML.\\nThe human AML cell line THP-1 was used to create a model of chemotherapy resistance in which ABCB1 expression was driven by a promoter fusion. The THP-1 model was used to establish a targeted nanopore long-read sequencing approach that was then applied to cases of ABCB1\\nProlonged in vitro daunorubicin exposure induced activating ABCB1 promoter translocations in human THP-1 AML cells, similar to those recently described in recurrent high-grade serous ovarian and breast cancers. Targeted nanopore sequencing proved an efficient method for identifying ABCB1 structural variants in THP-1 AML cells and HGSC; the promoter translocations identified in HGSC were both previously described and novel. In contrast, activating ABCB1 promoter translocations were not identified in ABCB1\\nDespite frequent high level expression of ABCB1 in relapsed primary AML we found no evidence of ABCB1 translocations and instead confirmed high-level activity of native ABCB1 promoters, consistent with endogenous regulation. The clinicopathological classification of breast cancer is proposed according to therapeutic purposes. It is simplified and can be conducted easily in clinical practice, and this subtyping undoubtedly contributes to the treatment selection of breast cancer. This study aims to investigate the feasibility of using a Fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI for predicting the clinicopathological subtypes of breast cancer.\\nPatients who underwent breast magnetic resonance imaging were confirmed by retrieving data from our institutional picture archiving and communication system (PACS) between March 2013 and September 2017. Five clinicopathological subtypes were determined based on the status of ER, PR, HER2 and Ki-67 from the immunohistochemical test. The radiomic features of diffusion-weighted imaging were derived from the volume of interest (VOI) of each tumour. Fisher discriminant analysis was performed for clinicopathological subtyping by using a backward selection method. To evaluate the diagnostic performance of the radiomic features, ROC analyses were performed to differentiate between immunohistochemical biomarker-positive and -negative groups.\\nA total of 84 radiomic features of four statistical methods were included after preprocessing. The overall accuracy for predicting the clinicopathological subtypes was 96.4% by Fisher discriminant analysis, and the weighted accuracy was 96.6%. For predicting diverse clinicopathological subtypes, the prediction accuracies ranged from 92 to 100%. According to the cross-validation, the overall accuracy of the model was 82.1%, and the accuracies of the model for predicting the luminal A, luminal B\\nThe Fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI is a reliable method for the prediction of clinicopathological breast cancer subtypes. Breast cancer is the most common cause of premature mortality among women, and screening is one of the most important means of early diagnosis of breast cancer. This qualitative study was conducted to explore strategies for promoting breast cancer screening behaviors from the perspective of health volunteers in south-east Iran. Data collection was performed through focus groups. Using the purposive sampling method, 35 participants were selected and data were analyzed using a specific qualitative content analysis framework. By analyzing the data to provide strategies for promoting breast cancer screening behaviors, the main theme of \"organizational transformation\" with five subthemes including the promotion of health-centered beliefs in society, the development of culture-based training, the media revolution, financial support, and the provision of efficient health-care providers were extracted. According to the results of the study, the development of organizational transformation plays an important role in planning for the promotion of breast cancer screening. Survivors of breast and other cancers often report protracted difficulty in performing tasks involving concentration and memory, even years after the completion of treatment. The current study investigated whether cancer and treatment history is associated with deficits in sensory filtering (gating out) and sensory memory (gating in), early processes in stimulus processing that may contribute to difficulties in later remembering. A group of breast cancer survivors and age-matched healthy control participants (mean age 54 years) underwent testing with paired-click and oddball tasks while electroencephalographic (EEG) signals were recorded. The survivors showed relatively poor inhibition of redundant sensory stimulation (P50 suppression). Dipole source analysis localized the survivors\\' impairment to the hippocampus, with preservation of function in gating mechanisms of the frontal lobe and auditory cortex. Survivors also showed disruption to sensory memory processes needed to register novel information in an otherwise uniform auditory environment (mismatch negativity). The findings suggest that survivors experience deficits in early, automatic mechanisms of sensory gating, which may trigger a cascade of later perceived attentional and memory deficits. If our account is accurate, ideal therapies might aim to restore early inhibitory processes, such as those gauged by P50 suppression.   The various components of the endocannabinoid system (ECS), such as the cannabinoid receptors (CBRs), cannabinoid ligands, and the signalling network behind it, are implicated in several tumour-related states, both as favourable and unfavourable factors. This review analyses the ECS\\'s complex involvement in the susceptibility to cancer, prognosis, and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, CNS tumours, and melanoma). Changes in the expression and activation of CBRs, as well as their ability to form distinct functional heteromers affect the cell\\'s tumourigenic potential and their signalling properties, leading to pharmacologically different outcomes. Thus, the same ECS component can exert both protective and pathogenic effects in different tumour subtypes, which are often pathologically driven by different biological factors. The use of endogenous and exogenous cannabinoids as anti-cancer agents, and the range of effects they might induce (cell death, regulation of angiogenesis, and invasion or anticancer immunity), depend in great deal on the tumour type and the specific ECS component that they target. Although an attractive target, the use of ECS components in anti-cancer treatment is still interlinked with many legal and ethical issues that need to be considered. Previous studies have been reported that the association between rheumatoid arthritis (RA) and breast cancer remains inconclusive. A two-sample Mendelian randomization (MR) analysis can reveal the potential causal association between exposure and outcome. A two-sample MR analysis using the penalized robust inverse variance weighted (PRIVW) method was performed to analyze the association between RA and breast cancer risk based on the summary statistics of six genome-wide association studies (GWAS) targeting RA in an East Asian population along with summary statistics of the BioBank Japan (BBJ), Breast Cancer Association Consortium (BCAC), and Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) targeting breast cancer. We found that the direction of the effect of RA on breast cancer varied among GWAS-summary data from BBJ, BCAC, and CIMBA. Significant horizontal pleiotropy based on a penalized robust MR-Egger regression was observed only for BBJ and CIMBA BRCA2 carriers. As the results of the two-sample MR analyses were inconsistent, the causal association between RA and breast cancer was inconclusive. The biological mechanisms explaining the relationship between RA and breast cancer were unclear in Asian as well as in Caucasians. Further studies using large-scale patient cohorts are required for the validation of these results. The process of heparan sulfate proteoglycan (HSPG) internalization has been described as following different pathways. The tumor-specific branched NT4 peptide has been demonstrated to bind HSPGs on the plasma membrane and to be internalized in tumor cell lines. The polycationic peptide has been also shown to impair migration of different cancer cell lines in 2D and 3D models. Our hypothesis was that HSPG endocytosis could affect two important phenomena of cancer development: cell migration and nourishment. Using NT4 as an experimental tool mimicking heparin-binding ligands, we studied endocytosis and trafficking of HSPGs in a triple-negative human breast cancer cell line, MDA-MB-231. The peptide entered cells employing caveolin- or clathrin-dependent endocytosis and macropinocytosis, in line with what is already known about HSPGs. NT4 then localized in early and late endosomes in a time-dependent manner. The peptide had a negative effect on CDC42-activation triggered by EGF. The effect can be explained if we consider NT4 a competitive inhibitor of EGF on HS that impairs the co-receptor activity of the proteoglycan, reducing EGFR activation. Reduction of the invasive migratory phenotype of MDA-MB-231 induced by NT4 can be ascribed to this effect. RhoA activation was damped by EGF in MDA-MB-231. Indeed, EGF reduced RhoA-GTP and NT4 did not interfere with this receptor-mediated signaling. On the other hand, the peptide alone determined a small but solid reduction in active RhoA in breast cancer cells. This result supports the observation of few other studies, showing direct activation of the GTPase through HSPG, not mediated by EGF/EGFR. Targeted cancer therapies against oncogenic drivers are actively being developed and tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation is present in most tumoral cells. Therefore, highly heterogeneous tumors may be refractory to these therapies. This makes tumor heterogeneity a major challenge in cancer therapy. Although heterogeneity has traditionally been attributed to genetic diversity within cancer cell populations, it is now widely recognized that human cancers are heterogeneous in almost all distinguishable phenotypic characteristics. Understanding the genetic variability and also the non-genetic influences of tumor heterogeneity will provide novel insights into how to reverse therapeutic resistance and improve cancer therapy. A new cytotoxic thiodepsipeptide, verrucosamide ( In the era of CDK4/6 inhibitors in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, few trials have been specifically studied to compare quality of life between palbociclib plus endocrine therapy (ET) and cytotoxic chemotherapy exclusively in premenopausal women. We aimed to evaluate differences of patient report outcomes (PROs) between palbociclib plus ET and capecitabine. PROs were assessed using EORTC QLQ-C30 at baseline, every 6 weeks, and the end of treatment. All EORTC QLQ-30 scores were maintained from baseline to the end of treatment. Patients treated palbociclib plus ET arm experienced delay in time-to-deterioration of physical functioning (HR = 0.58, 95% CI, 0.36 to 0.84,  To investigate the effects of cyclic GMP-AMP synthase (cGAS) on the proliferation, migration and epithelial to mesenchymal transition (EMT) of breast cancer cells.\\nThe cGAS lentiviral vector and control fluorescence vector were transfected into breast cancer MCF7 cells and were divided into negative group (NC) and MCF7-cGAS group. The effect of cGAS on proliferation in the MCF7 cells was detected by MTT. The effect of cGAS on cell migration was detected by Transwell assay. The expressions of EMT related proteins were analyzed by Western blot.\\nAfter over-expressed with cGAS, the proliferation and migration of MCF7 cells were increased (\\nThe over-expression of cGAS increased the proliferation and migration of breast cancer cells and induced EMT in breast cancer cells.\\n目的: 探讨环状GMP-AMP合成酶(cGAS)高表达对乳腺癌MCF7细胞发生上皮间质转化(EMT)的影响。方法: 构建稳定高表达cGAS的慢病毒载体并转染MCF7细胞;转染后细胞分别培养12 h,24 h,48 h,72 h,每组实验重复三次,采用MTT检测cGAS对MCF7细胞增殖的影响; transwell法检测高表达cGAS对MCF7细胞迁移能力的影响;蛋白免疫印迹(Western blot)法分析EMT相关蛋白E-cadherin和N-cadherin的表达情况。结果: 与对照组比较,cGAS上调后MCF7细胞增殖能力显著增强( This systematic review and meta-analysis investigated the association between consumption of ultraprocessed food and noncommunicable disease risk, morbidity and mortality. Forty-three observational studies were included (N = 891,723): 21 cross-sectional, 19 prospective, two case-control and one conducted both a prospective and cross-sectional analysis. Meta-analysis demonstrated consumption of ultraprocessed food was associated with increased risk of overweight (odds ratio: 1.36; 95% confidence interval [CI], 1.23-1.51; P < 0.001), obesity (odds ratio: 1.51; 95% CI, 1.34-1.70; P < 0.001), abdominal obesity (odds ratio: 1.49; 95% CI, 1.34-1.66; P < 0.0001), all-cause mortality (hazard ratio: 1.28; 95% CI, 1.11-1.48; P = 0.001), metabolic syndrome (odds ratio: 1.81; 95% CI, 1.12-2.93; P = 0.015) and depression in adults (hazard ratio: 1.22; 95% CI, 1.16-1.28, P < 0.001) as well as wheezing (odds ratio: 1.40; 95% CI, 1.27-1.55; P < 0.001) but not asthma in adolescents (odds ratio: 1.20; 95% CI, 0.99-1.46; P = 0.065). In addition, consumption of ultraprocessed food was associated with cardiometabolic diseases, frailty, irritable bowel syndrome, functional dyspepsia and cancer (breast and overall) in adults while also being associated with metabolic syndrome in adolescents and dyslipidaemia in children. Although links between ultraprocessed food consumption and some intermediate risk factors in adults were also highlighted, further studies are required to more clearly define associations in children and adolescents. STUDY REGISTRATION: Prospero ID: CRD42020176752. We aimed to examine: 1) the long-term association between coping styles and psychological distress, 2) if women diagnosed with breast cancer have a predominant coping style, 3) stability of coping styles, 4) predictors of changes in coping styles, 5) if maladaptive coping adversely impacts disease-free survival (DFS).\\nThis prospective study included women diagnosed with primary breast cancer during 2006-2009. Patients completed questionnaires for the Norwegian Mini-Mental Adjustment to Cancer scale, which includes positive attitude (PA), helplessness/hopelessness (HH), anxious preoccupation (AP), and avoidance (AV), and the Hospital Anxiety and Depression Scale at diagnosis and 1, 3, and 5 years post diagnosis.\\nTwo hundred and ninety-three of 367 women (79.8%) completed the questionnaires at all time points. Anxiety and depression were moderately to strongly correlated with HH and AP coping styles (r = .31 to r = .69) at all time points. The predominant coping style was PA (23.4-29.9%). Stability for PA and cognitive AV styles was found at the group level, but not at an individual level. Chemotherapy and comorbidity were predictors for HH, AP, and AV 5 years post diagnosis (P <. 05). Maladaptive coping was not associated with DFS.\\nHH and AP were associated with higher psychological distress at all times. Group level coping remained stable over time for PA and AV. Coping style stability at an individual level was not observed. Having received chemotherapy and experienced adverse events affected coping at 5 years post diagnosis. Maladaptive coping was not associated with DFS. This article is protected by copyright. All rights reserved. There has been considerable interest in the development of novel photosensitisers for photodynamic therapy (PDT). The use of liposomes as drug delivery systems containing simultaneously two or more drugs is an attractive idea to create a new platform for PDT application. Therefore, the aim of this study was to evaluate the synergistic effect of diethyldithiocarbamate (DETC) and zinc phthalocyanine (PDT) co-encapsulated in liposomes. The reverse-phase evaporation method resulted in the successful encapsulation of DETC and ZnPc in liposomes, with encapsulation efficiencies above 85 %, mean size of 308\\u2009nm, and zeta potential of - 36\\u2009mV. The co-encapsulation decreased the cytotoxic effects in mouse embryo fibroblast (NIH3T3) cells and inhibited damage to human erythrocytes compared to free DETC\\u2009+\\u2009ZnPc. In addition, both the free drugs and co-encapsulated ones promoted more pronounced phototoxic effects on human breast cancer cells (MDA-MB231) compared to treatment with ZnPc alone. This synergistic effect was determined by DETC-induced decreases in the antioxidant enzyme activity of superoxide dismutase (SOD) and glutathione (GSH). Pim-1 kinase targeted recently has proved an essential goal of breast cancer therapy. We report the design, synthesis with full characterization analysis of pyrazolo[3,4-b]pyridine scaffold-based derivatives targeting Pim-1 kinase as anti-breast cancer agents. All the newly synthesized compounds were screened for their in vitro cytotoxic activity against two breast cancer cell lines MCF-7 and MDA-MB-231, and non-cancerous MCF-10A cells. Four derivatives notably, 17 and 19 exhibited a remarkable cytotoxic activity with IC Breast cancer is the most common cancer in women that shows a predisposition to metastasize to the distant organs. Kojic acid is a natural fungal metabolite exhibiting various biological activities. Compounds derived from kojic acid have been extensively studied and proved to demonstrate anti-neoplastic features on different cancer types. In the present study, allomaltol-structural analog of kojic acid and its seven derivatives including four novel compounds, have been synthesized, characterized and their possible impact on breast cancer cell viability was investigated. It was discovered that compound 5, bearing 3,4-dichlorobenzyl piperazine moiety, could decrease the viability of both MCF-7 and MDA-MB-231 cell lines distinctively. To ascertain the death mechanism, cells were subjected to different tests following the application of IC Cross-sectional data have linked gut barrier abnormalities and endotoxemia with depression, even among those without gastrointestinal symptoms. This study examined longitudinal associations between endotoxemia markers and depressive symptoms, as well as the role of inflammation in this relationship.\\nAt three annual visits, 315 women (n=209 breast cancer survivors, n = 106 non-cancer patient controls, M=55 years old) completed the Center for Epidemiological Studies Depression questionnaire (CES-D) and provided blood samples to assess inflammatory markers - interleukin-6, tumor necrosis factor-alpha, and C-reactive protein - and endotoxemia markers - lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), and their ratio.\\nAdjusting for key demographic variables, health behaviors, visit 1 depressive symptoms, and cancer status and treatment, women with higher visit 1 LBP and LBP/sCD14 had more depressive symptoms at the two subsequent annual visits. Illustrating the notable impact, a woman at the 75th percentile for LBP or LBP/sCD14 at visit 1 was 18 % more likely to report clinically significant depressive symptoms (CES-D ≥16) at follow-up than a woman in the lowest quartile. Cancer status and treatment type did not modulate this relationship. In contrast, visit 1 depressive symptoms did not predict endotoxemia at follow-up. A significant interaction between LBP/sCD14 and inflammatory burden suggested that visit 1 endotoxemia fueled depressive symptoms only in the context of elevated inflammation.\\nThese results suggest that endotoxemia, combined with systemic inflammation, can drive depressive symptoms. These findings may implicate bacterial endotoxin translocation from the gut to the bloodstream in depression etiology. Interventions that reduce endotoxemia and inflammation may lessen the risk of depression. The management of women with cervical squamous intraepithelial lesions (SIL) is fundamental to prevention of cervical cancer in an organized cervical screening programme. Clinical guidance should improve quality of care and clinical effectiveness if developed and implemented appropriately. This survey provides an update on the current situation of national guidelines for management of cervical SIL amongst member countries of European Federation for Colposcopy (EFC).\\nA questionnaire was sent to representatives of each member country of EFC. The questionnaire contained questions on: guidelines for management of cervical SIL of the National Societies/Associations of Colposcopy or others national societies/associations including the development and the consultation processes, guidelines for management of lower genital tract diseases and the regulations in each country for colposcopy practice.\\nWe received responses from all 34 member countries. Thirty countries reported a national guideline for management of cervical SIL that were developed by, or in conjunction with, their national societies or associations of colposcopy. In most cases there was adherence to the recommended steps for guideline development: they were developed by a multi-disciplinary group of specialists (29 countries) and society members were consulted before publication (21 countries). A small number of countries (8) reported to have guidelines for the management of lower genital tract dysplasia (e.g. vulval disease) developed by other national societies. In most countries (26) the colposcopists are obliged to follow the guidelines but this is regulated in only 6 and in 12 countries the colposcopists need to be certified by the national society of colposcopy in order to practice.\\nThere are advances in the development and provision of country specific guidance on the management of cervical SIL. Most EFC member countries have appropriate national guidelines that were developed using a clear methodology, are updated according to progresses in the field and are accessible online to current practitioners. These guidelines support colposcopists to follow evidence-based practice and provides understanding of best practice in guideline development and access. Accurate breast mass segmentation of automated breast ultrasound (ABUS) is a great help to breast cancer diagnosis and treatment. However, the lack of clear boundary and significant variation in mass shapes make the automatic segmentation very challenging. In this paper, a novel automatic tumor segmentation method SC-FCN-BLSTM is proposed by incorporating bi-directional long short-term memory (BLSTM) and spatial-channel attention (SC-attention) module into fully convolutional network (FCN). In order to decrease performance degradation caused by ambiguous boundaries and varying tumor sizes, an SC-attention module is designed to integrate both finer-grained spatial information and rich semantic information. Since ABUS is three-dimensional data, utilizing inter-slice context can improve segmentation performance. A BLSTM module with SC-attention is constructed to model the correlation between slices, which employs inter-slice context to assist segmentation for false positive elimination. The proposed method is verified on our private ABUS dataset of 124 patients with 170 volumes, including 3636 2D labeled slices. The Dice similarity coefficient (DSC), Recall, Precision and Hausdorff distance (HD) of the proposed method are 0.8178, 0.8067, 0.8292 and 11.1367. Experimental results demonstrate that the proposed method offered improved segmentation results compared with existing deep learning-based methods. Co-expression of human epidermal growth factor receptor-2 (HER2) and hormone receptor (HR) predicted worse prognosis in early breast cancer before trastuzumab was developed. We aimed to investigate whether HER2 positivity was still associated with worse outcome in high-risk estrogen receptor (ER) positive patients treated with trastuzumab and chemotherapy. In the present study, 227\\xa0ER+/HER2+ patients treated with trastuzumab and chemotherapy (HER2-pos-T group) and 1097\\xa0ER+/HER2-patients treated with chemotherapy alone (HER2-neg group) during 2009 and 2015 were retrospectively enrolled for the comparison of disease-free survival (DFS) and overall survival (OS). At a median follow-up of 59 months, 174 DFS events and 69 deaths were observed. The estimated 5-year DFS rate was 94.2% in the HER2-pos-T group and 87.4% in the HER2-neg group (Log-rank P\\xa0=\\xa00.014). HER2-pos-T group was associated with significantly better DFS in multivariate analysis (HR 0.38, 95% CI: 0.22-0.67, Log-rank P\\xa0=\\xa00.001). The estimated 5-year OS rates for the two groups were 97.2% and 95.7%, respectively (Log-rank P\\xa0=\\xa00.183). In multivariable analysis, patients in the HER2-pos-T group had significantly better OS compared with those in the HER2-neg group (HR 0.40, 95% CI: 0.17-0.95, Log-rank P\\xa0=\\xa00.037). We concluded that high-risk ER+/HER2+ breast cancer patients treated with chemotherapy and trastuzumab had superior prognosis compared with ER+/HER2-patients. Therefore, HER2 positivity itself may not be considered as an unfavorable factor for ER\\xa0+\\xa0patients in the era of trastuzumab. Although the rates of many cancers are controlled in Western countries, those of some cancers, such as lung, breast, and colorectal cancer are currently increasing in many low- and middle-income countries due to increases in risk factors caused by development and societal problems. Additionally, endogenous factors, such as inherited mutations, steroid hormones, insulin, and insulin-like growth factor systems, inflammation, oxidative stress, and exogenous factors (including tobacco, alcohol, infectious agents, and radiation), are believed to compromise cell functions and lead to carcinogenesis. Chemotherapy, surgery, radiation therapy, hormone therapy, and targeted therapies are some examples of the approaches used for cancer treatment. However, various short- and long-term side effects can also considerably impact patient prognosis based on clinical factors associated with treatments. Recently, increasing numbers of studies have been conducted to identify novel therapeutic agents from natural products, among which plant-derived bioactive compounds have been increasingly studied. Naringin (NG) and its aglycone naringenin (NGE) are abundantly present in citrus fruits, such as grapefruits and oranges. Their anti-carcinogenic activities have been shown to be exerted through several cell signal transduction pathways. Recently, different pharmacological strategies based on combination therapy, involving NG and NGE with the current anti-cancer agents have shown prodigious synergistic effects when compared to monotherapy. Besides, NG and NGE have been reported to overcome multidrug resistance, resulting from different defensive mechanisms in cancer, which is one of the major obstacles of clinical treatment. Thus, we comprehensively reviewed the inhibitory effects of NG and NGE on several types of cancers through different signal transduction pathways, the roles on sensitizing with the current anticancer medicines, and the efficacy of the cancer combination therapy. Araliopsis soyauxii Engl. (Rutaceae) is a Cameroonian medicinal plant traditionally used to treat lung diseases, malaria, and gonorrhea. It has been demonstrated that infectious disease contribute to about 20% of all human tumours.\\n(1) To perform a phytochemical investigation of the dichloromethane-methanol 1:1 extracts of the bark (ASB), roots (ASR), and leaves (ASL) from Araliopsis soyauxii; (2) to evaluate the cytotoxicity of extracts and isolated compounds; (3) to determine the mode of induction of apoptosis of ASB and kihadanin B (12).\\nFourteen constituents of the crude extracts were isolated by column chromatography, while spectroscopic techniques were used for structural elucidation. The resazurin reduction assay (RRA) was applied to determine the cytotoxicity of samples towards a panel of 9 cancer cell lines. For caspases activity, the Caspase-Glo assay was used; flow cytometry was applied to investigate the cell cycle distribution (PI staining), apoptosis (annexin V/PI staining), mitochondrial membrane potential (MMP; JC-1 staining), and the reactive oxygen species (ROS; H\\nPhytochemical investigations of botanicals (ASB, ASR, and ASL) led to the isolation of 14 compounds. Extract ASB, obacunone (11), kihadanin B (12) as well as doxorubicin (control drug) revealed cytotoxicity towards the 9 cancer cell lines tested. The IC\\nThis study demonstrated that Araliopsis soyauxii is a potential source of cytotoxic phytochemicals such as kihadanin B and that ASB and compound 12. Extract and compounds will be explored further to develop anticancer drugs. Cisplatin (CDDP) is a potent first-line antitumor drug but suffers severe side effects and poor pharmacokinetics. Its complexation with polycarboxylic acids, such as polyglutamic acids, is generally used to fabricate nanoformulations for CDDP delivery; however, the multiple strong complexations makes intracellular drug release slow. Herein, we report a novel polyphenol-metal coordination method to fabricate CDDP-incorporated core-shell nanoparticles, which are stable in blood circulation but dissociate in the tumor. Methoxyl-PEG terminated with one or two gallic acids (PEG-GA or PEG-GA2) complexed CDDP and produced well-defined nanoparticles (PEG-GAx/Pt) with CDDP loading contents as high as 17.7% to 29.8%. The PEG-GAx/Pt nanoparticles were very stable in the physiological conditions and had slow blood clearance and efficient tumor accumulation, but dissociated quickly and released CDDP in response to the tumor acidity or elevated levels of reactive oxygen species (ROS). PEG-GAx/Pt nanoparticles exhibited improved antitumor efficiency against 4\\u202fT1 breast cancer and A549 lung carcinoma with much-reduced toxicity compared to free CDDP. The work demonstrates a new strategy of cisplatin-polyphenol coordination for developing platinum drugs\\' nanomedicines. Poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) and poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) form nano-assemblies, including micelles and nanoparticles, that increase the water solubility of anticancer drugs for injection. PEG-b-PLA and PEG-b-PCL are less toxic than commonly used organic solvents or solubilizers for injection, such as Cremophor EL® in Taxol®. Formulating paclitaxel in PEG-b-PLA micelles, as Genexol-PM®, permits dose escalation over Taxol®, enhancing antitumor efficacy in breast, lung and ovarian cancers. To expand the repertoire of anticancer drugs for injection, acyl and oligo(lactic acid) ester prodrugs have been synthesized for PEG-b-PLA and PEG-b-PCL nano-assemblies, compatibility, and novel nanomedicines for injection. Notably, acyl and oligo(lactic acid) taxane prodrugs delivered by PEG-b-PLA and PEG-b-PCL nano-assemblies display heightened plasma exposure, reduction in biodistribution into major organs and enhanced tumor exposure in murine tumor models, versus parent anticancer drugs in conventional formulations. As a result, acyl and oligo(lactic acid) ester prodrugs are less toxic and induce durable antitumor responses. In summary, acyl and oligo(lactic acid) ester prodrugs widen the range of anticancer drugs that can be tested safely and effectively by using PEG-b-PLA and PEG-b-PCL nano-assemblies, and they display superior anticancer efficacy over parent anticancer drugs, which are often approved products. Oligo(lactic acid) ester taxane prodrugs are in pre-clinical development as novel drug combinations and immunotherapy combinations for cancer therapy. Metastasis and mortality remain high among breast cancer patients with the claudin-low subtype because these tumors are aggressive, chemoresistant, and lack targeted therapies. Our objective was to utilize discovery-based proteomics to identify proteins associated with claudin-low primary and metastatic tumors to gain insight into pathways and mechanisms of tumor progression.\\nWe used nano-LC-MS/MS proteomics to analyze orthotopic and metastatic tumors from the syngeneic murine T11 tumor model, which displays gene expression profiles mirroring human claudin-low tumors. Galectin-1 identity, expression and spatial distribution were investigated by biochemical and immunochemical methods and MALDI/IMS. RNA seq data from mouse and human tumors in our study and publicly available microarray data were analyzed for differential galectin-1 expression across breast cancer subtypes.\\nGalectin-1, an N-acetyllactosamine-binding protein, exhibited the highest sequence coverage and high abundance rank order among nano-LC-MS/MS-identified proteins shared by T11 claudin-low tumors but not normal tissue. Label-free quantitation, Western immunoblot and ELISA confirmed galectin-1 identity and significant differential expression. MALDI/IMS spatial mapping and immunohistochemistry detected galectin-1 in T11 metastatic lung foci. Immunohistochemistry of human claudin-low tumors demonstrated intermediate-to-high intensity galectin-1 staining of tumor and stroma. Gene expression analysis of mouse and human tumors found the highest galectin-1 levels in claudin-low breast cancers.\\nProteomics and genomics reveal high expression of galectin-1 protein and RNA in primary and metastatic claudin-low breast cancer.\\nThis work endorses proteomic approaches in cancer research and supports further investigations of the function and significance of galectin-1 overexpression in claudin-low tumor progression. Copy number alterations are widespread in cancer genomes and are part of the genomic instability underlying the pathogenesis of neoplastic diseases. Recurrent copy number alterations of specific chromosomal loci may result in gains of oncogenes or losses of tumor suppressor genes and become entrenched in the genomic framework of certain types of cancers. The locus at chromosome 8p11.23 presents recurrent amplifications most commonly in squamous lung carcinomas, breast cancers, squamous esophageal carcinomas, and urothelial carcinomas. Amplification is rare in other cancers. The amplified segment involves several described oncogenes that may promote cancer cell survival and proliferation, as well as less well characterized genes that could also contribute to neoplastic processes. Genes proposed to be \"drivers\" in 8p11.23 amplifications include ZNF703, FGFR1 and PLPP5. Additional genes in the locus that could be functionally important in neoplastic networks include co-chaperone BAG4, lysine methyltransferase NSD3, ASH2L, a member of another methyltransferase complex, MLL and the mRNA processing and translation regulators LSM1 and EIF4EBP1. In this paper, genes located in the amplified segment of 8p11.23 will be examined for their role in cancer and data arguing for their importance for cancers with the amplification will be presented. Breast cancers with PIK3CA mutations can be treated with PIK3CA inhibitors in hormone receptor-positive HER2 negative subtypes. We applied a supervised elastic net penalized logistic regression model to predict PIK3CA mutations from gene expression data. This regression approach was applied to predict modeling using the TCGA pan-cancer dataset. Approximately 10,000 cases were available for PIK3CA mutation and mRNA expression data. In 10-fold cross-validation, the model with λ = 0.01 and α = 1.0 (ridge regression) showed the best performance, in terms of area under the receiver operating characteristic (AUROC). The final model was developed with selected hyper-parameters using the entire training set. The training set AUROC was 0.93, and the test set AUROC was 0.84. The area under the precision-recall (AUPR) of the training set was 0.66, and the test set AUPR was 0.39. Cancer types were the most important predictors. Both insulin like growth factor 1 receptor (IGF1R) and the phosphatase and tensin homolog (PTEN) were the most significant genes in gene expression predictors. Our study suggests that predicting genomic alterations using gene expression data is possible, with good outcomes. Nanomedicine, acting as the magic bullet, is capable of combining immunotherapy with other treatments to reverse a cold tumor (immune depletion) into a hot tumor. However, how to comprehensively inhibit the immunosuppressive tumor microenvironment (TME) remains a major challenge for immunotherapy to achieve the maximum benefits. Thus, a strategy that can simultaneously increase the recruitment of tumor infiltrating lymphocytes (TILs) and comprehensively reprogram the immunosuppressive TME is still urgently needed. Herein, a thermal-sensitive nitric oxide (NO) donor S-nitrosothiols (SNO)-pendant copolymer (poly(acrylamide- Various retroviral and lentiviral vectors have been used for up-the-teat intraductal injection to deliver markers, oncogenes, and other genes into mammary epithelial cells in mice. These methods along with the large number of genetically engineered mouse lines have greatly helped us learn normal breast development and tumorigenesis. Rats are also valuable models for studying human breast development and cancer. However, genetically engineered rats are still uncommon, and previous reports of intraductal injection of retroviral vectors into rats appear to be inefficient in generating mammary tumors. Here, we report, and describe the method for, stably introducing marker genes and oncogenes into mammary glands in rats using intraductal injection of commonly used lentiviral vectors. This method can infect mammary epithelial cells efficiently, and the infected cells can initiate tumorigenesis, including estrogen receptor-positive and hormone-dependent tumors, which are the most common subtype of human breast cancer but are yet still difficult to model in mice. This technique provides another tool for studying formation, prevention, and treatment of breast cancer, especially estrogen receptor-positive breast cancer. A solid self-emulsifying drug delivery system (SEDDS) of paclitaxel (PTX) was developed that could enhance its oral bioavailability and neutralize other niggles associated with conventional delivery systems of PTX. TPGS-centered SEDDS containing PTX was optimized by Box-Behnken experimental design and then formulated as fumed colloidal silica-based solid SEDDS microparticles (Si-PTX-S-SEDDS). AFM analysis exhibited round-shaped microparticles of approximately 2-3\\xa0μM diameter, whereas after reconstitution, particle size measurement showed nanoemulsion droplets of 30.00\\u2009±\\u20092.00\\xa0nm with a zeta potential of 17.38\\u2009±\\u20092.88\\xa0mV. Si-PTX-S-SEDDS displayed improved efficacy proven by reduced IC In breast cancer surgery, there has been a major shift toward less invasive local treatment. Although axillary lymph node dissection (ALND) was an integral part of surgical treatment for breast cancer, sentinel lymph node (SLN) biopsy was developed as an accurate method for axillary staging. ALND can be avoided not only in patients with negative SLNs but also in those with one or two positive SLNs receiving breast and/or axillary radiation. On the other hand, ALND has remained the standard treatment for patients with clinically positive nodes. However, axillary reverse mapping (ARM) was developed to map and preserve arm lymphatic drainage during ALND and/or SLN biopsy. This procedure allowed reduction of the rate of arm lymphedema without increasing axillary recurrence, although patients receive postoperative chemotherapy and high-risk patients undergo axillary radiation. Standard ALND may not be necessary even for patients with clinically positive nodes who receive axillary radiation and systemic therapy. Thus, the extent of axillary surgery in breast cancer has been decreased with increased use of systemic and radiation therapy. The purpose of this study is to confirm the position of DBT in breast cancer screening in Japan, to assess cancer detection rates, recall rates, positive predictive value (PPV), and to evaluate the type of mammographic findings of cancer with the use of digital mammography alone (2DDM) and combined with digital breast tomosynthesis (DBT).\\n11,894 examinations of the opportunistic breast cancer screening using only 2DDM and 2DDM plus DBT were performed from May 1, 2017 to March 31, 2019. The 11,894 women [3535 women who received DBT in addition to 2DDM (3D group) and 8359 who received 2DDM only (2D group)] participated in this study. The study was approved by the Institute\\'s Ethics Committee and all participants provided written informed consent.\\nThe recall rate was 2.6% for the 3D group and 3.6% for the 2D group (p\\u2009<\\u20090.01). The cancer detection rate was 0.17% in both 3D and 2D groups (p\\u2009=\\u20090.978). The positive predictive value (PPV) was 6.5% for the 3D group and 4.7% for the 2D group (p\\u2009=\\u20090.484). The cause of the decrease in recall rate was due to a decrease in the finding of focal asymmetric density (FAD).\\nThe recall rate was improved by using DBT for breast cancer screening in Japanese women. Cancer detection rates were exactly the same in DBT and 2DDM groups, so only DBT non-inferiority could be verified. We have verified that breast cancer screening combined with DBT is useful even for Japanese women to reduce unnecessary further examination. Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management OBJECTIVE: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists.\\nSymptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared.\\nA total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set.\\nSymptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment. Germline pathogenic sequence variants (PSVs) in BRCA1 substantially increase risk for developing breast (BC) and ovarian cancer (OvC). Yet, incomplete penetrance suggests that modifier factors affect phenotypic expression of mutant BRCA1 alleles. Analysis of identical BRCA1 PSV carriers of diverse ethnicities may provide further evidence for modifier factors. Female carriers of the 185delAG BRCA1 PSV identified through high-risk clinics in Israel, and Manchester England from 1998-2018 were eligible. Data were retrieved from patients records and confirmed (in Israel) by cross referencing with the Israeli National Cancer Registry. Overall, 2503 female carriers were included: 1715 (71.4%) Ashkenazi Jews (AJ), 201 (8.3%) Iraqi Jews and 383 (15.9%) of mixed ethnicity. In 102 (4.2%) cases ethnicity could not be ascertained. Of Israeli AJ carriers 649 (37.8%), 256 (14.9%) and 62 (3.6%) were diagnosed with BC, OvC or both cancers, respectively. For the Iraqi Jews these frequencies were 76 (37.8%), 43 (21.4%), and 8 (3.98%), respectively. Age at diagnosis of BC in AJ and Iraqi Jews was 46.7 ± 12.3 years and 52.8 ± 12.2 years, respectively (p = 0.001). For OvC age at diagnosis for AJ was 53.5 ± 10.7 years and for Iraqi Jews 50.1 ± 8.8 years (p = 0.0027). No differences in these parameters were noted between English Jews (n = 110) and non-Jews (n = 32). Age at diagnosis of BC and OvC differs between AJ and Iraqi Jews who carry an identical BRCA1 PSV. This finding supports the existence of modifier factors that may be ethnic specific. To calculate the diagnostic accuracy of nipple aspirate fluid (NAF) cytology.\\nEvaluation of NAF cytology in asymptomatic patients conceptually offers a non-invasive method for either screening for breast cancer or else predicting or stratifying future cancer risk.\\nStudies were identified by performing electronic searches up to August 2019. A meta-analysis was conducted to attain an overall pooled sensitivity and specificity of NAF for breast cancer detection.\\nA search through 938 studies yielded a total of 19 studies. Overall, 9308 patients were examined, with cytology results from 10,147 breasts [age (years), mean\\u2009±\\u2009SD\\u2009=\\u200949.73\\u2009±\\u20094.09\\xa0years]. Diagnostic accuracy meta-analysis of NAF revealed a pooled specificity of 0.97 (95% CI 0.97-0.98), and sensitivity of 0.64 (95% CI 0.62-0.66).\\nThe diagnostic accuracy of nipple smear cytology is limited by poor sensitivity. If nipple fluid assessment is to be used for diagnosis, then emerging technologies for fluid biomarker analysis must supersede the current diagnostic accuracy of NAF cytology. Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS).\\nData for stage IB2-IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed.\\nBeginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical response to CT/RT. The 5-year disease-free survival (DFS) was 73.7% in the O-RS patients and 73.0% in the MI-RS patients (HR 1.034, 95% CI 0.708-1.512, p\\u2009=\\u20090.861). The 5-year locoregional recurrence rate was 12.5% (O-RS) versus 15.2% (MI-RS) (HR 1.174, 95% CI 0.656-2.104, p\\u2009=\\u20090.588). The 5-year disease-specific survival (DSS) was 80.4% in O-RS patients and 85.3% in the MI-RS group (HR 0.731, 95% CI 0.438-1.220, p\\u2009=\\u20090.228). Estimated blood loss was lower in the MI-RS group (p\\u2009<\\u20090.001), as was length of hospital stay (p\\u2009<\\u20090.001). Early postoperative complications occurred in 77 patients (33.3%) in the O-RS group versus 88 patients (38.1%) in the MI-RS group (p\\u2009=\\u20090.331). Fifty-six (24.2%) patients experienced late postoperative complications in the O-RS group, versus 61 patients (26.4%) in the MI-RS group (p\\u2009=\\u20090.668).\\nMI-RS and O-RS are associated with similar rates of recurrence and death in LACC patients managed by surgery after CT/RT. No difference in early or late complications was reported. The role of sentinel lymph node biopsy (SLNB) in breast cancer patients who undergo neoadjuvant chemotherapy (NAC) remains controversial. This study aims to investigate if axillary lymph node dissection (ALND) could be safely omitted after a negative SLNB in cN1/2 patients who become cN0 after NAC.\\nWe retrospectively assessed T1-4, cN1/2 patients who were submitted to NAC between 2010 and 2016. T1-T3 patients who achieved complete axillary clinical response underwent SLNB. Those whose SLNs were negative were not subjected to additional ALND. The oncological outcomes of the patients were analyzed.\\nFifty-nine T1-T3 patients (45.0%) achieved a complete axillary response (cN0), and were selected to undergo SLNB. SLNs were detected in 55 of them (93.2%). Seventeen of those patients (30.9%) had SLN metastases detected and subsequently underwent ALND. In contrast, 38 patients (69.1%) had no nodal metastases detected and were managed without complementary ALND. After a mean follow-up of\\xa055.8\\xa0months, only one patient (2.6%) submitted to SLNB without a complementary ALND had axillary recurrence as compared with three patients (3.2%) in the ALND group (p\\u2009=\\u20090.71). Distant recurrence occurred more frequently among patients submitted to ALND (92.1%) than among those only submitted to SLNB (7.9%) (p\\u2009<\\u20090.0006). Overall survival and disease-free survival were significantly better in patients who were not submitted to ALND.\\nSLNB could be successfully used in guiding a more selective axillary approach in cN+\\u2009patients that became cN0 after NAC. Omitting ALND in CN0 patients with negative SLNs did not seem to compromise disease control and oncological outcomes. The present study evaluated tumor-infiltrating lymphocytes (TILs) based on standardized scoring method and investigated its predictive value for axillary pathologic complete response (apCR) and prognostic significance for event-free survival (EFS) in neoadjuvant-treated HER2-positive breast cancer with initially biopsy-proven nodal metastasis.\\nWe assessed TILs in a total of 187 pretherapeutic core biopsies of primary tumors. Receiver operating characteristic curve analysis was conducted to calculate the optimal cut-off point of TILs in discriminating axillary pathologic response. The associations of TILs with apCR or EFS were investigated by univariate and multivariate analyses.\\nReceiver operating characteristic curve analysis identified a 10% cut-off point of TILs that optimally discriminated apCR from non-apCR (P\\u2009<\\u20090.001). High TILs were determined as TILs\\u2009≥\\u200910%, and tumor with TILs\\u2009<\\u200910% was defined as lymphocyte-depleted breast cancer (LDBC). The apCR rate of the entire cohort was 66.3% (124/187). Tumors with high TILs had a significantly higher apCR rate compared with LDBC (78.5% vs. 43.9%; P\\u2009<\\u20090.001). High TILs (P\\u2009<\\u20090.001), breast pathologic complete response (P\\u2009=\\u20090.006), and negative status of hormone receptor (P\\u2009=\\u20090.021) were independent predictors for apCR. High TILs were a markedly powerful predictor with an odds ratio of 4.01 (P\\u2009<\\u20090.001). EFS was significantly better among patients with high TILs than among those with LDBC (P\\u2009<\\u20090.001). Univariate and multivariate analyses indicated that high TILs (P\\u2009=\\u20090.019) and apCR (P\\u2009=\\u20090.013) were independent predictors for favorable EFS.\\nTILs have predictive value for apCR and prognostic significance for EFS in initially node-positive and HER2-positive breast cancer treated with neoadjuvant therapy. LDBC (TILs\\u2009<\\u200910%) has a significantly unfavorable impact on apCR rate and EFS. Over the past few years, fabrication of\\xa0 nanoparticles (NPs) have been deployed widely in technologies and many concerns have emerged about the hazard effect on human health after nanoparticles exposure .\\nGreen synthesis of gold nanoparticles (AuNPs) and assessment of their activity in DMBA-induced breast cancer mouse model.\\nFormed nanoparticles were characterized with UV-vis spectrometry, Fourier-transform infrared spectroscopy (FTIR), Zetasizer measurement, Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM). Virgin female albino mice with DMBA-induced breast cancer treated with formed gold nanoparticles for 5 consecutive days and were dissected after 28 days of the beginning of treatment.\\nUV-vis spectrometry showed absorbance maximum peak at 530 nm for formed gold nanoparticles , zeta sizer measurement revealed 278.2 nm as an average size of produced\\xa0 nanoparticles\\xa0 , SEM and TEM approved formation of monodisperse spherical gold nanoparticles. Biochemical analysis of untreated breast cancer group revealed marked changes in liver and kidney. Whereas, the treated group with AuNPs post-breast cancer induction displayed reduction in\\xa0 the activities of (ALT, AST and creatinine) while, the BUN activity level was raised.\\xa0 Histopathological examination showed heavy incidence of tumor foci in the breast and lymph nodes belonged to the untreated breast cancer group. While , the treated group with AuNPs post-breast cancer induction showed degenerated tumor foci in the breast and lymph nodes.\\nGold nanoparticles (AuNPs) were successfully synthesized using HAuCl4 and Curcuma longa extract confirmed their ability to control DMBA-induced breast cancer in virgin female Swiss albino mice. Breast cancer (BC) in adolescents and young adults (AYAs) accounts for 5.6% of BC in all women. BC in this population is often characterized as aggressive. Two-thirds of BC in AYAs belong to the hormone-receptor positive (HR(+))/human epidermal growth factor receptor 2 negative (HER2(-)) subtype. However, the underlying pathogenesis of this subtype has not been fully elucidated. To study HR(+)/HER2(-) BC in AYAs, we downloaded the available RNA-seq data from The Cancer Genome Atlas (TCGA) database and then performed differential expression gene screening and constructed a protein-protein interaction (PPI) network, identified the key genes, and did gene set enrichment analysis (GSEA). Based on the analyses, 32.26% of patients were in stage III. Additionally, we identified 1671 differentially expressed genes (DEGs) and 35 key genes. In addition, GSEA showed that ether lipid metabolism and complement and coagulation cascades were significantly enriched in the GNAI1 high expression phenotype. The key genes CXCL2, CXCL5, CXCL3, GPR37L1, NPY2R, OXGR1, NPW, CCL21, GNAI1, SAA1, GRM4, HCAR2, CX3CL1, GRM8, CCL28, SSTR1, PENK, P2RY12, NMUR1, NMU, ADCY5, TAS1R1, OXER1, GNG13, CCL16, CCR8, NPY5R, CXCL11, CXCL10, CXCL9, CXCL1, CXCL6, CCR4, and ANXA1 may be molecular markers of tumorigenesis of HR(+)/HER2(-) BC in AYAs. In addition, ether lipid metabolism and complement and coagulation cascades may be key pathways for GNAI1 regulation in HR(+)/HER2(-) BC in AYAs. Breast cancer is still a leading threat to women\\'s lives. Long non-coding RNAs (lncRNA) associated with cancer progression are getting attention. The objective of this study was to investigate the role of lncRNA MAFG-antisense 1 (MAFG-AS1) and mechanisms of action in breast cancer.\\nThe expression of MAFG-AS1, microRNA-3196 (miR-3196) and transcription factor AP-2 alpha (TFAP2A) was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The cell proliferation was assessed by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The number of colonies was observed through colony formation assay. The protein levels of Cyclin D1, Ki67, Bcl-2 associated X protein (Bax), B-cell lymphoma2 (Bcl-2), Hexokinase II (HK2), lactate dehydrogenase A (LDHA), TFAP2A, Janus kinase 2 (JAK2), phosphorylated-JAK2 (p-JAK2), signal transducer and activator of transcription 3 (STAT3), and phosphorylated-STAT3 were quantified by western blot. The cell apoptosis was monitored using flow cytometry. The glycolysis progression was evaluated according to glucose consumption and lactate production. The relationship between miR-3196 and MAFG-AS1 or TFAP2A was predicted by the online tool starBase and verified by the dual-luciferase reporter assay. The role of MAFG-AS1 \\nMAFG-AS1 was highly expressed in tumor tissues and cells. MAFG-AS1 knockdown restrained proliferation, colony formation, and glycolysis but promoted apoptosis of breast cancer cells. MiR-3196 was a target of MAFG-AS1, and its inhibition reversed the role of MAFG-AS1 knockdown. TFAP2A was a target of miR-3196, and its overexpression abolished the effects of miR-3196 reintroduction. MAFG-AS1 knockdown suppressed the activity of the JAK2/STAT3 signaling pathway. Moreover, MAFG-AS1 knockdown reduced tumor growth \\nMAFG-AS1 knockdown attenuated breast cancer progression  [This retracts the article on p. 1284 in vol. 12, PMID: 31933942.]. EPDR1 is widely expressed in cancer, especially colorectal cancer. However, the biologic function of EPDR1 in breast cancer is uncertain.\\nThe expression profile of EPDR1 was assessed by Gene Expression Profiling Interactive Analysis (\\nmRNA expression of EPDR1 was significantly lessened in breast cancer tissues when compared to the adjacent normal tissues by data analysis from GEPIA. There was an impairment in proliferative ability, viability, invasion, and anti-apoptotic effect in EPDR1 overexpressed breast cancer cells. Mechanistic studies showed that EPDR1 overexpression increased the p53, p21 and Bcl-2 expression while inhibiting Bax expression.\\nEPDR1 inhibited malignant behaviors and promoted apoptosis in breast cancer cells by activation of the p53 signaling pathway. To explore the clinicopathologic features and differential diagnosis of breast primary mucinous cystadenocarcinoma (MCA).\\nPathological characteristics and immunophenotype of one case of MCA were analyzed. Literature was reviewed.\\nGrossly, the area of the tumor cut surface was gelationous. Microscopcally, the tumor was composed of variably sized cystic spaces lined by mucus-rich tumor cells with single columnar, stratified appearance and papillary formation. The degree of cytologic atypia varied from region to region. The tumor cells were positive for CK7, GATA3, negative for CK20, ER, PR and HER2. Most peripheral myoepithelial cells were negative for P63 and SMMHC.\\nMCA is a rare primary breast cancer and strikingly similar to ovarian, pancreatic and gastrointestinal counterparts. The diagnosis cannot be made until the metastatic lesion is ruled out. On the other hand, the biologic behavior of MCA is reportedly favorable despite a high proliferation index and triple negative biomarker status. Therefore, the role of adjuvant chemotherapy or radiation is questionable. The majority of patients receiving radiation therapy will experience a radiation skin reaction, ranging from mild erythema to severe moist desquamation. The anticipated skin reaction will vary by cancer diagnosis, dose of radiation, size of treatment field, and other treatment-and patient-related factors. Recently, research has dispelled long-held myths about avoiding skin care products prior to treatment, and the use of deodorant or antiperspirant during treatment for breast cancer and any potential for an increased skin dose with the use of skin care products. Patients no longer are restricted in using these products. Most of the research regarding skin reactions due to radiation has been conducted with women with breast cancer. No research has been found on the experience of a radiation skin reaction in patients with head and neck cancer (HNC), who often get the most severe skin reactions across all patient groups. Using the qualitative interpretive descriptive approach based on the methodological work by Thorne (1997), nine participants were interviewed about their experience of having a radiation skin reaction resulting from their treatment for HNC. Three themes emerged from the interviews, including 1) the symptom experience, 2) comparison to others, and 3) the experience of support and information. Implications include recommendations for practice and patient education. Endoscopic assisted total mastectomy (EATM) has been used for surgical intervention of breast cancer patients, however, large cohort studies with long term follow-up data are lacking.\\nBreast cancer patients who underwent EATM during the period of May 2009 to March 2018 were collected prospectively from multi-centers. Clinical outcome, impact of different phases, oncologic results, and patient-reported aesthetic outcomes of EATM were reported.\\nA total of 436 EATM procedures were performed, and 355 (81.4%) were endoscopic assisted nipple sparing mastectomy (E-NSM), and 81(18.6%) were endoscopic assisted skin sparing mastectomy (E-SSM). Three hundred and fourteen (75.4%) of the procedures were associated with immediate breast reconstruction (IBR), and 255 were prothesis based while 59 were associated with autologous flaps. The positive surgical margin rate for EATM was 2.1%. In morbidity evaluation, there were 19 (5.4%) cases with partial nipple necrosis, and 2 (0.6%) cases with total nipple necrosis, and 3 (0.7%) cases had implant loss. Compared with the early phase, surgeons operating on patients in the middle or late phase, had significantly decreased the operation time and blood loss. In patient-reported cosmetic outcomes, about 94.4% were satisfied with the aesthetic results. Patients with breast reconstruction, and preserving the nipple had higher satisfaction rates. Over a median follow-up of 54.1 ± 22.4 months, there were 14 (3.2%) cases of locoregional recurrences, 3 (0.7%) distant metastasis, and 1 (0.2%) mortality.\\nThis multi-centers\\' study showed that EATM is a reliable surgical intervention for early breast cancer with high patient satisfaction. The objective of this study was to examine the potential impact of provider social networks and experiences with patients on deimplementation of breast cancer screening.\\nWe constructed the Breast Cancer-Social network Agent-based Model (BC-SAM), which depicts breast cancer screening decisions, incidence, and progression among 10,000 women ages 40 and over and the screening recommendations of their providers over a 30-year period. The model has patient and provider modules that each incorporate social network influences. Patients and providers were connected in a network, which represented patient-patient peer connections, provider-provider peer connections, connections between providers and patients they treat, and friend/family relationships between patients and providers. We calibrated provider decisions in the model using data from the CanSNET national survey of primary care physicians in the United States, which we fielded in 2016.\\nFirst, assuming that providers\\' screening recommendations for women ages 50-74 remain unchanged but their recommendations for screening among younger (below 50\\u2009y old) and older (75+\\u2009y old) women decrease, we observed a decline in predicted screening rates for women ages 50-74 due to spillover effects. Second, screening rates for younger and older women were slow to respond to changes in provider recommendations; a 78% decline in provider recommendations to older women over 30 years resulted in an estimated 23% decline in patient screening in that group. Third, providers\\' experiences with unscreened patients, friends, and family members modestly increased screening recommendations over time (7 percentage points). Finally, we found that provider peer effects can have a substantial impact on population screening rates and can entrench existing practices.\\nModeling cancer screening as a complex social system demonstrates a range of potential effects and may help target future interventions designed to reduce overscreening. Social media is commonly used in public health interventions to promote cancer screening and early diagnosis, as it can rapidly deliver targeted public health messages to large numbers of people. However, there is currently little understanding of the breadth of social media interventions and evaluations, whether they are effective, and how they might improve outcomes.\\nThis scoping review aimed to map the evidence for social media interventions to improve cancer screening and early diagnosis, including their impact on behavior change and how they facilitate behavior change.\\nFive databases and the grey literature were searched to identify qualitative and quantitative evaluations of social media interventions targeting cancer screening and early diagnosis. Two reviewers independently reviewed each abstract. Data extraction was carried out by one author and verified by a second author. Data on engagement was extracted using an adapted version of the key performance indicators and metrics related to social media use in health promotion. Insights, exposure, reach, and differing levels of engagement, including behavior change, were measured. The behavior change technique taxonomy was used to identify how interventions facilitated behavior change.\\nOf the 23 publications and reports included, the majority (16/23, 70%) evaluated national cancer awareness campaigns (eg, breast cancer awareness month). Most interventions delivered information via Twitter (13/23, 57%), targeted breast cancer (12/23, 52%), and measured exposure, reach, and low- to medium-level user engagement, such as number of likes (9/23, 39%). There were fewer articles about colorectal and lung cancer than about breast and prostate cancer campaigns. One study found that interventions had less reach and engagement from ethnic minority groups. A small number of articles (5/23, 22%) suggested that some types of social media interventions might improve high-level engagement, such as intended and actual uptake of screening. Behavior change techniques, such as providing social support and emphasizing the consequences of cancer, were used to engage users. Many national campaigns delivered fundraising messages rather than actionable health messages.\\nThe limited evidence suggests that social media interventions may improve cancer screening and early diagnosis. Use of evaluation frameworks for social media interventions could help researchers plan more robust evaluations that measure behavior change. We need a greater understanding of who engages with these interventions to know whether social media can be used to reduce some health inequalities in cancer screening and early diagnosis.\\nRR2-10.1136/bmjopen-2019-033592. Current online prognostic prediction models for breast cancer, such as Adjuvant! Online and PREDICT, are based on specific populations. They have been well validated and widely used in the United States and Western Europe; however, several validation attempts in non-European countries have revealed suboptimal predictions.\\nWe aimed to develop an advanced breast cancer prognosis model for disease progression, cancer-specific mortality, and all-cause mortality by integrating tumor, demographic, and treatment characteristics from a large breast cancer cohort in China.\\nThis study was approved by the Clinical Test and Biomedical Ethics Committee of West China Hospital, Sichuan University on May 17, 2012. Data collection for this project was started in May 2017 and ended in March 2019. Data on 5293 women diagnosed with stage I to III invasive breast cancer between 2000 and 2013 were collected. Disease progression, cancer-specific mortality, all-cause mortality, and the likelihood of disease progression or death within a 5-year period were predicted. Extreme gradient boosting was used to develop the prediction model. Model performance was assessed by calculating the area under the receiver operating characteristic curve (AUROC), and the model was calibrated and compared with PREDICT.\\nThe training, test, and validation sets comprised 3276 (499 progressions, 202 breast cancer-specific deaths, and 261 all-cause deaths within 5-year follow-up), 1405 (211 progressions, 94 breast cancer-specific deaths, and 129 all-cause deaths), and 612 (109 progressions, 33 breast cancer-specific deaths, and 37 all-cause deaths) women, respectively. The AUROC values for disease progression, cancer-specific mortality, and all-cause mortality were 0.76, 0.88, and 0.82 for training set; 0.79, 0.80, and 0.83 for the test set; and 0.79, 0.84, and 0.88 for the validation set, respectively. Calibration analysis demonstrated good agreement between predicted and observed events within 5 years. Comparable AUROC and calibration results were confirmed in different age, residence status, and receptor status subgroups. Compared with PREDICT, our model showed similar AUROC and improved calibration values.\\nOur prognostic model exhibits high discrimination and good calibration. It may facilitate prognosis prediction and clinical decision making for patients with breast cancer in China. Matrine is one of the major alkaloids extracted from Sophora flavescens Ait of the traditional Chinese medicine, was the main chemical ingredient of compounds of Kushen injection. The Matrine is considered as a promising therapeutic agent for curing nonsmall cell lung cancer (NSCLC), used either alone or combined with chemotherapeutic agents. In the present study, we focused on the possible roles of Matrine exerted on the self-renewal ability of stem-like cells of the NSCLC group, as well as the cytotoxicity of chemotherapeutic agents, in vitro and in vivo. Here we reported that Matrine inhibits cancer stem-like cell (CSC) properties through upregulation of Let-7b and suppression of the Wnt pathway. Overexpression of Let-7b suppressed the ability of tumorsphere formation, decreased Wnt pathway activation through inhibiting its transcriptional activity in lung CSCs. Further studies revealed that Let-7b directly targeted CCND1 and decreased its expression, whereas Matrine increased Let-7b levels and followed by inactivation of the CCND1/Wnt signaling pathway and inhibition of EMT, which was characterized by loss of epithelial markers and acquisition of a mesenchymal phenotype in lung CSCs. What is more, we found that Matrine increased Let-7b level in an endoribonuclease DICER1-dependent manner. And xenografts in nude mice evidenced that Matrine increased the sensitivity of lung CSCs to 5-FU and inhibited the accumulation of CCND1 in tumor tissues induced by 5-FU. Taken together, these data illustrate the role of Let-7b in regulating lung CSCs traits and DICER1/let-7/CCND1 axis in Matrine or in combination with 5-FU intervention of lung CSCs\\' expansion, helping to fulfill the anti-cancer action of Matrine. Increasing evidence has shown that the tumor microenvironment (TME) plays an important role in tumor occurrence and development and can also affect patient prognosis. In this study, we screened key prognostic genes in the breast cancer (BC) TME by analyzing the immune and stromal scores of tumor samples to detect differentially expressed genes (DEGs) and also constructed a TME-related prognostic model. First, we obtained mRNA-Seq and related clinical information for patients with BC from The Cancer Genome Atlas (TCGA) and calculated the stromal and immune scores of tumor tissues using the ESTIMATE algorithm. Next, we performed functional enrichment analysis and generated protein-protein interaction networks from the DEGs that were highly related to the TME. Finally, Cox proportional hazards regression analysis was performed on BC datasets from TCGA, and analyses were conducted on infiltrating immune cells and the human protein atlas. Together, these analyses indicated that the  Recently, low dose radiotherapy delivered to the whole lung has been proposed as treatment for the pneumonia due to COVID-19. Although there is biological plausibility for its use, the evidence supporting its effectiveness is scarce, and the risks associated with it may be significant. Thus, based on a virtual case simulation, we estimated the risks of radiation-induced cancer (RIC) and cardiac disease.\\nLifetime attributable risks (LAR) of RIC were calculated for the lung, liver, esophagus, and breast of female patients. The cardiovascular risk of exposure-induced death (REID) due to ischemic heart disease was also calculated. The doses received by the organs involved in the treatment were obtained from a simulation of conformal radiotherapy (RT) treatment, delivering a dose of 0.5\\u2009Gy to 1.5\\u2009Gy to the lungs. We considered a LAR and REID <1% as acceptable, 1-2% cautionary, and >2% unacceptable.\\nThe lung was at the highest risk for RIC (absolute LAR below 5200 cases/100,000 and 2250 cases/100,000 for women and men, respectively). For women, the breast had the second-highest LAR, especially for young women. The liver and esophagus had LARs below 700/100,000 for both sexes, with a higher incidence of esophageal cancer in women and liver cancer in men. Regarding the LAR cutoff, we observed an unacceptable or cautionary LAR for lung cancer in all women and men <60 years with an RT dose >1\\u2009Gy. LAR for lung cancer with an RT dose of 1\\u2009Gy was cautionary for women >60 years of age and men <40 years of age. No LAR estimation was unacceptable for the RT dose ≤0.7\\u2009Gy in all groups irrespective of sex or age at exposure. Only 0.5\\u2009Gy had an acceptable REID.\\nA RT dose ≤0.5\\u2009Gy provides an acceptable LAR estimate (≤ 1%) for RIC and REID, irrespective of sex and age. The current ongoing trials should initially use doses ≤0.5\\u2009Gy to maintain the risks at an acceptable level and include only patients who fail or do not have any other treatment option. Cancer stem cells (CSCs) are a crucial therapeutic target because of their role in resistance to chemo- and radiation therapy, metastasis, and tumor recurrence. Differentiation therapy presents a potential strategy for \"defanging\" CSCs. To date, only a limited number of small-molecule and nanomaterial-based differentiating agents have been identified. We report here the integrated use of nanoparticle engineering and hypothesis-free sensing to identify nanoparticles capable of efficient differentiation of CSCs into non-CSC phenotypes. Using this strategy, we identified a nanoparticle that induces CSC differentiation by increasing intracellular reactive oxygen species levels. Importantly, this unreported phenotype is more susceptible to drug treatment than either CSCs or non-CSCs, demonstrating a potentially powerful strategy for anticancer therapeutics. To explore the mechanism of Scutellaria barbata-Hedyotis diffusa against breast cancer based on network pharmacological methods. The active components and corresponding target proteins of S. barbata and H. diffusa were screened by using Traditional Chinese Medicine Systems Pharmacology Database(TCMSP), and the targets of breast cancer were screened through the Genecards and OMIM databases. Venn online software was used to obtain the common targets of drugs and the disease, and then the &quot;compound-target-disease&quot; network diagram was constructed by using Cytoscape 3.7.2 software. The STRING database was used to draw the protein-protein interaction(PPI) network, and the David database was used to perform GO function and KEGG pathway enrichment analysis on effective targets. The results showed that 29 S. barbata compounds, 7 H. diffusa compounds, and 109 effective targets were screened. The 59 common targets for drugs and disease were obtained through Venn diagrams. The PPI network showed that MYC, CCND1, EGFR, ESR1, CASP3, VEGFA, etc. might be the key targets for &quot;S. barbata-H. diffusa&quot; in the treatment of breast cancer. In the GO function analysis, 88 entries were found, involving the regulation of transcription factor activity, receptor activity, cytokine activity, enzyme activity, and biosynthetic processes. In KEGG pathway analysis, 37 entries related to cancer, cell cycle, apoptosis, angioge-nesis and other pathways were found, including p53 signaling pathway, ErbB signaling pathway, nod like receptor signaling pathway, MAPK signaling pathway, VEGF signaling pathway, Wnt signaling pathway and mTOR signaling pathway and other classic signaling pathways. This study preliminarily revealed the key targets, biological processes and signal pathway of &quot;S. barbata-H. diffusa&quot; against breast cancer. It was found that its function was in a multi-target and multi-channel manner, which laid a foundation for future molecular biological experiments. None Overexpression of the ubiquitous protein kinase, CK2α, has been reported in various human cancers. Here, we demonstrate that nuclear and nucleolar CK2α localization in invasive ductal carcinomas of the breast is a reliable predictor of poor prognosis. Cellular localization of CK2α in nuclei and nucleoli, was analyzed immunohistochemically using surgical tissue blocks from 112 patients, who had undergone surgery without neoadjuvant chemotherapy. Clinical data collection and median follow-up period were for more than five years. 93.8% of patients demonstrated elevated CK2α expression in nuclei, and 36.6% of them displayed it predominantly in nucleoli. Clinicopathological malignancy was strongly correlated with elevated nuclear and nucleolar CK2α expression. Recurrence-free survival was significantly worse (p=0.0002) in patients with positive nucleolar CK2α staining. The five-year survival rate decreased to a roughly 50% in nucleolar CK2α-positive patients of triple negative (p=0.0069) and p Stage 3 (p=0.0073) groups. In contrast, no patients relapsed or died in the triple-negative group who exhibited a lack of nucleolar CK2α staining. Evaluation of nucleolar CK2α staining showed a high secondary index with a hazard ratio of 6.629 (p=0.001), following lymph node metastasis with a hazard ratio of 14.30 (p=0.0008). Multivariate analysis demonstrated that nucleolar CK2α is an independent factor for recurrence-free survival. Therefore, we propose that histochemical evaluation of nucleolar CK2α-positive staining may be a new and robust prognostic indicator for patients who need further treatment. Functional consequences of nucleolar CK2 dysfunction may be a starting point to facilitate development of novel treatments for invasive breast carcinoma. None Epithelial-mesenchymal transition (EMT) is a biological event, which critically regulates migration and invasion of cancer cells. EMT is regulated by several protein and nonprotein factors (such as noncoding RNAs). HOTAIR is an oncogenic long noncoding RNA\\xa0that stimulates EMT in cancers. In the current study, we investigated the effect of metformin on EMT behavior and HOTAIR expression in MDA-MB-231 breast cancer cells. The minimal effective concentrations of metformin (10 and 20\\u2009mM) were obtained by the MTT test. Cell migration and invasion in the metformin-containing medium were assayed in the scratch assay and transwell test. Meaningful decreases in both cell migration and invasion were observed in the presence of metformin. Vimentin, snail, β-catenin, and HOTAIR transcripts were quantified by real-time polymerase chain reaction (PCR). Reduction in the expression of vimentin, β-catenin, and HOTAIR was detected as the result of metformin treatment, but the snail showed a constant expression. Western blottingrevealed the downregulation of vimentin and β-catenin proteins. HOTAIR promoter methylation pattern was also investigated in metformin-exposed cells using bisulfite sequencing PCR which the result showed differences in the methylation profile of CpG islands between the treated and untreated cells. In conclusion, metformin modulated oncogenic expression of the HOTAIR gene in the MDA-MB-231 cells. This downregulation was associated with the modification of promoter methylation patterns. Since HOTAIR induces EMT in breast cancer, HOTAIR decline might be one of the mechanisms by which metformin reverses EMT. Chemotherapy causes off-target toxicity and is often ineffective against solid tumors. Targeted and on-demand release of chemotherapeutics remains a challenge. Here, cancer-cell-membrane-coated mesoporous organosilica nanoparticles (MONs) containing X-ray- and reactive oxygen species (ROS)-responsive diselenide bonds for controlled release of doxorubicin (DOX) at tumor sites are developed. DOX-loaded MONs coated with 4T1 breast cancer cell membranes (CM@MON@DOX) show greater accumulation at tumor sites and prolonged blood circulation time versus an uncoated control in mice bearing 4T1 orthotopic mammary tumors. Under low-dose X-ray radiation, the DOX-loaded MONs exhibit carrier degradation-controlled release via cleavage of diselenide bonds, resulting in DOX-mediated immunogenic cell death at the tumor site. Combination with a PD-L1 checkpoint blockade further enhances inhibition of tumor growth and metastasis with low systemic toxicity. Together, the findings show the promise of these biomimetic, radiation-responsive diselenide-bond-bridged MONs in chemo-immunotherapy. Radiation therapy is used as a form of treatment for various neoplastic diseases. There are many potential adverse effects of this therapy, including radiation-induced neurotoxicity. Radiation-induced brachial plexopathy (RIBP) may occur due to the fibrosis of neural and perineural soft tissues, leading to ischemic damage of the axons and Schwann cells. The dose of radiation exceeds 55\\xa0Gy in many patients who develop symptoms [1]. Current incidence in the United States is 1-2%, and RIBP is most commonly seen in patients who have undergone treatment for breast cancer, lung cancer, or lymphoma [1-3]. Common symptoms include numbness, paresthesia, dysesthesia, and occasional numbness of the arm. Pain is present in the shoulder and proximal arm and is typically mild to moderate in severity. Diagnosis is often made based on clinical presentation and evaluation of imaging to rule out concurrent malignant etiologies of the brachial plexus. Current recommended treatment includes physical therapy and medical management with anticonvulsants, tricyclic antidepressants, and selective serotonin-norepinephrine reuptake inhibitors. The detection and identification of estrogen receptor alpha (ERα), one of the main biomarkers in breast cancer, is crucial for the clinical diagnosis and therapy of the disease. Here, we use a non-destructive approach for detecting and localising ERα expression at the single cell level using surface enhanced Raman spectroscopy (SERS) combined with functionalised gold nanoparticles (AuNPs). Antibody functionalised nanotags (ERα-AuNPs) showed excellent biocompatibility and enabled the spatial and temporal understanding of ERα location in breast cancer cell lines with different ERα expression status. Additionally, we developed an approach based on the percentage area of SERS response to qualitatively measure expression level in ERα positive (ERα+) breast cancer cells. Specifically, the calculation of relative SERS response demonstrated that MCF-7 cells (ERα+) exhibited higher nanotag accumulation resulting in a 4.2-times increase in SERS signal area in comparison to SKBR-3 cells (ERα-). These results confirmed the strong targeting effect of ERα-AuNPs towards the ERα receptor. The functionalised ERα-AuNP nanotags were also used to investigate the activity of fulvestrant, the first-in-class approved selective estrogen receptor degrader (SERD). SERS mapping confirmed that ERα degradation occurred after fulvestrant treatment since a weaker SERS signal, and hence accumulation of nanotags, was observed in MCF-7 cells treated with fulvestrant. Most importantly, a correlation coefficient of 0.9 between the SERS response and the ERα expression level, obtained by western blot, was calculated. These results confirmed the strong relationship between the two approaches and open up the possibilities of using SERS as a tool for the estimation of ERα expression levels, without the requirement of destructive and time-consuming techniques. Therefore, the potential of using SERS as a rapid and sensitive method to understand the activity of SERDs in breast cancer is demonstrated. Hepatocellular carcinoma (HCC) initiation is characterized by stepwise accumulation of molecular alterations, during which the early events are largely unknown. Here, we presented a comprehensive genomic and transcriptomic landscape at stages of hepatitis, cirrhosis, and HCC by using a diethylnitrosamine-induced rat HCC model. We observed the early occurrence of gene instability and aberrant cancer associated signaling pathways in liver hepatitis. We further characterized the progressive molecular changes during hepatocarcinogenesis, wherein the intense rivalry between tumor-suppressive and oncogenic strengths occurred in cirrhosis stage. Despite the significant pathological difference, mutation signatures and expression landscape are highly similar between hepatitis and cirrhosis stages. Furthermore, we identified PI3K-Akt signaling pathway as a key pathway in the process of hepatocarcinogenesis through integrative analysis, and PIK3CD is a potential biomarker indicating HCC recurrence. The dynamic immune response during hepatocarcinogenesis, such as continuous decline of monocytes, suggests an immunological intervention strategy beyond chemoprevention for liver cancer. Estrogens play an important role in the development and progression of human cancers, particularly in breast cancer. Breast cancer progression depends on the malignant destabilization of adherens junctions (AJs) and disruption of tissue integrity. We found that estrogen receptor alpha (ERα) inhibition led to a striking spatial reorganization of AJs and microclustering of E-Cadherin (E-Cad) in the cell membrane of breast cancer cells. This resulted in increased stability of AJs and cell stiffness and a reduction of cell motility. These effects were actomyosin-dependent and reversible by estrogens. Detailed investigations showed that the ERα target gene and epidermal growth factor receptor (EGFR) ligand Amphiregulin (AREG) essentially regulates AJ reorganization and E-Cad microclustering. Our results not only describe a biological mechanism for the organization of AJs and the modulation of mechanical properties of cells but also provide a new perspective on how estrogens and anti-estrogens might influence the formation of breast tumors. How the extracellular matrix (ECM) affects the progression of a localized tumor to invasion of the ECM and eventually to vascular dissemination remains unclear. Although many studies have examined the role of the ECM in early stages of tumor progression, few have considered the subsequent stages that culminate in intravasation. In the current study, we have developed a three-dimensional (3D) microfluidic culture system that captures the entire process of invasion from an engineered human micro-tumor of MDA-MB-231 breast cancer cells through a type I collagen matrix and escape into a lymphatic-like cavity. By varying the physical properties of the collagen, we have found that MDA-MB-231 tumor cells invade and escape faster in lower-density ECM. These effects are mediated by the ECM pore size, rather than by the elastic modulus or interstitial flow speed. Our results underscore the importance of ECM structure in the vascular escape of human breast cancer cells. None The efficiency of cancer chemotherapy is seriously hampered by the development of resistance of neoplastic cells to cytotoxic agents. In the present investigation, the cytotoxicity of the dichloromethane-methanol (1:1) extract of  The unprecedented application of pesticides in Punjab, India during green revolution has lead to an environmental crisis due to the accumulation of persistent organic and pesticide pollutants in the environment and biota of this region. The present study aimed at estimating the abundance of pesticide contaminants in three biological matrices of 36 dogs suffering from malignant canine mammary tumor (mCMT) and 6 tumor free control dogs from Punjab, India. Presence of individual and total pesticides in canine biological samples, age and bodyweight of canine patients was assessed as a potential risk factor for mCMT using logistic regression analysis. Chi-square test was employed to determine tissue-specific accumulations of individual pesticides. Spearman\\'s correlation coefficient was estimated to determine the association between the levels of total pesticides in different tissue matrices and with age and bodyweight of mCMT cases. Gas chromatography-ECD analysis of serum, mammary tissue and adjoining mammary adipose tissue revealed fourteen different pesticides including γ-HCH, α-HCH, dieldrin, aldrin, heptachlor, butachlor, p,p-DDT, o,p-DDT, p,p-DDD, p,p-DDE, L-cyhalothrin, permethrin, fipronil, and fenitrothion. Heptachlor, γ-HCH, aldrin and p,p-DDT were more frequently detected, whereas, p,p-DDE and o,p-DDT were the least common. Differential accumulation of pesticides in tissue matrices, particularly between serum and mammary tissue/adipose tissue was observed. We could not find any association between the total pesticide concentrations among serum, mammary tissue and mammary adipose tissue in mCMT cases. We found that the odds for individual pesticide for serum, mammary tissue and adipose tissue were associated with high uncertainties; however, the total pesticide concentration in mammary tissue was near non-significantly associated with higher risk of mCMT with low uncertainty. Statistically non-significant higher odds of CMT occurrence with increase in age was noticed No association between the concentration of total pesticides in different matrices and age and bodyweight of canine subjects was found. We previously reported successful classification of breast cancer versus benign tissue using the Cole relaxation frequency measured on tissue excised during breast surgery as part of a study at two urban hospitals in the U.S. Midwest. Using that health system\\'s cancer registry, we have discovered retrospectively that outcomes for patients who participated in the initial study can be classified correctly in 3 well-differentiated categories: nonrecurrent (NR); recurrent with no metastasis (RNM); and recurrent with metastasis (RM). As Cole relaxation frequency increases, the classification moves from NR to RNM and finally to RM. Multivariate analysis showed a significant association of \"time-cancer-free\" for all patients in these recurrent categories, with P-values ranging between 0.0001 to 0.0047. Thus, this follow-up report shows the potential feasibility of using Cole relaxation frequency as a prognostic parameter in a larger prospective study. Despite comparable screening and incidence rates that are 26% below that of non-Hispanic Whites, Hispanic women present with breast cancer at more advanced stages of disease, representing a continuing and troubling health disparity for this population. Reducing these disparities warrant more innovative research approaches to better understand perspectives of Hispanic patients regarding barriers to treatment and how these perspectives compare to those of their providers. A pilot qualitative study was conducted at a major urban cancer center in Arizona that measured both patient and provider perspectives regarding barriers to treatment. Through a multimethod qualitative analysis, researchers surveyed patients and providers to identify perceived barriers and discordance in shared understanding. Data collection and analysis consisted of surveying patients and providers, then performing inductive qualitative analysis. Results indicated the highest concordance, or shared understanding, between patients and providers was in recognizing barriers within delivery of care, such as cost of care and insurance coverage. The greatest discordance, or gaps in shared understanding, existed in upstream barriers of the health care system, such as emotional support and trust in systems. These results underscore the gap in shared understanding between patients and providers regarding upstream barriers to care as well as the nonclinical social determinants of health Hispanic patients face in accessing breast cancer treatment. More research is warranted using this approach as a tool to reduce health disparities. Breast cancer survivors are at increased risk of cancer recurrence, second malignancies, and other comorbid conditions. This study examined if use of a convenient, commercially available, $65 per month app that gives breast cancer survivors access to a health and wellness coach is more effective than a self-guided toolkit and one-time health education session at achieving the following goals: 1) improving adherence to a plant-based diet, 2) increasing physical activity, 3) assisting with weight loss and reduction in body mass index, 4) reducing elevated depression and fatigue scores, and 5) leading to sustained adherence to lifestyle and wellness plan at and beyond 6 months.\\nA nonrandomized 2-group control study design with pre-post repeated measures (N=127 subjects) was utilized. Women 18 years of age or older, with curative-intent breast cancer, were included in the study. App users received a survivorship care plan and enrolled in a 6-month subscription to the health app. A control group received the same information but, instead of access to the app, were given a self-guided toolkit.\\nAt 6 months, more patients in the app group experienced weight loss and had a significantly greater reduction in overall body mass index (P<0.01). The app group also demonstrated statistically significant improvements in \"strenuous\" physical activity (P=0.04) and had significant improvement in their dietary patterns (P<0.001), as compared to the self-guided group. The app group had greater reduction in fatigue and improvement in depression, but these changes were not statistically significant. At 12 months, none of the app users were still using the app, but many were still following their wellness plan and had maintained their weight loss. Outliers in both groups and low rate of response made evaluation of results difficult.\\nThe results of this advanced practice provider-led study demonstrated that a live health coaching app that provides wellness coaching can offer motivated breast cancer survivors and cancer programs a modality that offers convenient, effective support at a reasonable cost. Participation in cancer support groups can provide a sense of community and may better prepare patients for interactions with their health care team. Online interactions may overcome some barriers to in-person support group participation. #BCSM (breast cancer social media), the first cancer support community established on Twitter, was founded in 2011 by two breast cancer survivors. The aims of this study are to describe the growth and changes in this community and to discuss future directions and lessons that may apply to other online support communities.\\nSymplur Signals was used to obtain all #BCSM Twitter data from January 1, 2011, to January 1, 2020 (00:00:00 Coordinated Universal Time for both). Hashtag use by selected stakeholder groups, user locations, weekly tweet chat activity, and topics were determined.\\nFrom year 1 (2011) to year 9 (2019), tweets using the #BCSM hashtag increased by 424%. Tweets by patient advocates increased by 226%, with a peak in 2016. Impressions, a measure of potential tweet views, by patient advocates increased by 517%. Tweets by doctors and nonphysician health care professionals increased by 693%. Weekly #BCSM tweet chat activity peaked in 2013, increasing by 58.1% from 2011. Chat topics have included survivorship, metastatic breast cancer, death and dying, advocacy, and highlights from national breast cancer meetings.\\n#BCSM has experienced tremendous growth since 2011, although there are challenges to community sustainability. The weekly chats, as well as discussions utilizing the hashtag but occurring outside of scheduled chat times, serve as an important resource for patients and offer physicians an opportunity to both support and learn from patients. The purposes of this study were to determine whether the presence of upper extremity chemotherapy-induced peripheral neuropathy (CIPN) symptoms (burning, pins/needles, numbness, pain, and skin crawls) among breast cancer survivors (BCS) varied according to age (≤45 years or 55-70 years) and to examine age group differences in upper extremity CIPN symptom distress.\\nThe study was a secondary analysis of younger (n=505) and older (n=622) BCS. Inclusion criteria were age of ≤45 years or 55-70 years; patient at 3-8 years postdiagnosis; patient received the chemotherapy regimen of paclitaxel, doxorubicin, and cyclophosphamide; and patient did not have recurrence. The Symptom Survivor Checklist was used to assess presence and distress of upper extremity CIPN symptoms. Analyses explored whether age group predicted CIPN symptom presence and distress while controlling for sociodemographic and medical variables.\\nOlder BCS reported fewer pins/needles, numbness, and pain symptoms (odds ratios: 0.623-0.751). Heart disease (odds ratios: 1.59-1.70) and progesterone-negative breast cancer (odds ratio: 0.663) were significantly associated with one or more CIPN symptoms. Symptom distress ratings did not differ by age groups; both age groups indicated distress from CIPN symptoms, with 25% or more reporting distress as \"moderately\" or \"quite a bit.\"\\nYounger BCS reported more upper extremity CIPN symptoms. BCS in both groups continued to report bothersome CIPN symptoms years after treatment. Study findings will assist clinicians in identifying BCS at higher risk for upper extremity CIPN as well as inform development of appropriate tailored interventions to mitigate these symptoms and facilitate restoration to age-related baseline function, thereby improving quality of life for BCS. None The extracellular matrix (ECM) provides cues to direct mammogenesis, tumourigenesis and metastatic processes. Over the past several decades, two-dimensional (2D) culture models have been invaluable in furthering our understanding of the tumor microenvironment (TME), however, they still do not accurately emulate the associated biological complexities. In contrast, three-dimensional (3D) culture models provide a more physiologically relevant platform to study relevant physicochemical signals, stromal-epithelial cell interactions, vascular and immune components, and cell-ECM interactions in the human breast microenvironment. A common thread that may weave these multiple interactions are the proteoglycans (PGs), a prominent family of molecules in breast tissue. This review will discuss how these PGs contribute to the breast cancer TME and provide a summary of the traditional and emerging technologies that have been utilized to better understand the role of PGs during malignant transformation. Furthermore, this review will emphasize the differences that PGs exhibit between normal tissues and tumor ECM, providing a rationale for the investigation of underexplored roles of PGs in breast cancer progression using state-of-the-art 3D culture models. Given the long history of investigation into cancer and its relevance to the lymph node (LN), it would be meaningful to plot the trends of research on cancer-related LN.\\nQueries such as \"cancer,\" \"lymph node,\" and \"cancer and lymph node\" were submitted to PubMed to collect articles on cancer and LN published between 1945 and 2017. The collected articles were then extracted by an automatic web crawler and examined through informetrics and linguistic analysis.\\nThe number of articles related to cancer was 2,795,476 and 127,897 articles (4.6%) were found to be relevant to LN. With regard to cancer types, breast cancer was the most studied (37%), followed by gastric cancer (17%). With regard to the subjects in which the surgeon is interested, LN metastasis (57%) was found to be the topic most discussed, followed by LN dissection (22%) and sentinel LN (17%). Publications on LN metastasis gradually increased over time from 1988 to 2017 although those on sentinel LN and LN dissection have stagnated since the early 2000s.\\nAlthough research on cancer was abundant, only a small portion was dedicated to investigating its relevance to LN. Western countries had led the research on cancer-related LN, but Asian countries began to participate as major players, expanding their contributions. While LN metastasis, one of the major cancer-related LN topics, showed a steady increase, those involved in oncologic surgery such as LN dissection and sentinel LN did not. Although metastasis occurs in 1 or 2 sentinel lymph nodes (SLNs), axillary lymph node dissection (ALND) has been widely not performed. For axillary staging and management, the necessity of intraoperative frozen section analysis of SLN has been controversial. The aim of this study is to evaluate the validity and benefit of SLN analysis by permanent section alone in clinically negative lymph node breast cancer patients.\\nWe conducted a retrospective study of 283 cases with negative node clinical findings between July 2018 and August 2019 in Samsung Medical Center. Clinical nodal stage was evaluated by physical examination, breast ultrasonography, breast magnetic resonance imaging, and chest computerized tomography. The cases were divided into 2 groups; the permanent group had 151 cases (53.4%) and the frozen group had 132 cases (46.6%). We retrospectively analyzed the differences in the number of metastatic lymph nodes and rates of performed ALND between the 2 groups.\\nBaseline and clinicopathologic characteristics between the 2 groups were well balanced. Three cases in the permanent group and 6 cases in the frozen group underwent additional or immediate ALND. The rates of ALND between the 2 groups were not significantly different (P = 0.312). The cased of 78.9% and 89.5% with metastatic lymph nodes in permanent and frozen groups were in the pathologic N1 stage, respectively.\\nSLNs analysis by permanent section alone may be performed in clinically negative axillary node breast cancer patients. Our findings can help to avoid unnecessary intraoperative frozen section analysis. This study aimed to comprehensively analyze the characteristics, treatment patterns, and survival outcomes of non-small-cell lung cancer (NSCLC) patients initially diagnosed with brain metastases (BMs) in real-world practice.\\nWe enrolled NSCLC patients initially diagnosed with BMs between Jan 2004 and Jan 2018 in our institution. Patient demographics, treatment modalities, and survival outcomes were then analyzed. Brain localized treatment (BLT) included early brain radiotherapy (EBR), deferred brain radiotherapy (DBR), and surgery.\\nA total of 954 patients were identified. Concerning initial treatment, 525 patients (55.0%) received systemic medication (SM)+BLT, 400 patients (41.9%) received SM only, and 29 patients received BLT only (3.0%). SM+BLT cohort was associated with longer median overall survival (mOS) than the SM only and the BLT only cohorts both in epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)-negative/unknown patients (15.3\\xa0months, 95% confidence interval [CI], 14.2-16.4; 11.1\\xa0months, 9.0-13.2; 7.0\\xa0months, 5.4-8.6; p<0.001) and in EGFR/ALK-positive patients (33.7\\xa0months, 28.5-38.9; 22.1\\xa0months, 17.8-26.4; 4.0\\xa0months, 3.6-4.4; p\\xa0<\\xa00.001). As for timing of radiotherapy, SM+EBR (14.1\\xa0months, 12.7-15.5) was associated with inferior mOS than SM+DBR (19.4\\xa0months, 14.2-24.6) in EGFR/ALK-negative/unknown patients. No significant difference was found in EGFR/ALK-positive patients (28.3\\xa0months, 19.1-37.5; 33.3\\xa0months, 28.1-38.5). Patients in the EGFR/ALK-negative/unknown cohort treated with first-line pemetrexed with platinum (PP) (15.8\\xa0months, 14.0-17.6, p<0.001) had longer mOS than those received non-PP regimens (13.1\\xa0months, 11.6-14.6). However, no difference was observed among EGFR/ALK-positive patients who were treated with tyrosine kinase inhibitors (TKIs) (29.5\\xa0months, 21.1-37.9; p\\xa0=\\xa00.140), PP (27.2\\xa0months, 21.6-32.8) and non-PP regimens (25.0\\xa0months, 16.0-34.0).\\nOur study confirmed that the use of SM+BLT is associated with superior mOS than those treated with SM only and BLT only. SM+DBR might be a better radiotherapeutic strategy for this patient population. EGFR/ALK-negative/unknown patients showed a survival benefit with PP treatment.  Immune response and immunotherapy play important roles in triple-negative breast cancer (TNBC). However, it is difficult to judge whether cancer is \"immune-inactivated\" or \"immune-activated\" by the carcinoma itself. The immune reaction of the microenvironment or the host to the tumor might be more informative. We assumed that clinically enlarged but pathologically negative regional lymph nodes served as an indicator for early immune response to tumors. First, we identified women with pN0 breast cancer disease from the current Surveillance, Epidemiology, and End Results database, and we compared the cN1 patients of breast cancer-specific survival (BCSS) with cN0 patients. Then, we extracted total RNA from 36 paired large (defined as minimum diameter more than 15 mm in size) and small lymph nodes (defined as maximum diameter less than 5 mm in size) from 12 TNBC, 12 HER2-enriched, and 12 luminal-like patients and performed RNA sequencing to explore the gene expression and cellular landscape of large nodes compared to small ones. Among 692 women with pathologically confirmed node-negative disease, cN1 patients unexpectedly had a better BCSS compared with cN0 in TNBC (adjusted hazard ratio 0.148, 95% CI, 0.040-0.546,  This study aimed to assess the efficacy of utidelone, a novel genetically engineered epothilone analog, combined with capecitabine in our center and, furthermore, to identify whether ganglioside monosialic acid (GM1) improved chemotherapy-induced peripheral neurotoxicity (CIPN).\\nFifty-five eligible female patients with metastatic breast cancer were enrolled in our single-center phase III BG01-1323L trial. Utidelone combined with capecitabine-induced peripheral neuropathy was analyzed, and susceptible genes were detected in a germline panel by next-generation sequencing (NGS).\\nIn our single-center study, median progression-free survival and overall survival (OS) improved in the utidelone plus capecitabine group (mPFS: 238 vs. 189 days, \\nGanglioside monosialic acid potentially decreases severe utidelone plus capecitabine-induced peripheral neuropathy in metastatic breast cancer, and further investigation is needed to validate the manageable efficacy of GM1 in CIPN.\\nClinicalTrials.gov, identifier NCT02253459. Modified Gail Model is a noninvasive, easy to implement risk estimation tool for absolute breast cancer risk. It was developed with data collected from non African American females and further modified for African-American, the Hispanic, and Native American populations. The use of this model for population outside the US and European country is not yet validated. We evaluated the prevalent risk factors and the effectiveness of the Gail model for risk assessment in our local Indian population.\\nA retrospective analysis of a prospectively maintained database was conducted on patients treated between 2008 and 2013. Six hundred and fifty patients were included in each group. Six questions were taken as per the breast cancer risk assessment tool calculator. A value of over 1.67% was taken as a high risk for breast cancer development.\\nThe mean age of the participant was 50 ± 21.3 years in cases and 41 ± 16.4 years in controls. Age and age at first childbirth >30 years were found to be significant and associated with increased risk of breast carcinoma, but the age at menarche, family history, previous breast biopsy, and atypical hyperplasia was no significant. The Gail model was assessed, and sensitivity was 10.30% and 96.30% specificity for our population. Positive and negative predictive values were 73.62% and 51.77%.\\nOur study concluded that the Gail model is not an appropriate risk assessment tool for the population in its present form. For the future application of this model, we need to perform a bigger study with a higher sample size representing a maximum number of local variabilities in the Indian population. The  [This corrects the article on p. 2621 in vol. 10, PMID: 32905506.]. Breast cancer remains a complex disease resulting in high mortality in women. A subset of cancer stem cell (CSC)-like cells expressing aldehyde dehydrogenase 1 (ALDH1) and SOX2/OCT4 are implicated in aggressive biology of specific subtypes of breast cancer. Targeting these populations in breast tumors remain challenging. We examined xenografts from three poorly studied triple negative (TN) breast cancer cells (MDA-MB-468, HCC70 and HCC1806) as well as HMLE Breast cancer (BC) is the most common female malignancy worldwide, and 70% of which are estrogen receptor α (ERα) positive. Endocrine treatment, such as tamoxifen, is a primary adjuvant therapy for patients with ER-positive BC. However, some patients will develop acquired resistance following long-time treatment. Further research on estrogen signaling is important to improve the therapy of these patients. In this study, we report that the E3 ubiquitin ligase tripartite motif 8 (TRIM8) acts as a novel regulator of ERα signaling. TRIM8 is downregulated in BC and is associated with poor prognosis. In addition, the protein level of TRIM8 is negatively correlated with ERα. RNA sequencing revealed that estrogen signaling maybe a potential target of TRIM8. Moreover, knockdown of TRIM8 can significantly enhance BC cell proliferation and migration both  To determine easy-to-use predictors of overall survival (OS), locoregional recurrence (LRR), and distant metastasis (DM) in breast invasive ductal carcinoma (IDC) patients receiving neoadjuvant chemotherapy (NACT) and total mastectomy (TM), we used the pathologic response (PR) of primary breast diseases (T stages), nodal diseases (N stages), and combined primary and nodal diseases (American Joint Committee on Cancer [AJCC] stages) based on existing clinical and pathologic reports as predictors. We enrolled patients with IDC who received NACT followed by TM. Cox regression analysis was used to calculate hazard ratios (HRs) and confidence intervals (CIs) of PR; other independent predictors were controlled for or stratified in the analysis. We analyzed 3654 IDC patients (1031, 1215, 1003, and 405 patients with clinical stages IIB, IIIA, IIIB, and IIIC, respectively) receiving NACT and TM. After multivariate Cox regression analyses, the adjusted HRs (aHRs) (95% CI) for all-cause mortality, LRR, and DM were noted to be 0.21 (0.13-0.34), 0.19 (0.08-0.48), and 0.33 (0.23-0.47), respectively, for pCR; 0.56 (0.48-0.65), 0.67 (0.51-0.89), and 0.61 (0.52-0.70), respectively, for AJCC downstaging; and 1.85 (1.56-2.18), 1.17 (0.84-1.62), and 1.61 (1.36-1.90), respectively, for AJCC upstaging. The PR parameters used in the study are easily applied because they are based on existing staging records, and they can strongly predict OS, LRR, and DM in IDC patients receiving NACT and TM, regardless of clinical stage. The results can be used to guide adjuvant treatment. Over the past two decades, elderly colon cancer patients experienced less improvement in survival than their younger counterparts, yet the contributing factors remain unknown. We aimed to evaluate factors that may contribute to the age disparity of survival improvement among patients with colon cancer. Using data from the National Cancer Database, we identified patients diagnosed with colon cancer between 2004 and 2012 with follow-up data up to 2017. The hazard ratios (HR) and 95% confidence intervals (CI) for 5-year OS associated with study variables were estimated using multivariable Cox regression. Among 486,284 patients included in this study, elderly patients (aged ≥75) had a lower adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines (% of non-adherence: 45.3%) than younger patients (aged <50, 19.3%;  Spatial organization of tumor microenvironment (TME) may influence tumor response to immunomodulatory therapies. Zeb1 is a driver of epithelial-mesenchymal transition, with several roles in immune cell development, however its role in shaping of the immune TME is not fully explored. We conducted a pre-multiplex spatial analysis study to verify whether Zeb1 influences spatial distribution of tumor-infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC). We applied single and double immunohistochemistry to analyze spatial relationships between CD8+, FoxP3+ and CD20+ tumor-infiltrating lymphocytes (TILs) and the cells expressing Zeb1 in formalin-fixed, paraffin-embedded surgical specimens of 113 TNBCs. 15.5% of cases had Zeb1+ tumor cells and 72.8% of cases had stroma rich in Zeb1+ cells. Low density of intratumoral CD8+ TILs was observed in almost all TNBCs with high or moderate Zeb1+ expression in tumor cells (22/23 cases, 95.6%), and in 90.4% of TNBCs (75/83 cases) with stroma rich in Zeb1+ cells. On the other side, a majority of TNBCs with stroma rich in Zeb1+ cells had high density of stromal CD8+ TILs (55/83 cases, 66.3%). These associations were not observed between Zeb1-expressing cells and FoxP3+ or CD20+ TILs. This in situ analysis showed specific spatial relationship between tumor or stromal Zeb1+ cells and CD8+ TILs, which need to be validated in other cohorts. Zeb1 was highlighted both as a marker of tumor cell EMT and of tumor stroma richness in mesenchymal cells. Several hypotheses about causes of the observed relationship between Zeb1 and TILs are generated and the approaches to verify them discussed. Zeb1 is worth further investigation as a potential biomarker of intratumor immunosuppression of TNBC and of its response to immunotherapies. It is known that an inflammatory condition in different types of cancer provides a sustained microenvironment that favors tumor growth, invasion, and metastasis. Non-steroidal anti-inflammatory drugs such as indomethacin have demonstrated chemo-preventive, anti-proliferative and cytotoxic effects in a variety of tumors. The aim of this study was to investigate the effects of an organotin indomethacin derivative (OID) on the proliferation of breast and prostate cancer cell lines and the possible mechanisms of action of this compound. Different cancer cell lines were treated in the presence of OID and cell proliferation was measured by quantification of the DNA content, changes in the cell cycle profile and the activation of caspase 3 were evaluated by flow cytometry, interleukin 6 (IL-6) gene expression was evaluated by qPCR and protein expression was analyzed by ELISA and Western blot assays. OID inhibited the cell proliferation of a panel of cancer cell lines in a concentration-dependent manner. Moreover, the addition of OID to lapatinib treatment, targeted therapy for breast cancer, significantly enhanced its antiproliferative response. The effects on cell proliferation of these compounds involved, among others, the induction of apoptosis, the downregulation of IL-6 and a decrease of the MAPK activation pathway. Our results suggest that the use of OID alone or in combination with tyrosine kinase inhibitors could be considered as adjuvants in the treatment of cancer. Multidrug chemoresistance is a major clinical obstacle in breast cancer treatment. We aimed to elucidate the sensitivity to therapeutics in gemcitabine-resistant breast cancer models. Pooled library screening combined with RNA-seq was conducted to explore the potential targets involved in gemcitabine resistance in breast cancer cells. Cytotoxicity and tumor xenograft assays were used to evaluate the effect of calcium-activated channel subfamily N member 4 (KCNN4) inhibitors on the cellular sensitivity of breast cancer cells to chemotherapeutic drugs both  The trans-activation response DNA-binding protein of 43 kDa (TDP-43) is a nuclear protein that has been shown to be involved in the growth and metastasis of breast cancer, neuroblastoma, and melanoma. However, the effect of TDP-43 on hepatocellular carcinoma (HCC) metastasis remains unclear. Here, we demonstrated that TDP-43 was highly upregulated in both clinical samples and cell lines of HCC. Moreover, knockdown and overexpression of TDP-43 efficiently affected the proliferation and metastasis of HCC cells as well as the expression of some proteins associated with epithelial-mesenchymal transition (EMT) and Wnt/β-catenin signaling pathway. Furthermore, activation of the Wnt/β-catenin pathway by LiCl restored the effect of TDP-43 knockdown on EMT and HCC cells, whereas inhibition of the Wnt/β-catenin pathway by XAV939 negated the effect of TDP-43 overexpression. Importantly, we found that TDP-43 protein could interact with  Autologous flap reconstruction is widely used after skin sparing mastectomy to reconstruct the appearance of the breast. We present 2 cases of breast cancer recurrence in a deep inferior epigastric perforator reconstruction, including a 65-year-old female with history of papillary carcinoma and a 35-year-old female with history of a high grade invasive ductal carcinoma with extensive ductal carcinoma in situ. Differential imaging considerations of the post mastectomy patient are reviewed. Typical appearance of a deep inferior epigastric perforator flap reconstruction as well as location and timing of presentation may help differentiate a recurrence from the more commonly encountered postsurgical etiologies. Carvacrol is a phenol monoterpene found in aromatic plants specially in Lamiaceae family, which has been evaluated in an experimental model of breast cancer. However, any proposed mechanism based on its antitumor effect has not been reported. In our previous study, carvacrol showed a protective effect on 7,12-dimethylbenz[ Breast cancer is one of the leading cause of cancer deaths in women. Metastasis in BC is caused by immunosurveillance deficiency, such NK cell maturation, low NK activity and decreasing cytotoxicity. This study was performed to improve activating receptors and cytotoxicity of NK cells using interleukins (ILs).\\nHuman recombinant IL-2, -15, and -18 were used to induce NK cells. We measured the activating and inhibiting receptors, proliferation activity of NK cells, and the cytotoxicity of NK cells on BC cells (MCF7). The effects of ILs were tested on the NK cell receptors CD314, CD158a and CD107a with flowcytometry, proliferation at various incubation times with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and concentrations of TNF-α and IFN-γ by NK cells with ELISA.\\nILs increased NK cell receptor levels (CD314, CD158a, and CD107a) at 24 hours of incubation. ILs increased NK cell viability, which increased with longer incubation. Moreover, ILs-induced NK cells inhibited proliferation in MCF7 cells, as well as increased TNF-α, IFN-γ, PRF1 and GzmB secretion.\\nIL-2, IL-15, and IL-18 improved activating receptors and proliferation of NK cells. IL-induced NK cells increased TNF-α, IFN-γ, PRF1 and GzmB secretion and cytotoxic activity on BC cells. High NK cell numbers increased BC cell growth inhibition. Members of the Fc receptor-like ( Cancer-associated fibroblasts (CAFs) are an essential component in the tumor microenvironment and have been reported to contribute to tumor progression through many mechanisms; however, the detailed mechanism underlying the immune-suppression effect of CAFs is not clearly defined. In this study, human breast cancer-derived CAFs were cultured, and CAF-derived exosomes in a culture medium were isolated. Using a miRNA profiles assay, we identify a significantly higher level of microRNA-92 isolated in CAFs exosomes. After treatment by CAF-derived exosomes, breast cancer cells express higher programmed cell death receptor ligand 1 (PD-L1), accompanied with increased miR-92 expression. Increased PD-L1 expression, which was induced by CAF-derived exosomes, significantly promotes apoptosis and impaired proliferation of T cells. The underlying mechanism of this effect was studied, proliferation and migration of breast cancer cells were increased after the transfection of miR-92, LATS2 was recognized as a target gene of miR-92, and further confirmed by a luciferase assay. Immunoprecipitation showed that LATS2 can interact with YAP1, chromatin immunoprecipitation confirmed that after nuclear translocation YAP1 could bind to the enhancer region of PD-L1 to promotes transcription activity. Furthermore, the animal study confirmed that CAFs significantly promoted tumor progression and impaired the function of tumor-infiltrated immune cells  Bone is the most frequent site of breast cancer and prostate cancer metastasis, and one of the most common sites of metastasis for many solid tumors. Once cancer cells colonize in the bone, it imposes a major clinical challenge for the treatment of the disease, and fatality rates increase drastically. Bone, the largest organ in the body, provides a fertile microenvironment enriched with nutrients, growth factors and hormones, a generous reward for cancer cells. Dependent on cancer type, cancer cells can cause osteoblastic (bone forming) or osteolytic lesions to promote the net resorption and/or release of growth factors from the bone extracellular matrix. These processes activate a \"vicious cycle\", leading to disruption of bone integrity and promoting cancer cell growth and migration. Cancer cells influence the bone microenvironment favoring their colonization and growth. In order to metastasize to the bone, cancer cells must first migrate from the site of origin, and once established within the bone, they must overcome the dormant inducing effects of resident cells. If successful, cancer cells can then colonize and continually disrupt bone homeostasis that is primarily maintained by osteocytes, the most abundant bone cell type. For example, it has been shown that exercise induces osteocytes to release anabolic factors that inhibit osteoclast resorptive activity, promote dormancy and the release of anti-cancer factors that inhibit breast cancer cell metastasis. In this review, we will summarize recent research findings and provide mechanistic insights related to the role of osteocytes in osteolytic metastasis.  Basal-like breast cancer is among the most aggressive cancers and there is still no effective targeted treatment. In order to identify new therapeutic targets, we performed mRNA-Seq on eight breast cancer cell lines. Among the genes overexpressed in basal-like tumors, we focused on the RhoA and RhoB genes, which encode small GTPases known to play a role in the actin cytoskeleton, allowing cells to migrate. qRT-PCR and Western blotting were used for expression studies. Migratory and invasive properties were analysed by wound healing and Boyden chambers assays. Stress fibers formation was evaluated by fluorescent actin labeling. Rho siRNA, small inhibitor Rhosin treatment and BRCA1 transfection were performed to study the role of Rho and BRCA1 proteins. We showed that strong expression of RhoA and low expression of RhoB was associated with the basal-like subtype of breast cancer. Decreasing RhoA expression reduced the migratory and invasive capacities of basal-like cell lines, while decreasing RhoB expression increased these capacities. Rhosin, an inhibitor of RhoA, could also reduce the migration of basal-like cell lines. Rho proteins are involved in the formation of stress fibers, a conformation of the actin cytoskeleton found in migrating cells: inhibition of RhoA expression decreased the formation of these fibers.  The role of HCK expression in the prognosis of breast cancer patients is unclear. Thus, this study aimed to explore the clinical implications of HCK expression in breast cancer. We assessed  Transfusion of allogeneic blood in breast cancer surgery is variable, and differences of transfusion incidence have been observed in the literature. Most hospital guidelines including ours dictate group and reserve policy of blood before breast surgery. Here, we aimed to audit the blood utilization in patients undergoing elective breast surgery in our hospital and thereby optimize the blood ordering schedule, economic burden, and loss of clinical resources.\\nThe study included 478 breast cancer surgeries over a period of 6 years. Patient and disease details were obtained from patient file and hospital information system. Blood samples sent to blood bank were subjected to compatibility test and reserved. All transfusions were documented, and statistical analysis was done.\\nOf the total 478 patients, most underwent wide local excision of the breast and modified radical mastectomy. A total of 16 patients received 71 units of blood and blood components in all categories of surgeries. Only 103 were younger women (≤40 years), with a mean age of 31 years. Nontransfused patients were significantly more than transfused ones (\\nWe conclude that routine compatibility test is not justified for all patients undergoing breast surgery. A more targeted approach is needed to reduce blood demand and associated cost to patient and blood transfusion services. This study aims to evaluate efficacy and safety of mastoscopic skin sparing mastectomy and sentinel lymph node biopsy combined with immediate mammary prosthesis reconstruction for early central breast cancer.\\nThe medical records of patients, who underwent mastoscopic skin sparing mastectomy and sentinel lymph node biopsy combined with immediate mammary prosthesis reconstruction during the period of March 2011 and November 2016, were collected from Fuxing Hospital. Data on clinicopathologic characteristics, operative time, the number of resected sentinel lymph nodes, and complications were analyzed.\\nThe procedures were performed in 11 patients with central breast cancer. Among these patients, 10 patients were diagnosed with infiltrating ductal carcinoma, while the remaining patient had Paget\\'s disease with infiltrating ductal carcinoma. The mean operation time was 148.2 minutes with minimal bleeding, and the median number of sentinel lymph nodes dissected from each operation was 4.6. The volume range of implants was 180-245 cc. There were no recurrences and upper limb swelling during the follow-up period. Merely two cases had sporadic axillary pain due to the mastoscopic lymph node dissection performed for the positive sentinel lymph nodes. All patients were satisfied with the reconstructive appearance.\\nThe present study shows that mastoscopic skin sparing mastectomy and sentinel lymph node biopsy combined with immediate mammary prosthesis reconstruction is a feasible procedure for early central breast cancer.\\nBreast cancer, Fat suction, Reconstructive surgery, Sentinel lymph node, Skin sparing mastectomy.\\nQuesto studio è finalizzato a valutare l’efficacia e la sicurezza della mastectomia mastoscopica risparmiante della pelle e della biopsia del linfonodo sentinella combinata con la ricostruzione protesica mammaria immediata per il carcinoma mammario centrale in fase iniziale. Sono state raccolte le cartelle cliniche delle pazienti sottoposte a mastectomia mastoscopica, con risparmio della pelle e biopsia del linfonodo sentinella combinate con la ricostruzione immediata della protesi mammaria, presso il Fuxing Hospital durante il periodo marzo 2011 novembre 2016. Sono stati analizzati i dati sulle caratteristiche clinico-patologiche, i tempi dell’intervento, il numero di linfonodi sentinella resecati e le complicanze. La procedura è stata eseguite in 11 pazienti con carcinoma mammario centrale. Tra queste pazienti, in 10 è stata diagnosticato un carcinoma duttale infiltrante, mentre l’altra paziente aveva la malattia di Paget con carcinoma duttale infiltrante. Il tempo medio di operazione è stato di 148,2 minuti con sanguinamento minimo e il numero mediano di linfonodi sentinella sezionati da ciascuna operazione è stato di 4.6. La gamma di volume degli impianti era di 180-245 cc. Non ci sono state recidive e gonfiore degli arti superiori durante il periodo di follow-up. Solo due casi hanno presentato dolore ascellare sporadico dovuto alla dissezione mastoscopica eseguita per i linfonodi sentinella positivi. Tutte le pazienti si sono dichiarate soddisfatte dell’aspetto ricostruttivo. Questo studio mostra che la mastectomia mastoscopica con risparmio della pelle e la biopsia del linfonodo sentinella combinate con la ricostruzione immediata della protesi mammaria, è una procedura praticabi. Limited data exist to guide appropriate use of magnetic resonance imaging (MRI) screening in women with a personal history of breast cancer. We developed an algorithm to inform the use of MRI screening in patients with a personal history, implemented it, and evaluated initial implementation at our community and academic practice sites.\\nA multidisciplinary committee of providers developed the initial algorithm on the basis of available literature and consensus. To evaluate projected MRI utilization based on the initial algorithm and inform algorithm revision, charts of patients\\xa0< 80 years of age diagnosed and treated in 2010 with stage 0-III breast cancer (n\\xa0= 236) were reviewed. The revised algorithm was implemented into the electronic medical record (September 2013). Thirteen months after implementation (2014-2015), chart review of patients with a personal history of breast cancer who underwent screening MRI was performed to assess algorithm adherence.\\nBefore algorithm development, 9% (20/236) of patients received MRI screening (6 genetic mutation/family history, 4 occult primary, 8 young age/breast density, 2 unknown). Use of MRI screening was projected to increase to 25% with algorithm implementation. In postimplementation review, we identified 183 patients with a personal history of breast cancer who underwent screening MRI, with 94% algorithm adherence.\\nWe successfully developed and implemented an algorithm to guide MRI screening in patients with a personal breast cancer history. Clinicians can use this algorithm to guide patient discussions regarding the utility of MRI screening. Further prospective study, including cancer detection rates, biopsy rate, and mortality, are necessary to confirm the algorithm\\'s usefulness. To strengthen cross-sectoral care by disseminating specialized knowledge about hereditary breast and ovarian cancer across underserved areas.\\nWe report on a training course about genetic counseling and testing of hereditary breast and ovarian cancer patients for gynecologists from certified cancer centers. In total, 50 gynecologists attended the course which was offered once annually between 2017 and 2019. Before and after the course, participants were asked to answer a self-assessment questionnaire and completed the training with a multiple-choice test. The results of the self-assessments and knowledge tests were analyzed to steadily improve the training.\\nThe self-assessments imply a perceived increase in certainty regarding the inclusion criteria for specialized genetic counseling, pedigree analysis, and contents of the initial consultation. Both the knowledge tests and self-assessments showed that participants had difficulties in interpreting and differentiating between age-specific and lifetime risks.\\nThe courses successfully conveyed knowledge necessary to identify patients at risk and to provide timely genetic analyses even in rural areas.\\nThe results are a promising basis for creating additional training courses addressing specialists in hospitals and gynecological practices. Further education of physicians might improve cross-sectoral cooperation and thereby enable specialized care supply in rural areas. The polyadenylation element binding protein 1 (CPEB1) plays an important role in the regulation of poly(A) tail length at the 3\\'UTR of mRNA during transcription. Downregulation of CPEB1 expression, which is associated with the loss of mammary epithelial polarity, has been reported in breast cancer. CPEB1 downregulation leads to an increase in tumor aggressiveness of breast cancer. Breast cancer is also known to be responsive to the treatment with steroid hormones, which promotes cancer development and progression; however, the nature of these associations remains unclear. This study aimed to investigate whether estrogen and progesterone impacted CPEB1 expression in breast cancer in order to regulate cell proliferation and migration. MCF7 cell proliferation was increased in response to estrogen treatment, and estrogen application suppressed the expression of CPEB1 mRNA. Cells treated with estrogen or those depleted for CPEB1 by shRNA showed increased wound healing capacity compared with that of control cells in migration assay. Moreover, we found that CPEB1 level of expression in human breast cancer tissue was low compared with that in the healthy tissue. CPEB1 expression was downregulated in response to estrogen activity and in turn, that caused a significantly induced cell migration in breast cancer cells. This suggests that CPEB1 is one of the estrogen responsive genes, which stimulates breast cancer progression. Increasing and/or maintaining CPEB1 expression level has the potential to control breast cancer behavior. To estimate the extent to which the approvals of new pharmacological therapies were associated with cancer mortality in the USA between 2000 and 2016.\\nThe analysis quantified cancer drug approvals across the 15 tumor types with the highest incidence. Number of approvals in a given time period for each tumor was translated into a treatment stock measure, defined as a weighted sum of new indication approvals since 1976. The primary outcome was the annual tumor-specific cancer mortality, defined as the number of deaths per 100,000\\u2009U.S. population. The analysis used a multivariable ordinary least squares and a fixed effects model, controlling for incidence (new cases per 100,000\\u2009U.S. population) and the primary exposure, the treatment stock measure by year.\\nBetween 2000 and 2016, deaths per 100,000 population across the 15 most common tumor types declined by 24%. Additionally, 10.2 new indications were approved per year across the 15 most common tumor types. Cancer drug approvals were associated with statistically significant deaths averted in 2016 for colorectal cancer (4,991, \\nCancer drug approvals between 2000 and 2016 were associated with significant reduction in deaths from the most common cancers in the USA. Mortality changes were largest in prevalent tumor types with relatively more approvals, i.e. lung cancer, breast cancer, melanoma, lymphoma and leukemia. Future research evaluating the relationship between drug approvals and cancer mortality post 2016 is needed. Myelophthisis (MPT) has been associated with a dreadful prognosis. Patients\\' access to palliative care (PC) and factors influencing its clinical outcomes are poorly described. Our aim was to analyze the impact of patient- and disease-specific characteristics on survival of patients with MPT and describe their use of PC in a resource-limited setting.\\nRetrospective study including patients with solid tumor MPT, diagnosed between 1996 and 2018.\\nSeventy patients (\\nMPT is highly heterogeneous and risk stratification to optimize the use of therapeutic interventions in unison with palliative interventions is needed to maximize efforts toward improving patient quality of life. There is an alarming need of PC services in the multidisciplinary management of patients within developing regions. Tumor-to-tumor metastasis describes the ability of primary tumors to metastasize to other primary tumors. These events generally occur in aggressive and widely-metastatic disease, with the appropriate management and significance of these events unknown. A 56-year-old woman with a history of bilateral, localized, invasive lobular breast carcinoma treated with surgery, systemic therapy, and adjuvant radiation presented five and two years post-treatment with progressive neurological symptoms. Imaging revealed an intracranial meningioma, and the patient underwent resection. Pathology revealed metastatic invasive lobular carcinoma cells within the resected meningioma, and the patient was treated with postoperative radiation without sequelae. Subsequent staging scans revealed a single osseous lesion suggestive of oligometastatic disease, and the patient was promptly started on systemic therapy. The goal of this study was to evaluate aprepitant usage in the context of routine clinical practice with dose/regimens at the discretion of prescribers for chemotherapy-induced nausea and vomiting (CINV) treatments.\\nIn this single arm, multicenter prospective study 1,000 patients with solid malignancies were enrolled across 21 centers in China. The primary endpoint was the rate of adverse events (AEs), including drug related AEs and serious AEs (SAEs). Secondary efficacy endpoints included the proportion of patients achieving complete response (CR; no vomiting, no nausea, and no use of rescue medication) within 120 h after highly emetogenic chemotherapy, the rates of no nausea and no vomiting, as well as quality of life (QoL). Multivariable logistic regression analysis was carried out to determine factors associated with the overall (0-120 h), acute (0-24 h) and delayed (25-120 h) CR.\\nOf the 1,000 highly emetogenic chemotherapy treated patients enrolled in the study ≥1 AE, ≥1 drug related AE, ≥1 SAE and drug related SAE rates in 998 patients were 45.9%, 2.5%, 4.0% and 0.1%, respectively. Approximately half of the patients (455/990, 46.0%) received aprepitant as part of a 3-drug anti-CINV regimen consistent with prescribing guidelines. The overall CR (0 to 120 h) for anti-emetic drug use was 41.0%, with an acute CR of 66.0% and a delayed CR of 46.5%. The rates of no vomiting and no nausea after solely aprepitant anti-emetic therapy from 0 to 120 h were 70.9% and 43.0%, for dual anti-emetic therapy 86.9% and 64.6%, and for triple therapy 86.4% and 69.5%, respectively. Multivariate regression analysis revealed that triple anti-emetic therapy (P=0.038), male gender (P<0.001) and a history of chemotherapy (P=0.016) were significantly associated with the overall acute CR.\\nEspecially as a combination treatment, aprepitant is safe and efficient for preventing CINV in patients receiving highly emetogenic chemotherapy. We sought to characterize the use of social media (SM) among breast and gynecologic cancer survivors, as well as associations between patterns of SM use and psychosocial outcomes.\\nTwo hundred seventy-three breast and gynecologic cancer survivors recruited at the Stanford Women\\'s Cancer Center completed the study. Participants completed questionnaires to measure quality of life (FACT-G), functional social support (Duke-UNC FSSQ), distress (PHQ-4), decision regret (DRS), and SM use.\\nIn total, 75.8% of the sample reported using SM. There was no difference in quality of life (QOL), functional social support (FSS), distress, or decision regret between SM users and non-users. SM users indicated using SM for social support (34.3%) and loneliness (24.6%) more than for information-seeking (15.9%), coping (18.8%), or self-disclosure (14%). SM use for coping was associated with lower QOL (p\\xa0<\\u2009.001), lower FSS (p\\xa0<\\u2009.001), and higher decision regret (p\\xa0=\\u2009.029). Use for social support was associated with lower FSS (p\\xa0=\\u2009.029). Use for information seeking was associated with lower QOL (p\\xa0=\\u2009.012). Use of SM\\xa0when lonely was associated with lower QOL (p\\xa0<\\u2009.001), higher distress (p\\xa0=\\u2009.007), lower FSS (p\\xa0<\\u2009.001), and higher decision regret (p\\xa0=\\u2009.020).\\nAssociations between SM use and psychosocial outcomes are nuanced and dependent on motivation for use. Further research is needed to better characterize SM use and associations with psychosocial outcomes among cancer survivors.\\nSM is an important potential avenue for understanding and addressing the psychosocial effects associated with cancer survivorship. Nucleolar protein 10 (NOP10) is required for ribosome biogenesis and telomere maintenance and plays a key role in carcinogenesis. This study aims to evaluate the clinical and prognostic significance of NOP10 in breast cancer (BC).\\nNOP10 expression was assessed at mRNA level employing the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n\\u2009=\\u20091980) and Cancer Genome Atlas (TCGA) BC cohorts (n\\u2009=\\u2009854). Protein expression was evaluated on tissue microarray of a large BC cohort (n\\u2009=\\u20091081) using immunohistochemistry. The correlation between NOP10 expression, clinicopathological parameters and patient outcome was assessed.\\nNOP10 expression was detected in the nucleus and nucleolus of the tumour cells. At the transcriptomic and proteomic levels, NOP10 was significantly associated with aggressive BC features including high tumour grade, high nucleolar score and poor Nottingham Prognostic Index. High NOP10 protein expression was an independent predictor of poor outcome in the whole cohort and in triple-negative BC (TNBC) class (p\\u2009=\\u20090.002 & p\\u2009=\\u20090.014, respectively). In chemotherapy- treated patients, high NOP10 protein expression was significantly associated with shorter survival (p\\u2009=\\u20090.03) and was predictive of higher risk of death (p\\u2009=\\u20090.028) and development of distant metastasis (p\\u2009=\\u20090.02) independent of tumour size, nodal stage and tumour grade.\\nHigh NOP10 expression is a poor prognostic biomarker in BC and its expression can help in predicting chemotherapy resistance. Functional assessments are necessary to decipher the underlying mechanisms and to reveal its potential therapeutic values in various BC subtypes especially in the aggressive TNBC class. Cyclin-dependent kinases (CDK) control the cell cycle and play a crucial role in oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical approval of dual CDK4/6 inhibitors for the treatment of breast and small cell lung cancer. While the anticancer cell effects of CDK inhibitors are well-established, preclinical and early clinical studies describe additional mechanisms of action such as chemo- and radiosensitization or immune stimulation. The latter offers great potential to incorporate CDK inhibitors in immune-based treatments. However, dosing schedules and accurate timing of each combination partner need to be respected to prevent immune escape and resistance. In this review, we provide a detailed summary of CDK inhibitors in the two solid cancer types head and neck cancer and glioblastoma multiforme; it describes the molecular mechanisms of response vs. resistance and covers strategies to avoid resistance by the combination of immunotherapy or targeted therapy. To estimate the effectiveness of tailored physical activity and dietary interventions amongst adults attending colorectal and breast cancer screening.\\nFive literature databases were systematically searched to identify randomised controlled trials (RCTs) of tailored physical activity and/or dietary interventions with follow-up support initiated through colorectal and breast cancer screening programmes. Outcomes included markers of body fatness, physical activity, and dietary intake. Mean differences (MDs) or standardised mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using random effects models.\\nFive RCTs met the inclusion criteria encompassing a total of 722 participants. Diet and physical activity interventions led to statistically significant reductions in body mass (MD\\u2009-\\u20091.6\\xa0kg, 95% CI\\u2009-\\u20092.7 to\\u2009-\\u20090.39\\xa0kg; I\\nThere is low quality evidence that lifestyle interventions involving follow-up support lead to modest weight loss and increased physical activity and fruit and vegetable intake. Due to the modest intervention effects, low quality of evidence and small number of studies, further rigorously designed RCTs with long-term follow-up of modifiable risk factors and embedded cost-benefit analyses are warranted (PROSPERO ref: CRD42020179960). Patients with cancer should appropriately receive antiemetic therapies against chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an important role in managing CINV. Accordingly, the first Japanese antiemetic guideline published in 2010 by the Japan Society of Clinical Oncology (JSCO) has considerably aided Japanese medical staff in providing antiemetic therapies across chemotherapy clinics. With the yearly advancements in antiemetic therapies, the Japanese antiemetic guidelines require revisions according to published evidence regarding antiemetic management worldwide. A revised version of the first antiemetic guideline that considered several upcoming evidences had been published online in 2014 (version 1.2), in which several updated descriptions were included. The 2015 JSCO clinical practice guideline for antiemesis (version 2.0) (in Japanese) has addressed clinical antiemetic concerns and includes four major revisions regarding (1) changes in emetogenic risk categorization for anti-cancer agents, (2) olanzapine usage as an antiemetic drug, (3) the steroid-sparing method, and (4) adverse drug reactions of antiemetic agents. We herein present an English update summary for the 2015 JSCO clinical practice guideline for antiemesis (version 2.0). CYP2D6 protein activity can be inferred from the ratio of N-desmethyl-tamoxifen (NDMT) to endoxifen (E). CYP2D6 polymorphisms are common and can affect CYP2D6 protein activity and E level. Some retrospective studies indicate that E\\xa0<\\xa016\\xa0nM may relate to worse outcome.\\nA target NDMT/E ratio was defined as associated with an E level of 15\\xa0nM in the 161 patient Test cohort of tamoxifen-treated patients, dichotomizing them into \\'Normal\\' (NM) and \\'Slow\\' (SM) CYP2D6 metabolizer groups. This ratio was then tested on a validation cohort of 52 patients. Patients were phenotyped based on the standard method (ultrarapid/extensive, intermediate or poor metabolizers; UM/EM, IM, PM) or a simplified system based on whether any variant allele (V) vs wildtype (wt) was present (wt/wt, wt/V, V/V). Comprehensive CYP2D6 genotyping was undertaken on germline DNA.\\nA target NDMT/E ratio of 35 correlated with the 15\\xa0nM\\xa0E level, dichotomizing patients into NM (<35; N\\xa0=\\xa0117) and SM (>35; N\\xa0=\\xa044) groups. The ratio was independently validated by a validation cohort. The simplified system was better in predicting patients without slow metabolism, with specificity and sensitivity of 96% and 44% respectively, compared with the standard method - sensitivity 81% and specificity 83%.\\nThe simplified classification system based on whether any variant was present better identified patients who were truly not CYP2D6 slow metabolizers more accurately than the current system. However, as CYP2D6 genotype is not the only determinant of endoxifen level, we recommend that direct measurement of endoxifen should also be considered. To present the 7-year results of accelerated partial breast irradiation (APBI) using three-dimensional conformal (3D-CRT) and image-guided intensity-modulated radiotherapy (IG-IMRT) following breast-conserving surgery (BCS).\\nBetween 2006 and 2014, 104 patients were treated with APBI given by means of 3D-CRT using 3-5 non-coplanar, isocentric wedged fields, or IG-IMRT using kV-CBCT. The total dose of APBI was 36.9\\xa0Gy (9\\xa0×\\xa04.1\\xa0Gy) using twice-a-day fractionation. Survival results, side effects and cosmetic results were assessed.\\nAt a median follow-up of 90 months three (2.9%) local recurrences, one (0.9%) regional recurrence and two (1.9%) distant metastases were observed. The 7-year local (LRFS), recurrence free survival was 98.9%. The 7-year disease-free (DFS), metastases free (MFS) and overall survival (OS) was 94.8%, 97.9% and 94.8%, respectively. Late side effects included G1 skin toxicity in 15 (14.4%), G1, G2, and G3 fibrosis in 26 (25%), 3 (2.9%) and 1 (0.9%) patients respectively. Asymptomatic (G1) fat necrosis occurred in 10 (9.6%) patients. No\\xa0≥\\xa0G2 or higher late side effects occurred with IMRT. The rate of excellent/good and fair/poor cosmetic results was 93.2% and 6.8%, respectively.\\n7-year results of APBI with 3D-CRT and IG-IMRT are encouraging. Toxicity profile and local tumor control are comparable to other series using multicatheter interstitial brachytherapy. Therefore, these external beam APBI techniques are valid alternatives to whole breast irradiation and brachytherapy based APBI. Breast cancer cells (BCC) and macrophages are known to interact via epidermal growth factor (EGF) produced by macrophages and colony stimulating factor-1 (CSF-1) produced by BCC. Despite contradictory findings, this interaction is perceived as a paracrine loop. Further, the underlying mechanism of interaction remains unclear. Here, we investigated interactions of BCC with macrophages in 2D and 3D. While both BCC and macrophages showed invasion/chemotaxis to fetal bovine serum, only macrophages showed chemotaxis to BCC in custom designed 3D cell-on-a-chip devices. These results were in agreement with gradient simulation results and ELISA results showing that macrophage-derived-EGF was not secreted into macrophage-conditioned-medium. Live cell imaging of BCC in the presence and absence of iressa showed that macrophages but not macrophage-derived-matrix modulated adhesion and motility of BCC in 2D. 3D co-culture experiments in collagen and matrigel showed that BCC changed their multicellular organization in the presence of macrophages. In custom designed 3D co-culture cell-on-a-chip devices, macrophages promoted and reduced migration of BCC in collagen and matrigel, respectively. Furthermore, adherent but not suspended BCC endocytosed EGFR when in contact with macrophages. Collectively, our data revealed that macrophages showed chemotaxis towards BCC whereas BCC required direct contact to interact with macrophage-derived-EGF. Therefore, we propose that the interaction between cancer cells and macrophages is a paracrine-juxtacrine loop of CSF-1 and EGF, respectively. Oligometastatic breast cancer (OMBC) is a disease-entity with potential for long-term remission in selected patients. Those with truly limited metastatic load (rather than occult widespread metastatic disease) may benefit from multimodality treatment including local ablative therapy of distant metastases. In this systematic review, we studied factors associated with long-term survival in patients with OMBC.\\nEligible studies included patients with OMBC who received a combination of local and systemic therapy as multimodal approach and reported overall survival (OS) or progression-free survival (PFS), or both. The Quality in Prognosis Studies (QUIPS) tool was used to assess the quality of each included study. Independent prognostic factors for OS and/or PFS are summarized.\\nOf 1271 screened abstracts, 317 papers were full-text screened and twenty studies were included. Eleven of twenty studies were classified as acceptable quality. Definition of OMBC varied between studies and mostly incorporated the number and/or location of metastases. The 5-year OS ranged between 30 and 79% and 5-year PFS ranged between 25 and 57%. Twelve studies evaluated prognostic factors for OS and/or PFS in multivariable models. A solitary metastasis, >24\\xa0months interval between primary tumor and OMBC, no or limited involved axillary lymph nodes at primary diagnosis, and hormone-receptor positivity were associated with better outcome. HER2-positivity was associated with worse outcome, but only few patients received anti-HER2 therapy.\\nOMBC patients with a solitary distant metastasis and >24\\xa0months disease-free interval have the best OS and may be optimal candidates to consider a multidisciplinary approach. The prevalence of HER2 alterations in pan-cancer indicates a broader range of application of HER2-targeted therapies; however, biomarkers for such therapies are still insufficient and limited to breast cancer and gastric cancer.\\nUsing multi-omics data from The Cancer Genome Atlas (TCGA), the landscape of HER2 alterations was exhibited across 33 tumor types. A HER2 index was constructed using one-class logistic regression (OCLR). With the predictive value validated in GEO cohorts and pan-cancer cell lines, the index was then applied to evaluate the HER2-enriched expression pattern across TCGA pan-cancer types.\\nIncreased HER2 somatic copy number alterations (SCNAs) could be divided into two patterns, focal- or arm-level. The expression-based HER2 index successfully distinguished the HER2-enriched subtype from the others and provided a stable and superior performance in predicting the response to HER2-targeted therapies both in breast tumor tissue and pan-cancer cell lines. With frequencies varying from 12.0% to 0.9%, tumors including head and neck squamous tumors, gastrointestinal tumors, bladder cancer, lung cancer and uterine tumors exhibited high HER2 indices together with HER2 amplification or overexpression, which may be more suitable for HER2-targeted therapies. The BLCA.3 and HNSC.Basal were the most distinguishable subtypes within bladder cancer and head and neck cancer respectively by HER2 index, implying their potential benefits from HER2-targeted therapies.\\nAs a pan-cancer predictive biomarker of HER2-targeted therapies, the HER2 index could help identify potential candidates for such treatment in multiple tumor types by combining with HER2 multi-omics features. The discoveries of our study highlight the importance of incorporating transcriptional pattern into the assessment of HER2 status for better patient selection.\\nThe National Key Research and Development Program of China; Clinical Research and Cultivation Project of Shanghai ShenKang Hospital Development Center. Breast cancer is the most common cancer type in women worldwide and its early detection is crucial to curing the disease. Tissue biopsy, currently the method of choice to obtain tumour molecular information, is invasive and might be affected by tumour heterogeneity rendering it incapable to portray the complete molecular picture. Liquid biopsy permits to study disease features in a more comprehensive manner by sampling biofluids and extracting tumour components such as circulating-tumour DNA (ctDNA), circulating-tumour cells (CTCs), and/or circulating-tumour RNA (ctRNA) amongst others in a monitoring-compatible manner. In this review, we describe the recent progress in the utilization of the circulating tumour components using early breast cancer samples. We review the most important analytes and technologies employed for their study. There is a need for more knowledge about the public awareness and attitudes towards gynecologic cancers. We employed a research-purpose population-based citizen panel to assess how often people recall gynecologic cancers compared to other cancer types and to explore the relative importance of different information channels in relaying cancer information.\\nWe conducted an online survey using the Norwegian Citizen Panel (n = 1441 respondents), exploring associations between demographic factors and frequency of mentioning specific cancer types. We also searched The Norwegian Media Archive to assess the media coverage of different cancer types. Factors affecting likelihood of mentioning different cancers were assessed by multivariate regression.\\nOnly 41 % of respondents listed one or more cancers in female genital organs. Of the gynecological cancers, cervical cancer was most frequently mentioned (28 %), followed by ovarian (12 %) and endometrial cancer (11 %). Female responders were more likely to mention cervical (OR 2.47, 95 % CI 2.16-2.78) and ovarian cancer (OR 2.09, 95 % CI 1.60-2.58) than male responders, but not endometrial cancer. Family and friends who have had cancer (50 %) and different types of media coverage (41 %) were reported as the most common sources of cancer information. The three most frequently mentioned cancer types in our survey were breast (77 %), hematologic (76 %) and lung cancer (75 %), which also were the cancer types having most media coverage.\\nGynecological cancers are less frequently mentioned by Norwegian citizens when compared to several other cancer types such as breast-, hematologic- and lung cancer. Sex and age are important factors that affect awareness of cancer types. Media is likely to play an important role in what cancer types the public recalls. Maternal deaths from indirect obstetric causes are the result of a pre-existing disease or condition that appeared during pregnancy without obstetric causes, but which was aggravated by the physiological effects of pregnancy. Twenty-six deaths from indirect causes related to a pre-existing pathology, excluding disease of the circulatory system or infection, were analysed by the committee of experts. Pre-existing pathology during pregnancy was documented in 13 women (asthma, n=3, genetic diseases, n=3, previous breast cancer, n=2, major sickle cell syndrome, n=2, epilepsy, n=1, brain tumour, n=1). In 13 women, the pathology was not known before pregnancy (breast cancer, n=6, brain tumours, n=3, uterine sarcoma, n=1, cervical cancer, n=1, malignant melanoma, n=1, acute myeloid leukaemia, n=1). For 16 women (61%), the death is related to a neoplastic pathology. Although the majority were considered inevitable for 11/16 women, 5 deaths were considered possibly preventable, the main preventable factor being a delay in diagnosis, and/or a delay in starting a specific treatment. For 10 women, the death is related to a chronic non-neoplastic pathology, known before pregnancy for 9 women, judged most often as possibly preventable, the main preventable factor being the failure of the medical team or the patient to take the pathology and/or its treatment into account. A pre-conception medical consultation with a specialist should be recommended to all patients with pre-existing disease. A clinical examination of the breasts is strongly recommended at the first visit and then during pregnancy. Bisphenol A (BPA) is a widely used endocrine disrupter. Its environmental exposure is a causative factor of cell aging via decreasing telomerase activity, thus leading to shortening of telomere length. Epidemiological studies confirm positive associations between BPA exposure and the incidence of obesity and type 2 diabetes (T2DM). Increased urinary BPA levels in obese females are both significantly correlated with shorter relative telomere length and T2DM. BPA is a critically effective endocrine disrupter leading to poor prognosis via the obesity-inflammation-aromatase axis in breast cancer. Environmental BPA exposure contributes to the progression of both estrogen dependent and triple negative breast cancers. BPA is a positive regulator of human telomerase reverse transcriptase (hTERT) and it increases the expression of hTERT mRNA in breast cancer cells. BPA exposure can lead to tamoxifen resistance. Among patients treated with chemotherapy, those with persistent high telomerase activity due to BPA are at higher risk of death. Cell cycle control is often disrupted in gastric cancer (GC), making it an attractive therapeutic target. Abemaciclib is a specific CDK4/6 inhibitor that has been shown to improve treatment efficacy in hormone receptor-positive advanced breast cancer; however, its potential therapeutic value and predictive markers have not yet been revealed in GC. In this study, we investigated the efficacy of abemaciclib using preclinical GC models representing defined molecular subtypes from The Cancer Genome Atlas. In these 49 GC cell lines, Epstein-Barr virus (EBV) and high microsatellite instability (MSI-H)-type cell lines were p16 methylated and sensitive to abemaciclib; further, genomically stable (GS), and chromosomal instability (CIN)-type cell lines with p16 methylation and intact Rb were also found to be responsive. In addition, we found that GC patients with p16 methylation often displayed a poor prognosis. Collectively, these data provide a foundation for clinical trials to assess the therapeutic efficacy of abemaciclib in GC and suggest that p16 methylation could be used as a predictive marker to identify patients with GC who may benefit from abemaciclib-based therapies. Peptidases are emerging as promising drug targets in tumour suppression. Neprilysin, also known as neutral endopeptidase, is a cell surface peptidase that degrades various peptides such as angiotensin II, endothelin I, Substance P, etc., and reduces their local concentration. Neprilysin is expressed in various tissues such as kidney, prostate, lung, breast, brain, intestine, adrenal gland, etc. The tumour-suppressor mechanisms of neprilysin include its peptidase activity that degrades mitogenic growth factors such as fibroblast growth factor-2 and insulin-like growth factors, and the protein-protein interaction of neprilysin with phosphatase and tensin homolog, focal adhesion kinase, ezrin/radixin/moesin, and phosphoinositide 3-kinase. Studies have shown that the levels of neprilysin play an important role in malignancies. NEP is downregulated in prostate, renal, lung, breast, urothelial, cervical, hepatic cancers, etc. Histone deacetylation and hypermethylation of the neprilysin promoter region are the common mechanisms involved in the downregulation of neprilysin. Downregulation of the peptidase promotes angiogenesis, cell survival and cell migration. This review presents an overview of the role of neprilysin in malignancy, the tumour suppression mechanisms of neprilysin, the epigenetic mechanisms responsible for downregulation of neprilysin, and the potential pharmacological approaches to upregulate neprilysin levels and its activity. The Paris System for Reporting Urinary Cytology (TPS) was first published in 2016 with clear objectives to standardize cytologic diagnostic criteria and provide uniform reporting, in order to improve patient stratification and associated clinical management. The aim of this paper is to evaluate the performance of TPS and review the literature published since TPS was introduced.\\nOriginal articles focusing on the utilization and performance of TPS in urinary cytology specimens were identified using PubMed for publications from January 2016 to July 2020, using the keywords \"Paris System\", \"urine cytology\", and \"urinary cytology\".\\nTwenty-three relevant articles in the literature regarding the use of TPS were included in the review from a total of 30,802 urine cytology specimens, of which 21,485 (69.8%) had available diagnoses. Distribution of cases among categories ranged from 50.5% to 95.3% for negative for high-grade urothelial carcinoma (NHGUC), 1.2% to 23% for atypical urothelial cells (AUC), 0.2% to 6.6% for suspicious for high-grade urothelial carcinomas (SHGUC), and 2.2% to 14.1% for high-grade urothelial carcinomas (HGUC). The calculated risk of high-grade malignancy (ROHM) ranged from 8.7% to 36.8% for NHGUC, 12.3% to 60.9%% for AUC, 33.3% to 100% for SHGUC, and 58.8% to 100% for HGUC. Mean ROHM weighted by sample size was calculated at 15.7% (±7.8%), 38.5% (±14.3%), 76.2% (±17.2%), and 88.8% (±12.7%) for NHGUC, AUC, SHGUC, and HGUC, respectively. Reported sensitivity of TPS ranged from 40% to 84.7%, specificity from 73% to 100%, PPV from 62.3% to 100%, and NPV from 46% to 90%.\\nThe application of TPS in the selected series has improved the screening and surveillance potential of urine cytology, while reducing high rates of indeterminate diagnoses, improving sensitivity and providing proper risk stratification for patients. Peritumoral features have been suggested to be useful in improving the prediction performance of radiomic models. The aim of this study is to systematically investigate the prediction performance improvement for sentinel lymph node (SLN) status in breast cancer from peritumoral features in radiomic analysis by exploring the effect of peritumoral region sizes.\\nThis retrospective study was performed using dynamic contrast-enhanced MRI scans of 162 breast cancer patients. The effect of peritumoral features was evaluated in a radiomics pipeline for predicting SLN metastasis in breast cancer. Peritumoral regions were generated by dilating the tumor regions-of-interest (ROIs) manually annotated by two expert radiologists, with thicknesses of 2 mm, 4 mm, 6 mm, and 8 mm. The prediction models were established in the training set (∼67% of cases) using the radiomics pipeline with and without peritumoral features derived from different peritumoral thicknesses. The prediction performance was tested in an independent validation set (the remaining ∼33%).\\nFor this specific application, the accuracy in the validation set when using the two radiologists\\' ROIs could be both improved from 0.704 to 0.796 by incorporating peritumoral features. The choice of the peritumoral size could affect the level of improvement.\\nThis study systematically investigates the effect of peritumoral region sizes in radiomic analysis for prediction performance improvement. The choice of the peritumoral size is dependent on the ROI drawing and would affect the final prediction performance of radiomic models, suggesting that peritumoral features should be optimized in future radiomics studies. There are limited data on pretreatment imaging features that can predict response to neoadjuvant chemotherapy (NAC). To extract volumetric pretreatment MRI radiomics features and assess corresponding associations with breast cancer molecular subtypes, pathological complete response (pCR), and residual cancer burden (RCB) in patients treated with NAC.\\nIn this IRB-approved study, clinical and pretreatment MRI data from patients with biopsy-proven breast cancer who received NAC between September 2009 and July 2016 were retrospectively analyzed. Tumors were manually identified and semi-automatically segmented on first postcontrast images. Morphological and three-dimensional textural features were computed, including unfiltered and filtered image data, with spatial scaling factors (SSF) of 2, 4, and 6 mm. Wilcoxon rank-sum tests and area under the receiver operating characteristic curve were used for statistical analysis.\\nTwo hundred and fifty nine patients with unilateral breast cancer, including 73 (28.2%) HER2+, 112 (43.2%) luminal, and 74 (28.6%) triple negative breast cancers (TNBC), were included. There was a significant difference in the median volume (p\\u202f=\\u202f0.008), median longest axial tumor diameter (p\\u202f=\\u202f0.009), and median longest volumetric diameter (p\\u202f=\\u202f0.01) among tumor subtypes. There was also a significant difference in minimum signal intensity and entropy among the tumor subtypes with SSF\\u202f=\\u202f4 mm (p\\u202f=\\u202f0.009 and p\\u202f=\\u202f0.02 respectively) and SSF\\u202f=\\u202f6 mm (p\\u202f=\\u202f0.007 and p < 0.001 respectively). Additionally, sphericity (p\\u202f=\\u202f0.04) in HER2+ tumors and entropy with SSF\\u202f=\\u202f2, 4, 6 mm (p\\u202f=\\u202f0.004, 0.02, 0.047 respectively) in luminal tumors were significantly associated with pCR. Multiple features demonstrated significant association (p < 0.05) with pCR in TNBC and with RCB in luminal tumors and TNBC, with standard deviation of intensity with SSF\\u202f=\\u202f6 mm achieving the highest AUC (AUC\\u202f=\\u202f0.734) for pCR in TNBC.\\nMRI radiomics features are associated with different molecular subtypes of breast cancer, pCR, and RCB. These features may be noninvasive imaging biomarkers to identify cancer subtype and predict response to NAC. Although the need for axillary lymph node dissection (AD) is decreasing in breast cancer patients, it remains necessary in some cases. Axillary reverse mapping (ARM) enables the detection of upper extremity lymphatic drainage that may be spared during selective axillary dissection (SAD) so as to reduce the risk of lymphedema. The ability of the ARM-SAD procedure to reduce the incidence of lymphedema is being tested in an ongoing randomized trial. Crossover between arm drainage and breast drainage is well documented in the axilla, however, and whether the procedure is oncologically safe remains controversial. We aim to assess the axillary failure rate when a few nodes draining the upper arm are being spared by the ARM-SAD.\\nWe report oncological outcomes, and axillary failure in particular, in the first 100 consecutive axillary node-positive patients treated with ARM-SAD as part of a pilot study and a randomized trial.\\nA median of 18 (IQR 14-22) axillary nodes were excised per patient. During the follow-up (median 51 months, IQR 34-91), 11 patients experienced a treatment failure, but only one - treated with neoadjuvant chemotherapy - developed overt axillary disease as a first (and isolated) event. The crude rate of axillary failure was 1.36% (95% CI: 0.19-9.63) with an estimated 5-year crude cumulative incidence of 1.85% (95% CI: 0-5.47%).\\nThe axillary failure rate was low in our patients and did not exceed rates reported in the literature after standard AD, thus indicating that the ARM-SAD procedure is oncologically safe. To evaluate the performances of systematic posttreatment pelvic magnetic resonance imaging (PPMRI) in predicting prognosis of patients treated with chemoradiation therapy (CRT) for locally advanced cervical cancer (LACC).\\nMulti-institutional data from 216 patients presenting FIGO IB2-IIB cervical cancer for which PPMRI was performed following CRT were retrospectively reviewed. Incomplete response was defined as the identification of persistent lesion on PPMRI. Primary endpoints were patients\\' 5-year recurrence free (RFS) and overall (OS) survivals. Secondary endpoint was the identification of residual histologic disease on hysterectomy specimens when completion surgery was performed.\\nPPMRI identified an incomplete response in 102 (47.2%) cases. A 70% or more reduction in tumor size on PPMRI was identified as the best predictive cut-off for recurrence (37.7% sensitivity and 78.7% specificity) and death (50% sensitivity and 77.9% specificity) with significant impact on those risks (HRa: 0.42; 95%CI: 0.23-0.77 and HRa: 0.18; 95%CI: 0.06-0.50, respectively). Completion hysterectomy was performed in 117 (54.4%) cases, with histologic residual disease in 55 (47.4%). PPMRI demonstrated 74.5% sensitivity and 50.8% specificity in predicting residual disease. Although survival of patients with complete response at PPMRI was not impacted by completion hysterectomy, it significantly increased 5-year RFS and OS of those with incomplete response: 38.7% vs. 65.3% (p\\xa0<\\xa00.001) and 63% vs. 82.9% (p\\xa0=\\xa00.038), respectively.\\nA 70% or more reduction of in tumor size on PPMRI following CRT in patients with LACC is predictive of RFS and OS. PPMRI could help triaging patients who could benefit from completion hysterectomy. Accumulating evidence has demonstrated that immune-related lncRNAs (IRLs) are commonly aberrantly expressed in breast cancer (BC). Thus, we aimed to establish an IRL-based tool to improve prognosis prediction in BC patients.\\nWe obtained IRL expression profiles in large BC cohorts (N\\u2009=\\u2009911) from The Cancer Genome Atlas (TCGA) database. Then, in light of the correlation between each IRL and recurrence-free survival (RFS), we screened prognostic IRL signatures to construct a novel RFS nomogram via a Cox regression model. Subsequently, the performance of the IRL-based model was evaluated through discrimination, calibration ability, risk stratification ability and decision curve analysis (DCA).\\nA total of 52 IRLs were obtained from TCGA. Based on multivariate Cox regression analyses, four IRLs (A1BG-AS1, AC004477.3, AC004585.1 and AC004854.2) and two risk parameters (tumor subtype and TNM stage) were utilized as independent indicators to develop a novel prognostic model. In terms of predictive accuracy, the IRL-based model was distinctly superior to the TNM staging system (AUC: 0.728 VS 0.673, P\\u2009=\\u20090.010). DCA indicated that our nomogram had favorable clinical practicability. In addition, risk stratification analysis showed that the IRL-based tool efficiently divided BC patients into high- and low-risk groups (P\\u2009<\\u20090.001).\\nA novel IRL-based model was constructed to predict the risk of 5-year RFS in BC. Our model can improve the predictive power of the TNM staging system and identify high-risk patients with tumor recurrence to implement more appropriate treatment strategies. Development of advanced therapeutic modalities for the treatment of cancer are become a thirst area in the field of biomedical science now a day. Current therapeutic approaches to treat this fatal disease always refer to partial curability with unavoidable obstacles. Here, we have developed stearic-g-polyethyleneimine acid amphiphilic nanomicelle functionalized with folic acid-based carbon dots (CDs) for targeted anticancer drug (doxorubicin, DOX) delivery and concurrent bio-imaging for triple negative breast cancer (TNBC). Developed nanomicelle was characterized by FTIR, XRD,  Cutaneous spread of solid visceral metastasis is very unusual presentation, usually in breast, lung, colon, ovarian carcinomas, and malignant melanoma. Less than 5% of cases of cutaneous spread are from renal neoplasms.\\nWe present the case of a 48-year-old woman with a large lower lip tumor whose anatomopathological analysis of the lesion led us to identify a Clear Cell Renal Cell Carcinoma (ccRCC).\\nThe clinical manifestations of the ccRCC can be mild, generating a late diagnosis through metastasis of primary neoplasia. Their presentations can be varied, as described in this report.\\nThe knowledge of the different types of presentation of CCCR metastases can assist in decision making, but the progression of staging often only allows palliative measures. Studies in the adjuvant setting have shown that endocrine therapy related side effects predict breast cancer recurrence risk. Here, we assess the relationship between early reported side effects and incidence of breast cancer in women randomised to tamoxifen for cancer prevention in the International Breast Intervention Study (IBIS)-I trial.\\nWomen randomised to tamoxifen in the IBIS-I trial and for whom side effect status was known at the 6-month follow-up visit were included in this analysis. Side effects included in this analysis were hot flushes, vaginal discharge, and vaginal dryness. The primary endpoint was all breast cancer and secondary endpoint was oestrogen receptor (ER) positive breast cancer. Cox proportional hazard models were used to investigate breast cancer incidence in the tamoxifen group with and without side effects reported within 6 months of randomisation.\\nWomen randomised to tamoxifen and reporting hot flushes at the 6-month follow-up visit had a non-statistically significant increase in breast cancer compared to those without hot flushes (HR\\xa0=\\xa01.26 (0.98-1.62), P\\xa0=\\xa00.08). A significant higher breast cancer risk was observed for postmenopausal women who reported hot flushes at the 6-month follow-up visit compared to those without hot flushes (HR\\xa0=\\xa01.59 (1.12-2.26), P\\xa0=\\xa00.01). A higher risk was observed for ER-positive breast cancer in postmenopausal women (HR\\xa0=\\xa01.81 (1.19-2.74), P\\xa0=\\xa00.01). No significant associations between gynaecological side effects and breast cancer occurrence was observed.\\nOverall, no association between side effects reported at 6 months and subsequent breast cancer occurrence was observed. Some side effects might be useful markers for breast cancer occurrence in postmenopausal women. The paper presents a novel procedure based on 3D scanning and 3D modelling to automatically assess linear and volumetric measurements of an arm and to be further applied to patients affected by post breast cancer lymphedema. The aim is the creation of a virtual platform easily usable by medical personnel to get more objective evaluations during the lymphedema treatment.\\nThe procedure is based on the 3D scanning of the arm using the Occipital Structure Sensor and an ad-hoc developed application, named Lym 3DLab. Lym 3DLab emulates the traditional measurement methods, which consist in taking manual circumference measurements or using the water displacement method. These measurements are also used to design the compression stockings, the typical orthopaedic device used for lymphedema treatment. A validation test has been performed to compare the measurements computed by Lym 3DLab with both water displacement and manual circumference measurements. Eight volunteers have been involved who are not affected by lymphedema. Furthermore, a specific usability test has been performed to evaluate the 3D scanning procedure by involving four physiotherapists.\\nThe comparison between the volumes has highlighted how all the 3D acquired models have their volumes inside a range of acceptability. This range has been defined by considering the sensitivity error of the tape measure used to measure the water displacement. The comparison between the perimeters of cross sections computed with Lym 3DLab and the circumference measurements has shown results that are very accurate with an average difference of 2 mm. The measure errors have been considered negligible by the medical personnel who have evaluated the proposed procedure more accurate than the traditional ones. The test with physiotherapists has shown a high level of usability of the whole virtual environment, but the 3D scanning procedure requires an appropriate training of the personnel to make the 3D acquisition as fast and efficient as possible.\\nThe achieved results and the physiotherapists\\' feedback allow planning a future test with patients affected by lymphedema in collaboration with the hospital. A further test has been planned to use the computed measurements to design orthopaedic compression stockings. Cutaneous angiosarcoma is a rare neoplasm. One important predictor of recurrence is the resection margin; however, identifying the tissue area containing the malignant cells is difficult. Indocyanine green fluorescence angiography (ICG-FA) has been used to identify superficial malignancies, including malignant tumors in the liver and sentinel lymph node metastasis of breast cancer. ICG-FA is also used to identify and define the resection margin of cutaneous angiosarcomas. However, there are currently only a few reports on the application of ICG-FA for detecting cutaneous angiosarcomas. We experienced a case of cutaneous angiosarcoma in the scalp in which one lesion, located in the parietal scalp, and showed high fluorescence intensity corresponding exactly with the lesion defined by physical examination, whereas the malignant area of the second lesion, located in the occipital scalp, was revealed more accurately by ICG-FA than by physical examination. Further, the second lesion was the first case diagnosed as angiosarcoma by the limited-area biopsy for a high-intensity area of ICG-FA. By determining where ICG is located within cutaneous angiosarcomas and quantitating the ICG intensity level corresponding to the malignant area, ICG-FA will be a promising tool for identifying cutaneous angiosarcomas. Most of the employed methods for preparation of targeted nanoparticles containing hydrophobic herbal drugs have multiple surface modifications with time-consuming steps. The present research was aimed to develop a facile method for preparation of hyaluronic acid (HA)-decorated mixed nanomicelles loaded with curcumin (as a hydrophobic drug model) to provide an efficient drug delivery system for targeted therapy of breast cancer cells with high expression of CD44 receptor. To this end, curcumin was first encapsulated in the hydrophobic core of Pluronic F127/didecyldimethylammonium bromide (PD) mixed nanomicelles using thin-film hydration method. Then, negatively charged HA was coated on the positively charged surface of PD mixed nanomicelles via electrostatic interactions. The drug loading and entrapment efficiency of the targeted nanomicelles were 2.8% and 95.1%, respectively. The average hydrodynamic size of the prepared nanomicelles before and after coating with HA were 19.8 and 35.8\\xa0nm, respectively. Moreover, in vitro cytotoxicity analyses showed that, HA-coated PD (HA-PD) mixed nanomicelles can enhance the cytotoxicity of curcumin against MDA-MB-231 cancer cells compared to non-targeted ones (PD mixed nanomicelles), and free curcumin. The IC The management of intraductal papilloma (IDP) diagnosed on core needle biopsy (CNB) is controversial due to the variable upgrade rates to breast carcinoma (BC) on subsequent surgical excision reported in the literature. The purpose of our study was to investigate the upgrade rate of IDP diagnosed on CNB to BC in subsequent surgical excision and the impact of clinical, pathologic and radiologic variables. This is a retrospective cohort of all women who had a diagnosis of IDP on a CNB between 2005 and 2018 in a tertiary academic center with subsequent surgical excision. Upgrade was defined as ductal carcinoma in situ (DCIS) and invasive carcinoma on surgical excision. Statistical analyses included Pearson\\'s chi-square, Wilcoxon rank-sum and logistic regression. A total of 216 women with IDP in a CNB were included. Nineteen patients (8.8%) upgraded to BC in the overall cohort, including 14 DCIS and 5 invasive carcinomas. An upgrade rate of 27% was found in atypical IDP (14 of 51 cases), while only 3% of pure IDP upgraded to BC (5 of 165 cases). Older age (>53 years) at time of biopsy (OR=1.05, 95%CI 1.01-1.09, p=0.027) and concomitant atypical ductal hyperplasia (ADH) (OR=9.69, 95%CI 3.37-27.81, p<0.0001) were significantly associated with upgrade. Our results support surgical excision of IDP on CNB when associated with ADH or diagnosed in women older than 53 years of age. The low surgical upgrade rate of 3% for pure IDP on CNB in younger women should be part of the management discussion. As a natural compound, docosahexaenoic acid (DHA) exerts anti-cancer and anti-angiogenesis functions through exosomes; however, little is known about the molecular mechanisms.\\nBreast cancer (BC) cells were treated with DHA (50\\xa0μM) and then tumor cell-derived exosomes (TDEs) were collected and characterized by electron microscopy, dynamic light scattering, and western blot analyses. By the time the cells were treated with DHA, RT-qPCR was used to investigate the expression of vascular endothelial growth factor (VEGF) and the selected pro- and anti-angiogenic microRNAs (miRNAs). The quantification of secreted VEGF protein was measured by enzyme-linked immunosorbent assay (ELISA). The effects of TDEs on endothelial cell angiogenesis were explored by transwell cell migration and in vitro vascular tube formation assays.\\nDHA treatment caused a significant and time-dependent decrease in the expression and secretion of VEGF in/from BC cells. This also increased expression of anti-angiogenic miRNAs (i.e. miR-34a, miR-125b, miR-221, and miR-222) while decreased levels of pro-angiogenic miRNAs (i.e. miR-9, miR-17-5p, miR-19a, miR-126, miR-130a, miR-132, miR-296, and miR-378) in exosomes derived from DHA-treated BC cells, TDE (DHA+). While treatment with exosomes (100\\xa0μg/ml) obtained from untreated BC cells, TDE (DHA-), enhanced the expression of VEGF-A in human umbilical vein endothelial cells (HUVECs), incubation with DHA or TDE (DHA+) led to the significant decrease of VEGF-A transcript level in these cells. We indicated that the incubation with TDE (DHA+) could significantly decrease endothelial cell proliferation and migration and also the length and number of tubes made by HUVECs in comparison with endothelial cells incubated with exosomes obtained from untreated BC cells.\\nDHA alters angiogenesis by shifting the up-regulation of exosomal miRNA contents from pro-angiogenic to anti-angiogenic, resulting in the inhibition of endothelial cell angiogenesis. These data can help to figure out DHA\\'s anti-cancer function, maybe its use in cancer therapy. 18F- Sodium Fluoride (NaF) is an excellent bone imaging agent used for skeletal staging but can also be localized in extra osseous calcifying lesions. We report a case of a 38-year-old woman with breast carcinoma referred for 18F-NaF PET-CT to evaluate possible metastatic lesions. 18F-NaF PET-CT detected incidental focal soft tissue tracer uptake in the right cerebellum with no sign of calcification seen on CT images. Subsequent MRI show high intensity signal lesion confirming brain metastasis. Extra osseous 18F-NaF uptake may provide important diagnostic information that might alter patient management. We previously reported that a strong immunoreactivity of tripartite motif-containing 44 (TRIM44) predicts the poor prognosis of patients with invasive breast cancer, and proposed that TRIM44 activates nuclear factor-κB (NF-κB) signaling as a causative mechanism. In the present study, we examined the clinicopathological roles of A20, which is known to be an NF-κB responsive gene, with TRIM44, in an updated cohort. Tissue samples of invasive breast cancer were obtained from 140 Japanese female breast cancer patients who underwent surgical treatment. Immunoreactivities of A20 and TRIM44 were analyzed using specific antibodies for each protein. A positive A20 immunoreactivity was significantly associated with a shorter disease-free survival (P = 0.043) and was positively correlated with TRIM44 immunoreactivity (P = 0.039). Combined use of the immunoreactivities for two proteins revealed that double-positive status for both A20 and TRIM44 immunoreactivities was associated with a shorter disease-free survival (P = 0.012) and was an independent factor for poor prognosis. These results indicate that a combined A20 and TRIM44 immunoreactivity predicted the prognosis of patients with invasive breast cancer. Moreover, the positive correlation between A20 and TRIM44 immunoreactivities suggested that the activation of NF-κB signaling by TRIM44 could occur in clinical breast cancer tissues. As circular RNAs (circRNAs) have been found to significantly involve in the onset and progression of multiple malignant tumors including breast cancer (BC), this study aims at evaluating the diagnostic and prognostic values of circRNAs in this malady.\\nAvailable databases were thoroughly searched to collect studies on the diagnosis and/or prognosis of BC using circRNA profiling. The updated Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool and the Newcastle Ottawa Scale (NOS) were used to assess the underlying bias of included studies. Clinical characteristics of the studies were merged by the quantitative-weighted integral method to obtain the combined effects.\\nSixteen studies were included, comprising 2438 BC cases and 271 noncancerous controls. The expression signature covered 24 circRNAs (down-regulated: circ-VRK1, hsa_circ_0068033, hsa_circ_103110, hsa_circ_104689, and hsa_circ_104821; up-regulated: circAGFG1, hsa_circ_0001785, hsa_circ_0108942, hsa_circ_0001785, hsa_circ_006054, hsa_circ_100219, hsa_circ_406697, circEPSTI1, circANKS1B, circGFRA1, circ_0103552, CDR1-AS, has_circ_001569, hsa_circ_001783, circFBXL5, circ_0005230, circAGFG1, circ-UBAP2, and circ_0006528). The sensitivity and specificity of circRNAs in distinguishing BC patients from noncancerous controls were 0.65 and 0.68, and the corresponding area under the curve was 0.66. Survival analysis revealed that patients showing highly expressed oncogenic circRNAs were associated with increased mortality risks of BC in overall survival (univariate analysis: hazard ratio [HR]\\xa0=\\xa03.30, P\\xa0=\\xa0.000; multivariate analysis: HR\\xa0=\\xa03.07, P\\xa0=\\xa0.000), and disease-free survival (HR\\xa0=\\xa08.26, P\\xa0=\\xa0.000). Stratified analysis based on circRNA expression status and control type also showed robust results.\\nCircular RNA profiling presents prominent diagnostic and prognostic values in BC, and can be rated as a promising tool facilitating its early diagnosis and survival. Breast cancer is the most common malignancy in women and has a risk of late recurrence. We report a case of metastasis to the stomach and colon 23\\xa0years after surgery, with characteristic findings. A 74-year-old woman underwent breast cancer resection at the age of 51. At the time, no additional therapy was performed despite the histological diagnosis of invasive lobular carcinoma with lymph node metastasis. Upper gastrointestinal endoscopy, which was performed as a follow-up for her chronic gastritis, revealed multiple erosions. Histology revealed diffuse proliferation of signet ring cell-like atypical cells, that were positive for cytokeratin CAM5.2 and estrogen receptor. These findings suggested metastasis from the invasive lobular breast carcinoma. Positron-emission tomography revealed sternal and vertebral metastases. Colonoscopy also performed to screen for intestinal metastasis revealed several lesions that resembled hyperplastic polyps. Although these lesions were not strongly suspected of metastasis, histology surprisingly revealed the same findings as the gastric metastasis. This case involved gastric and colorectal superficial metastases that were synchronously detected 23\\xa0years after primary treatment. We report that early-stage colorectal metastasis may resemble hyperplastic polyps, and biopsy should always be considered in patients with a history of breast cancer, regardless of years elapsed since treatment. Compared to tamoxifen, adjuvant treatment with aromatase inhibitors improves disease outcomes of postmenopausal women with hormone receptor-positive early breast cancer. In the international, randomized, double-blind BIG 1-98 trial, 8010 women were randomized to receive tamoxifen, letrozole, or sequential use of the agents for 5\\xa0years. With a focus on switching between agents, we investigated cardiovascular events over the entire 5-year treatment period.\\nOf the 6182 patients enrolled, 6144 started trial treatment and were included in this analysis. Adverse events occurring during study treatment until 30\\xa0days after cessation were considered. Eight cardiovascular event types were defined. Cumulative incidence of events were estimated using the Kaplan-Meier method, without consideration for competing events. Multivariable Cox models estimated hazard ratios (HR) with 95% confidence intervals (CI) for pairwise comparisons of treatment arms.\\nWhile on study treatment, 6.5% of patients (n\\u2009=\\u2009397) had any cardiac events reported; for 2.4%, the event was grades 3-5, of which 11 (0.2%) were grade 5. Letrozole monotherapy was associated with higher risk of grade 1-5 ischemic heart disease (HR\\u2009=\\u20091.81; 95% CI, 1.06-3.08) compared with tamoxifen monotherapy. Patients assigned sequential tamoxifen →letrozole (HR\\u2009=\\u20091.59; 95% CI, 0.92-2.74) or sequential letrozole → tamoxifen (HR\\u2009=\\u20091.20; 95% CI, 0.68-2.14) showed a lesser degree of risk elevation. Patients assigned to tamoxifen-containing regimens had significantly higher risk of grade 1-5 thromboembolic events (tamoxifen monotherapy HR\\u2009=\\u20092.10; 95% CI, 1.42-3.12; tamoxifen\\u2009→\\u2009letrozole HR\\u2009=\\u20091.96; 95% CI, 1.32-2.92; letrozole\\u2009→\\u2009tamoxifen HR\\u2009=\\u20091.56; 95% CI 1.03-2.35) as compared with patients assigned letrozole alone.\\nWhen initiating or switching between adjuvant endocrine treatments in postmenopausal patients, age and medical history, with special attention to prior cardiovascular events, should be balanced with expected benefit of the treatment. Aberrant activation of eIF4E signalling pathway is common in breast cancer and holds potential therapeutic options. In our work, galeterone as a chemical compound under clinical trials for the treatment of prostate cancer, was identified to be effective in targeting breast cancer cells via suppressing MNK-eIF4E and β-catenin. In despite of varying IC50, galeterone at nanomolar concentrations significantly decreased viability, proliferation and migration of a panel of breast cancer cell lines\\xa0regardless of clinical subtypes and genetic mutations, and to a higher extent than in normal breast cells. Galeterone significantly enhanced the effects of chemotherapeutic drugs in reducing proliferation and viability but not migration. The in vivo efficacy of galeterone as single drug alone and its ability in augmenting chemotherapy\\'s efficacy were also shown in breast cancer xenograft mouse model. Mechanism analysis demonstrated that galeterone decreased MNK1/2 level and phosphorylation of eIF4E. In addition, galeterone decreased β-catenin level via promoting GSK-3β-mediated β-catenin degradation, and furthermore that Akt but not CK1 was involved in β-catenin degradation by galeterone. Rescue studies demonstrated that both MNK/eIF4E and β-catenin were responsible for anti-breast cancer activity of galeterone. Our study provides pre-clinical evidence to initialize clinical trials for breast cancer using galeterone in combination with chemotherapy. African American cancer survivors disproportionately experience financial difficulties after cancer. Decreased work participation (going from being employed full time to part time or from employed to not employed) can contribute to financial hardship after cancer but employment outcomes among African American cancer survivors have not been well described. This study estimates the prevalence of work changes and identifies factors associated with decreased work participation among African American cancer survivors. We analyzed data from 916 African American breast, colorectal, lung, and prostate cancer survivors who participated in the Detroit Research on Cancer Survivors (ROCS) cohort and were employed before their cancer diagnosis. Modified Poisson models estimated prevalence ratios of decreased work participation and work changes, including changes to hours, duties, or schedules, between diagnosis and ROCS enrollment controlling for sociodemographic and cancer-related factors. Nearly half of employed survivors made changes to their schedules, duties, or hours worked due to cancer and 34.6% took at least one month off of work, including 18% who took at least one month of unpaid time off. More survivors employed full time (vs. part time) at diagnosis were on disability at ROCS enrollment (18.7% vs. 12.6%, P\\xa0<\\xa00.001), while fewer were unemployed (5.9% vs. 15.7%, P\\xa0<\\xa00.001). Nearly half (47.5%) of employed survivors decreased work participation. Taking paid time off was not associated with decreased work participation; however, taking unpaid time off and making work changes were associated with prevalence ratios of decreased work participation of 1.29 (95% CI: 1.03, 1.62) and 1.37 (95% CI: 1.07, 1.75), respectively. Employment disruptions are common after a cancer diagnosis. Survivors who take unpaid time off and make other work changes may be particularly vulnerable to experiencing decreased work participation. BRCA1/2 VUSs represent an important clinical issue in risk assessment for the breast/ovarian cancer families (HBOC) families. Among them, some occurring within the intron-exon boundary may lead to aberrant splicing process by altering or creating de novo splicing regulatory elements or unmasking cryptic splice site. Defining the impact of these potential splice variants at functional level is important to establish their pathogenic role.\\nGenomic DNA was extracted from peripheral blood sample of a young woman affected with breast cancer belonging to a HBOC family and the entire coding regions of the BRCA1 and BRCA2 genes were amplified using the Ion AmpliSeq BRCA1 and BRCA2 Panel. The BRCA2 c.682-2delA variant has been characterized by RT-PCR analysis performed on mRNA extracted from blood and lymphoblastoid cell line.\\nWe demonstrated that a novel BRCA2 c.682-2delA variant at the highly conserved splice consensus site in intron 8 disrupts the canonical splice acceptor site generating a truncated protein as predicted by several bioinformatics tools. Segregations analysis in the family and LOH performed on proband breast cancer tissue further confirmed its classification as pathogenic variant.\\nCombining different methodologies, we characterized this new BRCA2 variant and provided findings of clinical utility for its classification as pathogenic variant. Breast cancer is the major type among the women population globally. The treatment of cancer metastasis has made modest progress due to multiple factors. Thidiazuron (TDZ) is a novel plant growth regulator that has been shown to have anticancer effects. Therefore, we explored the anti-metastatic potentials of TDZ in cell lines by assessing its potential to suppress the epithelial-mesenchymal transition (EMT). We pretreated the BEAS-2B and breast cancer (MDA-MB-231) cells with TDZ and deliberated alteration in a cell viability, mammosphere, migration, NF-кB signalling, PI3K/AKT signalling and matrix metalloproteinase (MMP) expression and analysed the EMT induction by TGF-β/TNF-α-stimulated BEAS-2B cells. Treatment with TDZ (5-50\\xa0μmol) diminished the migration and invasion of the extremely metastatic MDA-MB-231 cells. Additionally, TDZ treatment led to down-regulation of uPAR, uPA, VEGF and MMP-2/-9 expression and up-regulation of TIMP-1/2 expression in these cells. Furthermore, TDZ treatment blocked invasion and EMT in non-tumorigenic BEAS-2B epithelial cells stimulated with TGF-β/TNF-α.TDZ prevents EMT and may thus block metastasis of breast cancer cells. Head and neck defect reconstruction is a common challenge for plastic surgeons. Microsurgical free tissue transfer is a frequently used solution but its success strictly depends on the quality of recipient vessels. A particularly demanding situation occurs when there are no nearby available vessels because of previous extensive neck dissection and radiotherapy. In similar cases, it is necessary to resort to other and farther vessels. Common alternatives might be the thoraco-acromial vessels, the transverse cervical vessels, and the internal mammary vessel. Recently, the perforator vessels of the internal mammary artery and vein were shown to be safe alternatives as recipient vessels for autologous breast reconstruction, causing less morbidity and allowing adequate perfusion of rather large flaps. Here we present a floor of the mouth reconstruction after cancer relapse resection. In this case, we employed a chimeric anterolateral thigh (ALT) free flap anastomosed to the internal mammary perforator vessels in end-to-end fashion. A 46-years-old male patient presented a defect in the floor of the mouth and base of the tongue after cancer removal. No nearby vessels were available because of extensive fibrosis and damages due to previous surgeries and radiotherapy. Therefore, on the basis of our experience in autologous breast reconstruction, we chose the internal mammary perforator vessels in the recipient side and we harvested a chimeric ALT-based skin island then split into two parts for mouth reconstruction and monitoring. We performed the anastomosis resorting to internal mammary perforator vessels and we obtained a satisfactory result from both the functional and aesthetic point of view. Postoperative course was uneventful and at 6\\u2009months follow up the reconstructive result was good with no functional issue. We believe that this might be a valid and modern evolution of the use of internal mammary vessels as recipient vessels and that it is a worthy addition in the field of perforator-anastomosed flaps, extending its application also to head and neck reconstructions. Moreover, a brief literature review about alternative recipient vessels for depleted neck is also provided. Assessing the pattern of nuclear chromatin is essential for pathological investigations. However, the interpretation of nuclear pattern is subjective. In this study, we performed the texture analysis of nuclear chromatin in breast cancer samples, to determine the nuclear pleomorphism score thereof. We used three different algorithms for extracting high-level texture features: the gray-level co-occurrence matrix (GLCM), gray-level run length matrix (GLRLM), and gray-level size zone matrix (GLSZM). Using these algorithms, 12 GLCM, 11 GLRLM, and 16 GLSZM features were extracted from three scores of breast carcinoma (scores 1-3). Classification accuracy was assessed using the support vector machine and k-nearest neighbor classification models. Three features of GLCM, eleven of GLRLM, and twelve of GLSZM were consistent across the three nuclear pleomorphism scores of breast cancer. Comparing scores 1 and 3, the GLSZM feature large zone high gray-level emphasis showed the largest difference among breast cancer nuclear scores among all features of the three algorithms. The support vector machine and k-nearest neighbor classifiers showed favorable results for all three algorithms. A multi-class classification was performed to compare and distinguish between the scores of breast cancer. Texture features of nuclear chromatin can provide useful information for nuclear scoring. However, further validation of the correlations of histopathologic features, and standardization of the texture analysis process, are required to achieve better classification results. This article is protected by copyright. All rights reserved. Incidence and mortality rates of cancer continue to increase greatly despite the improved diagnostic and therapeutic methods. Based on GLOBOCAN estimates, the numbers of new cancer cases reported in 2018 were ~18.1 million, while the numbers of cancer mortalities were ~9.6 million. It remains difficult to diagnose most cancer patients at early stages. Although cancer therapy market is rapidly evolving, the effectiveness of therapy is still inadequate. Therefore, exploring new biomarkers for diagnosis, prognosis and treatment is essential for cancer management. Long non-coding RNAs (lncRNAs) are unique regulatory molecules that control several cellular processes and are implicated in diverse human diseases including cancer. LncRNAs could serve as potential biomarkers for cancer patients to aid diagnosis and determine prognosis. In addition, numerous lncRNAs have proved their ability to predict response to cancer treatment. FAM83H antisense RNA 1 (FAM83H-AS1) is among those highly dysregulated lncRNAs in cancer. FAM83H-AS1 was demonstrated to participate in the progression of different malignancies and also shown to play a vital role in diagnosis, prognosis and treatment. Here, we analyse recent studies concerning the oncogenic role and molecular mechanisms of lncRNA FAM83H-AS1 in the following cancer types: bladder, breast, lung, hepatocellular, colorectal, gastric, pancreatic, ovarian, cervical cancer as well as glioma. Anti-mullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and one year after initiation of adjuvant chemotherapy on NSABP/NRG Oncology B-47 in female participants aged 42 years and younger (with median age 39 years). At baseline, median AMH was 1.2\\u2009ng/mL; 13 (4.7%) values were <0.1ng/mL (the threshold for detectable levels, in the perimenopause/menopause range), and 57 values (20.6%) were less than 0.5\\u2009ng/mL. At 1 year, 215 (77.6%) were less than 0.1ng/mL, and 264 (95.3%) were less than 0.5\\u2009ng/mL. Post-chemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having post-chemotherapy menses increased with younger age, higher BMI, and higher pre-chemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs. docetaxel-cyclophosphamide). We conclude that higher pre-chemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea, and that AMH one year after chemotherapy initiation is not informative in this setting because it is likely to be very low. Breast cancer is an important public health problem that is increasing in incidence, being a stressor with a negative impact on women\\'s quality of life. This study is focused on the evaluation of temporal precursors (one month before) of women\\'s quality of life undergoing chemotherapy, considering post-surgical personal, clinical, cognitive and neuropsychophysiological factors, according to the Transactional Stress and Coping Model.\\nThis longitudinal study included 112 patients with breast cancer. Data were collected in two different moments: before and during the adjuvant chemotherapy. Structural equation modelling was used to support a theoretically based model in which some antecedent factors impact patients\\' long-term quality of life through a set of mediators.\\nThe associations of breast symptoms, body image and sexual functioning with psychological distress and quality of life were totally mediated by illness perceptions, while the associations of working memory with psychological distress and quality of life were totally mediated by self-efficacy for coping. Patients with greater psychological distress showed higher levels of nadir cortisol.\\nResults showed the importance of assessing patients\\' perceptions of their illness, prior to chemotherapy, as well as promoting more self-efficacy for coping, in order to improve women\\'s emotional state and quality of life. To assess the decision-making process in fit and frail older breast cancer patients.\\nBreast cancer patients aged ≥70\\xa0years who completed the G8 frailty screening tool (G8) were included in this retrospective study. Socio-demographic and clinical characteristics were collected, as well as information from geriatric assessment (GA). Treatment decisions were compared with national guidelines.\\nOf 177 patients, 85 patients were considered fit by the G8 (G8-fit) and 92 patients frail (G8-frail). All G8-fit and 53 G8-frail were proposed for surgery. GA was performed in 34 patients (9 G8-fit; 25 G8-frail) of whom 16 (2 G8-fit;14 G8-frail) were considered frail (GA-frail). 28 out of these 34 patients were considered fit for surgery (including 11 GA-frail); their impairments were unlikely to interfere with surgery or life expectancy. Reasons for adjusting treatment were physical/cognitive condition and patient preference. Ultimately, 123 patients underwent surgery in accordance with guidelines (81 G8-fit;42 G8-frail, p\\xa0<\\xa00.001). Survival was reduced in G8-frail compared to G8-fit (p\\xa0=\\xa00.001), but G8 lost its association with mortality in multivariable survival analysis. Among patients undergoing surgery, no difference in mortality was seen between G8-fit and G8-frail (p\\xa0=\\xa00.996).\\nThe G8 is associated with treatment decisions and did not affect survival in patients undergoing surgery. In the decision-making process, the G8 may help and estimates the need for adaptive care. The purpose of this study was to develop and validate an individualized nomogram to predict venous thromboembolism (VTE) risk in hospitalized postoperative breast cancer patients.\\nA single-central retrospective and non-interventional trial.\\nFor model development, we used data from 4,755 breast cancer patients between 1 November 2016-30 June 2018 (3,310 patients in the development group and 1,445 in the validation group). Overall, 216 patients developed VTE (150 in development group and 66 in validation group). The model was validated by receiver operating characteristic curves and the calibration plot. The clinical utility of the model was determined through decision curve analysis.\\nThe individualized nomogram consisted of six clinical factors: age, body mass index, number of cardiovascular comorbidities, neoadjuvant chemotherapy, surgical treatment, hospital length of stay and two pre-operative biomarkers of Homocysteine and D-dimer. The model at the 3.9% optimal cut-off had the area under the curve of 0.854 (95% CI, 0.824-0.884) and 0.805 (95% CI, 0.740-0.870) in the development and validation groups. A p\\xa0=\\xa00.570 of the calibration test showed that the model was well-calibrated. The net benefit of the model was better between threshold probabilities of 5%-30% in decision curve analysis.\\nThe nomogram of VTE risk assessment, is applicable to hospitalized postoperative breast cancer patients. However, multi-central prospective studies are needed to improve and validate the model. Effectiveness and safety of thromboprophylaxis in high-risk patients are needed to demonstrate in interventional trials.\\nThis nomogram can be used in clinical to inform practice of physicians and nurses to predict the VTE probability and maybe direct personalized decision making for thromboprophylaxis in hospitalized postoperative breast cancer patients. This report describes local administration of submicron particle paclitaxel (SPP) (NanoPac®:\\xa0~\\xa0800-nm-sized particles with high relative surface area with each particle containing\\u2009~\\xa02 billion molecules of paclitaxel) in preclinical models and clinical trials evaluating treatment of carcinomas. Paclitaxel is active in the treatment of epithelial solid tumors including ovarian, peritoneal, pancreatic, breast, esophageal, prostate, and non-small cell lung cancer. SPP has been delivered directly to solid tumors, where the particles are retained and continuously release the drug, exposing primary tumors to high, therapeutic levels of paclitaxel for several weeks. As a result, tumor cell death shifts from primarily apoptosis to both apoptosis and necroptosis. Direct local tumoricidal effects of paclitaxel, as well as stimulation of innate and adaptive immune responses, contribute to antineoplastic effects. Local administration of SPP may facilitate tumor response to systemically administered chemotherapy, targeted therapy, or immunotherapy without contributing to systemic toxicity. Results of preclinical and clinical investigations described here suggest that local administration of SPP achieves clinical benefit with negligible toxicity and may complement standard treatments for metastatic disease. Although magnetic resonance imaging (MRI) has a higher sensitivity of early breast cancer than mammography, the specificity is lower. The purpose of this study was to develop a computer-aided diagnosis (CAD) scheme for distinguishing between benign and malignant breast masses on dynamic contrast material-enhanced MRI (DCE-MRI) by using a deep convolutional neural network (DCNN) with Bayesian optimization. Our database consisted of 56 DCE-MRI examinations for 56 patients, each of which contained five sequential phase images. It included 26 benign and 30 malignant masses. In this study, we first determined a baseline DCNN model from well-known DCNN models in terms of classification performance. The optimum architecture of the DCNN model was determined by changing the hyperparameters of the baseline DCNN model such as the number of layers, the filter size, and the number of filters using Bayesian optimization. As the input of the proposed DCNN model, rectangular regions of interest which include an entire mass were selected from each of DCE-MRI images by an experienced radiologist. Three-fold cross validation method was used for training and testing of the proposed DCNN model. The classification accuracy, the sensitivity, the specificity, the positive predictive value, and the negative predictive value were 92.9% (52/56), 93.3% (28/30), 92.3% (24/26), 93.3% (28/30), and 92.3% (24/26), respectively. These results were substantially greater than those with the conventional method based on handcrafted features and a classifier. The proposed DCNN model achieved high classification performance and would be useful in differential diagnoses of masses in breast DCE-MRI images as a diagnostic aid. Misconceptions regarding activity and toxicity of therapeutic interventions are common among cancer patients. There is little knowledge about the factors that contribute to a more realistic perception by patients.\\nThis pilot study was designed as a prospective questionnaire survey and included 101 therapy-naïve patients treated at the Division of Oncology, Medical University of Vienna. After obtaining written informed consent, patients\\' expectations about treatment aims, side effects and the satisfaction with their oncologic consultation were interrogated before the first treatment cycle by questionnaires.\\nOf 101 patients, 53 (53%) were female and 67/101 (66%) were treated with curative attempt in an adjuvant or neo-adjuvant setting. The most common diagnoses were lung cancer (31%) and breast cancer (30%). Although 92% of patients were satisfied with the information given by their oncologist, palliative patients were more likely to declare that not everything was explained in an intelligible manner (p\\u2009=\\u20090.01). Patients with a first language other than German stated more often that their physician did not listen carefully enough (p\\u2009=\\u20090.02). Of 30 patients, 26 (87%) receiving chemotherapy with palliative intent believed that their disease was curable. Concerning adverse events, female patients anticipated more frequently hair loss (p\\u2009=\\u20090.003) and changes in taste (p\\u2009=\\u20090.001) compared to men. Patients under curative treatment were more likely to expect weight loss (p\\u2009=\\u20090.02) and lack of appetite (p\\u2009=\\u20090.01) compared to patients with palliative treatment intent.\\nIn conclusion, cancer patients were satisfied with the patient-doctor communication. This prospective study aggregated patients\\' concerns on side effects and the perception of therapeutic goals in therapy-naïve patients. Of note, the majority of patients treated in the palliative setting expected their treatment to cure the disease. This study aims at merging the therapeutic effects associated to the inhibition of Carbonic Anhydrase IX (CAIX), an essential enzyme overexpressed by cancer cells including mesothelioma and breast cancer, with those ones brought by the application of Boron Neutron Capture Therapy (BNCT). This task was pursued by designing a sulfonamido-functionalised-carborane (CA-SF) that acts simultaneously as CAIX inhibitor and boron delivery agent. The CAIX expression, measured by Western blot analysis, resulted high in both mesothelioma and breast tumours. This finding was exploited for the delivery of a therapeutic dose of boron (>\\u200920\\xa0μg/g) to the cancer cells. The synergic cytotoxic effects operated by the enzymatic inhibition and neutron irradiation was evaluated in vitro on ZL34, AB22 and MCF7 cancer cells. Next, an in vivo model was prepared by subcutaneous injection of AB22 cells in Balb/c mice and CA-SF was administered as inclusion complex with a β-cyclodextrin oligomer. After irradiation with thermal neutrons tumour growth was evaluated for 25\\xa0days by MRI. The obtained results appear very promising as the tumour growth was definitively markedly lower in comparison to controls and the CAIX inhibitor alone. This approach appears promising and it call consideration for the design of new therapeutic routes to cure patients affected by this disease. Tamoxifen shows efficacy in reducing breast cancer-related mortality but clinically, is associated with increased risk for thromboembolic events. We aimed to determine whether breast tumour sub-phenotype could predict propensity for thrombosis. We present two ex vivo Models of Tamoxifen-therapy, Model 1 in which treatment recapitulates accumulation within breast tissue, by treating MCF7 and T47D cells directly prior to exposure to blood constituents; and Model 2 in which we recreate circulating Tamoxifen by treating blood constituents prior to exposure to cancer cells. Blood constituents included whole blood, platelet-rich plasma and platelet-poor plasma. Hypercoagulation was assessed as a function of thrombin activity, expression of CD62P and CD63 activation markers defined as an index of platelet activation, and platelet morphology; while oestrogen receptor expression was assessed using immunocytochemistry with quantitative analysis. We determined, in concert with clinical studies and contrary to selected laboratory investigations, that Tamoxifen induces hypercoagulation, dependent on sub-phenotypes, with the T47D cell line capacity most enhanced. We determined a weak positive correlation between oestrogen receptor expression, and CD62P and CD63; indicating an association between tumour invasion profiles and hypercoagulation, however, other yet unknown factors may play a predictive role in defining hypercoagulation. None The study aimed to identify the risk factors of cement leakage following percutaneous vertebroplasty for spinal metastases.\\n230 consecutive patients with 530 vertebrae were retrospectively reviewed. Characteristics including age, primary cancer, location, pathological fracture, the integrity of the posterior wall, and the volume of bone cement were considered as potential risk factors. Cement leakage was evaluated by postoperative imaging examination and classified into three subtypes with different potential sequelae: spinal canal leakage, intravascular leakage around vertebrae, intradiscal and paravertebral leakage. Univariate and multivariate analyses were used to assess the risk factors.\\nLeakage was detected in 185 vertebrae (34.9%), 18.3% for intradiscal and paravertebral, 13.2% for intravascular around vertebrae, and 7.0% for spinal canal. Multivariate analysis showed that incomplete posterior wall (P\\xa0=\\xa00.001) and breast cancer (P\\xa0=\\xa00.015) were strong predictive factors for spinal canal leakage, incomplete posterior wall (P\\xa0=\\xa00.024) was for intravascular leakage around vertebrae, thoracic (P\\xa0=\\xa00.010) and pathological fracture (P\\xa0=\\xa00.000) were for intradiscal and paravertebral leakage.\\nOur findings suggest that cement leakage is common following percutaneous vertebroplasty for spinal metastases. The incomplete posterior wall is an unfavourable factor for intravascular leakage around vertebrae. Vertebrae with incomplete posterior wall and breast cancer metastases are more likely to develop spinal canal leakage. The essential role of mammary gland stroma in the regulation of mammary epithelial development, function, and cancer has long been recognized. Only recently, though, the functions of individual stromal cell populations have begun to become more clarified. Mammary fibroblasts have emerged as master regulators and modulators of epithelial cell behavior through paracrine signaling, extracellular matrix production and remodeling, and through regulation of other stromal cell types. In this review article, we summarize the crucial studies that helped to untangle the roles of fibroblasts in mammary gland development. Furthermore, we discuss the origin, heterogeneity, and plasticity of mammary fibroblasts during mammary development and cancer progression. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of non-Hodgkin lymphoma (cancer of the immune system) that can develop around breast implants. Breast implants are among the most commonly used medical devices for cosmetic or reconstructive purposes. In the past few years, the number of women with breast implants diagnosed with anaplastic large cell lymphoma (ALCL) has increased, and several studies have suggested a direct association between breast implants and an increased risk of this disease. Although it has been hypothesized that chronic stimulation of the immune system caused by implant materials and biofilms as well as a possible genetic predisposition play an important role in this disease, the cellular and molecular causes of BIA-ALCL are not fully understood. This review aims to describe the current understanding around the environmental and molecular drivers of BIA-ALCL as well as the genetic and chromosomal abnormalities identified in this disease to date. Despite dramatic advances in cancer research and therapy, breast cancer remains a tricky health problem and represents a top biomedical research priority. Nowadays, breast cancer is still the leading cause of malignancy-related deaths in women, and incidence and mortality rates of it are expected to increase significantly the next years. Currently more and more researchers are interested in the study of breast cancer by its arising in young women. The common treatment options of breast cancer are chemotherapy, immunotherapy, hormone therapy, surgery, and radiotherapy. Most of them require chemical agents, such as PARP inhibitors, CDK4/6 inhibitors, and HER2 inhibitors. Recent studies suggest that some targets or pathways, including BRD4, PLK1, PD-L1, HDAC, and PI3K/AKT/mTOR, are tightly related to the occurrence and development of breast cancer. This article reviews the interplay between these targets and breast cancer and summarizes the progress of current research on small molecule inhibitors of these anti-breast cancer targets. The review aims to provide structural and theoretical basis for designing novel anti-breast cancer agents. Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials. To estimate the incidence and recurrence of breast cancer (BC) in patients with vulvovaginal atrophy (VVA) treated with ospemifene and matched untreated VVA patients using real-world data.\\nRetrospective matched cohort study.\\nVVA patients were identified from the 2011-2018 US MarketScan® insurance claims database. For incidence, ospemifene-treated VVA patients without evidence of BC prior to index treatment were matched to two untreated VVA controls similarly without history of BC on age, index VVA year, geographic region, Charlson Comorbidity categories, and follow-up time. BC after the index treatment was identified by BC diagnosis codes, mastectomy, chemotherapy, or radiation procedure. Incidence rate, rate ratio (RR) and their 95 % confidence intervals (CI) were calculated. The process was repeated to estimate BC recurrence in patients with a history of BC in 1:1, 1:2 and 1:3 matches.\\n1728 ospemifene users and 3456 untreated patients met the inclusion and matching criteria for assessing incidence. The average number of days for which ospemifene was supplied was 314 (standard deviation [SD]\\u2009=\\u2009340). Average follow-up time from index treatment was 937 days (SD\\u2009=\\u2009392) for treated patients and 915 days (SD\\u2009=\\u2009396) for controls. BC incidence rates per 1000 person-years was 2.03 (95 % CI: 1.06-3.91) for treated patients and 3.53 (95 % CI: 2.49-4.99) for controls (RR\\u2009=\\u20090.58, 95 % CI: 0.28-1.21). No difference in recurrence was observed between ospemifene-treated and matched untreated patients. Ten (32.3 %) treated vs. 25 (40.3 %) controls in the 1:2 matched analysis had a recurrence.\\nNo differences were observed in the BC incidence and recurrence rates in ospemifene users compared with matched controls. Numerous case studies have reported spontaneous regression of recognized metastases following primary tumor excision, but underlying mechanisms are elusive. Here, we present a model of regression and latency of metastases following primary tumor excision and identify potential underlying mechanisms.\\nUsing MDA-MB-231\\nThese results demonstrate regression and latency of micro-metastases following primary tumor excision and a crucial role for primary tumor secretome in promoting early metastatic growth in MDA-MB-231 S-1 and cyclophosphamide (CPA) can be given orally, and their combination may have great potential for treating metastatic breast cancer (MBC). A phase I study of sequential S-1 and CPA therapy was conducted in patients with MBC; the recommended doses that were determined for this regimen were 80\\u2009mg/m\\nThis was a single-arm, open-label, single-center prospective phase II study to evaluate the efficacy of a sequential S-1 and CPA regimen for MBC. S-1 was administered orally 2×/day for 14 consecutive days, and then CPA was administered orally 2×/day for 14 consecutive days in a repeating 4-week\\u2009cycle (S-1 for 2\\u2009weeks, CPA for 2\\u2009weeks). The primary endpoint was the overall response rate (ORR). Secondary endpoints included the overall survival (OS), progression-free survival (PFS), clinical benefit rate (CBR) and safety.\\nThirty-six patients were enrolled in this study. The overall response was complete response in 0 (0%), partial response in 12 (33.3%), stable disease in 12 (33.3%), and progressive disease in 11 (30.1%) patients. The ORR was 33.3% (12/36). The CBR was 66.7% (24/36). The median PFS was 9.5\\u2009months (95%CI: 7.8-12.6\\u2009months). The median OS was 20.2\\u2009months (95%CI: 15.0-25.4\\u2009months) Grade 3/4 adverse events included leukopenia in seven patients (19.4%). Dose reductions because of adverse events occurred in 12 patients (33.3%). There was no treatment-related mortality.\\nThe combination of sequential therapy with S-1 and CPA was tolerable and had efficacy with good disease control. Sequential therapy with S-1 and CPA may be a feasible new treatment option for patients with MBC; however, further study is warranted to explore the efficacy of this therapy.\\nJRCT, JRCTs031180296 . Registered 2 December 2019 - Retrospectively registered. Steroid hormone signaling induces vast gene expression programs which necessitate the local formation of transcription factories at regulatory regions and large-scale alterations of the genome architecture to allow communication among distantly related cis-acting regions. This involves major stress at the genomic DNA level. Transcriptionally active regions are generally instable and prone to breakage due to the torsional stress and local depletion of nucleosomes that make DNA more accessible to damaging agents. A dedicated DNA damage response (DDR) is therefore essential to maintain genome integrity at these exposed regions. The DDR is a complex network involving DNA damage sensor proteins, such as the poly(ADP-ribose) polymerase 1 (PARP-1), the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), the ataxia-telangiectasia-mutated (ATM) kinase and the ATM and Rad3-related (ATR) kinase, as central regulators. The tight interplay between the DDR and steroid hormone receptors has been unraveled recently. Several DNA repair factors interact with the androgen and estrogen receptors and support their transcriptional functions. Conversely, both receptors directly control the expression of agents involved in the DDR. Impaired DDR is also exploited by tumors to acquire advantageous mutations. Cancer cells often harbor germline or somatic alterations in DDR genes, and their association with disease outcome and treatment response led to intensive efforts towards identifying selective inhibitors targeting the major players in this process. The PARP-1 inhibitors are now approved for ovarian, breast, and prostate cancer with specific genomic alterations. Additional DDR-targeting agents are being evaluated in clinical studies either as single agents or in combination with treatments eliciting DNA damage (e.g., radiation therapy, including targeted radiotherapy, and chemotherapy) or addressing targets involved in maintenance of genome integrity. Recent preclinical and clinical findings made in addressing DNA repair dysfunction in hormone-dependent and -independent prostate and breast tumors are presented. Importantly, the combination of anti-hormonal therapy with DDR inhibition or with radiation has the potential to enhance efficacy but still needs further investigation. Coumarin-hydroxamic acid derivatives  The purpose of the current in silico planning study is to compare radiation doses of whole-breast irradiation (WBI) and whole-breast plus regional lymph node irradiation (WBI+RNI) administered to the regional lymph nodes (RLN) in pN1 breast cancer. Twenty-four participating institutions were asked to create plans of WBI and WBI+RNI for two dummy cases. To compare target coverage between the participants, an isodose line equal to 90% of the prescribed dose was converted to an isodose contour (contour Albendazole is a benzimidazole derivative with documented antitumor activity and low toxicity to healthy cells. The major disadvantage in terms of clinical use is its low aqueous solubility which limits its bioavailability. Albendazole was incorporated into stable and homogeneous polyurethane structures with the aim of obtaining an improved drug delivery system model. Spectral and thermal analysis was used to investigate the encapsulation process and confirmed the presence of albendazole inside the nanoparticles. The in vitro anticancer properties of albendazole encapsulated in polyurethane structures versus the un-encapsulated compound were tested on two breast cancer cell lines, MCF-7 and MDA-MB-231, in terms of cellular viability and apoptosis induction. The study showed that the encapsulation process enhanced the antitumor activity of albendazole on the MCF-7 and MDA-MB-23 breast cancer lines. The cytotoxic activity manifested in a concentration-dependent manner and was accompanied by changes in cell morphology and nuclear fragmentation. Insulin-regulated aminopeptidase (IRAP) is the only enzyme known to cleave oxytocin and vasopressin; however, it is also the high-affinity binding site for angiotensin IV (AngIV) receptor type 4 (AT4) ligands and it is related to insulin-dependent glucose transporters through the translocation of the glucose transporter type 4 (GLUT4). Previous studies have demonstrated an association between IRAP activity and the number and size of mammary tumors in an animal model of breast cancer (BC). Also, a highly significant increase in IRAP activity has been found in BC tissue from women patients. Here, we found no changes in circulating IRAP in premenopausal (preMP) women, but it increased significantly in postmenopausal (postMP) women not treated with neoadjuvant chemotherapy (NACH). However, in women treated with NACH, IRAP activity increased in both preMP and postMP women. Two years of follow-up indicated lower levels of IRAP activity in untreated preMP women, but a return to control levels in untreated postMP women, while IRAP activity returned to control levels in women treated with NACH. Circulating oxytocin decreased in both preMP and postMP women during the follow-up period. Differences in Oxytocin appeared between preMP and postMP women treated with NACH, but not in women who were not treated with NACH. On the contrary, circulating vasopressin increased in untreated and treated preMP and postMP women, with most of the differences related to the hormonal status as well as the neoadjuvant treatment during the two year follow-up We propose that IRAP is involved in mechanisms related not only to oxytocin and/or vasopressin regulation, but also to the local mammary RAS through AngIV and its role in glucose transportation through the IRAP/GLUT4 system. The relationship between solar ultraviolet radiation and the risk of breast cancer is conflicting. The purpose of our study was to quantitatively assess the relationship between solar ultraviolet radiation and breast cancer risk and to analyze related factors such as age and sunscreen use.Articles indexed in PubMed and Embase and published between January 2005 and March 2020 were searched for relevant keywords. The relative risk was calculated using random-effect or fixed-effect models in the meta-analysis and dose-response meta-analysis, which were conducted according to the Meta-Analyses of Observational Studies in Epidemiology reporting guidelines. Sensitivity analyses for heterogeneity and publication bias were evaluated.Six studies were eligible for inclusion in the meta-analysis, and three of these were included in the dose-response analysis. We found a correlation between exposure to solar ultraviolet radiation and breast cancer risk (relative risk: 0.70, 95% confidence interval: 0.65, 0.75). We also found a linear dose-response relationship between the exposure and breast cancer risk (relative risk: 0.86, 95% confidence interval: 0.81, 0.91) in women over 40. Not tanning and covering the limbs were associated with breast cancer risk, but sunscreen use was not.Exposure to solar ultraviolet radiation is negatively correlated with breast cancer risk, and the association is linear in women over 40. This is the first dose-response meta-analysis on the topic, and the influence of factors such as estrogen receptor status, occupational exposure, and ethnicity requires in-depth study. Cancer-related fatigue (CRF) is one of the most common and disabling outcomes in patients with breast cancer (BC). Traditional Chinese medicine (TCM) nonpharmacological interventions are becoming increasingly popular for cancer treatment and rehabilitation interventions. However, their efficacy and safety remain unclear and there is no systematic review or meta-analysis focusing fully on this issue. We aim to evaluate the effects of representative TCM nonpharmacological interventions, including Qigong, Tai Chi, acupuncture, and Tuina, on CRF in BC patients.\\nPublished randomized controlled trials (RCTs) that assessed the efficacy of these interventions on CRF for BC patients will be included. We will search from the following electronic databases: PubMed, Cochrane Library, EMBASE, MEDLINE, Web of Science, Scopus, PsycINFO, PSYINDEX, CINAHL, China National Knowledge Infrastructure (CNKI), WanFang Database, and Chinese Biomedical Literature Database (CBM). The primary outcomes are the improvement of CRF, which will be evaluated by the Piper Fatigue Scale (PFS), the Functional Assessment of Cancer Therapy (FACT)-Fatigue Scale, Schwartz Cancer Fatigue Scale (SCFS), the Multidimensional Fatigue Inventory (MFI). The secondary outcomes are quality of life and safety. The meta-analysis will be performed using RevMan ver 5.3(Cochrane) statistical software.\\nWe will provide more practical results investigating the efficacy of Qigong, Tai Chi, acupuncture, Tuina for BC patients with CRF from several respects including the improvement of fatigue, quality of life, and safety.\\nThis review will generate more stronger evidence in BC patients for TCM nonpharmacological interventions, including Qigong, Tai Chi, acupuncture, Tuina, in the treatment of CRF and help to inform clinicians and policymakers.\\nEthical approval is not necessary because all of the study base in our review will be based on published research. We will submit our results to a peer-reviewed journal.\\nThe study is priorly registered through International Platform of Registered Systematic Review and Meta-analysis Protocol on October 2, 2020 (INPLASY 2020100003). Breast cancer is a common disease in galactophore department. Patients with breast cancer are prone to depression, with the incidence of depression ranging from 13% to 23% and as high as 70% in patients with advanced stage. On the one hand, it is related to the physiological characteristics, personality characteristics, and social factors of women themselves. On the other hand, it is related to the common tumors of women, such as breast cancer, examination, and antitumor treatment. Due to the serious side effects of chemotherapy drugs, patients can always feel the presence of cancer. In addition, the mark of radiotherapy and fatigue make the psychological burden continue to have excessive economic burden, and lack of understanding from both social and family, discrimination and patients\\' own psychological endurance are all causes of breast cancer factors contributing to depressive symptoms in patients. Auricular acupuncture as a form of acupuncture therapy which is proved to be effective in RCTs and very suitable for patients, has been used in patients who suffer from breast cancer-related depression for a long time, therefore, a systematic review is necessary to provide available evidence for further study.\\nThe following databases will be searched from their inception to August 2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of Science, Nature, Science online, VIP medicine information, and China National Knowledge Infrastructure. Primary outcomes: Score of depression symptoms. Additional outcomes: The overall effective rate. Data will be extracted by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0.\\nThe results of this study will systematically evaluate the effectiveness and safety of auricular acupuncture intervention for people with breast cancer-related depression.\\nThe systematic review of this study will summarize the current published evidence of auricular acupuncture for the treatment of breast cancer-related depression, which can further guide the promotion and application of it.\\nSeptember 11, 2020 osf.io/5b7yw. (https://osf.io/5b7yw). Surgery followed by a chemotherapy agent is the first-line treatment for breast cancer patients. Nevertheless, new targets are required for women with triple-negative breast cancer (TNBC) in order to improve the treatment of this aggressive cancer subtype. Multiple pro-inflammatory molecules including lipid-based substances such as sphingosine-1-phosphate (S1P) promote cancer progression. In this preclinical study, we aim to investigate the efficacy of Fingolimod, an inhibitor of S1P / S1P receptors axis, already approved as an immunomodulator in multiple sclerosis. The impact of Fingolimod was analyzed using in vitro 2D and 3D cell survival analysis and in vivo orthotopic graft models, using mouse and human TNBC cells implanted in immunocompetent or immunodeficient mice, respectively. Resection of the tumor primary mass was also performed to mimic the clinical standard of care. We demonstrated that Fingolimod repressed tumor cell survival in vitro. We also showed in preclinical mouse TNBC models that Fingolimod repressed tumor progression and liver and spleen metastases without apparent adverse effects on the animals. Our data indicate that Fingolimod induces tumor cells apoptosis and thereby represses tumor progression. Globally, our data suggest that Fingolimod merits further evaluation as a potential therapeutic opportunity for TNBC. Immune activation plays an important role in achieving the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer. We evaluated how the immune response contributes to various therapeutic effects. This study was conducted on 43 patients with stages II-IV breast cancer who received preoperative chemotherapy followed by surgery. Peripheral natural killer (pNK) cell activity and the neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio (PLR) were assessed before and after chemotherapy. Tumor-infiltrating lymphocytes (TILs) and levels of 14 tumor microenvironmental factors, analyzed by next-generation sequencing, were assessed in formalin-fixed, paraffin-embedded sections of preoperative biopsy samples and surgical specimens. Univariate analysis showed that grade 2 (G2) and better therapeutic effects were significantly associated with human epidermal growth factor receptor 2 (HER-2)-positive cancer, lower PLRs, and higher NK cell and interleukin-6 levels after chemotherapy. The disappearance of axillary lymph-node metastasis was significantly associated with HER-2-positive cancer; increased pNK cell activity and lower PLRs and vascular endothelial growth factor (VEGF) levels after chemotherapy; and increased cytotoxic T lymphocyte antigen 4 (CTLA-4) levels in regulatory T cells (Tregs) and ≥5% TILs before chemotherapy. Multivariate analysis showed that G2 and better therapeutic effects tended to be associated with higher NK cell levels after chemotherapy (odds ratio\\u202f=\\u202f1.02; 95% confidence interval, 0.99-1.05; P\\u202f=\\u202f0.07). The activation of local and systemic immune responses by downregulation of immunosuppressive factors, such as VEGF and CTLA-4 in Tregs, had variable pathological and therapeutic effects after preoperative chemotherapy in patients with breast cancer. Nanoparticles show promise theranostic applications for cancer. The metal-based nanoparticles can be used as photosensitizers and delivery vehicles. In bimetallic particles based on gold or silver and iron, a combination of the plasmonic features of the gold or silver components with the magnetic properties of the iron makes these hybrid nanomaterials suitable for imaging and therapeutic applications. Herein, we discuss toxicity and cell internalization of metallic (silver and gold) and bimetallic (silver-iron, gold-iron, and silver-gold) aminolevulinic acid (ALA) nanoparticles. ALA can control the production of an intracellular photosensitizer, protoporphyrin IX (PpIX), commonly used in photodynamic therapy.\\nNanoparticles were synthesized by photoreduction method and characterized by UV/Vis spectra, Zeta potential, FTIR, XRD, and transmission electron microscopy. The amount of singlet oxygen generation by a yellow LED, and ultrasound was studied for gold, gold-iron, and silver-gold nanoparticles. Cytotoxicity assays of MCF-7 in the presence of nanoparticles were performed, and PpIX fluorescence was quantified by high content screening (HCS).\\nRed fluorescence observed after 24\\u2009h of nanoparticles incubation on MCF-7 cells, indicated that the ALA in surface of nanoparticles was efficiently converted to PpIX. The best results for singlet oxygen generation with LED or ultrasound irradiation were obtained with ALA:AgAuNPs.\\nThe studied nanoparticles present the potential to deliver aminolevulinic acid to breast cancer cells efficiently, generate singlet oxygen, and convert ALA into PpIX inside the cells allowing photodiagnosis and therapies as photodynamic and sonodynamic therapies. /Puprose: Rates of acute esophagitis in breast cancer patients undergoing regional nodal irradiation (RNI) are under-reported. We set to identify esophageal dose-volume constraints associated with grade 2 esophagitis (G2E). We hypothesized that the G2E rate was higher with intensity modulated radiation therapy (IMRT) vs. 3D conformal radiation therapy (3DCRT).\\n/Methods: We identified patients that received RNI (50 Gy/25 fractions) from 1/2013-6/2019. We retrospectively contoured the esophagus in a consistent manner and recorded esophageal mean dose, max dose, and V10-V50. Our primary endpoint was the G2E rate. Receiver operating characteristics curves analysis (e.g., Youden\\'s J statistic) were used to determine the cutpoints for the dosimetric parameters which were then tested in logistic regression models.\\nWe identified 531 patients (50% left-sided; 41% IMRT; 16.2% G2E). G2E was significantly higher in IMRT vs. 3DCRT patients (23.6% vs. 10.9%, p<0.0001). All esophageal dosimetric parameters were significantly associated with G2E after adjusting for age and laterality. The cutpoints for esophageal mean dose, V10 and V20 were 11 Gy, 30%, and 15%, respectively. The associations between the dichotomized dose-volume parameters and G2E were OR=3.82 (95% CI 2.28-6.40, p<0.0001) for esophageal mean dose, OR=5.37 (95% CI 3.01-9.58, p<0.0001) for esophageal V10, and OR=3.23 (95% CI 1.93-5.41, p<0.0001) for esophageal V20.\\nIn patients receiving RNI with modern techniques, we found that G2E occurs in >15%, and more frequently with IMRT. These data strongly support the routine contouring of the esophagus in RNI planning, and our constraints should be incorporated in future prospective protocols of RNI. Estrogen receptor (ER) alpha, a ligand-dependent nuclear transcription factor encoded by the ESR1 gene, is expressed in 70% of breast carcinomas (BC) and is utilized as a target for endocrine-based therapies. However, some patients develop resistance to endocrine-based therapies due to ESR1 mutation, which leads to constitutive activation in the absence of ligand. We retrospectively analyzed 223 clinically advanced BCs using the FoundationOne CDX assay and found 13.9% (31/223) of cases had ESR1 genetic alterations (26 mutations and 5 amplifications). All ESR1 mutations occurred within the ligand binding domain, with the most prevalent being Y537S (42.3%) and D538G (38.5%), and all ESR1-mutated cases had a history of aromatase inhibitor use. No significant difference in clinicopathologic features was identified between ESR1-mutated and ESR1-amplified cases except higher frequency of HER2 positivity and TP53 mutations in ESR1-amplified cases. The prevalence of ESR1 mutations in ER positive BCs was 19.1% (26/136). In comparison to ESR1-non-mutated ER-positive cases, ESR1-mutated cases demonstrated significantly higher percentage of tumor cells with ER and PR expression, an increased tendency for overall distant metastasis and liver metastasis, higher frequency of FGF3/4/19 mutations, lower frequency of TP53 mutation, but no difference in overall survival and metastatic/recurrent intervals. In conclusion, our findings suggest that development of ESR1 mutations are selected for under the influence of estrogen deprivation, and a positive correlation between ESR1 mutations and ER protein expression may exist. Dietary phytochemicals and diet types (e.g., the Mediterranean diet) have been shown to have anti-cancer properties. However, the effects of combined treatment with dietary phytochemicals and different diet types on primary and metastatic tumor growth have yet to be investigated. The purpose of this study is to investigate the effects of phytochemicals combined with diet types on breast cancer metastasis.\\nThe inhibitory effects on breast cancer metastasis of three phytochemicals (allicin, hesperidin, astragalus polysaccharides) and two diet types (Mediterranean diet, restricted diet), separately or in combination, were evaluated based on: (i) detection of circulating tumor cells (CTCs) using an in vivo capture method; and (ii) primary tumor growth.\\nAll dietary factors significantly inhibited the growth of primary tumors and metastases, with combinations showing enhancing the effects.\\nDietary phytochemicals and diet types should be further evaluated as adjunct therapies and lifestyle modifications in cancer patients. Furthermore, the in vivo CTC capture method allows dynamic monitoring of cancer metastasis over time, providing a useful approach to evaluating treatment effects in real-time. Triple-negative breast cancer (TNBC) grows fast and represents poor prognosis and management. This work is aimed to determine the effect of concomitant use of naringenin and metformin with doxorubicin chemotherapy using in vitro and in vivo breast carcinoma models. Cell viability and xenograft study were performed using TNBC cell lines. The use of naringenin and metformin together with doxorubicin, have shown a significant increase in cytotoxicity when compared with the same concentration of doxorubicin alone in MDA-MB-231\\u202fcells and 4T1 cells in vitro. In the xenograft mouse model, a significant reduction of tumor volume and tumor weight was observed in contrast to a similar dose of doxorubicin alone; suggesting combining treatment enhanced antitumor activity in vivo. Besides, H&E and Ki-67 staining of tumor biopsies showed enhancement of the antitumor activity via increasing necrosis and inhibiting cell proliferation respectively. Additionally, there was no marked change observed in the organ weights, blood glucose, cardiac histology and cardiac Troponin I levels under the study treatment groups. The beneficial effects of using both the naringenin and metformin along with the lower dose of doxorubicin were evident from the reduced dose-related body weight loss and increase in cytokines (TNF-α and IL-1β) compared to a large dose of doxorubicin alone. Thus, naringenin and metformin combination with doxorubicin found useful as an adjunct therapy to improve the effectiveness of doxorubicin at the lower dose against the breast carcinoma. Lower socioeconomic status is associated with more advanced cancer at the time of cancer diagnosis. It is unknown whether this leads to inferior survival in low- and middle-income countries. Here, we explore the association between educational level and survival in South India.\\nThe Trivandrum Cancer Registry (3.3 million population) was used to identify all cases of breast and cervical cancer (women) and oral cavity (OC) and lung cancer (men) diagnosed during 2012-2014. Educational level was classified as illiterate/primary school, middle school, and secondary school and above. Survival was measured from date of diagnosis using the Kaplan-Meier method. Cox proportional hazards regression modeling was used to describe the associations among education, stage of cancer at diagnosis, and survival.\\nThe study population included 3,640 patients with breast (n = 1,727), cervical (n = 425), OC (n = 702), and lung (n = 786) cancer. Educational level was 27%, 23%, and 32% for illiterate/primary, middle, and secondary school and above, respectively. The 5-year survival rate for breast cancer was 59%, 68%, and 73% (\\nData from this population-based study in South India demonstrate that patients from a lower educational background have inferior survival and that this is at least partially explained by having more advanced disease at the time of diagnosis. Public health efforts are needed to facilitate timely diagnosis and reduce disparities in cancer outcomes. There is a shortage of radiation therapy service centers in low- to middle-income countries. TARGIT-intraoperative radiation therapy (IORT) may offer a viable alternative to improve radiation treatment efficiency and alleviate hospital patient loads. The Breast Care Unit in Johannesburg became the first facility in Africa to offer TARGIT-IORT, and the purpose of this study was to present a retrospective review of patients receiving IORT at this center between November 2017 and May 2020.\\nPatient selection criteria were based mainly on the latest American Society of Radiation Oncology guidelines. Selection criteria included early-stage breast carcinoma (luminal A) and luminal B with negative upfront sentinel lymph node biopsy that negated external-beam radiation therapy (EBRT). Patient characteristics, reasons for choosing IORT, histology, and use of oncoplastic surgery that resulted in complications were recorded.\\nOne hundred seven patients successfully received IORT/TARGIT-IORT. Mean age was 60.8 years (standard deviation, 9.3 years). A total of 73.8% of patients presented with luminal A, 15.0% with luminal B, and 5.6% with triple-negative cancer. One patient who presented with locally advanced breast cancer (T4N2) opted for IORT as a boost in addition to planned EBRT. Eighty-seven patients underwent wide local excision (WLE) with mastopexy, and 12 underwent WLE with parenchymal. Primary reasons for selecting IORT/TARGIT-IORT were distance from the hospital (43.9%), choice (40.2%), and age (10.3%).\\nThis retrospective study of IORT/TARGIT-IORT performed in Africa confirms its viability, with low complication rates and no detrimental effects with breast conservation, resulting in positive acceptance and the potential to reduce Oncology Center patient loads. Limitations of the study include the fact that only short-term data on local recurrence were available. Health and socioeconomic value models must still be addressed in the African setting.  Solid papillary carcinoma (SPC) is a histological subtype of breast carcinomas. At least 50% of SPC show neuroendocrine differentiation. Insulinoma-associated protein 1 (INSM1) is a transcription factor now employed as a useful neuroendocrine marker. It is suppressed by the Notch signaling pathway in other neuroendocrine tumors. However, the usefulness of INSM1 as a neuroendocrine marker and the relationships between INSM1 and NOTCH receptors in SPC of the breast currently remain unclear. To clarify the usefulness of INSM1 as a neuroendocrine marker and the relationships between INSM1 and NOTCH receptors in SPC, we performed immunohistochemistry using 19 tissue specimens of SPC of the breast. We complementarily analyzed public RNA sequencing data on breast carcinomas. Immunohistochemical examinations revealed that the staining intensity of INSM1 was significantly higher in the neuroendocrine group than in the non-neuroendocrine group. Positive correlations were observed between INSM1 and synaptophysin (SYP), or chromogranin-A (CHGA). In all cases, NOTCH 2 and 3 were positive, while NOTCH 1 and 4 were negative. According to public RNA data analyses, there were positive correlations between INSM1 and SYP, or CHGA, and negative correlations between INSM1 and NOTCH1-3. INSM1 is useful as a diagnostic marker for SPC with neuroendocrine differentiation in the breast. To study the dental and periodontal status of women with breast cancer (BCa) having tamoxifen or aromatase inhibitors (AIs) treatment in comparison with control healthy women.\\nFifty-one women on tamoxifen therapy, 52 women on AIs therapy and 52 systemically healthy controls were included in the study. The total number of teeth, the number of teeth indicated for extraction, the number of decayed teeth, and the duration of medication were recorded. Periodontal status was evaluated with gingival index (GI); plaque index (PI); bleeding on probing (BOP); probing depth (PD) and clinical attachment loss (CAL).\\nThe lowest number of teeth and decayed teeth was found in AIs users (P\\xa0<\\xa0.001 and P\\xa0=\\xa0.003 respectively). The highest CAL value was seen in AIs users (P\\xa0=\\xa0.042) whereas no significant difference was found between the groups in terms of PI, GI, and PD (P\\xa0=\\xa0.102, P\\xa0=\\xa0.233, and P\\xa0=\\xa0.306, respectively). Lower PI was observed in patients using AIs for less than 2 years (P\\xa0=\\xa0.048).\\nWhile tamoxifen did not affect the dental and periodontal condition, AIs medication adversely affected the dental and periodontal condition by more tooth loss and higher CAL. Until recently, cancer registries have only collected cancer clinical stage at diagnosis, before any therapy, and pathological stage after surgical resection, provided no treatment has been given before the surgery, but they have not collected stage data after neoadjuvant therapy (NAT). Because NAT is increasingly being used to treat a variety of tumors, it has become important to make the distinction between both the clinical and the pathological assessment without NAT and the assessment after NAT to avoid any misunderstanding of the significance of the clinical and pathological findings. It also is important that cancer registries collect data after NAT to assess response and effectiveness of this treatment approach on a population basis. The prefix y is used to denote stage after NAT. Currently, cancer registries of the American College of Surgeons\\' Commission on Cancer only partially collect y stage data, and data on the clinical response to NAT (yc or posttherapy clinical information) are not collected or recorded in a standardized fashion. In addition to NAT, nonoperative management after radiation and chemotherapy is being used with increasing frequency in rectal cancer and may be expanded to other treatment sites. Using examples from breast, rectal, and esophageal cancers, the pathological and imaging changes seen after NAT are reviewed to demonstrate appropriate staging. None Metastatic breast cancer is the second leading cause of cancer-related death in women. The 5-year survival rate for metastatic breast cancer has remained near 26.9\\xa0% for over a decade. The recruitment of hematopoietic stem cells with high expression of the vascular endothelial growth factor receptor 1 (VEGFR-1) has been implicated in early stages of metastasis formation. We propose the use of an \\nscVR1 was \\nThe [\\nThe diagnostic capabilities of the [ Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called \"CW® campaigns\" which review recommendations submitted by that country\\'s oncology societies. We performed a scoping review to consolidate CW® recommendations from different groups with respect to breast cancer care.\\nA systematic search of Medline and Embase was designed by an information specialist for publications presenting CW® recommendations for breast cancer care practices from 2011-2020. We also reviewed the websites of all CW® campaigns and reference sections of each CW® recommendation. Two reviewers independently screened studies for inclusion and performed data extraction. Findings were summarized narratively.\\nReview of ABIM CW® recommendations showed 19 breast cancer-related recommendations pertaining to; screening (n\\u2009=\\u20094), radiological staging (n\\u2009=\\u20092), treatment (n\\u2009=\\u200910), surveillance (n\\u2009=\\u20092), and miscellaneous (genetic testing; n\\u2009=\\u20091). Of 22 countries with CW® campaigns, 10 published recommendations for breast cancer. Over half (57%) of recommendations were supported by more than one country. No recommendations were refuted between campaigns. Two campaigns developed 3 novel recommendations on new topics, including chemotherapy in ductal carcinoma in situ (Italy) and comparison of screening imaging modalities (Portugal).\\nCW® recommendations focus on reducing overutilization of investigations and treatments. There was a high rate of consensus between different CW® campaigns. As health care systems globally move attention to reduce low-value care, further studies are required to address adherence to these current recommendations and develop new recommendations. Breast cancer is one of the most common cancer forms in women and it is often detected by screening. However, women with drug use disorders (DUD) are less likely to be reached by screening programs. In this study, we aimed to investigate breast cancer incidence, mortality and stage at time of diagnosis among women with DUD compared to the general female population in Sweden.\\nWe performed a follow-up study based on Swedish national register data for the period January 1997-December 2015. The study was based on 3,838,248 women aged 15-75\\xa0years, of whom 50,858 were registered with DUD. Adjusted hazard ratios (HRs) for incident and fatal breast cancer, and cancer stage at time of diagnosis, were calculated for women with and without DUD using Cox regression analysis.\\nDUD was associated with incident breast cancer (HR 1.08, 95% confidence interval [CI] 1.02-1.14, p\\u2009=\\u20090.0069), fatal breast cancer (HR 1.60, 95% CI 1.42-1.82, p\\u2009<\\u20090.001), and stage IV breast cancer, i.e. metastasis at diagnosis (HR 2.06, 95% CI 1.44-2.95, p\\u2009<\\u20090.001).\\nWomen with DUD were identified as a risk group for incident, fatal and metastasized breast cancer, which calls for attention from clinicians and policy makers. Cancer screening attendance and other healthcare seeking barriers are likely to affect the risk increase among women who use drugs; however, more research is needed on the underlying mechanisms. Conventional methods for axillary sentinel lymph node biopsy (SLNB) are fraught with complications such as allergic reactions, skin tattooing, radiation, and limitations on infrastructure. A novel technique has been developed for lymphatic mapping utilizing fluorescence imaging. This meta-analysis aims to compare the gold standard blue dye and radioisotope (BD-RI) technique with fluorescence-guided SLNB using indocyanine green (ICG).\\nThis study was registered with PROSPERO (CRD42019129224). The MEDLINE, EMBASE, Scopus, and Web of Science databases were searched using the Medical Subject Heading (MESH) terms \\'Surgery\\' AND \\'Lymph node\\' AND \\'Near infrared fluorescence\\' AND \\'Indocyanine green\\'. Studies containing raw data on the sentinel node identification rate in breast cancer surgery were included. A heterogeneity test (using Cochran\\'s Q) determined the use of fixed- or random-effects models for pooled odds ratios (OR).\\nOverall, 1748 studies were screened, of which 10 met the inclusion criteria for meta-analysis. ICG was equivalent to radioisotope (RI) at sentinel node identification (OR 2.58, 95% confidence interval [CI] 0.35-19.08, p\\u2009<\\u20090.05) but superior to blue dye (BD) (OR 9.07, 95% CI 6.73-12.23, p\\u2009<\\u20090.05). Furthermore, ICG was superior to the gold standard BD-RI technique (OR 4.22, 95% CI 2.17-8.20, p\\u2009<\\u20090.001).\\nFluorescence imaging for axillary sentinel node identification with ICG is equivalent to the single technique using RI, and superior to the dual technique (RI-BD) and single technique with BD. Hospitals using RI and/or BD could consider changing their practice to ICG given the comparable efficacy and improved safety profile, as well as the lesser burden on hospital infrastructure. P2Et extract obtained from the Caesalpinia spinosa plant is abundant in phenolic compounds such as gallic acid and ethyl gallate and can generate signals to activate the immune response by inducing a mechanism known as immunogenic cell death in murine models of breast cancer and melanoma. Immunogenic cell death involves mechanisms such as autophagy, which can be modulated by various natural compounds, including phenolic compounds with a structure similar to those found in P2Et extract. Here, we determine the role of autophagy in apoptosis and the generation of immunogenic signals using murine wild-type B16-F10 melanoma cells and cells with beclin-1 gene knockout. We show that P2Et extract and ethyl gallate induced autophagy, partially protecting tumor cells from death and promoting calreticulin exposure and the release of ATP. Although ethyl gallate showed a mechanism similar to that of P2Et, the induction of apoptosis and immunogenic signals was significantly weaker. In contrast, gallic acid-induced autophagy acted by blocking autophagic flux, which was associated with increased cell death. However, this compound did not induce any of the immunogenic death signals evaluated. Therefore, the complex extract has greater antitumor potential than isolated compounds. Here, we show that inducing autophagic flux with P2Et protects cancer cells from cell death and that this delay in cell death is required for the generation of immunogenic signals. None To implement and evaluate outcomes from a comprehensive, multi-disciplinary debulking program in the United States.\\nInterest in and access to surgical treatment for chronic lymphedema (LE) in the United States have increased in recent years, yet there remains little attention on liposuction, or debulking, as an effective treatment option. In some other countries, debulking is a common procedure for the surgical treatment of LE, is covered by insurance, and has demonstrated excellent, reproducible outcomes. In this study we describe our experience implementing a debulking technique from Sweden in the United States.\\nPatients who presented with chronic lymphedema followed a systematic multi-disciplinary work-up. For debulking with power assisted liposuction, the surgical protocol was modeled after that developed by Håkan Brorson. A retrospective review of consecutive patients who underwent debulking at our institution was conducted.\\nBetween December 2017 and January 2020, 39 patients underwent 41 debulking procedures with power assisted liposuction, including 23 upper and 18 lower extremities. Mean patient age was 58 years and 85% of patients had LE secondary to cancer, the majority of which (64%) was breast cancer. Patients experienced excess volume reductions of 111% and 115% in the upper and lower extremities, respectively, at one year post-operatively. Overall quality of life (LYMQOL) improved by a mean of 33%. Finally, patients reported a decreased incidence of cellulitis and decreased reliance on conservative therapy modalities post-operatively.\\nDebulking with power assisted liposuction is an effective treatment for patients with chronic extremity lymphedema. The operation addresses patient goals and improves quality of life, and additionally reduces extremity volumes, infection rates and reliance on outpatient therapy. A comprehensive, multi-disciplinary debulking program can be successfully implemented in the United States healthcare system. None This study aimed to investigate the feasibility and accuracy of non-radioactive target lymph node (TLN) biopsy and targeted axillary dissection (TAD) in routine clinical practice.\\nTAD involves TLN biopsy (TLNB) and sentinel lymph node biopsy (SLNB) and was recently introduced as a new standard for less invasive axillary staging in breast cancer (BC) patients undergoing neoadjuvant systemic therapy (NST); however, clinical evidence is limited.\\nThe SenTa study is a prospective registry study conducted at 50 centers. Patients with invasive BC who underwent clip insertion into the most suspicious axillary lymph node (LN) were eligible. Axillary surgery was performed with or without SLNB, TLNB, and/or axillary lymph node dissection (ALND). Main endpoints were the detection rate (DR) and false-negative rate (FNR) of TLNB and TAD after NST.\\nBetween 2017 and 2018, 548 consecutive BC patients underwent clip placement into biopsy-confirmed positive LNs. After NST (n = 473), the clipped TLN was intraoperatively resected in 329 of 423 patients (77.8%, 95% confidence interval [CI]: 74.0 to 82.0). TAD was successful in 199 of 229 patients (DR: 86.9%, 95% CI: 81.8 to 91.0), the SLN and TLN were identical in 129 patient (64.8%). FNRs were 7.2% (8 of 111, 95% CI: 3.1 to 13.6) for TLNB followed by ALND (n = 203) and 4.3% (2 of 46, 95% CI: 0.5 to 14.8) for TAD followed by ALND (n = 77).\\nThe SenTa study demonstrates the feasibility of TAD in a real-world cohort of BC patients. Our findings are of great importance for de-escalation of surgical strategies. Metastatic involvement of the thyroid cartilage is rare due to the absence of vessels within the cartilaginous tissue. We present the case of a 65-year-old woman recently diagnosed with breast cancer referred for skeletal staging with F-NaF PET/CT. She was found to have multiple osteoblastic metastases along with thyroid cartilage metastasis. Rare thyroid cartilage metastasis on F-NaF PET/CT may have prognostic significance in cancer patients. Depressive symptoms are highly prevalent in breast cancer patients. These symptoms can contribute to lower treatment adherence, increased healthcare charges, and higher mortality rates. Growing evidence suggests that genetic variations may be associated with depressive symptom susceptibility.\\nTo comprehensively review current findings on the association of genetic variations with depressive symptoms in breast cancer patients.\\nA literature search was conducted using keywords such as gene variation, single-nucleotide polymorphism, depression/depressive symptoms, and breast cancer. Four hundred articles were retrieved from PubMed, Web of Science, CINAHL, and PsycINFO, yielding 9 full-text, data-based articles. The study quality was assessed using the STrengthening the REporting of Genetic Association studies guideline.\\nGenetic polymorphisms in brain-derived neurotrophic factor (BDNF), interferon γ receptor 1 (IFNGR1), interleukin-6 (IL-6), tumor necrosis factor α (TNFA), and IL-1B were found to be associated with depressive symptoms among breast cancer patients. The role of serotonin transporter gene linked promotor region (5-HTTLPR) functional polymorphisms on depressive symptoms was inconclusive. The overall quality of reporting results and methods was medium.\\nThis is the first review of genetic variations related to differences in levels of depressive symptoms among breast cancer patients. Genetic polymorphisms in inflammatory, neuronal system, and signal transduction pathways can influence the susceptibility. However, more research regarding this topic is needed to further clarify genetic risk factors.\\nHealthcare providers may determine patients at higher risk of developing depression and symptom outcomes if genetic biomarkers with good sensitivity/specificity are provided. This knowledge can potentially help the development of personalized treatment and decision making for those patients. A number of novel furo[2,3-b]quinoline derivatives were designed and synthesized by introducing different substituted anilines and phenols to C4-position of furo[2,3-b]quinoline. All target compounds were evaluated in vitro against two human breast cancer cell lines (MCF-7 and MDA-MB-231) and one normal breast cell (MCF-10A) by MTT (3-[4,5-dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium broide, Thiazolyl blue) method. Most derivatives showed significant cytotoxic activity on the two breast cancer cells with IC50 values in the range of (5.60-26.24 μM) and a certain selectivity, especially in the inhibition of MDA-MB-231. More notably, they were less toxic to normal breast cell (MCF-7-10A). Compound I7 could be considered as ideal selective candidate for further study. Mechanism studies showed that I7 could inhibit the proliferation of cells by arresting MDA-MB-231 cell cycle at G2/M phase. Overall, as a novel furo[2,3-b]quinoline derivative, I7 exhibited excellent inhibitory effect in MDA-MB-231 cell and was worthy of in-depth study. Triple negative breast cancer present aggressive form of breast cancer subtype which further lacks efficient treatment strategies and prognostic markers. Genomic heterogeneity in TNBC has led to the relapse of tumor and cancer stem cells with higher likelihood of distal metastasis. Several studies supported the notion that miRNAs may act as oncogene or tumor suppressors in TNBC. miRNAs may function as global regulator of TNBC by targeting post transcriptional regulation of several genes involved in influencing metastatic events but the exact mechanism involved in inducing the effect is yet to be elucidated. In this review, we summarized miRNA expression which can functionally suppress metastatic cascade in TNBC by targeting epithelial to mesenchymal transition, metastatic colonization, cancer stem cells, invasion, migration and metastasis. miRNAs may appear as metastatic biomarker to predict distal reoccurrence of TNBC in lungs, brain and lymph nodes. miRNA can act as prognostic marker in metastatic TNBC thereby predicting overall survival, disease free survival and distant metastasis free survival in affected patients. The present review article is an attempt to gain an insight into repertoire of miRNA that may emerged out as an effective treatment strategy, novel biomarker of distal reoccurrence and prognostic marker in metastatic TNBC. The Tip60 lysine acetyltransferase is a tumor suppressor in most cancers but an oncogene in prostate and gastric cancer. Tip60 is commonly found in the nucleus, where it acetylates proteins involved in transcription, DNA repair, and chromatin; however, it has also been shown to acetylate cytoplasmic targets. In this study, we investigated the relationship between Tip60 localization and breast and lung cancer. In cell fractionation experiments, cancer-derived cell lines showed a shift from nuclear to cytoplasmic endogenous Tip60 compared with cell lines derived from normal cells. With immunofluorescence, we observed four different localization patterns of overexpressed Tip60 and found that cancer cells had increased cytoplasmic localization of Tip60 compared with HEK-293 cells. The addition of a nuclear localization signal (NLS) increased the number of cells containing nuclear Tip60, whereas mutation of a putative endogenous NLS increased the number of cells with cytoplasmic Tip60. Overexpression of Tip60 increased cancer cell line sensitivity to paclitaxel regardless of changes in localization. These results suggest that dysregulation of Tip60 in breast and lung cancer is not limited to reduced expression but may also involve subcellular localization. Rational design of stimuli-responsive polymers for cytosolic protein delivery with robust efficiency is of great importance but remains a challenging task. Here, we reported a bioreducible and amphiphilic dendrimer bearing a fluoroalkyl tail for this purpose. The fluorolipid was conjugated to the focal point of a cysteamine-cored polyamidoamine dendrimer via disulfide bond, while phenylboronic acid moieties were decorated on dendrimer surface for efficient protein binding. The yielding polymer showed high protein binding capability and complex stability and could efficiently release the cargo proteins in a glutathione-responsive manner. The designed polymer was effective in the delivery of various membrane-impermeable proteins into living cells with reserved bioactivities. In addition, the polymer efficiently delivered a toxin protein saporin into 4T1 breast cancer cells and inhibited the tumor growth  Triple‑negative breast cancer (TNBC) is one of the most aggressive types of breast cancer, and there is no effective therapeutic target to date. Natural killer (NK) cells are functionally diverse lymphocytes that recognize and kill cancer cells. Although it is clear that NK cells exert antitumor activity in the tumor microenvironment, their role in the aggressive progression of TNBC has not been elucidated in detail. In the present study, we investigated the effect of NK cells on MDA‑MB‑231 TNBC cells using an indirect co‑culture system. The invasive phenotype of MDA‑MB‑231 cells was significantly inhibited by co‑culture with NK cells. Notably, the expression of urokinase‑type plasminogen activator (uPA) was markedly reduced by NK cells. Cytokine array analysis showed that the levels of interleukin (IL)‑10, IL‑6, IL‑8, C‑C motif ligand (CCL)5, and CCL2 were increased in conditioned media from the co‑cultured cells. Among these cytokines, IL‑6 played a crucial role in the NK cell‑induced uPA downregulation and inhibition of the invasive phenotype of MDA‑MB‑231 cells and Hs578T cells. We analyzed the Gene Expression Profiling Interactive Analysis database for correlations between IL‑6 and uPA with the overall survival of breast cancer patients. The Kaplan‑Meier survival analysis revealed that a low IL‑6/uPA ratio was associated with the poor survival of breast cancer patients, suggesting it as an important factor for determining the overall survival of breast cancer patients. Taken together, our findings demonstrate that NK cells in the tumor microenvironment inhibit the invasiveness of TNBC cells through the IL‑6‑mediated inhibition of uPA. Estrogen receptor alpha (ERα) acts as the transcription factor and the main therapeutic target against breast cancer. One of the compounds that has been shown to act as an ERα is α-mangostin. However, it still has weaknesses due to its low solubility and low potent activity. In this study, α-mangostin was modified by substituting -OH group at C6 using benzoyl derivatives through a step by step  Ulcerative ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by the presence of continuous, uniform, gapless lesions of healthy mucous membrane extending integrally from the anus over a variable portion of the colon. It is a multisystemic pathology for which we will describe one of its hepatic manifestations, primary sclerosing cholangitis (PSC). We present here the story of a patient, a carrier of the Breast Cancer type 1 gene mutation (BRCA1), who initially presented with epigastric and peri-umbilical abdominal pain associated with several episodes of bloody diarrhea. The initial assessment made it possible to diagnose BRCA1 and the fortuitous discovery of biliary tract stenosis of an undetermined nature. Further investigations led to the conclusion that there was a strong presumption of UC associated with PSC or even cholangiocarcinoma (CCA). In the course of treatment, cancer of the gallbladder was also detected. This clinical case makes it possible to review, in the light of recent publications, the pathophysiological link existing between UC and PSC. This article also presents an in-depth analysis of this entity with malignant potential that can affect different sites of the digestive tract, and its own management, which is the subject of new recommendations.\\nLa rectocolite ulcéro-hémorragique (RCUH) est une maladie inflammatoire chronique de l’intestin, caractérisée par la présence de lésions continues, uniformes et sans intervalle de muqueuse saine, s’étendant d’un seul tenant à partir de l’anus sur une portion variable du côlon. Il s’agit d’une pathologie multisystémique pour laquelle nous décrirons une de ses manifestations hépatiques, la cholangite sclérosante primitive (CSP). Nous exposons ici l’histoire d’un patient, porteur de la mutation du gène Breast Cancer de type 1 (BRCA1), s’étant initialement présenté pour douleurs abdominales épigastriques et péri-ombilicales, associées à plusieurs épisodes de diarrhées sanglantes. Le bilan initialement réalisé a permis de poser le diagnostic de RCUH ainsi que la mise en évidence fortuite d’une sténose des voies biliaires de nature indéterminée. Les explorations complémentaires ont permis de conclure à une forte présomption de RCUH associée à une CSP, voire un cholangiocarcinome (CCA). Dans le décours de la prise en charge, un cancer de la vésicule biliaire a également été mis en évidence. Ce cas clinique permet de revoir, à la lumière des publications récentes, le lien physiopathologique existant entre la RCUH et la CSP. L’article présente une analyse approfondie de cette entité qui possède un potentiel malin important, touchant plusieurs organes du tractus digestif, et qui requiert une prise en charge propre faisant l’objet de recommandations nouvelles. Mesenchymal stroma/stem-like cells (MSCs) have antitumour activity, and MSC-derived exosomes play a role in the growth, metastasis and invasion of tumour cells. Additionally, glycoprotein A repetition predominant (GARP) promotes oncogenesis in breast cancer. Therefore, GARP is speculated to be a target gene for cancer therapy. We aimed to explore the therapy role of MSC-derived exosomes targeting GARP in mouse colon cancer cell MC38. We successfully established a GARP knockdown system using three kinds of siRNA-GARP in MSC cells. Exosomes were isolated from MSC and siGARP-MSC cells, and verified by the exosome surface protein markers CD9, CD63 and CD81. GARP expression was significantly decreased in siGARP-MSC exosomes compared with that of MSC exosomes. We found that siGARP-MSC exosomes inhibited cell proliferation, migration and invasion of MC38 cells, using CCK-8, colony formation, wound-healing and Transwell invasion assays. Furthermore, siGARP-MSC exosomes impeded IL-6 secretion and partly inactivated JAK1/STAT3 pathway, measured using ELISA and RT-qPCR. In conclusion, MSC-derived exosomes targeting GARP are a potential strategy for cancer therapy. We report a series of hybrid quinazoline-1,3,5-triazine derivatives as EGFR inhibitors, which were synthesized and tested using a variety of in vitro, in silico, and in vivo studies. The derivatives were found to be active against different cancer and non-toxic against normal cell lines, with compounds 7c , 7d , 7e , and 7j being the most potent ones. The derivatives were also evaluated for angiogenesis inhibition potency in chicken eggs and molecular docking and dynamics simulation studies were carried out to elucidate fundamental substituent groups essential for their bioactivity. Additionally, a SAR study of the derivatives was performed for future compound optimization. These studies suggested that the derivatives have a high affinity towards EGFR with favourable pharmacological properties. The most active compound ( 7e ) was further evaluated for in vivo anticancer activity against DMBA induced tumour in female Sprague-Dawley rats as well as its effects on plasma antioxidant status, biotransformation enzymes, and lipid profile. The study suggested that the 7e compound has lead properties against breast cancer and can serve as a starting compound for further development of anti-EGFR compounds. Neoantigens have attracted attention as biomarkers or therapeutic targets. However, accurate prediction of neoantigens is still challenging, especially in terms of its accuracy and cost. Variant detection using RNA sequencing (RNA-seq) data has been reported to be a low-accuracy but cost-effective tool, but the feasibility of RNA-seq data for neoantigen detection has not been fully examined. In this study, we used whole-exome sequencing (WES) and RNA-seq data of tumor and matched normal samples from six breast cancer patients to evaluate the utility of RNA-seq data instead of WES data in variant calling to detect neoantigen candidates. Somatic variants were called in three protocols using: (1) tumor and normal WES data (DNA method, Dm); (2) tumor and normal RNA-seq data (RNA method, Rm); and (3) combination of tumor RNA-seq and normal WES data (Combination method, Cm). We found that the Rm had both high false-positive and high false-negative rates because this method depended greatly on the expression status of normal transcripts. When we compared the results of the Dm with those of the Cm, only 14% of the neoantigen candidates detected in the Dm were identified in the Cm, but the majority of the missed candidates lacked coverage or variant allele reads in the tumor RNA. On the other hand, about 70% of the neoepitopes with higher expression and rich mutant transcripts could be detected in the Cm. Our results showed that the Cm could be an efficient and a cost-effective approach to predict highly expressed neoantigens in tumor samples. Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor-infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses. Analysis of breast cancer and cancer tissue after neoadjuvant chemotherapy (nCT) may be helpful to find new biomarkers. It is known that long non-coding RNAs (lncRNAs) are involved in the carcinogenic pathway and drug resistance of breast cancer. Our aim was to determine the role of LINC02544 in the behavior and outcome of post-nCT breast cancer.\\nThe expression level of LINC02544 in breast cancer and its effect on the survival time of patients were predicted by lnCAR database. In vitro, EdU, Wound-healing and transwell assays were used to detect the effects of LINC02544 on the proliferation, migration and invasion of MCF-7 cells, and the related regulatory networks were analyzed by the database. Quantitative Reverse Transcriptase-Polymerase Chain Reaction (QRT-PCR) was used to detect the expression of LINC02544 in 147 cases of nCT before and after treatment, and the relationship between the expression of LINC02544 and survival time and clinicopathological features was analyzed.\\nLINC02544 was highly expressed in breast cancer and led to poor prognosis. Overexpression of LINC02544 promoted proliferation, invasion and migration of breast cancer cells. Compared with the residual tumor after nCT with low expression of LINC02544, the high expression of LINC02544 in the residual tumor after nCT was significantly correlated with overall survival and disease-free survival.\\nIn this study, it is suggested that LINC02544 has a potential application prospect as a biomarker and therapeutic target for breast cancer patients and neoadjuvant therapy patients. Emotional distress associated with genetic testing for hereditary breast and ovarian cancer syndrome (HBOC) is reported to interfere with adherence to treatment and prophylactic measures and compromise quality of life.\\nTo determine levels of anxiety, depression, and quality of life in patients tested for pathogenic BRCA1/2 mutations and identify risk factors for the development of adverse psycho-emotional effects.\\nCross-sectional observational trial involving 178 breast or ovarian cancer patients from a referral cancer hospital in Northeastern Brazil. Information was collected with the Hospital Anxiety and Depression Scale (HADS) and the World Health Organization (WHO) Quality of Life (QoL) questionnaire (WHOQOL-BREF).\\nPatients suspected of HBOC had higher levels of anxiety than depression. The presence of (probably) pathogenic BRCA1/2 mutations did not affect levels of anxiety and depression. High schooling, history of psychiatric disease, and use of psychotropic drugs were directly associated with high anxiety. High schooling was too inversely associated with QoL as such a breast tumor. Anxiety and depression were directly correlated and both reduced significantly QoL.\\nOur results highlight the importance of psychological support and screening of risk factors for anxiety and depression and low QoL in HBOC patients at the time of testing. Breast cancer is the most common female malignancy worldwide. Breast surgery and adjuvant oncological therapies are often required to increase survival. Treatment-related pain may persist and evolve into postmastectomy pain syndrome (PMPS) in a significant subset of breast cancer survivors. In this retrospective investigation, we will present our experience in applying an interventional algorithmic approach to treat PMPS.\\nA retrospective study.\\nAn academic cancer hospital.\\nAdult females with PMPS diagnosis.\\nWe reviewed 169 records with the diagnosis of PMPS from 2015 to 2019 within our health system. Pre- and post-injection pain scores, relief duration, and medication usage changes were collected. The decision to perform each procedure was based on the anatomic location of the painful area with the corresponding peripheral sensory innervation. Decision-making flow diagrams were created to present our experience in managing PMPS beyond peripheral nerve blocks.\\nUltrasound-guided peripheral nerve block results (n=350) were analyzed. The mean baseline pain score was 7, compared with the post-treatment mean score of 3 (95% confidence interval: 3.58 to 3.98, P\\u2009=\\u20090.0001). Among the responders, the mean pain relief duration was 45\\u2009days, with a median of 84\\u2009days. Opioid medication consumption was reduced by 11% (t\\u2009=\\u20090.72, P\\u2009=\\u20090.47).\\nUltrasound-guided nerve blocks of this area could be performed safely and effectively after breast surgeries. We also present our proposed algorithm to provide a stepwise application for selecting the appropriate therapies in the management of more complex PMPS. Joint models for longitudinal and time-to-event data are increasingly used for the analysis of clinical trial data. However, few methods have been proposed for designing clinical trials using these models. In this article, we develop a Bayesian clinical trial design methodology focused on evaluating the treatment\\'s effect on the time-to-event endpoint using a flexible trajectory joint model. By incorporating the longitudinal outcome trajectory into the hazard model for the time-to-event endpoint, the joint modeling framework allows for non-proportional hazards (e.g., an increasing hazard ratio over time). Inference for the time-to-event endpoint is based on an average of a time-varying hazard ratio which can be decomposed according to the treatment\\'s direct effect on the time-to-event endpoint and its indirect effect, mediated through the longitudinal outcome. We propose an approach for sample size determination for a trial such that the design has high power and a well-controlled type I error rate with both operating characteristics defined from a Bayesian perspective. We demonstrate the methodology by designing a breast cancer clinical trial with a primary time-to-event endpoint and where predictive longitudinal outcome measures are also collected periodically during follow-up. Accurate measurement of very low circulating estradiol (E [This corrects the article on p. 141 in vol. 23, PMID: 32395374.]. [This corrects the article on p. 355 in vol. 23, PMID: 32908787.]. [This corrects the article on p. 205 in vol. 23, PMID: 32395379.]. Primary pleomorphic liposarcoma of the breast is rare, and only a few cases in the literature have reported imaging findings. Herein, we report a rare case of primary pleomorphic liposarcoma of the breast in a 38-year-old woman and describe the imaging findings including mammography, ultrasonography, computed tomography, magnetic resonance imaging, and  Ectopic male breast cancer is very rare. Consequently, there is a lack of prospective clinical trials, and most recommendations for treatment are based on the experiences of clinicians and data from female breast cancer patients. The United States Food and Drug Administration has recently approved palbociclib combined with endocrine therapy for advanced male breast cancer because of the positive results of its use in metastatic female breast cancer. Therefore, it is worth considering cyclin-dependent kinase 4/6 inhibitors as alternatives to conventional chemotherapies for advanced male breast cancer patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative cancers. The present case report introduces the use of palbociclib plus letrozole as first-line therapy for an elderly male patient with relapsed ectopic breast cancer, notwithstanding the limitations of the current national health insurance policy. The combination of luteinizing hormone-releasing hormone analogs (LHRHa) with tamoxifen is used as a standard postoperative adjuvant therapy in patients with hormone receptor-positive/premenopausal breast cancer. Long-acting LHRHa formulations offer advantages in terms of patient convenience. However, data on the effectiveness of the 3-month (3M) acting formulation are still insufficient. This study was performed on patients who received the 3M LHRHa after surgery. The serum estradiol (E2) and follicle-stimulating hormone levels were measured before surgery, and periodically after surgery. In total, 318 patients were included in the study and analyzed. The mean E2 level before surgery was 63.7 pg/mL, while the mean E2 level during the administration of 3M LHRHa was 4.9 pg/mL. None of the patients were menstruating and had E2 values above 30.0 pg/mL. It is thought that the 3M LHRHa formulation can suppress the ovarian function effectively and be safely used to improve compliance. Prior to the coronavirus disease 2019 (COVID-19) pandemic, telehealth was rarely utilized for oncologic care in metropolitan areas. Our large New York City based outpatient breast/gynecologic cancer clinic administered an 18-question survey to patients from March to June 2020, to assess the perceptions of the utility of telehealth medicine. Of the 622 patients, 215 (35%) completed the survey, and of the 215 respondents, 74 (35%) had participated in a telehealth visit. We evaluated the use of telehealth services using the validated Service User Technology Acceptability Questionnaire. Sixty-eight patients (92%) reported that telehealth services saved them time, 54 (73%) reported telehealth increased access to care, and 58 (82%) reported telehealth improved their health. Overall, 67 (92%) of patients expressed satisfaction with the use of telehealth services for oncologic care during the COVID-19 pandemic. Telehealth services should be carefully adopted as an addition to in-person clinical care of patients with cancer. Seroma formation is a common complication in breast cancer patients undergoing mastectomy, and it negatively affects patient recovery after surgery. The present study aimed to evaluate a simple method using fascia suture technique to fix the flap and reduce the incidence of seroma.\\nA single-center, prospective, randomized controlled trial was carried out among 160 patients who had undergone mastectomy from May 2018 to September 2019. All patients were randomly divided into the fascia suture group (n = 80) or control group (n = 80) and were followed up for at least 3 months for the assessment of immediate and late complications after surgery.\\nNo significant differences were observed between the 2 groups with regard to the basic characteristics. Duration of surgery in the fascia suture group was longer by about 6 minutes compared with that in the control group (114.93 ± 13.67 minutes vs. 108.81 ± 15.20 minutes, \\nThe fascia suture technique is a simple and effective method for reducing seroma formation and should be used to prevent seroma formation after mastectomy.\\nChinese Clinical Trials Registry Identifier: ChiCTR1800015913. The regimen including concurrent docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as an important risk factor for febrile neutropenia (FN). This comparative study examined the clinical impact of long-acting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) during adjuvant TAC chemotherapy in Korean patients with advanced breast cancer.\\nWe analyzed data from 239 patients who received 6 cycles of adjuvant TAC chemotherapy. We categorized patients into 2 groups according to the use of primary prophylactic pegfilgrastim and compared the incidence and risk of FN, hospital care costs, and survival in the 2 groups.\\nThe incidence of FN decreased from 54.2% to 21.2% in all patients, after the use of pegfilgrastim. The analysis of a total of 1,432 chemotherapy cycles showed that the incidence of FN decreased from 36.1% to 9.1% after the use of pegfilgrastim. Moreover, the decrease in the incidence of FN with the use of pegfilgrastim resulted in a significant decrease in the mean duration of neutropenia (4.15 to 1.29 days), the risk of hospitalization (99.5% to 29.7%) and the mean total hospital care cost (USD 3,038 to USD 2,347). High relative dose intensity (RDI) in patients treated with pegfilgrastim than in those not treated with pegfilgrastim (99.18% vs. 93.85%) was associated with a better overall survival (\\nThe use of pegfilgrastim during adjuvant TAC chemotherapy was significantly associated with a decrease in the incidence and risk of FN, hospital care costs, and risk of death compared to the use of adjuvant TAC without primary prophylaxis. Gamma-glutamyl transferase (GGT) has been reported as being involved in tumor progression. Previous studies documented a potential relationship between serum GGT level and survival outcome in several types of human malignancies. However, the association between serum GGT levels and response to neoadjuvant chemotherapy (NAC) has not yet been reported. The present study aimed to evaluate the association between pre-therapeutic serum GGT level and the efficacy, long-term survival, and adverse reactions of NAC and to investigate its role in predicting NAC sensitivity in patients with breast cancer.\\nA total of 129 patients were recruited and stratified into 2 groups according to serum GGT level (< 29 U/L and ≥ 29 U/L). The association between pre-therapeutic serum GGT levels and clinicopathological parameters was examined. The correlation between pre-therapeutic serum GGT levels and pathological complete response (pCR) was analyzed using univariate and multivariate logistic regression. Survival analyses of relapse-free survival (RFS) and disease-free survival (DFS) were performed. Pearson\\'s χ\\nPre-therapeutic serum GGT levels were associated with pCR among breast cancer patients treated with NAC. Multivariate analysis showed that low-level GGT significantly increased pCR rate. Patients in the high-level GGT group had poorer survival than those in the low-level GGT group. Subgroup analysis demonstrated that serum GGT level was potentially related to RFS and DFS in the hormone receptor-positive group. Low levels of GGT are significantly associated with a higher incidence of neutropenia.\\nPre-therapeutic serum GGT level is an independent and novel biomarker for predicting the efficiency, prognosis, and adverse reactions to NAC in breast cancer patients. Patients with low pre-therapeutic serum GGT levels are more likely to have higher pCR rates, better RFS and DFS, and higher hematologic toxicity.\\nClinicalTrials.gov Identifier: NCT02199418, NCT02221999. The prognostic implications of serum vitamin D status after a 5-year adjuvant endocrine therapy on the risk of late recurrence among hormone receptor (HR)-positive breast cancer patients remain unclear. Hence, we investigated this among Korean HR-positive breast cancer patients.\\nA total of 455 patients with HR-positive stage I-III invasive breast cancer who underwent curative surgery at St. Vincent\\'s Hospital between February 2004 and April 2012 were included in this retrospective study. Patients were categorized based on their serum 25-hydroxyvitamin D (25(OH)D) levels after the 5-year adjuvant endocrine therapy. Initial recurrence sites were categorized. The primary clinical outcome was late recurrence-free survival (LRFS).\\nAmong the 455 patients, 242 and 213 were included in the 25(OH)D-deficient group and 25(OH)D-sufficient group, respectively. Forty-eight patients experienced late recurrence. Across all recurrence sites, the 25(OH)D-deficient group showed significantly worse LRFS rates than the 25(OH)D-sufficient group (hazard ratio [HR], 2.284; 95% confidence interval [CI], 1.155-4.515; \\nWe found that 25(OH)D deficiency after the 5-year adjuvant endocrine therapy was associated with worse LRFS among HR-positive breast cancer patients, particularly with respect to regional LN, bone, and visceral recurrence. In 2007, the American Society of Clinical Oncology and the College of American Pathologists had established a human epidermal growth factor receptor 2 (HER2) testing guideline, which was updated in 2013 and subsequently in 2018. We assessed the clinical impact of the recent update by comparing the \\nWe assessed 2 cohorts. The first cohort included 1,161 primary invasive breast cancer (IBC) samples including 18 bilateral IBC cases, with both immunohistochemistry (IHC) and silver-enhanced ISH (SISH) results available for the HER2 status. The second cohort included 160 IBC cases with equivocal HER2 IHC, assessed using SISH. We retrospectively evaluated and compared the HER2 SISH results.\\nThere were 22 (1.9%) and 20 (12.5%) cases with altered SISH results according to the 2013 guidelines in cohorts 1 and 2, respectively. As per the 2018 guidelines, final HER2 statuses of 16 (1.4%) and 14 (8.5%) cases changed in cohorts 1 and 2, respectively. The 2013 guidelines increased the positive rate compared to the 2007 guidelines, in both cohorts (0.6% and 6.2%, respectively). Most equivocal cases in cohorts 1 (92.3%) and 2 (100%) as per the 2013 guidelines were reclassified as HER2-negative according to the 2018 guidelines. The 2018 guidelines increased the negative rates (1.3% in cohort 1 and 8.7% in cohort 2) and slightly decreased the positive rates (-0.2% in cohort 1 and -3.1% in cohort 2), compared to the 2013 guidelines. With each update, minor changes in the positive and negative rates were observed in whole breast cancer samples (cohort 1). However, the 2018 guidelines affected previously defined HER2-positive IBC with equivocal IHC results.\\nUnder the 2013 guidelines, the positive and equivocal cases increased. However, the 2018 guidelines eliminated ambiguous cases by reclassifying them as HER2-negative. We aimed to explore what kind of endocrine treatments are optimal for hormone receptor-positive and human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer in some specific clinical situations. We searched randomized controlled trials in Embase, Medline, the Cochrane library, and PubMed from inception to April 1, 2020 and performed a network meta-analysis based on a Bayesian fixed-effects model. Progression-free survival (PFS) with hazard ratios and corresponding 95% confidence interval was defined as the primary endpoint, while overall survival (OS), objective response rate (ORR), clinical benefit rate and serious adverse events were used as secondary endpoints. A total of 35 studies involving 12,285 patients and 24 treatment options were included. In general, most co-treatment options prolonged PFS compared to single-agent therapy, of which aromatase inhibitor (AI) plus everolimus and fulvestrant plus palbociclib were probably the most effective agents, and the latter had the best safety record. However, despite the superior efficacy of fulvestrant plus capecitabine for PFS and OS, palpable toxic effects have been demonstrated for this treatment, so its application must be scrupulously considered. The results of subgroup analysis indicated that fulvestrant combined with palbociclib improved prognosis for phosphatidylinositol 3-kinase (PI3K)-mutated patients, PI3K-unmutated patients, patients with endocrine therapy resistance, and visceral metastatic patients, while no obvious improvement was detected in OS. Moreover, the efficacy of fulvestrant plus cyclin-dependent kinase 4/6 (CDK4/6) inhibitors was slightly better than that of AI plus CDK4/6 inhibitors, while AI plus everolimus was more efficacious than fulvestrant combined with everolimus in terms of PFS, OS, and ORR. In conclusion, our results provide moderate evidence that fulvestrant plus palbociclib and AI plus everolimus were the most effective treatments, while the efficacy and safety of fulvestrant plus palbociclib was obviously superior in some specific clinical situations. Breast cancer is the most common malignancy among women. Therefore, it is of paramount importance to study the adverse effects of oncological treatment of breast cancer, with one of adverse effects being pulmonary fibrosis (PF). PF is an irreversible condition and can significantly reduce the quality of life. Following lumpectomy, radiotherapy is the standard adjuvant treatment for breast cancer. Additionally, hormone receptor-positive breast cancers are treated with adjuvant hormonal therapy. While radiotherapy is one of the known causes of PF, the effect of hormone therapy on its development is not well-defined. Some studies have shown that the concomitant administration of endocrine therapy, primarily tamoxifen, and irradiation may potentiate the development of PF. However, guidelines regarding the timing of hormone therapy administration with respect to adjuvant radiotherapy are not clearly defined. This review aims to provide a comprehensive overview of the available information regarding the effect of hormone therapy and its timing of administration with respect to adjuvant radiotherapy on the incidence of PF. The rarity of male breast cancer continues to limit its study despite increasing incidence rates, particularly within the past decade [Speirs V, Shaaban AM. The rising incidence of male breast cancer.  The aim of the present study was to determine the efficacy and safety of lapatinib-based treatment for patients with human epidermal growth factor receptor-2-positive (HER2 Sentinel lymph nodes (SLNs) are the first lymph nodes that receive lymphatic drainage from the breast. However, all stained lymph nodes are dissected as SLNs during surgery. The present study aimed to identify and preserve the stained non-SLNs and evaluate the safety during sentinel lymph node biopsy (SLNB) in breast cancer. SLNB was performed with a methylene blue and indocyanine green double-tracer technique. The first lymph node, which was connected with lymphatic vessels from the breast, was designated as the true SLN. The lymph node that was directly connected with the output lymphatic duct of the SLN was defined as post-SLN (poSLN), whereas the stained poSLN was designated as non-SLN. Both the stained SLN and non-SLN were sent to the pathological department for definitive diagnosis. The present study demonstrated that intraoperative dissection of the lymphatic network could distinguish true SLNs and stained non-SLNs. The number of stained lymph nodes was time-dependent. Not all stained lymph nodes were real SLNs, whereas the poSLNs would be stained if the staining time interval was inappropriate. The data indicated that the poSLNs were negative for metastasis when the SLNs were negative for metastasis. Stained lymph nodes may contain non-SLNs in addition to SLNs. Resection of all stained lymph nodes is not recommended. To reduce the morbidity due to SLNB complications, the identification and preservation of stained non-SLNs during SLNB is feasible and warrants further study in the era of precision medicine. Osteosarcoma (OS) is a type of primary bone tumor, which is one of the leading causes of cancer-related death. MicroRNA (miR)-605 has been demonstrated to act as a prognostic biomarker and therapeutic target in various cancers, such as breast cancer and non-small cell lung cancer, but its function in OS remains unclear. The aim of the present study was to investigate the prognostic value of miR-605 in patients with OS by evaluating its expression levels and to explore the biological function of miR-605 in OS progression. For this purpose, tumor tissues and adjacent normal tissues were collected from OS patients, and the expression of miR-605 in the collected tissues and OS MG63, U2OS, HOS, and SAOS-2 cell lines was detected by quantitative real-time PCR. The prognostic value of miR-605 was evaluated by Kaplan-Meier survival curves and Cox regression analysis. The effects of miR-605 on OS cell proliferation, migration and invasion were analyzed by the CCK-8 and transwell assays, respectively. The results of the present study revealed that miR-605 was significantly downregulated in OS tissues compared with adjacent normal tissues, which was associated with the clinical stage and distant metastasis of patients. Additionally, the downregulation of miR-605 predicted the poor prognosis of patients with OS and served as an independent prognostic indicator. The downregulation of miR-605 enhanced cell proliferation, migration, and invasion of OS cells, which suggested that miR-605 may be involved in the progression of OS. The findings of the present study provide a new therapeutic target for the treatment of patients with OS. Matrix metalloproteinases (MMPs) are endopeptidases which are widely studied in terms of their role in the physiological and pathological processes in the organism. In this article, we consider usefulness of matrilysins and stromelysins in pathogenesis and diagnostic of the most common malignancies in the world, e.g., lung, breast, prostate, and colorectal cancers. In all of the mentioned cancers, matrilysins and stromelysins have a pivotal role in their development and also may have diagnostic utility. Influence to the cancerous process is connected with specific dependencies between these enzymes and components of the extracellular matrix (ECM), non-matrix components like cell surface components. All the information provided below allows to take a closer look at matrilysins and stromelysins and their functions in the cancer development. The nuclear factor kappa-B (NF-κB) is a major transcription factor responsible for the production of numerous inflammatory mediators, including the tumor necrosis factor (TNFα), which has a lethal association with cancer\\'s onset. The silver nanoparticles (AgNPs) are widely used in cancer treatment and several other biomedical applications.\\nThe study aimed to determine the effects of silver citrate nanoparticles (AgNPs-CIT) on NF-κB activation together with TNFα mRNA/protein expressions in the phorbol myristate acetate (PMA)-stimulated MCF-7 human breast cancer cell-lines.\\nThe AgNPs-CIT were synthesized by the reduction method, and the prepared AgNPs-CIT were characterized for their shape, absorption in UV-VIS electromagnetic radiations, size distribution, ζ-potential, and antioxidant activity. The MCF-7 cell-lines were pretreated with AgNPs-CIT and stimulated with PMA. The TNFα mRNA expressions were determined by real-time PCR, whereas the protein production was determined by the ELISA. The NF-κB activity was distinctly observed by highly-specific DNA-based ELISA, and by NF-κB-specific inhibitor, Bay 11-7082.\\nThe prepared AgNPs-CIT were spherical and have an absorption wavelength range of 381-452 nm wherein the particles size ranged between 19.2±0.1 to 220.77±0.12 nm with the charge range -9.99±0.8 to -34.63±0.1 mV. The prepared AgNPs-CIT showed comparative antioxidant activity at >40% inhibitions level of the DPPH radicals. The AgNPs-CIT were found to be non-toxic to MCF-7 cell-lines and inhibited PMA-induced activation of the NF-κBp65, and also the mRNA/protein expression of TNFα.\\nThis is the first report that showed AgNPs-CIT inhibited TNFα expression via deactivation of the NF-κB signaling event in stimulated breast cancer cells. The results have important implications for the development of novel therapeutic strategies for the prevention/treatment of cancers and/or inflammatory disorders. Cancer-associated fibroblasts (CAFs) play supporting roles in tumor progression by releasing microvesicles that transmit oncogenic cargoes. Indeed, extracellular vesicles (EVs) have emerged as important vehicles to deliver proteins, messenger RNAs (mRNAs), and microRNAs (miRs) between cells. In this study, we aimed to outline the role and function of CAFs-derived EVs carrying miR-1-3p in breast cancer. We first experimentally determined downregulated miR-1-3p in breast cancer tissues. EVs were isolated from CAFs extracted from breast cancer tissues, which showed downregulated miR-1-3p expression relative to EVs derived from normal fibroblasts (NFs). In a co-culture system, miR-1-3p cargo was transported into breast cancer cells via CAF-derived EVs. In gain-of-function experiments, the elevation of miR-1-3p in breast cancer cells inhibited cell viability, invasion, migration, and epithelial-to-mesenchymal transition, and suppressed tumor formation and metastasis. Furthermore, EVs derived from CAFs transfected with miR-1-3p mimic were more effective in transferring miR-1-3p to suppress cancer progression and metastasis. Krüppel-like zinc-finger protein Gli-similar 1 (GLIS1) was predicted to be a putative target of miR-1-3p, which was subsequently confirmed by dual-luciferase reporter assay. We then demonstrated that overexpression of GLIS1 neutralized the effects of miR-1-3 on the development of breast cancer in vitro. These findings shed light on the underlying mechanism by which CAFs-derived EVs carrying miR-1-3p mediate the progression and metastasis of breast cancer, and highlight the potential of miR-1-3p shuttled by CAFs-derived EVs serving as a therapeutic target for breast cancer. The pathologist\\'s role in the breast cancer treatment team has evolved from rendering a diagnosis of breast cancer, to providing a growing list of prognostic and predictive parameters such that individualized treatment decisions can be made based on likelihood of benefit from additional treatments and potential benefit from specific therapies. In all stages, ER and HER2 status help segregate breast cancers into treatment groups with similar outcomes and treatment response rates, however, traditional pathologic parameters such as favorable histologic subtype, size, lymph node status, and Nottingham grade also have remained clinically relevant in early stage disease decision-making. This is especially true for the most common subtype of breast cancer; ER positive, HER2 negative disease. For this same group of breast cancers, an ever-expanding list of gene-expression panels also can provide prediction and prognostication about potential chemotherapy benefit beyond standard endocrine therapies, with the 21-gene Recurrence Score, currently the only prospectively validated predictive test for this purpose. In the more aggressive ER-negative cancer subtypes, response to neoadjuvant therapy and` the extent of tumor infiltrating lymphocytes (TILs) are more recently recognized powerful prognostic parameters, and clinical guidelines now offer additional treatment options for those high-risk patients with residual cancer after standard neoadjuvant therapy. In stage four disease, predictive tests like germline BRCA status, tumor PIK3CA mutation status (in ER+ metastatic disease) and PDL-1 status (in triple negative metastatic disease) are now used to determine additional new treatment options. The objective of this review is to describe the latest in prognostic and predictive parameters in breast cancer as they are relevant to standard pathology reporting and how they are used in breast cancer clinical treatment decisions. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based serum N-glycan analysis has gained acknowledgment for the diagnosis of breast cancer in recent years. In this study, the possibilities of expanding its application for breast cancer management and surveillance were discovered and evaluated. First, a novel MALDI-TOF platform, IDsys RT, was confirmed to be effective for breast cancer analysis, showing a maximum area under the curve of 0.91. Multiple N-glycan markers were identified and validated using this process, and they were found to be applicable for differentiating recurring breast cancer samples from healthy control or ordinary breast cancer samples. Recurrence samples were especially distinct from non-recurrence samples when N-glycan signatures were sampled in multiple time points and monitored via MALDI-TOF, throughout the therapy. These results suggested the feasibility of MALDI-TOF-based N-glycan analysis for tracking the molecular signatures of breast cancer and predicting recurrence. Histological visualizations are critical to clinical disease management and are fundamental to biological understanding. However, current approaches that rely on bright-field microscopy require extensive tissue preparation prior to imaging. These processes are both labor intensive and contribute to creating significant delays in clinical feedback for treatment decisions that can extend to 2-3\\xa0weeks for standard paraffin-embedded tissue preparation and interpretation, especially if ancillary testing is needed. Here, we present the first comprehensive study on the broad application of a novel label-free reflection-mode imaging modality known as photoacoustic remote sensing (PARS) for visualizing salient subcellular structures from various common histopathological tissue preparations and for use in unprocessed freshly resected tissues. The PARS modality permits non-contact visualizations of intrinsic endogenous optical absorption contrast to be extracted from thick and opaque biological targets with optical resolution. The technique was examined both as a rapid assessment tool that is capable of managing large samples (>\\u20091\\xa0cm Ginger (Zingiber officinale) is one of the most widely consumed dietary supplements worldwide. Its anticancer potential has been demonstrated in various studies. However, ginger roots obtained from different geographical locations showed extensive variability in their activities, mainly due to differences in the levels of bioactive compounds. Here we evaluated the effect of these differences on the anticancer activity of ginger by performing efficacy-based fingerprinting. We characterized the fingerprint profiles of 22 ginger samples using liquid chromatography-mass spectroscopy, followed by a principal component analysis (PCA) and pearson correlation analysis. We also evaluated the anti-proliferative effects (IC Breast cancer is the most common female cancer in the world. Although early detection and systematic adjuvant therapy has improved survival, distant metastasis remains the leading cause of breast related mortality. The relationship between tumor and the hemostatic system is increasingly recognized as an important regulator of breast cancer progression. Tumors have the ability to induce platelet aggregation which is referred as tumor cell induced platelet aggregation (TCIPA). This study highlights that increased platelet aggregation plays an important role in metastasis of breast cancer. The aim here is to study the role of platelet aggregation in metastatic breast cancer patients using: • ADP • Thrombin.\\n30 cases (n = 30) of metastatic breast cancer and 30 controls (n = 30) of non-metastatic breast cancer which were clinically diagnosed and histopathologically confirmed were included in this study. Platelet aggregation studies in vitro using ADP and Thrombin were performed using an optical aggregometer in both cases and controls. Other parameters like platelet count, histological grade and surrogate molecular classification was also correlated with platelet aggregation.\\nIn this study, increased aggregation was seen with ADP and thrombin in the metastatic cases and none showed increased aggregation in the non-metastatic breast cancer patients. Also, high platelet count and higher histological grade correlated with increased aggregation. However, no correlation was seen between platelet aggregation and the surrogate molecular classification.\\nIt was concluded from this study that platelet aggregation has an important part to play in the tumor metastasis of breast cancer patients. The aim of this study is to evaluate the relationships between the expression of mucins in invasive breast carcinomas and clinicopathologic parameters.\\nWe examined 150 cases of invasive breast carcinoma, using the 2012 World Health Organization (WHO) classification of the tumors of the breast. We studied the expression of MUC1, MUC2, MUC5AC, and MUC6 by immunohistochemistry. We also evaluated normal breast tissue and ductal carcinoma in situ (DCIS) lesions in nearby invasive tumor areas.\\nIn invasive breast carcinomas, MUC1, MUC2, MUC5AC, and MUC6 were expressed in 98.6%, 11.3%, 9.9, and 8.5% of cases, respectively. MUC2, MUC5AC, and MUC6 were overexpressed in invasive tumors and DCIS lesions were compared with normal breast tissue. The apical pattern of MUC1 was correlated with low grade and ER expression. MUC2 was correlated with mucinous carcinoma and an inverse association with invasive ductal carcinoma, not otherwise specified (NOS). MUC6 expression was associated with lymphovascular invasion.\\nMost invasive breast tumors express MUC1 and the apical pattern of MUC1 is correlated with low grade and ER expression. MUC6 expression is associated with indicators of poor prognosis. Further comprehensive studies need to evaluate the role of mucins as a potential biomarker and to be used as a specific therapeutic target against breast cancer. In HER2-positive breast cancer, time elapsed between completion of (neo)adjuvant trastuzumab and diagnosis of metastatic disease (\\'trastuzumab-free interval\\', TFI) is crucial to choose the optimal first-line treatment. Nevertheless, there is no clear evidence to support its possible prognostic role.\\nIn the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial, patients with HER2-positive early breast cancer were randomised to 1 year of either trastuzumab alone, lapatinib alone, their sequence or their combination. This exploratory analysis included only patients in the trastuzumab alone or trastuzumab plus lapatinib arms who developed a distant disease-free survival (DDFS) event. Overall survival (OS) was defined as time between date of DDFS event and death; age at diagnosis, tumour size and hormone receptor status were the variables included in the multivariate models.\\nOut of 8381 patients included in ALTTO, 404 patients in the trastuzumab alone and trastuzumab plus lapatinib arms developed a DDFS event, of which 201 occurred \\nTFI has prognostic value in patients with HER2-positive early breast cancer treated with adjuvant trastuzumab-based therapy. TFI is a valid tool to better individualise clinical recommendations and to design future first-line treatment trials for metastatic patients. B7-H3 is an immune checkpoint molecule from the B7 superfamily. It has been widely studied in tumor immune evasion in certain types of cancer. In our preliminary study, we found that B7-H3 is specifically enriched in tumor-associated macrophages (TAMs) in triple-negative breast cancer (TNBC) patients and strongly correlated with poor clinical prognosis. However, the role of B7-H3 in breast cancer remains elusive. Our current study aims to explore the potential of B7-H3 as a novel target in TNBC therapy. Here, we demonstrated that B7-H3 enriched on TAMs is tightly correlated with TNBC clinical progression. B7-H3 None To identify the breast cancer specific survival (BCSS) associated with nodal metastasis identified by axillary core biopsy (ACB), and by sentinel node biopsy (SNB) compared with node negative patients. A further aim was to assess the prognostic effects of axillary ultrasound (US) features and amount of tumour in ACB specimens.\\nConsecutive patients with cancer were identified from a database of US lesions undergoing breast biopsy. The three study groups were: a) those with metastasis identified by ACB, b) those undergoing immediate surgery with positive SNB and c) those undergoing immediate surgery with a negative SNB. US features and the amount of tumour in the ACB specimen were assessed by review of US images and pathological reports. BCSS was assessed using Kaplan Meier survival curves.\\n967 patients were included, with mean follow-up of 6.0\\xa0yrs. There were 90 breast cancer deaths: 26% of those with a positive ACB, 11% with a positive SNB and 4% of those with a negative SNB. BCSS was significantly different between the groups (p\\xa0<\\xa00.001) with hazard ratio, compared with the negative SNB group, of 7.8 (95% CI 4.4-13.7) for patients with positive ACB and 2.5 (95% CI 1.3-4.6) for positive SNB. Axillary US findings and assessment of the amount of tumour in the ACB did not influence survival.\\nThis study suggests that women with a positive ACB have a worse BCSS compared to those with a positive SNB. This should be borne in mind when systemic therapy is being considered. Mastectomy may be performed to treat breast cancer or as a prophylactic approach in women with a high risk of developing breast cancer. In addition, mastectomies may be performed with or without reconstruction. Reconstruction approaches differ and may be autologous, involving a transfer of tissue (skin, subcutaneous fat, and muscle) from other parts of the body to the chest wall. Reconstruction may also involve implants. Implant reconstruction may occur as a single procedure or as multistep procedures with initial use of an adjustable tissue expander allowing the mastectomy tissues to be stretched without compromising blood supply. Ultimately, a full-volume implant will be placed. Reconstructions with a combination of autologous and implant reconstruction may also be performed. Other techniques such as autologous fat grafting may be used to refine both implant and flap-based reconstruction. This review of imaging in the setting of mastectomy with or without reconstruction summarizes the literature and makes recommendations based on available evidence. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. Cancer is considered as one of the most common leading causes of death worldwide. In developed countries, the lifestyles including poor diet, smoking, reproductive changes and physical inactivity are known to increase the susceptibility to cancer diseases. Moreover, the exposure to ionizing radiation, carcinomas chemicals, certain metals and some other specific substances even at low concentrations increase the risk to cancer diseases. Cancer progression is often associated with irregularities in cell cycle and these alterations induced mainly as a result of oxidative stress and generation of the reactive oxygen species (ROS). Colorectal cancer (CRC), hepatocellular carcinoma (HCC) and breast cancer are the most common and extensively studied types of cancers in modernized countries. The tumor suppressor genes are encoded by specific proteins. These proteins are required to regulate expression of these genes and involve in apoptosis, angiogenesis and genome maintenance. Therefore, the alterations in these proteins play role in cancers incidence and progression. Electrophoresis is standard technique used for separating, identifying and quantifying of different proteins according to their physical properties. Therefore, this article aimed to reveal role of this technique to analyze stoichiometry of a specific protein subunits in cancer diagnosis at early stage. Furthermore, the chemotherapeutic drugs that currently used in cancer treatment have shown adverse effects such as nephrotoxicity, cardiotoxicity and peripheral neuropathies in addition to sexual problems. Severity of these effects varies from person to person and according to type of the treatment. For this reason, the article shows role of the recent study that directed to enhance efficiency of the plant extracts like Moringa oleifera leaves extract by incorporating nanoparticles (silver (Ag-NPs) or gold Au-NPs) nanoparticles) and hence to investigate its efficiency against various cancers. The article concluded that electrophoresis might be added as an identification technique to reveal the qualitative and quantitative mutations induced as a result of cancer progression. Also, it might be able to show the differences induced in the native protein and isoenzymes patterns due to cancer treatment by mean of green nanotechnology as compared to traditional chemotherapy. To present the changes in 5-year relative survival of patients with breast and colorectal cancer in a northern Italian province in the 2000-2012 period. Changes are presented in relation to stage, period, and age in the screening population.\\nA total of 5073 breast cancer and 4093 colorectal cancer cases were registered. Breast cancer was divided into 5 age groups: <45, 45-49, 50-69, 70-74 (the target screening population is ages 45-74), and >74 years. Colorectal cancers were classified into 3 age groups: <50, 50-69 (screening target population), and >69 years. Survival was analysed by stage, period, and screening program.\\nFive-year breast cancer relative survival was 92.9% overall, with 100%, 91.9%, 78.8%, 34.2%, and 76.4% for stages I, II, III, IV, and unknown, respectively. Survival increased from 89.7%, 91.8%, and 93.4%, respectively, in the periods 2000-2005, 2006-2009, and 2010-2012. Breast cancer survival was stable in early stages (although already high); a slight improvement was seen for stages III and IV. Five-year colorectal cancer relative survival was 63.6% overall, with 93.3%, 78.6%, 69.8%, 13.2%, and 55.8% for stages I, II, III, IV, and unknown, respectively. No improvement in survival was seen in the periods analysed, although the introduction of screening in 2005 did lead to a sharp decrease in incidence and mortality.\\nFor breast cancer, extending the screening target age led to an improvement in survival; for colorectal cancer, the best impact was on incidence and mortality rate. The CREATE-X study, conducted in Japan and South Korea, established capecitabine as an adjuvant treatment option for patients with triple negative breast cancer (TNBC) who have residual disease (RD) following neoadjuvant anthracycline or taxane-based chemotherapy. However, there are no reports on the tolerability and outcomes of adjuvant capecitabine in the US setting following publication of the CREATE-X data.\\nWe retrospectively collected treatment and tolerability data from the medical records of the first 23 TNBC patients who received adjuvant capecitabine for RD post neoadjuvant chemotherapy at our institution. Disease-free survival was assessed using the Kaplan-Meier method.\\nThe median starting dosage of capecitabine was 1871\\u2009mg/m\\nTolerability was poor overall compared to the CREATE-X cohort. Administering adjuvant capecitabine for TNBC patients with residual disease in the United States is challenging given differences in tolerability. More research is needed to understand how poor tolerability will affect the efficacy of this approach in the US population. Molecular magnetic resonance imaging (MRI) allows visualization of biological processes at the molecular level. Upregulation of endothelial ALCAM (activated leukocyte cell adhesion molecule) is a key element for leukocyte recruitment in neurological disease. The aim of this study, therefore, was to develop a novel molecular MRI contrast agent, by conjugating anti-ALCAM antibodies to microparticles of iron oxide (MPIO), for detection of endothelial ALCAM expression  This study investigated a remote symptom monitoring intervention to examine if older participants with cancer received a similar magnitude of benefit compared with younger adults with cancer. We analyzed a longitudinal symptom monitoring intervention for 358 participants beginning a new course of chemotherapy treatment in community and academic oncology practices. The study design was a randomized control trial; participants were randomized to the intervention or usual care, the intervention was delivered during daily automated coaching. Older adults with moderate and severe symptoms derived similar benefit as those adults younger than 60 years of age, adherence to the study protocol which involved daily calls was high. There was no significant difference between the 2 age categories; on average, older adult participants made 88% of expected daily calls and younger adult participants made 90% of expected daily calls. Our results challenge the perception that older adults are unwilling or unable to use a technological tool such as interactive voice response and suggest that patient utilization may be guided by other factors, such as ease of use and perceived benefit from the intervention. None Characterization of breast cancer molecular subtypes has been the standard of care for breast cancer management. We aimed to provide a review of imaging features of breast cancer molecular subtypes for the field of precision medicine. We also provide an update on the recent progress in precision medicine for breast cancer, implications for imaging, and recent observations in longitudinal functional imaging with radiomics. ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) are co-localized at the blood-brain barrier (BBB), where they restrict the brain distribution of many different drugs. Moreover, ABCB1 and possibly ABCG2 play a role in Alzheimer\\'s disease (AD) by mediating the brain clearance of beta-amyloid (Aβ) across the BBB. This study aimed to compare the abundance and activity of ABCG2 in a commonly used β-amyloidosis mouse model (APP/PS1-21) with age-matched wild-type mice.\\nThe abundance of ABCG2 was assessed by semi-quantitative immunohistochemical analysis of brain slices of APP/PS1-21 and wild-type mice aged 6 months. Moreover, the brain distribution of two dual ABCB1/ABCG2 substrate radiotracers ([\\nImmunohistochemical analysis revealed a significant reduction (by 29-37%) in the number of ABCG2-stained microvessels in the brains of APP/PS1-21 mice. Partial ABCG2 inhibition significantly increased the brain distribution of [\\nDespite a reduction in the abundance of cerebral ABCG2 and ABCB1 in APP/PS1-21 mice, the brain distribution of two dual ABCB1/ABCG2 substrates was unaltered. Our results suggest that the brain distribution of clinically used ABCB1/ABCG2 substrate drugs may not differ between AD patients and healthy people. The role of tumour-infiltrating inflammatory cells (TIICs) in the disease progression of hormone-receptor-positive breast cancer (HR+ BC) is largely unclear since it is generally regarded as the least immunogenic BC subtype. This study investigated the prognostic significance of CD1a+ dendritic cells, CD20+ B cells, CD45RO+ memory T cells and CD4+ T-helper cells in HR+ BC. One hundred and forty-six patients were treated for early stage, distant-metastases-free HR+ BC in an accelerated partial breast irradiation (APBI) phase II trial. Immunohistochemistry was used to double-stain two adjoining sets of tissue microarrays from pre-RT (radiotherapy) tumour resection samples for CD1a/CD20 and CD45RO/CD4. Cell densities of CD1a+, CD20+, CD45RO+ and CD4+ TIICs in the stromal and intraepithelial compartment were registered semiautomatically. High densities of CD20+ and CD4+ TIICs were strongly associated with reduced disease-free survival (DFS), while high stromal CD45RO+ TIIC densities were indicators of subsequent successful treatment. An immunoscore based on CD20+ and CD45RO+ TIIC densities identified three different risk groups ( Several epidemiological and experimental studies have demonstrated that many human diseases are not only caused by specific genetic and environmental factors but also by gene-environment interactions. Although it has been widely reported that genetic polymorphisms play a critical role in human susceptibility to cancer and other chronic disease conditions, many single nucleotide polymorphisms (SNPs) are caused by somatic mutations resulting from human exposure to environmental stressors. Scientific evidence suggests that the etiology of many chronic illnesses is caused by the joint effect between genetics and the environment. Research has also pointed out that the interactions of environmental factors with specific allelic variants highly modulate the susceptibility to diseases. Hence, many scientific discoveries on gene-environment interactions have elucidated the impact of their combined effect on the incidence and/or prevalence rate of human diseases. In this review, we provide an overview of the nature of gene-environment interactions, and discuss their role in human cancers, with special emphases on lung, colorectal, bladder, breast, ovarian, and prostate cancers. The SOX family proteins are proved to play a crucial role in the development of the lymphatic ducts and the cardiovascular system. Moreover, an increased expression level of the SOX18 protein has been found in many malignances, such as melanoma, stomach, pancreatic breast and lung cancers. Another SOX family protein, the SOX30 transcription factor, is responsible for the development of male germ cells. Additionally, recent studies have shown its proapoptotic character in non-small cell lung cancer cells. Our preliminary studies showed a disparity in the amount of mRNA of the    O Exosomal microRNAs (miRNAs) have attracted great attention as predictive and prognostic biomarkers of cancer. Profiling of miRNAs plays a key role in the effective diagnosis of cancers. However, simultaneous quantification of multiple miRNAs is challenging due to their homology and low abundance especially in exosomes. Here, we developed a sensitive detection method for multiple exosomal miRNAs with the help of rolling circle amplification (RCA). In contrast of the traditional ways, this method takes the advantages of both the multiplex sensing ability and the simplicity of RCA. Specifically, multiple exosomal miRNAs from different cell lines were replicated simultaneously through RCA and detected using designed molecular beacons (MBs). miRNA-21, miRNA-122 and miRNA-155 were chosen as the targets, which are overexpressed in cancers. Normalized fluorescence intensities of MB were used to imply the relative concentrations of these miRNAs. The obtained relative miRNAs expression levels could be used to distinguish the breast cancer exosome from normal one. If the varieties of the detected exosomal miRNAs are abundant enough, the concentration ratios of miRNAs could basically indicate the corresponding exosome and exosome screening could be realized. Such exosomal miRNA profiling and exosome screening can assist cancer diagnosis, which is promising in clinical application. Metastatic staging imaging is not recommended for asymptomatic patients with stage I-II breast cancer. Greater distant metastatic disease risk may warrant baseline imaging in patients with stage II-III with high-risk biologic subtypes. NCCN Guidelines recommend considering CT of the chest, abdomen, and pelvis (CT CAP) and bone scan in appropriate patients. CT CAP and bone scan are considered standard of care (SoC), although PET/CT is a patient-centered alternative.\\nData were available for 799 high-risk patients with clinical stage II-III disease who initiated screening for the I-SPY2 trial at 4 institutions. A total of 564 complete records were reviewed to compare PET/CT versus SoC. Costs were determined from the payer perspective using the national 2018 Medicare Physician Fee Schedule and representative reimbursements to the University of California, San Francisco (UCSF). Incremental cost-effectiveness ratio (ICER) measured cost of using PET/CT per percent of patients who avoided a false-positive (FP).\\nThe de novo metastatic disease rate was 4.6%. Imaging varied across the 4 institutions (P<.0001). The FP rate was higher using SoC versus PET/CT (22.1% vs 11.1%; P=.0009). Mean time between incidental finding on baseline imaging to FP determination was 10.8 days. Mean time from diagnosis to chemotherapy initiation was 44.3 days with SoC versus 37.5 days with PET/CT (P=.0001). Mean cost per patient was $1,132 (SoC) versus $1,477 (PET/CT) using the Medicare Physician Fee Schedule, with an ICER of $31. Using representative reimbursements to UCSF, mean cost per patient was $1,236 (SoC) versus $1,073 (PET/CT) for Medicare, and $3,083 (SoC) versus $1,656 (PET/CT) for a private payer, with ICERs of -$15 and -$130, respectively.\\nConsiderable variation exists in metastatic staging practices. PET/CT reduced FP risk by half and decreased workup of incidental findings, allowing for earlier treatment start. PET/CT may be cost-effective, and at one institution was shown to be cost-saving. Better alignment is needed between hospital pricing strategies and payer coverage policies to deliver high-value care. None Malignant ovarian tumours are diagnosed at an advanced stage in the majority of cases. However, only a small percentage present as extra-abdominal, non-lymph-node solid metastases, as in the breast, and they are usually cases of relapse. The discovery of mono- or bilateral breast lesions with peritoneal carcinosis and/or abdomino-pelvic lesions can be cumbersome in the differential diagnosis of primary tumours. This article aims to summarize current evidence on the detection of breast metastases at diagnosis of ovarian cancer.\\nA systematic review of the literature in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including case reports and case series, was undertaken. Data regarding study features; population characteristics; clinical, radiological and histological assessment of the disease; treatment and follow-up were collected. In addition, a case report of a patient managed at the authors\\' centre is provided.\\nAccording to the search strategy, 16 articles (18 patients) were included in this review. Serous ovarian, fallopian tube or primary peritoneal cancer was detected in 61% of cases, while another type or a non-specified type of epithelial ovarian cancer was detected in 27.7% of cases; there was one case with granulosa cell tumour of the ovary and one case with mucinous ovarian tumour of low malignant potential. Breast metastases were mainly monolateral (66.6%), with other extra-abdominal sites of disease in the majority of the cases. A minority of patients (16.6%) received treatment for primary breast cancer with a subsequent diagnosis of ovarian cancer. Concomitant breast and abdominal surgery can be an option. PAX8, WT1 and CA125 immunohistochemical staining can aid in differential diagnosis.\\nBreast metastases of malignant ovarian tumours must be promptly recognized to ensure proper treatment. Specific immunohistochemical analysis can be a decisive assessment in uncertain cases. The clinical efficacy of the PEGylated doxorubicin liposomes (PLD) is limited by low tumor accumulation and limited intra-tumoral disposition. Decoration with the cell penetration enhancers (CPEs) can increase the PLD permeability via the biological barriers, however at the expense of enhanced distribution to the non-target organs and tissues, and may interfere with their tumor accumulation and with the resulting anti-cancer effects. We investigated the effect of the surface CPE agent tetraArg-[G-1]-distearoyl glycerol (DAG-Arg Cancer is a community health hazard which progress at a fatal rate in various countries across the globe. An agent used for chemotherapy should exhibit ideal properties to be an effective anticancer medicine. The chemotherapeutic medicines used for treatment of various cancers are, gemcitabine, paclitaxel, etoposide, methotrexate, cisplatin, doxorubicin and 5-fluorouracil. However, many of these agents present nonspecific systemic toxicity that prevents their treatment efficiency. Of all, Gemcitabine has shown to be an active agent against colon, pancreatic, colon, ovarian, breast, head and neck and lung cancers in amalgamation with various anticancer agents. Gemcitabine is considered a gold-standard and the first FDA approved agent used as a monotherapy in management of advanced pancreatic cancers. However due to its poor pharmacokinetics, there is need of newer drug delivery system for efficient action. Nanotechnology has shown to be an emerging trend in field of medicine in providing novel modalities for cancer treatment. Various nanocarriers have the potential to deliver the drug at the desired site to obtain information about diagnosis and treatment of cancer. This review highlights on various nanocarriers like polymeric nanoparticles, solid lipid nanoparticles, mesoporous silica nanoparticles, magnetic nanoparticles, micelles, liposomes, dendrimers, gold nanoparticles and combination approaches for delivery of gemcitabine for cancer therapy. The co-encapsulation and concurrent delivery of Gem with other anticancer agents can enhance drug action at the cancer site with reduced side effects. Primary breast cancer in the pediatric population is rare. No cases of intracystic papillary carcinoma have been previously reported in patients < 21 years.\\nA 16-year-old patient presented with a retroareolar mass and bloody nipple discharge in her left breast. A biopsy established papillary intracystic carcinoma. The patient was treated surgically and a risk reduction strategy developed in a multidisciplinary session was implemented. Eighty-seven newly diagnosed Lung, Breast, or Gastrointestinal Cancer patients undergoing chemotherapy in the Infusion Suite of a large urban hospital in NYC.\\nPatients were enrolled in this study of music therapy\\'s impact on resilience in coping with the impact of symptoms inclusive of symptom clustering.\\nPatients were randomly assigned to 3 arms: 43 subjects: clinical instrumental improvisation or clinical vocal improvisation, 44 subjects-control. All subjects received a Medical Music Psychotherapy Assessment including psychosocial information and music preferences, pre/post Resilience Scale (RS), Hospital Anxiety and Depression Scale (HADS), Visual Analogue Scale, Faces Scale (VAS) and a pain- Color Analysis Scale (CAS).\\n20-minute MT, and two additional sessions.\\nSignificant increases in RS in MT groups post treatment with instrumental and vocal MT interventions equally potent- reflect average changes of 3.4 and 4.83 (p = .625), respectively. Although HADS scores showed little impact of MT on perceived anxiety/depression, a strong correlation is seen between vocal intervention and lower depression scores through VAS rendered post sessions. This yielded a significant decrease in pain levels immediately after MT, with the final session showing the most significant change in pain level. Resilience in enduring procedures is a necessary component of combating potential negative illness perception.\\nOur study shows MT\\'s facility to propel resilience in newly diagnosed cancer patients, particularly when promoting and pairing adaptation toward coping through the expression of perceived negative effects of emotional and physiological symptoms. Obesity is one of the major modifiable risk factors in breast cancer, with obese adipose tissue showing a pathological role in breast cancer development and malignancy via the release of secretory factors, such as proinflammatory cytokines and adipocytokines. The current article focuses on visfatin and resistin, two such adipocytokines that have emerged over the last two decades as leading breast cancer promoting factors in obesity. The clinical association of circulating visfatin and resistin with breast cancer and their biological mechanisms are reviewed, in addition to their role in the context of tumor-stromal interactions in the breast cancer microenvironment. Recent findings have unraveled several mediators of visfatin and resistin that are involved in the crosstalk between breast cancer cells and adipose tissue in the breast tumor microenvironment, including growth differentiation factor 15 (GDF15), interleukin 6 (IL-6), and toll-like receptor 4 (TLR4). Finally, current therapeutics targeting visfatin and resistin and their respective pathways are discussed, including future therapeutic strategies such as new drug design or neutralizing peptides that target extracellular visfatin or resistin. These hold promise in the development of novel breast cancer therapies and are of increasing relevance as the prevalence of obesity-related breast cancer increases worldwide. We developed a pH-activatable cell-penetrating peptide dimer LH Multiple combination therapies with chemotherapeutic drugs and inhibitors of drug resistance have been effective in the clinical cases, but concerns have been raised about the severe toxicity of these chemotherapeutic drugs. Herein, we report a potent and safe combination strategy of cancer-specific doxorubicin (DOX) prodrug nanoparticles (PNPs) and B-cell lymphoma-2 (Bcl-2) anti-apoptotic inhibitor, Navitoclax, to overcome acquired drug resistance during chemotherapy. The cancer-specific PNPs were constructed by conjugating cathepsin B-specific cleavable peptide (Phe-Arg-Arg-Gly; FRRG) to DOX, resulting in FRRG-DOX that self-assembled into nanoparticles and the FRRG-DOX nanoparticles were further stabilized with the FDA-approved pharmaceutical excipient, Pluronic F68. The resulting PNPs are specifically cleaved and metabolized to free DOX in cathepsin B-overexpressing cancer cells, but they exhibited minimal cytotoxicity in cathepsin B-deficient normal cells. As expected, free DOX and PNPs induced overexpression of Bcl-2 in MDA-MB-231 cells, due to acquired drug resistance in a cell culture system. However, combination therapy with PNPs and Navitoclax showed the outstanding synergetic cytotoxicity by decreasing the expression level of Bcl-2. In MDA-MB231 breast tumor-bearing mice, intravenously injected PNPs efficiently accumulated in targeted tumor tissues via enhanced permeability and retention (EPR) effect. When combined with orally administered Navitoclax, PNPs exhibited more potent therapeutic efficacy in aquired drug resistant models than free DOX plus Navitoclax, whereas PNPs greatly reduced systemic toxic side effects in normal organs. Our cancer-specific PNP-based combination therapy with Bcl-2 inhibitor may provide a promising approach for the potent and safe treatment of acquired drug-resistant cancers. Coibamide A is a potent cancer cell toxin and one of a select group of natural products that inhibit protein entry into the secretory pathway via a direct inhibition of the Sec61 protein translocon. Many Sec61 client proteins are clinically relevant drug targets once trafficked to their final destination in or outside the cell, however the use of Sec61 inhibitors to block early biosynthesis of specific proteins is at a pre-clinical stage. In the present study we evaluated the action of coibamide A against human epidermal growth factor receptor (HER, ErbB) proteins in representative breast and lung cancer cell types. HERs were selected for this study as they represent a family of Sec61 clients that is frequently dysregulated in human cancers, including coibamide-sensitive cell types. Although coibamide A inhibits biogenesis of a broad range of Sec61 substrate proteins in a presumed substrate-nonselective manner, endogenous HER3 (ErbB-3) and EGFR (ErbB-1) proteins were more sensitive to coibamide A, and the related Sec61 inhibitor apratoxin A, than HER2 (ErbB-2). Despite this rank order of sensitivity (HER3 > EGFR > HER2), Sec61-dependent inhibition by coibamide A was sufficient to decrease cell surface expression of HER2. We report that coibamide A- or apratoxin A-mediated block of HER3 entry into the secretory pathway is unlikely to be mediated by the HER3 signal peptide alone. HER3 (G11L/S15L), that is fully resistant to the highly substrate-selective cotransin analogue CT8, was more resistant than wild-type HER3 but only at low coibamide A (3 nM) concentrations; HER3 (G11L/S15L) expression was inhibited by higher concentrations of either natural product. Time- and concentration-dependent decreases in HER protein expression induced a commensurate reduction in AKT/MAPK signaling in breast and lung cancer cell types and loss in cell viability. Coibamide A potentiated the cytotoxic efficacy of small molecule kinase inhibitors lapatinib and erlotinib in breast and lung cancer cell types, respectively. These data indicate that natural product modulators of Sec61 function have value as chemical probes to interrogate HER/ErbB signaling in treatment-resistant human cancers. None None None None None None None None None None None None In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic. As an aid to treatment decisions, we aimed to develop a prognostic assay that integrates multiple data types for predicting survival outcome in patients with newly diagnosed HER2-positive breast cancer.\\nWe derived a combined prognostic model using retrospective clinical-pathological data on stromal tumour-infiltrating lymphocytes, PAM50 subtypes, and expression of 55 genes obtained from patients who participated in the Short-HER phase 3 trial. The trial enrolled patients with newly diagnosed, node-positive, HER2-positive breast cancer or, if node negative, with at least one risk factor (ie, tumour size >2 cm, histological grade 3, lymphovascular invasion, Ki67 >20%, age ≤35 years, or hormone receptor negativity), and randomly assigned them to adjuvant anthracycline plus taxane-based combinations with either 9 weeks or 1 year of trastuzumab. Trastuzumab was administered intravenously every 3\\u2008weeks (8\\u2008mg/kg loading dose at first cycle, and 6\\u2008mg/kg thereafter) for 18 doses or weekly (4\\u2008mg/kg loading dose in the first week, and 2\\u2008mg/kg thereafter) for 9\\u2008weeks, starting concomitantly with the first taxane dose. Median follow-up was 91·4 months (IQR 75·1-105·6). The primary objective of our study was to derive and evaluate a combined prognostic score associated with distant metastasis-free survival (the time between randomisation and distant recurrence or death before recurrence), an exploratory endpoint in Short-HER. Patient samples in the training dataset were split into a training set (n=290) and a testing set (n=145), balancing for event and treatment group. The training set was further stratified into 100 iterations of Monte-Carlo cross validation (MCCV). Cox proportional hazard models were fit to MCCV training samples using Elastic-Net. A maximum of 92 features were assessed. The final prognostic model was evaluated in an independent combined dataset of 267 patients with early-stage HER2-positive breast cancer treated with different neoadjuvant and adjuvant anti-HER2-based combinations and from four other studies (PAMELA, CHER-LOB, Hospital Clinic, and Padova) with disease-free survival outcome data.\\nFrom Short-HER, data from 435 (35%) of 1254 patients for tumour size (T1 vs rest), nodal status (N0 vs rest), number of tumour-infiltrating lymphocytes (continuous variable), subtype (HER2-enriched and basal-like vs rest), and 13 genes composed the final model (named HER2DX). HER2DX was significantly associated with distant metastasis-free survival as a continuous variable (p<0·0001). HER2DX median score for quartiles 1-2 was identified as the cutoff to identify low-risk patients; and the score that distinguished quartile 3 from quartile 4 was the cutoff to distinguish medium-risk and high-risk populations. The 5-year distant metastasis-free survival of the low-risk, medium-risk, and high-risk populations were 98·1% (95% CI 96·3-99·9), 88·9% (83·2-95·0), and 73·9% (66·0-82·7), respectively (low-risk vs high-risk hazard ratio [HR] 0·04, 95% CI 0·0-0·1, p<0·0001). In the evaluation cohort, HER2DX was significantly associated with disease-free survival as a continuous variable (HR 2·77, 95% CI 1·4-5·6, p=0·0040) and as group categories (low-risk vs high-risk HR 0·27, 0·1-0·7, p=0·005). 5-year disease-free survival in the HER2DX low-risk group was 93·5% (89·0-98·3%) and in the high-risk group was 81·1% (71·5-92·1).\\nThe HER2DX combined prognostic score identifies patients with early-stage, HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment. Future clinical validation of HER2DX seems warranted to establish its use in different scenarios, especially in the neoadjuvant setting.\\nInstituto Salud Carlos III, Save the Mama, Pas a Pas, Fundación Científica, Asociación Española Contra el Cáncer, Fundación SEOM, National Institutes of Health, Agenzia Italiana del Farmaco, International Agency for Research on Cancer, and the Veneto Institute of Oncology, and Italian Association for Cancer Research. Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki67\\nPOETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO performance status 0-1 and hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI (letrozole 2·5 mg per day orally or anastrozole 1 mg per day orally) for 14 days before and following surgery or no POAI (control). Adjuvant treatment was given as per UK standard local practice. Randomisation was done centrally by computer-generated permuted block method (variable block size of six or nine) and was stratified by hospital. Treatment allocation was not masked. The primary endpoint was time to recurrence. A key second objective explored association between Ki67 (dichotomised at 10%) and disease outcomes. The primary analysis for clinical endpoints was by modified intention to treat (excluding patients who withdrew consent). For Ki67 biomarker association and endpoint analysis, the evaluable population included all randomly assigned patients who had paired Ki67 values available. This study is registered with ClinicalTrials.gov, NCT02338310; the European Clinical Trials database, EudraCT2007-003877-21; and the ISRCTN registry, ISRCTN63882543. Recruitment is complete and long-term follow-up is ongoing.\\nBetween Oct 13, 2008, and April 16, 2014, 4480 women were recruited and randomly assigned to POAI (n=2976) or control (n=1504). On Feb 6, 2018, median follow-up was 62·9 months (IQR 58·1-74·1). 434 (10%) of 4480 women had a breast cancer recurrence (280 [9%] POAI; 154 [10%] control), hazard ratio 0·92 (95% CI 0·75-1·12); p=0·40 with the proportion free from breast cancer recurrence at 5 years of 91·0% (95% CI 89·9-92·0) for patients in the POAI group and 90·4% (88·7-91·9) in the control group. Within the POAI-treated HER2-negative subpopulation, 5-year recurrence risk in women with low Ki67\\nPOAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy based on tumour Ki67. Most patients with low Ki67\\nCancer Research UK. None None 10-year results from several studies showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. We present the scheduled 15-year analysis of the European Organisation for Research and Treatment of Cancer (EORTC) 22922/10925 trial, which aims to investigate the impact on overall survival of elective internal mammary and medial supraclavicular (IM-MS) irradiation.\\nEORTC 22922/10925, a randomised, phase 3 trial done across 46 radiation oncology departments from 13 countries, included women up to 75 years of age with unilateral, histologically confirmed, stage I-III breast adenocarcinoma with involved axillary nodes or a central or medially located primary tumour. Surgery consisted of mastectomy or breast-conserving surgery and axillary staging. Patients were randomly assigned (1:1) centrally using minimisation to receive IM-MS irradiation at 50 Gy in 25 fractions (IM-MS irradiation group) or no IM-MS irradiation (control group). Stratification was done for institution, menopausal status, site of the primary tumour within the breast, type of breast and axillary surgery, and pathological T and N stage. Patients and investigators were not masked to treatment allocation. The primary endpoint was overall survival analysed according to the intention-to-treat principle. Secondary endpoints were disease-free survival, distant metastasis-free survival, breast cancer mortality, any breast cancer recurrence, and cause of death. Follow-up is ongoing for 20 years after randomisation. This study is registered with ClinicalTrials.gov, NCT00002851.\\nBetween Aug 5, 1996, and Jan 13, 2004, we enrolled 4004 patients, of whom 2002 were randomly assigned to the IM-MS irradiation group and 2002 to the no IM-MS irradiation group. At a median follow-up of 15·7 years (IQR 14·0-17·6), 554 (27·7%) patients in the IM-MS irradiation group and 569 (28·4%) patients in the control group had died. Overall survival was 73·1% (95% CI 71·0-75·2) in the IM-MS irradiation group and 70·9% (68·6-72·9) in the control group (HR 0·95 [95% CI 0·84-1·06], p=0·36). Any breast cancer recurrence (24·5% [95% CI 22·5-26·6] vs 27·1% [25·1-29·2]; HR 0·87 [95% CI 0·77-0·98], p=0·024) and breast cancer mortality (16·0% [14·3-17·7] vs 19·8% [18·0-21·7]; 0·81 [0·70-0·94], p=0·0055) were lower in the IM-MS irradiation group than in the control group. No significant differences in the IM-MS irradiation group versus the control group were seen for disease-free survival (60·8% [95% CI 58·4-63·2] vs 59·9% [57·5-62·2]; HR 0·93 [95% CI 0·84-1·03], p=0·18), or distant metastasis-free survival (70·0% [67·7-72·2] vs 68·2% [65·9-70·3]; 0·93 [0·83-1·04], p=0·18). Causes of death between groups were similar.\\nThe 15-year results show a significant reduction of breast cancer mortality and any breast cancer recurrence by IM-MS irradiation in stage I-III breast cancer. However, this is not converted to improved overall survival.\\nUS National Cancer Institute, Ligue Nationale contre le Cancer, and KWF Kankerbestrijding. None Knowledge of fundamental differences between breast cancer subtypes has driven therapeutic advances; however, basal-like breast cancer (BLBC) remains clinically intractable. Because BLBC exhibits alterations in DNA repair enzymes and cell-cycle checkpoints, elucidation of factors enabling the genomic instability present in this subtype has the potential to reveal novel anti-cancer strategies. Here, we demonstrate that BLBC is especially sensitive to suppression of iron-sulfur cluster (ISC) biosynthesis and identify DNA polymerase epsilon (POLE) as an ISC-containing protein that underlies this phenotype. In BLBC cells, POLE suppression leads to replication fork stalling, DNA damage, and a senescence-like state or cell death. In contrast, luminal breast cancer and non-transformed mammary cells maintain viability upon POLE suppression but become dependent upon an ATR/CHK1/CDC25A/CDK2 DNA damage response axis. We find that CDK1/2 targets exhibit hyperphosphorylation selectively in BLBC tumors, indicating that CDK2 hyperactivity is a genome integrity vulnerability exploitable by targeting POLE. Tumour stromal cells support tumourigenesis. We report that Syndecan-2 (SDC2) is expressed on a non-epithelial, non-haematopoietic, non-endothelial stromal cell population within breast cancer tissue. In-vitro, syndecan-2 modulated TGFβ signaling (SMAD7, PAI-1), migration and immunosuppression of patient-derived tumour-associated stromal cells (TASCs). In an orthotopic immunocompromised breast cancer model overexpression of syndecan-2 in TASCs significantly enhanced TGFβ signaling (SMAD7, PAI-1), tumour growth and metastasis, whereas reducing levels of SDC2 in TASCs attenuated TGFβ signaling (SMAD7, PAI-1, CXCR4), tumour growth and metastasis. To explore the potential for therapeutic application, a syndecan-2-peptide was generated that inhibited the migratory and immunosuppressive properties of TASCs in association with reduced expression of TGFβ-regulated immunosuppressive genes, such as CXCR4 and PD-L1. Moreover, using an orthotopic syngeneic breast cancer model overexpression of syndecan-2-peptide in TASCs reduced tumour growth and immunosuppression within the TME. These data provide evidence that targeting stromal syndecan-2 within the TME inhibits tumour growth and metastasis due to decreased TGFβ signaling and increased immune control. This article is protected by copyright. All rights reserved. The JAK/STAT3 signaling pathway may be aberrantly activated and have various and conflicting roles in breast cancer. The current study explored prognostic implications of activated STAT3 in human epidermal growth factor receptor 2 (HER2)-positive primary breast cancers in the context of a large prospective study (ALTTO). Activated STAT3 was determined by immunohistochemical analysis of STAT3 phosphorylation(Y705) performed on the primary tumors. This analysis evaluated whether patients with activated STAT3 had disease-free survival (DFS) and overall survival (OS) different from patients without activated STAT3. A total of 5,694 patients out of the 8,381 patients enrolled in ALTTO were included in this analysis (67.9%), and 2634 of them (46%) had evidence of STAT3 activation (minimum tumor Allred score ≥2). The median follow-up was 6.93\\u2009years (6.85 to 6.97\\u2009years), at the end of which 1035 (18.18%) and 520 (9.13%) patients experienced DFS and OS events, respectively. Patients with STAT3 activation experienced improved DFS compared to those without it (multivariable hazard ratio [HR], 0.84; 95% confidence interval [CI] 0.74-0.95; p =\\u20090.006). There were no group differences in OS (multivariable HR, 0.92; 95% CI 0.78-1.10; p =\\u20090.37). This effect was limited to ER-positive tumors. In conclusion, these findings support the role of STAT3 activation as a marker of favorable outcome in ER-positive/HER2-positive breast cancer patients. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is highly effective for the prevention of high-grade serous ovarian cancer (HGSOC) in BRCA1/2 pathogenic variant carriers (PVCs), but does not completely eliminate future risk of primary peritoneal cancer (PPC). The requirement to completely remove fallopian tubes at RRBSO and carefully exclude occult cancer/serous tubal intraepithelial carcinoma (STIC) lesions may not have been appreciated historically. We calculated rates of HGSOC and PPC in confirmed BRCA1/2 PVCs registered on the regional database in those who did (cases) and did not (controls) undergo RRBSO after genetic testing. Expected annual rates of ovarian/peritoneal cancer were 1% for BRCA1\\u2009≥\\u200935\\u2009years and 0.5% for BRCA2\\u2009≥\\u200945\\u2009years. Follow-up before 35/45\\u2009years was \"risk free\" and lead time excluded RRBSO <35\\u2009years and <45\\u2009years for BRCA1 and BRCA2, respectively. Women were followed from personal mutation report (controls) or RRBSO (cases) to death, ovarian/peritoneal cancer or last follow-up, whichever was sooner. In total, 891 cases (BRCA1 = 468, BRCA2 = 423) and 1302 controls had follow-up ≥35\\u2009years (BRCA1 = 736) and ≥45\\u2009years (BRCA2 = 566), respectively, over a total of 7261.1 risk eligible years (mean = 8.15\\u2009years). Twenty-one occult ovarian cancers were found at RRBSO (2.4%), 16 at stage 1. Post RRBSO, 56.97 ovarian/peritoneal cancers were expected but only 3 were observed (HR = 0.053; 95% CI = 0.013-0.14), with combined Kaplan-Meier analysis HR = 0.029 (95% CI = 0.009-0.100, P\\u2009<\\u2009.001). Risk reduction was greater in specialist (HR = 0.03; 95% CI = 0.001-0.13) compared to non-specialist centres (HR = 0.11; 95% CI = 0.02-0.37) (P = .07). In controls, 23.35 ovarian/peritoneal cancers were expected with 32 observed (HR = 1.37; 95% CI = 0.95-1.91). RRBSO <35/<45\\u2009years reduces the risk of ovarian/peritoneal cancer by 95% in BRCA1/2 PVCs and may be greater in specialist centres. High levels of stromal tumor-infiltrating lymphocytes (sTIL) are associated with increased pathological complete response (pCR) rate and longer survival after neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Here, we evaluated the value of sTIL in predicting pCR and explored prognosis in TNBC patients treated with neoadjuvant chemotherapy according to body mass index (BMI).\\nsTIL were scored centrally on pretreatment biopsies from 2 retrospective series of nonunderweight TNBC patients (n\\u2009=\\u2009445). sTIL and BMI were considered as binary (sTIL: <30.0% vs ≥30.0%; BMI: lean vs overweight and obese) and continuous variables. Associations with pCR (ypT0/isN0) were assessed using logistic regression, and associations with event-free survival and overall survival were assessed using Cox regressions.\\n236 (53.0%) patients were lean and 209 (47.0%) overweight and obese. pCR was achieved in 181 of 445 (41.7%) patients. Median sTIL was 11.0%, and 99 of 445 (22.2%) tumors had high sTIL. A statistically significant interaction between sTIL and BMI, considered as categorical or continuous variables, for predicting pCR was observed in the multivariable analysis (Pinteraction = .03 and .04, respectively). High sTIL were statistically significantly associated with pCR in lean (odds ratio [OR] = 4.24, 95% confidence interval [CI] = 2.10 to 8.56; P < .001) but not in heavier patients (OR = 1.48, 95% CI = 0.75 to 2.91; P = .26) in the multivariable analysis. High sTIL were further associated with increased event-free survival in lean (hazard ratio [HR] = 0.22, 95% CI = 0.08 to 0.62; P = .004) but not in heavier patients (HR = 0.53, 95% CI = 0.26 to 1.08; P = .08). Similar results were obtained for overall survival.\\nBMI is modifying the effect of sTIL on pCR and prognosis in TNBC patients treated with neoadjuvant chemotherapy. Toxicodendron vernicifluum Stokes has long been used as a food supplement and traditional herbal medicine in East Asia. We applied a new extraction method to produce Toxicodendron vernicifluum Stokes extract (TVSE), that doesn\\'t contain urushiol (an allergenic toxin) but dose have higher levels of some flavonoids such as fustin and fisetin. This study was conducted to investigate the anticancer effects of TVSE in an in vivo system. Fifty BALB/c mice were acclimated for one week and then injected with 4T1 murine mammary carcinoma cells in mammary fat pads. After 7 days, the mice were randomly divided into 5 groups, and orally administered with 0, 50, 100, 200 or 400 mg of TVSE/kg body weight (BW)/day for 20 days. TVSE reduced tumor volume and weight dose-dependently. The expression of Ki67 was significantly reduced and the number of TUNEL-positive apoptotic cells was significantly increased in the TVSE-treated group over 100 mg/kg BW/day. While tumor nodules were not found in the liver, but only in lungs, the number of tumor nodules was reduced in a dose-dependent manner in the TVSE treated groups compared to the control group. In breast tumors, expression of platelet endothelial cell adhesion molecule (PECAM-1) and vascular endothelial growth factor (VEGF) was reduced by TVSE treatment. TVSE treatment significantly suppressed mRNA expression in tumors of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-1, urokinase-type plasminogen activator (uPA), intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1 while increasing plasminogen activator inhibitor (PAI)-1. These results suggest that TVSE is potentially beneficial for the suppression of breast cancer growth and its-associated lung metastasis. The purpose of this paper is to report the baseline characteristics of EMPOWER participants-a group of newly diagnosed breast cancer survivors-and describe differences in hourly and salaried wage women\\'s experiences regarding cancer and work management in the three months following breast cancer diagnosis.\\nThe EMployment and Potential Outcomes of Working through canceER (EMPOWER) project is a prospective longitudinal, mixed methods pilot study designed to evaluate how employment influences treatment decisions among women diagnosed with breast cancer. Participants were women diagnosed with new breast cancer and treated at one of two clinical sites of the University of Maryland Medical System. Women were enrolled in the study within three months of first breast cancer diagnosis. Study visits occurred every three months for one year. This paper reports data from for the baseline and three-month visit which had been completed by all enrollees.\\nTrained research personnel collected demographic information, medical history and health status, social history, employment data, cancer-related data, psychosocial adjustment, and financial wellbeing at the baseline enrollment visit. A semi-structured qualitative interview was administered at the three-month study visit to assess employment decisions and the impact of job demands, cancer care, and cancer-work fit during the three months following diagnosis.\\nFifty women with new, primary diagnosis of breast cancer were enrolled in the study. Mean age of participants was 51 years, and 46% identified their race as Black or other. The majority of women disclosed their diagnosis to their employer and nearly all maintained some level of employment during the first three to six months of treatment. Women with hourly wage jobs were similar to those with salaried wage jobs with respect to demographic and social characteristics. Women with hourly wage jobs were more likely to report working in physically demanding jobs and taking unpaid leave. They were also more likely to experience side effects that required physical restrictions at work, to leave their jobs due to demands of treatment, and to report managing cancer and work concurrently as very difficult. Women in salaried wage jobs were more likely to report falling behind or missing work and working remotely as a cancer-management strategy. Women in hourly jobs more often reported difficulty managing the competing demands of cancer and work.\\nWhile further study is needed, these results suggest that women in hourly and salaried workers reported similar experiences managing cancer and work, with a few key exceptions. These exceptions pertain to the nature of hourly-wage work. Cancer survivors employed in hourly jobs may be more vulnerable to poor employment outcomes due to limited access to paid time off and workplace flexibility, and challenges related to managing physical aspects of cancer and employment. Following the discovery and approval of the oral contraceptive, the pharmaceutical industry sought new opportunities for the regulation of reproduction. The discovery of the first non-steroidal anti-oestrogen MER25, with antifertility properties in laboratory animals, started a search for \"morning after pills.\" There were multiple options in the 1960s, however one compound ICI 46,474 was investigated, but found to induce ovulation in subfertile women. A second option was to treat stage IV breast cancer. Although the patent for ICI 46,474 was awarded in the early 1960s in the United Kingdom and around the world, a patent in the United States of America (USA) was denied on the basis that the claims for breast cancer treatment were not supported by evidence. A trial at the Christie Hospital and Holt Radium Institute in Manchester, published in 1971, showed activity compared with alternatives: high dose oestrogen or androgen treatment, but the US Patent Office was unswayed until 1985! The future of tamoxifen to be, was in the balance in 1972 but the project went forward as an orphan drug looking for applications and a translational research strategy was needed. Today, tamoxifen is known as the first targeted therapy in cancer with successful applications to treat all stages of breast cancer, male breast cancer, and the first medicine for the reduction of breast cancer incidence in high risk pre and post-menopausal women. This is the unlikely story of how an orphan medicine changed medical practice around the world, with millions of women\\'s lives extended. Compression elastography allows the precise measurement of large deformations of soft tissue in vivo. From an image sequence showing tissue undergoing large deformation, an inverse problem for both the linear and nonlinear elastic moduli distributions can be solved. As part of a larger clinical study to evaluate nonlinear elastic modulus maps (NEMs) in breast cancer, we evaluate the repeatability of linear and nonlinear modulus maps from repeat measurements. Within the cohort of subjects scanned to date, 20 had repeat scans. These repeated scans were processed to evaluate NEM repeatability. In vivo data were acquired by a custom-built, digitally controlled, uniaxial compression device with force feedback from the pressure-plate. RF-data were acquired using plane-wave imaging, at a framerate of 200 Hz, with a ramp-and-hold compressive force of 8N, applied at 8N/sec. A 2D block-matching algorithm was used to obtain sample-level displacement fields which were then tracked at subsample resolution using 2D cross correlation. Linear and nonlinear elasticity parameters in a modified Veronda-Westmann model of tissue elasticity were estimated using an iterative optimization method. For the repeated scans, B-mode images, strain images, and linear and nonlinear elastic modulus maps are measured and compared. Results indicate that when images are acquired in the same region of tissue and sufficiently high strain is used to recover nonlinearity parameters, then the reconstructed modulus maps are consistent. Few studies have explored the relationship between body habitus and breast cancer outcomes in Caribbean women of African ancestry. This study evaluates the association between body mass index (BMI) and disease-free survival (DFS) in a retrospective cohort of 224 female Haitian patients with nonmetastatic breast cancer.\\nBMI was obtained from the medical records and categorized as normal weight (< 25 kg/m\\nEighty-three patients (37.1%) were normal weight, 66 (29.5%) were overweight, and 75 (33.5%) were obese. There were no statistical differences in baseline characteristics or treatments received by BMI group. Twenty-six patients died and 73 had disease recurrence. Median DFS was 41.1 months. Kaplan-Meier estimates showed no significant DFS differences by BMI categories. After controlling for confounders, normal weight patients, when compared with overweight and obese patients, had adjusted hazard ratios of 0.85 (95% CI, 0.49 to 1.49) and 0.90 (95% CI, 0.52 to 1.55), respectively. Overall, mean weight loss of 2% of body weight was noted over the course of adjuvant chemotherapy. Patients who were postmenopausal (\\nBaseline BMI and weight changes during adjuvant chemotherapy did not have an impact on DFS in this cohort. Future prospective studies in similar Caribbean breast cancer cohorts are needed to verify study findings. Given the potentially fatal consequences of inadequate adherence with oral anticancer treatment in persons with cancer, understanding the determinants of adherence is vital. This paper aims at identifying psychosocial determinants of adherence to oral anticancer treatment.\\nWe reviewed the literature on psychosocial determinants of adherence with oral anticancer treatment, based on published literature in English, from 2015 to present. Literature searches were performed in PubMed, Embase, Web of Science, Cochrane library, Emcare, and PsychINFO, with \\'cancer\\', \\'medication adherence\\', \\'psychology\\', and \\'oral anticancer treatment\\' as search terms. The obtained 608 papers were screened by two independent reviewers.\\nIn the 25 studies identified, illness perceptions, medication beliefs, health beliefs, and depression were found to be the major psychosocial determinants of adherence to oral anticancer treatment; sociodemographic and clinical characteristics were found to be of no major importance. The quality of the identified studies as assessed by two independent reviewers was found to be acceptable overall. The majority of papers were from North America and focused on patients with breast cancer; sample size varied from 13 to 1371; adherence was assessed with questionnaires derived from various theoretical models, pill counts and electronic pharmacy records; illness perceptions reflecting adaptive coping, and medication beliefs reflecting high necessity and low concerns were found to be associated with adherence.\\nPsychosocial concepts are major determinants of adherence with oral anticancer treatment. \\'Beliefs about medicines\\' and \\'illness perceptions\\' in particular determine adherence with this treatment. Studies aiming at impacting adherence would benefit from interventions with a solid basis in behavioral theory in order to help health care providers explore and address illness perceptions and medication beliefs. Pre-consultation screening of adherence behavior may be a helpful supportive approach to improve adherence. Blaming the victim (\\'patients should be educated about the importance of adherence\\') is better replaced by encouraging health professionals to identify and address maladaptive psychosocial determinants of adherence. We aimed to determine the longitudinal prevalence and the predictors of sickness absence (SA) and disability pension (DP) in breast cancer (BC) women who eventually developed relapse.\\nA total of 1293 BC women, who were ages 20-63\\xa0years, diagnosed between 1996 and 2011 and by 2016 had all developed relapse, were identified in Swedish registers and were followed from two years before to five years after their primary diagnosis, while they were relapse-free. Annual prevalence of SA and DP was calculated. Logistic regression was used to estimate adjusted odds ratios (AOR) for long-term SA (>30\\xa0days) at one (y1) and three (y3) years post-diagnosis.\\nPrevalence of long-term SA was 68.1% in y1 and 16.3% in y5. Prevalence of DP progressively increased from 16.3% in y1 to 29.0% in y5. Predictors of long-term SA included age <50\\xa0years (y1:AOR\\xa0=\\xa01.79 [1.39-2.29]), TNM stage III (y1:AOR\\xa0=\\xa01.54 [1.03-2.31]; y3:AOR\\xa0=\\xa02.21 [1.32-3.72]), metastasis (y1:AOR\\xa0=\\xa01.64 [1.26-2.12]; y3:AOR\\xa0=\\xa01.51 [1.05-2.18]), comorbidity (y1:AOR\\xa0=\\xa02.41 [1.55-3.76]; y3 AOR\\xa0=\\xa04.62 [2.49-8.57]) and any combination of radiotherapy, chemotherapy and hormonal therapy (y1:AOR\\xa0=\\xa02.05-5.71).\\nAmong BC women who later developed relapse, those who had higher stages of BC, had comorbidity and received neoadjuvant and/or adjuvant therapy were at significantly higher risk of needing long-term SA after their diagnosis. Cardiometabolic abnormalities are a leading cause of death among women, including women with cancer.\\nThis study examined the association between prediagnosis cardiovascular health and total and cause-specific mortality among 12,076 postmenopausal women who developed local- or regional-stage invasive cancer in the Women\\'s Health Initiative (WHI). Cardiovascular risk factors included waist circumference, hypertension, high cholesterol, and type 2 diabetes. Obesity-related cancers included breast cancer, colorectal cancer, endometrial cancer, kidney cancer, pancreatic cancer, ovarian cancer, stomach cancer, liver cancer, and non-Hodgkin lymphoma. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for important predictors of survival.\\nAfter a median follow-up of 10.0 years from the date of the cancer diagnosis, there were 3607 total deaths, with 1546 (43%) due to cancer. Most participants (62.9%) had 1 or 2 cardiometabolic risk factors, and 8.1% had 3 or 4. In adjusted models, women with 3 to 4 risk factors (vs none) had a higher risk of all-cause mortality (HR, 1.99; 95% CI, 1.73-2.30), death due to cardiovascular disease (CVD) (HR, 4.01; 95% CI, 2.88-5.57), cancer-specific mortality (HR, 1.37; 95% CI, 1.1-1.72), and other-cause mortality (HR, 2.14; 95% CI, 1.70-2.69). A higher waist circumference was associated with greater all-cause mortality (HR, 1.17; 95% CI, 1.06-1.30) and cancer-specific mortality (HR, 1.22; 95% CI, 1.04-1.42).\\nAmong postmenopausal women diagnosed with cancer in the WHI, cardiometabolic risk factors before the cancer diagnosis were associated with greater all-cause, CVD, cancer-specific, and other-cause mortality. These results raise hypotheses regarding potential clinical intervention strategies targeting cardiometabolic abnormalities that require future prospective studies for confirmation.\\nThis study uses information from the Women\\'s Health Initiative (WHI) to find out whether cardiac risk factors are related to a greater risk of dying among older women with cancer. The WHI is the largest study of medical problems faced by older women in this country. The results show that women who have 3 or 4 risk factors are more likely to die of any cause, heart disease, or cancer in comparison with women with no risk factors. It is concluded that interventions to help to lower the burden of cardiac risk factors can have an important impact on survivorship among women with cancer. Everolimus plus exemestane is approved for\\xa0the treatment of hormone receptor-positive metastatic breast cancer (MBC) after progression on nonsteroidal aromatase inhibitors. The role of everolimus is less well defined in other breast cancer phenotypes and in combination\\xa0with other drugs.\\nWe conducted a systematic review and meta-analysis to assess the efficacy and safety of adding everolimus to standard of care (SoC) in MBC regardless of tumor phenotype and treatment type.\\nThe electronic databases PubMed and EMBASE were searched for eligible randomized trials. Pooled hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) and pooled risk ratios (RR) and odds ratios for objective response rates, disease control rate (DCR), and grade 3 or higher toxicity were meta-analyzed. Subgroup analyses compared survival outcomes by tumor phenotype.\\nData from 2826 patients from eight trials were analyzed. The addition of everolimus to SoC reduced the risk of disease progression by 29% (HR 0.71; 95% confidence interval [CI] 0.56-0.90). This did not translate into an OS benefit (HR 0.95; 95% CI 0.80-1.13). In addition, everolimus improved the DCR (RR 0.82; 95% CI 0.68-0.98), whereas it increased the risk of developing grade 3 or higher toxicity. The PFS benefit was more prominent for patients with hormone receptor-positive (+)/human epidermal growth factor receptor 2 (HER2)-negative (-) disease. For the HER2 (+) subgroup, the PFS benefit was restricted to patients with hormone receptor (-) disease.\\nEverolimus reduces the risk of disease progression in hormone receptor (+) MBC. In patients with HER2 (+) disease, the benefit is limited for those with hormone receptor (-) disease. Given the approval and use of newer drugs in MBC, clinical trials and real-world data are needed to confirm the benefit of everolimus and define the best treatment sequence strategy to adopt in that setting. BCL2 apoptosis regulator (BCL2) is a cause of tumorigenesis whose CA-repeat promoter polymorphisms has inconsistent association with various types of cancers. The association of BCL2 polymorphism with breast cancer was investigated in the Isfahan province of Iran. PCRamplification of the CA-repeat was followed by polyacrylamide gel electrophoresis and direct sequencing for 120 breast cancer women and an equal number of corresponding healthy control individuals. Seven different alleles, ranging from 11 to 17 CA-repeats were observed. Short alleles with 11 to 14 repeats were protective (OR 0.363, P\\u2009=\\u20090.001), but large alleles with 15 to 17 repeats were threatening against breast cancer development (OR 2.780, P\\u2009=\\u20090.001). Accordingly, genotypes with large alleles showed a higher risk of breast cancer development (OR 3.400, P\\u2009=\\u20090.004). ERS1\\\\ERBB2 positive breast cancer patients, but not PGRpositive ones, showed protection against breast cancer (OR 0.405, OR 0.346 respectively). In conclusion, women with at least one large allele of BCL2 were 3.4 times at higher risk of breast cancer development in the Isfahan province of Iran. Breast cancer treatment has been associated with vascular pathology. It is unclear if such treatment is also associated with long-term cerebrovascular changes. We studied the association between radiotherapy and chemotherapy with carotid pathology and brain perfusion in breast cancer survivors.\\nWe included 173 breast cancer survivors exposed to radiotherapy and chemotherapy, assessed\\u2009±\\u200921.2\\xa0years after cancer diagnosis, and 346 age-matched cancer-free women (1:2) selected from the population-based Rotterdam Study. Outcome measures were carotid plaque score, intima-media thickness (IMT), total cerebral blood flow (tCBF), and brain perfusion. Additionally, we investigated the association between inclusion of the carotid artery in the radiation field (no/small/large part), tumor location, and these outcome measures within cancer survivors.\\nCancer survivors had lower tCBF (-\\xa019.6\\xa0ml/min, 95%CI -\\xa037.3;-\\xa01.9) and brain perfusion (-\\xa02.5\\xa0ml/min per 100\\xa0ml, 95%CI -\\xa04.3;-\\xa00.7) than cancer-free women. No statistically significant group differences were observed regarding plaque score or IMT. Among cancer survivors, a large versus a small part of the carotid artery in the radiation field was associated with a higher IMT (0.05, 95%CI0.01;0.09). Also, survivors with a right-sided tumor had lower left carotid plaque score (-\\xa00.31, 95%CI -\\xa00.60;-\\xa00.02) and higher brain perfusion (3.5\\xa0ml/min per 100\\xa0ml, 95%CI 0.7;6.2) than those with a left-sided tumor.\\nOn average two decades post-diagnosis, breast cancer survivors had lower tCBF and brain perfusion than cancer-free women. Also, survivors with a larger area of the carotid artery within the radiation field had a larger IMT. Future studies should confirm if these cerebrovascular changes underlie the frequently observed cognitive problems in cancer survivors. The main intent of this treatise was to encapsulate tamoxifen citrate (TMXC) into polymeric micellar delivery system and evaluate the influence of TMXC-loaded micelles as a promising carrier on the in vitro cytotoxicity and cellular uptake of TMXC in treatment of breast cancer. Different formulae of polymeric micelles loaded with TMXC using mixtures of different Pluronic polymers were fabricated by thin-film hydration method and evaluated for morphology, drug entrapment efficiency, particle size, surface charge, in vitro liberation of TMXC, uptake by cancer cell lines, and cytotoxic effect against breast cancer cell lines such as MCF-7. The optimal TMXC-loaded micelles exhibited nano-sized particles and entrapped about 89.09\\u2009±\\u20094.2% of TMXC. In vitro liberation study revealed an extended TMXC escape of about 70.23\\u2009±\\u20095.9% over a period of 36\\xa0h. The optimized TMXC-loaded micelles formula showed enhanced cellular uptake of TMXC by 2.28 folds and showed a significant cytotoxic effect with MCF-7 breast cancer cells compared to TMXC solution. The obtained yield proposed that Pluronic micelles could be a promising potential delivery system for anticancer moieties. Fatalism is defined by feelings of pessimism, hopelessness, and powerlessness regarding cancer outcomes. Early researchers reported associations between race and cancer fatalism. Yet current evidence suggests that social determinants of health are better predictors of cancer fatalism than race. Therefore, the aim of this study was to examine the association between age, race, education, and cancer fatalism.\\nThree hundred ninety (n\\u2009=\\u2009390) women who attended a screening mammogram at the Joanne Knight Breast Health Center at Siteman Cancer Center at Washington University School of Medicine (St. Louis, MO) completed the Powe Fatalism Inventory (PFI), a 15-item self-report instrument used to operationalize cancer fatalism. We used Pearson\\'s correlation, independent samples t-tests, one-way ANOVA with post hoc tests, and linear regression to analyze the relationships between PFI total scores and age, race, and education.\\nThere were no differences between the mean PFI scores for Non-Hispanic Whites (1.89, SD 0.55) and African Americans (2.02, SD 0.76, p\\u2009=\\u20090.092, 95% CI 0.27 to 0.02). We found significant differences between the mean PFI scores across levels of education. Women who attained a high school degree or less (n\\u2009=\\u200972) reported higher PFI scores (2.24, SD 0.77) than women who attended some college or post-high school vocational training (n\\u2009=\\u2009111; 1.95, SD 0.61) and women with a college or postgraduate degree (n\\u2009=\\u2009206; 1.83, SD 0.57). When PFI score was regressed onto age, race, and education, only education significantly explained fatalism (B\\u2009=\\u2009-0.19, p\\u2009<\\u20090.001).\\nIn this study, cancer fatalism did not differ between Non-Hispanic White and African American women attending a screening mammogram. However, lower educational levels were associated with higher cancer fatalism. The previously observed associations between race and cancer fatalism may be explained by racial disparities in social determinants of health, such as education. Importantly, study findings indicate that the people with the greatest need for cancer fatalism interventions are those with lower educational levels. The germline variant spectrum of triple-negative breast cancer (TNBC) is different from that of other subtypes and has demonstrated ethnic differences. However, the germline variants of TNBC among Chinese patients and its clinical significance remain unclear.\\nUsing our multi-omics TNBC cohort (n\\u2009=\\u2009325), we determined the spectrum of germline variants in TNBC and aimed to illustrate their biological and clinical implications.\\nOverall, 16.0% (52 of 325) of TNBC patients harbored at least one pathogenic or likely pathogenic germline variant. These germline variants were associated with early-onset of TNBC, the occurrence of contralateral breast cancer, the basal-like immune-suppressed mRNA subtype, and the homologous recombination deficiency (HRD) mutation subtype. Somatic allele-specific imbalance was observed in 54.1% of these germline variants, which was correlated with early-onset of breast cancer and elevated HRD. BRCA1 (7.4%), RAD51D (2.8%) and BRCA2 (2.2%) were the genes most frequently mutated. RAD51D germline variants, especially K91fs, were enriched in Chinese patients with TNBC compared to Caucasian and African American patients. The Chinese-specific RAD51D germline variants were functionally associated with the instability of the RAD51D protein, HRD and sensitivity to PARP inhibitors.\\nChinese TNBC patients have a distinct spectrum of germline variants, with a remarkable impact on the clinical and molecular characteristics of the tumor. Integrative germline-somatic analysis may help in identifying TNBC patients who are most likely to be affected by their germline variants and in performing clinical interventions more precisely. The RAD51D variants enriched in our cohort may serve as therapeutic targets and guide precision treatment of TNBC. Medicaid expansion under the Patient Protection and Affordable Care Act may be associated with increased screening and may improve access to earlier treatment for cancer, but its association with mortality for patients with cancer is uncertain.\\nTo determine whether Medicaid expansion is associated with improved mortality among patients with cancer.\\nThis is a quasi-experimental, difference-in-difference (DID), cross-sectional, population-based study. Patients in the National Cancer Database with breast, lung, or colorectal cancer newly diagnosed from January 1, 2012, to December 31, 2015, were included. Data analysis was performed from January to May 2020.\\nLiving in a state where Medicaid was expanded vs a nonexpansion state.\\nThe main outcome was mortality rate according to whether the patient lived in a state where Medicaid was expanded.\\nA total of 523\\u202f802 patients (385\\u202f739 women [73.6%]; mean [SD] age, 54.8 [6.5] years) had a new diagnosis of invasive breast (273\\u202f272 patients [52.2%]), colorectal (111\\u202f720 patients [21.3%]), or lung (138\\u202f810 patients [26.5%]) cancer; 289\\u202f330 patients (55.2%) lived in Medicaid expansion states, and 234\\u202f472 patients (44.8%) lived in nonexpansion states. After Medicaid expansion, mortality significantly decreased in expansion states (hazard ratio [HR],\\u20090.98; 95% CI,\\u20090.97-0.99; P\\u2009=\\u2009.008) but not in nonexpansion states (HR,\\u20091.01; 95% CI,\\u20090.99-1.02; P\\u2009=\\u2009.43), resulting in a significant DID (HR,\\u20091.03; 95% CI,\\u20091.01-1.05; P\\u2009=\\u2009.01). This difference was seen primarily in patients with nonmetastatic cancer (stages I-III). After adjusting for cancer stage, the mortality improvement in expansion states from the periods before and after expansion was no longer evident (HR,\\u20091.00; 95% CI,\\u20090.98-1.02; P\\u2009=\\u2009.94), nor was the difference between expansion vs nonexpansion states (DID HR,\\u20091.00; 95% CI,\\u20090.98-1.02; P\\u2009=\\u2009.84).\\nAmong patients with newly diagnosed breast, colorectal, and lung cancer, Medicaid expansion was associated with a decreased hazard of mortality in the postexpansion period, which was mediated by earlier stage of diagnosis. Genetic testing for BRCA1/2 pathogenic variants has been used for targeted, individualized cancer prevention and treatment. A positive BRCA test result indicates a higher risk for developing BRCA-related cancers. During the past decade, testing criteria have loosened. The impact of these loosened criteria on BRCA testing in older women has not previously been studied.\\nTo assess whether the rate of positive BRCA test results changed between 2008 and 2018 among older women in the United States.\\nThis cross-sectional study used a 10% random sample of women 65 years of age or older from Optum\\'s deidentified Integrated Claims-Clinical data set (2008-2018), a large national electronic health record data set. A total of 5533 women with BRCA test results from January 1, 2008, to March 31, 2018, were evaluated.\\nAnnual percentage change in positive BRCA test results was evaluated. Multivariable logistic regression models were used to assess the association between positive test results and race/ethnicity, region of residence, income, educational level, and personal history of breast or ovarian cancer.\\nOf 5533 women 65 years of age or older (mean age, 68.1 years [95% CI, 67.9-68.4 years]) who underwent BRCA testing from 2008 to 2018, most (4679 [84.6%]) were non-Hispanic White women, and 1915 (34.6%) resided in the Midwest. Positive BRCA test results decreased from 85.7% (36 of 42) in 2008 to 55.6% (140 of 252) in 2018 (annual percentage change, -2.55; 95% CI, -3.45 to -1.64). Among patients with breast or ovarian cancer, positive test results decreased from 83.3% (20 of 24) in 2008 to 61.6% (61 of 99) in 2018, while among women without breast or ovarian cancer, positive test results decreased from 87.5% (21 of 24) in 2008 to 48.4% (74 of 153) in 2018 (annual percentage change, -3.17 vs -2.49; P\\u2009=\\u2009.29). Women with positive test results were more likely to be non-Hispanic Black women, to live in the West or South, to live in areas with a low percentage of college graduates, or to not have a personal history of breast or ovarian cancer.\\nThis study suggests that there was a significantly decreasing rate of positive BRCA test results among women 65 years of age or older. Socioeconomic and regional disparities in testing use remain an issue. Indoleamine 2,3-dioxygenase 1 (IDO1) causes tumor immune suppression. The IDO1 pathway inhibitor indoximod combined with a taxane in patients with ERBB2-negative metastatic breast cancer was tested in a prospective clinical trial.\\nTo assess clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.\\nThis phase 2 double-blinded randomized 1:1 placebo-controlled clinical trial enrolled patients at multiple international centers from August 26, 2013, to January 25, 2016. Eligibility criteria included ERBB2-negative metastatic breast cancer, ability to receive taxane therapy, good performance status, normal organ function, no previous immunotherapy use, and no autoimmune disease. The study was discontinued in June 2017 because of lack of efficacy. Data analysis was performed from February 2019 to April 2020.\\nA taxane (paclitaxel [80 mg/m2] weekly 3 weeks on, 1 week off, or docetaxel [75 mg/m2] every 3 weeks) plus placebo or indoximod (1200 mg) orally twice daily as first-line treatment.\\nThe primary end point was progression-free survival (PFS); secondary end points were median overall survival, objective response rate, and toxic effects. A sample size of 154 patients would detect a hazard ratio of 0.64 with 1-sided α\\u2009=\\u2009.1 and β\\u2009=\\u2009.2 after 95 events. Archival tumor tissue was stained with immunohistochemistry for IDO1 expression as an exploratory analysis.\\nOf 209 patients enrolled, 169 were randomized and 164 were treated (85 in the indoximod arm; 79 in the placebo arm). The median (range) age was 58 (29-85) years; 166 (98.2%) were female, and 135 (79.9%) were White. The objective response rate was 40% and 37%, respectively (indoximod vs placebo) (P\\u2009=\\u2009.74). The median (range) follow-up time was 17.4 (0.1-39.4) months. The median PFS was 6.8 months (95% CI, 4.8-8.9) in the indoximod arm and 9.5 months (95% CI, 7.8-11.2) in the placebo arm (hazard ratio, 1.2; 95% CI, 0.8-1.8). Differences between the experimental and placebo arms in median PFS (6.8 vs 9.5 months) and overall survival (19.5 vs 20.6 months) were not statistically significant. Grade 3 or greater treatment-emergent adverse events occurred in 60% of patients in both arms.\\nThis randomized clinical trial found that, among patients with ERBB2-negative metastatic breast cancer, addition of indoximod to a taxane did not improve PFS compared with a taxane alone.\\nClinicalTrials.gov Identifier: NCT01792050. None The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high circulating tumor cell (CTC) count (≥5 CTCs/7.5 mL) is a strong adverse prognostic factor for overall survival and progression-free survival (PFS).\\nTo compare the efficacy of a clinician-driven treatment choice vs a CTC-driven choice for first-line treatment.\\nIn the CTC arm, patients received chemotherapy or endocrine therapy according to the CTC count (chemotherapy if ≥5 CTCs/7.5 mL; endocrine therapy if <5 CTCs/7.5 mL), whereas in the control arm, the choice was left to the investigator.\\nIn the STIC CTC randomized, open-label, noninferiority phase 3 trial, participants were randomized to a clinician-driven choice of first-line treatment or a CTC count-driven first-line treatment choice. Eligible participants were premenopausal and postmenopausal women 18 years or older diagnosed with hormone receptor-positive, ERBB2-negative metastatic breast cancer. Data were collected at 17 French cancer centers from February 1, 2012, to July 28, 2016, and analyzed June 2019 to October 2019.\\nThe primary end point was the investigator-assessed PFS in the per-protocol population, with a noninferiority margin of 1.25 for the 90% CI of the hazard ratio.\\nAmong the 755 women in the per-protocol population, the median (range) age was 63 (30-88) years [64 (30-88) years for the 377 patients allocated to the CTC arm and 63 (31-87) years for the 378 patients allocated to the standard arm]; 138 (37%) and 103 (27%) received chemotherapy, respectively. Median PFS was 15.5 months (95% CI, 12.7-17.3) in the CTC arm and 13.9 months (95% CI, 12.2-16.3) in the standard arm. The primary end point was met, with a hazard ratio of 0.94 (90% CI, 0.81-1.09).\\nThis randomized clinical trial found that the CTC count may be a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor-positive, ERBB2-negative metastatic breast cancer.\\nClinicalTrials.gov Identifier: NCT01710605. Genes associated with parkinsonism may also be implicated in carcinogenesis, but their interplay remains unclear. We systematically reviewed studies (PubMed 1967-2019) reporting gene variants associated with both parkinsonism and cancer. Somatic variants were examined in cancer samples, whereas germline variants were examined in cancer patients with both symptomatic and asymptomatic (carriers) genetic parkinsonisms. Pooled proportions were calculated with random-effects meta-analyses. Out of 9,967 eligible articles, 60 were included. Of the 28 genetic variants associated with parkinsonism, six were also associated with cancer. In cancer samples, SNCA was predominantly associated with gastrointestinal cancers, UCHL1 with breast cancer, and PRKN with head-and-neck cancers. In asymptomatic carriers, LRRK2 was predominantly associated with gastrointestinal and prostate cancers, PRKN with prostate and genitourinary tract cancers, GBA with sarcoma, and 22q11.2 deletion with leukemia. In symptomatic genetic parkinsonism, LRRK2 was associated with nonmelanoma skin cancers and breast cancers, and PRKN with head-and-neck cancers. Cancer was more often manifested in genetic parkinsonisms compared to asymptomatic carriers. These results suggest that intraindividual genetic contributions may modify the co-occurrence of cancer and neurodegeneration. Tryptanthrin is an indole quinazoline alkaloid from the indigo-bearing plants, such as Isatis indigotica Fort. Typically, this natural compound shows a variety of pharmacological activities such as antitumor, antibacterial, anti-inflammatory and antioxidant effects. This study was conducted to assess the antitumor activity of tryptanthrin in breast cancer models both in vitro and in vivo, and to explore the important role of the inflammatory tumor microenvironment (TME) in the antitumor effects of tryptanthrin. Human breast adenocarcinoma MCF-7 cells were used to assess the antitumor effect of tryptanthrin in vitro. MTT assay and colony formation assay were carried out to monitor the antiproliferative effect of tryptanthrin (1.56~50.0 μmol L-1) on inhibiting the proliferation and colony formation of MCF-7 cells, respectively. The migration and invasion of MCF-7 cells were evaluated by wound healing assay and Transwell chamber assay, respectively. Moreover, the 4T1 murine breast cancer model was established to examine the pharmacological activity of tryptanthrin, and three groups with different doses of tryptanthrin (25, 50 and 100 mg kg-1) were set in study. Additionally, tumor volumes and organ coefficients were measured and calculated. After two weeks of tryptanthrin treatment, samples from serum, tumor tissue and different organs from tumor-bearing mice were collected, and the enzyme-linked immunosorbent assay (ELISA) was performed to assess the regulation of inflammatory molecules in mouse serum. Additionally, pathological examinations of tumor tissues and organs from mice were evaluated through hematoxylin and eosin (H&E) staining. The expression of inflammatory proteins in tumor tissues was measured by immunohistochemistry (IHC) and Western blotting. Tryptanthrin inhibited the proliferation, migration and invasion of MCF-7 cells, up-regulated the protein level of E-cadherin, and down-regulated those of MMP-2 and Snail, as suggested by the MCF-7 cell experiment. According to the results from in vivo experiment, tryptanthrin was effective in inhibiting tumor growth, and it showed favorable safety without inducing the fluctuations of body mass and organ coefficient (p > 0.05). In addition, tryptanthrin also suppressed the expression levels of NOS1, COX-2 and NF-κB in mouse tumor tissues, and regulated those of IL-2, IL-10 and TNF-α in the serum of tumor cells-transplanted mice. Tryptanthrin exerted its anti-breast cancer activities through modulating the inflammatory TME both in vitro and in vivo. The molecular architecture of pH-responsive amphiphilic block copolymers, their self-assembly behavior to form nanoparticles (NPs), and doxorubicin (DOX)-loading technique govern the extent of DOX-induced cardiotoxicity. We observed that the choice of pH-sensitive tertiary amines, surface charge, and DOX-loading techniques within the self-assembled NPs strongly influence the release and stimulation of DOX-induced cardiotoxicity in primary cardiomyocytes. However, covalent conjugation of DOX to a pH-sensitive nanocarrier through a \"conditionally unstable amide\" linkage (PCPY-cDOX; PC = polycarbonate and PY = 2-pyrrolidine-1-yl-ethyl-amine) significantly reduced the cardiotoxicity of DOX in cardiomyocytes as compared to noncovalently encapsulated DOX NPs (PCPY-eDOX). When these formulations were tested for drug release in serum-containing media, the PCPY-cDOX systems showed prolonged control over drug release (for ∼72 h) at acidic pH compared to DOX-encapsulated nanocarriers, as expected. We found that DOX-encapsulated nanoformulations triggered cardiotoxicity in primary cardiomyocytes more acutely, while conjugated systems such as PCPY-cDOX prevented cardiotoxicity by disabling the nuclear entry of the drug. Using 2D and 3D (spheroid) cultures of an ER + breast cancer cell line (MCF-7) and a triple-negative breast cancer cell line (MDA-MB-231), we unravel that, similar to encapsulated systems (PCPY-eDOX-type) as reported earlier, the PCPY-cDOX system suppresses cellular proliferation in both cell lines and enhances trafficking through 3D spheroids of MDA-MB-231 cells. Collectively, our studies indicate that PCPY-cDOX is less cardiotoxic as compared to noncovalently encapsulated variants without compromising the chemotherapeutic properties of the drug. Thus, our studies suggest that the appropriate selection of the nanocarrier for DOX delivery may prove fruitful in shifting the balance between low cardiotoxicity and triggering the chemotherapeutic potency of DOX. 17β-Hydroxysteroid dehydrogenases act at the pre-receptor level, catalysing interconversion at the C17 position between oxidized and reduced forms of steroidal nuclear receptor ligands. The type 1 enzyme, expressed in malignant cells, catalyses reduction of the less active estrone to estradiol and inhibitors have therapeutic potential in estrogen-dependent diseases such as breast and ovarian cancers and in endometriosis. Synthetic decoration of the nonsteroidal\\xa0 N -phenyl-1,2,3,4-tetrahydroisoquinoline (THIQ) template in all three ring systems was pursued using Pomeranz-Fritsch-Bobbitt, Pictet-Spengler and Bischler-Napieralski approaches to explore the viability of this scaffold as a steroid mimic. Derivatives were evaluated biologically in vitro as type 1 enzyme inhibitors in a bacterial cell homogenate as source of recombinant protein. Structure-activity relationships are discussed. THIQs possessing a 6-hydroxyl group, lipophilic substitutions at the 1- or 4- positions in combination with\\xa0 N -4\\'-chlorophenyl substitution were most favourable for activity. Of these, racemic\\xa0 41c \\xa0had an IC 50 \\xa0of ca. 350 nM, testifying to the applicability of this novel approach. Polarization regulation of tumor-association macrophages (TAMs) is a promising treatment method for tumors, but aiming at TAMs alone shows unsatisfactory therapeutic efficiency. Therefore, we designed a parallel and cascade control system for both macrophage polarization and tumor cell inhibition. The system is composed of cationic lipopeptides with an arginine-rich periphery (RLS) and anionic magnetic nanoparticles (MNPs) for fleet transfection of miR-125b. Based on the highly efficient magnetofection, miR-125b successfully shows a parallel effect on both M1, promoting polarization by targeting interferon regulatory factor 4 (IRF4) in macrophages, and tumor cell inhibition, by targeting ETS proto-oncogene 1 and cyclin- J. The cascading effect on M1-associated genes is upregulated by up to two orders of magnitude, while M2-associated genes are downregulated. Meanwhile, MNPs also have an effect on the TAM polarization and 4T1 tumor cell inhibition via inflammatory related gene expression and Fenton reaction. Further mimicking the co-culture of RAW264.7 and 4T1 cells in vitro confirmed the synergistic therapy effect. In the treatment of orthotopic breast cancer in mice, considerable M1 macrophage polarization was observed in the RM125b treated group, showing distinct tumor-suppressive effects, with a tumor weight reduction of 60% and tumor metastasis suppression of 50%. None It has proved that there is an association between cancer and volatile organic compounds (VOCs) of exhaled breath. This study targets on verifying the existence of specific VOCs in breathing in breast cancer patients, especially those with ductal carcinoma in situ (DCIS).\\nThere were a total of 203 participants included in the final analysis, which included 71 (35.0%) patients with histologically confirmed breast cancer (including 13 with DCIS, 31 with lymph node metastasis-negative status, and 27 with lymph node metastasis-positive status), 78 (38.4%) healthy volunteers, and 54 (26.6%) patients with histologically confirmed gastric cancer. Gas chromatography-mass spectrometry and solid-phase microextraction were used to analyze the breath samples for the presence of VOCs.\\nThere were significant differences in the volatile organic metabolites between the DCIS, lymph node metastasis-negative breast cancer, and lymph node metastasis-positive breast cancer groups compared with the healthy controls as well as between the breast cancer and gastric cancer patients. An overlapping set of seven VOCs, including (S)-1,2-propanediol, cyclopentanone, ethylene carbonate, 3-methoxy-1,2-propanediol, 3-methylpyridine, phenol, and tetramethylsilane, was significantly different between the breast cancer patients and healthy individuals as well as between the breast cancer and gastric cancer patients. The combination of these seven compounds was considered as a biomarker for breast cancer. The sensitivity for predicting DCIS by this set of seven compounds was determined to be 80.77%, and the specificity was determined to be 100%.\\nThis set of seven breast cancer-specific VOCs can be regarded as one particular expiratory marker for DCIS and will help to establish new screening methods for early breast cancer. Withaferin A (WA) exhibits cancer chemopreventive efficacy in preclinical models representative of two different subtypes of breast cancer. However, the mechanism(s) underlying breast cancer chemoprevention by WA is not fully elucidated. We performed RNA-seq analyses using a non-tumorigenic mammary epithelial cell line (MCF-10A) and human breast cancer cells (BCC) belonging to the luminal-type (MCF-7), HER2-enriched (SK-BR-3), and basal-like subtype (MDA-MB-231) to identify novel cancer-selective mechanistic targets of WA. The WA-regulated transcriptome was strikingly different between MCF-10A versus BCC. The Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed downregulation of genes associated with cellular senescence in WA-treated BCC. Consequently, the number of senescence-associated β-galactosidase positive cells was decreased significantly in WA-treated BCC but not in the MCF-10A cells. WA treatment caused upregulation of senescence marker p21 more robustly in BCC than in MCF-10A. Breast cancer prevention by WA in rats was also associated with upregulation of p21 protein expression. The Reactome pathway analyses indicated upregulation of genes associated with cellular response to stress/external stimuli in WA-treated BCC but not in MCF-10A. Two proteins represented in these pathways (HSPA6 and NRF2) were further investigated. While HSPA6 was dispensable for WA-mediated apoptosis and autophagy or inhibition of cell migration, the NRF2 knockout cells were more resistant to apoptosis resulting from WA treatment than control cells. Finally, expression of some glycolysis-related proteins was decreased by WA treatment both in vitro and in vivo. In summary, this study provides novel insights into cancer-selective pathways affected by WA that may contribute to its chemopreventive efficacy in breast cancer. The application of minimally invasive interventional breast surgery is becoming more and more widespread. The accurate puncture of breast cancer needs to solve the problems of tissue deformation and target displacement.\\nIn this study, we analyzed the process of leech blood absorption and developed a robotic needle insertion method based on bionic technology to improve the accuracy of breast cancer diagnosis and treatment. Among them, the design purpose of the sucker manipulator is to adjust and fix the breast tissue. We use uncalibrated visual servo to control soft tissue deformation.\\nWe compare the puncture effect of bionic needle puncture robot and common needle puncture on breast prosthesis and in vitro tissue. Experimental data shows that, compared with ordinary needle insertion, the robotic needle insertion method based on bionic technology greatly reduces the targeting error.\\nThis method is expected to provide a safe and effective alternative to traditional puncture for breast cancer diagnosis and treatment. This article is protected by copyright. All rights reserved. To propose and evaluate a fully automated technique for quantification of fibroglandular tissue (FGT) and background parenchymal enhancement (BPE) in breast MRI.\\nWe propose a fully-automated method, where after preprocessing, FGT is segmented in T1-weighted, nonfat-saturated MRI. Incorporating an anatomy-driven prior probability for FGT and robust texture descriptors against intensity variations, our method effectively addresses major image processing challenges, including wide variations in breast anatomy and FGT appearance among individuals. Our frame-work then propagates this segmentation to dynamic contrast enhanced (DCE)-MRI to quantify BPE within the segmented FGT regions. Axial and sagittal image data from 40 cancer-unaffected women were used to evaluate our proposed method versus a manually-annotated reference standard.\\nHigh spatial correspondence was observed between the automatic and manual FGT segmentation (mean Dice similarity coefficient 81.14%). The FGT and BPE quantifications (denoted FGT% and BPE%) indicated high correlation (Pearson\\'s r = 0:99 for both) between automatic and manual segmentations. Furthermore, the differences between the FGT% and BPE% quantified using automatic and manual segmentations were low (mean differences: -0:66±2:91% for FGT% and -0:17±1:03% for BPE%). When correlated with qualitative clinical BI-RADS ratings, the correlation coefficient for FGT% was still high (Spearman\\'s ρ = 0:92), whereas that for BPE was lower (ρ = 0:65). Our proposed approach also performed significantly better than a previously validated method for sagittal breast MRI.\\nOur method demonstrated accurate fully-automated quantification of FGT and BPE in both sagittal and axial breast MRI. Our results also suggested the complexity of BPE assessment, demonstrating relatively low correlation between segmentation and clinical rating. This study examines breast and cervical cancer screening uptake in a cancer education and patient navigation (PN) program for residents of rural and border counties in Texas by level of participation (education only, PN only, or education and PN). Data collected from March 1, 2012, to November 5, 2016, included 6663 follow-up surveys from participants aged 21-74. Logistic regression models assessed program participation on the odds of completing breast or cervical cancer screening. For women aged 40-74\\xa0years (N\\u2009=\\u20094942; mean age\\u2009=\\u200952\\xa0years), 58.4% reported a mammogram within 6\\xa0months on average from initial contact. In the breast cancer screening model, women who only received PN (OR: 6.06, CI: 4.87-7.53) or who participated in both the education plus PN program (OR: 3.33, CI: 2.77-4.02) had higher odds of mammogram screening compared to women who only received education. For women aged 21-64\\xa0years (N\\u2009=\\u20096169; mean age\\u2009=\\u200946\\xa0years), 37.7% received a Papanicolaou (Pap) test within 6\\xa0months on average from initial contact. In the Pap screening model, both education and PN (OR: 3.23, CI: 2.66-3.91) and PN only (OR: 2.35, CI: 1.88-2.93) groups had higher odds of screening for cervical cancer compared to those only receiving education. Graphed predicted probabilities examined significant interactions between race/ethnicity/language and program participation (P\\u2009<\\u20090.0001) for both screenings. PN, solely or in combination with education, is an effective strategy to increase screening for breast and cervical cancer, beyond educational outreach efforts alone, among un-/underserved, racially/ethnically diverse women in rural and border Texas counties. We assessed pulmonary toxicity of cyclin-dependent kinase (CDK)4/6 inhibitors by analyzing the publicly available FDA Adverse Event Reporting System (FAERS).\\nReports of interstitial lung disease (ILD) were characterized in terms of demographic information, including daily dose, latency, concomitant drugs known to be associated with ILD, and causality assessment (adapted WHO system). Disproportionality analyses were carried out by calculating reporting odds ratios (RORs) with 95% confidence interval (CI), accounting for major confounders, including notoriety and competition biases.\\nILD reports (N\\xa0=\\xa0161) represented 2.1% and 0.3% of all reports for abemaciclib and palbocilcib/ribociclib, respectively, with negligible proportion of concomitant pneumotoxic drugs. Increased reporting was found for CDK4/6 inhibitors when compared to other drugs (ROR\\u2009=\\xa01.50; 95%CI\\u2009=\\xa01.28-1.74), and abemaciclib vs other anticancer agents (4.70; 3.62-5.98). Sensitivity analyses confirmed a strong and consistent disproportionality for abemaciclib. Higher-than-expected reporting emerged for palbociclib (1.38; 1.07-1.77) and ribociclib (2.39; 1.34-3.92) only when removing Japan reports. ILD occurred at recommended daily doses, with median latency ranging from 50 (abemaciclib) to 253 (ribociclib) days. Causality was highly probable in 55% of abemaciclib cases, probable in 68% of palbociclib cases.\\nIncreased reporting of ILD with CDK4/6 inhibitors calls for further comparative population-based studies to characterize and quantify the actual risk, taking into account drug- and patient-related risk factors. These findings strengthen the role of (a) timely pharmacovigilance to detect post-marketing signals through FAERS and other real-world data, (b) clinicians to assess early, on a case-by-case basis, the potential responsibility of CDK4/6 inhibitors when diagnosing a lung injury. The 21-gene Breast Recurrence Score test predicts benefit from adjuvant chemotherapy in estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer (BC). We examined whether the 21-gene assay predicts response to neoadjuvant chemotherapy (NCT).\\nWe identified patients with stage I-III ER+/HER2- BC treated with NCT from the Young Women\\'s Breast Cancer Study, a prospective cohort of women diagnosed with BC at age ≤40 years. The 21-gene assay was performed on tumor specimens removed prior to NCT either as part of clinical care or retrospectively for research. Pathological complete response (pCR) was defined as ypT0/is ypN0. The relationship between Recurrence Score result and pCR was evaluated using logistic regression modeling.\\n76 women received NCT for ER+/HER2- BC and were eligible for this analysis. Median age at diagnosis was 37 years (range 24-40). Scores ranged between 5 and 77 with 50% >25 and 5% <11. Median Recurrence Score result was significantly higher among tumors achieving pCR vs. non-pCR response (61.5 vs. 23, p\\nIn young women with ER+/HER2- BC who received NCT, higher pretreatment Recurrence Score result was associated with an increased likelihood of pCR. Gene expression profile assays may have a role in decision making in young women in need of neoadjuvant therapy. Breast spiradenoma is extremely rare, with only 4 cases reported previously. We describe an instructive case of breast spiradenoma resembling adenoid cystic carcinoma (AdCC). A 71-year-old woman underwent excisional biopsy of a breast mass after a conclusive diagnosis was unable to be obtained from core needle biopsy showing an AdCC-like pattern. Histopathologically, the lesion demonstrated solid and cribriform foci comprising basaloid cells, luminal cells, and eosinophilic hyaline material, reminiscent of solid-basaloid AdCC, alongside convoluted lumens, stromal edema, lymphocytic infiltration, and c-kit negativity. On molecular analysis, neither MYB fusion genes nor CYLD gene abnormalities were identified. These results were supportive of spiradenoma. Salivary gland- and skin adnexal-type tumors are challenging to diagnose due to morphological overlaps. This case, highlighting histopathological and molecular features, shows that breast spiradenoma can be a diagnostic pitfall among the differential diagnoses of AdCC. Male patients with breast cancer (BrC) have increased risk of developing 2nd-primary BrC (2nd-BrC). Given the relative rarity of male BrC, population-based registries are needed to analyze overall survival (OS) outcomes for these patients.\\nUsing the Surveillance, Epidemiology and End Results registry of patients diagnosed from 1975 to 2016, a cohort study of men whose only malignancy was BrC (BrC-O; \\nThe SIR for 2nd-BrC was 32.95 (95%CI:[23.85-44.38],\\nPatients with male BrC are at significantly increased risk of 2nd BrC, but they can expect similar post-BrC prognosis (versus those without 2nd-BrC), after adjusting for patient demographics and tumor characteristics known to affect OS.\\nNone.  Breast cancer is the common cancer among females and a leading cause of mortality among them globally, its rates are three times higher in developing countries. Breast self-examination (BSE) had an important role in early detection, increasing the survival rate of breast cancer patients, despite these benefits, the rates of practicing BSE are low, especially in developing countries.\\nTo assess the levels of awareness about breast cancer, and BSE among the detainees of Dar-Altaebat facility, a female\\'s detention facility in Khartoum, Sudan.\\nA cross-sectional study conducted at Dar-Altaebat a female imprisonment facility in Khartoum, Sudan. 354 participants were randomly selected from the total population of the facility. Data was collected using a self-administered structured questionnaire, which was composed of socio-demographic section, knowledge section, attitude section, and breast self-examination section. Data was analyzed using statistical package for social sciences(SPSS) software.\\n330 participants responded to the questionnaire, their mean age was (31, SD: 11.2) years, 126 (38.2%) of them were illiterate, 196 (59.4%) were married, and the majority of them 177 (76.3%) were housewives. their overall knowledge score revealed that 185(56.2%) of them had poor knowledge about breast cancer. 218 (66.3%) of them had poor knowledge about breast self-examination, however 314 (95.3%) thought that it was important. 315 (95.5%) of the participants had poor practice towards breast self-examination.\\nPoor levels of knowledge about breast cancer were reported among the detainees. Additionally, their level of knowledge and practice of breast self-examination was also low, thus more health education campaigns are recommended in such facilities. Metaplastic breast cancer (MBC) is a rare, aggressive variant of breast cancer, usually triple negative disease and chemotherapy refractory. Despite this, the standard of care remains the same as invasive ductal breast cancer. We sought to analyze patterns of care and outcomes among patients with metastatic MBC.\\nPatients over 18 years diagnosed with metastatic MBC from 2004-2015 were identified in the National Cancer Database (NCDB). Clinical and demographic details were compared between two groups (chemotherapy vs no chemotherapy). Logistic regression was performed to assess for predictors of receiving chemotherapy. The Kaplan-Meier method was used to assess overall survival (OS) and Cox regression analysis was used to assess the impact of covariates on OS.\\nThere were 7,580 patients with MBC of which 417 (5.5%) presented with metastatic disease. Median age was 65 years (interquartile range (IQR) 54-76) and median follow up for living patients was 48 months (IQR 31-77). One hundred and fifty-six (37.4%) patients received chemotherapy. On multivariable logistic regression analyses, treatment at an academic facility was associated with an increased likelihood of receiving chemotherapy (OR 3.14, 95% CI 1.95-5.03, p<0.001) while age ≥65 years (OR 0.54, 95% CI 0.34-0.86, p=0.009) and receipt of hormonal therapy (OR 0.35, 95% CI 0.15-0.85, p=0.021) were associated with a decreased likelihood of receiving chemotherapy. On multivariable Cox regression analysis, higher Charlson-Deyo score (hazard ratio (HR) 1.35-1.78, p<0.05) was associated with worse survival while receipt of chemotherapy (HR 0.76, 95% CI 0.59-0.99, p=0.041) and having insurance (HR 0.34-0.47, p<0.05) were associated with improved survival. Patients who received chemotherapy had improved median (twelve versus eight months), one-year (51% versus 38%), and two-year (35% versus 21%) OS, as compared to those who did not receive chemotherapy (p=0.006).\\xa0 Conclusions: In this study of MBC patients, there was a survival benefit with palliative chemotherapy in the setting of metastatic disease. As expected, treatment was most often given to younger patients. Immunoglobulin superfamily member 10 (IGSF10) is a member of the immunoglobulin superfamily that is expressed at high levels in both the gallbladder and ovary. Currently, the role and possible mechanism of IGSF10 in breast cancer remain unclear.\\nBy applying real-time quantitative polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC), the expression of IGSF10 in breast cancer cells and tissues was detected. We collected the clinical information from 700 patients with breast cancer in The Cancer Genome Atlas (TCGA), and analyzed the relationship between IGSF10 expression and the clinicopathological features and survival outcomes of these patients. The potential mechanisms and pathways associated with IGSF10 in breast cancer were explored by performing a gene set enrichment analysis (GSEA).\\nAccording to TCGA data, qRT-PCR and IHC experiments, levels of the IGSF10 mRNA and protein were significantly decreased in breast cancer tissues. IGSF10 expression was significantly correlated with age, tumor size, and tumor stage. Moreover, shorter overall survival (OS) and relapse-free survival (RFS) correlated with lower IGSF10 expression, according to the survival analysis. The multivariate analysis identified that IGSF10 as an independent prognostic factor for the OS (hazard ratio (HR) = 1.793, 95% confidence interval (CI) [1.141-2.815], \\nThis study revealed a clear relationship between IGSF10 expression and the tumorigenesis of breast cancer for the first time. Therefore, further studies are needed to understand the mechanism of IGSF10 in breast cancer. Antibodies targeting the co-inhibitory receptor programmed cell death 1 (PDCD1, best known as PD-1) or its main ligand CD274 (best known as PD-L1) have shown some activity in patients with metastatic triple-negative breast cancer (TNBC), especially in a recent Phase III clinical trial combining PD-L1 blockade with taxane-based chemotherapy. Despite these encouraging findings, however, most patients with TNBC fail to derive significant benefits from PD-L1 blockade, calling for the identification of novel therapeutic approaches. Here, we used the 4T1 murine mammary cancer model of metastatic and immune-resistant TNBC to test whether focal radiation therapy (RT), a powerful inducer of immunogenic cell death, in combination with various immunotherapeutic strategies can overcome resistance to immune checkpoint blockade. Our results suggest that focal RT enhances the therapeutic effects of PD-1 blockade against primary 4T1 tumors and their metastases. Similarly, the efficacy of an antibody specific for V-set immunoregulatory receptor (VSIR, another co-inhibitory receptor best known as VISTA) was enhanced by focal RT. Administration of cyclophosphamide plus RT and dual PD-1/VISTA blockade had superior therapeutic effects, which were associated with activation of tumor-infiltrating CD8 Studying tissue hemodynamics following breast compression has the potential to reveal new contrast mechanisms for evaluating breast cancer. However, how compression will be distributed and, consequently, how hemodynamics will be altered inside the compressed breast remain unclear. To explore the effect of compression, 12 healthy volunteers were studied by applying a step compression increase (4.5-53.4 N) using an optical imaging system capable of concurrently measuring pressure distribution and hemodynamic responses. Finite element analysis was used to predict the distribution of internal fluid pressure (IFP) in breast models. Comparisons between the measured pressure distribution and the reconstructed hemodynamic images for the healthy volunteers indicated significant (p\\u2009<\\u20090.05) negative correlations. The findings from a breast cancer patient showed that IFP distribution during compression strongly correlates with the observed differential hemodynamic images. We concluded that dynamic breast compression results in non-uniform internal pressure distribution throughout the breast that could potentially drive directed blood flow. The encouraging results obtained highlight the promise of developing dynamic optical imaging biomarkers for breast cancer by interpreting differential hemodynamic images of breast tissue during compression in the context of measured pressure distribution and predicted IFP. Ginseng polysaccharide (GPS) is known for its efficacy in cancer therapy; however, its regulatory mechanism in breast cancer (BC) remains unclear. To analyze the effect of GPS on BC cell proliferation, cell proliferation rate calculations, western blotting, plasmid transfections, electrophoretic mobility shift assays and chromatin immunoprecipitation assays were performed. GPS treatment in the culture cell medium inhibited cell proliferation in the BC cell line MDA-MB-231. In addition, the E-cadherin level was enhanced while the vimentin level was suppressed following GPS treatment (both P<0.05). Furthermore, the levels of apoptotic markers, including cleaved-Caspase-3 and p53, and inflammatory response markers, including plasminogen activator inhibitor and TNF-α, were induced by GPS treatment in MDA-MB-231 cells (all P<0.05). These results indicated that GPS supplementation activated the inflammatory response and apoptosis in BC cells. GPS treatment activated the phosphorylation levels of c-Jun N-terminal kinase, Akt and NF-κB. In MDA-MB-231 cells, GPS resulted in the accumulation of the NF-κB components p65, p50 and Ikaros family zing finger protein 1 (IKZF1; all, P<0.05). Chromatin immunoprecipitation and electrophoretic mobility shift assays indicated that p65 bound to the IKZF1 promoter. The overexpression of IKZF1 or p65 inhibited MDA-MB-231 cell proliferation (P<0.05), indicating that GPS treatment may inhibit BC cell proliferation by the activation of IKZF1. Taken together, these results suggested that GPS significantly inhibited BC cell proliferation via the control of the biological processes, including the activation of p65-IKZF1 signaling and apoptosis. The data indicated a novel mechanism for further understanding of cancer cell proliferation. To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) \\nThis randomized, double-blind, phase III study was conducted between 9 December 2016 and 29 March 2019. Postmenopausal women with HR-positive, HER2-negative ABC with no prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) received abemaciclib (150\\u2009mg twice daily) or placebo plus: anastrozole (1\\u2009mg/day) or letrozole (2.5\\u2009mg/day) (cohort A) or fulvestrant (500\\u2009mg per label) (cohort B). The primary endpoint was progression-free survival (PFS) in cohort A, analyzed using the stratified log-rank test. Secondary endpoints were PFS in cohort B (key secondary endpoint), objective response rate (ORR), and safety. This interim analysis was planned after 119 PFS events in cohort A.\\nIn cohort A, 207 patients were randomly assigned to the abemaciclib arm and 99 to the placebo arm. Abemaciclib significantly improved PFS \\nThe addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population. Poria cocos (Fuling), a natural plant, has recently emerged as a promising strategy for cancer treatment. However, the molecular mechanisms of Poria cocos action in breast cancer remain poorly understood.\\nTCMSP database was used to screen the potential active ingredients in Poria cocos. GEO database was used to identify differentially expressed genes. Network pharmacology was used to identify the specific pathways and key target proteins related to breast cancer. Finally, molecular docking was used to validate the results.\\nIn our study, 237 targets were predicted for 15 potential active ingredients found in Poria cocos. An interaction network of predicted targets and genes differentially regulated in breast cancers was constructed. Based on the constructed network and further analysis including network topology, KEGG, survival analysis, and gene set enrichment analysis, 3 primary nodes were identified as key potential targets that were significantly enriched in the PPAR signaling pathway.\\nThe results showed that potential active ingredients of Poria cocos might interfere with breast cancer through synergistic regulation of PTGS2, ESR1, and FOS. Breast cancer is the most frequently reported cancer among women in the Middle East and North Africa (MENA) region. However, the available data about women breast cancer from the MENA and particularly from the Northern Emirates region of the United Arab Emirates (UAE) are scarce and inconsistent. Therefore, this study estimated the incidence, patient-specific factors including 25(OH)D levels, and clinicopathological features of breast cancer in women from the Northern Emirates.\\nWe conducted this retrospective case-control study on 1,048 women who were referred to the Sharjah Breast Care Centre at University Hospital Sharjah between March 2016 and July 2018. Multivariate logistic regression was used for the statistical analysis of clinical data.\\nOut of 1048 women with breast-related conditions referred to our canter, 94 (10%) were diagnosed with breast cancer (1 in 11), and approximately 1 in 5 of these women was younger than 40 years. After adjusting for age, body mass index and menopause status, women with serum 25-hydroxyvitamin D [25(OH)D] levels lower than 20 ng/mL were found to be at higher risk of breast cancer (odd ratio, 4.63; 95% CI, 2.61-8.23). The majority of breast cancer cases had invasive-ductal carcinoma with hormone-positive receptor molecular subtype (78 cases out of 94, 83%). HER2 overexpressing tumor (3+ by immunohistochemistry (IHC) or by fluorescence in situ hybridization (FISH)) was seen more in women younger than 40 years as compared to older women (7 cases out of 19 HER2 expressed tumors, \\nOur study cohort showed a mean age of diagnosis of breast cancer in women a decade earlier than in the developed countries. Furthermore, women with breast cancer tend to be serum 25(OH)D deficient at diagnosis and to have luminal A tumors. The degree of confidence one should place on non-randomised observational trials studies which estimate the benefit of screening depends on the validity of the analytic method employed. As is the case for all observational trials, screening evaluation studies are subject to bias. The objective of this study was to create a simulated data set and to compare four analytic methods in order to identify the method which was the least biased in terms of estimating the underlying hazard ratio.\\nWe simulated a cohort of 100,000 women who were accorded US national rates of breast cancer incidence and breast cancer mortality over their lifetime. We assigned at random one-half of them to initiate mammography screening between ages 50 and 60. We used four different analytic approaches to estimate the hazard ratio under a null model (true HR = 1.0) and under a protective model (true HR = 0.80). Two models used the entire data set (with and without including mammography as a time-dependent covariate) and two models invoked matching of screened women with unscreened women (with and without excluding of women who had a mammogram after study initiation). For each of the four analytic methods, we compared the observed hazard ratio with the true hazard ratio. We considered an analytic method to be valid if the observed hazard ratio was close to the true hazard ratio.\\nTwo simple analytic methods generated biased results that led to spurious protective effects observed when none was there. The least biased method was based on matching screened and unscreened women and which emulated a randomized trial design, wherein the unexposed control had no mammogram prior to study entry, but she was not excluded or censored if she had a mammogram after the index date.\\nThere is no single ideal method to analyze observational data to evaluate the effectiveness of screening mammography (ie, which generates an unbiased estimates of the underlying hazard ratio) but designs which emulate randomised trials should be promoted. Breast cancer is a common malignancy worldwide. Smartphones have gradually become indispensable to our modern lives and have already changed lifestyles of human beings. To our best knowledge, no study has investigated the relationship between smartphone use and breast cancer. This case-control study purposely investigated the relationship between smartphone use and breast cancer risk.\\nThis was a case-control study comprising 894 healthy controls and 211 patients with breast cancer. All participants were asked to respond to standard questionnaires to collect information on sleep quality, smartphone addiction, and smartphone use.\\nParticipants with smartphone addiction had a significantly higher 1.43-fold risk of breast cancer. Individuals with the habitual behavior of smartphone use >4.5 minutes before bedtime had a significantly increased 5.27-fold risk of breast cancer compared to those who used a smartphone for ≤4.5 minutes before bedtime. Additionally, a closer distance between the smartphone and the breasts when using the smartphone exhibited a significantly increased 1.59-fold risk. Participants who carried their smartphone near their chest or waist-abdomen area had significantly increased 5.03-fold and 4.06-fold risks of breast cancer, respectively, compared to those who carried the smartphone below the waist. Moreover, there was a synergistic effect of smartphone addiction and smartphone use of >4.5 minutes before bedtime which increased the breast cancer risk.\\nExcessive smartphone use significantly increased the risk of breast cancer, particularly for participants with smartphone addiction, a close distance between the breasts and smartphone, and the habit of smartphone use before bedtime. Recently, the significant regulatory effects of lncRNAs on the oncogenesis and growth of tumor have been demonstrated by an increasing number of research projects. A previous study showed that \\nqRT-PCR was used to assess the relative expression of \\nWe identified that \\nRelying on the  Long noncoding RNAs (lncRNAs) exert important functions in the progression of cancers. Currently, we aim to investigate the potential roles of lncRNA ADAM Metallopeptidase with Thrombospondin Type 1 Motif 9 Antisense RNA 1 (ADAMTS9-AS1) in breast carcinoma.\\nThe expressions of ADAMTS9-AS1 and miR-513a-5p in breast carcinoma tissues and cell lines were detected using qRT-PCR. Cell Counting Kit-8 (CCK-8) and transwell assays were used to assess the viability and invasive ability of breast cancer cells. The direct interaction between ADAMTS9-AS1 and miR-513a-5p was predicted using bioinformatics tools. The target of miR-513a-5p, ZFP36 Ring Finger Protein (ZFP36) was validated by luciferase assay. The expression of ZFP36 was measured using Western blot assay. Breast cancer MDA-MB-231 cells growth in vivo was evaluated using xenograft tumor assay.\\nADAMTS9-AS1 was downregulated in breast cancer tissues as well as cell lines. Upregulation of ADAMTS9-AS1 suppressed the growth and invasiveness of breast carcinoma cells in vitro as well as inhibiting cellgrowth in vivo. Furthermore, ZFP36 was manifested as the target gene of miR-513a-5p and negatively modulated by ADAMTS9-AS1. In addition, overexpression of ADAMTS9-AS1 neutralized the promoting impact of miR-513a-5p on the aggressiveness of breast cancer cells.\\nIn conclusion, lncRNA ADAMTS9-AS1 inhibited the aggressive phenotypes of breast carcinoma cells via sponging miR-513a-5p and regulating ZFP36. The prognosis of HER2-positive metastatic breast cancer (MBC) has radically changed in recent years and continues to improve due to the broad application of effective therapies like monoclonal antibodies and small molecules targeting HER2. Persistent dependency of tumor cells on the oncogene HER2, on one hand, as well as low expression levels in healthy tissue, on the other hand, make this protein an ideal target for anti-cancer therapy. New HER2 targeting strategies including targeted delivery of cytotoxic drugs via HER2 receptor have been developed. Recently, the US Food and Drug Administration (FDA) approved three new drugs for the treatment of HER2-positive MBC: the antibody-drug conjugate trastuzumab deruxtecan and the two tyrosine kinase inhibitors neratinib and tucatinib. Here, we summarize recent publications and developments of novel anti-HER2 therapies like monoclonal antibodies with improved properties compared to trastuzumab and bispecific antibodies, which bind two different HER-epitopes or bring T cells closer to tumor cells. Furthermore, novel antibody-drug conjugates and small molecules against HER2 are discussed. These developments coupled with new combination strategies (eg, with CDK4/6 inhibitors or immunotherapy) will change the treatment landscape for patients with HER2-positive MBC very soon and will hopefully further improve clinical outcomes. To identify MRI-based radiomics signature (Rad-score) as a biomarker of risk stratification for disease-free survival (DFS) in patients with HER2-positive invasive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy (NAC) and establish a radiomics-clinicoradiologic-based nomogram that combines Rad-score, MRI findings, and clinicopathological variables for DFS estimation.\\nA total of 127 patients were divided into a training set and testing set according to the ratio of 7:3. Radiomic features were extracted from multiphase CE-MRI (CE\\nThe Rad-score stratified patients into high- and low-risk groups for DFS in the training set (\\nThe Rad-score is an independent biomarker for the estimation of DFS in invasive HER2-positive breast cancer with NAC and the radiomics-clinicoradiologic-based nomogram improved individualized DFS estimation. Breast self-examination is one of the cheapest screening methods for early detection of breast cancer which can be performed by women in privacy, and in their own schedule. Despite being simple, quick, and cost-free, the practice of breast self-examination is low. The study was carried out to assess the practice of breast self-examination among women of childbearing age in Jimma, Southwest Ethiopia.\\nTo assess the practice of breast self-examination among women of childbearing age in Jimma, Southwest Ethiopia.\\nA community-based cross-sectional study was conducted in Jimma town, Southwest Ethiopia in March 2018. Seven hundred and twenty-four women of childbearing age were selected by multistage sampling methods. They were interviewed using structured questionnaire and standardized scale. Bivariate logistic regression analysis was done to see crude association between each independent variable and outcome variable. Logistic regression was used for analysis on the basis of OR, 95% CI and a P value of less than 0. 05.\\nSix hundred and eighty-six respondents participated in the study giving 94.7% of response rate. Only 15% of them practiced breast self-examination. Respondents age (AOR = 2.07/1.14, 3.74/0.01), occupation (AOR=3.93/1.49, 10.35/0.00), family history of breast cancer (AOR=4.16/2.35, 7.36/0.00) and monthly income (AOR= 5.57/1.55, 19.92/0.00) are significantly associated with women\\'s practice of breast self-examination at a P-value less than 0.05.\\nThe practice of breast self-examination is very low. Respondent age, occupation, family history of breast cancer, and monthly income are significantly associated with the women\\'s practice of breast self-examination. Chemotherapy resistance has long been recognized as a major obstacle to cancer treatment. Therefore, elucidating the underlying mechanisms of chemotherapy resistance is conducive to developing new strategies to improve patients\\' response to chemotherapy drugs.\\nReal-time quantitative PCR (QPCR) was applied to measure the expression levels of lncRNAs. LINC01572 was down-regulated or up-regulated in GC cells transfected with either LINC01572 shRNA or overexpression vectors. In vitro and in vivo experiments were conducted to investigate the role of LINC01572 in autophagy-related chemotherapy resistance.\\nCompared with the parental cells, drug-resistant GC cells had a higher level of LINC01572. Silencing of LINC01572 inhibited chemotherapy-induced autophagy, while its knockout sensitized GC cells against chemotherapy drugs. As a competitive endogenous RNA of miR-497-5p, LINC01572 weakened the inhibitory effect of miR-497-5p on ATG14, leading to chemically induced autophagy and chemotherapy resistance in GC cells.\\nA new mechanism of GC autophagy-related chemotherapy resistance regulated by lncRNA was explored in this study, providing a new perspective for understanding chemotherapy resistance. Auraptene (AUR), a natural bioactive prenyloxy coumarin, is a highly pleiotropic molecule that can bind to the MT1 receptor and can effectively reduce the proliferation and migration of breast cancer cells. Cisplatin (CDDP), as the first synthetic platinum-based anticancer drug, is widely used in the clinic due to its definite mechanism and therapeutic effect on diverse tumors. However, both of AUR and CDDP exhibit some disadvantages when used alone, including poor solubility, low bioavailability, lack of selectivity and systemic toxicity when they are used singly.\\nTherefore, the biodegradable materials hyaluronic acid (HA) and β-cyclodextrin derivative (mono-(6-amino-mono-6-deoxy)-β-CD, CD) were employed as carriers to load AUR and CDDP to form nanogel (\\nWith the help of the CDDP-crosslinked CD-loaded structure, the newly synthesized nanogel exhibited excellent physiological stability and fluorescence effects. The release of AUR and CDDP was affected by the pH value, which was beneficial to the selective release in the tumor microenvironment. Cell experiments in vitro demonstrated that the nanogel could be selectively internalized by MCF-7 cells and exhibited low cytotoxicity to HK-2 cells. Antitumor experiments in vivo showed that the nanogel have better antitumor effects and lower systemic toxicity.\\nBased on these, the nanogel loaded with AUR and CDDP have the potential for targeted delivery against breast cancer. [This corrects the article DOI: 10.2147/DDDT.S237699.]. Cancer immunotherapies using monoclonal antibodies to block inhibitory checkpoints are showing durable remissions in many types of cancer patients, although the majority of breast cancer patients acquire little benefit. Human melanoma and lung cancer patient studies suggest that immune checkpoint inhibitors are often potent in patients that already have intratumoral T cell infiltrate; although it remains unknown what types of interventions can result in an intratumoral T cell infiltrate in breast cancer. Using non-T cell-inflamed mammary tumors, we assessed what biological processes and downstream inflammation can overcome the barriers to spontaneous T cell priming. Here we show a specific type of combination therapy, consisting of oncolytic virus and chemotherapy, activates necroptosis and limits tumor growth in autochthonous tumors. Combination therapy activates proinflammatory cytokines; intratumoral influx of myeloid cells and cytotoxic T cell infiltrate in locally treated and distant autochthonous tumors to render them susceptible to immune checkpoint inhibitors. The tumour microenvironment plays a crucial role in the growth and progression of cancer, and the presence of tumour-associated macrophages (TAMs) is associated with poor prognosis. Recent studies have demonstrated that TAMs display transcriptomic, phenotypic, functional and geographical diversity. Here we show that a sialylated tumour-associated glycoform of the mucin MUC1, MUC1-ST, through the engagement of Siglec-9 can specifically and independently induce the differentiation of monocytes into TAMs with a unique phenotype that to the best of our knowledge has not previously been described. These TAMs can recruit and prolong the lifespan of neutrophils, inhibit the function of T cells, degrade basement membrane allowing for invasion, are inefficient at phagocytosis, and can induce plasma clotting. This macrophage phenotype is enriched in the stroma at the edge of breast cancer nests and their presence is associated with poor prognosis in breast cancer patients. Homologous recombination deficiency (HRD) results in impaired double strand break repair and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar-based pan-cancer Classifier of HOmologous Recombination Deficiency (CHORD) that can discriminate BRCA1- and BRCA2-subtypes. Analysis of a metastatic (n\\u2009=\\u20093,504) and primary (n\\u2009=\\u20091,854) pan-cancer cohort reveals that HRD is most frequent in ovarian and breast cancer, followed by pancreatic and prostate cancer. We identify biallelic inactivation of BRCA1, BRCA2, RAD51C or PALB2 as the most common genetic cause of HRD, with RAD51C and PALB2 inactivation resulting in BRCA2-type HRD. We find that while the specific genetic cause of HRD is cancer type specific, biallelic inactivation is predominantly associated with loss-of-heterozygosity (LOH), with increased contribution of deep deletions in prostate cancer. Our results demonstrate the value of pan-cancer genomics-based HRD testing and its potential diagnostic value for patient stratification towards treatment with e.g. poly ADP-ribose polymerase inhibitors (PARPi). Two new megastigmane glucosides namely trewiosides A (1) and B (2), along with 20α-hydroxypregn-4-en-3-one β-D-glucopyranoside (3), sugeroside (4), and schizandriside (5) were isolated from the branches and leaves of Alchornea trewioides. The structure elucidation was confirmed by extensive analysis of the 1D and 2D NMR, electronic circular dichroism (ECD) as well as high resolution electrospray ionization quadrupole time-of-flight (HR-ESI-QTOF) mass spectra. Noteworthily, the isolation of compounds 1 and 2 represents the second finding of megastigmane derivatives with a methoxycarbonyl group at C-5 to date. In addition, compound 3 showed weak cytotoxicity against three human cancer cell lines as A549 (lung carcinoma), HepG2 (hepatocarcinoma), and MCF7 (breast carcinoma). Besides, compounds 2 and 3 exhibited moderate inhibitory effects on lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW264.7 cells. Whereas, the remaining compounds 1, 4 and 5 showed weak inhibitory activity. Mammary hamartoma is benign lesion and relatively rare. 17 cases of breast cancer associated with a hamartoma had been previously documented in the literature. We describe herein a case of noninvasive ductal carcinoma of the breast arising in hamartoma in a woman of 60\\'s. The discordance of images of the mass between mammogram and ultrasonogram can lead us to detect the carcinoma within the hamartoma in our case. J. Med. Invest. 67 : 368-371, August, 2020. BC200 is a non-coding RNA elevated in a broad spectrum of tumour cells that is critical for cell viability, invasion, and migration. Over-expression studies have implicated BC200 and the rodent analog BC1 as negative regulators of translation in both cell-based and in vitro translation assays. While consistent, these studies have not been confirmed in knock-down studies and direct evidence for this function is lacking. Herein, we have demonstrated that BC200 knock-down is correlated with a decrease in global translation rates. As this conflicts with the hypothesis that BC200 is a translational suppressor, we overexpressed BC200 by transfection of in vitro transcribed RNA and transient expression from transfected plasmids. In this context BC200 suppressed translation; however, an innate immune response confounded the data. To overcome this, breast cancer cells stably overexpressing BC200 and various control RNAs were developed by selection for genomic incorporation of a plasmid co-expressing BC200 and the neomycin resistance gene. Stable overexpression of BC200 was associated with elevated translation levels in pooled stable cell lines and isolated single-cell clones. Crosslinking sucrose density gradient centrifugation demonstrated an association of BC200 and its reported binding partners SRP9/14, CSDE1, DHX36 and PABPC1 with both ribosomal subunits and polysomal RNA, an association not previously observed due to the labile nature of the interactions. In summary, these data present a novel understanding of BC200 function as well as optimized methodology that has far reaching implications in the study of non-coding RNAs, particularly within the context of translational regulatory mechanisms. Diffusion-weighted magnetic resonance imaging (DW-MRI) is a contrast-free modality that has demonstrated ability to discriminate between pre-defined benign and malignant breast lesions. However, how well DW-MRI discriminates cancer from all other breast tissue voxels in a clinical setting is unknown. Here we explore the voxel-wise ability to distinguish cancer from healthy breast tissue using signal contributions from the newly developed three-component multi-b-value DW-MRI model.\\nPathology-proven breast cancer patients from two datasets (n=81 and n=25) underwent multi-b-value DW-MRI. The three-component signal contributions C\\nMean FPR\\nThe C Tumor-infiltrating immune cells play a key role in tumor progression. The purpose of this study was to analyze if the immune infiltrate predicts benefit from postoperative radiotherapy (RT) in a large randomized breast cancer RT trial.\\nIn the SweBCG91RT trial, patients with stage I and II breast cancer were randomized to breast conserving surgery (BCS) and postoperative RT or to BCS only and followed for a median time of 15.2 years. The primary tumor immune infiltrate was quantified through two independent methods; immunohistochemistry (IHC) and gene expression profiling. For IHC analyses, the absolute stromal area occupied by CD8+ T cells and FOXP3+ T cells, respectively, was used to define the immune infiltrate. For gene expression analyses, immune cells found to be prognostic in independent datasets were pooled into two groups consisting of antitumoral- and protumoral immune cells, respectively.\\nAn antitumoral immune response in the primary tumor was associated with a reduced risk of breast cancer recurrence and predicted less benefit from adjuvant RT. The interaction between RT and immune phenotype was significant for any recurrence in both the IHC and gene expression analyses (p=0.039 and p=0.035) and was also significant for IBTR in the gene expression analyses (p=0.025).\\nPatients with an antitumoral immune infiltrate in the primary tumor have a reduced risk of any recurrence and may derive less benefit from adjuvant RT. These results may impact decisions regarding postoperative RT in early breast cancer. Invasive lobular breast carcinoma (ILC), one of the major breast cancer histological subtypes, exhibits unique features compared to the well-studied ductal cancer subtype (IDC). The pathognomonic feature of ILC is loss of E-cadherin, mainly caused by inactivating mutations, but the contribution of this genetic alteration to ILC-specific molecular characteristics remains largely understudied. To profile these features transcriptionally, we conducted single-cell-RNA-sequencing on a panel of IDC and ILC cell lines, and an IDC cell line (T47D) with CRISPR-Cas9-mediated E-cadherin knock out (KO). Inspection of intra-cell line heterogeneity illustrated genetically and transcriptionally distinct subpopulations in multiple cell lines and highlighted rare populations of MCF7 cells highly expressing an apoptosis-related signature, positively correlated with a pre-adaptation signature to estrogen deprivation. Investigation of E-cadherin KO-induced alterations showed transcriptomic membranous systems remodeling, elevated resemblance to ILCs in regulon activation, and increased sensitivity to IFN-γ mediated growth inhibition via activation of IRF1. This study reveals single cell transcriptional heterogeneity in breast cancer cell lines and provides a resource to identify drivers of cancer progression and drug resistance. Emerging studies indicate that DNA damage in cancer cells triggers antitumor immunity, but its intrinsic regulatory mechanism in breast cancer cells remains poorly understood. Here, we show that ZMYND8 is upregulated and inhibits micronucleus formation and DNA damage in breast cancer cells. Loss of ZMYND8 triggered activation of the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate synthase in micronuclei, leading to further activation of the downstream signaling effectors stimulator of interferon genes and NF-kappaB, but not TANK-binding kinase 1 and interferon regulatory factor 3, thereby inducing the expression of interferon-beta and interferon-stimulated genes (ISGs) in breast cancer cells in vitro and tumors in vivo. ZMYND8 knockout (KO) in breast cancer cells promoted infiltration of CD4+ and CD8+ T cells leading to tumor inhibition in syngeneic mouse models, which was significantly attenuated by treatment of anti-CD4/CD8 depleting antibodies or anti-IFNAR1 antibody and in immunodeficient Rag1 KO mice. In human breast tumors, ZMYND8 was negatively correlated with ISGs, CD4, CD8A, CD8B, and the tumor-lymphocyte infiltration phenotype. Collectively, these findings demonstrate that maintenance of genome stability by ZMYND8 causes breast cancer cells to evade cytotoxic T-lymphocyte surveillance which leads to tumor growth. Breast neuroendocrine tumours (NETs) constitute a rare histologic subtype of oestrogen receptor (ER)-positive breast cancer, and their definition according to the WHO classification was revised in 2019. Breast NETs display histologic and transcriptomic similarities with mucinous breast carcinomas (MuBCs). Here, we sought to compare the repertoire of genetic alterations in breast NETs with MuBCs and NETs from other anatomic origins.\\nOn histologic review applying the new WHO criteria, 18 breast tumours with neuroendocrine differentiation were reclassified as breast NETs (n=10) or other breast cancers with neuroendocrine differentiation (n=8). We reanalysed targeted sequencing or whole-exome sequencing data of breast NETs (n=10), MuBCs type A (n=12) and type B (n=11).\\nBreast NETs and MuBCs were found to be genetically similar, harbouring a lower frequency of \\nBreast NETs are heterogeneous and are characterised by an enrichment of mutations in transcription factors and likely constitute a spectrum of entities histologically and genomically related to MuBCs. While most breast NETs are distinct from ER-positive/HER2-negative IDC-NSTs, a subset of breast NETs appears to be genetically similar to common forms of ER-positive breast cancer, suggesting that some breast cancers may acquire neuroendocrine differentiation later in tumour evolution. Gestational breast cancer (GBC) is the most common form of invasive cancer in pregnancy and has unique challenges in both staging and treatment given the dual goal of appropriate cancer management and minimising the risk of fetal toxicity. A 38-year-old woman with no significant medical history and 21 weeks pregnant presented with a palpable right breast mass. She was diagnosed with human epidermal growth factor receptor 2-positive infiltrating ductal carcinoma with advanced disease. The patient underwent treatment; however, unfortunately, she passed away after developing devastating distant disease recurrence.We highlight both the challenges and current guidelines for management of GBC. Our goal is to discuss the current limitations of GBC management and the necessity of further investigation for safe novel imaging and treatment modalities for pregnant women. It is crucial to increase awareness across multiple subspecialities, as a multidisciplinary team is necessary for proper treatment of GBC. A 32-year-old woman presented with a 3 cm×3 cm left breast lump associated with bloody nipple discharge during her early pregnancy. Examination and ultrasonography showed benign features, whereas core needle biopsies revealed a benign papilloma. Six months after her delivery, a 6 cm×6 cm benign papilloma was completely excised via circumareolar incision. The majority of intraductal papillomas are small; however, they can also present as a large mass rarely. We should be wary of a malignant papillary lesion when there is the presence of atypia on core needle biopsy or imaging-histology discordance. A concordant benign papilloma with benign imaging findings is otherwise reassuring. Clinicians need to be aware of this uncommon presentation of large intraductal papilloma as a complete curative excision can be achieved through a cosmetically placed incision. Lung cancer remains the leading cause of cancer-related deaths worldwide in women and men. In incidence, lung cancer ranks second, surpassed by breast cancer in women and prostate cancer in men. However, the historical differences in mortality and incidence rate between both sexes have changed in the last years. In the last decades, we have also witnessed an increased number of lung cancer in female never-smokers. These disparities have grown our interest in studying the impact of the gender and sex in the presentation of lung cancer. The aetiology is yet to be fully elucidated, but the data are clear so far: there is a growing divide between lung cancer presentation in women and men that will change our management and study of lung cancer. This article aims to review the sex and gender differences in lung cancer. To quantify the association of cancer treatment delay and mortality for each four week increase in delay to inform cancer treatment pathways.\\nSystematic review and meta-analysis.\\nPublished studies in Medline from 1 January 2000 to 10 April 2020.\\nCurative, neoadjuvant, and adjuvant indications for surgery, systemic treatment, or radiotherapy for cancers of the bladder, breast, colon, rectum, lung, cervix, and head and neck were included. The main outcome measure was the hazard ratio for overall survival for each four week delay for each indication. Delay was measured from diagnosis to first treatment, or from the completion of one treatment to the start of the next. The primary analysis only included high validity studies controlling for major prognostic factors. Hazard ratios were assumed to be log linear in relation to overall survival and were converted to an effect for each four week delay. Pooled effects were estimated using DerSimonian and Laird random effect models.\\nThe review included 34 studies for 17 indications (n=1\\u2009272\\u2009681 patients). No high validity data were found for five of the radiotherapy indications or for cervical cancer surgery. The association between delay and increased mortality was significant (P<0.05) for 13 of 17 indications. Surgery findings were consistent, with a mortality risk for each four week delay of 1.06-1.08 (eg, colectomy 1.06, 95% confidence interval 1.01 to 1.12; breast surgery 1.08, 1.03 to 1.13). Estimates for systemic treatment varied (hazard ratio range 1.01-1.28). Radiotherapy estimates were for radical radiotherapy for head and neck cancer (hazard ratio 1.09, 95% confidence interval 1.05 to 1.14), adjuvant radiotherapy after breast conserving surgery (0.98, 0.88 to 1.09), and cervix cancer adjuvant radiotherapy (1.23, 1.00 to 1.50). A sensitivity analysis of studies that had been excluded because of lack of information on comorbidities or functional status did not change the findings.\\nCancer treatment delay is a problem in health systems worldwide. The impact of delay on mortality can now be quantified for prioritisation and modelling. Even a four week delay of cancer treatment is associated with increased mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers. Policies focused on minimising system level delays to cancer treatment initiation could improve population level survival outcomes. Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor administered continuously for hormone receptor-positive (HR\\nnextMONARCH is an open-label, controlled, randomized, phase II study of women with endocrine-refractory HR\\nThe median PFS was 9.1 months for A+T versus 7.4 months for A-200 (hazard ratio, 0.815; 95% confidence interval, 0.556-1.193; P\\xa0= .293). The A-200 PFS was comparable to that with A-150 at 6.5 months (hazard ratio, 1.045; 95% confidence interval, 0.711-1.535; P\\xa0= .811). The ORR was 34.6%, 24.1%, and 32.5% for A+T, A-150, and A-200, respectively. No new safety signals were identified. The incidence and severity of diarrhea (62.3%; grade 3, 7.8%) with A-200 was similar to that with A-150 (67.1%; grade 3, 3.8%). The pharmacokinetics were comparable to previous observations.\\nThe addition of tamoxifen to abemaciclib did not significantly improve PFS or ORR compared with abemaciclib monotherapy but confirmed the single-agent activity of abemaciclib in heavily pretreated HR Objective To establish a triple negative breast cancer cell line stably expressing human epidermal growth factor receptor (EGFR) promoter and luciferase (Luc) reporter gene and to preliminarily verify its application. Methods Using genetic recombination technology, the lentiviral vector carrying Luc reporter and EGFR promoter sequence was designed and constructed to infect MDA-MB231 cells and obtain MDA-MB231-EGFR-Luc2 cell lines by the selection with puromycin. The Luc luminescence value after stimulating with EGFR activator EGF or inhibitor gefitinib regulating the EGFR promoter activities was detected. Results Gene sequencing and enzyme digestion verified that the lentiviral expression vector carrying Luc reporter vector recombined with EGFR promoter was successfully constructed. Lentivirus-infected MDA-MB231 cells were screened by puromycin, the MDA-MB231-EGFR-Luc2 cells stably expressing firefly Luc was obtained. EGF increased the Luc luminescence value of MDA-MB231-EGFR-Luc2 cells in a dose-dependent manner, while gefitinib did the opposite. Conclusion The cell line of MDA-MB231-EGFR-Luc2 containing EGFR promoter and Luc reporter gene has been successfully constructed, which provides a new cell model for high throughput screening of EGFR-targeting drugs. The role of nuclear receptors in both the aetiology and treatment of breast cancer is exemplified by the use of the oestrogen receptor (ER) as a prognostic marker and treatment target. Treatments targeting the oestrogen signalling pathway are initially highly effective for most patients. However, for the breast cancers that fail to respond, or become resistant, to current endocrine treatments, the long-term outlook is poor. ER is a member of the nuclear receptor superfamily, comprising 48 members in the human, many of which are expressed in the breast and could be used as alternative targets in cases where current treatments are ineffective.\\nWe used sparse canonical correlation analysis to interrogate potential novel nuclear receptor expression relationships in normal breast and breast cancer. These were further explored using whole transcriptome profiling in breast cancer cells after combinations of ligand treatments.\\nUsing this approach, we discovered a tumour suppressive relationship between the mineralocorticoid receptor (MR) and retinoic acid receptors (RAR), in particular RARβ. Expression profiling of MR expressing breast cancer cells revealed that mineralocorticoid and retinoid co-treatment activated an expression program consistent with a reverse Warburg effect and growth inhibition, which was not observed with either ligand alone. Moreover, high expression of both MR and RARB was associated with improved breast cancer-specific survival.\\nOur study reveals a previously unknown relationship between MR and RAR in the breast, which is dependent on menopausal state and altered in malignancy. This finding identifies potential new targets for the treatment of breast cancers that are refractory to existing therapeutic options. Oncological care was largely derailed due to the reprioritisation of health care services to handle the initial surge of COVID-19 patients adequately. Cancer screening programmes were no exception in this reprioritisation. They were temporarily halted in the Netherlands (1) to alleviate the pressure on health care services overwhelmed by the upsurge of COVID-19 patients, (2) to reallocate staff and personal protective equipment to support critical COVID-19 care, and (3) to mitigate the spread of COVID-19. Utilising data from the Netherlands Cancer Registry on provisional cancer diagnoses between 6 January 2020 and 4 October 2020, we assessed the impact of the temporary halt of national population screening programmes on the diagnosis of breast and colorectal cancer in the Netherlands. A dynamic harmonic regression model with ARIMA error components was applied to assess the observed versus expected number of cancer diagnoses per calendar week. Fewer diagnoses of breast and colorectal cancer were objectified amid the early stages of the initial COVID-19 outbreak in the Netherlands. This effect was most pronounced among the age groups eligible for cancer screening programmes, especially in breast cancer (age group 50-74\\xa0years). Encouragingly enough, the observed number of diagnoses ultimately reached and virtually remained at the level of the expected values. This finding, which emerged earlier in age groups not invited for cancer screening programmes, comes on account of the decreased demand for critical COVID-19 care since early April 2020, which, in turn, paved the way forward to resume screening programmes and a broad range of non-critical health care services, albeit with limited operating and workforce capacity. Collectively, transient changes in health-seeking behaviour, referral practices, and cancer screening programmes amid the early stages of the initial COVID-19 epidemic in the Netherlands conjointly acted as an accelerant for fewer breast and colorectal cancer diagnoses in age groups eligible for cancer screening programmes. Forthcoming research is warranted to assess whether the decreased diagnostic scrutiny of cancer during the COVID-19 pandemic resulted in stage migration and altered clinical management, as well as poorer outcomes. Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, typically epithelial and mesenchymal components. This variant harbors a triple-negative breast cancer (TNBC) phenotype, yet has a worse prognosis and decreased survival compared to TNBC. There are currently no standardized treatment guidelines specifically for MpBC. However, prior studies have found that MpBC typically has molecular alterations in epithelial-to-mesenchymal transition, amplification of epidermal growth factor receptor, PI3K/Akt signaling, nitric oxide signaling, Wnt/β-catenin signaling, altered immune response, and cell cycle dysregulation. Some of these molecular alterations have been studied as therapeutic targets, in both the preclinical and clinical setting. This current review discusses the histological organization and cellular origins of MpBC, molecular alterations, the role of radiation therapy, and current clinical trials for MpBC. Wide implementation of mammography screening has resulted in increased numbers of women diagnosed with breast carcinoma in situ. We aimed to determine the risk of invasive breast cancer in relatives of patients with breast carcinoma in situ in comparison to the risk in relatives of patients with invasive breast cancer.\\nWe analyzed the occurrence of cancer in a nationwide cohort including all 5,099,172 Swedish women born after 1931 with at least one known first-degree relative. This was a record linkage study of Swedish family cancer datasets, including cancer registry data collected from January 1, 1958, to December 31, 2015. We calculated standardized incidence ratios (SIRs) and 10-year cumulative risk of breast cancer diagnosis for women with a family history of in situ and invasive breast cancer.\\nHaving one first-degree relative with breast carcinoma in situ was associated with 50% increased risk of invasive breast cancer (SIR\\u2009=\\u20091.5, 95% CI 1.4-1.7) when compared to those who had no family history of invasive breast cancer or breast carcinoma in situ in either first- or second-degree relatives. Similarly, having one first-degree relative with invasive breast cancer was associated with 70% (1.7, 1.7-1.8) increased risk. The 10-year cumulative risk for women at age 50 with a relative with breast carcinoma in situ was 3.5% (2.9-3.9%) and was not significantly different from 3.7% (3.6-3.8%) risk for 50-year-old women with a relative with invasive breast cancer (95% confidence intervals overlapped).\\nThe risk of invasive breast cancer for women with a family history of breast carcinoma in situ was comparable to that for women with a family history of invasive breast cancer. Therefore, family history of breast carcinoma in situ should not be overlooked in recommendations for breast cancer prevention for women with a family history of breast cancer. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. The purpose of this study was to evaluate the ability of β-catenin signaling blockade to enhance the efficacy of anti-CTLA-4 and anti-PD-1 immune checkpoint blockade in immunocompetent, preclinical models of TNBC.\\nTreatment with RX-5902, anti-PD-1, anti-CTLA-4 or the combination was investigated in BALB/c mice injected with the 4\\u2009T1 TNBC cell line. Humanized BALB/c-Rag2\\nThe addition of RX-5902 to CTLA-4 or PD-1 inhibitors resulted in decreased tumor growth in the 4\\u2009T1 and human immune system and MDA-MB-231 xenograft models. Immunologic analyses demonstrated a significant increase in the number of activated T cells in tumor infiltrating lymphocytes (TILs) with RX-5902 treatment compared to vehicle (p\\u2009<\\u20090.05). In the RX-5902/nivolumab combination group, there was a significant increase in the percentage of CD4+ T cells in TILs and increased systemic granzyme B production (p\\u2009<\\u20090.01).\\nConclusions: RX-5902 enhanced the efficacy of nivolumab in a humanized, preclinical model of TNBC. Several changes in immunologic profiles were noted in mice treated with RX-5902 and the combination, including an increase in activated TILs and a decrease in human myeloid populations, that are often associated with immunosuppression in a tumor microenvironment. RX-5902 also was shown to potentiate the effects of checkpoint inhibitors of CTLA4 and the PD-1 inhibitor in the 4\\u2009T-1 murine TNBC model. These findings indicate that RX-5902 may have important immunomodulatory, as well as anti-tumor activity, in TNBC when combined with a checkpoint inhibitor. Pancreatic cancer is a malignant tumor with high mortality. Acidic nuclear phosphoprotein 32 family member E (ANP32E), a specific H2A.Z chaperone, has been shown to contribute to breast cancer development. However, the significance of ANP32E in pancreatic cancer is poorly understood. This study aimed to investigate the role of ANP32E in pancreatic cancer.\\nThe expression of ANP32E in 179 pancreatic cancer tissues and 171 normal tissues, and the correlation between ANP32E expression and patients\\' survival were analyzed from the TCGA database. ANP32E was over-expressed and silenced using lentivirus. siRNA was used to knock down β-catenin. CCK8, colony formation, cell cycle and transwell experiments were performed to determine cell proliferation and migration. qRT-PCR and Western blot were conducted to detect mRNA and protein expression.\\nANP32E was up-regulated in pancreatic cancer tissues and cells. Up-regulation of ANP32E predicted poor prognosis in pancreatic cancer patients. Lentivirus-mediated knockdown of ANP32E suppressed the proliferation, colony growth and migration of PANC1 and MIA cells. By contrast, ANP32E over-expression promoted the proliferation and migration of both cells. In addition, ANP32E accelerated the cell cycle progression in PANC1 and MIA cells. Molecular experiments showed that ANP32E activated β-catenin/cyclin D1 signaling. Silencing of β-catenin reduced cell proliferation and migration in ANP32E over-expressed cells.\\nOur results propose that ANP32E functions as an oncogene in pancreatic cancer via activating β-catenin. MicroRNAs (miRNA) are a type of non-coding RNA molecules that are effective on the formation and the progression of many different diseases. Various researches have reported that miRNAs play a major role in the prevention, diagnosis, and treatment of complex human diseases. In recent years, researchers have made a tremendous effort to find the potential relationships between miRNAs and diseases. Since the experimental techniques used to find that new miRNA-disease relationships are time-consuming and expensive, many computational techniques have been developed. In this study, Weighted [Formula: see text]-Nearest Known Neighbors and Network Consistency Projection techniques were suggested to predict new miRNA-disease relationships using various types of knowledge such as known miRNA-disease relationships, functional similarity of miRNA, and disease semantic similarity. An average AUC of 0.9037 and 0.9168 were calculated in our method by 5-fold and leave-one-out cross validation, respectively. Case studies of breast, lung, and colon neoplasms were applied to prove the performance of our proposed technique, and the results confirmed the predictive reliability of this method. Therefore, reported experimental results have shown that our proposed method can be used as a reliable computational model to reveal potential relationships between miRNAs and diseases. Estrogen and progesterone congeners as found in various oral contraceptive formulations have been implicated as the cause of cancer in sex and tissue-specific targets. The mechanism of carcinogenesis by sex steroids is still debatable. In this study, we evaluated the genotoxicity induced by two components of one of the commonly used oral contraceptive formulation; drospirenone and ethinylestradiol in human breast cells (MCF-7)  None Herein, we report facile procedures for synthesis of a new Schiff base ligand (H Laser Raman spectroscopy (LRS) is a highly specific biomolecular technique which has been shown to have the ability to distinguish malignant and normal breast tissue. This paper discusses significant advancements in the use of LRS in surgical breast cancer diagnosis, with an emphasis on statistical and machine learning strategies employed for precise, transparent and real-time analysis of Raman spectra. When combined with a variety of \"machine learning\" techniques LRS has been increasingly employed in oncogenic diagnostics. This paper proposes that the majority of these algorithms fail to provide the two most critical pieces of information required by the practicing surgeon: a probability that the classification of a tissue is correct, and, more importantly, the expected error in that probability. Stochastic backpropagation artificial neural networks inherently provide both pieces of information for each and every tissue site examined by LRS. If the networks are trained using both human experts and an unsupervised classification algorithm as gold standards, rapid progress can be made understanding what additional contextual data is needed to improve network classification performance. Our patients expect us to not simply have an opinion about their tumor, but to know how certain we are that we are correct. Stochastic networks can provide that information. Methylene blue is a fluorescent dye discovered in 1876 and has since been used in different scientific fields. Only recently has methylene blue been used for intraoperative fluorescent imaging. Here, the authors review the emerging role of methylene blue, not only as a dye used in clinical practice, but also as a fluorophore in a surgical setting. We discuss the promising potential of methylene blue together with the challenges and limitations among specific surgical techniques. A literature review of PubMed and Medline was conducted based on the historical, current and future usage of methylene blue within the field of medicine. We reviewed not only the current usage of methylene blue, but we also tried to grasp its\\' function as a fluorophore in five main domains. These domains include the near-infrared imaging visualization of ureters, parathyroid gland identification, pancreatic tumors imaging, detection of breast cancer tumor margins, as well as breast cancer sentinel node biopsy. Methylene blue is used in countless clinical procedures with a relatively low risk for patients. Usage of its fluorescent properties is still at an early stage and more pre-clinical, as well as clinical research, must be performed to fully understand its potentials and limitations. Toll-like receptor 3 (TLR3) is a member of the TLR family, which has been extensively studied for its antiviral function. It is highly expressed in the endosomes of antigen-presenting immune cells and epithelial cells. TLR3 binds specifically double-strand RNAs (dsRNAs), leading to the activation of mainly two downstream pathways: the phosphorylation of IRF3, with subsequent production of type I interferon, and the activation of NF-κB, which drives the production of inflammatory cytokines and chemokines. Several studies have demonstrated TLR3 expression in multiple neoplasia types including breast, prostate, and lung cancer. Most studies were focused on the beneficial role of TLR3 activation in tumor cells, which leads to the production of cytotoxic cytokines and interferons and promotes caspase-dependent apoptosis. Indeed, ligands of this receptor were proposed for the treatment of cancer, also in combination with conventional chemotherapy. In contrast to these findings, recent evidence showed a link between TLR3 and tumor progression, metastasis, and therapy resistance. In the present review, we summarize the current knowledge of the mechanisms through which TLR3 can either lead to tumor regression or promote carcinogenesis as well as the potential of TLR-based therapies in resistant cancer. None Dysregulated gene expression is a common feature of cancer and may underlie some aspects of tumor progression, including tumor relapse. Here, we show that recurrent mammary tumors exhibit global changes in gene expression and histone modifications and acquire dependence on the G9a histone methyltransferase. Genetic ablation of G9a delays tumor recurrence, and pharmacologic inhibition of G9a slows the growth of recurrent tumors. Mechanistically, G9a activity is required to silence pro-inflammatory cytokines, including tumor necrosis factor (TNF), through H3K9 methylation at gene promoters. G9a inhibition induces re-expression of these cytokines, leading to p53 activation and necroptosis. Recurrent tumors upregulate receptor interacting protein kinase-3 (RIPK3) expression and are dependent upon RIPK3 activity. High RIPK3 expression renders recurrent tumors sensitive to necroptosis following G9a inhibition. These findings demonstrate that G9a-mediated silencing of pro-necroptotic proteins is a critical step in tumor recurrence and suggest that G9a is a targetable dependency in recurrent breast cancer. Human Guanine nucleotide binding protein like 1 (GNL1) is an evolutionary conserved putative nucleolar GTPase belonging to HSR1_MMR1 subfamily of GTPases. GNL1 was found to be highly upregulated in various cancers. Here, we report for the first time that GNL1 inhibits apoptosis by modulating the expression of Bcl2 family of proteins and the cleavage of caspases 7 and 8. Furthermore, GNL1 protects colon cancer cells from chemo-drug induced apoptosis. Interestingly, GNL1 upregulates the expression of p53 and its transcriptional target, p21 but the upregulation of p21 was found to be p53 dependent as well as independent mechanisms. Our results further demonstrate that GNL1 promotes cell growth and survival by inducing cytoplasmic retention and stabilization of p21 through AKT-mediated phosphorylation. In addition, GNL1 failed to inhibit apoptosis under p21 knockdown conditions suggest the critical role of p21 in GNL1 mediated cell survival. Finally, an inverse correlation of GNL1, p21 and AKT expression in primary colon and breast cancer with patient survival suggests their critical role in tumorigenesis. Collectively, our study reveals that GNL1 executes its anti-apoptotic function by a novel mechanism and suggests that it may functions as a regulatory component of the PI3K/AKT/p21 signaling network, to promote cell proliferation and survival in cancers.  Claudins are essential components of tight junctions, which are frequently deregulated in breast cancer. The aim of the current study was to assess claudin-3 and -4 expression in bilateral breast cancer (BBC) and unilateral breast cancer (UBC). Immunohistochemical expression of claudin-3, claudin-4 was evaluated in tissue microarrays containing 174 cases of BBCs paired with 174 cases of solitary tumors. Each case was classified as claudin-high or claudin-low depending on the H-score value. The results were correlated with histopathological features and the expression of basic breast cancer biomarkers. Median H-scores for claudin-3 were significantly higher in the synchronous BBC (sBBC) than in UBC. Claudin-4-high cases were more prevalent than within the whole BBC group, and sBBC and metachronous BBC (mBBC) alone. In the BBC group negative ER, high Ki-67, and high claudin-3 were independent factors correlated with high claudin-4. In the UBC group Ki-67 > 14% and high claudin-3 were associated with high claudin-4. Our study demonstrates that the expression of claudin-4 is significantly higher in UBC compared to BBC tumors. We also demonstrated that high claudin-4 expression in BBC is associated with a more aggressive phenotype (lack of steroid receptors, HER2 overexpression, and high Ki-67). It is possible that claudins down- and upregulation may depend on different triggers and lead to various consequences in UBC and BBC. The increasing number of diagnosed breast lesions lead to the critical need for new markers that would elucidate the process of tumorigenesis. The objective of the study was to examine COX-2, p16, and Ki67 expression in a broad spectrum of breast lesions in order to define the proteins\\' phenotype throughout the tumorigenesis. Expression was studied by immunohistochemistry in 308 human breast samples divided into 7 subgroups - flat epithelial atypia (FEA), atypical hyperplasia (ADH), intraductal carcinoma (DCIS), invasive cancer (IC), benign lesions (BLs), normal tissue adjacent to breast cancer (CANT), and fatty tissue (FT). Analysis among 4 subgroups - premalignant lesions (DIN), IC, BLs, and normal tissue was also performed. High prevalence of COX-2 overexpression was found in all breast lesions including BLs (70% FEA, 89% ADH, 86% DCIS, 81% IC, 44% CANT, 92% BLs, 29% FT). Significant dominance of p16 overexpression was found in premalignant lesions and BLs (50% FEA, 67% ADH, 50% DCIS, 37% IC, 8% CANT, 58% BLs, 21% FT). The location of staining within p16+ cells differed - BLs showed nuclear positivity, whereas in IC it was exclusively cytoplasmic. Premalignant lesions showed all types of p16 positivity. Significantly higher prevalence of COX-2+p16+Ki67+ phenotype was in premalignant tumors with the highest prevalence in ADH (40% of FEA, 67% ADH, 35% DCIS, 20% IC, 3% CANT, 20% BLs, 14% FT). Our observations showed a high prevalence of COX-2+p16+Ki67+ phenotype in premalignant lesions. Further studies are needed in order to elucidate if this phenotype reflects any specific pathway of future progression of premalignant breast lesions. For reversing the treatment failure in P-glycoprotein (P-gp)-associated MDR (multidrug resistance) of breast cancer, a high dose of Lapatinib (Lap), a substrate of breast cancer-resistant protein, was encapsulated into safe and effective acid-cleavable polysaccharide-doxorubicin (Dox) conjugates to form targeted HPP-Dox/Lap nanoparticles with an optimal drug ratio and appropriate nanosize decorated with oligomeric hyaluronic acid (HA) for specially targeting overexpressed CD44 receptors of MCF-7/ADR. The markedly increased cellular uptake and the strongest synergetic cytotoxicity revealed the enhanced reversal efficiency of HPP-Dox/Lap nanoparticles with reversal multiples at 29.83. This was also verified by the enhanced penetrating capacity in multicellular tumor spheroids. The reinforced Dox retention and substantial down-regulation of P-gp expression implied the possible mechanism of MDR reversal. Furthermore, the efficient  Approximately 5% to 10% of women diagnosed with breast cancer will have a pathogenic variant (PV) in a hereditary cancer susceptibility gene, and this has significant implications for the management of these patients and their relatives. Despite the benefits of genetic testing, many eligible patients with breast cancer never undergo testing because of various barriers, including complicated testing criteria such as those from the National Comprehensive Cancer Network (NCCN). In 2019, the American Society of Breast Surgeons (ASBrS) proposed germline genetic testing for all patients with breast cancer to increase the identification of PV carriers. In 2020, a Mayo Clinic study highlighted the limitations of these 2 genetic testing guidelines (NCCN and ASBrS) and proposed a hybrid approach of testing all women diagnosed with breast cancer by the age of 65 years and using NCCN criteria for older patients. This commentary presents an updated analysis of the Mayo Clinic data and discusses the rationale for using the age of 60 years rather than 65 years as the cutoff for this hybrid approach. Using an age at diagnosis of ≤60 or ≤65 years for the universal testing of patients with breast cancer detected more PVs (11.9% [16 of 134] and 15.7% [21 of 134], respectively) in comparison with using the NCCN criteria. Lowering the age for universal testing from 65 to 60 years maintained the sensitivity of detecting a PV at >90% while sparing testing for an additional 10% of women. Compared with the testing of all patients, the hybrid approach would allow 31% of all women with breast cancer to forgo testing and result in fewer variants of uncertain significance identified and, therefore, would decrease the chance of harm from misinterpretation of these variants. The synthesis, docking study, and investigation of the anticancer activities of some coumarin derivatives containing the triazole ring are reported in this study. The newly synthesized compounds were screened for their in vitro anticancer activity against the cell lines CRL5807 (human bronchioalveolar carcinoma), CRL5826 (human squamous cell carcinoma), MDA-MB231 (human breast cancer cells), HTB177 (human lung cancer), PC-3 (human prostate adenocarcinoma), PANC-1 (human pancreatic cancer cells), used as cancer cells, and CCD34Lu (normal human lung fibroblasts), used as a healthy cell line. Cytotoxicity effects of the samples were determined by the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay. In silico studies were also performed to explore the binding interactions of the molecules. To find immune-related genes with prognostic value in breast cancer, and construct a prognostic risk assessment model to make a more accurate assessment. Moreover, looking for potential immune markers for breast cancer immunotherapy.\\nThe breast cancer (BC) data were retrieved from The Cancer Genome Atlas (TCGA) database as a training set. Through the Weighted gene co-expression network analysis (WGCNA), Kaplan-Meier (KM) analysis, lasso regression analysis and stepwise backward Cox regression analysis, screening for prognosis-related immune genes, a prognostic index was built, and external validation with two data sets of Gene Expression Omnibus (GEO) database was performed. Transcription factor (TF) regulatory network was constructed to identify key transcription factors that regulate prognostic immune genes. Gene set enrichment analysis (GSEA) was used to explore the signal pathways differences between high and low-risk groups, estimate package and TIMER database were used to evaluate the relationship between risk score and tumor immune microenvironment.\\nWe obtained 10 prognosis-related immune genes, and the index showed accurate prognostic value. We also identified 7 prognostic transcription factors. Multiple signaling pathways that inhibit tumor progression were enriched in the low-risk group, and risk score was significantly negatively related to the degree of immune infiltration and the expression level of immune checkpoint genes.\\nWe successfully constructed an independent prognostic index, which not only has a stronger predictive ability than the tumor pathological stage, but also can reflect the immune infiltration of breast cancer patients. Obesity increases the risk for breast cancer and is associated with poor outcomes for cancer patients. A variety of rodent models have been used to investigate these relationships; however, key differences in experimental approaches, as well as unique aspects of rodent physiology lead to variability in how these valuable models are implemented. We combine expertise in the development and implementation of preclinical models of obesity and breast cancer to disseminate effective practices for studies that integrate these fields. In this review, we share, based on our experience, key considerations for model selection, highlighting important technical nuances and tips for use of preclinical models in studies that integrate obesity with breast cancer risk and progression. We describe relevant mouse and rat paradigms, specifically highlighting differences in breast tumor subtypes, estrogen production, and strategies to manipulate hormone levels. We also outline options for diet composition and housing environments to promote obesity in female rodents. While we have applied our experience to understanding obesity-associated breast cancer, the experimental variables we incorporate have relevance to multiple fields that investigate women\\'s health. Febrile neutropenia (FN) incidence during docetaxel and cyclophosphamide (TC) chemotherapy, known as a high-risk regimen, differs among countries. The role of prophylactic granulocyte colony-stimulating factor (G-CSF) in FN is unclear. This study aimed to investigate FN frequency and relative dose intensity (RDI) of TC chemotherapy in patients with breast cancer and identify the correct population requiring prophylactic G-CSF.\\nIn total, 205 patients with breast cancer were scheduled for TC chemotherapy (docetaxel/cyclophosphamide 75/600 mg/m\\nFN occurred in 70 patients (35.7%). FN incidence was noted in 41.1% without any prophylactic measures and in 5.0% with prophylactic G-CSF. In multivariate analysis, the independent risk factors of FN were older age (≥ 60 years, P = 0.017) and without primary prophylactic G-CSF (P = 0.011). Eleven patients (5.6%) were hospitalized of which 8 (72.7%) were elderly. The median RDIs of docetaxel and cyclophosphamide were 96.7% and 99.7%, respectively.\\nFN frequency during TC chemotherapy was high, and primary prophylactic G-CSF reduced FN incidence. Primary prophylactic G-CSF is an effective therapy for preventing FN during TC chemotherapy. However, prophylactic G-CSF should be considered for elderly patients based on the low hospitalization rate and the high RDI. Myeloid-derived suppressor cells (MDSCs) play an important role in tumor progression through both immunologic and non-immunologic mechanisms. This study was conducted to evaluate the expression of S100A8, a well-known MDSC marker, and the significance of its expression in pre-invasive and invasive breast cancers. S100A8 expression in tumor cells (TCs) and immune cells (ICs) was assessed by immunohistochemistry, and its association with clinicopathologic features and infiltration of other IC subsets including CD4+, CD8+, and FOXP3+\\u2009tumor-infiltrating lymphocytes (TILs) and PD-L1+\\u2009ICs was evaluated. S100A8 expression in TCs and ICs showed a positive correlation in pre-invasive carcinoma and invasive carcinoma. S100A8+\\u2009ICs, but not S100A8+\\u2009TCs, were significantly higher in number in invasive carcinoma than in pre-invasive carcinoma. Infiltration of S100A8+\\u2009ICs was revealed as a poor prognostic indicator in pre-invasive and invasive carcinomas, especially in hormone receptor-positive subgroup. Infiltration of CD4+, CD8+, and FOXP3+\\u2009TIL subsets and PD-L1+\\u2009ICs was significantly higher in S100A8+\\u2009IC (+) group than in S100A8+\\u2009IC (-) group. Combined analyses of IC subset infiltration revealed that infiltration of S100A8+\\u2009ICs was associated with poor clinical outcome in the PD-L1+\\u2009IC (-), CD8+\\u2009TIL-low, and FOXP3+\\u2009TIL-low subgroups. In conclusion, S100A8+\\u2009ICs seem to undergo a dynamic change during breast cancer progression in association with other IC subset infiltration. The prognostic impact of S100A8+\\u2009IC infiltration was greater in less immunogenic tumors. Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is an uncommon peripheral T cell lymphoma usually presenting as a delayed peri-implant effusion. Chronic inflammation elicited by the implant has been implicated in its pathogenesis. Infection or implant rupture may also be responsible for late seromas. Cytomorphological examination coupled with CD30 immunostaining and eventual T-cell clonality assessment are essential for BI-ALCL diagnosis. However, some benign effusions may also contain an oligo/monoclonal expansion of CD30\\u2009+\\u2009cells that can make the diagnosis challenging. Since cytokines are key mediators of inflammation, we applied a multiplexed immuno-based assay to BI-ALCL seromas and to different types of reactive seromas to look for a potential diagnostic BI-ALCL-associated cytokine profile. We found that BI-ALCL is characterized by a Th2-type cytokine milieu associated with significant high levels of IL-10, IL-13 and Eotaxin which discriminate BI-ALCL from all types of reactive seroma. Moreover, we found a cutoff of IL10/IL-6 ratio of 0.104 is associated with specificity of 100% and sensitivity of 83% in recognizing BI-ALCL effusions. This study identifies promising biomarkers for initial screening of late seromas that can facilitate early diagnosis of BI-ALCL. To investigate the feasibility and effectiveness of SMS rs-EPI for evaluating breast lesions.\\nThis prospective study was approved by IRB. Ninety-six patients had 102 histopathologically verified lesions (80 malignant and 22 benign) that were evaluated. Conventional rs-EPI and SMS rs-EPI data were acquired on a 3T scanner. Mean kurtosis (MK), mean diffusion (MD), and apparent diffusion coefficient (ADC) values were quantitatively calculated for each lesion on both sequences. Images were qualitatively and quantitatively analyzed with respect to image sharpness, geometric distortion, lesion conspicuity, anatomic structure, overall image quality, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR). Student\\'s t test, Pearson correlation, receiver operating characteristic curve, Wilcoxon rank sum test, and paired-sample t tests were used for statistical analysis.\\nCompared to conventional rs-EPI, the acquisition time of SMS rs-EPI was markedly reduced (2:17 min vs 4:27 min). Pearson\\'s correlations showed excellent linear relationships for each parameter between conventional rs-EPI and SMS rs-EPI (MK, r = 0.908; MD, r = 0.938; and ADC, r = 0.975; p < 0.01 for all). Furthermore, SMS rs-EPI had similar diagnostic performance compared with conventional rs-EPI. SMS rs-EPI had comparable visual image quality as conventional rs-EPI, with excellent inter-reader reliability (ICC = 0.851-0.940). No differences existed between conventional rs-EPI and SMS rs-EPI for either SNR or CNR (p > 0.05).\\nApplying the SMS technique can significantly reduce the acquisition time and produce similar diagnostic accuracy while generating comparable image quality as the conventional rs-EPI.\\n• SMS rs-EPI reduces scan time from 4:27 min to 2:17 min compared with conventional rs-EPI. • SMS rs-EPI has a comparable diagnostic performance to conventional rs-EPI in the differentiation between malignant and benign breast lesions. • SMS rs-EPI demonstrates comparable image quality to conventional rs-EPI with shorter scan time. In British Columbia (BC), there have been 2790 confirmed COVID-19 cases as of June 20, 2020. The aim of this project is to capture the effect of COVID-19 on the volume of surgery and adaptations to the surgical care of patients at a breast centre in BC.\\nAll proven or suspected breast cancer cases treated with surgery between March 16, 2019 and April 30, 2019 and March 16, 2020 and April 30, 2020 through the Providence Breast Centre were included in this review. The date ranges in 2020 mark the early COVID-19 pandemic period in BC and the large shift in operating room access during this time.\\nIn 2019, 99 patients underwent surgery for proven breast cancer and 30 patients for suspected breast cancer. In 2020, 162 patients underwent surgery for breast cancer and 34 for suspected breast cancer. Wait times from core biopsy to surgery and surgery to oncology consultation were improved in 2020 with a reduction of core biopsy to surgery time from 58 to 28\\xa0days for patients seen during the pandemic. There was an increased use of regional anesthesia and same day discharge compared to 2019 with increases in regional anesthesia (41%-89%) and same day discharge (64%-86%) after adaptations to the pandemic were implemented.\\nChanges such as improved access to telemedicine, timing for cancer surgeries, and safer anesthetic techniques in response to the pandemic will change breast cancer surgical care beyond the pandemic era. Centralization and team-based care is the way forward. Postoperative seromas are a problem in the surgical treatment of breast cancer. The aim of the study was to evaluate whether the lysine-urethane-based tissue adhesive TissuGlu\\nThe study was designed as a prospective, randomized, multicentre non-inferiority study comparing the use of TissuGlu\\nAlthough the statistical power was not reached, twice as many clinical interventions were performed in the TissuGlu\\nThe present evaluation shows no advantage of the tissue adhesive TissuGlu We performed breast-conserving surgery (BCS) using periareolar incisions for cancers located far from the nipple-areolar complex (NAC) and examined if BCS via a periareolar incision maximized cosmesis and maintained oncologic safety. One of the most important goals of BCS is to improve cosmesis after surgery and quality of life, but the skin incision can affect cosmesis based on the tumor location.\\nFifty-five patients with breast cancers located far from the NAC underwent BCS via periareolar incisions between January 2017 and April 2018. If a sentinel lymph node biopsy was required, another skin incision was created in the axilla using the conventional technique. Medical records of patients were reviewed retrospectively.\\nThe mean patient age was 48.1\\u2009±\\u200910.6\\xa0years. The mean tumor size was 1.8\\u2009±\\u20091.0\\xa0cm (range 0.2-4.5\\xa0cm) on preoperative magnetic resonance imaging (MRI); the mean distance from the NAC to the tumor was 5.9\\u2009±\\u20091.9\\xa0cm (range 4.0-12.3\\xa0cm). Patients with cancers in the subareolar area were excluded even though the distance from the nipple was\\u2009>\\u20094\\xa0cm on MRI. Negative microscopic margins were obtained in all patients. There was no surgical complication such as seroma, bleeding, or infection. Re-operation was not needed. All patients received whole breast radiation therapy. After surgery and radiation therapy, periareolar incision scars were nearly invisible.\\nFor cancers located far from the NAC, BCS via periareolar incisions is feasible and leads to superior cosmesis in selective patients. Moreover, BCS seems oncologically safe, although long-term outcomes need to be evaluated. Neighborhood deprivation is associated with age-related disease, mortality, and reduced life expectancy. However, biological pathways underlying these associations are not well understood.\\nTo evaluate the association between neighborhood deprivation and epigenetic measures of age acceleration and genome-wide methylation.\\nThis cross-sectional study used data from the Sister Study, a prospective cohort study comprising 50\\u202f884 women living in the US and Puerto Rico aged 35 to 74 years at enrollment who had a sister with breast cancer but had not had breast cancer themselves. Cohort enrollment occurred between July 2003 and March 2009. Participants completed a computer-assisted telephone interview on demographic, socioeconomic, lifestyle, and residential factors and provided anthropometric measures and peripheral blood samples at a home examination. DNA methylation data obtained for 2630 non-Hispanic White women selected for a case-cohort study in 2014 were used in this cross-sectional analysis. DNA methylation was measured using the HumanMethylation450 BeadChips in whole blood samples collected at baseline. Data analysis for this study was performed from October 17, 2019, to August 27, 2020.\\nEach participants\\' primary address was linked to an established index of neighborhood deprivation.\\nEpigenetic age was estimated using 4 epigenetic clocks (Horvath, Hannum, PhenoAge, and GrimAge). Age acceleration was determined using residuals from regressing chronologic age on each of the 4 epigenetic age metrics. Linear regression was used to estimate associations between neighborhood deprivation and epigenetic age acceleration as well as DNA methylation at individual cytosine-guanine sites across the genome.\\nMean (SD) age of the 2630 participants was 56.9 (8.7) years. Those with the greatest (>75th percentile) vs least (≤25th percentile) neighborhood deprivation had higher epigenetic age acceleration estimated by Hannum (β\\u2009=\\u20090.23; 95% CI, 0.01-0.45), PhenoAge (β\\u2009=\\u20090.28; 95% CI, 0.06-.50), and GrimAge (β\\u2009=\\u20090.37; 95% CI, 0.12-0.62). Increasing US quartiles of neighborhood deprivation exhibited a trend with Hannum, PhenoAge, and GrimAge. For example, GrimAge showed a significant dose-response (P test for trend <.001) as follows: level 2 vs level 1 (β\\u2009=\\u20090.30; 95% CI, 0.17-0.42), level 3 vs level 1 (β\\u2009=\\u20090.35; 95% CI, 0.19-0.50), and level 4 vs level 1 (β\\u2009=\\u20090.37; 95% CI, 0.12-0.62). Neighborhood deprivation was found to be associated with 3 cytosine-phosphate-guanine sites, with 1 of these annotated to a known gene MAOB (P\\u2009=\\u20099.71\\u2009×\\u200910-08).\\nThe findings of this study suggest that residing in a neighborhood with a higher deprivation index appears to be reflected by methylation-based markers of aging. MicroRNAs (miRNAs) regulate the progression of human malignancy by targeting oncogenes or tumor suppressors, which are as promising targets for cancer treatment. Increasing evidence has suggested the aberrant expression and tumor-suppressive function of miR-1298 in cancers, however, the regulatory mechanism of miR-1298 in breast cancer (BC) remains unclear. Here, our findings showed that miR-1298 was down-regulated in BC tissues and cell lines. Lower level of miR-1298 was significantly correlated with the advanced progression of BC patients. Experimental study showed that overexpression of miR-1298 inhibited the proliferation, induced apoptosis and cell cycle arrest in BC cells. The in vivo xenograft mice model showed that highly expressed miR-1298 significantly reduced the tumor growth and metastasis. Further mechanism analysis revealed that miR-1298 bound the 3\\'-untranslated region (UTR) of A Disintegrin and metalloproteinase 9 domain (ADAM9) and suppressed the expression of ADAM9 in BC cells. ADAM9 was overexpressed in BC tissues and inversely correlated with that of miR-1298. Down-regulation of ADAM9 induced apoptosis and cell cycle arrest of BC cells. Moreover, ectopic expression of ADAM9 by transiently transfected with vector encoding the full coding sequence of ADAM9 attenuated the inhibitory effects of miR-1298 on the proliferation and cell cycle progression of BC cells. Collectively, our results illustrated that miR-1298 played a suppressive role in regulating the phenotype of BC cells through directly repressing ADAM9, suggesting the potential application of miR-1298 in the therapy of BC. Breast cancer is the most common malignancy among females worldwide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host to reject the tumor. CC chemokines play a significant role in inflammation and infection.\\nIn our study, we analyzed the expression and survival data of CC chemokines in patients with breast cancer using several bioinformatics analyses tools.\\nThe mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remarkably increased while CCL14/21/23/28 was significantly down-regulated in breast cancer tissues compared to normal tissues. Methylation could downregulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in breast cancer. Low expression of CCL3/4/23 was found to be associated with drug resistance in breast cancer. Results from Kaplan-Meier plotter and bcGenExMiner v4.2 demonstrated that breast cancer patients with high CCL8 and low CCL19/21/22 expression were more like to have a worse prognosis. CCL8 expression was significantly upregulated in breast cancer tissues compared to normal tissues. High CCL8 expression was significantly correlated with negative PR, negative ER, positive nodal status, triple-negative breast cancer subtype, basal-like breast cancer subtype, triple-negative & basal-like breast cancer subtype and high grades. CCL21 was down-regulated in breast cancer, while high levels of CCL21 was associated with negative PR, triple-negative subtype, basal-like subtype and low tumor grade. Functional analysis demonstrated that CCL8 and CCL21 were involved in carcinogenesis, tumor immune escape and chemoresistance in breast cancer.\\nIntegrative bioinformatics analysis demonstrated CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment. The reactive oxygen species (ROS)-mediated anti-cancer therapy that shows the advantages of tumor specificity, high curative effect, and less toxic side-effects has powerful potential for cancer treatment. However, hypoxia in the tumor microenvironment (TME) and low penetrability of photosensitizers further limit their clinical application. Here, we present a composite core-shell-structured nanozyme (MS-ICG@MnO2@PEG) that consists of a mesoporous silica nanoparticle (MS) core and a MnO2 shell loaded with the photosensitizer indocyanine green (ICG) and then coated with PEG as the photodynamic/chemodynamic therapeutic agent for the ROS-mediated cancer treatment. On the one hand, MS-ICG@MnO2@PEG catalyzes H2O2 to produce O2 for enhanced photodynamic therapy (PDT), and on the other hand, it consumes GSH to trigger a Fenton-like reaction that generates *OH, thus enhancing the chemodynamic therapy (CDT). At the cellular level, MS-ICG@MnO2@PEG nanozymes exhibit good biocompatibility and induce the production of ROS in 4T1 tumor cells. It disrupts the redox balance in tumor cells affecting the mitochondrial function, and specifically kills the tumor cells. In vivo, the MS-ICG@MnO2@PEG nanozymes selectively accumulate at tumor sites and inhibit tumor growth and metastasis in 4T1 tumor-bearing mice. Accordingly, this study shows that the core-shell nanozymes can serve as an effective platform for the ROS-mediated breast cancer treatment by enhancing the combination of PDT and CDT. Epidemiological studies showing the correlation between folate and the breast cancer risk have revealed inconsistent results. Hence, we conducted a dose-response meta-analysis of observational studies to obtain more reliable conclusions. We searched PubMed and Embase for studies published before April 2019 and identified 39 studies on folate intake and 12 studies on plasma folate level. The combined odds ratios (ORs) and 95% confidence intervals (CIs) were extracted to estimate the breast cancer risk. Folate intake was inversely correlated with the breast cancer risk when the highest and lowest categories (OR = 0.85, 95% CI = 0.79-0.92) were compared, and the dose-response result showed that folate intake had a linear correlation with the breast cancer risk. Moreover, a higher folate intake correlated with a lower breast cancer risk in premenopausal women (OR = 0.80, 95% CI = 0.66-0.97), but not in postmenopausal women (OR = 0.94, 95% CI = 0.83-1.06). However, plasma folate levels were not correlated with the breast cancer risk (OR = 0.98, 95% CI = 0.82-1.17). Folate intake was negatively correlated with the breast cancer risk; however, its practical clinical significance requires further study. Furthermore, additional folate supplements should be considered carefully. Survival rates for breast cancer (BC) are increasing, leading to growing interest in treatment-related late-effects. The aim of the present study was to explore late effects using Patient-Reported Outcome Measures in postmenopausal BC survivors in standard follow-up care. The results were compared to age- and gender-matched data from the general Danish population.\\nPostmenopausal BC survivors in routine follow-up care between April 2016 and February 2018 at the Department of Oncology, Aarhus University Hospital, Denmark were asked to complete the EORTC QLQ-C30 and BR23 questionnaires together with three items on neuropathy, myalgia, and arthralgia from the PRO-CTCAE. Patients were at different time intervals from primary treatment, enabling a cross-sectional study of reported late effects at different time points after primary treatment. The time intervals used in the analysis were year ≤1, 1-2, 2-3, 3-4, 4-5 and 5+. The QLQ-C30 results were compared with reference data from the general Danish female population. Between-group differences are presented as effect sizes (ESs) (Cohen\\'s \\nA total of 1089 BC survivors participated. Compared with the reference group, BC survivors reported better global health status 2-3 and 4-5 years after surgery (\\nOnly small to medium ESs were found for better global health and physical functioning and poorer outcomes for cognitive functioning, fatigue, insomnia, emotional functioning, and social functioning in postmenopausal BC survivors, who otherwise reported similar overall health-related quality of life compared with the general Danish female population. Cardiovascular diseases (CV) are the most common factor affecting prognosis in cancer survivors. Cardio-oncology (CO) services have developed to solve this issue. The paucity of outcomes regarding patient demographics and clinical findings prevails and the available data are limited to CO services evaluating patients undergoing only chemotherapy.\\nTo show initial experiences of the CO service implemented in tertiary oncology center.\\nThe CO service was designed to include two major domains: general CO and electrotherapy consultations. Patients referred to the CO service with a collection of baseline demographics, cancer type, the reason for referral, cardiac evaluation, and initial clinical outcomes were included in this observational study.\\nAll cancer patients referred to our CO service between March 2016 and December 2019 were included in the study. A total of 2762 (77% females) patients at the mean (SD) age of 62 (12) years were referred (63% on an out-patient basis) for general consultations. The most frequent diagnosis was breast cancer (66%). In 18% of patients, the reason of referral to the CO service was cancer treatment related CV complications. A total of 652 patients (515 patients with a cardiac implantable electronic device (CIED) qualified for radiotherapy (RT), 48 patients with CIEDs diagnosed with magnetic resonance imaging (MRI), and 89 patients with CIED treated with cancer surgery) were evaluated by the CO-CIED team. During the total of 5,872 RT sessions, two harmful interactions and no other complications during MRI and surgery were recorded.\\nThe CO-service established within the cancer center seems to be safe and feasible. Among patients with osseous metastases, breast cancer (BC) patients typically have the best prognosis. In the palliative setting, BC is often considered a single disease, but based on receptor status there are four distinct subtypes: luminal A (LA), luminal B (LB), triple negative (TN), and HER2-enriched (HER2). We hypothesize that survival and palliative outcomes following palliative RT for osseous metastases correlate with breast cancer subtype (BCS).\\nWe identified 3,895 BC patients with known receptor status who received palliative RT for osseous metastases from 2004-2013 in the National Cancer Database. Kaplan-Meier method with log-rank testing and univariate/multivariate Cox-regression was used to identify survival factors. Incomplete radiation courses, 30-day mortality rate, and percentage remaining life spent receiving RT (PRLSRT) were calculated.\\nSubtypes were 54% LA, 33% LB, 8% TN, and 5% HER2 with median survival of 34.1, 28.2, 5.3, and 15.7\\xa0months, respectively (p\\xa0<\\xa00.001). Overall 82% of patients received ≥10 fractions. Although BCS had limited effect on radiation regimens, TN received nearly twice as many single or hypofractionated (≤5 fractions) treatments, but the overall rate of these fraction schemes was low at 3.7 and 13.7%, respectively. Compared to LA and LB, TN and HER2 patients had worse palliative outcomes; higher rates of incomplete courses at 18.8% and 18.3% versus 12.7%-14.4%; higher 30-day mortality post-radiotherapy at 21.5% and 16.0% versus 6.3%-7.9%, and higher median PRLSRT of 7.7% and 3.7% versus 2.2%-2.4% for LA and LB. On multivariate analysis, BCS was associated with overall survival with TN (HR 3.7), HER2 (HR 1.75), and LB (HR 1.28) fairing worse than LA (p\\xa0<\\xa00.001).\\nBCS correlated with survival and palliative outcome following radiation to osseous metastases. BCS should be considered by physicians when planning palliative RT to maximize quality-of-life, avoid unnecessary treatment, and ensure palliative benefits. To investigate the value (survival benefit and cost) of first-line chemotherapy and targeted therapy in breast cancer at a population level.\\nBased on guideline recommendations, a model of optimal utilisation was constructed for first-line chemotherapy and targeted therapy in breast cancer, calculating the survival benefit and average cost of all regimens recommended for each treatment indication at 5\\xa0years and at 10\\xa0years.\\nSurvival benefits from chemotherapy and targeted therapy differ markedly depending on the treatment indications. The cost per life-year gained at 5\\xa0years is $38,044 for stages I and II, $33,749 for stage III and $ 151,668 for patients presenting with stage IV breast cancer. The cost per life-year gained at 10\\xa0years is $ 13,587 for early breast cancer. The most expensive chemotherapy indication in breast cancer is the treatment of metastatic HER2-positive breast cancer costing $330,978 per LYG for a survival benefit of 11% at 5\\xa0years falling to zero survival benefit at 10\\xa0years.\\nThere are large differences in value between the different indications for first-course chemotherapy and targeted therapy in the treatment of breast cancer that should be considered when pricing cancer drugs. To evaluate the racial/ethnic differences in prevalence of germline pathogenic variants (PVs) and the effect of race/ethnicity on breast cancer (BC) risk among carriers, results of multigene testing of 77,900 women with BC (Non-Hispanic White [NHW] = 57,003; Ashkenazi-Jewish = 4,798; Black = 6,722; Hispanic = 5,194; and Asian = 4,183) were analyzed and the frequency of PVs in each gene were compared between BC cases and race/ethnicity-matched gnomAD reference controls. Compared to NHWs, BRCA1 PVs were enriched in Ashkenazi-Jews and Hispanics while CHEK2 PVs were statistically significantly lower in Blacks, Hispanics, and Asians (all two-sided P< 0.05). In case-control studies BARD1 PVs were associated with high risks (Odds Ratio>4.00) of BC in Blacks, Hispanics and Asians; ATM PVs were associated with increased risk of BC among all races/ethnicities except Asians; whereas CHEK2 and BRIP1 PVs were associated with increased risk of BC among NHWs and Hispanics only. These findings suggest a need for personalized management of BC risk in PV carriers based on race/ethnicity. This study aimed to determine the relationship between rs17576 (MMP-9) polymorphism and increased cancer risk in a Brazilian breast cancer cohort.\\nThis study included 141 women (71 breast cancer patients and 70 controls without breast cancer) who donated 3 mL of their peripheral blood for genomic DNA extraction. This DNA was then genotyped using a real-time polymerase chain reaction.\\nThe AG (rs17576) genotype was identified in 26 (18.43%) participants in the case group and in 22 (15.60%) participants in the control group (p=0.274), while the GG genotype was identified in ten (7.09%) participants in the case group and in one (0.70%) participant in the control group (p<0.003 - OR (95% CI) 13.13 (1.73, 593.08). No significant difference in the incidence rates was observed for AG or GG rs17576 genotypes in premenopausal women, p=0.813 and p=0.556, respectively. However, in postmenopausal women, the AG genotype was shown to occur in 14 (22.5%) participants in the case group and in 4 (6.45%) participants in the control (p<0.043), while GG genotype occurred in eight (12.90%) of the individuals in the case group and in none of the individuals in the control group (p<0.006).\\nIn this study, the MMP-9 rs17576 GG polymorphic variant was shown to be significantly associated with breast cancer risk in premenopausal women, while the AG and GG genotypes were associated with increased cancer risk in postmenopausal women. To present the methodological approach used in a research that analyzed the use and performance of specialized health care, from primary care access, in four major Brazilian cities: Fortaleza (CE), Campinas (SP), São Paulo (SP) and Porto Alegre (RS).\\nPresentation and discussion of the quantitative-qualitative components of the proposed research strategy.\\nFour tracing conditions were studied: systemic arterial hypertension, high-risk pregnancy, breast cancer and severe mental disorder. For each health condition, indicators were constructed based on health information systems data, pointing out frequencies, temporal trends and local differences. This initial contextualization was enriched with a descriptive-qualitative study of the performance of each municipal health service network. Next, a cross-sectional study was conducted through a survey of 7,053 users of specialized services for each health condition. Finally, in-depth interviews were conducted with key actors to complement selected operational aspects of each municipality\\'s network. The results of all these data sources were triangulated, allowing us to explore the variability of SUS implementations in different regional scenarios.\\nThe multifaceted analytical model presented allows us to understand relevant aspects of the Unified Health System performance, paying attention to the singularities, heterogeneities and inequalities that characterize its implementation in Brazil and emphasizing the performance of local networks for the addressed health conditions. Breast cancer (BC) is a commonly diagnosed cancer in females. MicroRNA-660-5p (miR-660-5p) has been reported to be involved in the occurrence and development of BC. However, the regulatory network of miR-660-5p in BC has not been fully addressed. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the enrichment of miR-660-5p and tet-eleven translocation 2 (TET2) in BC tissues and cells. Cell counting kit-8 (CCK8), flow cytometry, and transwell migration and invasion assays were used to measure cell proliferation, apoptosis, migration, and invasion. The target relationship between miR-660-5p and TET2 was confirmed by dual luciferase reporter assay. Protein expression was measured by western blot. The expression of miR-660-5p was elevated in BC, and high expression of miR-660-5p was closely related to lymph node metastasis, advanced TNM stage, and vascular invasion of BC tumors. miR-660-5p silencing inhibited cell proliferation and metastasis, but induced apoptosis of BC cells. TET2 was identified as a direct target of miR-660-5p, and the interference of TET2 partly reversed the suppressive effects of miR-660-5p silencing on the malignant potential of BC cells. miR-660-5p promoted BC progression partly through modulating TET2 and PI3K/AKT/mTOR signaling. miR-660-5p/TET2 axis might be a promising target for BC treatment. Port catheter (PC) is a classical route of administering chemotherapy for breast cancer patients. We established a standard operating procedure (SOP) of intraoperative ipsilateral subclavian PC implantation in selected resectable breast cancer patients.\\nWe conducted a prospective clinical study to assess its safety and complications. A total of seventy six resectable breast cancer patients were included for intraoperative ipsilateral subclavian PC implantation. Thirty patients receiving conventional percutaneous contralateral PC implantation under local anesthesia at the same period were recruited as control group. The time consuming of implantation, and PC-related complications were recorded. Visual analog scale questionnaires were used to assess patients\\' satisfaction.\\nCompared with conventional contralateral PC implantation under local anesthesia, SOP for intraoperative ipsilateral subclavian PC implantation significantly shortens the time consuming (11.6 vs. 28.6\\xa0min, p\\xa0<\\xa00.001). With a median retention time of 6.3\\xa0months, the overall incidence rate of PC-related complications is 21%, of which the most common complications are infections and venous thromboembolism (7.9% for each). Most patients (86.8%) with intraoperative ipsilateral subclavian PC implantation have completed the whole chemotherapy successfully. Due to the general anesthesia and shorter time consuming, intraoperative implantation gains significantly more patients\\' satisfaction.\\nIn the present study, we develop a SOP for intraoperative ipsilateral subclavian PC implantation in resectable breast cancer patients, which is noval, convenient, and safe. In selected breast cancer patients with indications for adjuvant chemotherapy, this practice could significantly shorten the time consuming of PC implantation and improve the degree of patients\\' satisfaction. Breast cancer is the most frequent malignant tumor among Chinese women. Breast self-examination (BSE) is a simple, effective method for early detection of screening and it is essential for the prevention and control of breast cancer. The aim of this study was to create a hypothetical model to determine the factors influencing women\\'s BSE behavior in Eastern China.\\nA survey was conducted using an online questionnaire and targeting 1200 women aged 18-70\\u2009years in Eastern China. Collected data were analyzed using ibm spss 25.0 and amos 24.0 software.\\nThe final model showed a desirable fitness to sample data. A direct positive relationship exists between knowledge on risk factors and BSE. A direct positive association was found between positive attitudes and BSE, while negative attitudes have a direct negative impact on BSE. Objective factors not only had a significant direct impact on BSE, but also directly affected the positive attitudes. Positive attitudes play an intermediary role between objective factors and BSE.\\nKnowledge on risk factors about breast cancer, attitudes toward BSE and objective factors are new predictors which may influence BSE by using the structural equation modeling method. Human diversity is one of the main pitfalls in the development of robust worldwide biomarkers in oncology. Epigenetic variability across human populations are associated with different genetic backgrounds, as well as variable lifestyles and environmental exposures, each of which should be investigated. To identify potential non-invasive biomarkers of sporadic breast cancer in the Uruguayan population, we studied genome-wide DNA methylation using Illumina methylation arrays in leukocytes of 22 women with sporadic breast cancer and 10 healthy women in a case-control study. We described a panel of 38 differentially methylated CpG positions that was able to cluster breast cancer patients and controls, and that also recapitulated methylation differences in 12 primary breast tumors and their matched normal breast tissue. Moving forward we simplified the detection method to improve its applicability in a clinical setting, and used an independent well-characterized cohort of 80 leukocyte DNA samples from breast cancer patients and 80 healthy controls to validate methylation results at specific cancer-related genes. Our investigations identified methylation at CYFIP1 as a novel epigenetic biomarker candidate for sporadic breast cancer in the Uruguayan population. These results provide a proof-of-concept for the design of larger studies aimed at validating biomarker panels for the Latin American population. Various factors in the tumor microenvironment (TME) regulate the expression of PD-L1 in cancer cells. In TME, mesenchymal stem cells (MSCs) play a crucial role in tumor progression, metastasis, and drug resistance. Emerging evidence suggests that MSCs can modulate the immune-suppression capacity of TME through the stimulation of PD-L1 expression in various cancers; nonetheless, their role in the induction of PD-L1 in breast cancer remained elusive. Here, we assessed the potential of MSCs in the stimulation of PD-L1 expression in a low PD-L1 breast cancer cell line and explored its associated cytokine. We assessed the expression of MSCs-related genes and their correlation with PD-L1 across 1826 breast cancer patients from the METABRIC cohort. After culturing an ER+/differentiated/low PD-L1 breast cancer cells with MSCs conditioned-medium (MSC-CM) in a microfluidic device, a variety of in-vitro assays was carried out to determine the role of MSC-CM in breast cancer cells\\' phenotype plasticity, invasion, and its effects on induction of PD-L1 expression. In-silico analysis showed a positive association between MSCs-related genes and PD-L1 expression in various types of breast cancer. Through functional assays, we revealed that MSC-CM not only prompts a phenotype switch but also stimulates PD-L1 expression at the protein level through secretion of various cytokines, especially CCL5. Treatment of MSCs with cytokine inhibitor pirfenidone\\xa0showed a significant reduction in the secretion of CCL5 and consequently, expression of PD-L1 in breast cancer cells. We concluded that MSCs-derived CCL5 may act as a PD-L1 stimulator in breast cancer. Triple-negative breast cancer (TNBC) is a heterogeneous entity that encompasses several subtypes with distinct molecular characteristics. The patients with TNBCs show unpredictable response to the chemotherapy, and further there is the lack of effective agents. Thus, many studies have been underway to discover targeted therapy suitable for patients with specific genetic alterations in each molecular subtypes. TNBCs are classified as four major molecular subtypes according to the gene expression patterns. These are luminal androgen receptor (LAR), mesenchymal-like, immunomodulatory (IM), and basal-like types.\\nHere, we discuss the unique molecular features of each subtype as well as promising targets for anti-cancer therapy. Breast cancer in young women (< 40 years) is rare and carries a poor prognosis relative to breast cancer in older women. Most studies examining global breast cancer patterns do not describe the trends in young women specifically.\\nData from GLOBOCAN 2018 were used to compare breast cancer incidence and mortality rates among younger (ages 0-39) vs. older (ages 40+) women across 185 countries. The coefficient of variation (the ratio of the standard deviation to the mean) was used to quantify relative variability.\\nThe risk of developing breast cancer to age 39 ranged from 0.13% in Guinea to 0.95% in South Korea (coefficient of variation: 46%), and the risk of death from breast cancer to age 39 ranged from 0.02% in China to 0.72% in Cameroon (coefficient of variation: 81%). In contrast, the risk of developing breast cancer to age 74 ranged from 1.5% in Mozambique to 12.2% in Belgium (coefficient of variation: 50%), and the risk of death from breast cancer to age 74 ranged from 0.65% in South Korea to 3.0% in Somalia (coefficient of variation: 36%).\\nAmong young women, breast cancer mortality rates varied more worldwide than breast cancer incidence. In contrast, among older women/women of all ages, breast cancer incidence varied more than breast cancer mortality. Further research is required to examine the impact of stage at diagnosis, clinicopathologic features, and treatments received, on variations in the survival and mortality of breast cancer in young women around the world. Breast cancer is a popular fatal malignant tumor for women with high of rates incidence and mortality. Development of the new approaches for breast cancer targeted diagnosis and chemotherapy is emergently needed by the current clinical practice, the important first step is finding a breast cancer specifically binding molecule or fragment as early clinical indicators.\\nBy a phage-displayed peptide library, a 12-mer peptide, CSB1 was screened out using MCF-7 cells as the target. The consequently results under immunofluorescence and laser scanning confocal microscope (LSCM) indicated that CSB1 bound MCF-7 cells and breast cancer tissues specifically and sensitively with high affinity. Bioinformatics analysis suggested that the peptide CSB1 targets the 5-Lipoxygenase-Activating Protein (FLAP), which has been implicated in breast cancer progression and prognosis.\\nThe peptide, CSB1 is of the potential as a candidate to be used for developing the new approaches of molecular imaging detection and targeting chemotherapy of breast cancer in the future. Agreement measures are useful tools to both compare different evaluations of the same diagnostic outcomes and validate new rating systems or devices. Cohen\\'s kappa (κ) certainly is the most popular agreement method between two raters, and proved its effectiveness in the last sixty years. In spite of that, this method suffers from some alleged issues, which have been highlighted since the 1970s; moreover, its value is strongly dependent on the prevalence of the disease in the considered sample. This work introduces a new agreement index, the informational agreement (IA), which seems to avoid some of Cohen\\'s kappa\\'s flaws, and separates the contribution of the prevalence from the nucleus of agreement. These goals are achieved by modelling the agreement-in both dichotomous and multivalue ordered-categorical cases-as the information shared between two raters through the virtual diagnostic channel connecting them: the more information exchanged between the raters, the higher their agreement. In order to test its fair behaviour and the effectiveness of the method, IA has been tested on some cases known to be problematic for κ, in the machine learning context and in a clinical scenario to compare ultrasound (US) and automated breast volume scanner (ABVS) in the setting of breast cancer imaging. Graphical Abstract To evaluate the agreement between the two raters [Formula: see text] and [Formula: see text] we create an agreement channel, based on Shannon Information Theory, that directly connects the random variables X and Y, that express the raters outcomes. They are the terminals of the chain X⇔ diagnostic test performed by [Formula: see text] ⇔ patient condition[Formula: see text] ⇔ diagnostic test performed by [Formula: see text] ⇔ Y. Human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification is an important predictive biomarker for identifying patients with breast cancer, who may benefit from HER2-targeted therapy. However, little is known about the molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. We analysed the HER2 mutation features of 1184 patients with invasive breast cancer. In addition, a single-arm, prospective, phase-II study (NCT03412383) of pyrotinib was conducted in patient with metastatic HER2 amplification-negative, mutation-positive breast cancer. Peripheral blood was collected from each patient and circulating tumour DNA (ctDNA) sequencing was performed using a 1021 gene panel. HER2 mutations were detected in 8.9% (105/1184) of patients. The HER2 amplification-positive patients had a higher mutation frequency than the HER2 amplification-negative patients (19.5% vs. 4.8%,  RNA exosome can target the specific RNAs for their processing/degradation by distinct exosome cofactors. As a key component in exosome cofactors, RNA binding motif protein 7 (RBM7) shows the binding specificity for uridine-rich sequences in mRNAs via its RNA recognition motifs. However, the specific function of RBM7 in human breast cancer remains unclear. In vitro, experiments revealed that knockdown of RBM7 dramatically inhibited breast cancer cell proliferation, while inducing G1 cell cycle arrest; the opposite was true when RBM7 was overexpressed. Meanwhile, experiments in vivo confirmed the oncogenic function of RBM7 in breast cancer. RNA sequencing and the following pathway analysis found that cyclin-dependent kinase1 (CDK1) was one of the main gene regulated by RBM7. Overexpression of RBM7 increased CDK1 expression, while RBM7 knockdown decreased it. RIP assays additionally found that RBM7 bound directly to CDK1 mRNA. It was also showed that RBM7 could directly bind to the AU-rich elements (AREs) in 3\\'-UTR of CDK1 mRNA, which contributed to the stability of CDK1 mRNA by lengthening its half-life. More importantly, the oncogenic activity reduced by knockdown of RBM7 could be rescued by overexpression of CDK1 both in vitro and in vivo, but mutant CDK1 failed. All the evidences implied RBM7 promoted breast cancer cell proliferation by stabilizing CDK1 mRNA via binding to AREs in its 3\\'-UTR. As we knew, it was the first attempt to connect the RNA exosome to the tumor development, providing new insights into the mechanisms of RNA exosome-linked diseases. Over 97% of individuals diagnosed with ductal carcinoma in situ (DCIS) will choose to receive guideline concordant care (GCC), which was originally designed to treat invasive cancers and is associated with treatment related morbidity. An alternative to GCC is active surveillance (AS) where therapy is delayed until medically necessary. Differences in mortality risk between the two approaches in women age 65+ are analyzed in this study. SEER and Medicare information on treatment during the first year after diagnosis was used to identify three cohorts based on treatment type and timing: GCC ( Measles virus (MV) Edmonston derivative strains are attractive vector platforms in vaccine development and oncolytic virotherapy.  One of the most refractory breast cancer types is triple negative (TN) breast cancer, in which cells are resistant to both hormone and Herceptin treatments and, thus, often cause recurrence and metastasis. Effective treatments are needed to treat TN breast cancer. We previously demonstrated that rMV-SLAMblind, a recombinant measles virus, showed anti-tumor activity against breast cancer cells. Here, we examined whether rMV-SLAMblind is effective for treating TN breast cancer. Nectin-4, a receptor for rMV-SLAMblind, was expressed on the surface of 75% of the analyzed TN breast cancer cell lines. rMV-SLAMblind infected the nectin-4-expressing TN breast cancer cell lines, and significantly decreased the viability in half of the analyzed cell lines  Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up.\\nThe evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months.\\nComplication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival.\\nThis is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown. The heat shock protein 90 (HSP90s) family is composed of molecular chaperones composed of four isoforms in humans, which has been widely reported as unregulated in various kinds of cancers. Nevertheless, the role of each HSP90s isoform in prognosis and immune infiltration in distinct subtypes of breast cancer (BRAC) remains unclear.\\nPublic online databases including the Oncomine, UALCAN, Kaplan-Meier Plotter, Tumor IMmune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), GeneMANIA, and Database for Annotation, Visualization, and Integrated Discovery (DAVID) were integrated to perform bioinformatic analyses and to explore the possible associations among HSP90s gene expression, prognosis, and immune infiltration in BRAC.\\nThe mRNA expression of all HSP90s members was elevated in distinct clinical stages and subtypes of BRAC, compared with the normal breast tissue (\\nThis study demonstrated that HSP90s family genes were overexpressed and might be serve as prognostic biomarkers in subtypes of BRAC. It might be a novel breakthrough point of BRAC treatment to regulate immune infiltration in BRAC microenvironment for more effective anticancer immunity through pharmacological intervention of HSP90s. Transfer RNA-derived small RNA (tsRNA)s are novel non-coding RNAs, expressed in a variety of tissues and organs. Two subtypes of tsRNAs have been reported: tRNA-derived stress-induced RNA (tiRNA)s and tRNA-derived fragment (tRF)s. tsRNAs have been reported to play essential roles and possess different biological functions in a variety of physiological activities. Recently, tsRNAs have been implicated in a large number of diseases, such as cancers (including breast cancer, ovarian cancer, lung cancer, prostate cancer, colorectal cancer, etc.), neurological disorders, viral infections, metabolic diseases and angiogenesis-related diseases. Although the biological functions of tsRNAs are still poorly understood, correlations between dysregulated tsRNA expression and disease development have been recently reported. Additionally, their capabilities as potential biomarkers for disease diagnosis and prognosis have been revealed in clinical studies. In this review, we summarize the current knowledge of tsRNAs, and discuss their potential clinical applications as biomarkers in different diseases. Although the regulation of tsRNAs is similar to miRNAs in regards to the related physiological and pathological processes, the higher stability and expression levels of tsRNAs place them as ideal biomarkers for the diagnosis and prognosis in cancer and other diseases. Therefore, it is worth to verify the possibility and reliability of these reported tsRNAs as potential biomarkers for clinical applications in disease diagnosis and prognosis. To evaluate safety and clinical outcome of repeated transarterial \\nBetween 2009 and 2018, n=288 patients underwent TARE for treatment of malignant liver disease in a tertiary care hospital. This retrospective single center study analyzed the safety and outcome of patients (n=11/288) undergoing repeated resin microsphere TARE. Included patients suffered from hepatocellular carcinoma (n=3), colorectal cancer (n=2), breast cancer (n=2), intrahepatic cholangiocarcinoma (n=3), and neuroendocrine carcinoma (n=1). All patients had shown either partial response (n=9) or stable disease (n=2) after first TARE. Lab parameters, response assessed by the Response Evaluation Criteria in Solid Tumors (mRECIST/RECIST) at 3 months and overall survival was analyzed. Additionally, patients with repeated TARE were compared to a matched control group (n=56) with single TARE therapy. Kaplan Meier analysis was performed to analyze survival.\\nPatients after repeated TARE showed similar increase in lab parameters as compared to their first TARE. No case of radioembolization induced liver disease was observed. While n=5/11 patients showed a partial response and n=4/11 patients a stable disease after repeated TARE, only n=2/11 patients suffered from progressive disease. Median overall survival was 20.9±11.9 months for the repeated TARE group while it was 5.9±16.2 months for the control group.\\nRepeated  In locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of cancer therapy, though whether it is applicable to TNBC is still unclear.\\nA total of 14 non-pCR TNBC patients were enrolled, and tissue samples from radical operation were collected. Of these, 7 cases developed disease progression within 12 months after operation [short disease-free survival (short DFS)], while others showed longer DFS over 1 year (long DFS). Next generation sequencing (NGS) analysis targeting 422 cancer-related genes and \\nA total of 72 mutations were detected within 14 patients, which ranged from 1 to 8 per patient with a median mutations number of 5. The median number of mutations in the short-DFS group was higher than that in the long-DFS group (6.0 \\nIn non-pCR TNBC,  The increase of breast cancer (BC) incidence has drawn attention to BC risk as means of reducing mortality and morbidity of the disease. The aim of this study was to determine the accuracy of BC risk perception, evaluate factors that affect risk perception and assess the correlation between BC risk perception and attitudes towards BC chemoprevention. A cross-sectional study included total of 258 women with average and high-risk for BC according to the Breast Cancer Risk Assessment Tool (BCRAT). All data were collected by face-to-face interview by three trained 6th year medical school students using a 54-item questionnaire. Each participant\\'s actual BC risk was compared to a perceived risk and the accuracy of the BC risk self-assessment was determined. 72% of high-risk women underestimated their BC risk (p\\xa0<\\xa00.001). One third of subjects with a family history of BC have also underestimated their own risk (p\\xa0=\\xa00.002). Women who responded to screening mammography were more informed about BC risk factors (p\\xa0=\\xa00.001). General knowledge about BC chemoprevention was surprisingly low, regardless of the accuracy of BC risk self-assessment. High-risk women appear to be unrealistically optimistic, since there was a significant difference between the accuracy of self-perceived risk and the objective BC risk. Vitamin D is well known for its effects on the homeostasis of calcium and phosphorus. Lately, considerable research has brought the extra-skeletal role of vitamin D under the spotlight, including its anti-cancer activity. Colorectal cancer (CRC) is the most extensively studied neoplasia that has been observed to be affected by vitamin D; the list includes breast, prostate, and ovarian cancer. This review aims to shine a light on the influence of vitamin D over CRC and to further understand its ability to be used as a potential economical treatment for CRC patients.\\xa0For this review, PubMed was used as the main database for the literature search. Studies on the role of vitamin D on CRC within 10 years\\xa0and all of the study types were included.\\xa0Post the extensive research over PubMed, it was noted that vitamin D, through its effect on multiple pathways, especially Wnt/β-catenin, apoptosis, and inflammation, hinders the progression of CRC carcinogenesis. High levels of this steroid hormone can delay the progression and may provide a cost-effective way of treating CRC patients. Further research and additional human trials are still due to bring about more knowledge on this topic. In conclusion, high serum levels of vitamin D are associated with a lower risk of incidence and progression of CRC. Alpelisib is a first-in-class α-specific phosphatidylinositol 3-kinase inhibitor approved for the treatment of patients with estrogen receptor-positive metastatic breast cancer. High absolute risk (AR) of relevant toxicities has been observed with this treatment. This meta-analysis aimed to improve the precision of the estimated AR of selected adverse events (AEs) associated with this new agent.\\nA literature search was conducted in August 2019 to identify trials analyzing the anti-tumor efficacy and toxicity profile of alpelisib. Heterogeneity was assessed by using \\nThere was no evidence of heterogeneity between studies regarding the AR of most AEs except for all-grade weight loss and grade 3-4 stomatitis. The number of serious AEs was clearly reported in only one study, of which the most common was hyperglycemia; the most common all-grade AEs were hyperglycemia (59%), diarrhea (56%), nausea (44%), and rash (38%). Grade 3/4 hyperglycemia and rash occurred in 28% and 10% of patients, respectively. No treatment-associated deaths were observed, and 18% of patients had to stop treatment due to toxicities.\\nAlpelisib is associated with clinically relevant AEs that can lead to treatment discontinuation. The most common AE was hyperglycemia. No treatment-related deaths were observed. To investigate quantitative ultrasound (QUS) based higher-order texture derivatives in predicting the response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC).\\n100 Patients with LABC were scanned before starting NAC. Five QUS parametric image-types were generated from radio-frequency data over the tumor volume. From each QUS parametric-image, 4 grey level co-occurrence matrix-based texture images were derived (20 QUS-Tex\\nA KNN-model provided the best results with sensitivity, specificity, accuracy, and area under curve (AUC) of 87%, 81%, 82%, and 0.86, respectively. The most helpful features in separating the two response groups were QUS-Tex\\nWe report the first study demonstrating QUS texture-derivative methods in predicting NAC responses in LABC, which leads to better results compared to using texture features alone. ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. The compound is currently being tested in patients with hematological malignancies and solid tumors, including those of the breast. We investigated strategies to convert the response of breast cancers to ONC201 from anti-proliferative to apoptotic. ONC201 treatment upregulates TRAIL and primes TRAIL-resistant non-triple negative breast cancer (TNBC) cells to undergo cell death through the extrinsic pathway. Remarkably, the addition of exogenous recombinant human TRAIL (rhTRAIL) converts the response of TRAIL-resistant non-TNBC cells to ONC201 from anti-proliferative to apoptotic in a death receptor 5 (DR5)-dependent manner  Interest in the use of cell-free nucleic acids (CFNAs) as clinical non-invasive biomarker panels for prediction and prevention of multiple diseases has greatly increased over the last decade. Indeed, circulating CFNAs are attributable to many physiological and pathological processes such as imbalanced stress conditions, physical activities, extensive apoptosis of different origin, systemic hypoxic-ischemic events and tumour progression, amongst others. This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as\\xa0their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Presented considerations conform with principles of 3P medicine and serve for improving individual outcomes and cost efficacy of medical services provided to the population. Cytochromes P450 (CYPs) constitute an enzyme family involved in the oxidative metabolism of a wide variety of endogenous and exogenous compounds, including anti-cancer drugs and carcinogens. Unlike other human CYPs, CYP4Z1 is highly expressed in human breast carcinoma and is associated with poor prognosis. As a result, CYP4Z1 was hypothesised to be a potential biomarker or drug target for the discovery and development of promising anti-cancer therapies.\\nCYP4Z1 expression was immunohistochemically studied in a set of 100 different human tissues, including normal, benign, malignant and metastatic tissues, which originated from 27 anatomical sites. As a tumour model for CYP4Z1 expression, a panel of different breast cancers was evaluated for CYP4Z1 expression and its relation to histopathological features and prognostic immunohistochemical markers.\\nThe immunohistochemical results revealed that CYP4Z1 was expressed in only one (4.3%) of the normal tissues from the mammary glands, while the expression of the enzyme was positive in 1 (11%), 12 (19%) and 2 (40%) of the benign, malignant and metastatic tissues, respectively. Interestingly, several tumour entities showed prominent expressions of CYP4Z1, including carcinomas of adrenal cortex, squamous cells of oesophagus, lung and cervix, as well as seminoma, astrocytoma, melanoma and lastly endometrial adenocarcinoma. In breast cancers, CYP4Z1 was expressed in 82% of the cases. Its expression was significantly associated with the pathology of tumour, histological grade and status of lymph node metastasis. Importantly, it was also significantly associated with the expressions of Her2, P53 and Ki-67.\\nThese findings greatly support future plans for the use of CYP4Z1 as a biomarker or target for anti-cancer drugs. However, large-scale validation studies are needed to better delineate the potential use of CYP4Z1 for therapeutic purposes. The 4th  Herein, we present a case of a male patient with breast cancer and a recent history of COVID-19 pneumonia, diagnosed with pseudofungi on pathological examination of lymph nodes after mastectomy. Pseudofungi are septate hyphae-like structures that morphologically mimic fungal elements despite the absence of true mycosis and thus predispose to overtreatment if not properly identified. We report a review of similar cases involving this diagnostic mimicker in the literature. Upregulation of sialyltransferases-the enzymes responsible for the addition of sialic acid to growing glycoconjugate chains-and the resultant hypersialylation of up to 40-60% of tumour cell surfaces are established hallmarks of several cancers, including lung, breast, ovarian, pancreatic and prostate cancer. Hypersialylation promotes tumour metastasis by several routes, including enhancing immune evasion and tumour cell survival, and stimulating tumour invasion and migration. The critical role of enzymes that regulate sialic acid in tumour cell growth and metastasis points towards targeting sialylation as a potential new anti-metastatic cancer treatment strategy. Herein, we explore insights into the mechanisms by which hypersialylation plays a role in promoting metastasis, and explore the current state of sialyltransferase inhibitor development. Mutant TP53 interacts with other proteins to produce gain-of-function properties that contribute to cancer metastasis. However, the underlying mechanisms are still not fully understood.\\nUsing immunoprecipitation and proximity ligation assays, we evaluated breast cancer anti-estrogen resistance 1 (BCAR1) as a novel binding partner of TP53\\nWe discovered a novel interaction between TP53\\nThe interaction between TP53 Progesterone receptors (PR) are potent modifiers of endocrine responses. In aberrant signalling cancer contexts, phosphorylation events dramatically alter steroid hormone receptor action.\\nThe transcriptomes of primary tumours and metastases in mice harbouring ER+ breast cancer patient-derived xenografts (PDXs) were analysed following single-cell RNAseq. In vitro assays were employed to delineate mechanisms of endocrine resistance and stemness.\\nA 16-gene phospho-Ser294 PR (p-PR) signature predicted poor outcome in ER+ breast cancer. Relative to primary PDX tumours, metastatic lesions expressed abundant p-PR and exhibited an activated PR gene programme with elevated expression of PGR and IRS-1. Breast cancer models of activated PR lost the expression of IGF1R and acquired insulin hypersensitivity with tamoxifen insensitivity. Activated p-PR+ breast cancer cells formed increased tumourspheres with enlarged ALDH+ and CD24-/CD44 populations. E2 induced PR/IRS-1 interaction and exchange of IGF1Rβ for IRS-1 in p-PR-containing transcriptional complexes. Inhibition of IRS-1 or IR and inducible IRS-1 knockdown reduced tumourspheres. Endocrine-resistant models of luminal B breast cancer induced p-PR in 3D cultures and required PR and IRS-1 for tumoursphere formation.\\nPhospho-PR-B cooperates with IRS-1 to promote outgrowth of endocrine-resistant and stem-like breast cancer cells. Targeting phospho-PR/IRS-1 crosstalk may block the emergence of endocrine resistance. Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clinical trials; however, rapalogs resistance remains an unresolved clinical challenge. Therefore, understanding the mechanisms by which cells become resistant to rapalogs may guide the development of successful mTOR-targeted cancer therapy. In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the negative-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors. Therefore, disruption of eEF-2K simultaneously abrogates the two critical resistance signaling pathways, sensitizing breast cancer cells to rapalogs. Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy. We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer. In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor. Cellular transformation is associated with dramatic changes in gene expression, but it is difficult to determine which regulated genes are oncogenically relevant. Here we describe Pheno-RNA, a general approach to identifying candidate genes associated with a specific phenotype. Specifically, we generate a \"phenotypic series\" by treating a nontransformed breast cell line with a wide variety of molecules that induce cellular transformation to various extents. By performing transcriptional profiling across this phenotypic series, the expression profile of every gene can be correlated with the strength of the transformed phenotype. We identify ∼200 genes whose expression profiles are very highly correlated with the transformation phenotype, strongly suggesting their importance in transformation. Within biological categories linked to cancer, some genes show high correlations with the transformed phenotype, but others do not. Many genes whose expression profiles are highly correlated with transformation have never been associated with cancer, suggesting the involvement of heretofore unknown genes in cancer. It is unclear whether the de-escalated therapy that omits anthracycline-based chemotherapy is as beneficial as standard therapy for patients with stage I human epidermal growth factor receptor 2-positive (HER2\\nWe retrospectively investigated 95 patients with pathological stage I HER2\\nWe assessed 45 patients who underwent standard therapy containing anthracyclines, 35 patients who underwent paclitaxel plus trastuzumab (P+TRA group), and 15 patients who underwent trastuzumab monotherapy or no adjuvant therapy; the 5-year invasive disease-free survival rates were 97.8%, 92.9%, and 93.3%, respectively (p=0.255). Adverse events were significantly less frequent in the P+TRA group than that in the standard therapy group.\\nIn a real-world setting, de-escalated therapy without anthracyclines demonstrated excellent outcomes similar to the standard therapy containing anthracyclines as well as lower adverse events. Extranodal marginal zone lymphoma (EMZL) presents only rarely within the breast, although the incidence of breast EMZL has increased in the past decade for unclear reasons. Due to its rarity, the etiology, course, and treatment response of this cancer are less studied. Case Report: We present the case of a 64-year-old female who had bilateral diffuse irregularity in a trabecular pattern on screening mammogram. Random ultrasound-guided breast biopsy of the right breast demonstrated an extra-nodal marginal zone B-cell lymphoma. She also had approximately 25% marrow involvement by mucosa-associated lymphoid tissue-type marginal zone lymphoma and splenomegaly. Clinically she remained asymptomatic during a 1-year follow-up. Although she presented with advanced-stage disease involving both breasts, spleen and bone marrow, given her lack of associated symptoms, she was observed with active surveillance. Conclusion: Asymptomatic cases of breast EMZL can be managed with close observation as exemplified by our case. Capecitabine is a prodrug that is metabolized to its active form, 5-fluorouracil (5-FU), in three enzymatic steps. This prospective pharmacokinetic study evaluated cytidine deaminase (CDA) activity, the second drug-metabolizing enzyme that generates 5\\'-deoxy-5-fluorouridine (5\\'-DFUR) from 5\\'-deoxy-5-fluorocytidine (5\\'-DFCR), as well as creatinine clearance (CLcr).\\nPatients with colorectal cancer who received capecitabine plus oxaliplatin were selected. Pharmacokinetics of capecitabine and its metabolites, and CDA activity in plasma were analyzed.\\nEighteen patients were examined. The area under the plasma concentration-time curve (AUC) of 5\\'-DFUR showed a significant inverse correlation with CLcr (p=0.003). The metabolic ratio, i.e. the ratios of the AUC of 5\\'-DFUR plus that of 5-FU to the AUC of 5\\'-DFCR, significantly increased when CLcr decreased (p=0.001) but did not depend on plasma CDA activity.\\nMetabolism of 5\\'-DFCR to form 5\\'-DFUR increased as CLcr decreased but the mechanism remains unknown. Symptomatic cancers display a different biological behaviour from screen-detected cancers, which may impact the management of axillary metastases. We aimed to determine the role of unselected axillary nodal clearance (ANC) in symptomatic patients with positive sentinel node biopsies (SNBs).\\nA case-note review was performed on 95 symptomatic breast cancer patients who underwent ANC following positive SNB.\\nThirty-eight (40%) patients were treated with a mastectomy and 57 (60%) with breast-conserving surgery. At ANC, 25 patients (26.3%) showed evidence of further lymph node metastases, with 15 (60%) having two or fewer macrometastases. The presence of more than 2 SNB macrometastases was associated with further ANC metastases (p<0.001). The presence of further metastases at ANC was not associated with either reduced overall survival or disease-free survival.\\nA number of symptomatic breast cancer patients with positive SNBs may be overtreated. Ongoing trials examining the management of low volume SNB macrometastases need to consider the symptomatic subgroup in their conclusions. We evaluated the usefulness of topoisomerases (TOPs) expression as prognostic predictors in breast cancer.\\nWe retrospectively investigated sixty cases with primary breast cancer. We evaluated the tumor and non-tumor mRNA levels of TOP1 and TOP2α using quantitative reverse-transcription polymerase chain reaction. TOP1/TOP2α positivity was defined as the ratio of the mRNA expression of cancer/normal tissue of >1 for both TOP1 and TOP2α.\\nTOP1 and TOP2α were markedly overexpressed in breast cancer tissues compared to normal breast tissues. Of the 60 cases, 46 (76.7%) were positive for TOP1/TOP2α. The relapse-free survival was relatively shorter for patients with positive TOP1/TOP2α. There was no recurrent disease among the 14 patients who were negative for TOP1/TOP2α, whereas four of the 46 TOP1/TOP2α-positive patients had disease recurrence.\\nNegative TOP1 or TOP2α expression may be useful for predicting better prognoses in breast cancer patients. The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic.\\nThe present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients.\\nA significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours.\\nIncreased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time. Male breast-cancer (MBC) is often diagnosed late. Our purpose was to evaluate fine-needle aspiration cytology (FNAC) versus Tru-Cut biopsy (TCNB) in MBC diagnosis.\\nMen with suspicious breast lesions were prospectively enrolled; 54 met the inclusion criteria and underwent FNAC and TCNB. FNAC, TCNB and gold-standard results were compared.\\nUnsatisfactory results were 11.1% after FNAC and none after TCNB (p=0.027). After gold-standard evaluation, the diagnosis of FNAC and TCNB was confirmed, respectively, in 63.0% and 98.1% and changed in 37.0% and 1.9% (p<0.001). The malignancy rate after FNAC, TCNB and surgery were, respectively, 25.9%, 33.3% and 35.1% (FNAC vs. TCNB p=0.5276, FNAC vs. surgery p=0.404; TCNB vs. surgery p=1). Among invasive carcinomas, 93.8% were identified by FNAC vs. 87.5% by TCNB (p=1); all ductal carcinoma in situ (DCIS) were detected after TCNB and none after FNAC (p=0.1).\\nFNAC leads to a significantly higher number of inadequate samplings and seems to be subject to increased DCIS misdiagnoses. TCNB correlated better to the final histological report. Human mesenchymal stem cells (hMSC) represent a versatile cell population, able to modulate the tumor microenvironment. Our aim was to recreate an open scene for the in vivo interaction between hMSC and the MCF-7 breast cancer cells (MCF-7), in order to enlighten the intimate involvement of hMSC in tumor vasculogenesis and angiogenesis.\\nhMSC and MCF-7 were seeded onto the chick embryo chorioallantoic membrane (CAM) and incubated for 7 days. Consecutively, the morphology and the immunohistochemical profile of CAM were assessed.\\nFollowing this complex interaction, MCF-7 acquired a more aggressive phenotype, hMSC switched to a vascular precursor phenotype, while CAM underwent a major reset to an earlier stage, with hotspots of angiogenesis, vasculogenesis and hematopoiesis.\\nThe hallmark of this study was the establishment of a veritable in vivo experimental model of MSC involvement in tumor vasculogenesis and angiogenesis, allowing further analysis in the field. The discovery of the nude mouse model enabled the experimental growth of human-patient tumors. However, the low establishment rate of tumors in nude and other immunodeficient strains of mice has limited wide-spread clinical use.\\nIn order to increase the establishment rate of surgical specimens of patient tumors, we transplanted tumors to nude mice subcutaneously along with large amounts of surrounding tissue of the tumor.\\nThe new transplantation method increased the establishment rate in nude mice to 66% compared to the old method of implanting the surgical tumor specimen with surrounding tissue removed (14%). High stage and presence of metastasis in the patient donor are positively correlated to tumor engraftment in nude mice.\\nThe new method can potentially allow most cancer patients who undergo surgery or biopsy to have their own mouse model for drug-sensitivity testing. The aim of this study was to establish a patient-derived orthotopic xenograft (PDOX) mouse model of liver metastasis of triple-negative breast cancer (TNBC) and examine the efficacy of oral recombinant methioninase (o-rMETase) on the liver metastasis.\\nTNBC from a patient was implanted in the left hepatic lobe of nude mice to simulate liver metastasis in a PDOX model. Ten days later, all mice underwent laparotomy to measure tumor size and were randomized to three groups: control; o-rMETase 100 U once daily (qd); and o-rMETase 200 U qd. After 9 days of treatment, all mice were sacrificed.\\nAt the end of the treatment period for the liver metastasis, the size of liver metastases was 372.6 mm\\nThe TNBC liver metastasis was highly aggressive resulting in re-metastasis and ascites. o-rMETase tended to inhibit the liver metastasis and significantly improved the mouse body-condition score. This new PDOX model of TNBC liver metastasis will be useful for identifying effective agents for this recalcitrant disease. None PI3K and CDK 4/6 inhibitors are targeted therapies approved to treat advanced breast cancer; CDK 4/6 inhibitors are more widely used. Here we discuss trials that examine PI3K inhibitors with novel drug combinations including a CDK 4/6 inhibitor given data implicating the pathway in CDK 4/6 resistance. Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers.\\nUsing LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e. inverse-variance meta-analysis, co-localization, and M-values), and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data.\\nGenetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10-9). In addition, four novel sub-genome wide regions at 7p22.2, 7q22.1, 9p12 and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines, and expression quantitative trait loci (eQTL) data highlighted candidate target genes for further investigation.\\nUsing cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis.\\nOur research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings. Population-based pharmacoepidemiological studies are used to assess post-marketing drug safety and discover beneficial effects of off-label drug use. We conducted a drug-wide association study (DWAS) to screen for associations between prescription drugs and cancer risk.\\nThis registry-based nested case-control study, 1:10 matched on age, sex and date of diagnosis of cases comprises approximately 2 million Norwegian residents including their drug history from 2004-2014. We evaluated the association between prescribed drugs, categorized according to the Anatomical Therapeutic Chemical (ATC) classification system, and the risk of the 15 most common cancer types, overall and by histology. We used stratified Cox regression, adjusted for other drug use, comorbidity, county and parity, and explored dose-response trends.\\nWe found 145 associations among 1230 drug-cancer combinations on the ATC2-level and 77 of 8130 on the ATC4-level. Results for all drug-cancer combinations are presented in this paper and an online tool (https://pharmacoepi.shinyapps.io/drugwas/). Some associations have been previously reported, i.e. menopausal hormones and breast cancer risk, or are likely confounded, i.e. chronic obstructive pulmonary diseases and lung cancer risk. Other associations were novel, i.e. inverse association between proton pump inhibitors and melanoma risk, and carcinogenic association of propulsives and lung cancer risk.\\nThis study confirmed previously reported associations and generated new hypotheses on possible carcinogenic or chemopreventive effects of prescription drugs. Results from this type of explorative approach need to be validated in tailored epidemiological and preclinical studies.\\nDWAS studies are robust and important tools to define new drug-cancer hypotheses. Exposure to higher levels of melatonin may be associated with lower breast cancer risk, but epidemiological evidence has been limited. We examined the relationship in a case-control study nested within the Diagnostisch Onderzoek Mammacarcinoom (DOM) study, and conducted a meta-analysis of prospective studies.\\nConcentrations of 6-sulfatoxymelatonin in pre-diagnostic first-morning urine voids were measured in 274 postmenopausal women diagnosed with breast cancer and 274 matched controls from the DOM study. Conditional logistic regression models were used to estimate multivariable-adjusted odds ratios (ORs) of breast cancer for thirds of 6-sulfatoxymelatonin. Meta-analysis of the current and previous prospective studies of urinary melatonin with breast cancer risk estimated the inverse-variance weighted averages of study-specific log-relative risks (RRs) of breast cancer for the highest versus lowest levels of 6-sulfatoxymelatonin.\\nIn the DOM study, the ORs of breast cancer for the middle and highest versus lowest thirds of 6-sulfatoxymelatonin were 0.70(95%CI:0.45-1.09) and 0.72(0.44-1.19), respectively. In the meta-analysis of the DOM study with six previous studies(2,296 cases), RR of breast cancer for the highest versus lowest levels of 6-sulfatoxymelatonin was 0.87(0.76-1.01).\\nResults from the DOM study, together with the published prospective data, do not support a strong association of melatonin with breast cancer risk.\\nThis study adds to the relatively scarce prospective data on melatonin in relation to breast cancer risk. The totality of the prospective evidence does not clearly show an association between melatonin and breast cancer risk, but further data are needed to be able to exclude a modest association. Breast cancer is one of the most frequent cancers in women and the globally leading cause of cancer-related deaths. Bioinformatics and experimental analyses found that miR-937-5p may play a proto-oncogenic role in breast cancer; however, the specific effects and the molecular mechanism need further investigation. GSEA-KEGG and GSEA-GO suggested that miR-937-5p might be related to cell cycle and DNA replication. The experimental data indicated that miR-937-5p inhibition significantly repressed the proliferation of breast carcinoma cells and elicited S-phase cell cycle arrest. Meanwhile, the protein levels of proliferating marker ki-67 and cell cycle regulators Cyclin A2, Cyclin B1, CDK1, and Cyclin D1 were also decreased by miR-937-5p inhibition. miR-937-5p could directly bind to and negatively regulate SOX17. SOX17 overexpression also significantly repressed the proliferation of breast carcinoma cells and elicited S-phase cell cycle arrest and decreased ki-67, β-catenin, c-Myc, Cyclin A2, Cyclin B1, Cyclin D1, and CDK1 protein contents. More importantly, the effects of miR-937-5p were reversed by SOX17. We investigated the role of protein arginine methylation (PAM) in estrogen receptor (ER)-positive breast cancer cells through pharmacological intervention. Tamoxifen (TAM) or adenosine dialdehyde (ADOX), independently, triggered cell cycle arrest and down-regulated PAM, as reduced protein arginine methyltransferase1 (PRMT1) mRNA and asymmetric dimethylarginine (ADMA) levels. Synergistic effect of these compounds elicited potent anti-cancer effect. However, reduction in ADMA was not proportionate with the compound-induced down-regulation of PRMT1 mRNA. We hypothesized that the disproportionate effect is due to the influence of the compounds on other methyltransferases, which catalyze the arginine dimethylation reaction and the diversity in the degree of drug-protein interaction among these methyltransferases. In silico analyses revealed that independently, ADOX or TAM, binds with phosphatidylethanolamine-methyltransferase (PEMT) or betaine homocysteine-methyl transferase (BHMT); and that the binding affinity of ADOX with PEMT or BHMT is prominent than TAM. These observations suggest that in breast cancer, synergistic effect of ADOX\\xa0+\\xa0TAM elicits impressive protective function by regulating PAM; and plausibly, restoration of normal enzyme activities of methyltransferases catalyzing arginine dimethylation could have clinical benefits. The primary objective of this work was to implement and evaluate a cardiac atlas-based autosegmentation technique based on the \"Workflow Box\" software (Mirada Medical, Oxford UK), in order to delineate cardiac substructures according to European Society of Therapeutic Radiation Oncology (ESTRO) guidelines; review and comparison with other cardiac atlas-based autosegmentation algorithms published to date.\\nOf an atlas of data set from 20 breast cancer patients\\' CT scans with recontoured cardiac substructures creation according to the ESTRO guidelines. Performance evaluation on a validation data set consisting of 20 others CT scans acquired in the same treatment position: cardiac substructure were automatically contoured by the Mirada system, using the implemented cardiac atlas, and simultaneously manually contoured by a radiation oncologist. The Dice similarity coefficient was used to evaluate the concordance level between the manual and the automatic segmentations.\\nDice similarity coefficient value was 0.95 for the whole heart and 0.80 for the four cardiac chambers. Average Dice similarity coefficient value for the left ventricle walls was 0.50, ranging between 0.34 for the apical wall and 0.70 for the lateral wall. Compared to manual contours, autosegmented substructure volumes were significantly smaller, with the exception of the left ventricle. Coronary artery segmentation was unsuccessful. Performances were overall similar to other published cardiac atlas-based autosegmentation algorithms.\\nThe evaluated cardiac atlas-based autosegmentation technique, using the Mirada software, demonstrated acceptable performance for cardiac cavities delineation. However, algorithm improvement is still needed in order to develop efficient and trusted cardiac autosegmentation working tools for daily practice. Breast cancer is the most frequently diagnosed cancer in women globally. Although there have been many significant advances made in the diagnosis and treatment of breast cancer, numerous unresolved challenges remain, which include prevention, early diagnosis, metastasis and recurrence. The role of inflammation in cancer development is well established and is believed to be one of the leading hallmarks of cancer progression. Recently, the role of the inflammasome, a cytosolic multiprotein complex, has received attention in different cancers. By contributing to the activation of inflammatory cytokines the inflammasome intensifies the inflammatory cascade. The inflammasome can be activated through several pathways, which include the binding of pattern associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) to toll-like receptors (TLRs). Serum amyloid A (SAA), a non-specific acute-phase protein, can function as an endogenous DAMP by binding to pattern recognition receptors like TLRs on both breast cancer cells and cancer associated fibroblasts (CAFs). SAA can thus stimulate the production of IL-1β, thereby creating a favourable inflammatory environment to support tumour growth. The aim of this review is to highlight the possible role of SAA as an endogenous DAMP in the tumour microenvironment (TME) thereby promoting breast cancer growth through the activation of the NLRP3 inflammasome. To determine the association between E-cadherin expression and hormone receptors status in patients with breast cancer.\\nCross-sectional study.\\nDepartment of Medical Oncology, Jinnah Postgraduate Medical Centre, Karachi, Pakistan, from March to December 2019.\\nTwo hundred and forty-eight women, aged 18-65 years with histologically proven diagnosis of breast carcinoma, were included in the study. Immunohistochemistry (IHC) staining was performed for the evaluation of E-Cadherin expression and status of hormonal receptors [Estrogen receptor (ER), Progesterone receptor (PR) and HER-2-neu]. The positive homogeneous pattern of staining for the cellular membranes is considered normal. The non-homogeneous or the heterogeneous pattern of the cytoplasm and membrane, represented aberrant E-cadherin expression (loss of E-cadherin expression). SPSS version 23 was used to analyse data.\\nThe results of IHC showed that 82.7% of the tumours were E-cadherin positive, 65.7% were ER positive, 62.9% were PR positive and 29.4% were HER 2 positive. A normal pattern of immunostaining of E-cadherin for the membranes is seen in hormone receptor positive and young patients with low grade tumour. Aberrant E-cadherin expression (loss of E-Cadherin)was noticed in\\xa0HER 2 negative, postmenopausal women with high grade large size tumour(p<0.05).\\nThe study showed that there is significant association between E-cadherin expression and hormone receptor status, HER2-neu, menopausal status, age of patients, grade of tumour and size of tumour. Key Words: E-cadherin, Hormone receptors, Breast carcinoma, ER, PR and HER 2. To develop direct and indirect (response) mapping algorithms from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy General (FACT-G) onto the EQ-5D-5L index.\\nWe conducted the QOL-MAC study where EQ-5D-5L, EORTC QLQ-C30, and FACT-G were cross-sectionally evaluated in patients receiving drug treatment for solid tumors in Japan. We developed direct and indirect mapping algorithms using 7 regression methods. Direct mapping was based on the Japanese value set. We evaluated the predictive performances based on root mean squared error (RMSE), mean absolute error, and correlation between the observed and predicted EQ-5D-5L indexes.\\nBased on data from 903 and 908 patients for EORTC QLQ-C30 and FACT-G, respectively, we recommend two-part beta regression for direct mapping and ordinal logistic regression for indirect mapping for both EORTC QLQ-C30 and FACT-G. Cross-validated RMSE were 0.101 in the two methods for EORTC QLQ-C30, whereas they were 0.121 in two-part beta regression and 0.120 in ordinal logistic regression for FACT-G. The mean EQ-5D-5L index and cumulative distribution function simulated from the recommended mapping algorithms generally matched with the observed ones except for very good health (both source measures) and poor health (only FACT-G).\\nThe developed mapping algorithms can be used to generate the EQ-5D-5L index from EORTC QLQ-C30 or FACT-G in cost-effectiveness analyses, whose predictive performance would be similar to or better than those of previous algorithms. The Collaborative Cross (CC) mouse population is a valuable resource to study the genetic basis of complex traits, such as obesity. Although the development of obesity is influenced by environmental factors, underlying genetic mechanisms play a crucial role in the response to these factors. The interplay between the genetic background and the gene expression pattern can provide further insight into this response, but we lack robust and easily reproducible workflows to integrate genomic and transcriptomic information in the CC mouse population.\\nWe established an automated and reproducible integrative workflow to analyse complex traits in the CC mouse genetic reference panel at the genomic and transcriptomic levels. We implemented the analytical workflow to assess the underlying genetic mechanisms of host susceptibility to diet induced obesity and integrated these results with diet induced changes in the hepatic gene expression of susceptible and resistant mice. Hepatic gene expression differs significantly between obese and non-obese mice, with a significant sex effect, where male and female mice exhibit different responses and coping mechanisms.\\nIntegration of the data showed that different genes but similar pathways are involved in the genetic susceptibility and disturbed in diet induced obesity. Genetic mechanisms underlying susceptibility to high-fat diet induced obesity are different in female and male mice. The clear distinction we observed in the systemic response to the high-fat diet challenge and to obesity between male and female mice points to the need for further research into distinct sex-related mechanisms in metabolic disease. Racial disparities in breast cancer are well-documented, and Black women assume a disproportionate burden of breast cancer mortality. Black women also commonly use hair products containing endocrine disrupting chemicals (EDCs) more often at an increased rate, as compared to other racial/ethnic groups. Emerging findings have reported the use of hair and other personal care products containing EDCs may contribute to breast cancer risk. While some sociocultural perspectives about hair and identity have been explored, the role of beauty expectations upheld by males has not been studied. Through a community-based participatory methodology, we explored perceptions and beliefs held by Black men regarding Black women\\'s hair, chemical exposures in hair products, and breast cancer risk. Focus groups and key informant interviews-among men with and without partners with a history of breast cancer-were used to examine the male perspective regarding the attractiveness of Black hairstyles, opinions of beauty norms, and knowledge of breast cancer risk factors. Interviews were audio-recorded, transcribed, and analyzed guided by grounded theory methods. From the 66 participants interviewed, there was general support for natural hairstyles, which were associated with confidence and self-esteem in women. Men agreed that beauty standards and societal pressures play notable roles in the women\\'s personal behaviors though they mostly lacked knowledge of women\\'s breast cancer risk related to EDCs found in personal care products. Participants suggested a multipronged strategy centered on community education involving social and traditional media campaigns, and the engagement of policy makers in intervention efforts. Metastasis is one of the main causes of failure in the treatment of triple-negative breast cancer (TNBC). Immunotherapy brings hope and opportunity to solve this challenge, while its clinical applications are greatly inhibited by the tumor immunosuppressive environment. Here, an intelligent biomimetic nanoplatform was designed based on dendritic large-pore mesoporous silica nanoparticles (DLMSNs) for suppressing metastatic TNBC by combining photothermal ablation and immune remodeling. Taking advantage of the ordered large-pore structure and easily chemically modified property of DLMSNs, the copper sulfide (CuS) nanoparticles with high photothermal conversion efficiency were  Being one of the major pillars of liquid biopsy, isolation and characterization of circulating tumor cells (CTCs) during cancer management provides critical information on the evolution of cancer and has great potential to increase the success of therapies. In this article, we define a novel strategy to effectively enrich CTCs from whole blood based on size, utilizing a spiral microfluidic channel embedded with a hydrofoil structure at the downstream of the spiral channel. The hydrofoil increases the distance between the streams of CTCs and peripheral blood cells, which are already distributed about two focal axes by the spiral channel, thereby improving the resolution of the separation. Analytical validation of the system has been carried out using Michigan Cancer Foundation-7 (MCF7) breast cancer cell lines spiked into blood samples from healthy donors, and the performance of the system in terms of white blood cell (WBC) depletion, CTC recovery rate and cell viability has been shown in single or two-step process: by passing the sample once or twice through the microfluidic chip. Single step process yielded high recovery (77.1%), viable (84.7%) CTCs. When the collected cell suspension is re-processed by the same chip, recovery decreases to 65.5%, while the WBC depletion increases to 88.3%, improving the purity. Cell viability of >80% was preserved after two-step process. The novel microfluidic chip is a good candidate for CTC isolation applications requiring high recovery rate and viability, including functional downstream analyses for variety of cancer types. Bioassay-guided fractionation of a cytotoxic extract derived from a solid potato dextrose agar (PDA) culture of  MicroRNAs (miRNAs) act as negative regulators of gene expression in the cytoplasm. Previous studies have identified the presence of miRNAs in the nucleus. Here we study human breast cancer-derived cell-lines (MCF-7 and MDA-MB-231) and a non-tumorigenic cell-line (MCF-10A) and compare their miRNA sequences at the spliceosome fraction (SF). We report that the levels of miRNAs found in the spliceosome, their identity, and pre-miRNA segmental composition are cell-line specific. One such miRNA is miR-7704 whose genomic position overlaps HAGLR, a cancer-related lncRNA. We detected an inverse expression of miR-7704 and HAGLR in the tested cell lines. Specifically, inhibition of miR-7704 caused an increase in HAGLR expression. Furthermore, elevated levels of miR-7704 slightly altered the cell-cycle in MDA-MB-231. Altogether, we show that SF-miR-7704 acts as a tumor-suppressor gene with HAGLR being its nuclear target. The relative levels of miRNAs found in the spliceosome fractions (e.g., miR-100, miR-30a, and let-7 family) in non-tumorigenic relative to cancer-derived cell-lines was monitored. We found that the expression trend of the abundant miRNAs in SF was different from that reported in the literature and from the observation of large cohorts of breast cancer patients, suggesting that many SF-miRNAs act on targets that are different from the cytoplasmic ones. Altogether, we report on the potential of SF-miRNAs as an unexplored route for cancerous cell state.  Natural compounds have had increasing applications in the biotechnological sector, with a large fraction of these substances being channeled to the pharmaceutical industry due to their important pharmacological properties. The discovery of new bioactive molecules with novel mechanisms of action constitutes a promising solution for the design of alternative therapeutic solutions. Actinobacteria are a large group of morphologically and physiologically diverse bacteria well known for their production of biotechnologically relevant compounds. The Portuguese coast is scantly explored in terms of Actinobacteria diversity and respective bioactive potential, offering a good opportunity to find new Actinobacteria taxa and bioactive natural products. In this study, we investigated the Actinobacteria diversity associated with a sediment sample collected from the intertidal zone of a beach in northern Portugal, through a cultivation-dependent approach, and screened its antimicrobial and cytotoxic potential. A total of 52 Actinobacteria strains were recovered from the marine sediment, with the largest fraction of the isolates belonging to the genus  The epidermal growth factor receptor (EGFR) pathway functions through the autocrine or paracrine activation of cellular EGFR by a number of transmembrane ligands. Amplified or mutant EGFR can lead to tumour formation due to increased cell proliferation, growth, migration and survival signals. These oncogenic effects were thought to be confined to aberrant cells hosting genetic alterations in EGFR. However, in the past decade, numerous studies identified that tumour cells could harness extracellular vesicles (EVs) to disseminate EGFR, mutant EGFR, phosphorylated EGFR and EGFR ligands to local and distant cells. This functions to impart a pro-tumourigenic phenotype in recipient cells. EVs play an essential role in intracellular communication, through receptor signalling or the release of their intra-vesicular content into recipient cells. This review will discuss the role of EVs delivering EGFR or EGFR ligands either to or from tumour cells and how this can promote metastases, pre-metastatic niche formation, osteoclastogenesis, angiogenesis and immune modulation in cancer. We will examine how circulating EVs positive for EGFR may be exploited as diagnostic, prognostic or therapeutic markers in cancers including breast, lung, glioblastoma, ovarian and prostate. Finally, we will explore recent breakthroughs in bio-engineering EVs with EGFR targeting abilities for targeted drug delivery. Disruption of signaling pathways that plays a role in the normal development and cellular homeostasis may lead to the dysregulation of cellular signaling and bring about the onset of different diseases, including cancer. In addition to genetic aberrations, DNA methylation also acts as an epigenetic modifier to drive the onset and progression of cancer by mediating the reversible transcription of related genes. Although the role of DNA methylation as an alternative driver of carcinogenesis has been well-established, the global effects of DNA methylation on oncogenic signaling pathways and the presentation of cancer is only emerging. In this article, we introduced a differential methylation parsing pipeline (MethylMine) which mined for epigenetic biomarkers based on feature selection. This pipeline was used to mine for biomarkers, which presented a substantial difference in methylation between the tumor and the matching normal tissue samples. Combined with the Data Integration Analysis for Biomarker discovery (DIABLO) framework for machine learning and multi-omic analysis, we revisited the TCGA DNA methylation and RNA-Seq datasets for breast, colorectal, lung, and prostate cancer, and identified differentially methylated genes within the NRF2-KEAP1/PI3K oncogenic pathway, which regulates the expression of cytoprotective genes, that serve as potential therapeutic targets to treat different cancers. Mucinous (colloid) adenocarcinomas (MAs) are a rare histological subtype of adenocarcinomas where extracellular mucin comprises more than 50% of the tumor. Most literature on MAs relate to cancers from colorectal and breast sites; however, the literature lacks a standardized overview of the MA disease entity. Particularly in colorectal cancer, some MAs may have signet ring cells floating within the mucin, which may represent a highly metastatic phenotype. MAs and signet ring cell adenocarcinomas represent a spectrum of mucin-producing neoplastic conditions where in the latter most mucin is intracellular rather than extracellular. We recently published a standardized overview of signet ring cells, and in this companion work, using a retrospective cohort approach, we summarize the clinicodemographic and mortality outcomes of MAs in sixteen primary sites, comprising 95.6% of all MAs in the Surveillance, Epidemiology, and End Results Program (SEER), a population-level cancer database covering nearly one-third of the United States population. Compared to matching nonvariant adenocarcinomas, MAs have a slightly earlier age of onset with increased rates of regional and distant disease at presentation. Survival outcomes are highly dependent on tumor location, illustrating our poor understanding of MA tumor biology. The clinical significance of MA histology depends largely on tumor site. Breast cancer evolves thanks to a dense and close interaction with the surrounding tumor microenvironment (TME). Fibroblasts, leukocytes, blood and lymphatic endothelial cells and extracellular matrix are the constituents of this entity, and they synergistically play a pivotal role in all of the stages of breast cancer development, from its onset to its metastatic spread. Moreover, it has been widely demonstrated that variations to the TME can correspond to prognosis variations. Breast cancer not only modulates the transformation of the environment within the mammary gland, but the same process is observed in metastases as well. In this minireview, we describe the features of TME within the primitive breast cancer, throughout its evolution and spread into the main metastatic sites. The increasing interest in developing potent non-toxic drugs in medicine is widening the opportunities for studying the usage of nanostructures in the treatment of various diseases. The present work reports a method for a facile and an eco-friendly synthesis of silver nanoparticles (AgNPs) using  Cutaneous squamous-cell carcinoma (cSCC) is one of most common type of non-black skin cancer. The malignancy degree and the death risk of cSCC patients are significantly higher than basal cell carcinoma patients. GL-V9 is a synthesized flavonoid derived from natural active ingredient wogonin and shows potent growth inhibitory effects in liver and breast cancer cells. In this study, we investigated the anti-cSCC effect and the underlying mechanism of GL-V9. The results showed that GL-V9 induced both apoptosis and autophagy in human cSCC cell line A431 cells, and prevented the growth progression of chemical induced primary skin cancer in mice. Metabolomics assay showed that GL-V9 potentially affected mitochondrial function, inhibiting glucose metabolism and Warburg effect. Further mechanism studies demonstrated that AKT played important roles in the anti-cSCC effect of GL-V9. On one hand, GL-V9 suppressed AKT-modulated mitochondrial localization of HK2 and promoted the protein degradation of HK2, resulting in cell apoptosis and glycolytic inhibition. On the other hand, GL-V9 induced autophagy via inhibiting Akt/mTOR pathway. Interestingly, though the autophagy induced by GL-V9 potentially antagonized its effect of apoptosis induction, the anti-cSCC effect of GL-V9 was not diluted. All above, our studies suggest that GL-V9 is a potent candidate for cSCC treatment. The incidence of brain metastases (BM) in breast cancer patients is increasing [...]. Breast cancer is the most common cancer in women. Early diagnosis improves outcome and survival, which is the cornerstone of breast cancer treatment. Thermography has been utilized as a complementary diagnostic technique in breast cancer detection. Artificial intelligence (AI) has the capacity to capture and analyze the entire concealed information in thermography. In this study, we propose a method to potentially detect the immunohistochemical response to breast cancer by finding thermal heterogeneous patterns in the targeted area. In this study for breast cancer screening 208 subjects participated and normal and abnormal (diagnosed by mammography or clinical diagnosis) conditions were analyzed. High-dimensional deep thermomic features were extracted from the ResNet-50 pre-trained model from low-rank thermal matrix approximation using sparse principal component analysis. Then, a sparse deep autoencoder designed and trained for such data decreases the dimensionality to 16 latent space thermomic features. A random forest model was used to classify the participants. The proposed method preserves thermal heterogeneity, which leads to successful classification between normal and abnormal subjects with an accuracy of 78.16% (73.3-81.07%). By non-invasively capturing a thermal map of the entire tumor, the proposed method can assist in screening and diagnosing this malignancy. These thermal signatures may preoperatively stratify the patients for personalized treatment planning and potentially monitor the patients during treatment. Carbon nanodots (CDs) have recently attracted attention in the field of nanomedicine because of the biocompatibility, cost-effective nature, high specific surface, good near infrared (NIR) photothermal conversion into heat and tunable fluorescence properties, which have paved the way toward incorporating use of CDs into innovative anticancer theranostic platforms. However, a reliable synthesis of CDs with established and controlled physiochemical proprieties is precluded owing to the lack of full manipulation of thermodynamic parameters during the synthesis, thus limiting their use in real world medical applications. Herein, we developed a robust solvothermal protocol which allow fine controlling of temperature and pressure in order to obtain CDs with tunable properties. We obtained different CDs by modulating the operating pressure (from 8 to 18.5 bar) during the solvothermal decomposition of urea and citric acid in N,N-dimethylformamide at fixed composition. Atomic force microscopy (AFM), Fourier transform infrared (FTIR), ultraviolet-visible (UV-vis) and fluorescence spectroscopy were used to assess the role of pressure in influencing size, optical and surface properties of the obtained CDs. While preliminary biological and anticancer performance of CDs was established on the MDA-MB-231 cell line, used as triple negative breast cancer model. Our results indicate that pressure impinge on the formation of carbon nanoparticles under solvothermal conditions and impart desired optical, size distribution, surface functionalization and anticancer properties in a facile way. However, we have highlighted that a strategic surface engineering of these CDs is needed to limit the adsorption of corona proteins and also to increase the average surface diameter, avoiding a rapid renal clearance and improving their therapeutic efficacy in vivo. Formalin-fixed paraffin embedded (FFPE) clinical tissues represent an abundant and unique resource for translational proteomic studies. In the US, melanoma is the 5th and 6th most common cancer in men and women, respectively, affecting over 230,000 people annually and metastasising in 5-15% of cases. Median survival time for distant metastatic melanoma is 6-9 months with a 5-year-survival of < 15%. In this study, 24 primary FFPE tumours which have metastasised (P-M) and 24 primary FFPE tumours which did not metastasise (P-NM) were subjected to proteomic profiling. In total, 2750 proteins were identified, of which 16 were significantly differentially expressed. Analysis of TCGA data demonstrated that expression of the genes encoding for 6 of these 16 proteins had a significant effect on survival in cutaneous melanoma. Pathway analysis of the proteomics data revealed mechanisms likely involved in the process of melanoma metastasis, including cytoskeleton rearrangement, extracellular changes and immune system alterations. A machine learning prediction model scoring an AUC of 0.922, based on these 16 differentially expressed proteins was able to accurately classify samples into P-M and P-NM. This study has identified potential biomarkers and key processes relating to melanoma metastasis using archived clinical samples, providing a basis for future studies in larger cohorts. Patients with cancer often carry the dual burden of the cancer itself and other co-existing medical conditions. The problems associated with comorbidities among elderly cancer patients are more prominent compared with younger patients. This study aimed to identify common cancer-related comorbidities in elderly patients through routinely collected hospital discharge data and to use association rules to analyze the prevalence and patterns of these comorbidities in elderly cancer patients at different cancer sites. We collected the discharge data of 80,574 patients who were diagnosed with cancers of the esophagus, stomach, colorectum, liver, lung, female breast, cervix, and thyroid between 2016 and 2018. The same number of non-cancer patients were randomly selected as the control group and matched with the case group by age and gender. The results showed that cardiovascular diseases, metabolic diseases, digestive diseases, and anemia were the most common comorbidities in elderly patients with cancer. The comorbidity patterns differed based on the cancer site. Elderly patients with liver cancer had the highest risk of comorbidities, followed by lung cancer, gastrointestinal cancer, thyroid cancer, and reproductive cancer. For example, elderly patients with liver cancer had the higher risk of the comorbid infectious and digestive diseases, whereas patients with lung cancer had the higher risk of the comorbid respiratory system diseases. The findings can assist clinicians in diagnosing comorbidities and contribute to the allocation of medical resources. In this work, the cytotoxic behavior of six ruthenium(II) complexes of stoichiometry [(η according to the latest ESMO-ESGO recommendations, laparotomy is the standard surgical approach to treat and stage patients with presumed early stage epithelial ovarian cancer (EOC). A few studies have investigated the efficacy and the safety of laparoscopy for the staging of early stage EOC, and this question is still in the center of debates. Recurrence-free survival (RFS) and overall survival (OS) benefits of the minimally invasive surgery (MIS) have still to be specified. The aim of this multicenter and retrospective study is to assess the survival outcomes of laparoscopic staging in comparison with laparotomic staging for patients presenting with an early stage EOC.\\ndata of patients with early stage EOC (FIGO I-IIA) who underwent primary surgery between 2000 and 2018 were extracted from the FRANCOGYN database. OS and RFS of these two groups, constituted according to the surgical route, were compared using Log rank test.\\nof the 144 patients included, 107 patients underwent laparotomy and 37 underwent laparoscopy for a staging purpose. The median follow-up was 36.0 months (18.0 to 58.0). For the laparoscopy and the laparotomy group, the median follow-up period was 24 (11.0 to 50.0) and 42.0 (24.0 to 66.0) months, respectively, (\\nthere is no difference associated with the laparoscopic approach for the staging of early stage EOC on RFS and OS in comparison with laparotomy. MIS may be proposed as a safe and adequate alternative to laparotomy when performed by well-trained surgeons. A novel folic acid mediated chitosan oligosaccharide-grafted disulfide-containing polyethylenimine copolymer-based silica nanohybrids were fabricated for co-delivering paclitaxel and P-shRNA. These nanoparticles could efficiently protect P-shRNA against degradation, and exhibited well redox-responsive P-shRNA release and pH-responsive drug release behaviors. Folic acid as the targeting head, could improve cellular uptake of nanoparticles by multidrug-resistant breast cancer cells. Moreover, these nanoparticles showed excellent delivery P-shRNA into cells and displayed high gene silencing efficiency at the targeted mRNAs to downregulate the expression of P-gp which induced up to 63% decrease. Finally, nanoparticles could completely reverse the resistance of breast cancer cells to paclitaxel and the resistance reversion index was 50.59. These results suggested that our nanoparticles could efficiently co-deliver paclitaxel and P-shRNA into cancer cells to exert its synergistic antitumor effect, and opened up a new avenue for overcoming multidrug resistance. In this article, we describe the synthesis of 3-phenylquinoxaline-2-carbonitrile 1,4-dioxides bearing cyclic diamine residues at positions 6 or 7; the synthesis is based on the nucleophilic substitution of halogens. All synthesized 6(7)-aminoquinoxaline-2-carbonitrile 1,4-dioxides 3-6 demonstrated higher cytotoxicity and hypoxia selectivity compared to the reference agent tirapazamine against breast adenocarcinoma cell lines (MCF7, MDA-MB-231). The structure and position of the diamine residue considerably affects the antiproliferative properties of the quinoxaline-2-carbonitrile 1,4-dioxides. The introduction of a halogen atom at position 7 in the quinoxaline ring of 4a considerably increases the cytotoxicity of compounds 5a and 6a under both normoxic and hypoxic conditions. However, the most hypoxia-selective derivatives were non-halogenated 7-aminosubstituted 3-phenylquinoxaline-2-carbonitrile 1,4-dioxides 3a-j. Of the 32 novel synthesized derivatives, approximately 20 of the 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides demonstrated high antiproliferative potency against wild type leukemia cells K562 and drug-resistant subline K562/4 with the expression of p-glycoprotein (p-gp) compared to the reference agent doxorubicin, which exhibited one order of magnitude lower activity towards K562/4 cells than towards K562 cells. Lead compounds 5a and 3f inhibited HIF-1α expression and activity and induced apoptosis in hypoxic tumor cells, which was confirmed by poly(ADP-ribose)polymerase (PARP) cleavage. Moreover, 5a and 3f showed strong antiestrogenic potencies in MCF7 breast cancer cells. Thus, the described series of quinoxaline 1,4-dioxides has high anticancer potential and good aqueous solubility. Therefore, these compounds are promising for further drug development of hypoxia-targeted anticancer agents. Novel series of diazepam bearing sulfonamide moieties 5 A series of artemisinin-sulfonamide hybrids (1-16) have been designed and synthesized by using molecular hybridization approach and investigated for the inhibitory activity of four human (h) carbonic anhydrases (CAs, EC 4.2.1.1), hCA I, II, IX and XII. The results indicated most of the target compounds showed better CA IX and CA XII inhibitory activity than the starting segment sulfanilamide. Among all the compounds, compound 3 (IC Louisiana is one of the few Southern states that enacted the Medicaid expansion of the Patient Protection and Affordable Care Act (ACA). To the authors\\' knowledge, the issue of how this has affected the breast cancer landscape in Louisiana is unknown. The authors have postulated that ACA expansion had a positive impact for Louisiana women diagnosed with breast cancer.\\nData from the Louisiana Tumor Registry regarding 14,640 women aged 20 to 64 years who resided in Louisiana and were diagnosed with American Joint Committee on Cancer stage 0 to stage IV breast cancer between 2012 and 2018 were analyzed. The study period was divided into 2 groups: 1) before ACA expansion (January 1, 2012-May 31, 2016); and 2) after ACA expansion (June 1, 2016-December 31, 2018). The chi-square test and multivariable logistic regression models were used to assess the impact of ACA expansion. A P value <.05 was considered statistically significant.\\nAfter ACA expansion, the rate of uninsured patients decreased from 5.4% to 3.0% (P < .0001), and the rate of Medicaid recipients increased from 11.6% to 17.7% (P < .0001). The diagnosis of stage I breast cancer increased from 36.8% to 44.7% (P < .0001), whereas the diagnosis of stage III breast cancer decreased from 10.7% to 8.5% (P < .0001). The receipt of radiotherapy after breast-conserving surgery increased from 81.2% to 84.0% (P = .0035), and the receipt of radiotherapy within 90 days increased from 57.2% to 61.7% (P = .0012). After adjustment for sociodemographic and clinical variables, the models demonstrated that ACA expansion decreased the uninsured rate by 48% (odds ratio [OR], 0.52; 95% CI, 0.43-0.63), increased the diagnosis of early-stage disease (stage0 to stage II) by 27% (OR, 1.27; 95% CI, 1.15-1.41), increased receipt of radiotherapy after breast-conserving surgery by 19% (OR, 1.19; 95% CI, 1.03-1.37), and reduced the delay of receipt of radiotherapy by 16% (OR, 0.84; 95% CI, 0.74-0.95).\\nACA expansion in Louisiana reduced the uninsured rate, increased the diagnosis of early-stage disease, and increased access to treatment. Curcumin (C) is a natural antioxidant which has many beneficial effects. However, poor bioavailability and less water solubility render it unsuitable as an anti-cancer drug. Herein, curcumin was delivered through Mesoporous silica nanoparticle (MSN) based drug delivery system to enhance its anticancer efficacy. Targeted delivery of curcumin in cancer cells was also achieved by conjugating hyaluronic acid (HA) on the surface of MSN. HA showed its targeting ability through the binding with CD-44 receptors in cancer cells. The synthesis of MSN-HA-C was verified by used several characterization techniques like TEM, SEM, XRD and DLS. MSN-HA-C showed diameter of ∼ 75 nm with negatively charged surface and drug loading content of 14.76 %. The synthesized nanohybrid showed MDA-MB-231 cell death by the induction of ROS, cell cycle arrest and modulation of NF-κB and Bax mediated apoptotic pathway. The nanohybrid also effectually decreased tumor volume in tumor-bearing mice compared with free C due to the increased bioavailability and higher cellular uptake of C in tumor tissue. Overall, the study offered that MSN-HA-C has increased anticancer efficacy than that of free curcumin. Development of imaging methods capable of furnishing tumor-specific morphological, functional, and molecular information is paramount for early diagnosis, staging, and treatment of breast cancer. Ultrasound (US) and optoacoustic (OA) imaging methods exhibit excellent traits for tumor imaging in terms of fast imaging speed, ease of use, excellent contrast, and lack of ionizing radiation. Here, we demonstrate simultaneous tomographic whole body imaging of optical absorption, US reflectivity, and speed of sound (SoS) in living mice. In vivo studies of 4T1 breast cancer xenografts models revealed synergistic and complementary value of the hybrid imaging approach for characterizing mammary tumors. While neovasculature surrounding the tumor areas were observed based on the vascular anatomy contrast provided by the OA data, the tumor boundaries could be discerned by segmenting hypoechoic structures in pulse-echo US images. Tumor delineation was further facilitated by enhancing the contrast and spatial resolution of the SoS maps with a full-wave inversion method. The malignant lesions could thus be distinguished from other hypoechoic regions based on the average SoS values. The reported findings corroborate the strong potential of the hybrid imaging approach for advancing cancer research in small animal models and fostering development of new clinical diagnostic approaches. The cellular heterogeneity of breast cancers still represents a major therapeutic challenge. The latest genomic studies have classified breast cancers in distinct clusters to inform the therapeutic approaches and predict clinical outcomes. The mammary epithelium is composed of luminal and basal cells, and this seemingly hierarchical organization is dependent on various stem cells and progenitors populating the mammary gland. Some cancer cells are conceptually similar to the stem cells as they can self-renew and generate bulk populations of nontumorigenic cells. Two models have been proposed to explain the cell of origin of breast cancer and involve either the reprogramming of differentiated mammary cells or the dysregulation of mammary stem cells or progenitors. Both hypotheses are not exclusive and imply the accumulation of independent mutational events. Cancer stem cells have been isolated from breast tumors and implicated in the development, metastasis, and recurrence of breast cancers. Recent advances in single-cell sequencing help deciphering the clonal evolution within each breast tumor. Still, few clinical trials have been focused on these specific cancer cell populations. Glyoxalase-1 (GLO-1) is the key enzyme in aldehyde defence in cancer cells. We here evaluated the prognostic impact and association with clinico-pathological parameters and relapse-free as well as overall survival in tumor samples from 187 breast cancer patients. The determined GLO1-immunoreactive score (GLO1-IRS) did not correlate with parameters such as grading, size, hormone receptors or ki67. However, an association of GLO1-IRS with the advanced glycation end product N Cascade genetic testing is essential to clarify cancer risk in families with hereditary breast and ovarian cancer syndrome (HBOC) due to pathogenic variants (PVs) in BRCA1 or BRCA2. To date, data suggest that family communication of genetic testing results, with or without the aid of clinical resources such as a provider-written family letter, is impacted by multiple barriers. These barriers eventually lead to sub-optimal uptake of cascade genetic testing. We designed a 2-min animated video that a proband can share with relatives to notify them that the proband has tested positive for a pathogenic variant in BRCA1 or BRCA2. We studied the video via hypothetical scenario in an unselected population to simulate the process by which a relative receives unsolicited genetics information about their family member. We assessed the impact of the video on three specific domains: knowledge, cognitive message processing, and affective reactions. A total of 399 participants recruited through Amazon Mechanical Turk completed the study, and 373 were analyzed. The video significantly improved content knowledge/recall (p\\xa0<\\xa0.0001) from pre- to post-video viewing, indicating effective message communication. Items used to measure cognitive processing showed preliminary tendencies toward systematic message processing, which could be desired in familial communication aimed at initiating a specific action-in this case, cascade genetic testing. A majority of participants (66%) reported positive affective reaction as they indicated that they would feel gratitude if they received the video message from a relative, and did not evidence a negative affective reaction to receiving the information. Our data suggest that a video message can effectively communicate information about cascade genetic testing to potential relatives with as little as two minutes of content. Our data suggest that video messaging to assist family communication is a reasonable approach that increases understanding and is unlikely to cause harm. The senescence of tumor cells is an important tumor suppressor mechanism. The present study aimed to investigate the role of long noncoding RNA (lncRNA) MEG3 in the senescence process of tumor cells and its potential molecular mechanism by competitively binding with microRNA miR-16-5p to regulate the expression of VGLL4 (encoding vestigial like family member 4).\\nWe used etoposide to construct senescence models of tumor cells. The degree of cellular senescence was detected by senescence associated β-galactosidase, cell cycle and senescence-associated secretory phenotype. The expression of lncRNA MEG3, miR-16-5p, and VGLL4 in senescent or non-senescent cells was evaluated using quantitative real-time reverse transcription PCR (qRT-PCR) or western blotting. Dual luciferase reporter assays were used to detect the binding of miR-16-5p to lncRNA MEG3 and VGLL4. The mRNA and protein expression levels of senescence-related markers (p53, p21, and p16) were detected using qRT-PCR or western blotting.\\nCompared with that in control group, the expression of lncRNA MEG3 and VGLL4 were significantly upregulated in senescent cells. Knockdown of lncRNA MEG3 and VGLL4 reduced the degree of senescence and the expression of p21 and p16. LncRNA MEG3 interfered with expression of miR-16-5p in senescent A549 and MCF-7 cells. The expression of VGLL4 was regulated by miR-16-5p in senescent A549 and MCF-7 cells. LncRNA MEG3 participated in the senescent progress of tumor cells induced by etoposide via the miR-16-5p/VGLL4 axis.\\nOur study confirmed the regulatory role of the lncRNA MEG3/miR-16-5p/VGLL4 axis in the low-dose etoposide-induced tumor cell senescence model, which has potential clinical application value to treat malignant tumors. The combination of enobosarm and pembrolizumab was well tolerated and showed a modest clinical benefit rate of 25% at 16\\u2009weeks. Future trials investigating androgen receptor-targeted therapy in combination with immune checkpoint inhibitors are warranted.\\nLuminal androgen receptor (LAR) is a distinct molecular subtype of triple-negative breast cancer (TNBC) defined by overexpression of androgen receptor (AR). AR targeted therapy has shown modest activity in AR-positive (AR\\nThis study was an open-label phase II study for AR\\nThe trial was stopped early due to the withdrawal of GTx-024 drug supply. Eighteen patients were enrolled and 16 were evaluable for responses. Median age was 64 (range 36-81) years. The combination was well tolerated with only a few grade 3 adverse events: one dry skin, one diarrhea, and one musculoskeletal ache. The responses were: 1/16 (6%) complete response (CR), 1/16 (6%) partial response (PR), 2/16 (13%) stable disease (SD), and 12/16 (75%) progressive disease (PD). Response rate (RR) was 2/16 (13%). Clinical benefit rate (CBR) at 16\\u2009weeks was 4/16 (25%). Median follow-up was 24.9 months (95% CI [17.5, 30.9]). Progression-free survival (PFS) was 2.6 months (95% CI [1.9, 3.1]) and overall survival (OS) was 25.5 months (95% CI [10.4, NR]).\\nThe combination of enobosarm and pembrolizumab was well tolerated with a modest clinical benefit rate of 25% at 16\\u2009weeks in heavily pretreated AR None Numerous publications have reported the incidental detection of occult malignancies upon routine noninvasive prenatal testing (NIPT). However, these studies were not designed to evaluate the NIPT performance for cancer detection.\\nWe investigated the sensitivity of a genome-wide NIPT pipeline, called GIPSeq, for detecting cancer-specific copy number alterations (CNAs) in plasma tumor DNA (ctDNA) of patients with breast cancer. To assess whether a pregnancy itself, with fetal cell-free DNA (cfDNA) in the maternal circulation, might influence the detection of ctDNA, results were compared in pregnant (n\\u2009=\\u200925) and nonpregnant (n\\u2009=\\u200925) cancer patients. Furthermore, the ability of GIPSeq to monitor treatment response was assessed.\\nOverall GIPSeq sensitivity for detecting cancer-specific CNAs in plasma cfDNA was 26%. Fifteen percent of detected cases were asymptomatic at the time of blood sampling. GIPSeq sensitivity mainly depended on the tumor stage. Also, triple negative breast cancers (TNBC) were more frequently identified compared to hormone-positive or HER2-enriched tumors. This might be due to the presence of high-level gains and losses of cfDNA or high ctDNA loads in plasma of TNBC. Although higher GIPSeq sensitivity was noted in pregnant (36%) than in nonpregnant women (16%), the limited sample size prohibits a definite conclusion. Finally, GIPSeq profiling of cfDNA during therapy allowed monitoring of early treatment response.\\nThe results underscore the potential of NIPT-based tests, analyzing CNAs in plasma cfDNA in a genome-wide and unbiased fashion for breast cancer detection, cancer subtyping and treatment monitoring in a pregnant and nonpregnant target population. BACKGROUND Breast cancer has a long-term prognosis with various multimodality treatments. This report introduces the effectiveness of radiofrequency (RF) hyperthermia in the long-term treatment for recurrent/metastatic breast cancer. CASE REPORT In the first case, the patient had bone and liver metastases during the course of chemotherapy, hormone therapy, and radiotherapy for 27 years after curative resection of breast cancer. Finally, she received RF hyperthermia alone for liver metastasis and showed a decrease in tumor markers and reduction in liver metastasis on computed tomography (CT). In the second case, the patient underwent curative resection for multiple occurrences on the left side of the breast. She received postoperative chemotherapy combined with hormone therapy but had metachronous local recurrences. She continued hormone therapy after 2 local recurrence resections; unfortunately, she had bone, liver, and lung metastases and pleural dissemination. Eventually, the patient received RF hyperthermia combined with oral chemotherapy. Her tumor markers decreased, and CT showed disappearance of lung metastasis and improved pleural dissemination. Furthermore, the reduction of chemotherapy adverse events due to hyperthermia allowed the patient to continue chemotherapy and improved her quality of life. CONCLUSIONS We present 2 cases in which RF hyperthermia had a positive effect despite the presence of a recurrent tumor after various types of surgery, chemotherapy, and radiotherapy. This report suggests that the addition of RF hyperthermia to conventional multidisciplinary therapies may enhance the therapeutic effect of these treatments and improve the quality of life in patients with recurrent breast cancer. There remains disagreement on the long-term effect of mammographic screening in women aged 40-49 years.\\nThe long-term follow-up of a randomised controlled trial that offered annual mammography to women aged 40-49 years. The estimation of the effect of these mammograms on breast cancer and other-cause mortality, and the effect on incidence, with implications for overdiagnosis.\\nAn individually randomised controlled trial comparing offering annual mammography with offering usual care in those aged 40-48 years, and thus evaluating the effect of annual screening entirely taking place before the age of 50 years. There was follow-up for an average of 23 years for breast cancer incidence, breast cancer death and death from other causes. We analysed the mortality and incidence data by Poisson regression and estimated overdiagnosis formally using Markov process models.\\nTwenty-three screening units in England, Wales and Scotland within the NHS Breast Screening Programme.\\nWomen aged 39-41 years were recruited between 1990 and 1997. After exclusions, a total of 53,883 women were randomised to undergo screening (the intervention group) and 106,953 women were randomised to have usual care (the control group).\\nThe intervention group was invited to an annual breast screen with film mammography, two view at first screen and single view thereafter, up to and including the calendar year of their 48th birthday. The control group received no intervention. Both groups were invited to the National Programme from the age of 50 years, when screening is offered to all women in the UK.\\nThe main outcome measures were mortality from breast cancers diagnosed during the intervention phase of the trial (i.e. before the first National Programme screen at 50 years), mortality from all breast cancers diagnosed after randomisation, all-cause mortality, mortality from causes other than breast cancer, and the incidence of breast cancer.\\nThere was a statistically significant 25% reduction in mortality from breast cancers diagnosed during the intervention phase at 10 years\\' follow-up (relative rate 0.75, 95% confidence interval 0.58 to 0.97; \\nThere was 31% average non-compliance with screening and three centres had to cease screening for resource and capacity reasons.\\nAnnual mammographic screening at the age of 40-49 years resulted in a relative reduction in mortality, which was attenuated after 10 years. It is likely that digital mammography with two views at all screens, as practised now, could improve this further. There was no evidence of overdiagnosis in addition to that which already results from the National Programme carried out at later ages.\\nThere is a need for research on the effects of modern mammographic protocols and additional imaging in this age group.\\nCurrent Controlled Trials ISRCTN24647151.\\nThis project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in \\nIt is known that breast cancer screening with mammography (i.e. X-ray of the breasts) in women aged ≥\\u200950 years leads to a reduction in the number of deaths from breast cancer. In the UK, the NHS Breast Screening Programme offers regular screening to women aged 50–70 years. There is still some disagreement about the effect of such screening on the risk of death from breast cancer for those aged 40–49 years. There is also concern about overdiagnosis, that is, the finding of breast cancer that would not have been diagnosed in a woman’s lifetime if she had not been screened. This study recruited 160,921 women aged 39–41 years and randomly assigned one in three of the women to be offered annual mammographic screening from age 40 to 48 years. The women were followed up for occurrence of breast cancer, death from breast cancer and death from all other causes. We found that the women who were offered the screening were 25% less likely to die of breast cancer in the first 10 years in the trial. This mortality reduction was reduced with later follow-up, with a 12% reduction after an average of 23 years. There was no effect of offering screening on death from other causes. During the early years of the trial, the women offered screening had larger numbers of breast cancers diagnosed, but this excess disappeared after the first National Programme screen. This suggests that there is no overdiagnosis from screening those aged 40–49 years over and above that which already results from screening those aged ≥ 50 years. Despite the rise in rates of contralateral prophylactic mastectomy, few studies have used patient-reported outcomes to assess satisfaction between unilateral and bilateral breast reconstruction with autologous tissue. The purpose of this study was to investigate patient satisfaction and quality of life following autologous reconstruction to determine whether differences exist between unilateral and bilateral reconstructions to better guide clinical decision-making.\\nThe current study examined prospectively collected BREAST-Q results following abdominal free flap breast reconstruction procedures performed at a tertiary academic medical center from 2009 to 2017. The reconstruction module of the BREAST-Q was used to assess outcomes between laterality groups (unilateral versus bilateral) at 1 year, 2 years, 3 years, and more than 3 years.\\nOverall, 405 patients who underwent autologous breast reconstruction completed the BREAST-Q. Cross-sectional analysis at 1 year, 2 years, and 3 years revealed similar satisfaction scores between groups; however, bilateral reconstruction patients demonstrated higher satisfaction scores at more than 3 years (p = 0.04). Bilateral reconstruction patients reported lower scores of abdominal well-being at 1 year, 2 years, and more than 3 years (p = 0.01, p = 0.03, and p = 0.01, respectively).\\nThese results suggest that satisfaction with breasts does not differ with the laterality of the autologous reconstruction up to 3 years postoperatively but may diverge thereafter. Bilateral reconstruction patients, however, have lower satisfaction with the abdominal donor site. These data can be used in preoperative counseling, informed consent, and expectations management in patients considering contralateral prophylactic mastectomy. The number of elderly patients in Japan with breast cancer has been gradually increasing. The aim of this study was to determine the efficacy of radiotherapy (RT) after breast-conserving surgery (BCS) for elderly patients with early breast cancer who were restaged according to the 8th Edition Breast Cancer Staging System.\\nWe reviewed patients age\\u2009≥\\u200965\\xa0years who received BCS and adjuvant RT or BCS alone for breast cancer between 2010 and 2015 in our institution and restaged those patients using the AJCC 8th edition pathological prognostic staging system. We compared relapse-free survival (RFS) and overall survival (OS) rates in the RT group and no RT group.\\nA total of 170 patients were eligible for analysis: 94 (55.3%) were treated with RT and 76 (44.7%) were treated without RT. Age (p\\u2009<\\u20090.01) was associated with the use of RT. Adjuvant RT significantly improved RFS (95.75% vs 84.21%, p\\u2009=\\u20090.02). There was no significant difference between the OS rates in the two groups. Univariate analysis showed that pathologic T stage and N stage were significantly associated with both RFS and OS and that histologic grade, chemotherapy, HER2, and RT were significantly associated with RFS, but not with OS. RT reduced the risk of recurrence (HR\\xa0=\\xa00.56, 95% CI\\xa0=\\xa00.19-0.96, p\\u2009=\\u20090.04).\\nRT was associated with significantly improved RFS, but had no significant impact on OS in elderly patients with breast cancer after BCS. Adjuvant RT should be performed even for elderly patients with early breast cancer. Despite the efficacy of tamoxifen in preventing disease relapse, a large portion of breast cancer patients show intrinsic or acquired resistance to tamoxifen, leading to treatment failure and unfavorable clinical outcome. MYB proto-oncogene like 2 (MYBL2) is a transcription factor implicated in the initiation and progression of various human cancers. However, its role in tamoxifen resistance in breast cancer remained largely unknown. In the present study, by analyzing public transcriptome dataset, we found that MYBL2 is overexpressed in breast cancer and is associated with the poor prognosis of breast cancer patients. By establishing tamoxifen-resistant breast cancer cell lines, we also provided evidence that MYBL2 overexpression contributes to tamoxifen resistance by up-regulating its downstream transcriptional effectors involved in cell proliferation (PLK1, PRC1), survival (BIRC5) and metastasis (HMMR). In contrast, inhibiting those genes via MYBL2 depletion suppresses cancer progression, restores tamoxifen and eventually reduces the risk of disease recurrence. All these findings revealed a critical role of MYBL2 in promoting tamoxifen resistance and exacerbating the progression of breast cancer, which may serve as a novel therapeutic target to overcome drug resistance and improve the prognosis of breast cancer patients. While stages of reproductive aging for women in the general population are well described by STRAW+10 criteria, this is largely unknown for female adolescent and young adult cancer survivors (AYA survivors).\\nTo evaluate applying STRAW+10 criteria in AYA survivors using bleeding patterns with and without endocrine biomarkers, and assess how cancer treatment gonadotoxicity is related to reproductive aging stage.\\nThe sample (n=338) included AYA survivors from the Window Study cohort. Menstrual bleeding data and dried blood spots for AMH and FSH measurements (Ansh DBS ELISAs) were utilized for reproductive aging stage assessment. Cancer treatment data were abstracted from medical records.\\nAmong participants, mean age 34.0±4.5 and at a mean of 6.9±4.6 years since cancer treatment, the most common cancers were lymphomas(31%), breast(23%), and thyroid(17%). Twenty-nine percent was unclassifiable by STRAW+10 criteria, occuring more frequently in the first 2 years from treatment . Most unclassifiable survivors exhibited bleeding patterns consistent with the menopausal transition, but had reproductive phase AMH and/or FSH levels. For classifiable survivors (48% peak reproductive, 30% late reproductive, 12% early transition, 3% late transition, 7% post-menopause), endocrine biomarkers distinguished among peak, early and late stages within the reproductive and transition phases. Gonadotoxic treatments were associated with more advanced stages.\\nWe demonstrate a novel association between gonadotoxic treatments and advanced stages of reproductive aging. Without endocrine biomarkers, bleeding pattern alone can misclassify AYA survivors into either more or less advanced stages. Moreover, a large proportion of AYA survivors exhibited combinations of endocrine biomarkers and bleeding patterns that do not fit STRAW+10 criteria, suggesting the need for modified staging for this population. Bisphosphonates (BPs) are characterized by their ability to bind strongly to bone mineral and inhibit bone resorption. However, BPs exert a wide range of pharmacological activities beyond the inhibition of bone resorption, including the inhibition of cancer cell metastases and angiogenesis and the inhibition of proliferation and apoptosis in vitro. Additionally, the inhibition of matrix metalloproteinase activity, altered cytokine and growth factor expression, as well as reductions in parameters of pain have also been reported. In humans, clinical BP use has transformed the treatment of post-menopausal osteoporosis, rare bone diseases such as osteogenesis imperfecta, as well as multiple myeloma and metastatic breast and prostate cancer, albeit not without infrequent but significant adverse events. Despite the well-characterized health benefits of BP use in humans, the evidence-base for the therapeutic efficacy of BPs in veterinary medicine is, by comparison, limited. Notwithstanding, BPs are used widely in small animal veterinary practice for the medical management of hyperparathyroidism, idiopathic hypercalcemia in cats, as well as for the palliative care of bone tumors which are common in dogs, and in particular, primary bone tumors such as osteosarcoma. Palliative BP treatment has also recently increased in veterinary oncology to alleviate tumor-associated bone pain. In equine veterinary practice, non-nitrogen-containing BPs are FDA-approved to control clinical signs associated with navicular syndrome in adult horses. However, there are growing concerns regarding the off-label use of BPs in juvenile horses. Here we discuss the current understanding of the strengths, weaknesses and current controversies surrounding BP use in veterinary medicine to highlight the future utility of these potentially beneficial drugs. Breast cancer is the most common cancer in women and the leading cause of cancer mortality in women over 40 it\\'s the year. The existence of the PI3K/AKT/mTOR pathway aberrations in more than 70% of breast cancer has caused to become a therapeutic target. AZD3463 is an anti-cancer agent used as a potential inhibitor of ALK/IGF1R. It also induces apoptosis and autophagy of the PI3K/AKT/mTOR pathway in cancer cells. Although the mTOR signaling might be inhibited by rapamycin treatment, signals transmitted from the upstream pathway supports cell survival and proliferation. The WST-1 assay test was performed to evaluate the anti-proliferative effects of rapamycin and AZD3463. Besides, the effects of them on apoptosis, autophagy, cytostatic, and metabolism in MCF7 breast cancer cells were investigated. Also, changes in the expression of apoptotic regulatory genes, cell cycle, and metabolism in the PI3K/AKT/mTOR Pathway were determined by Quantitative RT-PCR. The results showed that rapamycin and AZD3463 treatments significantly reduced survival in MCF7 cells. Also, apoptosis, autophagy, and cell population in the G0/G1 stage in the MCF7 cell category in the treatment group showed an increase compared to the control group. The combination of rapamycin and AZD3463 (AZD-RAPA) was determined as an additive according to isobologram analysis. In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases. Our results showed that the use of AZD-RAPA reduced the resistance of cancer cells to treatment and it leads cancer cells to apoptosis. Tumor-induced osteomalacia (TIO) can cause severe, persistent hypophosphatemia due to high fibroblast growth factor-23 (FGF-23) levels, which lead to urinary phosphate wasting. TIO is frequently encountered in association with mesenchymal tumors and responds well to resection of the primary malignancy. Rarely, TIO may be seen as a paraneoplastic phenomenon with solid organ malignancies where correction of biochemical abnormalities requires ongoing phosphorus replacement. We report a case of TIO in a patient with metastatic breast cancer complicated by increased parathyroid hormone release secondary to denosumab-induced hypocalcemia. The patient required intensive intravenous and oral phosphate supplementation in addition to vitamin D repletion. A high index of clinical suspicion can yield the correct diagnosis where TIO arises in the setting of a solid organ tumor and help the clinician appropriately manage these challenging cases. Melanoma is the most aggressive skin cancer and in metastatic advanced states, it is completely refractory to chemotherapy. Therefore, it is relevant to understand the molecular bases that rule their aggressiveness. Connexins (Cxs) are proteins that under normal physiological conditions participate in intercellular communication, via the exchange of signaling molecules between the cytoplasm and extracellular milieu and the exchange of ions/second messengers between the cytoplasm of contacting cells. These proteins have shown important roles in cancer progression, chemo- and radiotherapy resistance, and metastasis. Accordingly, Cx26 and Cx43 seem to play important roles in melanoma progression and metastasis. On the other hand, Cx46 is typically expressed in the eye lens, where it seems to be associated with oxidative stress protection in fiber lens cells. However, in the last decade, Cx46 expression has been associated with breast and brain cancers, due to its role in potentiation of both extracellular vesicle release and cancer stem cell-like properties. In this review, we analyzed a potential role of Cx46 as a new biomarker and therapeutic target in melanoma. Breast cancer is one of the most common cancers in the female population worldwide, and its development is thought to be associated with genetic mutations that lead to uncontrolled and accelerated growth of breast cells. This abnormal behavior requires extra energy, and indeed, tumor cells display a rewired energy metabolism compared to normal breast cells. Inorganic phosphate (Pi) is a glycolytic substrate of glyceraldehyde-3-phosphate dehydrogenase and has an important role in cancer cell proliferation. For cells to obtain Pi, ectoenzymes in the plasma membrane with their catalytic site facing the extracellular environment can hydrolyze phosphorylated molecules, and this is an initial and possibly limiting step for the uptake of Pi by carriers that behave as adjuvants in the process of energy harvesting and thus partially contributes to tumor energy requirements. In this study, the activity of an ectophosphatase in MDA-MB-231 cells was biochemically characterized, and the results showed that the activity of this enzyme was higher in the acidic pH range and that the enzyme had a K None The CDKN1B gene, encoding for the CDK inhibitor p27 Preliminary results and emerging data have shown that lipid droplet high (LD \\'Explanatory Models\\' (EMs) are frameworks through which individuals and groups understand diseases, are influenced by cultural and religious perceptions of health and illness, and influence both physicians and patients\\' behaviors.\\nTo examine the role of EMs of illness (cancer-related perceptions) in physicians\\' and laywomen\\'s behaviors (decision to recommend undergoing regular mammography, adhering to mammography) in the context of a traditional-religious society, that is, the Arab society in Israel.\\nTwo combined samples were drawn: a representative sample of 146 Arab physicians who serve the Arab population and a sample composed of 290 Arab women, aged 50-70 years, representative of the main Arab groups residing in the north and center of Israel (Muslims, Christians) were each randomly sampled (cluster sampling). All respondents completed a closed-ended questionnaire.\\nWomen held more cultural cancer-related beliefs and fatalistic beliefs than physicians. Physicians attributed more access barriers to screening as well as fear of radiation to women patients and lower social barriers to screening, compared with the women\\'s community sample. Higher fatalistic beliefs among women hindered the probability of adherence to mammography; physicians with higher fatalistic beliefs were less likely to recommend mammography.\\nThe role of cultural perceptions needs to be particularly emphasized. In addition to understanding the patients\\' perceptions of illness, physicians must also reflect on the social, cultural, and psychological factors that shape their decision to recommend undergoing regular mammography. The combination of eribulin with FAC/FEC was not superior to the combination of paclitaxel with FAC/FEC and was associated with greater hematologic toxicity. Eribulin followed by an anthracycline-based regimen is not recommended as a standard neoadjuvant therapy in nonmetastatic operable breast cancer.\\nNeoadjuvant systemic therapy is the standard of care for locally advanced operable breast cancer. We hypothesized eribulin may improve the pathological complete response (pCR) rate compared with paclitaxel.\\nWe conducted a 1:1 randomized open-label phase II study comparing eribulin versus paclitaxel followed by 5-fluorouracil, either doxorubicin or epirubicin, and cyclophosphamide (FAC/FEC) in patients with operable HER2-negative breast cancer. pCR and toxicity of paclitaxel 80 mg/m\\nAt the interim futility analysis, in March 2015, 51 patients (28 paclitaxel, 23 eribulin) had received at least 1 dose of the study drug and were thus evaluable for toxicity; of these, 47 (26 paclitaxel, 21 eribulin) had undergone surgery and were thus evaluable for efficacy. Seven of 26 (27%) in the paclitaxel group and 1 of 21 (5%) in the eribulin group achieved a pCR, and this result crossed a futility stopping boundary. In the paclitaxel group, the most common serious adverse events (SAEs) were neutropenic fever (grade 3, 3 patients, 11%). In the eribulin group, 9 patients (39%) had neutropenia-related SAEs, and 1 died of neutropenic sepsis. The study was thus discontinued. For the paclitaxel and eribulin groups, the 5-year event-free survival (EFS) rates were 81.8% and 74.0% (HR, 1.549; 95% CI, 0.817 to 2.938; p = .3767), and the 5-year OS rates were 100% and 84.4% (HR, 5.813; 95% CI, 0.647 to 52.208; p = .0752), respectively.\\nWe did not observe a higher proportion of patients undergoing breast conservation surgery in the eribulin group than in the paclitaxel group. The patients treated with eribulin were more likely to undergo mastectomy and less likely to undergo breast conservation surgery, but the difference was not statistically significant. As neoadjuvant therapy for operable HER2-negative breast cancer, eribulin followed by FAC/FEC is not superior to paclitaxel followed by FAC/FEC and is associated with a higher incidence of neutropenia-related serious AEs. Patients with PTEN Hamartoma Tumor Syndrome (PHTS, comprising Cowden, Bannayan-Riley-Ruvalcaba, and Proteus-like syndromes) are at increased risk of developing cancer due to pathogenic PTEN germline variants. This review summarizes age-, sex- and type-specific malignant cancer risks for PHTS patients, which is urgently needed for clinical management. A PubMed literature search for Standardized Incidence Ratios or Cumulative Lifetime cancer risks (CLTRs) resulted in nine cohort studies comprising four independent PHTS cohorts, including mainly index cases and prevalent cancer cases. The median age at diagnosis was 36\\u2009years. Reported CLTRs for any cancer varied from 81% to 90%. The tumor spectrum included female breast cancer (CLTRs including sex-specific estimates at age 60-70: 67% to 85%), endometrium cancer (19% to 28%), thyroid cancer (6% to 38%), renal cancer (2% to 24%), colorectal cancer (9% to 32%), and melanoma (0% to 6%). Although these estimates provide guidance for clinical care, discrepancies between studies, sample sizes, retrospective designs, strongly ascertained cases, and lack of pediatric research emphasizes that data should be interpreted with great caution. Therefore, more accurate and more personalized age-, sex- and cancer-specific risk estimates are needed to enable counseling of all PHTS patients irrespective of ascertainment, and improvement of cancer surveillance guidelines. This article is protected by copyright. All rights reserved. None Adjuvant systemic treatments in breast cancer are indicated to reduce the risk of relapse. Their systemic side effects have been well documented and include menopausal symptoms such as impaired libido and vaginal dryness, increased risk of endometrial cancer, stroke, musculoskeletal symptoms including arthralgia and myalgia, osteopenia and fractures, skin rashes, and hypercholesterolemia. However, few articles have focused on the oral mucosal reactions related to adjuvant endocrine therapies (AETs) which clearly differ from those reported with chemotherapies or other targeted therapies used for breast cancer. AETs primarily expose patient to a higher risk of worsened periodontal health, salivary flow modifications, taste disturbance, and global deterioration of oral health-related quality of life. Although the rate of permanent discontinuation of AETs because of oral mucosal changes remains low, an interdisciplinary approach to evaluate oral health and to optimize oral supportive care appears essential to ensure an appropriate management and limit dose adjustment in treated patients. In this respect and based on our clinical experience, we propose recommendations to allow oncologists, nurses, and attending practitioners to implement appropriate measures rapidly and/or refer patients to dentists. Retrospectively obvious events are frequently missed when attention is engaged in another task-a phenomenon known as inattentional blindness. Although the task characteristics that predict inattentional blindness rates are relatively well understood, the observer characteristics that predict inattentional blindness rates are largely unknown. Previously, expert radiologists showed a surprising rate of inattentional blindness to a gorilla photoshopped into a CT scan during lung-cancer screening. However, inattentional blindness rates were higher for a group of naïve observers performing the same task, suggesting that perceptual expertise may provide protection against inattentional blindness. Here, we tested whether expertise in radiology predicts inattentional blindness rates for unexpected abnormalities that were clinically relevant. Fifty radiologists evaluated CT scans for lung cancer. The final case contained a large (9.1 cm) breast mass and lymphadenopathy. When their attention was focused on searching for lung nodules, 66% of radiologists did not detect breast cancer and 30% did not detect lymphadenopathy. In contrast, only 3% and 10% of radiologists (N = 30), respectively, missed these abnormalities in a follow-up study when searching for a broader range of abnormalities. Neither experience, primary task performance, nor search behavior predicted which radiologists missed the unexpected abnormalities. These findings suggest perceptual expertise does not protect against inattentional blindness, even for unexpected stimuli that are within the domain of expertise. In the tumor microenvironment, macrophages polarize into the M2 phenotype to facilitate tumorigenesis. Tumor-derived exosomes can act as mediators between the tumor microenvironment and stromal cells by transporting proteins, mRNAs, and miRNAs. Exosomal miRNAs play a pivotal role in modulating tumor microenvironment and macrophage polarization. Here, we overexpressed miR-130 and miR-33 in exosomes of MDA-MB-231 cells and investigated their effect on macrophage polarization and tumor progression. For this purpose, exosomes were extracted from MDA-MB-231 cells and characterized using dynamic light scattering, electron microscopy, and western blotting of exosomal markers. Then, miR-130 or miR-33 containing exosomes were used to treat IL4-induced M2 or tumor-associated macrophages (TAMs). After treatment, the polarization status of macrophages, including the expression of M1 specific genes, and the secretion of cytokines were evaluated. Finally, the conditioned medium from exosome-treated macrophages was incubated with cancer cells to evaluate its effect on the migration and invasion ability of cancer cells and, in vivo experiments investigated the effect of exosome-treated macrophages on breast cancer progression. Exosomes characterization results approved the range of size and homogeneity of extracted exosomes. Overexpression of miR-130 and miR-33 in exosomes increased the expression of M1 signature genes (IRF5, MCP1, CD80) and secretion of cytokines (IL-1β and TNF-α) as well as yeast phagocytic activity of macrophages. Besides, the conditioned medium of macrophages treated with miRNA containing exosomes declined the migration and invasion ability of cancer cells. The in vivo results indicated the inhibitory effect of exosome-treated macrophages on tumor growth. Furthermore, the results showed that in response to exosome-treated macrophages, the production of TNF-α by spleen cells increased, while the production of IL-10 and TGF-β by these cells decreased. These findings suggest that overexpression of miR-130 and miR-33 in exosomes can decrease tumor progression by shifting macrophage polarization from M2 to M1 phenotype and can be a potential therapeutic strategy for tumor interventions. Background\\xa0Nanoparticle albumin-bound paclitaxel (nab-PTX) and docetaxel (DOC) both demonstrated favorable efficacy as neoadjuvant therapy in breast cancer. We retrospectively evaluated the efficacy and safety of nab-PTX-based chemotherapy (nPBC) and DOC-based chemotherapy (DBC) as neoadjuvant therapy in patients with breast cancer.\\xa0Methods Breast cancer patients who received neoadjuvant nPBC or DBC and underwent surgery from January 2018 to June 2020 were consecutively analyzed. Pathologic complete response (pCR) was defined as no residual invasive cells in the breast and axillary nodes (ypT0/is ypN0) after surgery. The pCR, clinical complete response (cCR), and safety profiles were assessed in the two groups.\\xa0Results A total of 104 breast cancer patients were included in this study. Fourty one patients received nPBC, and 63 patients received DBC The pCR was 34.1% in the nPBC group and 12.7% in the DBC group. Additionally, the cCR was 36.6% in the nPBC group and 15.9% in the DBC group. Peripheral sensory neuropathy was more common in the nPBC group, while hematologic toxicity was observed more frequently in the DBC group.\\xa0Conclusions This study presented antitumor activity of nPBC and DBC in patients with early breast cancer receiving neoadjuvant treatment in a real-world setting. Further prospective research is warranted to confirm the results and to develop biomarkers for better patient selection. Ever since the development of the first antibiotic compound with anticancer potential, researchers focused on isolation and characterization of prospective microbial natural products with potential anti-infective and anticancer activities. The present work describes the production of bioactive metabolites by\\xa0heterotrophic bacteria associated with intertidal seaweeds with potential anti-infective and anticancer activities. The bacteria were isolated in a culture-dependent method and were identified as Shewanella algae MTCC 12715 (KX272635) and Bacillus amyloliquefaciens MTCC 12716 (KX272634) based on combined phenotypic and genotypic methods. Further, the bacteria were screened for their ability to inhibit drug-resistant infectious pathogens and prevent cell proliferation of human liver carcinoma (HepG2) and breast cancer (MCF7) cell lines, without affecting the normal cells. Significant anti-infective activity was observed with bacterial cells and their organic extracts against broad-spectrum multidrug-resistant pathogens, such as vancomycin-resistant Enterococcus faecalis, methicillin-resistant Staphylococcus aureus, Klebsiella pneumonia and Pseudomonas aeruginosa with minimum inhibitory concentration\\u2009≤\\u20093.0\\xa0µg\\xa0mL Preoperative chemotherapy produces tumor shrinkage in most patients with locally advanced breast cancer, including some pathological complete responses (pCRs). We attempted this using a much less toxic sequential regimen, given with concurrent bevacizumab.\\nPatients with locally advanced breast cancer received 3 intravenous doses each of preoperative sequential liposome encapsulated doxorubicin 25 mg/m\\nBetween March 2008 and December 2009, 32 patients received treatment. There was no cardiotoxicity, and other toxicity was mild (no grade 4 or 5 toxicity). No long-term toxicity, including cardiotoxicity, has been observed. Every patient had ≥30% reduction in tumor size; 9 of 31 patients who completed chemotherapy had pCR at operation. Seven years later, 22 of 32 patients remain free of recurrence and 27 of 32 are alive.\\nThe preoperative chemotherapy used appears to be comparably effective, but much less toxic than that used in most conventional regimens and should be studied further. Concurrent treatment with bevacizumab (reported separately) did not provide any additional benefit. Radiation-induced enteritis is a major side effect in cancer patients undergoing abdominopelvic radiotherapy. The Nrf2/HO-1 pathway is a critical endogenous antioxidant stress pathway, but its precise role in radiation-induced enteritis remains to be clarified. Polysaccharides extracted from Rheum tanguticum (RTP) can protect the intestinal cells from radiation-induced damage, but the underlying mechanism is unknown. SD rats and IEC-6 cells were exposed to 12\\xa0or 10 Gy X-ray radiation. Rat survival, and histopathological and immunohistochemical profiles were analyzed at different time points. Indicators of oxidative stress and inflammatory response were also assessed. Cell viability, apoptosis and Nrf2/HO-1 expression were evaluated at multiple time points. Significant changes were observed in the physiological and biochemical indexes of rats after radiation, accompanied by significant oxidative stress response. The mRNA and protein expression of Nrf2 peaked at 12\\xa0h after irradiation, and HO-1 expression peaked at 48\\xa0h after irradiation. RTP administration reduced radiation-induced intestinal damage, upregulated Nrf2/HO-1, improved physiological indexes, significantly decreased apoptosis and inflammatory factors, and upregulated HO-1, particularly at 48\\xa0h after irradiation. In conclusion, Nrf2 is activated in the early stage of radiation-induced intestinal injury and plays a protective role. RTP significantly ameliorates radiation-induced intestinal injury via the regulation of Nrf2 and its downstream protein HO-1. The biggest concerns in the current pandemic are enormous workload pressure, psychological distress, caregiver burnout, and, even worse, transmission of the virus among healthcare workers. One of the potentially beneficial tools in reducing the above-mentioned risks for overwhelming the healthcare system is telemedicine. Although the role of telemedicine and related interventions as a crisis management tool has increased, the current state of the implementation of telemedicine in surgery and surgical subspecialties has not been adequately evaluated.\\nThe objective of this review is to screen the literature, extract expert opinions, qualitative, and quantitative data on the current use and future directions in the implementation of telemedicine in surgery and surgical subspecialties during the COVID-19 pandemic. The findings would potentially help in understanding the challenges and future directions of telemedicine use in surgery.\\nThe databases to be searched include PubMed, EMBASE, and MEDLINE (via Ovid). In addition, ClinicalTrials.gov and medRxiv.org will be searched for any ongoing and/or unpublished studies. The reference lists of articles included in the review will be screened to assess the sensitivity of the search. Literature search, quality assessment, followed by data extraction will be performed by two independent researchers. The findings of the data synthesis will be reported in diagrams, tables, and text. This review will consider reports that include expert opinions, qualitative and quantitative data on the implementation of telemedicine in surgery and surgical subspecialties (including patients with surgical disease of any age) during the COVID-19 pandemic. In addition, future perspectives reported based either on the evidence provided by the data or on expert opinions will be considered.\\nThis study does not require an institutional review board approval given its summary design nature. Findings of this systematic review will be published in a peer-reviewed journal.\\nPROSPERO does not currently accept registrations for scoping reviews, literature reviews or mapping reviews. Primary cutaneous follicle center lymphoma (PCFCL) is defined as a low-grade B-cell non- Hodgkins lymphoma, which primarily occurs and remains confined to the skin, without evidence of extracutaneous or systemic involvement at the time of diagnosis. PCFCL affecting the breast skin is an exceedingly rare entity with only two cases reported in the English literature. We present a case of PCFCL affecting the periareolar breast skin and review the relevant literature. Our patient was a 64-year-old female who presented with an erythematous plaque in the periareolar region of the left breast. The diagnosis of PCFCL was confirmed by a biopsy performed with a seven-month delay, as the tumor had been initially misdiagnosed as a benign lesion. The patient was successfully treated with local radiation therapy. PCFCL is an indolent lymphoma associated with an excellent prognosis. For localized lesions, skin-directed therapies mainly consisting of radiation therapy or complete surgical excision are curative therapeutic approaches, while systemic chemotherapy should be reserved for patients with extensive disease. This case highlights the need to consider PCFCL as an important differential diagnosis in patients presenting with non-resolving erythematous breast skin lesions. A timely biopsy should be obtained to avoid delays in the initiation of appropriate treatment. Primary neuroendocrine carcinoma of the breast (NEBC) is a very rare occurrence accounting for less than 0.1% of all breast cancers. Typically, the tumor presents with ER- and PgR-positive and HER-2-negative status. Despite its luminal type, NEBC is associated with a more aggressive clinical course and poorer prognosis compared to the other types of invasive breast cancer. Clinical and radiological findings are nonspecific. The most common clinical manifestation is a palpable mass whereas in mammography the tumor most commonly appears as a round or oval mass without spiculated margins. Herein, a very rare case of NEBC is described in an asymptomatic patient who presented with an area of architectural distortion and the presence of microcalcifications that was incidentally detected on a screening mammography. A review of the literature has also been conducted. The diagnosis of NEBC requires a thorough investigation to exclude the possibility of a metastatic neuroendocrine tumor from another site because the two entities require different treatment approaches. Due to the rarity of the disease, the optimal therapeutic approach has not been clearly defined. Surgical resection is the mainstay of treatment. Further research is needed to better understand the molecular characteristics of NEBC and identify novel targeted therapies. Cancer metastases and recurrence after surgical resection remain an important cause of treatment failure. Here we demonstrate a general strategy to fabricate personalized nanovaccines based on a cationic fluoropolymer for post-surgical cancer immunotherapy. Nanoparticles formed by mixing the fluoropolymer with a model antigen ovalbumin, induce dendritic cell maturation via the Toll-like receptor 4 (TLR4)-mediated signalling pathway, and promote antigen transportation into the cytosol of dendritic cells, which leads to an effective antigen cross-presentation. Such a nanovaccine inhibits established ovalbumin-expressing B16-OVA melanoma. More importantly, a mix of the fluoropolymer with cell membranes from resected autologous primary tumours synergizes with checkpoint blockade therapy to inhibit post-surgical tumour recurrence and metastases in two subcutaneous tumour models and an orthotopic breast cancer tumour. Furthermore, in the orthotopic tumour model, we observed a strong immune memory against tumour rechallenge. Our work offers a simple and general strategy for the preparation of personalized cancer vaccines to prevent post-operative cancer recurrence and metastasis. An amendment to this paper has been published and can be accessed via a link at the top of the paper. To circumvent Warburg effect, several clinical trials for different cancers are utilising a combinatorial approach using metabolic reprogramming and chemotherapeutic agents including metformin. The majority of these metabolic interventions work via indirectly activating AMP-activated protein kinase (AMPK) to alter cellular metabolism in favour of oxidative phosphorylation over aerobic glycolysis. The effect of these drugs is dependent on glycaemic and insulin conditions.\\xa0\\xa0Therefore, development of small molecules, which can activate AMPK, irrespective of the energy state, may be a better approach for triple-negative breast cancer (TNBC) treatment.\\nTherapeutic effect of SU212 on TNBC cells was examined using in vitro\\xa0and\\xa0in vivo\\xa0models.\\nWe developed and characterised the efficacy of novel AMPK activator (SU212) that selectively induces oxidative phosphorylation and decreases glycolysis in TNBC cells, while not affecting these pathways in normal cells.\\xa0\\xa0 SU212 accomplished this metabolic reprogramming by activating AMPK independent of energy stress and irrespective of the glycaemic/insulin state. This leads to mitotic phase arrest and apoptosis in TNBC cells.\\xa0In vivo, SU212 inhibits tumour growth, cancer progression and metastasis.\\nSU212 directly activates AMPK in TNBC cells, but does not hamper glucose metabolism in normal cells. Our study provides compelling preclinical data for further development of SU212 for the treatment of TNBC. Digital analysis of pathology whole-slide images is fast becoming a game changer in cancer diagnosis and treatment. Specifically, deep learning methods have shown great potential to support pathology analysis, with recent studies identifying molecular traits that were not previously recognized in pathology H&E whole-slide images. Simultaneous to these developments, it is becoming increasingly evident that tumor heterogeneity is an important determinant of cancer prognosis and susceptibility to treatment, and should therefore play a role in the evolving practices of matching treatment protocols to patients. State of the art diagnostic procedures, however, do not provide automated methods for characterizing and/or quantifying tumor heterogeneity, certainly not in a spatial context. Further, existing methods for analyzing pathology whole-slide images from bulk measurements require many training samples and complex pipelines. Our work addresses these two challenges. First, we train deep learning models to spatially resolve bulk mRNA and miRNA expression levels on pathology whole-slide images (WSIs). Our models reach up to 0.95 AUC on held-out test sets from two cancer cohorts using a simple training pipeline and a small number of training samples. Using the inferred gene expression levels, we further develop a method to spatially characterize tumor heterogeneity. Specifically, we produce tumor molecular cartographies and heterogeneity maps of WSIs and formulate a heterogeneity index (HTI) that quantifies the level of heterogeneity within these maps. Applying our methods to breast and lung cancer slides, we show a significant statistical link between heterogeneity and survival. Our methods potentially open a new and accessible approach to investigating tumor heterogeneity and other spatial molecular properties and their link to clinical characteristics, including treatment susceptibility and survival. Cyclin D1 is one of the most important oncoproteins that drives cancer cell proliferation and associates with tamoxifen resistance in breast cancer. Here, we identify a lncRNA, DILA1, which\\xa0interacts with Cyclin D1 and is overexpressed in tamoxifen-resistant breast cancer cells. Mechanistically, DILA1 inhibits the phosphorylation of Cyclin D1 at Thr286 by directly interacting with Thr286 and blocking its subsequent degradation, leading to overexpressed Cyclin D1 protein in breast cancer. Knocking down DILA1 decreases Cyclin D1 protein expression, inhibits cancer cell growth and restores tamoxifen sensitivity both in vitro and in vivo. High expression of DILA1 is associated with overexpressed Cyclin D1 protein and poor prognosis in breast cancer patients\\xa0who received tamoxifen treatment. This study shows the previously unappreciated importance of post-translational dysregulation of Cyclin D1 contributing to tamoxifen resistance in breast cancer. Moreover, it reveals the novel mechanism of DILA1 in regulating Cyclin D1 protein stability and suggests DILA1 is a specific therapeutic target to downregulate Cyclin D1 protein and reverse tamoxifen resistance in treating breast cancer. Since its discovery, partner and localizer of breast cancer 2 (BRCA2) (PALB2) has emerged as a major tumor suppressor gene linked to breast cancer (BC), pancreatic cancer (PC), and ovarian cancer (OC) susceptibility. Its protein product plays a pivotal role in the maintenance of genome integrity. Here we discuss the first functional evaluation of a large set of PALB2 missense variants of uncertain significance (VUSs). Assessment of 136 VUSs interrogating a range of PALB2 biological functions resulted in the identification of 15 variants with consistent loss of function across different assays. All loss-of-function variants are located at the PALB2 coiled coil (CC) or at the WD40 domain, highlighting the importance of modular domains mechanistically involved in the DNA damage response (DDR) and pinpointing their roles in tumor suppression. None Βradykinin stimulation of B2 receptor is known to activate the oncogenic ERK pathway and overexpression of bradykinin receptors B1 and B2 has been reported to occur in glioma, colorectal and cervical cancers. B1R and B2R antagonists have been shown to reverse tumor proliferation and invasion. Paradoxically, B1R and B2R agonism has also been reported to elicit antiproliferative benefits. In order to complement the data accumulated to date with the natural substrate bradykinin and peptidic B2R antagonists, we decided to examine for the first time the response elicited by B2R stimulation in breast cancer lines with a non-peptidic small molecule B2R agonist. We synthesized and assessed the highly selective and potent B2R partial agonist FR-190997 in MCF-7 and MDA-MBA-231 breast cancer lines and found it possessed significant antiproliferative activity (IC  Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer.\\nThis was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated with buparlisib at a starting dose of 100\\u2009mg daily. The primary endpoint was clinical benefit, defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) for ≥\\u20094\\u2009months, per RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. A subset of patients underwent pre- and on-treatment tumor tissue biopsies for correlative studies.\\nFifty patients were enrolled. Median number of cycles was 2 (range 1-10). The clinical benefit rate was 12% (6 patients, all SD ≥\\u20094\\u2009months). Median PFS was 1.8\\u2009months (95% confidence interval [CI] 1.6-2.3). Median OS was 11.2\\u2009months (95% CI 6.2-25). The most frequent adverse events were fatigue (58% all grades, 8% grade 3), nausea (34% all grades, none grade 3), hyperglycemia (34% all grades, 4% grade 3), and anorexia (30% all grades, 2% grade 3). Eighteen percent of patients experienced depression (12% grade 1, 6% grade 2) and anxiety (10% grade 1, 8% grade 2). Alterations in PIK3CA/AKT1/PTEN were present in 6/27 patients with available targeted DNA sequencing (MSK-IMPACT), 3 of whom achieved SD as best overall response though none with clinical benefit ≥\\u20094\\u2009months. Of five patients with paired baseline and on-treatment biopsies, reverse phase protein arrays (RPPA) analysis demonstrated reduction of S6 phosphorylation in 2 of 3 patients who achieved SD, and in none of the patients with progressive disease.\\nBuparlisib was associated with prolonged SD in a very small subset of patients with triple-negative breast cancer; however, no confirmed objective responses were observed. Downmodulation of key nodes in the PI3K pathway was observed in patients who achieved SD. PI3K pathway inhibition alone may be insufficient as a therapeutic strategy for triple-negative breast cancer.\\nNCT01790932 . Registered on 13 February 2013; NCT01629615 . Registered on 27 June 2012. The epidemiology of esophageal cancer (EC) can elucidate its causes and risk factors and help develop prevention strategies. We aimed to provide an overview of the burden, trends, and risk factors of EC in China from 1990 to 2017. We also investigated the differences between China, Japan, and South Korea and discussed the possible causes of the disparities.\\nWe used the Global Burden of Disease Study 2017 to obtain data on incident cases, deaths, disability-adjusted life-year (DALY) cases, age-standardized incidence rate (ASIR), age-standardized death rate (ASDR), and age-standardized DALY rate of EC in China, Japan, and South Korea from 1990 to 2017. Trend analysis was performed using joinpoint analysis. We measured the associations between ASIR, ASDR, and age-standardized DALY rate and the socio-demographic index (SDI) for 1990-2017. We also analyzed the risk factors associated with EC deaths and DALYs.\\nChina recorded 234,624 (95% uncertainty intervals: 223,240-246,036) incident cases of and 212,586 (202,673-222,654) deaths from EC in 2017. The ASIR and ASDR declined from 1990 to 2017. Until 2017, the ASIR was 12.23, and ASDR was 11.25 per 100,000 persons. The DALYs were 4,464,980 (4,247,816-4,690,846) with an age-standardized rate of 222.58 per 100,000 persons in 2017. The ASIR, ASDR, and age-standardized DALY rate in China were twice those of Japan and South Korea. These three indicators showed a decreasing trend, whereas SDI increased, in all three countries from 1990 to 2017. Tobacco and alcohol use remained the major risk factors for EC death and DALYs, especially for men in China and women in Japan and South Korea. High body mass index (BMI) and low-fruit diet were the main risk factors for women in China.\\nThe incident cases and deaths of EC in China, Japan, and South Korea increased from 1990 to 2017, whereas the ASIR, ASDR, and age-standardized DALY rate declined. China had the greatest burden of EC among three countries. SDI and aging along with tobacco use, alcohol use, high BMI, and low-fruit diet were the main risk factors of death and DALYs and should be paid more attention. The impact of different disease stages and treatment for human epidermal growth factor 2 positive (HER2-positive) breast cancer (BC) on work productivity and health-related quality of life (HRQoL) is poorly understood.\\nThis was a UK cross-sectional study of 299 adult patients with HER2-positive early or metastatic BC (NCT03099200). Productivity was assessed using the work productivity and activity impairment scale; HRQoL was measured using EuroQol-5 Dimensions-5 levels (EQ-5D-5L), and Functional Assessment of Cancer Therapy Breast (FACT-G and -B) instruments. Three balanced patient groups were recruited: (1) early BC on treatment post-surgery, (2) early BC after completion of adjuvant treatment, (3) during metastatic BC treatment. Between-group comparisons were performed using an analysis of variance.\\nGroup 1 comprised 89 patients, Group 2, 108 and Group 3, 102. Age, ethnicity and comorbidities were similar across groups. Patients in Group 3 reported more often being unable to work (significant Bonferroni adjusted p\\u2009<\\u20090.003). Proportions of employed patients were 50.6%, 50.9% and 27.5% in Groups 1, 2 and 3, respectively. For patients in part-time employment, the number of hours worked was significantly higher in Group 2 patients versus Group 3 (p\\u2009=\\u20090.002). Group 2 also had significantly lower levels of work absenteeism and overall work impairment compared with Group 1 (p\\u2009<\\u20090.001). Patients in Group 3 reported worse health utility scores (p\\u2009≤\\u20090.002), moderate or worse problems in the EQ-5D-5L self-care and usual activity domains (p\\u2009≤\\u20090.001), and lower HRQoL as assessed by FACT summary scores (p\\u2009<\\u20090.001 for FACT-B and -G) than Groups 1 and 2. Poorer HRQoL was significantly associated with higher work impairment (p\\u2009<\\u20090.001), with the strongest relationships being observed between activity impairment and HRQoL (Pearson\\'s r: 0.67).\\nMetastatic disease and treatment of HER2-positive BC adversely impacted on work productivity and HRQoL. The results of this study support the idea that being able to delay or prevent the metastatic recurrence of BC, for example by extending the time patients are in remission or at early stage of BC, has wider benefits in terms of patient productivity and HRQoL. Triple-Negative Breast Cancer (TNBC) is an aggressive and complex subtype of breast cancer. The current biomarkers used in the context of breast cancer treatment are highly dependent on the targeting of oestrogen receptor, progesterone receptor, or HER2, resulting in treatment failure and disease recurrence and creating clinical challenges. Thus, there is still a crucial need for the improvement of TNBC treatment; the discovery of effective biomarkers that can be easily translated to the clinics is essential.\\nWe report an approach for the discovery of biomarkers that can predict tumour relapse and pathologic complete response (pCR) in TNBC on the basis of mRNA expression quantified using the NanoString nCounter Immunology Panel. To overcome the limited sample size, prediction models based on random Forest were constructed using the differentially expressed genes (DEGs) as selected features. We also evaluated the differences between pre- and post-treatment groups aiming for the combinatorial assessment of pCR and relapse using additive models in edgeR.\\nWe identify nine and 13 DEGs strongly associated with pCR and relapse, respectively, from 579 immune genes in a small number of samples (n\\u2009=\\u200955) using edgeR. An additive model for the comparison of pre- and post-treatment groups via the adjustment of the independent subject in the relapse group revealed associations for 41 genes. Comprehensive analysis indicated that our prediction models outperformed those constructed using features extracted from the existing feature selection model Elastic Net in terms of accuracy. The prediction models were assessed using a randomization test to validate the robustness (empirical P for the model of pCR\\u2009=\\u20090.015 and empirical P for the model of relapse\\u2009=\\u20090.018). Furthermore, three DEGs (FCER1A, EDNRB, and TGFBI) in the model of relapse showed prognostic significance for predicting the survival of patients with cancer through Cox proportional hazards regression model-based survival analysis.\\nGene expression quantified via the NanoString nCounter Immunology Panel can be seamlessly analysed using edgeR, even considering small sample sizes. Our approach provides a scalable framework that can easily be applied for the discovery of biomarkers based on the NanoString nCounter Immunology Panel.\\nThe source code will be available from github at https://github.com/sungheep/nanostring . Germline TP53 mutations are associated with Li-Fraumeni syndrome, a severe and rare hereditary cancer syndrome. Despite the rarity of germline TP53 mutations, the clinical implication for mutation carriers and their families is significant. The risk management of TP53 germline mutation carriers is more stringent than BRCA carriers, and radiotherapy should be avoided when possible.\\nTP53 gene mutation screening was performed in 2538\\xa0Chinese breast cancer patients who tested negative for BRCA mutations.\\nTwenty TP53 mutations were identified with high next-generation sequencing concerning for germline mutations in Chinese breast cancer families. The majorities of the TP53 carriers had early-onset, hormone receptor-positive breast cancer, and had strong family history of cancer. Among all, 11 patients carried a germline mutation and 6 of which were likely de novo germline mutations. In addition, 1 case was suspected to be induced by chemotherapy or radiation, as this patient had no significant family history of cancer and aberrant clonal expansion can commonly include TP53 mutations. Furthermore, we have identified one mosaic LFS case. Two novel mutations (c.524_547dup and c.529_546del) were identified in patients with early-onset.\\nIn view of the high lifetime risk of malignancy, identification of patients with germline TP53 mutations are important for clinicians to aid in accurate risk assessment and offer surveillance for patients and their families. Pain is a common symptom in oncologic patients and its management is generally guided by pain individually perceived by patients and expressed through self-reported scales. However, the utility of these tools is limited because strongly dependent on patients\\' opinions. For this reason, more objective instruments are desirable.\\nIn this overview scientific articles indicating potential markers to be used for pain management in cancer were collected and discussed.\\nresearch was performed on principal electronic scientific databases by using the words \"pain\", \"cancer\", \"markers\" as \"biomarkers\" as the main keywords, and findings describing potential biomarkers for the management of cancer pain were reported.\\nStudies on pain markers not specific for cancer typology (inflammatory, genetic, markers predicting response to analgesic drugs, neuroimaging markers) and pain markers for specific types of cancer (bone cancer, breast cancer, lung cancer, head and neck cancer, prostate cancer, cancer in pediatrics) are presented and commented.\\nThis overview supports the view of the involvement of inflammatory mediators in the mechanisms underlying cancer pain. Up today only a few data from research on markers can help in the management of pain, except for pro-inflammatory cytokines and other inflammatory indexes such as C-reactive protein (CRP). However, biomarkers are a promising strategy useful to predict pain intensity and to purchase objective quantification of analgesic response in guiding decisions on individual-tailored treatments in cancer patients. HOX genes belong to the highly conserved homeobox superfamily, responsible for the regulation of various cellular processes that control cell homeostasis, from embryogenesis to carcinogenesis. The abnormal expression of HOX genes is observed in various cancers, including breast cancer; they act as oncogenes or as suppressors of cancer, according to context. In this review, we analyze HOX gene expression patterns in breast cancer and examine their relationship, based on the three-dimensional genome structure of the HOX locus. The presence of non-coding RNAs, embedded within the HOX cluster, and the role of these molecules in breast cancer have been reviewed. We further evaluate the characteristic activity of HOX protein in breast cancer and its therapeutic potential. Previous findings demonstrate that psychological flexibility (PF) might be a protective factor regarding distress in breast cancer patients. Our research aimed to examine the moderating effect of psychological inflexibility (PI) on the relationship between emotional state, fatigue, functional status and quality of life (QOL) in breast cancer. The research was conducted on 64 women (M Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer for more than 30 years. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have been demonstrated to be effective therapeutic approaches for ER positive breast cancers. Unfortunately, 30-50% of ER positive tumors become resistant to SERM/AI treatment after 3-5 years. Fulvestrant, the only approved selective estrogen receptor degrader (SERD), is currently an important therapeutic approach for the treatment of endocrine-resistant breast cancers. The poor pharmacokinetic properties of fulvestrant have inspired the development of a new generation of oral SERDs to overcome drug resistance. In this review, we describe recent advances in ERα structure, functions, and mechanisms of endocrine resistance and summarize the development of oral SERDs in both academic and industrial areas. An effective biomarker for the diagnosis of breast cancer (BC) and benign breast diseases (BBD) is crucial for improving the prognosis. We investigated whether N6-methyladenosine (m6A) can be a diagnostic biomarker of BC.\\nWe detected the contents of peripheral blood m6A in 62 patients with BC, 41 patients with BBD, and 41 normal controls (NCs) using the colorimetric method. The relative expression of the m6A regulated genes METTL14 and FTO was analyzed using quantitative real-time polymerase chain reaction.\\nm6A in peripheral blood RNA was significantly higher in patients with BC than that in patients with BBD (p < 0.0001) or the NCs (p < 0.0001). m6A was closely associated with the disease stage (from stage 0 to stage I-Ⅳ; p = 0.003). The receiver operating characteristic curve of m6A contained an area under the curve (AUC) value of 0.887 in BC, which was greater than that of CEA or CA153. The combination of m6A, CEA, and CA153 improved the AUC to 0.914. The up- and downregulated mRNA expression of METTL14 and FTO, respectively, might contribute to the increase of m6A in patients with BC. m6A combined with METTL14 and FTO improved the AUC to 0.929 with a specificity of 97.4% in the peripheral blood of patients with BC.\\nThe peripheral blood RNA of m6A might be a valuable biomarker for the diagnosis of BC. Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib.\\nBetween April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2-negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed.\\nMedian age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI]; 19.1 to not reached) and 6.37 months (95% CI; 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1, [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).\\nTo our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice. Bone destruction and pain caused by cancer is one of the most devastating complications of cancer patients with bone metastases, and it seriously affects the quality of patients\\' life. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a cell adhesion molecule with increased expression in a variety of tumors. This study focused to clarify the specific function of EMMPRIN in bone metastasis of breast cancer.\\nAdenovirus with shRNA-EMMPRIN was transfected into MRMT-1 rat breast carcinoma cells, and the MRMT-1 cells with different expression levels of EMMPRIN were implanted into the bone marrow cavity of rat tibia. Next, the effect of down-regulation of EMMPRIN was evaluated as follows: (1) bone damage was detected by x-ray radiological and TRAP staining; (2) the tumor burden was evaluate by Hematoxylin-Eosin (H&E) staining; (3) the test of Pain-related behaviors was assessed used the bilateral paw withdrawal mechanical threshold (PWMT); (4) the levels of secretory factors in tumor conditioned medium (TCM) were determined by using ELISA assay.\\nWe found that down-regulation of EMMPRIN in tumor cells can simultaneously reduce tumor burden, relieve cancer-induced bone destruction and pain.\\nEMMPRIN is expected to be a therapeutic target for relieving bone metastasis of breast cancer and alleviating cancer-induced bone destruction and pain. The method of targeting EMMPRIN may be a promising strategy for the treatment of cancer in the future. Assessing the use of multiple medications in cancer patients is crucial as such use may affect cancer outcomes. This study reports the prevalence of non-cancer medication use at breast cancer diagnosis, its associated factors, and its effect on survival.\\nWe identified all women diagnosed with primary invasive breast cancer between 1 January 2007 and 31 December 2016, from four population-based breast cancer registries, in Auckland, Waikato, Wellington, and Christchurch, New Zealand. Through linkage to the pharmaceutical records, we obtained information on non-cancer medications that were dispensed for a minimum of 90 days\\' supply between one year before cancer diagnosis and first cancer treatment. We performed ordered logistic regressions to identify associated factors and Cox regressions to investigate its effect on patient survival.\\nOf 14,485 patients, 52% were dispensed at least one drug (mean-1.3 drugs; maximum-13 drugs), with a higher prevalence observed in patients who were older, treated at a public facility, more economically deprived, and screen-detected. The use of 2-3 drugs showed a reduced non-breast cancer mortality (HR = 0.75, 95%CI = 0.60-0.92) in previously hospitalised patients, with other groups showing non-significant associations when adjusted for confounding factors. Drug use was not associated with changes in breast cancer-specific mortality.\\nNon-cancer medication use at breast cancer diagnosis was common in New Zealand, more prevalent in older and disadvantaged women, and showed no effect on breast cancer-specific mortality, but a reduction in other cause mortality with the use of 2-3 drugs. Ribociclib (RIB, LE011, Kisqali The incidence of depression is two-to-three times higher in cancer survivors than the general population. Acid-producing diets may play important roles in the development of depression. Cancer survivors are more susceptible to acid-producing diets, yet few prospective studies have investigated the association of acid-producing diets with depression among breast cancer survivors. We leveraged a large cohort of 2975 early stage breast cancer survivors, which collected detailed dietary data via 24-h recalls. Potential renal acid load (PRAL) and net endogenous acid production (NEAP), two commonly used dietary acid load scores, were used to estimate acid-producing diets. Intakes of PRAL and NEAP were assessed at baseline and years one and four. Increased PRAL and NEAP were each independently associated with increased depression in the longitudinal analyses, after adjusting for covariates. The magnitude of the associations was stronger for PRAL than NEAP. Women with the highest quartile intakes of PRAL had 1.34 (95% CI 1.11-1.62) times the risk of depression compared to women with the lowest quartile. Furthermore, we also observed a joint impact of PRAL and younger age on depression, as well as a joint impact of PRAL and physical activity on depression. Decreasing the consumption of acid-producing diets may be a novel and practical strategy for reducing depressive symptoms among breast cancer survivors, especially those who are younger and have a sedentary lifestyle. Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer which presents a high rate of relapse, metastasis, and mortality. Nowadays, the absence of approved specific targeted therapies to eradicate TNBC remains one of the main challenges in clinical practice. Drug discovery is a long and costly process that can be dramatically improved by drug repurposing, which identifies new uses for existing drugs, both approved and investigational. Drug repositioning benefits from improvements in computational methods related to chemoinformatics, genomics, and systems biology. To the best of our knowledge, we propose a novel and inclusive classification of those approaches whereby drug repurposing can be achieved in silico: structure-based, transcriptional signatures-based, biological networks-based, and data-mining-based drug repositioning. This review specially emphasizes the most relevant research, both at preclinical and clinical settings, aimed at repurposing pre-existing drugs to treat TNBC on the basis of molecular mechanisms and signaling pathways such as androgen receptor, adrenergic receptor, STAT3, nitric oxide synthase, or AXL. Finally, because of the ability and relevance of cancer stem cells (CSCs) to drive tumor aggressiveness and poor clinical outcome, we also focus on those molecules repurposed to specifically target this cell population to tackle recurrence and metastases associated with the progression of TNBC. Treatment strategies for hormone receptor-positive (HR Nipple-sparing mastectomy (NSM) offers patients who are not candidates for breast-conserving treatment an aesthetically pleasing alternative to traditional mastectomy. Some studies have demonstrated its oncologic safety while others have demonstrated residual occult tumor cells at the nipple-areolar complex (NAC). These data prompt further review of oncologic outcomes after NSM.A single institution retrospective chart review was performed of all NSMs performed by 4 breast surgeons at Thomas Jefferson University Hospital over a span of 2012-2019. In this cohort, we review the reconstruction performed, axillary lymph node status, surgical margins, final pathology, loss of the NAC, recurrence rates, and follow-up. In our cohort, we reviewed 170 NSMs performed on 105 patients. All patients were female, and the average age was 46.9\\xa0years. Prophylactic procedures were performed on 43% of patients with 17.1% of patients being BRCA positive. Of those undergoing NSM for cancer (n\\xa0=\\xa094), the associated pathology was 28.8% DCIS, 32.9% IDC, and 3.5% ILC (this accounts for some patients with multiple diagnoses on final pathology). Sentinel lymph node biopsy (SLNB) was performed in 52.9% of cases with 10.6% of cases being positive for axillary disease. Margins were positive in 10.6% (n\\xa0=\\xa010) of cases performed for cancer with 8.5% (n\\xa0=\\xa08) of cases having positive margin at the NAC and the remainder being at the deep margin. Based on margin positivity, 2.4% (n\\xa0=\\xa04) of patients underwent redo surgery with 1 patient requiring re-resection at the NAC margin and 3 patients having total NAC resection. Total loss of NAC occurred in 5.9% (n\\xa0=\\xa010) of cases due to positive margins (n\\xa0=\\xa03) and necrosis (n\\xa0=\\xa07). Recurrence occurred in 7.2% (n\\xa0=\\xa07) of cases who underwent NSM for cancer. Locoregional recurrence in breast tissue, skin, or axilla occurred in 4.1% (n\\xa0=\\xa04) of cases with 0 recurrences at the NAC. Distant recurrence occurred in 4.1% (n\\xa0=\\xa04) of cases at both liver and bone. Average time to recurrence was 27.3\\xa0months. Of the 170 NSM performed, 98% had immediate tissue expander placement with 60% converting to permanent subpectoral implant reconstruction, 14% latissimus dorsi flap reconstruction, 0.6% delayed deep inferior epigastric artery perforator free-flap reconstruction, and 5.2% undergoing delayed free transversus abdominus muscle flap reconstruction. Of all the cases reviewed, there was only 1 death. Our average follow-up was 26.7\\xa0months. We demonstrate similar numbers in our analysis as other studies that have looked at oncologic outcomes after NSM. Although we demonstrate evidence of occult disease at the NAC margin when performing NSM, there was no evidence of recurrence at the NAC demonstrating its efficacy and safety. With proper patient selection, this procedure can be safely offered as an esthetically appealing alternative to traditional mastectomy. The preparation of two new Ru(II)/diphosphine complexes containing Lapachol (Lap) and Lawsone (Law): (1) [Ru(Lap)(dppm) DNA helicases, known for their fundamentally important roles in genomic stability, are high profile players in cancer. Not only are there monogenic helicase disorders with a strong disposition to cancer, it is well appreciated that helicase variants are associated with specific cancers (e.g., breast cancer). Flipping the coin, DNA helicases are frequently overexpressed in cancerous tissues and reduction in helicase gene expression results in reduced proliferation and growth capacity, as well as DNA damage induction and apoptosis of cancer cells. The seminal roles of helicases in the DNA damage and replication stress responses, as well as DNA repair pathways, validate their vital importance in cancer biology and suggest their potential values as targets in anti-cancer therapy. In recent years, many laboratories have characterized the specialized roles of helicase to resolve transcription-replication conflicts, maintain telomeres, mediate cell cycle checkpoints, remodel stalled replication forks, and regulate transcription. In vivo models, particularly mice, have been used to interrogate helicase function and serve as a bridge for preclinical studies that may lead to novel therapeutic approaches. In this review, we will summarize our current knowledge of DNA helicases and their roles in cancer, emphasizing the latest developments. To identify intra-lesion imaging heterogeneity biomarkers in multi-parametric Magnetic Resonance Imaging (mpMRI) for breast lesion diagnosis.\\nDynamic Contrast Enhanced (DCE) and Diffusion Weighted Imaging (DWI) of 73 female patients, with 85 histologically verified breast lesions were acquired. Non-rigid multi-resolution registration was utilized to spatially align sequences. Four (4) DCE (2\\nLASSO regression resulted in 7, 6 and 7 features subsets from DCE, DWI and mpMRI, respectively. Best classification performance was obtained by the RF multi-parametric scheme (Area-Under-ROC-Curve, (AUC)\\xa0±\\xa0Standard-Error (SE), AUC\\xa0±\\xa0SE\\xa0=\\xa00.984\\xa0±\\xa00.025), as compared to DCE (AUC\\xa0±\\xa0SE\\xa0=\\xa00.961\\xa0±\\xa00.030) and DWI (AUC\\xa0±\\xa0SE\\xa0=\\xa00.938\\xa0±\\xa00.032) and statistically significantly higher as compared to DWI. The selected mpMRI feature subset highlights the significance of entropy (1\\nCapturing breast intra-lesion heterogeneity, across mpMRI lesion segments with 1 Pyrano[3,2-c]quinoline derivatives have been synthesized and utilized to obtain various new hetero-annulated triazolopyrimidine, containing quinoline, pyran, 1,2,4-triazine and pyrimidine in good yields. Newly synthesized compounds have been characterized by spectral data and elemental analysis. Most of the synthesized compounds showed moderate to weak antiproliferative activity on most cancer cell lines, especially leukemia and breast cancer cell lines. The open chain formimidic acid ethyl ester is slightly more potent than hetero-annulated systems. The most active compounds were further investigated for caspase activation, Bax activation and Bcl-2 down regulation compared to doxorubicin as a standard, and indeed exhibited mainly cell cycle arrest at the Pre-G1 and G2/M phases. The transcription effects of 5a and 5b on the p53 were assessed and compared with the reference doxorubicin. The results revealed an increase of 12-19 in p53 level compared to the test cells and that p53 protein level of 5a and 5b was significantly inductive (991, and 639\\xa0pg/mL, respectively) in relation to doxorubicin (1263\\xa0pg/mL). Despite the conventional reputation of neutrophils to have antibacterial properties, recent studies have put emphasis and are interested in the role of neutrophils in the spread and treatment of cancer. It has been shown that the infiltration of neutrophils, either by exerting pro- or anti-tumoral effects, probably affects tumor prognosis. Tumor-associated neutrophils (TANs) probably participate in tumor promotion and development in different ways, such as increasing genomic instability, induction of immunosuppression, and increasing angiogenesis. Despite major advances in breast cancer treatment, it is the second leading cause of death in American women. It has been revealed that inflammation is a fundamental issue in the treatment of this cancer because tumor growth, invasion, metastasis, and vascularization can be affected by inflammatory factors. It is demonstrated that enhanced neutrophil to lymphocyte ratio probably contributes to the raised rate of mortality and decreased survival among breast cancer cases. The present review explores the biology of TANs, their suspected interactions in the breast cancer microenvironment, and their functions in preserving the tumor microenvironment and progression of tumors. Furthermore, their potential as therapeutic targets and clinical biomarkers has been discussed in this paper. None To evaluate the psychosocial situation of breast cancer (BC) patients with dependent children, with regard to who used family-centered psychosocial support (PS) services, reasons against using it, as well as existing, unmet needs and current PS need.\\nData were collected via survey and patient files during an inpatient rehabilitation program for mothers with BC, who were accompanied by a child <12 years. Descriptive statistics and tests for statistical significance were used.\\nOut of the total of 561 patients, 23.0% had used family-centered PS services before. Common reasons against it were enough support, no anticipated need and organizational issues. Patients stated a high number of unmet needs. The most urgent ones related to their children. 59.3% of mothers stated a current PS need (PSN) and 33.3% a need for their children. Little social support and a worse maternal HRQOL, but not time since diagnosis, were related to a higher PSN in mothers and children (bivariate association).\\nAmong BC patients with dependent children, clinicians need to take the whole family and their support needs into account. They should know about the existing organizational barriers, which need to be overcome with the help of tailored offers. Patients with low HRQOL, little social support and single-mothers (with regard to children\\'s PSN) need special attention as these can be indicators of high PSN. This article is protected by copyright. All rights reserved. There is ongoing debate regarding the optimal timing of contralateral prophylactic mastectomy fueled by concern that performing it at the time of the mastectomy for the index breast cancer may delay adjuvant therapy. The study objective was to examine the effect of simultaneous contralateral prophylactic mastectomy with immediate breast reconstruction on the complication rate and adjuvant therapy timing.\\nA retrospective study was conducted of consecutive patients who underwent contralateral prophylactic mastectomy with immediate breast reconstruction and received adjuvant therapy over a 6-year period. Demographic, treatment, and outcomes data were collected, and relationships between multiple variables and outcomes were evaluated.\\nOf 241 patients (482 breasts) included, 186 (372 breasts) underwent simultaneous index breast mastectomy and contralateral prophylactic mastectomy with immediate breast reconstruction followed by adjuvant therapy (immediate group), and 55 (110 breasts) underwent index mastectomy, then adjuvant therapy, followed by delayed contralateral prophylactic mastectomy with immediate breast reconstruction (delayed group). Demographics were similar, although breast cancer stage (p < 0.001), tumor category (p = 0.0072), and nodal category (p < 0.001) were significantly higher in the delayed group. In the immediate group, complications before adjuvant therapy occurred in 31 patients (16.7 percent), and in six patients (3.2 percent) complications occurred only in the contralateral prophylactic mastectomy breast; delay to adjuvant therapy occurred in 11 patients (5.9 percent), in four (2.2 percent) of whom the contralateral prophylactic mastectomy breast was responsible for the delay.\\nContralateral prophylactic mastectomy with immediate breast reconstruction can be performed safely at the time of the index mastectomy in carefully selected patients. These findings will engage patients seeking contralateral prophylactic mastectomy in shared decision-making regarding optimal timing with respect to the risks and benefits.\\nTherapeutic, III. Circular RNAs (circRNAs) have been shown to play a functional role in a variety of cancers. However, few studies on circRNAs in estrogen receptor-positive breast cancer have been conducted. Here, we investigated the role of circRNA circTP63 in estrogen receptor-positive breast cancer progression and malignant behaviors. First, we observed increased expression of circTP63 in MCF7 cells relative to normal human mammary epithelial cell lines, such as DU4475 and MCF-10A, and the changed oncogenicity of MCF7 cells correlated with circTP63 overexpression and downregulation. Interestingly, a series of gain- and loss-of-function assays revealed that a higher level of FOXM1 was closely associated with MCF7 malignant behaviors induced by circTP63 overexpression. Further investigations showed that circTP63 sponged to miR-873-3p, which targeted FOXM1 mRNA and inhibited its expression. Mechanistically, circTP63 binds to miR-873-3p and prevents the targeting of FOXM1, thus inducing the progression and malignant behaviors of estrogen receptor-positive breast cancer, such as cell proliferation, cell cycle dysregulation, invasion, migration and even tumor growth. CircTP63 might be a potential biomarker or target to treat estrogen receptor-positive breast cancer patients in the future. In recent years, cancer immunotherapy has evolved as an exciting novel strategy for researchers and clinicians worldwide. Immunotherapeutic agents\\xa0such as immune checkpoint blockers have changed the standard-of-care treatment provided for many tumors. Unfortunately, only a small proportion of patients respond effectively to these checkpoint inhibitors. Moreover, the immunosuppressive pathways for cancer are probably too\\xa0complicated to achieve optimal outcome with immune checkpoint inhibitors alone. Combining current therapeutic options and immunotherapy-based approaches is being explored as an effective strategy to treat cancer. The use of nanotechnology-based platforms for delivery of immunotherapeutic agents or combination therapy could offer a major advantage over conventional anticancer treatment options. This review highlights the potential role\\xa0of different nanotechnology-based strategies in improving the efficacy of immune checkpoint blockade therapy. Early presentation with breast cancer symptoms is crucial to the effectiveness of treatment and the affected women\\'s long-term survival. However, in Indonesia, 60-70% of breast cancer patients first present themselves to the hospital in an advanced stage. Knowledge about the determinants of breast cancer early presentation could inform efforts to promote healthcare seeking at earlier symptomatic stages. In the current study, we explored the psychosocial determinants of early presentation among female breast cancer survivors.\\nFace-to-face semi-structured interviews were conducted with 23 female breast cancer survivors in Surabaya, Indonesia (mean age = 49.8\\u2009years). Directed content analysis approach was used to analyse the data.\\nHalf of the respondents underwent breast cancer screening prior to onset of symptoms. Nine determinants of breast cancer early presentation were reflected in the women\\'s responses: (lack of) knowledge, perceived behavioural control, previous health related experiences and risk perceptions, attitudes and beliefs, norms, competing priorities, financial issues, instrumental factors, and health provider factors.\\nHealth promotion efforts should focus on both internal and external psychosocial determinants related to the breast cancer early presentation, and on involving women\\'s social environment as target for education. Additionally, providing accessible and affordable healthcare is important for early presentation. Mounting evidence shows that long noncoding RNAs play important roles in human diseases and radioresistance could be an important factor for tumor recurrence. We observed that HOX antisense intergenic RNA ( Interactions between tumor cells and the extracellular matrix (ECM) are an important factor contributing to therapy failure in cancer patients. Current in vitro breast cancer spheroid models examining the role of mechanical properties on spheroid response to chemotherapy are limited by the use of two-dimensional cell culture, as well as simultaneous variation in hydrogel matrix stiffness and other properties, e.g., hydrogel composition, pore size, and cell adhesion ligand density. In addition, currently used hydrogel matrices do not replicate the filamentous ECM architecture in a breast tumor microenvironment. Here, we report a collagen-alginate hydrogel with a filamentous architecture and a 20-fold variation in stiffness, achieved independently of other properties, used for the evaluation of estrogen receptor-positive breast cancer spheroid response to doxorubicin. The variation in hydrogel mechanical properties was achieved by altering the degree of cross-linking of alginate molecules. We show that soft hydrogels promote the growth of larger MCF-7 tumor spheroids with a lower fraction of proliferating cells and enhance spheroid resistance to doxorubicin. Notably, the stiffness-dependent chemotherapeutic response of the spheroids was temporally mediated: it became apparent at sufficiently long cell culture times, when the matrix stiffness has influenced the spheroid growth. These findings highlight the significance of decoupling matrix stiffness from other characteristics in studies of chemotherapeutic resistance of tumor spheroids and in development of drug screening platforms. Although uncommon, breast cancer is the leading cause of cancer death in young women. There are limited studies on the presentation and characteristics of breast cancer in women under age 40.\\nThis is a retrospective study investigating patient demographics, clinical presentations, imaging findings, and cancer characteristics of a cohort of 145 women under age 40 with breast cancer.\\nOur cohort had more aggressive cancer subtypes than reported in older women; 33.1% triple negative, 80% high Ki-67, and 21.3% with stage 3+ disease. Most were referred from primary care or obstetrician/gynecologist, though 5.5% initially presented from the emergency department and another 2.1% were incidental findings. 16.6% of patients presented while pregnant or breastfeeding. Most patients presented with breast related symptoms. Of the 9.1% of patients diagnosed through our high-risk screening program, 84.6% of the cancers were identified on mammography or simultaneously with mammography and MRI. Most breast cancers presented with typically worrisome imaging (82.6%), though several cancers presented with findings that were typically benign.\\nWe recommend prompt breast imaging for young women presenting with breast-related symptoms or an incidental breast finding, as younger patients have more aggressive cancer subtypes and are of a higher grade at presentation compared to older women. We also recommend vigilance when distinguishing suspicious symptoms from pregnancy-related breast changes to minimize delays in diagnosis. Additionally, it is important to identify patients who qualify for high risk screening, since cancers in screening patients were found at a lower grade than those presenting with symptoms. Health-related quality of life (HRQOL) among older cancer survivors can be impaired by factors such as treatment, comorbidities, and social challenges. These HRQOL impairments may be especially pronounced in rural areas, where older adults have higher cancer burden and more comorbidities and risk factors for poor health. This study aimed to assess rural-urban differences in HRQOL for older cancer survivors and controls.\\nData came from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS), which links cancer incidence from 18 U.S. population-based cancer registries to survey data for Medicare Advantage Organization enrollees (1998-2014). HRQOL measures were 8 standardized subscales and 2 global summary measures. We matched (2:1) controls to breast, colorectal, lung, and prostate cancer survivors, creating an analytic dataset of 271,640 participants (ages 65+). HRQOL measures were analyzed with linear regression models including multiplicative interaction terms (rurality by cancer status), controlling for sociodemographics, cohort, and multimorbidities.\\nHRQOL scores were higher in urban than rural areas (e.g., global physical component summary score for breast cancer survivors: urban mean\\u2009=\\u200938.7, standard error [SE]\\u2009=\\u20090.08; rural mean\\u2009=\\u200937.9, SE\\u2009=\\u20090.32; p\\u2009<\\u20090.05), and were generally lower among cancer survivors compared to controls. Rural cancer survivors had particularly poor vitality (colorectal: p\\u2009=\\u20090.05), social functioning (lung: p\\u2009=\\u20090.05), role limitation-physical (prostate: p\\u2009<\\u20090.01), role limitation-emotional (prostate: p\\u2009<\\u20090.01), and global mental component summary (prostate: p\\u2009=\\u20090.02).\\nSupportive interventions are needed to increase physical, social, and emotional HRQOL among older cancer survivors in rural areas. These interventions could target cancer-related stigma (particularly for lung and prostate cancers) and/or access to screening, treatment, and ancillary healthcare resources. None Cumulative epidemiologic evidence has shown that early-life adiposity is strongly inversely associated with breast cancer risk throughout life, independent of adult obesity. However, the molecular mechanisms remain poorly understood.\\nWe assessed the association of early-life adiposity, defined as self-reported body size during ages 10-20\\u2009years from a validated 9-level pictogram, with the transcriptome of breast tumor (N\\u2009=\\u2009835) and tumor-adjacent histologically-normal tissue (N\\u2009=\\u2009663) in the Nurses\\' Health Studies. We conducted multivariable linear regression analysis to identify differentially expressed genes in tumor and tumor-adjacent tissue, respectively. Molecular pathway analysis using Hallmark gene sets (N\\u2009=\\u200950) was further performed to gain biological insights. Analysis was stratified by tumor estrogen receptor (ER) protein expression status (N\\u2009=\\u2009673 for ER+ and 162 for ER- tumors).\\nNo gene was statistically significantly differentially expressed by early-life body size after multiple comparison adjustment. However, pathway analysis revealed several statistically significantly (FDR\\u2009<\\u20090.05) up or down regulated gene sets. In stratified analyses by tumor ER status, larger body size during ages 10-20\\u2009years was associated with decreased cellular proliferation pathways, including MYC target genes, in both ER+ and ER- tumors. In ER+ tumors, larger body size was also associated with upregulation in genes involved in TNFα/NFkB signaling. In ER- tumors, larger body size was additionally associated with downregulation in genes involved in IFNα and IFNγ immune response and PI3K/ATK/mTOR signaling; the INFγ response pathway was also downregulated in ER- tumor-adjacent tissue though at borderline statistical significance (FDR\\u2009=\\u20090.1).\\nThese findings provide new insights into the biological and pathological underpinnings of the early-life adiposity and breast cancer association. Vasomotor symptoms (hot flushes, flashes, night sweats) occur in the majority of menopausal women, and are reported as being of the highest symptom priority as they often persist over many years and can be highly disruptive. Hormone therapy is the most effective available treatment but is not without risk if taken long term, and is sometimes contraindicated; for example, in women with a personal or family history of breast cancer, which is the most common female cancer worldwide. Other treatment alternatives are not as efficacious, can cause side effects, and/or are not widely available. A new, effective, targeted treatment could therefore benefit millions of women worldwide. This became possible to investigate after accumulated evidence from both animal and human models implicated heightened signaling of a hypothalamic neuropeptide together with its receptor (neurokinin B/NK3R) in the etiology of sex-steroid-deficient vasomotor symptoms. Four clinical trials of three chemically distinct oral NK3R antagonists for the treatment of menopausal flushes have since completed and published, which consistently demonstrate efficacy and tolerability of these agents. These suggest great promise to change practice in the future if ongoing further larger-scale studies of longer duration confirm the same; as, estrogen exposure will no longer be required to effectively and safely treat vasomotor symptoms. There is a growing need for biomarkers which predict age-onset pathology. Although this is challenging, the methylome offers significant potential. Cancer is associated with the hypermethylation of many gene promoters, among which are developmental genes. Evolutionary theory suggests developmental genes arbitrate early-late life trade-offs, causing epimutations that increase disease vulnerability. Such genes could predict age related disease. The aim of this work was to optimise an electrochemical procedure for the future investigation of a broad range of ageing related pathologies. An electrochemical approach, which adopted three analytical techniques, was used to investigate DNA methylation in the EN1 gene promoter. Using synthetic single stranded DNA, one technique was able to detect DNA at concentrations as low as 10nM, with methylation status distinguishable at concentrations >25nM. A negative correlation could be observed between % methylation of heterogeneous solution and the key electrochemical parameter, Rct (r = -0.982, p < 0.01). The technique was applied to the breast cancer cell line MCF-7, where a similar correlation was observed (r = -0.965, p < 0.01). These results suggest electrochemistry can effectively measure DNA methylation at low concentrations of DNA. This has implications for the future detection of age-related disease. Metastasis is the main cause of treatment failure in breast cancer, and integrated phototheranostics is a promising strategy to achieve both precision theranostics and metastasis inhibition. In this work, a multifunctional phototheranostic nanoprobe composed of chlorin e6 (Ce6)-conjugated and polydopamine (PDA)-coated gold nanostars (AuNSs) was synthesized for simultaneous photoacoustic (PA) imaging, photothermal therapy (PTT) and photodynamic therapy (PDT). Under the irradiation of near infrared laser, AuNSs@PDA showed enhanced photothermal conversion and amplified PA imaging performance, compared with single AuNSs. By the covalent conjugation of Ce6, the AuNSs@PDA-Ce6 nanoprobe showed robust stability and excellent singlet oxygen (1O2) generation ability. Under the combination of PTT/PDT, the AuNSs@PDA-Ce6 nanoprobes significantly reduced the growth of 4T1 tumors and suppressed their lung metastasis. All the results demonstrated the considerable potential of AuNSs@PDA-Ce6 phototheranostic nanoprobes for precision theranostics and metastasis inhibition of breast cancer. Epidemiological studies demonstrated that, in postmenopausal women, high circulating levels of testosterone, especially when associated with weight gain, positively correlated with an increased risk of breast cancer because of the augmented production of oestrogen via testosterone aromatization in the adipose tissue. Besides, growing evidence suggests that sulfatase can increase the tissue concentration of bioactive estradiol through the reconversion of estrone sulfate, thus providing a favourable milieu for epithelial cells expressing the oestrogen receptor. In this review, we will discuss how the \"obesity-insulin-testosterone\" connection and the abnormal production of bioactive oestrogen - as a result of the conversion of the androgens by aromatase and the estrone reconversion by sulfatase-, may affect the response to hormone therapy and the outcome of postmenopausal breast cancer patients, and how a combined therapy including metformin, anti-inflammatory drugs, and aromatase/sulfatase inhibitors could successfully improve patient\\'s outcome. Cancer stem cells (CSCs) are quiescent and self-renewing, having low levels of reactive oxygen species (ROS), and are responsible for cancer recurrence after chemotherapy and radiotherapy. However, the interplay between the ROS production and scavenging from the oxidative stress has never been studied in breast CSCs. In this present study, we have investigated\\xa0the cellular energetics of two triple-negative breast cancer stem cells (MDA-MB-231 and MDA-MB-468) treated with two pharmacological doses of vitamin C (10 and 20\\u2009mM) that generated ROS. Our results indicate a differential behavior of ROS scavenging by both the CSCs. MDA-MB-468 CSCs exhibited higher resistance to ROS induced damage owing to the higher antioxidant activity, lower mitochondrial damage, and less decrease in membrane potential (ΔΨ None A number of studies have shown that self-rated health reliably predicts mortality. This study assessed the impact of perseveration on self-rated health, physical functioning, and physical symptoms (pain, fatigue, breast cancer symptoms) among breast cancer patients. We hypothesized that cancer-related distress would serve as an intervening variable between both worry and rumination and self-rated health, physical functioning, and physical symptoms. Women (N\\u2009=\\u2009124) who were approximately 7 weeks post-surgery but pre adjuvant treatment completed the Impact of Events Scale, the Penn State Worry Questionnaire, and the Rumination Scale. They also rated their pain, fatigue, physical functioning, and self-rated health using the RAND-36 and breast cancer symptoms with the Breast Cancer Prevention Trial Symptom Checklist (BCPT). Covariates included body mass index, age, cancer stage, menopause status, and physical comorbidities. Worry was associated with higher cancer-related distress, which in turn predicted greater pain and breast cancer symptoms, poorer physical functioning, and lower self-rated health. Rumination also predicted greater cancer-related distress, which ultimately contributed to greater pain along with poorer physical functioning and self-rated health. Models with fatigue as an outcome were not significant. These findings suggest that perseveration can heighten cancer-related distress and subsequent perceptions of physical symptoms and health among breast cancer patients prior to adjuvant treatment. Perseveration early in the cancer trajectory can adversely increase the impact of a cancer diagnosis and treatment on functioning and quality of life. Fatigue and insomnia are common symptoms experienced by breast cancer patients undergoing adjuvant radiation therapy (RT), yet the underlying mechanisms of these symptoms are unclear. In particular, the roles of hematopoietic stem cells (HSCs) and inflammatory cytokines remain to be elucidated.\\nBreast cancer patients (n\\u2009=\\u2009147) completed questionnaires to longitudinally assess symptoms before, during, and after adjuvant RT. Phlebotomies were performed prior to RT, at the second and fifth treatment fractions, end of treatment (EOT), and 1 month after completing RT, assessing for CD34\\nGeneral fatigue and insomnia worsened with RT, with peak levels observed at EOT, which remained statistically significant even after controlling for anxiety and depression (\\nThis is the first longitudinal study to examine linkages between symptoms, HSCs, and cytokines, demonstrating that fatigue and insomnia shared associations with increasing serum levels of IP-10 and TNF-RII, and mental fatigue was associated with increasing serum levels of MMP-2. Our findings highlight opportunities for further research into mechanisms and potential interventions for these symptoms. Endometriosis is generally considered as a benign condition; however, there is a possibility for it to become cancerous. miR-125b is upregulated in both endometriotic tissues and serum samples of women with endometriosis but its potential targets in endometriosis are still not fully understood.\\nThe role of miR-125b in the regulation of \\nIn this case-control study, the Eu-p and Ec-p samples were collected from 20 women who underwent laparoscopic surgery, and the normal endometrium tissues were collected from 20 controls with no evidence of endometriosis. For bioinformatics approach, a protein-protein interaction network was constructed based on co-expressed potential targets of miR-125b. Quantitative polymerase chain reaction technique was used for the measurement of miR125b and \\nOur results showed that miR-125b was significantly overexpressed in Ec-p (p-value: 0.021). In addition, there was a significant \\nThe negative correlation between miR-125b and  Cyclin-dependent kinase 6 (CDK6) is a potential drug target that plays an important role in the progression of different types of cancers. We performed  It is unclear whether the methyltransferase-like 14 (METTL14) protein promotes or suppresses cancer growth. We examined the association between METTL14 expression, cancer progression, and patient prognosis in a total of 398 breast cancer tissue specimens. Significantly fewer cancer tissue specimens compared with normal breast tissue expressed high levels of METTL14 (52.8% vs. 75.0%). METTL14 expression was negatively associated with tumor grade and positively associated with patient age, estrogen, and progesterone receptor status. High METTL14 expression was more common in luminal A and luminal B tissue (75.9% and 60.8%, respectively), compared with human epidermal growth factor receptor 2- (HER2-) enriched and triple-negative breast cancer (TNBC) samples (38.2% and 18.6%, respectively). In multiple logistic regression analysis, independent predictors of METTL14 expression in breast cancer included higher tumor grade (odds\\u2009ratio\\u2009(OR) = 0.494, 95% confidence interval (CI): 0.289-0.844;  Therapeutic drug monitoring (TDM) in cancer, while imperative, has been challenging due to inter-patient variability in drug pharmacokinetics. Additionally, most pharmacokinetic monitoring is done by assessments of the drugs in plasma, which is not an accurate gauge for drug concentrations in target tumor tissue. There exists a critical need for therapy monitoring tools that can provide real-time feedback on drug efficacy at target site to enable alteration in treatment regimens early during cancer therapy. Here, we report on theranostic optical imaging probes based on shortwave infrared (SWIR)-emitting rare earth-doped nanoparticles encapsulated with human serum albumin (abbreviated as ReANCs) that have demonstrated superior surveillance capability for detecting micro-lesions at depths of 1 cm in a mouse model of breast cancer metastasis. Most notably, ReANCs previously deployed for detection of multi-organ metastases resolved bone lesions earlier than contrast-enhanced magnetic resonance imaging (MRI). We engineered tumor-targeted ReANCs carrying a therapeutic payload as a potential theranostic for evaluating drug efficacy at the tumor site.   There is strong evidence that physical activity (PA) reduces risk, recurrence, and mortality from breast cancer. Emerging data suggest that PA induces changes in inflammatory and immune mediators that may contribute to beneficial effects on breast cancer outcomes. Thus, the goal of this review was to evaluate the evidence linking the protective benefit of PA to modulation of immune responses in breast cancer. A literature search was conducted to identify studies that evaluated the impact of PA on tumor and immune outcomes in breast cancer patients and in mammary tumor models. Nineteen studies investigated the effect of PA interventions on cancer immune outcomes using preclinical breast cancer models. Tumor growth was reduced in 11 studies, unchanged in three studies, and increased in one study. Spontaneous metastasis was reduced in two studies and survival was improved in four studies. Frequently assessed immune outcomes include splenic cell number and function, circulating inflammatory cytokines, and intratumoral immune cells and inflammatory markers. Circulating inflammatory cytokine responses were heterogeneous in preclinical models. Within the tumor microenvironment (TME), several studies documented a change in the infiltration of immune cells with an increase in effector cells and a reduction in immune suppressive cells. Twenty-three studies investigated the effect of PA interventions on immune outcomes in breast cancer patients. Thirteen studies used aerobic PA interventions and 10 studies used a combination of aerobic and resistance exercise interventions. Cycling and treadmill activities were the most commonly used PA modalities. Circulating immune cells and inflammatory cytokines were the most frequently assessed immune outcomes in the clinical studies. Among the 19 studies that evaluated a PA intervention during the post treatment period, 10 reported a reduction in the levels of at least one inflammatory cytokine. No inflammatory cytokines were quantified in the three studies that evaluated a PA intervention during treatment with chemotherapy. Immune outcomes within the tumor were assessed in only one study performing a PA intervention prior to surgery. Results from preclinical and clinical studies suggest that PA exerts heterogeneous effects on inflammatory cytokines, but may alter the gene expression profile and immune infiltrates in the tumor which may result in a reduction in immunosuppressive factors. However, additional studies are needed to better understand the effect of PA on immune outcomes in the TME. The use of gene panels introduces a new dilemma in the genetics field due to the high frequency of variants of uncertain significance (VUS). The objective of this study was to provide evidence that may help in the classification of these germline variants in terms of their clinical impact and association with the disease in question. A total of 52 unrelated women at-risk for HBOC and negative for    The contralateral lateral section (zone IV) of a pedicled transverse rectus abdominis musculocutaneous (TRAM) flap is generally removed intraoperatively. The border of zone IV is usually identified anatomically using the Hartrampf classification. In this study, we used the indocyanine green (ICG) fluorescence method to determine the border of zone IV and find the correlation with clinical flap outcome.\\nThe study recruited breast cancer patients who underwent a pedicled TRAM flap reconstruction. The border of zone IV was identified using the intraoperative ICG fluorescence imaging. The medial border of the removed specimen was sent for a pathological examination of vascular density.\\nA total of 29 patients underwent a pedicled TRAM reconstruction. In 16 patients, the border of zone IV identified by ICG fluorescent imaging was identical to the anatomical border. The ICG imaging showed distinct perfusion patterns, which we divided into 4 categories: sequential, simultaneous, low midline scar, and delayed pattern. Overall, there were no patient with total flap loss, 1 patient had a partial flap loss and 4 patients had a fat necrosis. Neither the ICG perfusion time nor the pathological vascular density correlates with the clinical flap outcome. The delayed ICG perfusion pattern (category IV) has the highest fat necrosis rate, although it is not statistically significant.\\nIn this study, more than half of the patients have ICG perfusion corresponding with the Hartrampf zone, which reflected the conventional practice of zone IV pedicled TRAM flap removal. Some ICG perfusion patterns could be helpful, especially in low midline and delayed pattern. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) awareness has increased, resulting in concerns regarding the safety of implant-based reconstruction. Breast cancer patients are first seen by surgical oncologists, who are therefore potentially the first health-care professionals to encounter concerns regarding BIA-ALCL. We therefore surveyed surgical oncologists on their understanding of BIA-ALCL to better assess potential effects on plastic surgery practice.\\nAn anonymous web-based survey consisting of 9 multiple-choice questions was sent to breast surgical oncologists that are members of the Canadian Society of Surgical Oncology (n = 135).\\nForty-two members responded (n = 42/135, 31%) and all participants were aware of BIA-ALCL. All participants reported that BIA-ALCL has not deterred them from referring patients for implant-based reconstruction. Twenty-two respondents (52%) discuss BIA-ALCL with their patients and 21% (n = 9) believe that BIA-ALCL typically follows a metastatic course. Eight respondents (19%) reported having a poor understanding of BIA-ALCL, while 14% (n = 6) were unable to identify the link to textured implants. There were no statistical differences based on case-load volume.\\nApproximately half of the respondent Canadian breast surgical oncologists discuss BIA-ALCL with their patients, yet there is a knowledge gap in terms of the epidemiology and clinical-pathological course of BIA-ALCL. It is of utmost importance to ensure that the plastic surgery community aims at including surgical oncologist colleagues in educational platforms regarding BIA-ALCL to ensure collaboration and unity in an effort to offer the most accurate information to patients, and prevent misinformation that may deter patients from seeking implant-based reconstruction. Lymphazurin 1% (isosulfan blue dye) is the most frequently used blue dye in the United States, and it is commonly used for sentinel node biopsy in breast cancer patients. Although cases of allergic reaction to lymphazurin have been reported in the general surgery literature, to our knowledge, no cases of an adverse reaction to isosulfan blue have been reported in the plastic surgery literature. We describe a case of an intraoperative biphasic anaphylactic reaction to isosulfan blue in a female patient undergoing bilateral mastectomy and immediate bilateral DIEP breast reconstruction. The severity of her anaphylactic reaction required that we stop flap dissection and abort the reconstruction. Although an allergic reaction is uncommon, recognizing the signs of an acute hypersensitivity reaction is critical to good outcomes in these situations. Given the volume of combined breast oncologic and breast reconstruction surgeries and the increasing number of vascularized lymph node transfer and lymphovenous anastomosis performed annually, it is essential for the plastic surgeon to be cognizant of this rare hypersensitivity reaction. None Roughly 80% of patients undergoing mastectomy in the United States opt for reconstruction with implants. The introduction of acellular dermal matrices has allowed for placement of breast prostheses in the prepectoral plane, while a new carbon dioxide tissue expander (TE) (AeroForm) allows for needle-free, patient-controlled expansion. These 2 novel technologies have ushered in a new patient-centered era of breast reconstruction, with the possibility of reducing patient morbidity for the first time in decades. We hypothesize that AeroForm expanders placed in the prepectoral plane reduce time to second-stage reconstruction, reduce the number of clinic visits, and have lower complications than traditional saline TEs.\\nThis is a retrospective review of all patients undergoing breast mastectomy and TE placement in the prepectoral plane over a 21-month period (169 patients, 267 breasts), comparing AeroForm expanders to TEs.\\nThe AeroForm group (n = 57) had a shorter period to second-stage reconstruction than the TE group (n = 210) (135.4 versus 181.7 days; \\nTwo-staged breast reconstruction with the use of AeroForm expanders in the prepectoral space marks progress in improving care for breast cancer patients by demonstrating a reduction in some adverse events, the number of clinic visits, and the time to second-stage reconstruction. Lower pole breast cancers are challenging to manage because conventional wide local excision may produce a \"bird\\'s beak\" deformity. In an era of oncoplastic surgery, techniques that balance oncological results with cosmetic outcomes such as local flaps have extended the role of breast-conserving surgery. Local flaps are particularly useful for partial breast reconstruction due to the relative simplicity of the surgical procedure and reduced morbidity. Intercostal artery perforator flaps have a shorter duration of surgery than free flaps and do not require microsurgical anastomoses. Anterior intercostal artery perforator (AICAP) flaps provide excellent cosmesis, yet traditional crescenteric harvest yields limited volume for reconstruction. We describe a modification to an established reconstructive technique for lower pole breast defects. The technique is based on 3 extensions of tissue, providing a larger volume of tissue replacement compared with traditional AICAP flaps. The technique is particularly suitable for small- and medium-sized non-ptotic breasts, with lower pole tumors. The modified crescenteric AICAP technique can be used to increase the available tissue when performing lower pole reconstructions. Superior mesenteric artery\\xa0(SMA) syndrome\\xa0has been described in medical literature as a rare cause of duodenal occlusion. It has a varied presentation, with distressing gastrointestinal symptoms such as nausea, abdominal pain, and further weight loss. Several conditions contribute to duodenal obstruction in SMA syndrome. We present a case of SMA syndrome in a patient with malignant breast cancer who presented with sudden onset of severe nausea and voluminous vomiting. Various imaging studies revealed a distended proximal intestine with a transition point in the third part of the duodenum. The patient was managed conservatively with nasogastric decompression and fluid electrolyte management, leading to symptomatic relief. Background Breast cancer (BC) is known to be the second leading cause of cancer deaths after lung cancer in Saudi Arabia. Early detection using screening methods can improve\\xa0disease outcomes. In Saudi Arabia, the rates of BC screening are very low although it is a country that provides free healthcare services. This discrepancy between the availability of free healthcare services and women not utilizing these services necessitates an in-depth understanding of the health-related beliefs and barriers towards BC screening among Saudi women.\\xa0 Objective We aimed to use the Health Belief Model (HBM) to predict the uptake of mammographic screening among Saudi women. The secondary objective was to determine the knowledge, attitudes, and practices related to BC and mammography screening. Research methodology\\xa0 This was an analytical cross-sectional study using a self-administered questionnaire, which consisted of sociodemographic data, family history of BC, general information about BC, and the Champion\\'s Health Belief Model Scale (CHBMS). The study was conducted among Saudi women visiting the King Khalid University Hospital in Riyadh from September 2018 to February 2019. The data were analyzed using\\xa0SPSS Statistics software version 26.00 (IBM, Armonk, NY). Results A total of 401 females participated in the study; the median age of the subjects was 49 years [interquartile range (IQR): 43-53 years]. Among them, 69.6% were married and 21.1% had a family history of BC. There was a statistically significant association of younger age, marital status, and a positive family history of BC with women undergoing mammographic screening (p<0.05). Of the participants, 61.6% knew about the warning signs of BC, while only 59.9% were aware of the risk factors associated with it. The binary logistic regression did not show any significant association between CHBMS and mammogram screening. We concluded that the CHBMS components cannot be used in isolation to predict the risk of not undergoing\\xa0mammogram screening. However, barriers and motivation components along with the knowledge and other factors can be used to predict mammogram screening. Conclusion Among our cohort of Saudi women, 62.1% had general awareness about BC, and younger age, marital status, and positive family history of BC were significantly associated with women undergoing mammography screening.\\xa0The CHBMS components cannot be used in isolation to predict the risk of not undergoing\\xa0mammogram screening, while barriers and motivation components along with the knowledge and other factors can be used to predict mammogram screening. Breast cancer is the most commonly diagnosed form of cancer in women comprising 16% of all female cancers. The disease shows high intertumoral and intratumoral heterogeneity posing diagnostic and therapeutic challenges with unpredictable clinical outcome and response to existing therapy. Mounting evidence is ascertaining that breast cancer stem cells (CSCs) are responsible for tumor initiation, progression, recurrence, evolution, metastasis, and drug resistance. Therapeutics selectively targeting the CSCs based on distinct surface molecular markers and enhanced intracellular activities of these cells continue to evolve and hold significant promise. Having plethora of heterogeneity accompanied with failure of existing conventional therapeutics and poor prognosis, the present review focuses on elucidating the main signaling pathways in breast CSCs as major therapeutic targets. The role of developments in nanomedicine and miRNA as targeted delivery of therapeutic anticancer agents is also highlighted. Breast cancer is the most common cancer in women, and metastasis is the leading cause of death in breast cancer patients. Although chemoprevention is widely employed to treat breast cancer, anticancer drugs can cause significant adverse effects.   To explore the associations between dietary factors and breast cancer (BC) molecular subtypes. The retrospective cases were confirmed by pathological diagnosis with breast cancer were gathered in two major hospitals in Xuzhou city, China, from 2015 to 2016. These cases were classified by the meeting standard of 13th St Gallen: luminal A, luminal B, Her-2 overexpression, and triple-negative breast cancer (TNBC) subtypes. A 1:2 paired retrospective case-control study with 210 cases and 420 controls was conducted to evaluate individual dietary intake, by food frequency questionnaire (FFQ) and estimate odds ratios ( Neurofibromatosis type 1 (NF-1)-also commonly known as Von Recklinghausen\\'s disease-is an autosomal dominant disease that represents a constellation of clinical features. There are well-established links between NF-1 and many tumors; however, the link between NF-1 and breast cancer has more recently been elucidated. While the management of breast cancer is generally well established, there are unique challenges noted in patients with NF-1. There may be delayed presentations due to difficulty in differentiating underlying neurofibroma from a sinister breast mass. Additionally, multiple skin lesions seen in NF-1 create challenges in the interpretation of mammography. Furthermore, a surgical conundrum is created, as these patients appear to have a higher risk of angiosarcoma following radiotherapy. A mastectomy may be the best option as it obviates the need for radiation therapy and ongoing surveillance. A case exemplifying these dilemmas and a review of the literature are presented. Cyclin-dependent kinase 6 (CDK6) is an important regulator of the cell cycle. Together with CDK4, it phosphorylates and inactivates retinoblastoma (Rb) protein. In tumour cells, CDK6 is frequently upregulated and CDK4/6 kinase inhibitors like palbociclib possess high activity in breast cancer and other malignancies. Besides its crucial catalytic function, kinase-independent roles of CDK6 have been described. Therefore, targeted degradation of CDK6 may be advantageous over kinase inhibition. Proteolysis targeting chimeras (PROTACs) structurally based on the cereblon (CRBN) ligand thalidomide have recently been described to degrade the targets CDK4/6. However, CRBN-based PROTACs have several limitations including the remaining activity of immunomodulatory drugs (IMiDs) on Ikaros transcription factors as well as CRBN inactivation as a resistance mechanism in cancer. Here, we systematically explored the chemical space of CDK4/6 PROTACs by addressing different E3 ligases and connecting their respective small-molecule binders  Although genome-wide association studies (GWASs) have successfully identified thousands of risk variants for human complex diseases, understanding the biological function and molecular mechanisms of the associated SNPs involved in complex diseases is challenging. Here we developed a framework named integrative multi-omics network-based approach (IMNA), aiming to identify potential key genes in regulatory networks by integrating molecular interactions across multiple biological scales, including GWAS signals, gene expression-based signatures, chromatin interactions and protein interactions from the network topology. We applied this approach to breast cancer, and prioritized key genes involved in regulatory networks. We also developed an abnormal gene expression score (AGES) signature based on the gene expression deviation of the top 20 rank-ordered genes in breast cancer. The AGES values are associated with genetic variants, tumor properties and patient survival outcomes. Among the top 20 genes,  One of the most consistent models for estimating personalized breast cancer (BC) risk is the Tyrer-Cuzick algorithm that is incorporated into the International Breast Cancer Intervention Study (IBIS) software. Our main objective was to provide criteria for the classification of the Slovenian population, which has BC incidence below the European average, into risk groups, and to evaluate the integration of the criteria in Slovenian guidelines. Our main focus was on women age <50 with higher BC risk, since no organized BC screening is available for these women.\\nSlovenian age-specific BC risks were incorporated into IBIS software and threshold values of risk categories were determined. Risk categories were assigned according to the individual\\'s ten-year risk for women aged 40 and older, and lifetime risk for women between 20 and 39. To test the software, we compared screening strategies with the use vs. no use of IBIS.\\nOf the 197 women included in the study IBIS assigned 75.1% to the BC risk group, and the rest to the moderately increased risk. Without IBIS 80 women were offered mammographic and 33 ultrasound screening. In contrast, 28 instead of 80 would have been offered mammographic screening and there would have been no referrals for ultrasound if IBIS had been used.\\nThe Slovenian IBIS has been developed, tested and suggested for personalized breast cancer risk assessment. The implementation of the software with the consideration of Slovenian risk thresholds enables a more accurate and nationally unified assessment.\\nTrenutno je kot najdoslednejši model za oceno individualizirane ogroženosti za raka dojk razpoznan Tyrer-Cuzickov algoritem, vključen v program IBIS (International Breast Cancer Intervention Study), ki temelji na angleških podatkih o incidenci raka dojk. Glavni cilj naše raziskave je bil postaviti merila za razvrščanje slovenskih žensk, ki imajo ogroženost za raka dojk pod evropskim povprečjem, v skupine ogroženosti glede na izračun ogroženosti z uporabo programa IBIS. Prav tako smo želeli oceniti morebitno vpeljavo teh meril v slovenske smernice. Poseben poudarek je namenjen bolj ogroženim pod petdesetim letom starosti, saj za ženske v teh starostnih skupinah nimamo organiziranega presejanja.\\nV program IBIS smo umestili slovensko generacijsko specifično incidenco raka dojk in določili mejne vrednosti skupin ogroženosti (populacijska, zmerno povečana in visoka). Skupine ogroženosti so bile določene na podlagi 10-letne ogroženosti za ženske, ki so stare 40 let ali več, in doživljenjske ogroženosti za ženske, stare med 20 in 39 let. S programom IBIS smo izračunali ogroženost za raka dojk za ženske, ki so prišle na preventivni pregled v okviru primarnega in sekundarnega zdravstvenega varstva, in primerjali priporočila, ki so bila svetovana po pregledu, s priporočili, ki bi veljala, če bi uporabili program IBIS.\\nV raziskavo smo vključili 197 žensk in za vsako posameznico izračunali ogroženost za raka dojk s pomočjo programa IBIS. Program je 75,1 % žensk umestil v skupino populacijsko ogroženih, ostale pa v skupino zmerno povečane ogroženosti. Brez uporabe IBIS-a je bilo 80 žensk umeščeno v bolj ogroženo skupino, opravile so presejalno mamografijo, 33 ženskam pa so opravili ultrazvočno preiskavo dojk. Če bi uporabili nova merila razvrščanja v skupine ogroženosti s pomočjo izračuna programa IBIS, bi jih 28 namesto 80 opravilo presejalno mamografijo. Prav tako ne bi nobene ženske po novih merilih poslali na ultrazvočno preiskavo dojk.\\nRazvili smo program IBIS, ki vsebuje slovensko populacijsko incidenco raka dojk. Program smo testirali in predlagali za orodje izračunavanja individualizirane ogroženosti za raka dojk. Uvedba programa bi, ob upoštevanju enotnih mejnih vrednosti kategorij ogroženosti, omogočala natančnejšo in bolj poenoteno obravnavo žensk na državni ravni. Tumor necrosis factor-α-induced protein 8-like 1 (TIPE1) functions as a tumor suppressor in several types of cancer, including lung and breast cancer. The present study aimed to determine the level of expression and the function of TIPE1 in ovarian cancer. TIPE1 expression was determined in tissue microarrays and ovarian cancer cells, and these data were analyzed to assess the association between TIPE1 expression and prognosis in patients with ovarian cancer. The potential antitumor effects of TIPE1 were investigated  Pseudolaric acid B (PAB) is a diterpene-type acid isolated from the root and trunk bark of  The aim of the present study was to investigate the role of edema surrounding breast cancer masses in the prognostic prediction of magnetic resonance imaging (MRI) T2-weighted fat suppression sequence. For this purpose, 80 patients with mass-type breast cancer underwent conventional plain breast MRI, dynamic contrast-enhanced (DCE)-MRI or diffusion-weighted MRI scan. The associations between edema around the mass on MRI T2 fat suppression sequence plain scan and tumor stage, pathological findings, immunohistochemical findings and axillary lymph node metastasis were analyzed. The results revealed the presence of edema around the mass on the MRI T2 fat suppression sequence plain scan in 35 patients. By contrast, there was no abnormal enhancement on the DCE-MRI, and the apparent diffusion coefficient value did not decrease in these areas. Compared with the remaining 45 patients, the 35 patients with peritumoral edema exhibited a higher tumor stage and a higher rate of axillary lymph node metastasis (all P<0.05). However, there was no significant difference in pathological classification or the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (as determined by immunohistochemistry) between the two groups. In total, 12 cases of tumor shrinkage during neoadjuvant chemotherapy were accompanied by an improvement in edema. Taken together, the findings of the present study indicated that the presence of edema around the mass on the MRI T2 fat suppression sequence may predict poor prognosis in patients with mass-type breast cancer. Furthermore, the improvement of the peritumoral edema post-neoadjuvant chemotherapy may also be a predictor of a more favorable prognosis. [This corrects the article DOI: 10.1155/2019/8607859.]. The epigenetic effects of transmission of certain regulatory molecules, such as miRNAs, through maternal milk on future generations, are still unknown and have not been fully understood yet. We hypothesized that breastfeeding regularly by adoptive-mother may cause transmission of miRNAs as epigenetic regulating factors to the infant, and the marriage of milk-siblings may cause various pathologies in the future generations.\\nA cross-fostering model using a/a and \\nOur findings support for the first time that the factors modifying the epigenetic mechanisms may be transmitted by breast milk and these epigenetic interactions may be transferred transgenerationally. Results also suggested hereditary epigenetic effects of cross-fostering on future generations and the impact of mother-infant dyad on epigenetic programming. Breast cancer is the most frequent malignant tumor in women, and the estrogen receptor (ER) plays a vital role in the vast majority of breast cancers. The purpose of the present study was to identify the significant genes regulated by ER in ER-positive breast cancer and to explore their expression pattern changes when tamoxifen or fulvestrant resistance occurs. For this purpose, the gene expression profiles GSE11324, GSE27473, and GSE5840 from the Gene Expression Omnibus database were used, which contain gene expression data from MCF7 cells treated with estrogen, MCF7 cells with silencing of ER, and tamoxifen- and fulvestrant-resistant MCF7 cells treated with estrogen (17β-estradiol), respectively. Differentially expressed genes (DEGs) between the treatment group and negative control were identified and subjected to pathway enrichment and protein-protein interaction (PPI) analyses. There were 230 DEGs in common among the three datasets, including 160 genes positively regulated by ER and 70 genes negatively regulated by ER. DEGs mainly showed enrichment for pathways in cancer, progesterone-mediated oocyte maturation, RNA transport, glycerophospholipid metabolism, oocyte meiosis, platelet activation, and so on. PPI network and modular analysis selected three significant clusters containing 19 genes. A total of 44 genes were involved in Kyoto Encyclopedia of Gene and Genome pathway results or PPI modular analysis, and 16 of them were found to correlate with relapse-free survival in patients with ER Recently, cancer has been characterized as a heterogeneous disease composed of many different subtypes. Early diagnosis of cancer subtypes is an important study of cancer research, which can be of tremendous help to patients after treatment. In this paper, we first extract a novel dataset, which contains gene expression, miRNA expression, and isoform expression of five cancers from The Cancer Genome Atlas (TCGA). Next, to avoid the effect of noise existing in 60, 483 genes, we select a small number of genes by using LASSO that employs gene expression and survival time of patients. Then, we construct one similarity kernel for each expression data by using Chebyshev distance. And also, We used SKF to fused the three similarity matrix composed of gene, Iso, and miRNA, and finally clustered the fused similarity matrix with spectral clustering. In the experimental results, our method has better  The liver is an immunologically tolerant organ and a common site of distant metastasis for various cancers. The expression levels of glucose-regulated protein 78 (GRP78) have been associated with tumor malignancy. Secretory GRP78 (sGRP78) released from tumor cells contributes to the establishment of an immunosuppressive tumor microenvironment by regulating cytokine production in macrophages and dendritic cells (DCs). However, the role of sGRP78 on tumor cell colonization and metastasis in the liver remains unclear. Herein, we found that GRP78 was expressed at higher levels in the liver compared to other tissues and organs. We performed intravital imaging using a sGRP78-overexpressing breast cancer cell line (E0771) and found that sGRP78 interacted with dendritic cells (DCs) and F4/80 G protein-coupled estrogen receptor 1 (GPER1), is a functional estrogen receptor involved in estrogen related actions on several systems including processes of the nervous, reproductive, metabolic, cardiovascular, and immune system. Regarding the latter, GPER is expressed in peripheral B and T lymphocytes as well as in monocytes, eosinophils, and neutrophils. Several studies have implicated GPER in immune-mediated diseases like multiple sclerosis, Parkinson\\'s disease, and atherosclerosis-related inflammation, while a recent report suggests that its deletion could be responsible for a form of familial immunodeficiency. It has also been suggested that it is a key regulator of immune-mediated events in breast, pancreatic, prostate, and hepatocellular cancer as well as in melanoma. GPER has been also reported to interact with classic ER-alpha or its splice variants in order to modify immune functions. This review aims to present current knowledge relating GPER to immune functions, the cellular and signaling pathways involved, as well as the potential clinical implications of GPER modulation in immune-related diseases. Globally, breast cancer is the most common malignancy in women and the second most common cause of cancer-related death among women. There is therefore a need to identify more efficacious therapies for this neoplasm.  Polysaccharides isolated from SD were analyzed using Fourier transform infrared (FT-IR) spectroscopy and gas chromatography-mass spectroscopy (GC-MS). Their effects on cell growth of U937, MCF-7, and MDA-MB-231, and tumor growth in a mouse MDA-MB 231 xenograft model were examined. Their role in U937 activation, MCF-7, and MDA-MB 231 cytokine release profiles were also tested.\\nIn vitro studies showed that SD polysaccharides (SDPs) promoted U937 cell growth dose-dependently, with no obvious effect on growth of breast cancer cell lines MCF-7 and MDA-MB-231. SDP also showed an antagonistic effect against the growth inhibition of U937 by the culture supernatants of MCF-7 and MDA-MB-231, and reversed the polarization status of U937. Treatment of SCID mice bearing MDA-MB-231-derived xenograft tumors with SDP significantly reduced tumor growth. At all tested concentrations, no obvious toxic side-effects were recorded.\\nWe tentatively concluded that SDPs potently promote the growth of U937 and activate it to inhibit the tumor growth of SCID mice bearing MDA-MB-231-derived xenograft tumors indirectly, with no obvious growth inhibition effects on MCF-7 and MDA-MB-231 in vitro. Our finding indicated that SDP could be a potential anticancer agent for breast cancer. An angiogenesis assay was performed by seeding A549 cells on extracellular matrix solution and observing tube formation using an inverted microscope. Enzyme-linked immunosorbent assay for αvβ3, matrix metalloproteinase (MMP)-2, and MMP-9 was performed by analyzing the cell lysate after a given treatment.\\nOS ethanolic extract significantly inhibited tube formation of A549 cells and suppressed the expression of integrin αvβ3, MMP-2, and MMP-9.\\nOur findings indicate that OS ethanolic extract disrupts angiogenesis of A549 cells, which may result from the disruption of cell migration and proliferation as a consequence of downregulation of αvβ3, MMP-2, and MMP-9. Taken together, OS ethanolic extract may represent a good therapeutic candidate for the treatment of metastasis in lung adenocarcinoma. Further studies are warranted to further establish the efficacy of OS in the treatment of lung adenocarcinoma.  Neoadjuvant chemotherapy (NAC) using the combination of anthracycline and taxanes is the standard regimen for patients with primary breast cancer. Among the taxanes, conventional paclitaxel (PTX) and docetaxel have usually been adopted in the neoadjuvant or adjuvant setting. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a solvent-free formulation that can be delivered to cancer cells at higher doses than conventional PTX. This study is a retrospective observational study in a single institution. We evaluated the efficacy and safety of nab-PTX followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) in the neoadjuvant setting. In this study, 50 patients with primary breast cancer received nab-PTX (q3w, 260 mg/m Cathepsin G (CG), a neutrophil serine protease, induces cell migration and multicellular aggregation of human breast cancer MCF-7 cells. It has been suggested that tumor cell aggregates are associated with tumor embolism, thus CG-induced cell aggregation may promote tumor metastasis. We have revealed that cell aggregation is caused by elevated free insulin-like growth factor (IGF)-1 in the medium, followed by activation of IGF-1 receptor (IGF-1R). However, the molecular mechanism underlying IGF-1 elevation induced by CG remains unclear. Here, we aimed to elucidate the mechanism by examining the degradative effects of CG on IGF-1, and the IGF binding proteins (IGFBPs), which interfere with the binding of IGF-1 to its receptor. CG specifically evoked MCF-7 cell aggregation at less than 1\\u2009nM in a dose-dependent manner, however, neutrophil elastase (NE), chymotrypsin, and trypsin did not. Free IGF-1 concentration was continuously elevated in the medium of cells treated with CG, whereas treatments with other serine proteases resulted in only a transient or slight increase. IGFBP-2, the predominant IGFBP in MCF-7 cells, was gradually digested by CG. CG did not cleave IGF-1 for at least 48\\u2009h, whereas other proteases completely digested it. Moreover, CG induced continuous phosphorylation of IGF-1R and Akt, whereas NE-induced phosphorylation was transient, possibly due to insulin receptor substrate (IRS)-1 digestion. These results indicated that CG-specific IGF-1 elevation in the medium is caused by digestion of IGFBP-2, not IGF-1. Hence, this study clarifies the molecular mechanism of CG-specific cell aggregation. Quinazolines 1 to 6, with an aromatic or aryl-vinyl substituent in position 2 are selected with the aim to compare their structures and biological activity. The selection includes a natural alkaloid, schizocommunin, and the synthetic 2-(2\\'-quinolyl)-3H-quinazolin-4-one, known to interact with guanine-quadruplex dependent enzymes, respectively telomerase and topoisomerase.\\nBreast cancer cells of the MDA cell line have been used to study the bioactivity of the tested compounds by the method of Comet Assay and FACS analyses. We model observed effects assuming stacking interactions of studied heterocycles with a naked skeleton of G-quadruplex, consisting of guanine quartet layers and potassium ions. Interaction energies are computed using a dispersion corrected density functional theory method, and an electron-correlated molecular orbital theory method.\\nSelected compounds do not remarkably delay nor change the dynamics of cellular progression through the cell cycle phases, while changing significantly cell morphology. Our computational models quantify structural effects on heterocyclic G4-complex stabilization energies, which directly correlate with observed biological activity.\\nOur computational model of G-quadruplexes is an acceptable tool for the study of interaction energies of G-quadruplexes and heterocyclic ligands, predicting, and allowing design of novel structures.\\nGenotoxicity of quinazolin-4-one analogues on human breast cancer cells is not related to molecular metabolism but rather to their interference with G-quadruplex regulatory mechanisms. Computed stabilization energies of heterocyclic ligand complexes of G-quadruplexes might be useful in the prediction of novel telomerase / helicase, topoisomerase and NA polymerase dependent drugs. The purpose of the study is to evaluate long-term clinical outcomes and prognostic factors after accelerated partial breast irradiation (APBI) in the elderly using high-dose-rate interstitial multicatheter brachytherapy (HIBT).\\nBetween 2005 and 2018, 109 patients underwent APBI using HIBT (34\\xa0Gy/10f/5d or 32\\xa0Gy/8f/4d). Based on a prospective database, outcomes were retrospectively analyzed (local relapse-free survival, metastatic-free survival, specific survival (SS), and overall survival (OS)). Prognostic factors were investigated. Late toxicity and cosmetic evaluation were reported.\\nWith a median followup of 97\\xa0months [7-159], median age was 81.7\\xa0years [58-89]. In accordance with the GEC-ESTRO APBI classification, 72.5%, 11.9%, and 15.6% were classified as low, intermediate, and high risk, respectively. The histological type was mainly invasive ductal carcinoma (87.1%). The median tumor size was 10\\xa0mm [range 1-35]. Eight-year local relapse-free survival, SS, and OS were 96.7% [95% confidence interval (CI) [0.923; 1]), 96.7% [95% CI [0.924; 1], and 72% [95% CI [0.616; 0.837], respectively. In univariate analysis, APBI classification was not considered as prognostic factor, whereas molecular classification was prognostic factor for OS (p < 0.0001), SS (p\\xa0= 0.007), and metastatic-free survival (p\\xa0= 0.009) but not for local recurrence (p\\xa0= 0.586). No Grade ≥3 late toxicity was observed, whereas 61 patients (88.4%) and 8 patients (11.6%) presented Grade 1 and 2 toxicities, respectively. The cosmetic outcome was excellent/good for 96.4%.\\nLong-term followup confirms that HIBT is safe and effective for elderly early breast cancer. Our results suggest that selected elderly women presenting with high-risk breast cancer could be also considered for APBI. Ras-GTPase activating protein SH3-domain-binding proteins (G3BP) are a small family of RNA-binding proteins implicated in regulating gene expression. Changes in expression of G3BPs are correlated to several cancers including thyroid, colon, pancreatic and breast cancer. G3BPs are important regulators of stress granule (SG) formation and function. SG are ribonucleoprotein (RNP) particles that respond to cellular stresses to triage mRNA resulting in transcripts being selectively degraded, stored or translated resulting in a change of gene expression which confers a survival response to the cell. These changes in gene expression contribute to the development of drug resistance. Many RNA viruses, including Chikungunya (and potentially Coronavirus), dismantle SG so that the cell cannot respond to the viral infection. Non-structural protein 3 (nsP3), from the Chikungunya virus, has been shown to translocate G3BP away from SG. Interestingly in cancer cells, the formation of SG is correlated to drug-resistance and blocking SG formation has been shown to reestablish the efficacy of the anticancer drug bortezomib.\\nChikungunya nsP3 was transfected into breast cancer cell lines T47D and MCF7 to disrupt SG formation. Changes in the cytotoxicity of bortezomib were measured.\\nBortezomib cytotoxicity in breast cancer cell lines changed with a 22 fold decrease in its IC\\nChikungunya nsP3 disrupts SG formation. As a result, it increases the cytotoxicity of the FDA approved drug, bortezomib. In addition, the increased cytotoxicity appears to correlate to improved bortezomib selectivity when compared to control cell lines. This historical surgical retrospection focuses on the temporal de-escalation axillary surgery, focusing on the unceasing efforts of researchers toward new challenges, as documented by extensive studies and trials. Axillary surgery has evolved, aiming to offer the best oncologic treatment and improve the quality of life of women. Axillary lymph-node dissection (ALND) has been replaced by sentinel lymph-node biopsy (SLNB) in women with early clinically node-negative breast cancer, providing adequate axillary nodal staging information with minimal morbidity, and becoming the standard of care in the management of breast cancer. However, this is only the beginning. Strategies in defining systemic and radiotherapeutic treatments have gradually been optimized, offering increasingly refined and targeted breast cancer treatment tools. In recent years, the paradigm of completion ALND after a positive SLNB has been questioned, and several studies have led to revolutionary changes in clinical practice. Moreover, the increasingly pivotal role played by neoadjuvant chemotherapy (NAC) has had a profound effect on the extent of axillary surgery, paving the way to a more finite \"targeted\" procedure in women with node-positive breast cancer who convert to negative nodes clinically after NAC. The utility of SLNB itself and its subsequent omission in women with negative nodes clinically and breast conservative surgery is also under scientific evaluation. The changes over time in the surgical approach to breast cancer have been numerous and significant. The novel emerging perspective characterized by recent advances in biology and genetics, in dedicated axillary ultrasound imaging and chemotherapy regimens, is the present reality that points to the future of axillary node treatment in breast cancer. With the unprecedented urbanization light pollution has emerged as a ubiquitous problem, and there has been accumulating evidence on the links between exposure to light at night (LAN) and breast cancer risk. We conducted a systematic review and meta-analysis of published studies on the associations between LAN exposure and breast cancer risk.\\nWe included all observational human studies wherein the exposure variable was LAN measured in indoor and outdoor environments, and the outcome was breast cancer. We employed summary relative risks (SRR) for breast cancer by comparing highest versus lowest categories of LAN exposure within a random-effects model. The National Toxicology Program\\'s (NTP) Office of Health Assessment and Translation (OHAT) risk of bias rating tool was adopted to assess the risk of bias in individual studies and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guideline was employed to assess confidence in the body of evidence.\\nA total 14 studies comprising four cohorts (13,155 cases among 373,153 exposed subjects), nine case-control and one case-referent studies of female subjects (39,757 cases and 21,541 controls) across seven countries and published between 2001 and 20 were included for review. Participants in the highest LAN exposure category were associated with higher risk of breast cancer in reference to those in the lowest (SRR: 1.12; 95% CI: 1.06-1.18; I\\nLAN exposure was consistently associated with higher breast cancer risk corroborating NTP\\'s recommendations which anticipates excessive LAN as human carcinogen. Insufficient T cell infiltration in triple-negative breast cancer (TNBC) has limited its response rate to immune checkpoint blockade (ICB) therapies and motivated the development of immunostimulatory approaches to enhance the ICB therapy. CXCR4 is a chemokine receptor highly upregulated both on cell surface and cytoplasm in tumor tissues. Activating CXCR4 has been associated with increased immunosuppression in the tumor microenvironment. Here, we developed a CXCR4-targeted liposomal formulation (Liposomal-AMD3100) to enhance therapeutic efficacy of AMD3100, a CXCR4 antagonist. Particularly, AMD3100 is not only encapsulated into the liposome but coated on the surface of the formulation to serve as a targeting moiety and a dual blocker capable of inhibiting CXCR4 activation extracellularly and intracellularly. The Liposomal-AMD3100 remodeled both immune and stromal microenvironment more efficiently compared with free AMD3100, indicating better pharmacodynamic profile of AMD3100 achieved by liposomal formulation. The combination of anti-PD-L1 with Liposomal-AMD3100 formulation exhibited an increased antitumor effect and prolonged survival time compared with monotherapies in a murine TNBC model (4T1). This work proves that immune activation via liposomal delivery of CXCR4 inhibitors has a great potential to expand ICB therapies to originally ICB-insensitive cancer types. While animal data support an association between prenatal exposure to endocrine disrupting chemicals (EDCs) and altered mammary gland development and tumorigenesis, epidemiologic studies have only considered a few classes of EDCs in association with pubertal growth and development in girls. Polycyclic aromatic hydrocarbons (PAH) are a class of EDCs that have not been rigorously evaluated in terms of prenatal exposure and pubertal growth and development in girls.\\nIn a New York City birth cohort of Black and Hispanic girls (n\\xa0=\\xa0196; recruited 1998-2006), we examined associations of prenatal PAH exposure with self-reported age at growth spurt onset, breast development onset and menarche, and clinical measures of adolescent body composition including body mass index, waist-to-hip ratio, and body fat measured at ages 11-20 years.\\nWe measured prenatal exposure to PAH using personal air monitoring data collected from backpacks worn by mothers during the third trimester of pregnancy (data available for all 196 girls) and biomarkers of benzo[α]pyrene-DNA adducts in umbilical cord blood (data available for 106 girls). We examined associations of prenatal PAH with the timing of pubertal milestones and adolescent body composition (11-20 years) using multivariable linear regression models adjusted for race/ethnicity, household public assistance status at birth, and age at outcome assessment. We also fit models further adjusted for potential mediators, including birthweight and childhood body size (BMI-for-age z-score measured at 6-8 years).\\nGirls in the highest versus lowest tertile of ambient exposure to PAH, based on a summary measure of eight carcinogenic higher-molecular weight non-volatile PAH compounds (Σ8 PAH), had a 0.90 year delay in growth spurt onset (95% confidence interval (CI)\\xa0=\\xa00.25, 1.55; n\\xa0=\\xa0196), a 0.35 year delay in breast development onset (95% CI\\xa0=\\xa0-0.26, 0.95; n\\xa0=\\xa0193), and a 0.59 year delay in menarche (95% CI\\xa0=\\xa00.06, 1.11; n\\xa0=\\xa0191) in models adjusted for race/ethnicity and household public assistance at birth. The statistically significant associations for age at growth spurt onset and menarche were not impacted by adjustment for birthweight or childhood body size. No differences in BMI-for-age z-score, waist-to-hip ratio, or percent body fat were found between girls in the highest versus lowest tertile of ambient Σ8 PAH. Results were similar when we evaluated benzo[α]pyrene-DNA adduct levels.\\nOur results suggest that prenatal exposure to PAH might delay pubertal milestones in girls, but findings need to be replicated in other cohorts using prospectively collected data on pubertal outcomes. None A higher vitamin D intake improves the prognosis of early stage breast cancer (BC) patients. We hypothesized that vitamin D intake should refer to vitamin D receptor (VDR) expression. In order to prove this hypothesis, we first intend to evaluate the correlation between VDR expression and prognosis of BC patients using meta-analysis.\\nLiteratures from PubMed, Embase, and the Cochrane Library (last update by May 20, 2020) were retrieved to find studies assessing the prognostic role of VDR in BC. The hazard ratios (HRs) for patients\\' survival were extracted for pooled analyses. Subgroup analysis, sensitivity analysis and meta-regression were performed to explore the sources of heterogeneity.\\nSeven articles containing eight studies with 2503 patients were enrolled. The results from the pooled analyses showed that the VDR expression generally had no relationship with BC patients\\' overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and progression-free survival (PFS) (P\\u2009>\\u20090.05). Because only the number of studies exploring the relationship between VDR expression and OS is greater than five and there is heterogeneity, we explored the sources of heterogeneity of these studies. Subgroup analyses showed that the VDR expression in the nucleus had no relationship with OS, but high total VDR expression in the nucleus and cytoplasm was related to a better OS (pooled HR\\u2009=\\u20090.41; 95% CI\\u2009=\\u20090.18-0.95; P\\u2009=\\u20090.038). In addition, in subgroup of studies using cut-off values other than \\'immunoreactive score (IRS)>5\\' and \\'IRS\\u2009>\\u200925\\', high VDR expression was associated with a better OS (pooled HR\\u2009=\\u20090.47; 95% CI\\u2009=\\u20090.30-0.74; P\\u2009=\\u20090.001). Sensitivity analysis showed that the result pattern was not obviously affected by any single study. Meta-regression showed that the source of heterogeneity was not country (P\\u2009=\\u20090.657), pathological type (P\\u2009=\\u20090.614), molecular type (P\\u2009=\\u20090.423), staining location (P\\u2009=\\u20090.481), or cut-off value (P\\u2009=\\u20090.509).\\nThe protein expression level of VDR in entire BC cells evaluated by immunohistochemistry is related to the OS of BC patients. It is expected that a more individualized vitamin D intake and a more accurate prognosis assessment can be recommended for BC patients based on the VDR expression. Of course, more preclinical and clinical studies are needed. Cancer diagnosis and therapy is quickly moving from the traditional histology-based approaches to genomic stratification, providing a huge opportunity for radiogenomics, associating imaging features with genomic data. Genome sequencing is time consuming, expensive and invasive whereas  Gender parity within academic oncology is important. We hypothesized that gender differences exist in subspecialty choice and academic rank among medical oncologists. We performed a cross-sectional study of adult medical oncologists at the top 15 cancer centers. Gender, rank, subspecialty (breast, thoracic, gastrointestinal, and genitourinary) and board certification year were recorded. 570 medical oncologists were identified (60% men; 40% women). More women practice breast oncology (OR 3.1,  Chondrosarcomas are rare cartilage-like mesenchymal tumors. Some rib-sited tumors can mimic other common tumors. We present the case of a 24-year-old female with chondrosarcoma of the fourth left rib, mimicking breast cancer. Complete resection with chest wall reconstruction was performed successfully with good prognostic results. Physicians should bear in mind the possibility of a primary chest wall tumor mimicking breast cancer that needs a different therapeutic strategy. Complete surgical resection and chest wall reconstruction is the mainstay of treatment for chondrosarcoma. None In Korean women, a westernized lifestyle is associated with an increased risk of breast cancer. Fertility preservation has become an increasingly important issue for women with breast cancer, in accordance with substantial improvements in survival rate after cancer treatment. The methods of controlled ovarian hyperstimulation (COH) for fertility preservation in breast cancer patients have been modified to include aromatase inhibitors to reduce the potential harm associated with increased estradiol levels. Random-start COH and dual ovarian stimulation are feasible options to reduce the total duration of fertility preservation treatment and to efficiently collect oocytes or embryos. Using a gonadotropin-releasing hormone agonist as a trigger may improve cycle outcomes in breast cancer patients undergoing COH for fertility preservation. In young breast cancer patients with BRCA mutations, especially BRCA1 mutations, the possibility of diminished ovarian reserve may be considered, although further studies are necessary. Herein, we review the current literature on the practical issues surrounding COH for fertility preservation in women with breast cancer. Pathogenic variants in the BRCA1 and BRCA2 genes increase the risk of breast and ovarian cancer. Individuals with identified pathogenic variants in the BRCA1 or BRCA2 gene can benefit from cancer risk-reducing strategies. In the recent years, there has been an increase in the demand of genetic services. In light of the ongoing COVID19 pandemic, alternatives to face-to-face consultations have had to be considered and adopted, including telemedicine. Informed consent is necessary for genetic testing. Studies have suggested that increased levels of cancer-specific distress may impair the patient\\'s ability to retain information, therefore, providing informed consent. This systematic review and meta-analysis aimed to answer if telephone genetic counseling for BRCA1 and BRCA2 genetic testing is non-inferior to in-person genetic counseling for the outcomes of cancer-specific distress and genetic knowledge. Databases of Medline, Embase, PsycINFO, CINAHL, SciELO, Web of Science, CENTRAL, ProQuest Dissertation & Theses Database, Clinicaltrials.gov, EU clinical trials register were accessed to identify any published or unpublished relevant literature. Random-effects models were used for the meta-analysis. Four studies were included in the qualitative synthesis of the results. Three studies were included in the quantitative synthesis of the results. Telephone genetic counseling was non-inferior compared to in-person genetic counseling for the outcomes of cancer-specific distress and genetic knowledge. Sensitivity analysis corroborated the main results. Telephone genetic counseling for BRCA1/BRCA2 genetic testing may be an alternative model of delivering genetic services in front of the increased demand/or when required by social context. However, the paucity of the evidence prevents from drawing strong conclusions regarding the generalizability of these results. Further research is needed to strengthen the conclusions. We report a case of a 55-year-old woman with left breast cosmetic augmentation performed 5\\xa0years earlier, showing at ultrasound a left small amount of peri-implant effusion suspicious for an anaplastic large cell lymphoma localization. The final diagnosis was obtained by cytology using a small amount of fluid (6\\xa0ml). Subsequently, hybrid 18F-FDG PET/MRI was used for pre-operative staging and follow-up. An appropriate management of BIA-ALCL could be obtained even in cases of a small amount of peri-implant effusion, using a comprehensive approach of clinical and imaging evaluation, including PET/MRI as useful and innovative staging imaging technique. Endothelial-mesenchymal transition (EndMT) is the transformation of endothelial cell morphology to mesenchymal cell morphology, accompanied by decline of endothelial function and enhancement of mesenchymal function, which promotes tumor progression and tumor cell invasion and metastasis. 27-Hydroxycholesterol (27-HC) is a cholesterol metabolite, which has a high content in human blood. 27-HC promotes breast cancer cell proliferation, invasion, and migration. We previously showed that 27-HC promotes EndMT; however, the underlying mechanism still needs to be further explored. We studied the role of the 14-3-3η/GSK-3β/β-catenin complex in EndMT. Our results show that 27-HC induces oxidative stress in HUVECs and activates the p38 signaling pathway, thereby inhibiting the binding of 14-3-3η/GSK-3β/β-catenin, promoting the increase of free β-catenin and nuclear translocation, and finally inducing EndMT. Treatment with N-acetylcysteine (NAC) blocked 27-HC-induced ROS generation and p38 signaling pathway activation, prevented β-catenin from release from binding, and inhibited EndMT. Blocking ROS production or p38 signaling or knocking down 14-3-3η inhibited 27-HC-induced EndMT and inhibited breast cancer cell metastasis. These findings indicate 14-3-3η is necessary for interactions between the p38 kinase and the GSK-3β/β-catenin complex and serves as an adaptor to transmit the upstream kinase signal to the downstream signal, thereby promoting EndMT and breast cancer cell migration. The study aimed to investigate the role of spindle assembly checkpoint (SAC) in cancer cells with compromised genomic integrity. Chromosomal instability (CIN) gives cancer cells an adaptive advantage. However, maintaining the balance of this instability is crucial for the survival of cancer cells as it could lead them to the mitotic catastrophe. Therefore, cancer cells adapt to the detrimental effects of CIN. We hypothesized that changes in SAC might be one such adaptation mechanism. The focus of the study was BUB1B, an integral part of the checkpoint.\\nClinical datasets were analyzed to compare expression levels of SAC genes in normal tissue vs. breast carcinoma. The effects of the reduction of BUB1B expression was examined utilizing RNA interference method with siRNAs. In vitro viability, clonogenicity, apoptosis, and SAC activity levels of a variety of breast cancer (BrCa) cell lines, as well as in vivo tumorigenicity of the triple-negative breast cancer (TNBC) cell line MDA-MB-468, were tested. Additionally, the chromosomal stability of these cells was tested by immunofluorescence staining and flow cytometry.\\nIn clinical breast cancer datasets, SAC genes were elevated in BrCa with BUB1B having the highest fold change. BUB1B overexpression was associated with a decreased probability of overall survival. The knockdown of BUB1B resulted in reduced viability and clonogenicity in BrCa cell lines and a significant increase in apoptosis and cell death. However, the viability and apoptosis levels of the normal breast epithelial cell line, MCF12A, were not affected. BUB1B knockdown also impaired chromosome alignment and resulted in acute chromosomal abnormalities. We also showed that BUB1B knockdown on the MDA-MB-468 cell line decreases tumor growth in mice.\\nA functional spindle assembly checkpoint is essential for the survival of BrCa cells. BUB1B is a critical factor in SAC, and therefore breast cancer cell survival. Impairment of BUB1B has damaging effects on cancer cell viability and tumorigenicity, especially on the more aggressive variants of BrCa. Active growth hormone (GH) signaling triggers cellular growth and invasion-metastasis in colon, breast, and prostate cancer. Curcumin, an inhibitor of NF-ҡB pathway, is assumed to be a promising anti-carcinogenic agent. Atiprimod is also an anti-inflammatory, anti-carcinogenic agent that induces apoptotic cell death in hepatocellular carcinoma, multiple myeloma, and pituitary adenoma. We aimed to demonstrate the potential additional effect of atiprimod on curcumin-induced apoptotic cell death via cytokine expression profiles in MCF-7 and MDA-MB-231 cells with active GH signaling. The effect of curcumin and/or atiprimod on IL-2, IL-4, and IL-17A levels were measured by ELISA assay. MTT cell viability, trypan blue exclusion, and colony formation assays were performed to determine the effect of combined drug exposure on cell viability, growth, and colony formation, respectively. Alteration of the NF-ҡB signaling pathway protein expression profile was determined following curcumin and/or atiprimod exposure by RT-PCR and immunoblotting. Finally, the effect of curcumin with/without atiprimod treatment on Reactive Oxygen Species (ROS) generation and apoptotic cell death was examined by DCFH-DA and Annexin V/PI FACS flow analysis, respectively. Autocrine GH-mediated IL-6, IL-8, IL-10 expressions were downregulated by curcumin treatment. Atiprimod co-treatment increased the inhibitory effect of curcumin on cell viability, proliferation and also increased the curcumin-triggered ROS generation in each GH In Japan, where the population is aging, the number of elderly lung cancer cases is expected to increase. Therefore, we retrospectively compared and examined about elderly lung cancer.\\nThere were 1,283 patients undergoing surgery for lung cancer between 2009 and 2018 at our institution. We classified them into 75~85 years old, 85 years old or older, and younger than 75 years, and examined the patient background, surgical procedure, and perioperative complications.\\n96.2% of 75~85 years group and 100% of 85 years old or older group had some history. There was a significant difference between the ages of 85 years old or older in PS 1 and above. There was a significant difference in limited resection between the 2 elderly groups compared to younger than 75 years group. The perioperative complication rates were 75~85 years old group (23.2%), 85 years old or older (30.9%), and younger than 75 years group (23.2%), with no significant difference. There were significant differences in postoperative delirium and chronic respiratory failure in 75~85 years group and 85 years old or older compared with younger than 75 years group. We performed a multivariate analysis of risk factors for complications. Males, PS 1 or higher, approach[ thoracotomy, video-assisted thoracic surgery (VATS)], and limited resection were considered to be independent factors. The 5-year survival rate was 70.9% in 75~85 years group, 39.3% in 85 years old or older group, and 81.0% in younger than 75 years group, and was significantly lower in 85 years old or older group.\\nElderly patients need to be aware of postoperative delirium and chronic respiratory failure. It is possible that the complication rate can be reduced by performing a thorough evaluation of operative resistance and selecting an appropriate surgical procedure in the elderly. Case 1: A 68-year-old woman was diagnosed with advanced HER2-positive breast cancer(T2N2aM0, cStage ⅢA). She was treated with 4 courses of preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel. She was diagnosed to have achieved partial remission(PR), and subsequently underwent a mastectomy and axillary dissection. Pathological examination revealed smaller than 1 mm(Grade 2b). Case 2: A 59-year-old woman was diagnosed with advanced HER2-positive breast cancer(T4bN1M0, cStage ⅢB). She was treated with 4 courses of preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel. She was diagnosed to have achieved PR(primary lesion: complete remission), and subsequently underwent a mastectomy and axillary dissection. Pathological examination revealed complete pathological response(Grade 3). Combination therapy with pertuzumab, trastuzumab, and docetaxel appears to be a useful preoperative chemotherapy regimen for locally advanced HER2-positive breast cancer. This retrospective study aimed to evaluate the effect of the antiemetic drug olanzapine(OLZ)on blood sugar levels in patients treated with adjuvant or neoadjuvant chemotherapy(AC: doxorubicin plus cyclophosphamide or CEF: cyclophosphamide plus epirubicin plus fluorouracil) for breast cancer. Here, we evaluated the frequency of diabetes(postprandial blood sugar: PBS≥200 mg/dL)and the change in PBS in 149 patients who were prescribed OLZ between September 2016 and August 2017 at our hospital. No diabetic patients were identified during the observation period(median: 3 cycles of chemotherapy). Among the 95 patients with more than 2 PBS readings, no difference was observed in the incidence of increased PBS, regardless of the diabetic risk, before and after OLZ administration. This study therefore found that the short term use of OLZ as an antiemetic had little effect on PBS, suggesting that it can be used safely during treatment with AC or CEF. We investigated factors related to the recurrence and prognosis of patients with triple-negative breast cancer (TNBC)after neoadjuvant chemotherapy(NAC). Of the 545 patients who underwent surgery after NAC between January 2013 and December 2016, 131 patients had TNBC. An analysis of each TNBC case indicated that the presence or absence of clinical lymph node metastasis(cN)before treatment might be a predictive factor of prognosis. There were 57(43.5%)pathological complete response(pCR)(ypT0 or ypTis/N0)cases after NAC. Overall survival(OS)and disease free survival(DFS) were significantly better in pCR cases than in non-pCR cases. However, recurrence was observed in 8 of 57(14%)pCR cases and 29 of 74(39%)non-pCR cases. The factors defining DFS from the univariate analysis of the non-pCR group were cN, ypT, ypN, and vascular invasion. The multivariate analysis of these factors suggested that residual cN and vascular invasion might be independent factors predicting DFS. Residual vascular invasion was found to predict OS, and was considered to be a poor prognostic factor. Papillary fibroelastoma is a benign tumor of the heart, constituting less than 10% of heart tumors. When papillary fibroelastoma is diagnosed, surgical treatment must be considered because it may cause embolization such as myocardial infarction and strokes. We experienced a patient with papillary fibroelastoma of the tricuspid valve after total resection of the right breast for breast cancer and partial lung resection for lung cancer. Minimally invasive cardiac surgery (MICS) with right thoracotomy was perfomed to resect the tumor. Though median sternotomy is still the most widely used approach for cardiac tumor, MICS is a useful method for preventing sternal wound infection and promoting wound healing, particularly in a patient with high risk of wound infection like this case. A woman in her 30s presented to our hospital with the chief complaint of a right breast mass after the birth of her first child. She was diagnosed as having right invasive ductal carcinoma of Luminal-B type and T3N3cM0, stage Ⅲc. While undergoing neoadjuvant chemotherapy, she received genetic counseling and underwent genetic testing and was determined to have deleterious BRCA1 and BRCA2 mutations. After completing chemotherapy, she underwent a right total mastectomy and axillary lymph node dissection. Two years postoperatively, she requested to undergo a contralateral risk-reducing mastectomy( CRRM)of her left breast. Therefore, CT and breast MRI were performed to confirm the absence of contralateral lesions and distant metastases, and subsequently, CRRM was performed. Postoperative pathology results showed non-invasive ductal carcinoma lesions at 5 sites. In the case of hereditary breast and ovarian cancer syndrome such as in this study, lesions may be discovered at an early stage by performing risk-reducing mastectomy. The characteristic adverse events of olaparib, a PARP inhibitor, are nausea, vomiting, and anemia, and interstitial pneumonia is rarely reported. We report a case of interstitial pneumonia following the treatment of a metastatic breast cancer with olaparib. The patient was a 34-year-old woman. In March 2018, she was diagnosed with stage Ⅳ breast cancer(multiple lung metastases). She was treated with epirubicin and cyclophosphamide followed by paclitaxel. In November 2018, brain and spinal cord metastases were detected, and she was treated with radiation. In December 2018, a BRCA1 deleterious mutation was confirmed, and treatment with olaparib was initiated. Six weeks later, olaparib was discontinued due to anemia; it also caused interstitial pneumonia. The interstitial pneumonia resolved following multidisciplinary treatment during hospitalization. Subsequently, she was treated with cyclophosphamide/methotrexate/fluorouracil. It is necessary to consider interstitial pneumonia as an adverse effect of olaparib. The study subjects consisted of 54 patients with inoperable or recurrent breast cancer who were administered a combination of palbociclib plus endocrine therapy. We examined the onset of neutropenia during the first course of treatment and evaluated the influence that various risk factors had on treatment continuity. Patients with neutropenia Grade≥3 had significantly lower relative dose intensity(RDI) values during the first course of treatment than did patients with neutropenia Grade ≤2. Patients with neutropenia Grade≥3 showed significantly longer treatment to failure than did patients with neutropenia Grade≤2. These results suggest that the degree of neutropenia during the first course of treatment might contribute to treatment continuity and that it is important to improve the curative effect by maintaining appropriate RDI and by continuously administering palbociclib in patients with neutropenia Grade≥3. The growth hormone (GH)-insulin-like growth factor-1 (IGF1) endocrine axis has a key role in normal growth and development. Laron syndrome (LS) is a type of dwarfism that results from mutation of the GH receptor, leading to congenital IGF1 deficiency. Epidemiological studies have shown that LS patients are protected from cancer. Genome-wide profiling led to the identification of a series of metabolic genes whose differential expression in LS might be linked to cancer protection. Nephronectin (NPNT) is an intracellular and secreted extracellular matrix protein with important roles in kidney development. NPNT was identified as the top-downregulated gene in LS-derived cells in comparison with ethnic-, age- and gender-matched controls (p-value\\xa0=\\xa00.0148; fold-change\\xa0=\\xa0-3.12 versus controls). NPNT has not been previously linked to the IGF1 signaling pathway. The present study was aimed at evaluating the hypothesis that NPNT is a new target for IGF1 action and that decreased expression of NPNT in LS is correlated with cancer protection.\\nBasal and IGF1-stimulated NPNT expression were assessed in LS lymphoblastoid cells as well as in human breast and prostate cancer cells. NPNT silencing experiments were conducted using siRNA methodology.\\nWe provide evidence that IGF1 stimulates NPNT expression in LS-derived lymphoblastoids and various cancer cell lines. In addition, we demonstrate that NPNT silencing results in diminished activation of the AKT and ERK1/2 pathways, with ensuing decreases in cellular proliferation.\\nOur data identified the NPNT gene as a target for IGF1 action. The clinical implications of the functional and physical interactions between NPNT and the IGF1 pathway merit further investigation. Anti-neutrophil antibodies are capable of activating neutrophils in sterile environments, releasing extracellular traps containing myeloperoxidase (MPO) and anti-MPO antibodies (MPO-ANCAs or anti-MPO-ANCAs), which have been implicated in the pathogenesis of several diseases. The present study evaluated systemic and tumor tissue levels of anti-MPO-ANCAs breast cancer patients, and its relation to clinicopathological characteristics. Anti-MPO-ANCAs were measured in serum and tissue samples of 150 patients by enzyme-linked immunoassay. Samples were pooled according to clinicopathological characteristics of patients. Higher anti-MPO-ANCAs levels were detected in groups presenting negative clinicopathological characteristics, such as high histological grade tumors and risk factors such as body mass index, menopausal status and early onset at diagnosis. The present data highlights anti-MPO-ANCAs as associated to poor prognosis in breast cancer, a role beyond its actually discussed role in autoimmunity and vasculitis. Occult breast cancer (OBC) is described as an axillary metastatic carcinoma without detection of a primary breast lesion and is uncommon. Significant advances in breast imaging have occurred since its description, decreasing its incidence. However current management is based upon old studies, with variable clinical, radiological and pathological definitions of OBC. We suggest standardised definitions of OBC to facilitate more homogenous data representation in the literature. This review also discusses the conflicting heterogeneous data and its influence in determining the current management guidelines. We discuss whether the current significant surgical recommendations are necessary and postulate whether they could be safely substituted with less invasive management. One year of adjuvant trastuzumab is considered the standard treatment for patients with HER2 positive breast cancer. However, a shorter duration of trastuzumab may be associated with reduced costs and side effects. Results from randomized trials with diverse non-inferiority margins comparing one year to a shorter duration of adjuvant trastuzumab are not consistent and have not been systematically reviewed using a non-inferiority meta-analysis approach. We conducted a systematic review and meta-analysis of randomized trials to assess whether a shorter duration of adjuvant trastuzumab was non-inferior to one year of treatment or not. The non-inferiority margin for the meta-analysis was pre-defined as the median of the margins of all the trials included. Data of 11,376 patients from 5 trials were analyzed. Non-inferiority margins in included studies varied from 1.15 to 1.53 with median of 1.29 for HR of DFS. A shorter duration of trastuzumab was non-inferior to one year of therapy for DFS (HR 1.13, 95%CI 1.03-1.24) but inconclusive for OS (HR 1.14, 95%CI 1.00-1.30). In a subgroup analysis for DFS outcome, shorter therapy was non-inferior in patients with ER positive disease (HR 1.10, 95%CI 0.95-1.28) and those with sequential therapy (HR 0.97, 95%CI 0.75-1.27) and when the duration of treatment was 6 months (HR 1.09, 95%CI 0.98-1.22). Although a shorter duration of adjuvant trastuzumab was non-inferior to one year of therapy for DFS in patients with HER2 positive breast cancer based on our HR margin of 1.29, any benefit of a shorter duration comes at a loss of efficacy with an increase in absolute risk up to 3.9% for 5 year DFS. Whether the potential increased risk is clinically acceptable for the benefits of a shorter duration remains debatable. Family members are a part of the team to improve the outcomes of the person with cancer. Families require support and information to optimise their care, however, their needs are often unacknowledged and within clinical areas there is a lack of family focused interventions. Studies highlight families\\' needs but lack a family representation. The aim was to explore research with family as the unit-of-care during cancer treatment.\\nThe Pickering systematic quantitative literature review method; a 15-step process from searching, database development and analysis was followed. Research published 2008-2019 within databases: MEDLINE, SCOPUS, PsycINFO, Cochrane, CINAHL; key words, \\'family* or caregiver*, and cancer*, neoplasm* and coping*, distress* in November 2019. Quality assessment completed using Mixed Methods Appraisal Tool, descriptive quantitative analysis and thematic analysis.\\nStudies involving patients and family members were included in the review (N\\xa0=\\xa073). The analysis identified participants had a mean age of 58 years and primarily lung, breast or prostate cancer. Over 80% were from America and European countries; 93% had a dyad sample, quantitative studies (76%). There was eight intervention studies between four to sixteen weeks long, focused on family wellbeing. Themes described the impact of cancer on the whole family, the importance of communication between family members, and resources for family members.\\nThe review identified four main scales and optimum intervention styles. Family research in the adult cancer needs to focus on intervention studies, increase international focus and inclusion of other family members such as children, friends and older adults. Mycoleptodiscin B is a natural product extracted from the endophytic fungus Mycoleptodiscus sp. found in Sri Lanka and Panama with experimentally unexplored activities for human targets. In this study, a computational methodology was applied to determine druggable targets of mycoleptodiscin B. According to the computational toxicity and pharmacokinetics assessment, mycoleptodiscin B was proven to be a suitable drug candidate. Druggable targets for this compound, aromatase, acidic plasma glycoprotein and androgen receptor, were predicted using reverse docking. A two-step validation of those targets was performed using conventional molecular docking and molecular dynamic (MD) simulations, resulting in aromatase being determined as the potential therapeutic target. Based on molecular mechanics/Generalized Born Surface Area (GBSA) free energies and ligand stability inside the active site cavity during its 120 ns MD run, it can be concluded that mycoleptodiscin B is a potent aromatase inhibitor and could be subjected to further in\\xa0vitro and in\\xa0vivo experiments in the drug development pipeline. Consequently, natural product chemists can quickly identify the hidden medicinal properties of their miracle compounds using the computational approach applied in this research. A series of sixteen novel methyl β-orsellinate based 3, 5-disubstituted isoxazole hybrids (3-18) were synthesized in excellent yields by employing 1,3-dipolar cycloaddition reaction of terminal alkyne and corresponding nitriloxides as the key step. The structures of all the synthesized compounds were elucidated by spectroscopic data such as  Metal-based inhibitors of histone deacetylases (HDAC), DNA topoisomerases (Topos) and Epidermal Growth Factor Receptor (EGFR) have demonstrated their cytotoxic potential against various cancer types such as breast, lung, uterus, colon, etc. Additionally, these have proven their role in resolving the resistance issues, enhancing the affinity, lipophilicity, stability, and biocompatibility and therefore, emerged as potential candidates for molecularly targeted therapeutics. This review focusses on nature and role of metals and organic ligands in tuning the anticancer activity in multiple modes of inhibition considering HDACs, Topos or EGFR as one of the primary targets. The conceptual design and synthetic approaches of platinum and non-platinum metal complexes comprising of chiefly ruthenium, rhodium, palladium, copper, iron, nickel, cobalt, zinc metals coordinated with organic scaffolds, along with their biological activity profiles, structure-activity relationships (SARs), docking studies, possible modes of action, and their scope and limitations are discussed in detail. Human epidermal growth factor receptor (HER) is a family of multidomain proteins that plays important role in the regulation of several biological functions. HER2 is a member of HER that is highly presented in breast cancer cells. Here, we designed and synthesized a series of diaryl urea/thiourea compounds. The compounds were tested on HER2 The United States Preventive Services Task Force recommends against breast self-examination. However, racial disparities exist in mammogram screening. We aimed to evaluate the presentation of women with newly diagnosed breast cancer in the underserved African-American and Hispanic community to provide insight regarding breast cancer screening in this population.\\nThis retrospective cohort study included women newly diagnosed with breast cancer from 1/1/2016 to 1/1/2018 in an inner city public community hospital. Data was collected via chart review. Patients were divided based on whether they presented with self-detected breast mass. Logistic regression was used for analysis.\\n59 women were newly diagnosed with breast cancer. 34 women (58%) were African-American, 20 (34%) were Hispanic, and 5 (8%) were other race. Of 59 women, 36 (61%) presented with self-detected breast mass, and only 21 (36%) reported prior mammography. For women who presented with breast mass, the odds of having prior mammography were 78% lower (OR\\xa0=\\xa00.22, 95% CI 0.07-0.69, p\\xa0=\\xa00.009), while the odds of having invasive ductal carcinoma were 4.33 times higher (OR\\xa0=\\xa04.33, 95% CI 1.09-17.25, p\\xa0=\\xa00.037), as compared to the odds for women not presenting with breast mass.\\nMany of our newly diagnosed breast cancer patients were African-American or Hispanic women presenting with self-detected breast mass without prior screening mammography. Further studies should evaluate whether supplemental screening methods, such as breast self-examination or clinical examination, can help with early breast cancer detection in minority women with limited access to care, and such disparities should be considered by organizations when creating screening guidelines. The treatment with anticancer drugs remains a challenge, as available drugs still entail the risk of deleterious off-target effects. The present study describes folic acid conjugated nanostructured lipid carriers (NLCs) as an effective doxorubicin delivery approach targeted to breast cancer cells. Two distinct NLCs formulations were designed and optimized leading to an encapsulation efficiency over than 65%. Cytotoxic and targeting potential of NLCs were studied in vitro, using MDA-MB-231 cell line. Results showed an enhanced cellular uptake of conjugated NLCs. In vitro release studies, mimicking the path in the body after oral administration, show that all formulations would reach the tumor microenvironment bearing 50% of the encapsulated doxorubicin. Moreover, NLCs demonstrated storage stability at 25 °C for at least 42 days. Overall, results revealed that the developed NLCs enable the possibility of oral administration and are a promising approach for the targeted delivery of doxorubicin to breast cancer cells. Five to 7% of breast cancers affect women under 40 years old. The survival of these patients has been improved thanks to therapeutic advances, often to the detriment of their fertility. The objective of this study is to evaluate the activity of oncofertility and the future of young women with breast cancer managed at the Montpellier University Hospital.\\nThis is a retrospective study including women aged from 18 to 43 years-old diagnosed with breast cancer and referred in oncofertility consultation at the Montpellier University Hospital between July 2011 and December 2018.\\n190 patients were eligible, three refused to participate to the study, hence 187 patients were included. We estimate that only 33% of young breast cancer patients potentially eligible for fertility preservation (FP) benefited from an oncofertility consultation in our region. Of these 187 patients, 58 (31%) underwent ovarian stimulation for oocyte or embryo vitrification. They were significantly younger: 32.9 vs 34.6 years old (p 0.01) and had fewer invaded lymph nodes. A total of 66 cycles were achieved and 11.4 oocytes or 3 embryos were vitrified per patient. The reuse rate was 3.6% with 91% of post cancer pregnancies being spontaneous.\\nThe oncofertility care network seems effective at the regional level. Enhancing health professionals\\' awareness and creating a regional register could improve our long-term follow-up. Our institution introduced a Patient-Specific Heart Constraint (PSHC) and a mean heart dose (MHD) constraint of 4Gy for all patients receiving breast radiation therapy (RT) with a simultaneous boost (SIB). This was introduced as a method to calculate the predicted MHD before optimising IMRT fields. We sought to determine whether the introduction of a PSHC reduced MHD, whilst maintaining optimally-dosed treatment plans.\\nPatients were retrospectively divided into two groups, pre- and post-introduction of the PSHC. The breast and SIB Planning Target Volumes (PTVs) were prescribed to 50Gy and 57Gy respectively, in 25 fractions. Plans were generated using a hybrid IMRT technique, 30Gy using an open tangential field arrangement, and 27Gy using IMRT fields. The PSHC was calculated using: MHD of open tangential field x 2. A paired t-test compared PTV coverage and heart doses between cohorts (p<0.05 significant).\\nA total of 264 patients were included (138 pre-PSHC and 126 post-PSHC) with 137 right-sided and 127 left-sided treatments. MHD was significantly reduced across both right (-.04 Gy p <0.0001) and left-sided (-1.2 Gy, p <0.0001) treatments overall. Left-sided treatments were further examined between free-breathing and deep inspiration breath hold (DIBH). DIBH showed reduction in MHD, though not significant (-0.46 Gy, p=0.34). Heart V5 Gy showed reduction in right (-1%, p=0.002) and left-sided (-9.2%, p<0.0001) treatments overall. Left-sided free-breathing showed significant reduction (-8.8%, p<0.0001), whilst DIBH also showed significant reduction (-5.1%, p=0.0034). Tumour bed doses remained above the 54.15Gy (95% of 57 Gy) threshold for all plans.\\nIntroduction of a PSHC can reduce MHD and V5 Gy for patients receiving whole breast RT with SIB, whilst maintaining optimally-dosed plans, with the greatest benefit shown for left-sided, free-breathing treatments. Arginine depleting enzymes are found effective to treat arginine-auxotrophic cancers and therapy-resistant malignancies, alone or in combination with cytotoxic agents or immune checkpoint inhibitors. We aim to select and validate a long-lasting, safe and effective PEGylated and cobalt-chelated arginase conjugated at the selective cysteine residue as a therapeutic agent against cancers.\\nExploring pharmacokinetic and pharmacodynamic properties of the three arginase conjugates with different PEG modality (20\\xa0kDa linear as A20L, 20\\xa0kDa branched as A20Y, and 40\\xa0kDa branched as A40Y) by cell-based and animal studies.\\nArginase conjugates showed comparable systemic half-lives, about 20\\xa0h in rats and mice. The extended half-life of PEGylated arginase was concurrent with the integrity of conjugates of which PEG and protein moieties remain attached in bloodstream for 72\\xa0h after drug administration. Arginase modified with a linear 20\\xa0kDa PEG (A20L) was chosen as the lead candidate (PT01). In vitro assays confirmed the very potent cytotoxicity of PT01 against cancer cell lines of breast, prostate, and pancreas origin. In MIA PaCa-2 pancreatic and PC-3 prostate tumor xenograft models, weekly infusion of the PT01 at 5 and 10\\xa0mg/kg induced significant tumor growth inhibition of 44-67%. All mice experienced dose-dependent but rapidly reversible weight loss following each weekly dose, suggesting tolerable toxicity.\\nThese non-clinical data support PT01 as the lead candidate for clinical development that may benefit cancer patients by providing an alternative cytotoxic mechanism. For a drug candidate to be fully developed takes years and investment of hundreds of millions of dollars. There is no doubt that drug development is difficult and risky, but vital to protecting against devastating disease. This difficulty is clearly evident in BRCA1 and BRCA2 related breast cancer, with current treatment options largely confined to invasive surgical procedures, as well as chemotherapy and radiotherapy regimes which damage healthy tissue and can leave remnant disease. Consequently, patient survival and relapse rates are far from ideal, and new candidate treatments are needed. The preclinical stages of drug discovery are crucial to get right for translation to hospital beds. Disease models must take advantage of current technologies and be accurate for rapid and translatable treatments. Careful selection of cell lines must be coupled with high throughput techniques, with promising results trialled further in highly accurate humanised patient derived xenograft models. Traditional adherent drug screening should transition to 3D culture systems amenable to high throughput techniques if the gap between in vitro and in vivo studies is to be partially bridged. The possibility of organoid, induced pluripotent stem cell, and conditionally reprogrammed in vitro models is tantalising, however protocols are yet to be fully established. This review of BRCA1 and BRCA2 cancer biology and current modelling systems will hopefully guide the design of future drug discovery endeavours and highlight areas requiring improvement. Many studies have confirmed the function of SET domain-containing 5 (SETD5) in post-translational modifications of non-histone proteins. Mutation of the SETD5 gene has been implicated in the progression of many human cancers, such as breast cancer (BC), but its functional role in BC progression is yet to be revealed. Herein, we investigated the clinical significance and the functional role of SETD5 in BC. Our studies show that SETD5 expression in BC was related to poor clinical outcomes, including lymph node metastasis and advanced clinical stage. Also, SETD5 expression positively correlates with tumor associated macrophages. SETD5 was an independent predictor of poor overall survival in BC. Further, our studies show that down-regulation of SETD5 significantly decreased BC cell proliferation, metastasis and angiogenesis, and increased apoptosis of BC cells. The mechanistic analysis showed that SETD5 contributes BC progression by interacting with AKT1 pathway. Also, in vivo experiments show that blocking of SETD5 expression significantly inhibited tumor growth and pulmonary metastasis of BC cells. These findings indicate that SETD5 is a potential prognosis marker and facilitates tumor progression of BC. This study sought to determine whether the breast gland adipose tissue is associated with different rates of major adverse cardiac events (MACEs) in pre-menopausal women.\\nTo our knowledge, no study investigated the impact of breast adipose tissue infiltration on MACEs in pre-menopausal women.\\nProspective multicenter cohort study conducted on pre-menopausal women >40 years of age without cardiovascular disease and breast cancer at enrollment. The study started in January 2000 and ended in January 2009, and the end of the follow-up for the evaluation of MACEs was in January 2019. Participants underwent mammography to evaluate breast density and were divided into 4 groups according to their breast density. The primary endpoint was the probability of a MACE at 10 years of follow-up in patients staged for different breast deposition/adipose tissue deposition.\\nThe propensity score matching divided the baseline population of 16,763 pre-menopausal women, leaving 3,272 women according to the category of breast density from A to D. These women were assigned to 4 groups of the study according to baseline breast density. At 10 years of follow-up, we had 160 MACEs in group 1, 62 MACEs in group 2, 27 MACEs in group 3, and 16 MACEs in group 4. MACEs were predicted by the initial diagnosis of lowest breast density (hazard ratio: 3.483; 95% confidence interval: 1.476-8.257). Further randomized clinical trials are needed to translate the results of the present study into clinical practice. The loss of ex\\xa0vivo breast density models to study the cellular/molecular pathways implied in MACE is another study limitation.\\nAmong pre-menopausal women, a higher evidence of adipose tissue at the level of breast gland (lowest breast density, category A) versus higher breast density shows higher rates of MACEs. Therefore, the screening mammography could be proposed in overweight women to stage breast density and to predict MACEs. (Breast Density in Pre-menopausal Women Is Predictive of Cardiovascular Outcomes at 10 Years of Follow-Up [BRECARD]; NCT03779217). To compare cellular uptake and cytotoxicity of fluorescein (FL)-labeled polyethylene glycols (PEGs) carrying 2 folate groups (targeted delivery vehicles [TDVs]) to non-PEGylated molecules with 1 or 2 folate groups.\\nThree PEGylated TDVs and 2 non-PEGylated folic acid (FA)-fluorescein (FL) conjugates (FA-FL and FA-FL-FA) were synthesized. Two triple-negative breast cancer cell lines (MDA-MB-231and MDA-MB-468) were cultured to 70% confluency and incubated for 2 h in a folate-depleted medium. Folate receptor (FR) expression was confirmed by immunocytochemistry. Cellular uptake and cytotoxicity of compounds were measured by flow cytometry. Intracellular localization was confirmed using confocal microscopy.\\nMDA-MB-231 demonstrated 40% more FR staining than MD-MB-468. Intracellular localization of the 2 non-PEGylated molecules (FA-FL and FA-FL-FA) and the 3 PEGylated TDVs was confirmed with confocal microscopy. Cellular uptake was independent of concentration for FA-FL, but there was 26.8% more cytotoxicity at 30 μg/mL compared with no treatment (P ≤ .05). Uptake was > 90% for FA-FL-FA at 10 μg/mL and 30 μg/mL without significant cytotoxicity (P ≤ .005). Cellular uptake was > 80% for all TDVs. The molecule containing monodispersed PEG with M\\nThe molecule containing monodispersed PEG with M We performed a systematic review and meta-analysis to evaluate the prognostic significance of \\nWe searched PubMed, Embase, and the Cochrane Library databases until June 2020 to identify studies that assessed the prognostic value of \\nTwenty-one studies consisting of 1630 patients were included in the qualitative synthesis. Twelve studies investigated the use of PET scans for interim response evaluation (during NAC) and 10 studies assessed post-treatment PET evaluation (after NAC). The most widely evaluated parameter distinguishing metabolic responders from poor responders on interim or post-treatment PET scans was %ΔSUVmax, defined as the percent reduction of SUVmax compared to baseline PET, followed by SUVmax and complete metabolic response (CMR). For the 17 studies included in the meta-analysis, the pooled HR of metabolic responses on DFS was 0.21 (95% confidence interval [CI], 0.14-0.32) for interim PET scans and 0.31 (95% CI, 0.21-0.46) for post-treatment PET scans. Regarding the influence of metabolic responses on OS, the pooled HRs for interim and post-treatment PET scans were 0.20 (95% CI, 0.09-0.44) and 0.26 (95% CI, 0.14-0.51), respectively.\\nThe currently available literature suggests that the use of  Although anti-inflammatory agents could theoretically have anticancer properties, results from cohort studies on nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer (BC) risk are inconsistent.\\nWe investigated the association between NSAID use and BC incidence in the French E3N prospective cohort, which includes 98,995 women born between 1925 and 1950 and insured by a health insurance plan that covers mostly teachers. Self-reported information on lifestyle and medical history has been collected biennially by questionnaires and matched with data from a drug reimbursement database covering the period 2004-2014. Women who self-reported current NSAID use in the 2000 or 2002 questionnaires or with at least two reimbursements in any previous 3-month period were defined as exposed to NSAIDs. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for the association of NSAID use with BC risk.\\nIn the current analysis, 62,512 postmenopausal women were followed between 2004 and 2014 (9\\u2009years on average, starting at a mean age of 63\\u2009years; 2864 incident BC). In multivariable models, there was no statistically significant association between NSAID use and BC risk [HR\\u2009=\\u20091.00 (0.92-1.08), compared with non-exposed women]. The NSAID-BC associations did not differ by NSAID types, BC subtypes, risk factors, and comorbidities, nor by duration and dose of use. However, a statistically significant interaction was observed by proton pump inhibitor (PPI) drug use (P\\nOnly women who used NSAIDs after having used PPI had a lower risk of BC. This result is novel and requires replication in other studies. DNA methylation is a potential biomarker for early detection of breast cancer. However, robust evidence of a prospective relationship between DNA methylation patterns and breast cancer risk is still lacking. The objective of this study is to provide a systematic analysis of the findings of epigenome-wide DNA methylation studies on breast cancer risk, in light of their methodological strengths and weaknesses.\\nWe searched major databases (MEDLINE, EMBASE, Web of Science, CENTRAL) from inception up to 30th June 2019, for observational or intervention studies investigating the association between epigenome-wide DNA methylation (using the HM450k or EPIC BeadChip), measured in any type of human sample, and breast cancer risk. A pre-established protocol was drawn up following the Cochrane Reviews rigorous methodology. Study selection, data abstraction, and risk of bias assessment were performed by at least two investigators. A qualitative synthesis and systematic comparison of the strengths and weaknesses of studies was performed.\\nOverall, 20 studies using the HM450k BeadChip were included, 17 of which had measured blood-derived DNA methylation. There was a consistent trend toward an association of global blood-derived DNA hypomethylation and higher epigenetic age with higher risk of breast cancer. The strength of associations was modest for global hypomethylation and relatively weak for most of epigenetic age algorithms. Differences in length of follow-up periods may have influenced the ability to detect associations, as studies reporting follow-up periods shorter than 10\\u2009years were more likely to observe an association with global DNA methylation. Probe-wise differential methylation analyses identified between one and 806 differentially methylated CpGs positions in 10 studies. None of the identified differentially methylated sites overlapped between studies. Three studies used breast tissue DNA and suffered major methodological issues that precludes any conclusion. Overall risk of bias was critical mainly because of incomplete control of confounding. Important issues relative to data preprocessing could have limited the consistency of results.\\nGlobal DNA methylation may be a short-term predictor of breast cancer risk. Further studies with rigorous methodology are needed to determine spatial distribution of DNA hypomethylation and identify differentially methylated sites associated with risk of breast cancer.\\nCRD42020147244. Measurement of serum human epidermal growth factor receptor-2 (HER-2/neu) levels might play an essential role as a diagnostic/screening marker for the early selection of therapeutic approaches and predict prognosis in breast cancer patients. We aimed to undertake a systematic review and meta-analysis focusing on the diagnostic/screening value of serum HER-2 levels in comparison to routine methods.\\nWe performed a systematic search via PubMed, Scopus, Cochrane-Library, and Web of Science databases for human diagnostic studies reporting the levels of serum HER-2 in breast cancer patients, which was confirmed using the histopathological examination. Meta-analyses were carried out for sensitivity, specificity, accuracy, area under the ROC curve (AUC), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR).\\nFourteen studies entered into this investigation. The meta-analysis indicated the low sensitivity for serum HER2 levels (Sensitivity: 53.05, 95%CI 40.82-65.28), but reasonable specificity of 79.27 (95%CI 73.02-85.51), accuracy of 72.06 (95%CI 67.04-77.08) and AUC of 0.79 (95%CI 0.66-0.92). We also found a significant differences for PPV (PPV: 56.18, 95%CI 44.16-68.20), NPV (NPV: 76.93, 95%CI 69.56-84.31), PLR (PLR: 2.10, 95%CI 1.69-2.50) and NLR (NLR: 0.58, 95%CI 0.44-0.71).\\nOur findings revealed that although serum HER-2 levels showed low se nsitivity for breast cancer diagnosis, its specificity, accuracy and AUC were reasonable. Hence, it seems that the measurement of serum HER-2 levels can play a significant role as a verification test for initial negative screening test results, especially in low-income regions due to its cost-effectiveness and ease of implementation. Herein, we review the current findings of how a variety of accessory cells could participate in shaping the tumor microenvironment and supporting the mechanisms by which cancer cells undertake the epithelial-mesenchymal transition (EMT). EMT, a complex of phenotypic changes, promotes cancer cell invasion and creates resistance to chemotherapies. Among the accessory cells present in the EMT, immune cells (both native and adaptive) can reciprocally influence the tumor cells features, promote EMT and negatively regulate the anticancer immune response. In this review, we look over the role of EMT in crosstalk between tumor cells and the immune system, with specific emphasis on breast tumors. Finally, we suggest that understanding the role of immune cells in cancer progression could create new opportunities for diagnostic and therapeutic interventions in cancer combination therapy. Trends in the incidence of cancer in the population of Kyadondo County, Uganda - which comprises the city of Kampala and a peri-urban hinterland - are presented for a period of 25\\u2009years (1991-2015) based on data collected by the Kampala Cancer Registry. Incidence rates have risen overall - age adjusted rates are some 25% higher in 2011-2015 compared with 1991-1995. The biggest absolute increases have been in cancers of the prostate, breast, and cervix, with rates some 100% (prostate), 70% (breast) and 45% (cervix) higher in 2010-2015 than in 1991-1995. There were also increases in the incidence of cancers of the oesophagus and colon-rectum (statistically significant in men), while the incidence of liver cancer - the fifth most common in this population - increased until 2007, and subsequently declined. By far the most commonly registered cancer over the 25-year period was Kaposi sarcoma, but the incidence has declined, consistent with the decreasing population-prevalence of HIV. Non-Hodgkin lymphomas, also AIDS-related, increased in incidence until 2006/7 and then declined - possibly as a result of availability of anti-retroviral therapy. The trends reflect the changing lifestyles of this urban African population, as well as the consequences of the epidemic of HIV/AIDS and the availability of treatment with ARVs. At the same time, it highlights the fact that the decreases in cancer of the cervix observed in high and upper-middle income countries are not a consequence of changes in lifestyle, but demand active intervention through screening (and, in the longer term, vaccination). The aim of this study was to quantify the prevalence of Fear of Cancer Recurrence (FCR) in patients with a prior haematology malignancy surviving more than one year post allogeneic haematopoietic stem cell transplantation (HSCT), and to identify the demographic, medical and psychological factors associated with FCR occurrence.\\nParticipants were adult allogeneic HSCT recipients who had undergone the procedure for acute leukaemia or other haematological malignancy between the years 2000-2012 in Sydney, Australia. They completed a purpose designed survey and six other validated instruments which assessed FCR, psychological functioning, quality of life, demographic, social and clinical variables.\\nOf the 364 respondents, approximately 11% of the sample lived with severe FCR while only 5% of subjects reported having no FCR. Variables significantly associated with higher FCR included unemployment, a shorter time (years) post-transplant, not attending to health screening (PAP smear), a secondary diagnosis of skin cancer, younger age, referral to a psychiatrist and taking psychotropic medication. Higher psychological distress (depression, anxiety, stress) and lower quality of life made a significant contribution to the prediction of FCR.\\nPost HSCT follow-up care should include an assessment and discussion regarding FCR to balance both realistic and unrealistic cancer recurrence risks. Managing FCR is one of the most ubiquitous unmet needs of survivors of haematological disease and it is important that HSCT nurses are both aware of the fear, and are equipped with knowledge on how to help patients navigate it with realistic expectations. National Comprehensive Cancer Network (NCCN) guidelines can include recommendations for off-label use of anti-cancer drugs. Here, we evaluate NCCN recommendations not supported by US Food and Drug Administration (FDA) approval and explore associations with such recommendations.\\nAll NCCN recommendations for MBC and their supporting data were identified. Drug labels were reviewed to determine whether recommendations are FDA approved. Logistic regression was used to compare FDA approved and off-label recommendations for pre-specified categories, including drug type, tumor subtype, level of recommendation and line of therapy.\\nOf 124 recommendations identified, 68 (55%) were off-label. Chemotherapy and human epidermal growth factor receptor 2 (HER2) targeted drugs were associated with lower odds of FDA approval (OR\\xa0=\\xa00.28, p\\xa0=\\xa00.001 and OR\\xa0=\\xa00.29, 95% p\\xa0=\\xa00.005, respectively). Recommendations for endocrine therapy (OR\\xa0=\\xa03.44, p\\xa0=\\xa00.009) and non-HER2 targeted treatment (OR\\xa0=\\xa010.0, p\\xa0<\\xa00.001) were more commonly FDA approved indications. Compared to combination therapies, monotherapies were more likely to be FDA approved (OR\\xa0=\\xa03.45, p\\xa0=\\xa00.001) as were category 1 (OR\\xa0=\\xa07.63, p\\xa0=\\xa00.001) and preferred NCCN recommendations (OR\\xa0=\\xa04.07, p\\xa0<\\xa00.001). Compared to off-label recommendations, NCCN recommendations of approved drugs were based on significantly higher sample size (mean 477 vs. 342 patients, p\\xa0=\\xa00.02) and were non-significantly associated with availability of randomized data (OR\\xa0=\\xa02.0, 95% CI 0.89-4.49, p\\xa0=\\xa00.09).\\nMore than half of all NCCN recommendations for MBC are off-label, mostly involving chemotherapy containing regimes for HER2 negative disease and combinations which include HER2-targeted drugs. Improved transparency of NCCN guidelines may result from reporting of the strength of the evidence supporting recommendations for MBC. Centrosome amplification (CA) is a common feature of human tumors, but it is not clear whether this is a cause or a consequence of cancer. The centrosome amplification observed in tumor cells may be explained by a series of events, such as failure of cell division, dysregulation of centrosome cycle checkpoints, and de novo centriole biogenesis disorder. The formation and progression of breast cancer are characterized by genomic abnormality. The centrosomes in breast cancer cells show characteristic structural aberrations, caused by centrosome amplification, which include: an increase in the number and volume of centrosomes, excessive increase of pericentriolar material (PCM), inappropriate phosphorylation of centrosomal molecular, and centrosome clustering formation induced by the dysregulation of important genes. The mechanism of intracellular centrosome amplification, the impact of which on breast cancer and the latest breast cancer target treatment options for centrosome amplification are exhaustively elaborated in this review. To evaluate a mixture of selected lactic acid bacteria (LAB) (a riboflavin-producer, a folate-producer and an immunomodulatory strain) as co-adjuvant for 5-fluorouracil (5-FU) chemotherapy in cell culture and using a 4T1 cell animal model of breast cancer.\\nThe viability of Caco-2 cells exposed to 5-FU and/or LAB was analyzed. Mice bearing breast tumor were treated with 5-FU and/or LAB. Tumor growth was measured. Intestinal mucositis (IM) was evaluated in small intestine; hematological parameters and plasma cytokines were determined. The bacterial mixture did not negatively affect the cytotoxic activity of 5-FU on Caco-2 cells. The LAB mixture attenuated the IM and prevented blood cell decreases associated to 5-FU treatment. Mice that received 5-FU and LAB mixture decreased tumor growth and showed modulation of systemic cytokines modified by both tumor growth and 5-FU treatment. The LAB mixture by itself delayed tumor growth.\\nThe mixture of selected LAB was able to reduce the side-effects associated with chemotherapy without affecting its primary anti-tumor activity.\\nThis bacterial mixture could prevent the interruption of conventional oncologic therapies by reducing undesirable side-effects. In addition, this blend would provide essential nutrients (vitamins) to oncology patients. Physical activity (PA) is important for well-being and coping among cancer survivors. Social support (SS) encourages adoption and maintenance of PA behavior, and PA contexts can provide opportunities for obtaining support for coping with cancer. The qualitative literature examining cancer survivors\\' experience with SS in and for PA could inform understanding of behaviors experienced as supportive. The purpose of this meta-study was to synthesize the research on adult cancer survivors\\' experiences with SS related to PA.\\nFollowing meta-study guidelines, we searched nine databases and retrieved 39 articles describing intervention and observation studies, and extracted, analyzed, and synthesized information addressing SS and PA in cancer survivors.\\nResults emphasized ways that PA contexts facilitate relationships, which are a foundation for obtaining supportive behaviors that enable PA (e.g., providing encouragement and accountability) and assist with coping with cancer (e.g., understanding and talking about cancer). Some themes identified were unique to studies with female breast cancer, advanced cancer, interventions or programs, and that used interviews versus focus groups.\\nUnderstanding supportive behaviors could improve PA and coping with cancer in interventions. Future research should focus on identifying supportive behaviors, incorporating theory and methods to address the development of supportive relationships, and recruiting more diverse samples of participants in terms of gender, race/ethnicity, and cancer type.\\nPA can provide opportunities for positive social connections ranging from loose to close social ties, and this research identifies several behaviors in the PA context that may be supportive of PA behavior (e.g., providing actionable information), and coping with cancer (e.g., opportunities but low obligation to talk about cancer). The association between polycystic ovary syndrome (PCOS) and breast cancer remains inconclusive. Conventional observational studies are susceptible to inverse causality and potential confounders. With a Mendelian randomization (MR) approach, we aimed to investigate the causal relationship between genetically predicted PCOS and breast cancer risk.\\nOur study included 11 PCOS-associated single nucleotide polymorphisms as instrumental variables identified by the latest genome-wide association study. Individual-level genetic summary data of participants were obtained from the Breast Cancer Association\\xa0Consortium, with a total of 122,977 cases and 105,974 controls. The inverse-variance weighted method was applied to estimate the causality between genetically predicted PCOS and breast cancer risk. To further evaluate the pleiotropy, the weighted median and MR-Egger regression methods were implemented as well.\\nOur study demonstrated that genetically predicted PCOS was causally associated with an increased risk of overall breast cancer (odds ratio (OR)\\u2009=\\u20091.07; 95% confidence interval (CI) 1.02-1.12, p\\u2009=\\u20090.005). The subgroup analyses according to immunohistochemical type further illustrated that genetically predicted PCOS was associated with an increased risk of estrogen receptor (ER)-positive breast cancer (OR\\u2009=\\u20091.09; 95% CI 1.03-1.15, p\\u2009=\\u20090.002), while no causality was observed for ER-negative breast cancer (OR\\u2009=\\u20091.02; 95% CI 0.96-1.09, p\\u2009=\\u20090.463). In addition, no pleiotropy was found in our study.\\nOur findings indicated that PCOS was likely to be a causal factor in the development of ER-positive breast cancer, providing a better understanding for the etiology of breast cancer and the prevention of breast cancer. Development of biocompatible and multifunctional nanoprobes for tumor targeting, imaging, and therapy still remains a great challenge. Herein, gold nanoparticles (AuNPs) were synthesized in the cavity of horse spleen apoferritin protein (HoSAF) and protein surface was labeled with 2-amino-2-deoxy-glucose (2DG) as a cell surface glucose transport protein specific targeting probe to study the feasibility of its usage as a computer tomography (CT) contrast agent with tumor targeting capability through in vitro experiments. 2DG conjugated and gold-loaded apoferritin (Au-HoSAF-2DG) nanoparticles (NPs) showed selective targeting for human breast adenocarcinoma (MCF-7) cells when compared to normal breast (MCF-10A) cells. This AuNP-based imaging agent was found to be non-cytotoxic in a given concentration range with an apoptotic effect upon longer exposure times towards MCF-7 cells, while MCF-10A cells were affected less. This selective cell death would also be useful for further cancer treatments with the ability of X-ray attenuation in in vitro X-ray and computed tomography (CT) imaging. Arginase I (ARG1) is a cytosolic enzyme that catalyzes the hydrolysis of L-arginine to L-ornithine and urea. The association of ARG1 with cancer has mostly been focused on the ARG1 released by tumor-associated myeloid cells in tumor microenvironment. However, the role of ARG1 expressed in cancer cells is unclear. Here, we showed that the expression of ARG1 in human breast cancer (BC) is related to a good prognosis in BC patients. Overexpression of ARG1 suppresses BC cell proliferation and migration in vitro and xenograft tumor growth and development in mouse models. Furthermore, ARG1 expression down-regulates the expression of p-AKT, leading to the de-activation of AKT signal pathway in BC cells. Thus, our results established that in contrast to the role of ARG1 released from tumor-associated myeloid cells in tumor microenvironment that promotes tumor immune escape, ARG1 expressed in BC cells suppresses AKT signaling pathway and functions as a tumor suppressor. Secondary AS most commonly follows breast cancer and includes postirradiation AS (PRAS) and lymphedema-associated AS. The frequent amplification of MYC (8q24.21) in secondary AS and the rising incidence of PRAS and atypical vascular lesions (AVLs) have prompted interest in the diagnostic and prognostic utility of MYC in AS.\\nRetrospective series with ≥\\u20092 cases of cutaneous AS and describing the use of FISH for MYC amplification or IHC for MYC overexpression were included.\\nSixteen studies met inclusion criteria. Overall, 93 percent of cases evaluated by FISH and IHC were concordant. The sensitivity of FISH in primary AS was only 6.8 percent, and protein overexpression occurred without amplification in sun-damaged skin. FISH and IHC were over 78 percent sensitive in secondary AS, but negative in over 98 percent of AVLs. MYC amplification and FLT4 coamplification were associated with shorter overall survival in secondary AS.\\nFISH for MYC amplification and IHC for MYC overexpression are useful in distinguishing PRAS from AVLs and may also have prognostic value in secondary AS. In contrast, these methods have little diagnostic or prognostic value in primary AS and should not be used to distinguish primary AS from benign vascular neoplasms. This article is protected by copyright. All rights reserved. The efficacy of radiotherapy for breast cancer has greatly improved owing to better irradiation methods. Radiotherapy aims to deliver therapeutic doses to predetermined target volumes while sparing surrounding healthy tissues. However, there are few reports on radiation exposure to eye lenses, and the recommended exposure limits to ocular lens have been substantially reduced in recent years. This study aimed to investigate the amount of radiation exposure to eye lenses using optically stimulated luminescence dosimeters (OSLDs) and determine whether wearing special protective devices to protect the eyes, as an organ at risk, during whole breast irradiation, is necessary.\\nThis experiment used OSLDs on water-equivalent phantom to measure the change in scattered radiation dose due to the difference of irradiation field while using 4- and 6-MV photons of TrueBeam linear accelerator. Using a total treatment dose of 50\\xa0Gy, a target was positioned to approximate the breast, and a plan was formulated to deliver 2\\xa0Gy per treatment by tangential irradiation. The mean (SD) irradiation dose at the lens position outside the irradiation field was reported.\\nThe scattered radiation dose outside the irradiation field was more affected by the irradiation field size than by the radiation energy. The out-of-field irradiation dose with a larger field of view was higher than that with a smaller field of view. The use of 0.07- and 0.83-mm-thick lead shield protective glasses reduced the radiation dose by 56.1% (P\\xa0<\\xa0.001) and 55.6% (P\\xa0<\\xa0.001), respectively.\\nIn this experimental model, the amount of radiation the eye was exposed to during whole breast irradiation was determined by the distance of the eye from the radiation field edge and by wearing protective glasses. In clinical practice, the protection offered by eyeglasses may reduce the risk of long-term side effects and allow the use of higher intensive radiotherapy. Out-of-field organs are not commonly designated as dose calculation targets during radiation therapy treatment planning, but they might entail risks of second cancer. Risk components include specific internal body scatter, which is a dominant source of out-of-field doses, and head leakage, which can be reduced by external shielding. Our simulation study quantifies out-of-field organ doses and estimates second cancer risks attributable to internal body scatter in whole-breast radiotherapy (WBRT) with or without additional regional nodal radiotherapy (RNRT), respectively, for right and left breast cancer using Monte Carlo code PHITS. Simulations were conducted using a complete whole-body female model. Second cancer risk was estimated using the calculated doses with a concept of excess absolute risk. Simulation results revealed marked differences between WBRT alone and WBRT plus RNRT in out-of-field organ doses. The ratios of mean doses between them were as large as 3.5-8.0 for the head and neck region and about 1.5-6.6 for the lower abdominal region. Potentially, most out-of-field organs had excess absolute risks of less than 1 per 10,000 persons-year. Our study surveyed the respective contributions of internal body scatter to out-of-field organ doses and second cancer risks in breast radiotherapy on this intact female model. The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60\\xa0mg twice daily (BID) in a first-in-human (FIH) study (NCT02361723).\\nChinese patients with advanced non-mucinous high-grade ovarian cancer (HGOC) or triple-negative breast cancer (TNBC) whose disease either progressed despite standard therapy, or for which there is no standard therapy were enrolled in the dose-escalation (DE) portion of a phase 1/2 study (NCT03333915). The primary endpoint was safety/tolerability; secondary objectives were pharmacokinetics and antitumor activity. BRCA1/2 mutation status was retrospectively evaluated.\\nNine HGOC and six TNBC patients (N\\xa0=\\xa015; n\\xa0=\\xa04, 20\\xa0mg; n\\xa0=\\xa04, 40\\xa0mg; n\\xa0=\\xa07, 60\\xa0mg) were enrolled; as of 30 September 2019, one HGOC patient remained on treatment. Seven patients (n\\xa0=\\xa05, HGOC; n\\xa0=\\xa02, TNBC) had germline BRCA1/2 mutation (gBRCA\\nPamiparib was generally well tolerated in Chinese patients, with durable responses observed in patients with HGOC. Based on these results, pamiparib 60\\xa0mg BID was confirmed as the RP2D. Digital breast tomosynthesis (DBT) is a limited-angle tomographic breast imaging modality that can be used for breast cancer screening in conjunction with full-field digital mammography (FFDM) or synthetic mammography (SM). Currently, there are five commercial DBT systems that have been approved by the U.S. FDA for breast cancer screening, all varying greatly in design and imaging protocol. Because the systems are different in technical specifications, there is a need for a quantitative approach for assessing them. In this study, the DBT systems are assessed using a novel methodology with an inkjet-printed anthropomorphic phantom and four alternative forced choice (4AFC) study scheme.\\nA breast phantom was fabricated using inkjet printing and parchment paper. The phantom contained 5 mm spiculated masses fabricated with potassium iodide (KI)-doped ink and microcalcifications made with calcium hydroxyapatite. Images of the phantom were acquired on all five systems with DBT, FFDM, and SM modalities where available using beam settings under automatic exposure control. A 4AFC study was conducted to assess reader performance with each signal under each modality. Statistical analysis was performed on the data to determine proportion correct (PC), standard deviations, and levels of significance.\\nFor masses, overall detection was highest with DBT. The difference in PC was statistically significant between DBT and SM for most systems. A relationship was observed between increasing PC and greater gantry span. For MCs, performance was highest with DBT and FFDM compared to SM. The difference between PC of DBT and PC of SM was statistically significant for all manufacturers.\\nThis methodology represents a novel approach for evaluating systems. This study is the first of its kind to use an inkjet printed anthropomorphic phantom with realistic signals to assess performance of clinical DBT imaging systems. Automatic breast ultrasound (ABUS) imaging has become an essential tool in breast cancer diagnosis since it provides complementary information to other imaging modalities. Lesion segmentation on ABUS is a prerequisite step of breast cancer computer-aided diagnosis (CAD). This work aims to develop a deep learning-based method for breast tumor segmentation using three-dimensional ABUS automatically.\\nFor breast tumor segmentation in ABUS, we developed a Mask scoring region-based convolutional neural network (R-CNN) that consists of five subnetworks, i.e., a backbone, a regional proposal network, a region CNN head, a mask head, and a mask score head. A network block building direct correlation between mask quality and region class was integrated into a Mask scoring R-CNN based framework for the segmentation of new ABUS images with ambiguous regions of interest (ROIs). For segmentation accuracy evaluation, we retrospectively investigated 70 patients with breast tumor confirmed with needle biopsy and manually delineated on ABUS, of which 40 were used for five-fold cross-validation and 30 were used for hold-out test. The comparison between the automatic breast tumor segmentations and the manual contours was quantified by I) six metrics including Dice similarity coefficient (DSC), Jaccard index, 95% Hausdorff distance (HD95), mean surface distance (MSD), residual mean square distance (RMSD), and center of mass distance (CMD); II) Pearson correlation analysis and Bland-Altman analysis.\\nThe mean (median) DSC was 85% ± 10.4% (89.4%) and 82.1% ± 14.5% (85.6%) for cross validation and hold-out test, respectively. The corresponding HD95, MSD, RMSD and CMD of the two tests was 1.646 ± 1.191 and 1.665 ± 1.129 mm, 0.489 ± 0.406 and 0.475 ± 0.371 mm, 0.755 ± 0.755 and 0.751 ± 0.508 mm, and 0.672 ± 0.612 and 0.665 ± 0.729 mm. The mean volumetric difference (mean and ± 1.96 standard deviation) was 0.47 cc ([-0.77, 1.71)) for the cross-validation and 0.23 cc ([-0.23 0.69]) for hold-out test respectively.\\nWe developed a novel Mask scoring R-CNN approach for the automated segmentation of the breast tumor in ABUS images and demonstrated its accuracy for breast tumor segmentation. Our learning-based method can potentially assist the clinical CAD of breast cancer using 3D ABUS imaging. Rab-interacting lysosomal protein (RILP) has been suggested to perform as a tumor suppressor in breast and prostate cancer cell lines. However, its expression profile and functional role in lung cancer have never been investigated. We applied the well-established cancer genomic database-The Cancer Genome Atlas to compare the RILP expression and methylation between lung cancer tissues and normal tissues. The potential correlation of RILP with clinical characteristics of lung cancer patients (e.g., stages, smoking, TP53, and methylation) was also be explored. Our results showed that the downregulation of RILP and upregulation of RILP methylation were identified in lung cancer tissues compared to normal healthy tissues. Downregulation of RILP was positively associated with lung cancer later stage (N3), smoking history, TP53 mutation, and poor prognosis, as well as inversely correlated with DNA (cytosine-5)-methyltransferase 1 (DNMT1) expression. Demethylation treatment enhanced RILP expression in lung cancer cells, suggesting hypermethylation is responsible for RILP silencing in lung cancer. We further found that RILP depletion promoted lung cancer cell proliferation, migration, and invasion.\\xa0We concluded that RILP acts as a tumor suppressor in lung cancer cells. Our results provided the theoretical basis for developing RILP-targeting or demethylating agents for lung cancer treatment. Associations between anthropometric factors and breast cancer (BC) risk have varied inconsistently by estrogen and/or progesterone receptor (ER/PR) status. Associations between prediagnostic anthropometric factors and risk of premenopausal and postmenopausal BC overall and ER/PR status subtypes were investigated in a pooled analysis of 20 prospective cohorts, including 36,297 BC cases among 1,061,915 women, using multivariable Cox regression analyses, controlling for reproductive factors, diet and other risk factors. We estimated dose-response relationships and tested for nonlinear associations using restricted cubic splines. Height showed positive, linear associations for premenopausal and postmenopausal BC risk (6-7% RR increase per 5\\xa0cm increment), with stronger associations for receptor-positive subtypes. Body mass index (BMI) at cohort baseline was strongly inversely associated with premenopausal BC risk, and strongly positively-and nonlinearly-associated with postmenopausal BC (especially among women who never used hormone replacement therapy). This was primarily observed for receptor-positive subtypes. Early adult BMI (at 18-20\\xa0years) showed inverse, linear associations for premenopausal and postmenopausal BC risk (21% and 11% RR decrease per 5\\xa0kg/m This study was designed to compare usnic acid with anti-breast cancer drug molecules (A-BCDM) routinely used in the treatment of breast cancer. The miRNA information of 17 anti-breast cancer drug used in breast cancer treatment was obtained from the Small Molecule-miRNA Network-Based Inferance (SMIR-NBI) tool. We had been determined common and different expressed miRNAs between 17 A-BCDM & usnic acid and were classified according to the common miRNAs to reveal molecular similarity. As a result of the bioinformatic analyzes, 20 common miRNAs were determined between 17 A-BCDM and usnic acid. The common miRNAs were analyzed with bioinformatic tolls for determining pathways and targets. The most common miRNAs for 6 of 17 A-BCDM and usnic acid were determined as miR-374a-5p and miR-26a-5p. We compared the anti-proliferative effect of usnic acid and one of the 17 A-BCDM that tamoxifen on MDA-MB-231 triple negative breast cancer cell with real-time cell analysis system. The real time PCR assay was carried out with miR-26a-5p for evaluate to expression level of MDA-MB-231 breast cancer cell and MCF-12A non-cancerous epithelial breast cell. As a result of study, usnic acid as novel candidate drug molecule showed high similarity ratio with 5-Fluorouracil, Sulindac Sulfide, Curcumin and Cisplatin A-BCDM used in treatment of breast cancer. miR-26a-5p as common response miRNA of usnic acid and tamoxifen was showed a decreased level of expression by validated qRT-PCR assay. The obtained from study, in addition to 17 A-BCDM, usnic acid has also the potential to be used as a candidate molecule in the treatment of breast cancer. Moreover, miR-26a-5p might be used as a biomarker in the treatment of breast cancer but further analysis is required. The use of contralateral prophylactic mastectomy (CPM) continues to grow despite the absence of evidence supporting a survival benefit. This study\\'s objectives were to (1) describe the trends in the rates of unilateral and bilateral mastectomy (BM) in women diagnosed with unilateral breast cancer (UBC) in Ontario, Canada from 1991 to 2013, and (2) identify factors associated with BM to treat UBC.\\nThis retrospective cohort analysis included all women aged 18 and older diagnosed with UBC between January 1991 and December 2013. Health administrative data from the Institute for Clinical Evaluative Sciences, the Ontario Cancer Registry, and the Discharge Abstract Database were used to identify all breast cancer and mastectomy cases. Age-adjusted mastectomy rates were plotted over time. Univariable and multivariable analyses included clinically significant covariates.\\nFrom 1991 to 2013 there were 172,165 cases of UBC and 64,886 mastectomies (37.7%) performed in Ontario. 13.6% of the mastectomies were bilateral. BM rates increased over sixfold (from 4 to 25%) across all age groups under age 70 over a 23-year period. On multivariable analysis, younger age, higher income, rural community, earlier breast cancer stage, lobular histology, availability of reconstruction and teaching hospitals were associated with increased odds of BM.\\nThis is the largest population study of breast cancer patients in Canada and shows an increasing rate of BM for UBC. The results are similar to those already described in the US and highlight the importance of continued efforts to promote efficient communication and evidence-based decision-making prior to breast surgery. Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across several cancer types, including breast, lung, gastric and colorectal cancer. In this setting, several novel anti-HER2 agents with relevant CNS activity are emerging, including tucatinib and trastuzumab deruxtecan. Both agents are already FDA-approved for treating advanced breast cancer, but are also being tested for the treatment of other HER2-driven histologies. The confirmation of their activity in other cancer types may provide histology-agnostic weapons against HER2-driven brain metastasis, possibly improving the prognosis of a wide population of cancer patients. This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil.\\nThe study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of BRCA1/2 genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer.\\nOverall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes: ATM (1), CHEK2 (2), PALB2 (1), and TP53 (1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms.\\nA detailed mutational profile of non-BRCA genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort. ATM, CHEK2, PALB2 and TP53 are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives. None For the 6% of breast cancer patients with a diagnosis of stage IV disease, systemic therapy is the cornerstone of treatment, with an unclear role for surgery. Limited evidence exists to delineate treatment methods with regard to hormone receptor and human epidermal growth factor receptor 2 (HER2) status.\\nThe National Cancer Database was used to identify 12,838 stage IV breast cancer patients with known hormone receptor and HER2 status from 2010 to 2015. Chi square tests examined subgroup differences between the treatment methods received. Using the Kaplan-Meier method, 5-year overall survival (OS) was assessed. Multivariate Cox proportional hazard models examined factors associated with survival.\\nA survival advantage was noted for patients who received either systemic therapy and surgery (ST\\u2009+\\u2009Surg: hazard ratio [HR] 0.723; 95% confidence interval [CI] 0.671-0.779) or systemic therapy, surgery, and radiation (Trimodality: HR 0.640; 95% CI 0.591-0.694) (both p\\u2009<\\u20090.0001) compared with systemic therapy alone (ST). The HER2+ patients who received Trimodality or ST\\u2009+\\u2009Surg had a better 5-year OS rate than those who received ST (Trimodality [48%], ST\\u2009+\\u2009Surg [41%], ST [29%]; p\\u2009<\\u20090.0001). The sequence of chemotherapy in relation to surgery is significant, with the greatest survival advantage noted for recipients of neoadjuvant chemotherapy (NAC) compared with patients who had adjuvant chemotherapy when they had positive hormone receptor and HER2 status (HER2\\u2009+\\u2009NAC: HR 0.477; estrogen receptor-positive [ER+] NAC: HR 0.453; progesterone receptor-positive [PR+] NAC: HR 0.448; all p\\u2009<\\u20090.0001).\\nSurgery in addition to ST has a survival benefit for stage IV breast cancer patients with known hormone receptor and HER2 status and should be considered after NAC for patients with ER+, PR+, or HER2+ disease. Earlier pubertal development is only partially explained by childhood body mass index (BMI); the role of other factors like childhood infections is less understood. Using data from the LEGACY Girls Study (2011 - 2016), we prospectively examined the associations between childhood viral infections (Cytomegalovirus (CMV), Epstein Barr Virus (EBV), Herpes Simplex Virus 1 (HSV1), HSV2 and pubertal timing. We measured exposures based on seropositivity in pre-menarcheal girls (n=490). Breast and pubic hair development were classified based on mother-reported Tanner Stage (TS: TS2+ compared with TS1), adjusting for age, BMI, and sociodemographic factors. The average age at first blood draw was 9.8 years (Stdev=1.9 years). The prevalences were 31% CMV+, 37% EBV+, 14% HSV1+, 0.4% HSV2+, and 16% for both CMV+/EBV+. CMV+ infection without co-infection was associated with developing breasts an average of 7 months earlier (Hazard Ratio (HR)=2.12, 95% CI 1.32, 3.40). CMV+ infection without co-infection and HSV1+ and/or HSV2+ infection were associated with developing pubic hair 9 months later (HR 0.41, 95% CI 0.24, 0.71, HR 0.42, 95% CI 0.22, 0.81, respectively). Infection was not associated with menarche. If replicated in larger cohorts with blood collection prior to any breast development, this study supports that childhood infections may play a role in altering pubertal timing. Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers are treated using targeted antibodies and kinase inhibitors, but resistance to these therapies leads to systemic tumor recurrence of metastatic disease. Herein, we conducted gene expression analyses of HER2 kinase inhibitor-resistant cell lines as compared to their drug-sensitive counterparts. These data demonstrate the induction of epithelial-mesenchymal transition (EMT), which included enhanced expression of fibroblast growth factor receptor 1 (FGFR1) and axonal guidance molecules known as neuropilins (NRPs). Immunoprecipitation of FGFR1 coupled with mass spectroscopy indicated that FGFR1 forms a physical complex with NRPs, which is enhanced upon induction of EMT. Confocal imaging revealed that FGFR1 and NRP1 predominantly interact throughout the cytoplasm. Along these lines, short hairpin RNA-mediated depletion of NRP1, but not the use of NRP1-blocking antibodies, inhibited FGFR signaling and reduced tumor cell growth in vitro and in vivo. Our results further indicate that NRP1 upregulation during EMT is mediated via binding of the chromatin reader protein, bromodomain containing 4 (BRD4) in the NRP1 proximal promoter region. Pharmacological inhibition of BRD4 decreased NRP1 expression and ablated FGF-mediated tumor cell growth. Overall, our studies indicate that NRPs facilitate aberrant growth factor signaling during EMT-associated drug resistance and metastasis. Pharmacological combination of epigenetic modulators with FGFR-targeted kinase inhibitors may provide improved outcomes for breast cancer patients with drug-resistant metastatic disease. Breast cancer is a highly heterogeneous disorder characterized by dysregulation of expression of numerous genes and cascades. In the current study, we aim to use a system biology strategy to identify key genes and signaling pathways in breast cancer. We have retrieved data of two microarray datasets (GSE65194 and GSE45827) from the NCBI Gene Expression Omnibus database. R package was used for identification of differentially expressed genes (DEGs), assessment of gene ontology and pathway enrichment evaluation. The DEGs were integrated to construct a protein-protein interaction network. Next, hub genes were recognized using the Cytoscape software and lncRNA-mRNA co-expression analysis was performed to evaluate the potential roles of lncRNAs. Finally, the clinical importance of the obtained genes was assessed using Kaplan-Meier survival analysis. In the present study, 887 DEGs including 730 upregulated and 157 downregulated DEGs were detected between breast cancer and normal samples. By combining the results of functional analysis, MCODE, CytoNCA and CytoHubba 2 hub genes including MAD2L1 and CCNB1 were selected. We also identified 12 lncRNAs with significant correlation with MAD2L1 and CCNB1 genes. According to The Kaplan-Meier plotter database MAD2L1, CCNA2, RAD51-AS1 and LINC01089 have the most prediction potential among all candidate hub genes. Our study offers a framework for recognition of mRNA-lncRNA network in breast cancer and detection of important pathways that could be used as therapeutic targets in this kind of cancer. Extracellular vesicles (EVs), such as exosomes, have garnered increasing interest because of their potential clinical applications that range from diagnostics to therapeutics. The development of an automated and reproducible EV purification platform would therefore aid the introduction of EV biomarkers and therapies into the clinic. Here, we demonstrate that K8- as well as K-16 peptides (containing 8 and 16 lysine residues with dissociation constants of 102\\xa0nM and 11.6\\xa0nM for phosphatidylserine, respectively) immobilized on magnetic beads can capture small EVs (<\\u20090.2\\xa0µm) from culture supernatants of MCF7 human breast cancer cells. Importantly, the bound EVs could be dissociated from the beads under mild conditions (e.g. 0.5\\xa0M NaCl), and the isolated EVs had the typical shapes of EVs under SEM and TEM with a mean particle size of 99\\xa0nm. Using the peptide-immobilized beads, we adapted a pre-existing bench top instrument for magnetic separation to perform automated EV purification with higher purity and yield than that obtained using the standard ultracentrifugation method. The objective of this study was to evaluate the severity of acute pain and side effects in breast cancer patients postoperatively treated with two regimens of tramadol with paracetamol in a prospective double-blind study. Altogether 117 breast cancer patients who had axillary lymphadenectomy were randomized into two analgesic study groups and the analgesic treatment lasted 4\\xa0weeks. Stronger analgesia group received every 8\\xa0h 75/650\\xa0mg of tramadol with paracetamol, while weaker analgesia group received every 8\\xa0h 37.5/325\\xa0mg of tramadol with paracetamol. Patients with the higher dose of tramadol had less pain during the 1st and 4th week than patients with the lower dose. Frequency of nausea, vomiting, lymphedema or range of shoulder movement was not significantly different between the two groups of patients. Constipation was significantly more common in the group with stronger analgesia during the 2nd week in comparison to patients with weaker analgesia. The patients who were on 75/650\\xa0mg of tramadol with paracetamol had less pain in comparison to patients who were on 37.5/325\\xa0mg. Side effects were mild, but common in both groups of patients. Breast cancer is the most common form of cancer in women. Despite significant therapeutic advances in recent years, breast cancer also still causes the greatest number of cancer-related deaths in women, the vast majority of which (>\\u200990%) are caused by metastases. However, very few mouse mammary cancer models exist that faithfully recapitulate the multistep metastatic process in human patients. Here we assessed the suitability of a syngrafting protocol for a Myc-driven mammary tumor model (WAP-Myc) to study autochthonous metastasis. A moderate but robust spontaneous lung metastasis rate of around 25% was attained. In addition, increased T cell infiltration was observed in metastatic tumors compared to donor and syngrafted primary tumors. Thus, the WAP-Myc syngrafting protocol is a suitable tool to study the mechanisms of metastasis in MYC-driven breast cancer. The 17q23 amplicon is associated with poor outcome in ER BACKGROUND Our study aims to investigate the role of segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) in the monitoring of upper limb water changes of patients with breast cancer before and after surgery to aid in establishing a new approach to preventing lymphedema. MATERIAL AND METHODS This study included 442 female patients with breast cancer. We used SMF-BIA to monitor changes in body composition. Data were collected 1 day before surgery and 7 days and 3 months after surgery. RESULTS The average body mass index (BMI) of patients was normal but, in 22.8% of patients, the percentage of body fat exceeded the average, which is known as invisible obesity. Moreover, the weight, BMI, basal metabolic rate, inorganic salt content, muscle content, total body water, and extracellular water of patients increased 7 days after surgery (P<0.05), but recovered to preoperative levels within 3 months. In addition, protein content, skeletal muscle content, and intracellular water increased 7 days after surgery, but decreased within 3 months to even lower levels than before surgery (P<0.05). The extracellular water and total body water ratios increased continuously within the 3 months after surgery. Finally, the segmental water ratio of the healthy and affected upper limbs increased, while the bioelectrical impedance value decreased; however, they were still within the normal range. CONCLUSIONS SMF-BIA monitoring may provide more detailed information for making individual nursing care plans in patients with breast cancer. Further studies with long-term follow-up are urgently needed to establishment a lymphedema risk predictive model.  Dysregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) by unknown mechanisms is highly prevalent in human disease. In this study, we identify direct cross-talk between CDK4/6 and the epigenome via its previously unidentified substrate, SMYD2, a histone/lysine methyltransferase. CDK4/6 positively regulates the phosphorylation and enzymatic activity of SMYD2, while SMYD2 also positively regulates the expression of CDK4/6. We also identify SMYD2 as an α-tubulin methyltransferase, thus connecting CDK4/6-SMYD2 signaling to microtubule dynamics. In addition, depletion or inhibition of CDK4/6 and SMYD2 resulted in increased cilia assembly by affecting (i) microtubule stability and (ii) the expression of IFT20, further connecting CDK4/6-SMYD2 to ciliogenesis. In clinical settings such as breast cancer and autosomal dominant polycystic kidney disease (ADPKD), targeting the up-regulated CDK4/6 and SMYD2 with inhibitors results in restoration of the primary cilium in tumor and cystic cells, which may normalize cilia-mediated extracellular signals that regulate growth, development, and cellular homeostasis. Two early observations about the first generation bisphosphonate, clodronate, suggested that it would likely have clinical utility; specifically, it was a more potent anti-resorptive but a less potent inhibitor of mineralisation than its predecessor etidronate. The known mechanism of action differs from that of the later nitrogen-containing bisphosphonates, as clodronate is metabolised intracellularly to a toxic analog of adenosine triphosphate, AppCCl2p, which causes mitochondrial dysfunction, impaired cellular energy metabolism and osteoclast apoptosis. For pre-clinical studies in a variety of disease models, liposomal clodronate has become the agent of choice for macrophage depletion, for example in a recent study to enhance haematopoietic chimerism and donor-specific skin allograft tolerance in a mouse model. For clinical use, clodronate was developed in oral and injectable formulations; while poorly absorbed from the gastro-intestinal tract, its absorption at 1-3% of the administered dose is approximately three-fold higher than for nitrogen-containing bisphosphonates. Following an early setback due to an erroneous association with toxic adverse events, a number of successful clinical studies have established clodronate, predominantly in its oral formulations, as a highly successful treatment in Paget\\'s disease, hypercalcaemia (benign and malignant), multiple myeloma, and early or metastatic breast cancer. Novel uses in other disease areas, including veterinary use, continue to be explored. Locally known as \\'pecah batu\\', \\'bayam karang\\', \\'keci beling\\' or \\'batu jin\\', the Malaysian medicinal herb, Strobilanthes crispus (S. crispus), is traditionally used by the local communities as alternative or adjuvant remedy for cancer and other ailments and to boost the immune system. S. crispus has demonstrated multiple anticancer therapeutic potential in vitro and in vivo. A pharmacologically active fraction of S. crispus has been identified and termed as F3. Major constituents profiled in F3 include lutein and β-sitosterol.\\nIn this study, the effects of F3, lutein and β-sitosterol on tumor development and metastasis were investigated in 4T1-induced mouse mammary carcinoma model.\\nTumor-bearing mice were fed with F3 (100\\xa0mg/kg/day), lutein (50\\xa0mg/kg/day) and β-sitosterol (50\\xa0mg/kg/day) for 30 days (n\\xa0=\\xa05 each group). Tumor physical growth parameters, animal body weight and development of secondary tumors were investigated. The safety profile of F3 was assessed using hematological and histomorphological changes on the major organs in normal control mice (NM).\\nOur findings revealed significant reduction of physical tumor growth parameters in all tumor-bearing mice treated with F3 (TM-F3), lutein (TM-L) or β-sitosterol (TM-β) as compared with the untreated group (TM). Statistically significant reduction in body weight was observed in TM compared to the NM or treated (TM-F3, TM-L and TM-β) groups. Histomorphological examination of tissue sections from the F3-treated group showed normal features of the vital organs (i.e., liver, kidneys, lungs and spleen) which were similar to those of NM. Administration of F3 to NM mice (NM-F3) did not cause significant changes in full blood count values.\\nF3 significantly reduced the total tumor burden and prevented secondary tumor development in metastatic breast cancer without significant toxicities in 4T1-induced mouse mammary carcinoma model. The current study provides further support for therapeutic development of F3 with further pharmacokinetics studies. To compare the risk of subclinical breast cancer-related lymphedema (sBCRL) using Bioimpedance Spectroscopy (BIS) or Tape-Measure (TM) by the extent of axillary surgery and regional nodal irradiation (RNI).\\nPatients were randomized to surveillance with TM or BIS. A BIS ≥ 6.5 L-Dex units or TM volume change ≥ 5 and <10% above pre-surgical baselines \"triggered\" sBCRL. The incidence of sBCRL by sentinel node biopsy (SNB) or axillary lymph node dissection (ALND) +/- RNI was examined for 484 patients. Radiation was categorized as \"Limited RNI\": Axilla Level I/II only or \"Extensive RNI\": Axilla Level III and/or supraclavicular fossa (SCF) +/- Level I/II.\\nAt a median follow-up of 20.5 months, 109 of 498 patients (21.9%) triggered (BIS 13.5% vs TM 25.6%, p<0.001). In patients not receiving RNI, BIS triggered 12.9% of patients undergoing SNB and 25.0% undergoing ALND (p=0.18). Extensive RNI significantly increased triggering with BIS versus no RNI after SNB (33.3% vs 12.9%, p=0.03) but not ALND (30.8% vs 25.0%, p=0.69). Triggering by TM was over 25% for most subgroups and was inferior to BIS in discriminating the risk of sBCRL by utilization of RNI or axillary surgery.\\nThe lower triggering rates with BIS and its better discrimination of the risk of sBCRL by receipt and type of RNI as compared to TM support its use for post-treatment surveillance to detect sBCRL and initiate early intervention. The risk of sBCRL increased with more extensive axillary treatment. Patients having ALND or extensive RNI require close surveillance for BCRL. Longer follow-up is required to determine rates of progression to clinical lymphedema. Recruitment and retention are two of the most important factors in successfully running clinical trials. Many trials encounter problems with both, causing delays or preventing study progress. These issues are greater in older adults and patients with cancer.\\nWe assessed recruitment and retention in a large, multicentre, observational breast cancer study in older female patients (>70\\xa0years, N\\xa0=\\xa03440). Data collected by the Age Gap study were used to assess rates of, and reasons for, patients not being recruited or retained. Statistical analysis assessed the impact of age as a predictor of recruitment and retention.\\nBetween February 2013 and June 2018, 6876 patients were screened and 3456 were consented across 56 United Kingdom (UK) breast units. Reasons for non-recruitment included ineligibility, clinician issues, staffing resource issues, patients\\' lack of interest or time and trial burden. In comparison with the age demographics of patients with breast cancer in the UK, women aged 70-75\\xa0years were over-represented compared to older age groups. Logistic regression demonstrated that older age significantly reduced the odds of consent (OR\\xa0=\\xa00.96, CI: 0.938-0.982; p\\xa0<\\xa00.001). Multivariate analysis showed that age (p\\xa0<\\xa00.001), markers of poor functional ability (Eastern Cooperative Oncology Group Performance Status (p\\xa0=\\xa00.011)) and instrumental activities of daily living (p\\xa0=\\xa00.026) were significant predictors of withdrawal.\\nThis study has demonstrated that selection and attrition bias for age are apparent despite a range of \\'age friendly\\' study design measures. Exploration of the underlying reasons for this and development of measures to address this should be the focus of further research. Oncoplastic surgery (OS) has added plastic surgery concepts and techniques to the breast cancer surgery. However, reports of the impact of OS on cosmesis after breast-conserving surgery (BCS) are limited in the literature.\\nThis cross-sectional prospective study included patients who underwent BCS. The patients self-evaluated the cosmetic outcome of the breasts and had them photographed. The photos were evaluated by BCCT.core software and by 6 breast surgeons (mastologists and plastic surgeons) using the Harvard, Garbay, and Fitoussi scales. Kappa and weighted kappa tests were used to analyze agreement for categorical variables; for continuous variables, the interclass correlation index and the chi-square test to analyze the association between the OS and the symmetrization.\\nA total of 300 patients were evaluated: 228 (76.0%) underwent traditional BCS and 72 (24.0%) underwent OS, and of these, 37 (51.4%) underwent contralateral symmetrization surgery. In the evaluation of the cosmetic result, the correlation between patients and observers (BCCT.core and surgeons) was weak; between the 2 groups of surgeons, the correlation was moderate (Fitoussi scale) and excellent (Garbay scale). Plastic surgeons are more critical for evaluating cosmetic results; they considered it good or excellent in 30.0% whereas patients, mastologists, and BCCT.core results considered it so in 78.8%, 34.0%, and 30.0%, respectively. In terms of cosmesis, OS and symmetrization did not influence the results in this study with long follow-up.\\nPatients\\' self-evaluation reported better cosmesis than surgeons\\' analyses. Plastic surgeons were the most critical. OS and symmetrization did not influence the results. Scapular kinematics of breast cancer survivors are most often evaluated during arm elevation. However, known compensations exist during functional task performance. The purpose of this study was to determine if scapular kinematics of breast cancer survivors during arm elevation are related to scapular kinematics during functional task performance.\\nScapular kinematics of 25 non-cancer controls and 25 breast cancer survivors (split by presence of impingement pain) during arm elevation in 3 planes and 3 reaching and lifting functional tasks were measured. Scapular upward rotation and scapulohumeral rhythm (SHR) at 30° increments of arm elevation were calculated. Between-group differences of upward rotation during arm elevation were evaluated with one-way ANOVAs (p\\xa0<\\xa00.05). The association of upward rotation angle and SHR during arm elevation and functional tasks was tested with Pearson correlations (p\\xa0<\\xa00.05).\\nScapular upward rotation was reduced for the breast cancer survivor with pain at lower levels of arm elevation in each plane by up to 7.1° (p\\xa0=\\xa0.014 to 0.049). This is inconsistent with functional task results, in which upward rotation decrements occurred at higher levels of arm elevation. Upward rotation angles and SHR during arm elevation had an overall weak-to-moderate relationship (r\\xa0=\\xa00.003 to 0.970, p\\xa0=\\xa0.001 to 0.048) to values from functional tasks. Arm elevation during sagittal plane elevation demonstrated scapular upward rotation that was most closely associated to upward rotation during functional task performance.\\nInconsistent relationships suggests that clinical evaluations should adopt basic functional movements for scapular motion assessment to complement simple arm elevations. Large secondary databases, such as those containing insurance claims data, are increasingly being used to compare the effects and costs of treatments in routine clinical practice. Despite their appeal, however, caution must be exercised when using these data. In this study, we aimed to identify and assess the methodological quality of studies that used claims data to compare the effectiveness, costs, or cost-effectiveness of systemic therapies for breast cancer.\\nWe searched Embase, the Cochrane Library, Medline, Web of Science, and Google Scholar for English-language publications and assessed the methodological quality using the Good Research for Comparative Effectiveness principles. This study was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under number CRD42018103992.\\nWe identified 1251 articles, of which 106 met the inclusion criteria. Most studies were conducted in the United States (74%) and Taiwan (9%) and were based on claims data sets (35%) or claims data linked to cancer registries (58%). Furthermore, most included large samples (mean 17 130 patients) and elderly patients, and they covered various outcomes (eg, survival, adverse events, resource use, and costs). Key methodological shortcomings were the lack of information on relevant confounders, the risk of immortal time bias, and the lack of information on the validity of outcomes. Only a few studies performed sensitivity analyses.\\nMany comparative studies of cost, effectiveness, and cost-effectiveness have been published in recent decades based on claims data, and the number of publications has increased over time. Despite the availability of guidelines to improve quality, methodological issues persist and are often inappropriately addressed or reported. Severe coronavirus disease 2019 (COVID-19) causes a hyperactivation of immune cells, resulting in lung inflammation. Recent studies showed that COVID-19 induces the production of factors previously implicated in the reawakening of dormant breast cancer cells such as neutrophil extracellular traps (NETs). The presence of NETs and of a pro-inflammatory microenvironment may therefore promote breast cancer reactivation, increasing the risk of pulmonary metastasis. Further studies will be required to confirm the link between COVID-19 and cancer recurrence. However, an increased awareness on the potential risks for breast cancer patients with COVID-19 may lead to improved treatment strategies to prevent metastatic relapse. Among Latin American women, breast cancer incidences vary across populations. Uruguay and Argentina have the highest rates in South America, which are mainly attributed to strong, genetic European contributions. Most genetic variants associated with breast cancer were described in European populations. However, the vast majority of genetic contributors to breast cancer risk remain unknown. Here, we report the results of a candidate gene association study of sporadic breast cancer in 176 cases and 183 controls in the Uruguayan population. We analyzed 141 variants from 98 loci that have been associated with overall breast cancer risk in European populations. We found weak evidence for the association of risk variants rs294174 ( Epstein-Barr-virus-associated Gastric Cancer (EBVaGC) comprises approximately 10% of global gastric cancers and is known to be the most hypermethylated of all tumor types. EBV infection has been shown to directly induce the hypermethylation of both the host and viral genome following initial infection of gastric epithelial cells. Many studies have been completed in an attempt to identify genes that frequently become hypermethylated and therefore significant pathways that become silenced to promote tumorigenesis. It is clear that EBV-induced hypermethylation silences key tumor suppressor genes, cell cycle genes and cellular differentiation factors to promote a highly proliferative and poorly differentiated cell population. EBV infection has been shown to induce methylation in additional malignancies including Nasopharyngeal Carcinoma and Burkitt\\'s Lymphoma though not to the same level as in EBVaGC. Lastly, some genes silenced in EBVaGC are common to other heavily methylated tumors such as colorectal and breast tumors; however, some genes are unique to EBVaGC and can provide insights into the major pathways involved in tumorigenesis. Arsenic is a widespread environmental contaminant and recognized carcinogen for the skin, bladder and lungs. In recent years, there has been an increasing number of studies that have investigated the effects of arsenic exposure and cancer risk at other sites, including the breast. However, to date, the association between arsenic exposure and breast cancer risk remains unclear. This article will provide an overview of arsenic metabolism, the clinically important biomarkers commonly used to assess arsenic exposure, and review the epidemiologic studies examining the role of arsenic exposure on breast cancer risk. Given the large burden of disease associated with breast cancer, it is of the upmost importance to identify risk factors and preventative strategies that could reduce cancer incidence. Limiting exposure to endemic environmental toxins, such as arsenic, represents one such strategy. More studies are required to better ascertain this relationship and to develop the public policy necessary to significantly reduce breast cancer incidence. Cancer is a relevant risk factor for venous thromboembolism (VTE). Circulating tumor cells (CTC) are associated with an increased risk of VTE in breast cancer. In addition, circulating cell-free nucleic acids have been associated with cardiovascular events (CVE).\\nTo investigate the association of CTC status and the risk of VTE as well as CVE in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).\\nWe collected data of 189 UCB patients treated with RC at our institution. Blood samples were acquired preoperatively and analyzed for CTC using the CellSearch\\nCTC were present in 43 patients (22.8%). Overall, six patients experienced VTE (3.2%) and eight patients (4.2%) experienced CVE. There was no association of VTE or CVE according to CTC status. In total, 168 patients (89%) experienced a total of 801 complications, of which the majority was classified as \"minor\" (CDC grade ≤ IIIa; 79%). There was no association between CTC status and any grade of a complication or CCI\\nThe overall rate of VTE and CVE was low in our study. Presence of CTC was neither associated with an increased risk of VTE nor CVE in UCB patients treated with RC. According to this study, CTC are not a qualified biomarker for individualized thromboprophylaxis management in these patients. Treatment of breast cancer with doxorubicin causes numerous side effects, of which cardiac fibrosis is considered the main one. This study was designed to investigate the underlying molecular mechanisms for the potential anti-fibrotic effect of pirfenidone and vitamin D against doxorubicin-induced cardiac fibrosis. Seventy mice carrying solid Ehrlich\\'s ascites carcinoma (EAC) discs on the ventral side were treated with orally administered pirfenidone (500 mg/kg) and intraperitoneal injection of vitamin D (0.5 µg/kg) either individually or in combination with a doxorubicin (15 mg/kg; i.p.) single dose. All treatments commenced one week post-tumor inoculation and continued for 14 days. Compared to control EAC mice, the doxorubicin group showed a significant increase in heart and left ventricle weights, troponin T, and creatinine kinase serum levels. Furthermore, the doxorubicin group depicts a high expression of monocyte chemoattractant protein (MCP-1), nuclear factor-kappa B (NF-κB), transforming growth factor-beta 1 (TGF-β1), smad3, Jun N-terminal Kinase-1 (JNK1), and alpha-smooth muscle actin (α-SMA). Treatment with pirfenidone or vitamin D significantly decreased all of these parameters. Furthermore, the expression of smad7 was downregulated by doxorubicin and improved by pirfenidone or vitamin D. Furthermore, all treated groups showed a marked decrease in tumor weight and volume. Current data demonstrate that pirfenidone and vitamin D represent an attractive approach to ameliorate the cardiac fibrosis produced by doxorubicin through inhibiting both JNK1 signaling and MCP-1 inflammatory pathways, thus preserving heart function. Further, this combination demonstrated an anti-tumor effect to combat breast cancer. Chronic inflammation and redox imbalance are strongly influenced by diet and nutritional status, and both are risk factors for tumor development. This prospective study aimed to explore the associations between inflammatory and antioxidant markers and nutritional status in women with breast cancer undergoing chemotherapy. The women were evaluated at three times: T0, after the infusion of the first cycle; T1, after infusion of the intermediate cycle; and T2, after the infusion of the last chemotherapy cycle. The consumption of antioxidant nutrients and the Total Dietary Antioxidant Capacity reduced between T0 and T2 and the Dietary Inflammatory Index scores increased throughout the chemotherapy. Blood samples taken at the end of the chemotherapy showed lower levels of glutathione reductase and reduced glutathione, with greater quantification of the transcripts for Interleukin-6 and Tumor Necrosis Factor α. It should be emphasized that the Total Dietary Antioxidant Capacity is lower and the Dietary Inflammatory Index is higher in the group of overweight patients at the end of the follow-up, besides showing lower levels of the redox status, especially the plasma levels of glutathione reductase ( Cancer stem cells (CSCs) exist in solid tumors and contribute to therapeutic resistance and disease recurrence. Previously, we reported that radiotherapy-resistant (RT-R)-MDA-MB-231 cells from highly metastatic MDA-MB-231 cells produced more CSCs than any other RT-R-breast cancer cells and showed therapeutic resistance and enhanced invasiveness. Hypoxia inducible factor-1α (HIF-1α) induced in the tumor microenvironment leads to the release of lysyl oxidase (LOX), which mediates collagen crosslinking at distant sites to facilitate environmental changes that allow cancer cells to easily metastasize. Therefore, in this study, we investigated whether RT-R-MDA-MB-231 cells induce greater HIF-1α expression, LOX secretion, and premetastatic niche formation than MDA-MB-231 cells do. RT-R-MDA-MB-231 cells increased HIF-1α expression and LOX secretion compared with MDA-MB-231 cells. Mice harboring RT-R-MDA-MB-231 cell xenografts showed enhanced tumor growth and higher expression of the CSC markers, CD44, Notch-4, and Oct3/4. In addition, mice injected with RT-R-MDA-MB-231 cells exhibited a higher level of HIF-1α in tumor tissue, increased secretion of LOX in plasma, higher induced levels of crosslinked collagen, and a higher population of CD11b N-α-acetyltransferase 10 (NAA10) is an acetyltransferase that acetylates both N-terminal amino acid and internal lysine residues of proteins. NAA10 is a crucial player to regulate cell proliferation, migration, differentiation, apoptosis, and autophagy. Recently, mounting evidence presented the overexpression of NAA10 in various types of cancer, including liver, bone, lung, breast, colon, and prostate cancers, and demonstrated a correlation of overexpressed NAA10 with vascular invasion and metastasis, thereby affecting overall survival rates of cancer patients and recurrence of diseases. This evidence all points NAA10 toward a promising biomarker for cancer prognosis. Here we summarize the current knowledge regarding the biological functions of NAA10 in cancer progression and provide the potential usage of NAA10 as a prognostic marker for cancer progression. The aim of this study is to investigate the accuracy of tumor size assessment by shear wave elastography (SWE) in invasive breast cancer and also evaluated histopathologic factors influencing the accuracy.A total of 102 lesions of 102 women with breast cancers of which the size was 3\\u200acm or smaller were included and retrospectively analyzed. Tumor size on B-mode ultrasound (US) and SWE were recorded and compared with the pathologic tumor size. If tumor size measurements compared to pathological size were within ±3\\u200amm, they were considered as accurate. The relationship between the accuracy and histopathologic characteristics were evaluated.The mean pathologic tumor size was 16.60\\u200a±\\u200a6.12\\u200amm. Tumor sizes on SWE were significantly different from pathologic sizes (18.00\\u200a±\\u200a6.71\\u200amm, P\\u200a<\\u200a0.001). The accuracy of SWE (69.6%) was lower than that by B-mode US (74.5%). There was more size overestimation than underestimation (23.5% vs 6.9%) using SWE. Conversely, there was more size underestimation than overestimation (18.6% vs 6.9%) using B-mode US. The accuracy of SWE was associated with ER positivity (P\\u200a=\\u200a.004), PR positivity (P\\u200a=\\u200a.02), molecular subtype (P\\u200a=\\u200a.02), and histologic grade (P\\u200a=\\u200a.03). In the multivariate analysis, ER positivity (P\\u200a=\\u200a.002) and molecular subtype (P\\u200a=\\u200a.027) significantly influenced the accuracy of tumor size measurement by SWE.In conclusion, the accuracy of the tumor size measured with SWE was lower than that measured with B-mode US and SWE tends to overestimate the size. ER positivity and molecular subtype are significantly associated with the accuracy of SWE in tumor size assessment. The incidence of pregnancy-associated breast cancer (PABC) is increasing nowadays, and its diagnosis and treatment remain complicated due to the consideration of the fetus. The available data on PABC are primarily derived from case reports since there are ethical restrictions on conducting randomized clinical trials. In the present work, we reported a case of the human epidermal growth factor receptor 2 (HER2)-positive PABC and described the diagnosis and treatment for such type of breast cancer.\\nA 27-year-old patient was admitted to our hospital with the complaints of right breast mass for 3 days, and she was a first-time pregnant woman with a single live intrauterine fetus at 26 + 3 weeks of gestation. Physical examination of the right breast revealed a palpable and hard mass with obscure boundaries (5.0\\u200acm\\u200a×\\u200a4.0\\u200acm) in the upper outer quadrant. Significant axillary lymph nodes (2.0\\u200acm) were also present.\\nPABC.\\nTo protect the fetus, breast ultrasonography was used to test her breast mass, a core needle biopsy was adopted to confirm the diagnosis, and abdominal ultrasound and chest X-ray were used to evaluate the metastasis. The patient was scheduled for neoadjuvant therapy using bi-weekly pirarubicin in combination with cyclophosphamide (AC) without anti-HER2 therapy for consideration of the fetus\\'s safety. After 4 cycles of AC, the patient delivered a healthy male infant. After the delivery, all the treatments were carried out according to the standard recommendation for HER2\\u200a+\\u200abreast cancer as non-pregnant patients.\\nAfter the surgery, the disease-free survival for the patient was 12 months until brain metastasis was diagnosed. She was still undergoing second-line anti-HER2 therapy and currently in a stable situation. Besides, the child was also healthy so far.\\nThe methods for the diagnosis and treatment of PABC that result in teratogenesis should be avoided to protect the fetus. Mammogram and chest X-ray were safe approaches for the fetus. Moreover, chemotherapy-based on pirarubicin in combination with cyclophosphamide had no risk to the fetus. This study was to investigate clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia (CML-DPMNs). Clinical data of thirteen CML-DPMN patients who were admitted to the First Hospital of Jilin University from May 2008 to December 2018 were collected and retrospectively analyzed. Female patients (9/13) were predominant in this cohort study. Nine patients were metachronous DPMNs (metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia) with 5 years median interval time from primary malignancy to secondary malignancy. The other 4 patients were diagnosed as synchronous CML-DPMNs. Seven of the metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia suffered from CML following many years of comprehensive anti-cancer therapy. Two of CML-MDPMN patients had invasive ductal carcinoma of breast after many years of treatment with imatinib. There was no difference between treatment-related CML group and non-treatment-related CML group in regard as the gender, age, white blood cell count, hemoglobin level, platelet count, and risk level. The median overall survival time of these thirteen patients with CML-DPMNs was not reached. In conclusion, female patients are more likely to suffer from the CML-DPMNs in the present article. Overall survival time of patients with DPMNs involving CML could be promising if timely and effective treatment therapy is adopted. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that retains the antitumor effects of trastuzumab while also delivering the cytotoxic antimicrotubule agent, DM1, directly to tumor cells that overexpress human epidermal growth factor receptor 2. The pharmacokinetic (PK) profile of T-DM1 has been well characterized in Western, Asian, and Japanese patients; this single-center, phase I study (NCT03153163) examined the PK of T-DM1 and safety specifically in Chinese patients.\\nPatients with locally advanced or metastatic breast cancer, previously treated with trastuzumab and a taxane, received open-label T-DM1 at 3.6 mg/kg every 3 weeks. Serum T-DM1 and total trastuzumab, and plasma DM1 were evaluated, and PK parameters were calculated using standard noncompartmental approaches. Adverse events (AEs) were assessed, and immunogenicity was evaluated by measuring antidrug antibodies to T-DM1.\\nAmong 11 Chinese patients, mean (±standard deviation) PK parameters (maximum serum concentration, 77.6 ±\\u200a17.4 μg/mL; clearance 11.0\\u200a±\\u200a2.6 mL/d/kg; terminal half-life 3.8\\u200a±\\u200a1.0 days) were similar to those previously reported in Western and Japanese patients. One patient transiently developed antidrug antibodies, which did not appear to influence safety or PK. T-DM1 was generally well tolerated. Grade 3-4 AEs occurred in 7 patients (63.6%) and serious AEs occurred in 4 patients (36.4%). Platelet count decrease was the most common all-grade AE (10/11; 90.9%), grade 3-4 AE (5/11; 45.5%), and serious AE (3/11; 27.3%), but did not appear to be associated with any clinically significant bleeding events.\\nT-DM1 PK in Chinese patients was consistent with those in global and Asian populations, supporting its use in patients with advanced human epidermal growth factor receptor 2-positive breast cancer following progression on trastuzumab and a taxane. The safety profile of T-DM1 was consistent with prior experience. Recently, increased expression of TET1 has been shown to inhibit tumor development in many studies. Therefore, a meta-analysis was conducted to assess the prognostic role of TET1 in solid tumors.\\nPubMed, Embase, and the Web of Science (last updated on June 13, 2019) were searched and 16 eligible studies involving 3100 patients were eventually taken forward into the meta-analysis.\\nPooled results indicated that higher TET1 expression in cancer tissues was associated with improved overall survival (OS) [hazard ratio (HR)\\u200a=\\u200a0.736, 95% confidence interval (95% CI)\\u200a=\\u200a0.542-0.998, P\\u200a=\\u200a.049]. In the subgroup analysis, higher TET1 expression in respiratory tumors (HR\\u200a=\\u200a0.778, 95% CI\\u200a=\\u200a0.639-0.946, P\\u200a=\\u200a.012) and breast cancer in Asian patients (HR\\u200a=\\u200a0.326, 95% CI\\u200a=\\u200a0.199-0.533, P\\u200a<\\u200a.001) were significantly associated with better OS. In addition, the association between high TET1 expression and prolonged OS was also statistically significant in the following subgroups; data source from samples (HR\\u200a=\\u200a0.561, 95% CI\\u200a=\\u200a0.384-0.819, P\\u200a=\\u200a.003), reported in text (HR\\u200a=\\u200a0.539, 95% CI\\u200a=\\u200a0.312-0.931, P\\u200a=\\u200a.027), TET1 protein (HR\\u200a=\\u200a0.635, 95% CI\\u200a=\\u200a0.409-0.984, P\\u200a=\\u200a.042), Asians (HR\\u200a=\\u200a0.563, 95% CI\\u200a=\\u200a0.376-0.844, P\\u200a=\\u200a.005).\\nThis meta-analysis displays that high expression levels of TET1 in tissues is significantly associated with better survival in patients with solid tumors. This finding can be used as evidence to the tone that TET1 may be a useful target for the treatment of patients with solid tumors in the future. Although several studies have identified an association between the receptor for advanced glycation end-product (RAGE) rs1800624 polymorphism and breast cancer, the results have been conflicting. Therefore, we conducted a meta-analysis to assess the relationship between the RAGE rs1800624 polymorphism and breast cancer risk.\\nStudies were searched in the PubMed, Web of Science, Embase, Wanfang Med Online, and China National Knowledge Infrastructure databases until September 20, 2019 to identify all potential literature on this association. Fixed-effect or random-effect models were used to calculate odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs). Subgroup and sensitivity analyses and tests for publication bias were also performed.\\nFive eligible studies involving 2823 subjects (1410 patients and 1413 healthy controls) were included in the current meta-analysis. The pooled analysis indicated a positive correlation between the RAGE rs1800624 polymorphism and the risk of breast cancer in a homozygous genetic model (OR\\u200a=\\u200a1.423, 95% CI\\u200a=\\u200a1.043-1.941, P\\u200a=\\u200a.026). Ethnicity-based subgroup analysis demonstrated that RAGE rs1800624 polymorphism may increase the risk of breast cancer in the Asian population in homozygous model (OR\\u200a=\\u200a1.661, 95% CI\\u200a=\\u200a1.178-2.342, P\\u200a=\\u200a.004).\\nThe RAGE rs1800624 polymorphism may increase the risk of breast cancer in the homozygous genetic model, especially in Asian populations. Large-scale and well-designed studies are needed in different populations to further evaluate the role of the RAGE polymorphism in breast cancer. Breast cancer is a highly heterogeneous disease, and there are many forms of categorization for breast cancer based on gene expression profiles. Gene expression profiles are variables and may show differences if measured at different time points or under different conditions. In contrast, biological networks are relatively stable over time and under different conditions. In this study, we used a gene interaction network from a new point of view to explore the subtypes of breast cancer based on individual-specific edge perturbations measured by relative gene expression value. Our study reveals that there are four breast cancer subtypes based on gene interaction perturbations at the individual level. The new network-based subtypes of breast cancer show strong heterogeneity in prognosis, somatic mutations, phenotypic changes and enriched pathways. The network-based subtypes are closely related to the PAM50 subtypes and immunohistochemistry index. This work helps us to better understand the heterogeneity and mechanisms of breast cancer from a network perspective. Medical adherence is often higher in clinical trials than in real world practice. The aim of this study was to investigate the effects of traditional Chinese medicine (TCM) on medical adherence to hormonal therapy (HT) and survival outcome in ER (+) breast cancer patients in Taiwan.\\nUsing a nationwide longitudinal population-based database, we enrolled patients with newly diagnosed ER-positive breast cancer who had received HT, and followed for up to 5 years (N\\xa0=\\xa0872). Medication adherence in terms of medication possession ratios (MPR) and patient outcome were evaluated with or without TCM exposure. We applied logistic regression and Cox proportional hazards (PH) analysis to identify factors, including TCM exposure, associated with adherence to HT and mortality.\\nMPR to HT in general decreased over the 5-year period post breast cancer diagnosis. Both TCM and MPR to HT ≥ 80% were significantly associated with reduced risk of breast cancer-associated mortality. Subgroup analysis revealed that TCM annual visits ≥ 3 times with CHP prescription 1~90 days per year affected mortality reduction most significantly (HR: 0.26; 95% CI\\xa0=\\xa00.08-0.83; p\\xa0<\\xa00.05) compared to other TCM use. In contrast, using TCM (either short-term or long-term) was not associated with MPR in HT.\\nOur results supported the potential advantage of TCM on breast cancer-associated mortality, whereas TCM use does not compromise medical adherence to HT. This study offers important insights in integrative therapy for HT in patients with estrogen receptor (+) breast cancer. Capecitabine (brand name Xeloda) is a chemotherapy agent that belongs to the drug class of fluoropyrimidines. It is widely used in the treatment of several malignancies including colon cancer, metastatic colorectal cancer, and metastatic breast cancer. Capecitabine is a prodrug that is enzymatically converted to its active form, fluorouracil (also called 5-fluorouracil), which acts as an antimetabolite to slow tumor growth. The '"
      ]
     },
     "execution_count": 287,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "col_abstract = articlesPD['abstract'].tolist()\n",
    "related_abstact = ' '.join(map(str, col_abstract)) \n",
    "related_abstact"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 289,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "167957\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[('breast', 2348),\n",
       " ('treatment', 600),\n",
       " ('tumor', 569),\n",
       " ('cell', 515),\n",
       " ('women', 503),\n",
       " ('survival', 321),\n",
       " ('therapy', 284),\n",
       " ('screening', 229),\n",
       " ('chemotherapy', 228),\n",
       " ('potential', 212),\n",
       " ('diagnosis', 209),\n",
       " ('surgery', 197),\n",
       " ('metastasis', 195),\n",
       " ('genes', 190),\n",
       " ('protein', 162),\n",
       " ('primary', 161),\n",
       " ('receptor', 155),\n",
       " ('tnbc', 154),\n",
       " ('drug', 140),\n",
       " ('imaging', 139),\n",
       " ('therapeutic', 139),\n",
       " ('tissue', 139),\n",
       " ('metastatic', 137),\n",
       " ('lung', 135),\n",
       " ('models', 127),\n",
       " ('positive', 123),\n",
       " ('immune', 121),\n",
       " ('mortality', 120),\n",
       " ('prognostic', 117),\n",
       " ('carcinoma', 116)]"
      ]
     },
     "execution_count": 289,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import nltk\n",
    "from nltk import sent_tokenize\n",
    "from nltk import word_tokenize\n",
    "\n",
    "###sentence tokenizing:\n",
    "senteces = sent_tokenize(related_abstact)\n",
    "###senteces\n",
    "#word tokenizing\n",
    "words = word_tokenize(related_abstact)\n",
    "#wordsimport nltk\n",
    "from nltk.corpus import stopwords\n",
    "import pandas\n",
    "import pycountry\n",
    "\n",
    "#Empty list to store words:\n",
    "words_no_punc = []\n",
    "\n",
    "#Removing punctuation marks :\n",
    "for w in words:\n",
    "    if w.isalpha():\n",
    "        words_no_punc.append(w.lower())\n",
    "\n",
    "##Print the words without punctution marks :\n",
    "#print (words_no_punc)\n",
    "#print (\"\\n\")\n",
    "#Length :\n",
    "print (len(words_no_punc))\n",
    "from nltk import FreqDist\n",
    "#Frequency distribution :\n",
    "fdist = FreqDist(words_no_punc)\n",
    "fdist.most_common(10)\n",
    "##Plot the most common words on grpah:\n",
    "\n",
    "#fdist.plot(10)\n",
    "\n",
    "from nltk.corpus import stopwords\n",
    "\n",
    "#List of stopwords\n",
    "stopwords = stopwords.words(\"english\")\n",
    "#print(stopwords)\n",
    "\n",
    "#Empty list to store clean words :\n",
    "clean_words = []\n",
    "\n",
    "for w in words_no_punc:\n",
    "    if w not in stopwords:\n",
    "        clean_words.append(w)\n",
    "        \n",
    "#print(clean_words)\n",
    "#print(\"\\n\")\n",
    "#print(len(clean_words))\n",
    "#Frequency distribution :\n",
    "fdist = FreqDist(clean_words)\n",
    "#fdist.most_common(10)\n",
    "\n",
    "no_need_words = [\"using\", \"show\", \"result\", \"large\", \"also\", \"iv\", \"one\", \"two\", \"new\", \"previously\", \"shown\", \"department\",\"addition\",\"therefore\",\\\n",
    "            \"university\", \"clinic\", \"authors\",\"usa\", \"a\",\"b\",\"c\",\"r\",\"x\",\"z\",\"d\",\"e\",\"f\",\"g\",\"n\",\"p\",\"j\",\"l\",\"q\",\"t\",\"oct\",\"author\",\"conclusion\",\\\n",
    "            \"de\",\"sep\",\"results\",\"college\",\"methods\",\"print\",\"used\",\"ci\",\"doi\",\"author\",\"clinical\",\"bc\",\"may\",\"should\",\"function\",\"clin\",\"cause\",\\\n",
    "            \"science\",\"conclusion\",\"study\",\"k\",\"o\",\"higher\",\"high\",\"address\",\"role\",\"level\",\"school\",\"institute\",\"de\",\"one\",\"two\",\"hong\",\"might\",\\\n",
    "            \"information\",\"research\",\"china\",\"ahead\",\"interest\",\"pmid\",\"show\",\"showed\",\"center\",\"significantly\",\"disease\",\"three\",\"system\",\\\n",
    "            \"japan\",\"epub\",\"h\",\"os\",\"national\",\"analysis\",\"sciences\",\"pmcid\",\"months\",\"however\",\"studies\",\"data\",\"first\",\"area\",\"spanish\",\\\n",
    "            \"second\",\"people\",\"copyright\",\"key\",\"respectively\",\"patient\",\"factors\",\"wang\",\"level\",\"significant\",\"care\",\"levels\",\"conclusions\",\\\n",
    "            \"li\",\"affiliated\",\"early\",\"outcomes\",\"model\",\"increased\",\"republic\",\"conflict\",\"overall\",\"rate\",\"rights\",\"chinese\",\"factor\",\\\n",
    "            \"efficacy\",\"years\",\"year\",\"total\",\"month\",\"effect\",\"reserved\",\"median\",\"among\",\"korea\",\"could\",\"must\",\"health\",\"healthy\",\"sc\",\"union\"\\\n",
    "            \"shanghai\",\"found\",\"find\",\"background\",\"response\",\"performed\",\"growth\",\"shanghai\",\"zhang\",\"aug\",\"jul\",\"jan\",\"feb\",\"published\",\\\n",
    "            \"include\",\"including\",\"included\",\"cases\",\"cases\",\"spain\",\"case\",\"hr\",\"time\",\"identified\",\"treated\",\"effects\",\"elsevier\",\"aim\"\\\n",
    "            \"primary\",\"chen\",\"ji\",\"general\",\"medicine\",\"yang\",\"evaluated\",\"conflicts\",\"faculty\",\"germany\",\"beijing\",\"age\",\"progression\",\"centre\",\"assay\",\"received\",\\\n",
    "            \"lower\",\"higher\",\"province\",\"liu\",\"based\",\"fees\",\"south\",\"taiwan\",\"compared\",\"advanced\",\"pfs\",\"ratio\",\"groups\",\"nanjing\",\"statement\",\"jiangsu\",\\\n",
    "            \"human\",\"development\",\"revealed\",\"w\",\"poor\",\"cancers\",\"associated\",\"cancer\",\"gc\",\"patients\",\"group\",\"hospital\",\"medical\",\"expression\",\\\n",
    "            \"via\",\"tokyo\",\"italy\",\"value\",\"division\",\"via\",\"medline\",\"western\",\"vivo\",\"cells\",\"risk\",\"zhejiang\",\"analyzed\",\"analyze\",\"findings\",\"guangzhou\",\"present\",\\\n",
    "            \"remains\",\"underwent\",\"review\",\"independent\",\"et\",\"report\",\"low\",\"lower\",\"high\",\"well\",\"method\",\"state\",\"common\",\"changes\",\"change\",\"status\",\\\n",
    "            \"increase\",\"declare\",\"crc\", \"canada\",\"pathway\",\"within\",\"with\",\"in\",\"united\",\"med\",\"different\",\"al\",\"diseases\",\"work\",\"use\",\"used\",\"important\",\\\n",
    "            \"three\",\"japan\",\"university\",\"information\",\"work\",\"novel\",\"life\",\"unit\",\"biology\",\"australia\",\"la\",\"approach\",\"related\",\"relation\",\"control\",\\\n",
    "            \"science\",\"ca\",\"effective\",\"samples\",\"various\",\"many\",\"several\",\"evidence\",\"reported\",\"demonstrated\",\"amount\",\"size\",\"number\",\"iran\",\"due\" ,\\\n",
    "            \"france\",\"solid\",\"observed\",\"known\",\"better\",\"worse\",\"rare\",\"recent\",\"current\",\"type\",\"activity\",\"baseline\",\"This article is protected by copyright. All rights reserved\",\\\n",
    "            \"outcome\",\"mean\",\"average\",\"available\",\"controls\",\"assess\",\"score\",\"outcome\",\"scores\",\"uk\",\"assess\",\"ckd\",\"condition\",\"test\",\"article\",\"journal\",\\\n",
    "            \"index\",\"indexed\",\"mar\",\"apr\",\"may\",\"jun\",\"oct\",\"nov\",\"dec\",\"public\",\"seoul\",\"incidence\",\"association\",\"stage\" ,\"stages\",\"rate\",\"rates\",\"population\",\"tumors\", \\\n",
    "            \"fujian\",\"laboratory\",\"lab\",\"surg\",\"whether\",\"en\",\"hangzhou\",\"london\",\"singapore\",\"kim\",\"lin\",\"india\",\"rev\",\"conducted\",\"kong\",\"fuzhou\",\"normal\",\"internal\",\"lines\",\"although\",\"because\",\"san\",\"lee\",\\\n",
    "            \"small\",\"problem\",\"confirmed\",\"assessed\",\"according\",\"wu\",\"jh\",\"per\",\"ii\",\"yongsei\",\"B\" ,\"gene\",\"french\"   ]\n",
    "freq = fdist.most_common(0)\n",
    "freq_word = [i[0] for i in freq]\n",
    "\n",
    "New_clean_words = []\n",
    "for w in clean_words:\n",
    "    if w not in freq_word and w not in pycountry.countries and w not in no_need_words:\n",
    "        New_clean_words.append(w)                                \n",
    "fdist2 = FreqDist(New_clean_words)  \n",
    "fdist2.most_common(30)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#below dealing with title"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['[Why is it important to detect atrophic gastritis and gastric intestinal metaplasia? What is the proper way to do it?]',\n",
       " '18F-FDG PET/CT in a Rare Case of Poland Syndrome and Gastric Cancer.',\n",
       " 'Postgastrectomy gastric cancer patients are at high risk for colorectal neoplasia: a case control study.',\n",
       " 'Colonic interposition, a contemporary experience: technical aspects and outcomes.',\n",
       " 'Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes.',\n",
       " 'Voluminous abdominal gastrointestinal stromal tumor of unknown origin manifested with bleeding in a young man: synchronous management of the emergency and oncological approach-case report.',\n",
       " 'Crosstalk Between Cancer Associated Fibroblasts and Cancer Cells in Scirrhous Type Gastric Cancer.',\n",
       " 'Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.',\n",
       " '[Tubular gastric elongation surgery for high esophageal-gastric anastomosis after resection of esophageal cancer: analysis of 5 cases].',\n",
       " 'Innovative marking method using novel endoscopic clip equipped with fluorescent resin to locate gastric cancer.',\n",
       " 'Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma.',\n",
       " 'Association of right breast cancer and ileal gastrointestinal stromal tumor in a patient with type I neurofibromatosis: Case report and review of the literature.',\n",
       " 'Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.',\n",
       " 'A Comparison of the Short-Term Clinical Effects Between Totally Laparoscopic Radical Gastrectomy With Modified Roux-en-Y Anastomosis and Laparoscopic-Assisted Radical Gastrectomy With Roux-en-Y Anastomosis.',\n",
       " 'The Trained Sniffer Dog Could Accurately Detect the Urine Samples from the Patients with Cervical Cancer, and Even Cervical Intraepithelial Neoplasia Grade 3: A Pilot Study.',\n",
       " 'D2 Lymphadenectomy According to the Arterial Variations in Gastric and Hepatic Irrigation.',\n",
       " 'Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study.',\n",
       " 'Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.',\n",
       " 'The Potential Anticancer Activity of Phytoconstituents against Gastric Cancer-A Review on In Vitro, In Vivo, and Clinical Studies.',\n",
       " 'The bacterial association with oral cavity and intra-abdominal abscess after gastrectomy.',\n",
       " 'MicroRNA-451a targets caveolin-1 in stomach cancer cells.',\n",
       " 'Intra-mural distribution of the blood vessels in the stomach demonstrated by contrast medium injection: a cadaver study.',\n",
       " 'The pattern of postoperative quality of life following minimally invasive gastrectomy for gastric cancer: a prospective cohort from Korean multicenter robotic gastrectomy trial.',\n",
       " 'A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010).',\n",
       " 'Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues.',\n",
       " 'Colorectal and gastric metastases from lobular breast cancer that resembled superficial neoplastic lesions.',\n",
       " 'Development and evaluation of a prototype detector for an intraoperative laparoscopic coincidence imaging system with PET tracers.',\n",
       " 'Deep learning-enabled multi-organ segmentation in whole-body mouse scans.',\n",
       " 'Association between Socioeconomic Status and Digestive Tract Cancers: A Case-Control Study.',\n",
       " 'Clinicopathological features and lymph node metastasis risk in early gastric cancer with WHO criteria in China: 304 cases analysis.',\n",
       " 'Evaluations on laser ablation of ex vivo porcine stomach tissue for development of Ho:YAG-assisted endoscopic submucosal dissection (ESD).',\n",
       " 'Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.',\n",
       " 'Metastasis of Breast Cancer Presenting as Enlarged Folds in the Stomach.',\n",
       " 'Role of SOX Protein Groups F and H in Lung Cancer Progression.',\n",
       " '[Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].',\n",
       " 'Clinical benefit of the multibending endoscope for gastric endoscopic submucosal dissection: a randomized controlled trial.',\n",
       " \"Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.\",\n",
       " 'Severe Dumping Symptoms Are Uncommon Following Transthoracic Esophagectomy But Significantly Decrease Health-Related Quality of Life in Long-Term, Disease-Free Survivors.',\n",
       " 'Radiofrequency Ablation and Alcohol Neurolysis of the Splanchnic Nerves for a Patient With Abdominal Pain From Pancreatic Cancer.',\n",
       " 'The Mechanisms of Sijunzi Decoction in the Treatment of Chronic Gastritis Revealed by Network Pharmacology.',\n",
       " 'Propofol Inhibits Proliferation and Invasion of Stomach Cancer Cells by Regulating miR-205/YAP1 Axis.',\n",
       " '[Serum of SD rats lavaged by modified Zuojin decoction promotes apoptosis and inhibits proliferation of human gastric cancer cells by activating mitochondrialpathways].',\n",
       " 'Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020.',\n",
       " 'Impact of examined lymph node count on staging and long-term survival of patients with node-negative stage III gastric cancer: a retrospective study using a Chinese multi-institutional registry with Surveillance, Epidemiology, and End Results (SEER) data validation.',\n",
       " 'Systemic Review and Meta-analysis of Impact of Splenectomy for Advanced Gastric Cancer.',\n",
       " 'Comorbidity in Older Patients Hospitalized with Cancer in Northeast China based on Hospital Discharge Data.',\n",
       " 'Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach.',\n",
       " 'Prevalence and Risk Factors of Gastric and Colorectal Cancer after Cholecystectomy.',\n",
       " 'Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.',\n",
       " 'Drinking-water nitrate and cancer risk: A systematic review and meta-analysis.',\n",
       " 'Serum lipid levels correlate to the progression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study.',\n",
       " 'Expression and functionality of allergenic genes regulated by simulated gastric juice in Anisakis pegreffii.',\n",
       " 'Potential relationship between the selenoproteome and cancer.',\n",
       " 'A case of cardiac amyloidosis in an elderly Japanese patient with amyloidogenic transthyretin Val122Ile variant.',\n",
       " 'Artificial Intelligence-Based Multiclass Classification of Benign or Malignant Mucosal Lesions of the Stomach.',\n",
       " 'Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology.',\n",
       " 'SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation.',\n",
       " '[Esophageal Reconstruction with Vascular Anastomosis and Perioperative Management].',\n",
       " 'Population-Based Prevalence of Gastrointestinal Abnormalities at Colon Capsule Endoscopy.',\n",
       " 'PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.',\n",
       " 'Statistical deformation reconstruction using multi-organ shape features for pancreatic cancer localization.',\n",
       " 'Electroceuticals in the Gastrointestinal Tract.',\n",
       " 'Preoperative CT feature of incomplete overlying enhancing mucosa as a high-risk predictor in gastrointestinal stromal tumors of the stomach.',\n",
       " 'Patient-reported outcomes collected in ambulatory oncology practices: Feasibility, patterns, and correlates.',\n",
       " 'Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.',\n",
       " 'The Function of LncRNA FTX in Several Common Cancers.',\n",
       " '[Structure and function of proximal segment of the dorsal mesogastrium: from the perspective of radical resection of gastric carcinoma].',\n",
       " 'Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report.',\n",
       " '[Single nucleotide polymorphism of rs28416520 in ',\n",
       " 'Hematological Indices of Distant Metastases and Prognostic Nomogram in Gastro-Pancreatic and Biliary Tract Cancers.',\n",
       " 'Effects of the food additive monosodium glutamate on cisplatin-induced gastrointestinal dysmotility and peripheral neuropathy in the rat.',\n",
       " 'Prognostic Value of the Site of Distant Metastasis and Surgical Interventions in Metastatic Gastric Cancer: A Population-Based Study.',\n",
       " 'Intracorporeal semi-hand-sewn Billroth I reconstruction in total laparoscopic distal gastrectomy.',\n",
       " 'Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer.',\n",
       " '',\n",
       " 'Gastric Cancer Disparities Among Asian American Subpopulations.',\n",
       " 'Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion.',\n",
       " 'Ovarian metastasis from nongynecologic primary sites: a retrospective analysis of 177 cases and 13-year experience.',\n",
       " 'The first cancer patient with COVID-19 in Slovakia.',\n",
       " 'LUCAT1 Epigenetically Downregulates the Tumor Suppressor Genes ',\n",
       " 'Metformin and Gastrointestinal Cancer Development in Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea.',\n",
       " 'Using breath analysis as a screening tool to detect gastric cancer: A systematic review.',\n",
       " 'Single-cell expression profiles of ',\n",
       " 'Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.',\n",
       " 'Cancer prevalence by phase of care: an indicator for assessing health service needs.',\n",
       " 'Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.',\n",
       " 'The effect of helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia : a retrospective single center research.',\n",
       " 'The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer.',\n",
       " 'ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.',\n",
       " 'Predictive value of thromboelastography for postoperative lower extremity deep venous thrombosis in gastric cancer complicated with portal hypertension patients.',\n",
       " 'Polyphenol Intake and Gastric Cancer Risk: Findings from the Stomach Cancer Pooling Project (StoP).',\n",
       " 'Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2018.',\n",
       " 'Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective population-based nested case-control study.',\n",
       " 'Impact of the Endoscopic Surgical Skill Qualification System on the safety of laparoscopic gastrectomy for gastric cancer.',\n",
       " 'Red Cell Distribution Width as a Predictor of Malignancy in Patients Who Underwent Upper Gastrointestinal System Endoscopy.',\n",
       " '[Diagnosis and treatment of gastric cancer with immediate double primary carcinoma].',\n",
       " 'Intraabdominal Schwannomas Single-center experience.',\n",
       " 'Long-Term MALT1 Inhibition in Adult Mice Without Severe Systemic Autoimmunity.',\n",
       " 'JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma.',\n",
       " 'Localized primary gastric amyloidosis: Three case reports.',\n",
       " 'High expression of squamous cell carcinoma antigen in poorly differentiated adenocarcinoma of the stomach: A case report.',\n",
       " 'Establishment and validation of a nomogram to predict the risk of ovarian metastasis in gastric cancer: Based on a large cohort.',\n",
       " 'The Mismatch Repair System (MMR) in Head and Neck Carcinogenesis and Its Role in Modulating the Response to Immunotherapy: A Critical Review.',\n",
       " 'The Wnt Signalling Pathway: A Tailored Target in Cancer.',\n",
       " 'Is the 5-port approach necessary in laparoscopic gastrectomy? Comparison of surgical effects of reduced-port laparoscopic gastrectomy and conventional laparoscopic-assisted gastrectomy: A meta-analysis.',\n",
       " 'Banxia Xiexin Decoction in the treatment of chronic atrophic gastritis: A protocol for systematic review and meta-analysis.',\n",
       " 'Esophageal Cancer Surgery.',\n",
       " 'Investigation of INDEL variants in apoptosis: the relevance to gastric cancer.',\n",
       " 'Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract : A Randomized Trial.',\n",
       " '[Analysis on the relationship between smoking status and the onset age of onset and the direct medical expenditure expenses of gastric cancer patients].',\n",
       " 'A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors.',\n",
       " 'CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative.',\n",
       " 'Ileal Signet Ring Cell Carcinoma Masked by Crohn Disease.',\n",
       " 'Calcifying fibrous tumor of the gastrointestinal tract: A clinicopathologic review and update.',\n",
       " 'Prognostic Value of Serum Soluble Programmed Death-Ligand 1(sPDL1) and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients.',\n",
       " 'Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer Over a 16-year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting.',\n",
       " 'Claudin-18 Loss Alters Transcellular Chloride Flux but not Tight Junction Ion Selectivity in Gastric Epithelial Cells.',\n",
       " 'Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer.',\n",
       " 'The panoramic picture of pepsinogen gene family with pan-cancer.',\n",
       " 'A Novel Technique to Improve Anastomotic Perfusion Prior to Esophageal Surgery: Hybrid Ischemic Preconditioning of the Stomach. Preclinical Efficacy Proof in a Porcine Survival Model.',\n",
       " 'Relationship Between Health Literacy and Social Support and the Quality of Life in Patients With Cancer: Questionnaire Study.',\n",
       " 'Significance of E-cadherin Gene Mutations in Patients With Hereditary Diffuse Gastric Cancer Syndrome: A Systematic Review.',\n",
       " 'Identification of potential biomarkers and their clinical significance in gastric cancer using bioinformatics analysis methods.',\n",
       " 'Novel Pathologic Factors for Risk Stratification of Gastric \"Indefinite for Dysplasia\" Lesions.',\n",
       " 'Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.',\n",
       " '[Current status of anti-reflux surgery of proximal gastrectomy for esophagogastric junction tumor].',\n",
       " '[Surgical treatment strategies for Siewert type II adenocarcinoma of the esophagogastric junction].',\n",
       " '[Safety and feasibility of laparoscopic radical gastrectomy in gastric cancer patients with liver cirrhosis].',\n",
       " '[Clinical value of carbon nanoparticles tracer in gastric cancer surgery to increase the number of lymph nodes retrieval].',\n",
       " '[Safety of two and a half layered esophagojejunal anastomosis in total gastrectomy for gastric cancer].',\n",
       " '[Clinicopathological characteristics of gastric cancer in adolescents aged 10-24 years: 17-year experience of 17 years in a single institute].',\n",
       " '[Influence of different biological behaviors on prognosis of patients with advanced gastric cancer at the same TNM stage].',\n",
       " '[Minimally invasive treatment with function preservation for submucosal tumors in the gastric cardia].',\n",
       " '[Combined laparoscopy-endoscopy local resection for early gastric cancer].',\n",
       " '[Significance of celiac branch of the vagal nerve in function-preserving gastrectomy].',\n",
       " '[Segmental gastrectomy with cardia preservation for early gastric cancer].',\n",
       " '[Influence of different anastomotic methods on gastric function].',\n",
       " '[Function reconstruction and preserving surgery for gastric cancer].',\n",
       " 'Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review).',\n",
       " 'Laparoscopic Mesogastrium Excision for Gastric Cancer: Only the Beginning.',\n",
       " 'Differential expression of full length and N-terminally truncated FAM134B isoforms in normal physiology and cancer.',\n",
       " 'Application of CT imaging in diagnosis of endocrine nerve of gastric cancer and nursing intervention effect.',\n",
       " 'Pooled analysis of the oncological outcomes in robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer.',\n",
       " 'The Impact of Radiation Energy on Dose Homogeneity and Organ Dose in the Göttingen Minipig Total-Body Irradiation Model.',\n",
       " 'Gastric Stem Cells: Physiological and Pathological Perspectives.',\n",
       " 'Identification of immune checkpoint inhibitors and biomarkers among STAT family in stomach adenocarcinoma.',\n",
       " 'The clinicopathological features and prognosis of serum AFP positive gastric cancer: a report of 16 cases.',\n",
       " 'Metastatic colorectal micropapillary carcinoma presenting as lymphangitic lung carcinomatosis.',\n",
       " 'The ALPK1/TIFA/NF-κB axis links a bacterial carcinogen to R-loop-induced replication stress.',\n",
       " 'Late simultaneous carcinomatous meningitis, temporal bone infiltrating macro-metastasis and disseminated multi-organ micro-metastases presenting with mono-symptomatic vertigo - a clinico-pathological case reporT.',\n",
       " 'Distal gastrectomy for early gastric conduit carcinoma after Ivor-Lewis esophagectomy.',\n",
       " 'Exploration of gastric neuroendocrine carcinoma (GNEC) specific signaling pathways involved in chemoresistance via transcriptome and ',\n",
       " 'The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study.',\n",
       " 'Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.',\n",
       " 'Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple Myeloma.',\n",
       " 'Dieulafoy disease with gastric MALT lymphoma: A case report.',\n",
       " 'CRS\\u200a+\\u200aHIPEC combined with IP\\u200a+\\u200aIV chemotherapy for gastric signet-ring cell carcinoma: Case report of long-term survival.',\n",
       " 'Impact of endoscopic sedation on gastric polyp detection: A one-center retrospective observational study.',\n",
       " 'Somatic SDHA mutations in paragangliomas in siblings: Case report of 2 cases.',\n",
       " 'Clinical significance of E-Cadherin and β-catenin in early gastric cancer: A protocol of systematic review.',\n",
       " 'An Incidental Uptake of 18F-Choline at PET/CT in Gastric Neuroendocrine Tumor.',\n",
       " 'Caudal type homeoboxes as a driving force in ',\n",
       " 'Identification of sugar moieties in chief cells of the rat fundic gastric glands.',\n",
       " 'Histopathologic Change of a Case of Gastric Oxyntic Neoplasm (Gastric Adenocarcinoma of Fundic Gland Mucosa Type) Through 5 Years With Concurrent Other Oxyntic Gland Lesions.',\n",
       " '[Laparothoracoscopic Ivor Lewis esophagectomy with esophageal-gastric intrapleural anastomosis].',\n",
       " 'Measuring progress against cancer in the Azores, Portugal: Incidence, survival, and mortality trends and projections to 2025.',\n",
       " 'Omeprazole and adenocarcinoma in the stomach of rats submitted to duodenogastric reflux. Is there a protective effect?',\n",
       " \"Gastrointestinal stromal tumor in perforated Meckel's diverticulum: a case report and literature review.\",\n",
       " 'Development of white globe appearance lesions in the noncancerous stomach after vonoprazan administration: a report of two cases with a literature review.',\n",
       " 'Gut wrenching: cases of missed gastrointestinal tumors and their mimics on computed tomography.',\n",
       " 'Prognostic Factors in Stage IB Gastric Cancer after Surgical Resection.',\n",
       " 'Proximal Anterior-Antrum Posterior (PAAP) Overlapping Anastomosis in Minimally Invasive Pylorus-Preserving Gastrectomy for Early Gastric Cancer Located in the High Body and Posterior Wall of the Stomach.',\n",
       " 'Validation of the ACS NSQIP Surgical Risk Calculator for Patients with Early Gastric Cancer Treated with Laparoscopic Gastrectomy.',\n",
       " 'Non-exposure Simple Suturing Endoscopic Full-thickness Resection with Sentinel Basin Dissection in Patients with Early Gastric Cancer: the SENORITA 3 Pilot Study.',\n",
       " 'Efficacy of Endoscopic Vacuum-Assisted Closure Treatment for Postoperative Anastomotic Leak in Gastric Cancer.',\n",
       " 'H. pylori modulates DC functions via T4SS/TNFα/p38-dependent SOCS3 expression.',\n",
       " 'Coffee Consumption and Its Inverse Relationship with Gastric Cancer: An Ecological Study.',\n",
       " 'The Different Clinicopathological Features of Remnant Gastric Cancer Depending on Initial Disease of Partial Gastrectomy.',\n",
       " 'Idylla microsatellite instability assay versus mismatch repair immunohistochemistry: a retrospective comparison in gastric adenocarcinoma.',\n",
       " 'Angiosarcoma characterized by colonic polyps: A case report.',\n",
       " 'A multicenter non-randomized phase III study of sentinel node navigation surgery for early gastric cancer.',\n",
       " 'Dye chromoendoscopy leads to a higher adenoma detection in the duodenum and stomach in patients with familial adenomatous polyposis.',\n",
       " 'Full-thickness resection device (FTRD) for treatment of upper gastrointestinal tract lesions: the first international experience.',\n",
       " 'A Single Centre Randomised Control Study to Assess the Impact of Pre-Operative Carbohydrate Loading on Women Undergoing Major Surgery for Epithelial Ovarian Cancer.',\n",
       " 'Prognostic Score-based Clinical Factors and Metabolism-related Biomarkers for Predicting the Progression of Hepatocellular Carcinoma.',\n",
       " 'Gastrointestinal Stromal Tumours (GIST): Indian Experience of Rare Malignancy.',\n",
       " 'Diffuse large B-cell lymphoma of the gallbladder arised 8 years after malignant lymphoma of the right testis: A case report and literature review.',\n",
       " 'The impact of COVID-19 on gastric cancer surgery: a single-center retrospective study.',\n",
       " 'Current status of proximal gastrectomy for gastric and esophagogastric junctional cancer: A review.',\n",
       " 'Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine.',\n",
       " 'Asymptomatic solitary metastasis to the stomach from breast cancer: A case report.',\n",
       " 'Identification of a nine-gene prognostic signature for gastric carcinoma using integrated bioinformatics analyses.',\n",
       " 'A Multi-Gene Model Effectively Predicts the Overall Prognosis of Stomach Adenocarcinomas With Large Genetic Heterogeneity Using Somatic Mutation Features.',\n",
       " \"Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients.\",\n",
       " 'Three-Dimensional Culture Systems in Gastric Cancer Research.',\n",
       " 'Robot-assisted laparoscopic total gastrectomy for Epstein-Barr virus-associated multiple gastric cancer: A case report.',\n",
       " 'Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study.',\n",
       " 'Gastric cancer risk: between genetics and lifestyle.',\n",
       " '[Weight loss, diarrhea and dystrophic alterations of the fingernails in an 80-year-old male patient].',\n",
       " 'Effectiveness of Huachansu injection combined with chemotherapy for treatment of gastric cancer in China: a systematic review and Meta-analysis.',\n",
       " 'Persistent Poverty and Cancer Mortality Rates: An Analysis of County-Level Poverty Designations.',\n",
       " 'A rare case of Helicobacter pylori-uninfected intramucosal poorly differentiated adenocarcinoma that occurred in the gastric fornix.',\n",
       " 'Forecasting disability-adjusted life years for chronic diseases: reference and alternative scenarios of salt intake for 2017-2040 in Japan.',\n",
       " 'Image Quality and Interpretation of [',\n",
       " 'High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.',\n",
       " 'Deep learning analysis of the primary tumour and the prediction of lymph node metastases in gastric cancer.',\n",
       " 'Preoperative endoscopic marking of the gastrointestinal tract using fluorescence imaging: submucosal indocyanine green tattooing versus a novel fluorescent over-the-scope clip in a survival experimental study.',\n",
       " 'Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.',\n",
       " 'Is it Necessary to Confirm Negative Margins in Gastrectomy for Peritoneal Lavage Cytology-positive Gastric Cancer?',\n",
       " 'Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.',\n",
       " 'A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.',\n",
       " 'Efficacy of MLC based cobalt-60 plans: A DVH comparison and analysis with 6 MV plans.',\n",
       " 'Normal Components and Contaminants.',\n",
       " 'Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.',\n",
       " 'Cancer cure for 32 cancer types: results from the EUROCARE-5 study.',\n",
       " 'Primary neuroendocrine tumor of liver: An eye opener for a pathologist.',\n",
       " 'Gastric carcinoma: Insights into risk factors, methods of diagnosis, possible lines of management, and the role of primary care.',\n",
       " 'Small bowel gastrointestinal stromal tumor presenting with involvement of the adjacent small bowel and hemoperitoneum case report.',\n",
       " 'Development of a Hyaluronic Acid-Based Nanocarrier Incorporating Doxorubicin and Cisplatin as a pH-Sensitive and CD44-Targeted Anti-Breast Cancer Drug Delivery System.',\n",
       " 'Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database.',\n",
       " 'Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity.',\n",
       " 'Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.',\n",
       " 'Novel minimally invasive approach to lymph node dissection around the left renal vein in patients with esophagogastric junction cancer.',\n",
       " 'CT-based deep learning radiomics analysis for evaluation of serosa invasion in advanced gastric cancer.',\n",
       " 'An invited commentary on \"Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis\".',\n",
       " 'Overexpression of NCAPG inhibits cardia adenocarcinoma apoptosis and promotes epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway.',\n",
       " 'Hospital clinical staging accuracy for upper gastrointestinal malignancy.',\n",
       " 'Difficult Diagnosis and Surgical Procedure for Scirrhous Gastric Cancer Complicated by Upside-Down Stomach: A Case Report.',\n",
       " 'Combined effects of occupational exposure to hazardous operations and lifestyle-related factors on cancer incidence.',\n",
       " 'Unraveling the identity of gastric cardiac cancer.',\n",
       " 'Primary Tumor Resection Improves Survival in Patients With Metastatic Gastrointestinal Stromal Tumors: A Preliminary Population-Based Analysis.',\n",
       " 'Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study.',\n",
       " 'MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer.',\n",
       " 'Helicobacter pylori infection induces STAT3 phosphorylation on Ser727 and autophagy in human gastric epithelial cells and mouse stomach.',\n",
       " 'Early-stage multi-differentiated gastric carcinosarcoma and post-resection local recurrence: a case report.',\n",
       " '',\n",
       " 'Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders.',\n",
       " 'Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma.',\n",
       " 'Laparoscopic Gastric Resection for Gastric Cancer: Is Intracorporeal Anastomosis Necessary?',\n",
       " 'Hand-assisted robotic surgery in the abdominal phase of robot-assisted oesophagectomy.',\n",
       " 'Release of hazardous volatile organic compounds from endoscopic submucosal dissection.',\n",
       " 'High ADAMTS18 expression is associated with poor prognosis in stomach adenocarcinoma.',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'PDQ Cancer Information Summaries',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'A study protocol of population-based cancer screening cohort study on esophageal, stomach and liver cancer in rural China.',\n",
       " 'Management of complicated inflammatory fibroid polyp by partial laparoscopic esophagogastrectomy - A case report.',\n",
       " 'Genotoxic Effect of ',\n",
       " 'Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.',\n",
       " 'Acute Gastric Dilation of the Post-Roux-en-Y Gastric Bypass Remnant Stomach: Image-Guided Surgery Approach.',\n",
       " 'Synchronous duodenal mucosa-associated lymphoid tissue lymphoma and gastric cancer.',\n",
       " 'Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.',\n",
       " 'REC8 suppresses tumor angiogenesis by inhibition of NF-κB-mediated vascular endothelial growth factor expression in gastric cancer cells.',\n",
       " 'Hedgehog Signaling and Truncated GLI1 in Cancer.',\n",
       " 'Endoscopic findings of gastric mixed adenoneuroendocrine carcinoma: A case report.',\n",
       " 'DDIT4 licenses only healthy cells to proliferate during injury-induced metaplasia.',\n",
       " 'Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma.',\n",
       " 'Detection of ',\n",
       " '',\n",
       " 'Surgical outcomes and survival for T4 gastric cancer extending to the transverse colon.',\n",
       " 'Professor Yanghee Woo: globalization of surgical innovation for stomach cancer treatment-a long but exciting road.',\n",
       " 'Rare postoperative hemorrhage after robotic-assisted pancreatoduodenectomy for pancreatic head cancer: a case report.',\n",
       " 'Adult height is not associated with the risk of stomach cancer in a meta-analysis.',\n",
       " 'Integrative bioinformatics analysis of prognostic alternative splicing signatures in gastric cancer.',\n",
       " 'Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study.',\n",
       " 'Clinical observation on the effect of Chinese medicine-\"TCM formula\" intervention on recurrence and metastasis of triple negative breast cancer.',\n",
       " 'Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW.',\n",
       " 'A network pharmacology study on analgesic mechanism of Yuanhu-Baizhi herb pair.',\n",
       " 'Cancer risk in patients with primary immune thrombocytopenia - A Swedish nationwide register study.',\n",
       " 'A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin.',\n",
       " 'Juvenile polyposis syndrome-hereditary hemorrhagic telangiectasia associated with a SMAD4 mutation in a girl.',\n",
       " 'Periampullary duodenal schwannoma mimicking ampullary neoplasm.',\n",
       " 'Establishment and characterization of a new gastric cancer cell line, XGC-1.',\n",
       " 'Predictive Factors and Long-Term Outcomes of Early Gastric Carcinomas in Patients with Non-Curative Resection by Endoscopic Submucosal Dissection.',\n",
       " 'LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1.',\n",
       " 'Analysis of clinicopathological and molecular features of crawling-type gastric adenocarcinoma.',\n",
       " 'Perception of cancer in patients diagnosed with the most common gastrointestinal cancers.',\n",
       " 'An incidental finding of pheochromocytoma in a 33-year-old patient with Lynch syndrome.',\n",
       " 'Gastric adenomas and their management in familial adenomatous polyposis.',\n",
       " 'Lifetime Mortality Risk from Cancer and Circulatory Disease Predicted from the Japanese Atomic Bomb Survivor Life Span Study Data Taking Account of Dose Measurement Error.',\n",
       " 'Autophagy induced by Helicobacter pylori infection is necessary for gastric cancer stem cell emergence.',\n",
       " 'Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis.',\n",
       " 'Single-Incision Proximal Gastrectomy With Double-Flap Esophagogastrostomy Using Novel Laparoscopic Instruments.',\n",
       " 'Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.',\n",
       " 'Evolutionary dynamics of neoantigens in growing tumors.',\n",
       " 'Low Levels of Alcohol Consumption and Risk of Intestinal Metaplasia: A Cohort Study.',\n",
       " 'Risk factor and clinicopathologic characteristics of synchronous multiple early gastric neoplasms for surgical treatment.',\n",
       " 'Risk of second primary malignancies of adolescent and young adult patients with germ cell cancer: A US population-based analysis.',\n",
       " 'Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA.',\n",
       " 'Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol.',\n",
       " '[Efficacy comparison between laparoscopy and open surgery in the treatment of gastric gastrointestinal stromal tumors larger than 2 cm using multicenter propensity score matching method].',\n",
       " '[Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].',\n",
       " '[Evidence-based standardized diagnosis and treatment of small gastrointestinal stromal tumors].',\n",
       " 'Development and characterization of a mouse model of duodenogastric reflux.',\n",
       " 'Management and evaluation of sodium [131I] iodide contamination after oral administration.',\n",
       " 'MicroRNA expression profiling and target gene analysis in gastric cancer.',\n",
       " 'Adult height and risk of gastric cancer: a pooled analysis within the Stomach cancer Pooling Project.',\n",
       " 'Incidence and Grading of Complications After Gastrectomy for Cancer Using the GASTRODATA Registry: A European Retrospective Observational Study.',\n",
       " 'Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma.',\n",
       " 'Has-miR-17 increases the malignancy of gastric lymphoma by HSP60/TNFR2 pathway.',\n",
       " 'Ingestible transiently anchoring electronics for microstimulation and conductive signaling.',\n",
       " 'Novel virulence factor ',\n",
       " 'High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.',\n",
       " 'Total length of positive resection margins can predict remnant gastric cancer following endoscopic submucosal dissection.',\n",
       " 'Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006-17.',\n",
       " 'Use of metformin and aspirin is associated with delayed cancer incidence.',\n",
       " \"Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma.\",\n",
       " 'Microvascular grafting to enhance perfusion in colonic long-segment oesophageal reconstruction.',\n",
       " 'Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.',\n",
       " 'Implementation effect of institutional policy of esophagogastroduodenoscopy observation time on neoplasm detection.',\n",
       " 'Proteomic and transcriptomic studies of BGC823 cells stimulated with Helicobacter pylori isolates from gastric MALT lymphoma.',\n",
       " 'Eating disorders and the risk of esophageal and stomach cancers-A nationwide, population-based cohort study in Taiwan.',\n",
       " 'Concurrent hepatocellular carcinoma metastasis to stomach, colon, and brain: A case report.',\n",
       " 'Clinical Significance of Paraspinal Muscle Parameters as a prognostic factor for survival in Gastric Cancer Patients who underwent Curative Surgical Resection.',\n",
       " 'Occupational disparities in survival in Korean women with cancer: a nationwide registry linkage study.',\n",
       " 'Distal phalanx: an unusual site for a gastric adenocarcinoma metastasis.',\n",
       " 'Emphysematous gastritis after metastatic malignant melanoma: a radiological surprise.',\n",
       " 'Primary malignant melanoma of the stomach: a rare entity.',\n",
       " 'Colonic Interposition Provides Better Function at Short Term Than the Stomach for Benign Esophagectomy.',\n",
       " 'Green Tea Consumption and Stomach Cancer Risk in Women: A Meta-analysis of Population-based Cohort Studies.',\n",
       " 'Isolated Metastasis to Spleen-Stomach Space From Follicular Thyroid Cancer Combined With a Benign Subcutaneous Nodule on 18F-FDG PET/CT and 131I Scintigraphy.',\n",
       " 'Laparoscopic surgery versus open surgery for gastric cancer: big data analysis based on nationwide administrative claims data.',\n",
       " 'Metachronous Sporadic Sextuple Primary Malignancies Including Bilateral Breast Cancers.',\n",
       " \"Single-cell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells' heterogeneity.\",\n",
       " 'miR-92a-3p promotes the proliferation and invasion of gastric cancer cells by targeting KLF2.',\n",
       " 'Hispidulin: A promising flavonoid with diverse anti-cancer properties.',\n",
       " 'The role of non-',\n",
       " 'Totally laparoscopic proximal gastrectomy with double tract reconstruction: outcomes of 37 consecutive cases.',\n",
       " 'Perineural Invasion and Postoperative Complications are Independent Predictors of Early Recurrence and Survival Following Curative Resection of Gastric Cancer.',\n",
       " 'USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer.',\n",
       " 'Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review.',\n",
       " \"Easy fixation effects the prevention of Peterson's hernia and Roux stasis syndrome.\",\n",
       " 'Sister Mary Joseph Nodule as an Initial Presentation of Pancreatic Adenocarcinoma.',\n",
       " 'Palliative radiotherapy for gastric cancer: Is there a dose relationship between bleeding response and radiotherapy?',\n",
       " 'Incidence Trend of Gastrointestinal Cancer in Markazi, in the Center of Iran, Population-Based Cancer Registry Results: 2010-2014.',\n",
       " 'Endoscopic submucosal dissection comparing with surgical resection in patients with early gastric cancer - A single center experience in Taiwan.',\n",
       " 'Primary gastric squamous cell carcinoma presenting as a large submucosal mass: A case report and literature review.',\n",
       " 'Immunoglobulin G4-related disease in the stomach presenting as a gastric subepithelial tumor: Case report.',\n",
       " 'Increased proportion of the squamous cell carcinoma component is associated with worse survival in resected gastric adenosquamous carcinoma: A STROBE compliant cohort study.',\n",
       " 'Expression and clinical significance of aquaporin-1, vascular endothelial growth factor and microvessel density in gastric cancer.',\n",
       " 'Risk stratification of patients with gastric lesions indefinite for dysplasia.',\n",
       " 'Regional variations in Helicobacter pylori infection, gastric atrophy and gastric cancer risk: The ENIGMA study in Chile.',\n",
       " \"Role of amoebae for survival and recovery of 'non-culturable' Helicobacter pylori cells in aquatic environments.\",\n",
       " '[BUB1 gene is highly expressed in gastric cancer:analysis based on Oncomine database and bioinformatics].',\n",
       " 'Sleep duration and risk of overall and 22 site-specific cancers: A Mendelian randomization study.',\n",
       " 'Reduced Intravenous Fluorescein Dose for Upper and Lower Gastrointestinal Tract Probe-Based Confocal Laser Endomicroscopy.',\n",
       " 'Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.',\n",
       " 'Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.',\n",
       " 'Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms.',\n",
       " '[Research progress on mechanism of active ingredients in traditional Chinese medicine for gastric cancer].',\n",
       " 'Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities.',\n",
       " '[',\n",
       " '[Spindle cell carcinoma of the breast with gastric metastasis: report of a case].',\n",
       " '[Gastric signet ring cell neuroendocrine tumor: report of a case].',\n",
       " '[Gastric adenocarcinoma with enteroblastic differentiation and elevated serum alpha fetoprotein].',\n",
       " '[Interpretation of the fifth edition of World Health Organization classification of tumors of the digestive system: selected topic on early gastric cancer].',\n",
       " 'Using a Chinese time trade-off approach to explore the health utility level and quality of life of cancer patients in urban China: a multicentre cross-sectional study.',\n",
       " 'Modified controlling nutritional status score: A refined prognostic indicator depending on the stage of gastric cancer.',\n",
       " 'Gastrointestinal stromal tumor of the excluded stomach after Roux-en-Y gastric bypass: A case report and literature review.',\n",
       " 'Advances in the treatment of gastric cancer.',\n",
       " 'A Novel Intragastric Satiety-Inducing Device to Inhibit Weight Gain in Juvenile Pigs: a Pilot Study.',\n",
       " 'Transforming growth factor-β1 induces connective tissue growth factor expression and promotes peritoneal metastasis of gastric cancer.',\n",
       " 'Long-term observational study on 6223 survivors of arsenic poisoning due to contaminated milk powder during infancy.',\n",
       " 'Iron Deficiency Anemia-Induced Lymphocytopenia in a Young Female.',\n",
       " 'Good or not good: Role of miR-18a in cancer biology.',\n",
       " 'Exosomal CircPRRX1 Enhances Doxorubicin Resistance in Gastric Cancer by Regulating MiR-3064-5p/PTPN14 Signaling.',\n",
       " 'Cancer mortality in the oldest old: a global overview.',\n",
       " 'Traditional use, phytochemistry, toxicology, and pharmacology of Origanum majorana L.',\n",
       " 'The Methodology Used to Assess Doses from the First Nuclear Weapons Test (Trinity) to the Populations of New Mexico.',\n",
       " 'Estimated Radiation Doses Received by New Mexico Residents from the 1945 Trinity Nuclear Test.',\n",
       " 'Helicobacter pylori-related precancerous lesions in Turkey: a retrospective endoscopic surveillance study.',\n",
       " 'Risk of lymph node metastasis in early gastric cancer and indications for endoscopic resection: is it worth applying the east rules to the west?',\n",
       " 'Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma.',\n",
       " 'A 500-year tale of co-evolution, adaptation, and virulence: Helicobacter pylori in the Americas.',\n",
       " '[A Case of Change from Normal-flow High-pressure Gradient Severe Aortic Stenosis to Paradoxical Low-flow Low-pressure Gradient Severe Aortic Stenosis].',\n",
       " 'Status and progress in the treatment for locally resectable progressive gastric cancer and metastatic gastric cancer.',\n",
       " 'An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer.',\n",
       " '',\n",
       " 'Laparoscopic Central Pancreatectomy with Pancreato-Gastric Anastomosis for Pancreatic Cystadenoma.',\n",
       " 'Post-Gastrectomy Complications - An Overview.',\n",
       " 'Duplicate left gastric artery identified during laparoscopic distal gastrectomy.',\n",
       " 'Cancer risk in Korean patients with gout.',\n",
       " 'A clinical study of Yiqi Huayu Jiedu decoction reducing the risk of postoperative gastric cancer recurrence and metastasis: Study protocol for a randomized controlled trail.',\n",
       " 'An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.',\n",
       " 'Self-expandable metal stent of esophagogastric junction versus pyloric area obstruction in advanced gastric cancer patients: Retrospective, comparative, single-center study.',\n",
       " 'A protocol of systematic review and meta-analysis of narrow band imaging endoscopy in detection of early gastric cancer.',\n",
       " 'Nodes staging score to quantify lymph nodes for examination in gastric cancer.',\n",
       " 'Gastropathy associated with lanthanum phosphate deposition that was endoscopically tracked for 3\\u2009years. A case report.',\n",
       " '[The impact of surgical treatment on the life quality of patients with locally advanced hypopharyngeal carcinoma].',\n",
       " '[KDM6A mutation and expression in gastric cancer are associated with prognosis].',\n",
       " 'Urinary titin N-terminal fragment concentration is an indicator of preoperative sarcopenia and nutritional status in patients with gastrointestinal tract and hepatobiliary pancreatic malignancies.',\n",
       " 'Primary Gastric Adenosquamous Carcinoma: A Case Report.',\n",
       " 'Early gastric cancer with three gastric gastrointestinal stromal tumors combined with synchronous colon cancer: a case report.',\n",
       " 'Gastric cancer.',\n",
       " 'Outcomes of laparoscopic primary gastrectomy with curative intent for gastric perforation: experience from a single surgeon.',\n",
       " 'Construction and validation of a TP53-associated immune prognostic model for gastric cancer.',\n",
       " 'Synchronous robotic right hemicolectomy and subtotal gastrectomy.',\n",
       " 'Salivary IL-17A, IL-17F, and TNF-',\n",
       " 'A Rare Case of Extramedullary Plasmacytoma Presenting as Large Abdominal Mass.',\n",
       " 'Clinically applicable histopathological diagnosis system for gastric cancer detection using deep learning.',\n",
       " 'The burden of disease and the cost of illness attributable to child maltreatment in Japan: long-term health consequences largely matter.',\n",
       " 'Letter: does Helicobacter pylori infection limit the health effects of the Mediterranean diet?',\n",
       " 'Expenditure and Financial Burden for Stomach Cancer Diagnosis and Treatment in China: A Multicenter Study.',\n",
       " 'Computed Tomography Features and Clinicopathological Characteristics of Gastric Sarcomatoid Carcinoma.',\n",
       " 'Gender Differential Transcriptome in Gastric and Thyroid Cancers.',\n",
       " 'Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.',\n",
       " 'Can Cephalopods Vomit? Hypothesis Based on a Review of Circumstantial Evidence and Preliminary Experimental Observations.',\n",
       " 'Construction and Analysis of the Tumor-Specific mRNA-miRNA-lncRNA Network in Gastric Cancer.',\n",
       " 'Traditional Chinese Medicine Xiaoai Jiedu Recipe Suppresses the Development of Hepatocellular Carcinoma via Regulating the microRNA-29a/Signal Transducer and Activator of Transcription 3 Axis.',\n",
       " 'Bioadhesive hydrogels demonstrating pH-independent and ultrafast gelation promote gastric ulcer healing in pigs.',\n",
       " 'PIWIL1 promotes gastric cancer via a piRNA-independent mechanism.',\n",
       " 'Cancer surveillance among workers in plastics and rubber manufacturing in Ontario, Canada.',\n",
       " 'Efficacy and safety of Huaier granules combined with chemotherapy for gastric cancer: A protocol for systematic review and meta-analysis.',\n",
       " 'The potential of bacterial cultures to degrade the mutagen 2-methyl-1,4-dinitro-pyrrole in a processed meat model.',\n",
       " 'Gastrointestinal Myeloid Sarcoma.',\n",
       " 'II BRAZILIAN CONSENSUS ON GASTRIC CANCER BY THE BRAZILIAN GASTRIC CANCER ASSOCIATION.',\n",
       " 'THE ROLE OF CONVENTIONAL ECHOENDOSCOPY (EUS) IN THERAPEUTIC DECISIONS IN PATIENTS WITH NEUROENDOCRINE GASTROINTESTINAL TUMORS.',\n",
       " 'Reconstruction of the esophagus of patients with middle thoracic esophageal carcinoma using the remnant stomach following Billroth II gastrectomy.',\n",
       " 'Multivisceral robotic resection: a glimpse into the future of minimally invasive abdominal surgery.',\n",
       " 'Skipping Exon-v6 from CD44v6-Containing Isoforms Influences Chemotherapy Response and Self-Renewal Capacity of Gastric Cancer Cells.',\n",
       " '[Progress on screening for gastric cancer].',\n",
       " '[Laparoscopic diagnosis of postoperative recurrence of peritoneal metastasis in gastric cancer patients and the clinical efficacy of bidirectional intraperitoneal and systemic chemotherapy].',\n",
       " '[Study of association between drinking water and gastric cancer of the residents in Sheyang county Jiangsu Province: a case-control study].',\n",
       " 'Gastric cancer in proximal site exerts poorer survival outcome with divergent genetic features than distal site.',\n",
       " 'Profiling of immune related genes silenced in EBV-positive gastric carcinoma identified novel restriction factors of human gammaherpesviruses.',\n",
       " 'Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.',\n",
       " 'Prediction models for acute kidney injury in patients with gastrointestinal cancers: a real-world study based on Bayesian networks.',\n",
       " 'Sesquiterpenes and their derivatives-natural anticancer compounds: An update.',\n",
       " 'Helicobacter Pylori and Precancerous Lesions of the Stomach in a Southwestern Nigerian Population.',\n",
       " 'Gastrointestinal Lesions in a Nigerian Tertiary Care Centre: A Histopathological Study.',\n",
       " 'Prognostic Impact of Frozen Section Investigation and Extent of Proximal Safety Margin in Gastric Cancer Resection.',\n",
       " 'Curcumin Alleviates the Side Effects of Cisplatin on Gastric Emptying of Mice by Inhibiting the Signal Changes of Acetylcholine and Interstitial Cells of Cajal.',\n",
       " 'Percutaneous transesophageal gastro-tubing for the management of anastomotic leakage after upper GI surgery: a report of two clinical cases.',\n",
       " 'Clinical outcomes of endoscopic resection for undifferentiated intramucosal early gastric cancer larger than 2\\xa0cm.',\n",
       " 'Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.',\n",
       " 'Preoperative neutrophil-lymphocyte ratio, an independent risk factor for postoperative cognitive dysfunction in elderly patients with gastric cancer.',\n",
       " '[Analysis of clinical prognosis of 68 patients with gastric mucosa-associated lymphoid tissue lymphoma].',\n",
       " '[A Case of Effective Disease Control of Advanced Gastric Cancer with Distant Lymph Node Metastases Following Nivolumab Treatment].',\n",
       " '[A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].',\n",
       " '[A Case of a Huge, Mixed-Type IPMC with Suspected Rupture of the Omental Bursa That Was Effectively Treated with Gemcitabine plus Nab-Paclitaxel].',\n",
       " '[A Case of Gastric Cancer with Pericardial Effusion as an Immune-Reactive Adverse Events].',\n",
       " '[Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].',\n",
       " 'Nerve input to tumours: Pathophysiological consequences of a dynamic relationship.',\n",
       " 'Anisakiasis and Anisakis: An underdiagnosed emerging disease and its main etiological agents.',\n",
       " 'Corrigendum to \"Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer\"[Canc. Lett. 369 (2015) 58-66].',\n",
       " 'Clinicopathologic Features of Varicella Zoster Virus Infection of the Upper Gastrointestinal Tract.',\n",
       " 'The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.',\n",
       " 'Frequency and clinical characteristics of early gastric cancer in comparison to advanced gastric cancer in a health area of Spain.',\n",
       " 'The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer.',\n",
       " 'Effects of Multi-Strain Probiotics on Immune Responses and Metabolic Balance in ',\n",
       " 'Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers.',\n",
       " 'Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis.',\n",
       " 'Using autoencoders as a weight initialization method on deep neural networks for disease detection.',\n",
       " 'Exploring Single Nucleotide Polymorphisms in ITGAV for Gastric, Pancreatic and Liver Malignancies: An Approach towards Biomarker Discovery.',\n",
       " 'Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis.',\n",
       " 'Environmental tobacco smoke and cancer risk, a prospective cohort study in a Chinese population.',\n",
       " '\"Single-cell pattern\" of adenocarcinoma cells in effusion cytology: Morphologic challenges of lung cancer.',\n",
       " 'Large cell neuroendocrine carcinoma in the unusual location of the descending colon.',\n",
       " 'Microsatellite frameshift variants in ',\n",
       " 'Delivering esophago-gastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.',\n",
       " '[Gastric and pancreatic cancers: Will neoadjuvant (chemo)radiotherapy replace adjuvant chemoradiotherapy?]',\n",
       " 'Overview on new progress of hereditary diffuse gastric cancer with ',\n",
       " '[A case of highly differentiated adenocarcinoma of gastric type with special morphology].',\n",
       " '[Application of correct anatomy of the plane between transverse mesocolon and mesogastrium in the resection of No.6 lymph node in gastric cancer].',\n",
       " '[Verification of clinical applicability of the non-special perioperative administration for enhanced recovery after surgery of gastric cancer patients: a Chinese single-center observational report].',\n",
       " '[Proximal gastrectomy and digestive tract reconstruction: status survey of perceptions and treatment selection in Chinese surgeons].',\n",
       " 'Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer.',\n",
       " 'A New Approach to Deriving Prognostic Gene Pairs from Cancer Patient-specific Gene Correlation Networks.',\n",
       " 'Cell-Membrane-Localizing, Two-Photon Probe for Ratiometric Imaging of γ-Glutamyl Transpeptidase in Cancerous Cells and Tissues.',\n",
       " 'An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.',\n",
       " 'Case report expanding the germline AXIN2- related phenotype to include olfactory neuroblastoma and gastric adenoma.',\n",
       " 'Colonic clear cell adenocarcinoma with enteroblastic differentiation.',\n",
       " 'Comprehensive Analysis of a circRNA-miRNA-mRNA Network to Reveal Potential Inflammation-Related Targets for Gastric Adenocarcinoma.',\n",
       " 'Secular Trend of Cancer Death and Incidence in 29 Cancer Groups in China, 1990-2017: A Joinpoint and Age-Period-Cohort Analysis.',\n",
       " 'The Somatic Mutation Landscape and RNA Prognostic Markers in Stomach Adenocarcinoma.',\n",
       " '',\n",
       " 'Anatomical classification of upper gastrointestinal organs under various image capture conditions using AlexNet.',\n",
       " 'Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study).',\n",
       " 'Correct Identification of Cell of Origin May Explain Many Aspects of Cancer: The Role of Neuroendocrine Cells as Exemplified from the Stomach.',\n",
       " 'Social gradient in cancer incidence in Costa Rica: Findings from a national population-based cancer registry.',\n",
       " 'Association of Helicobacter pylori vacA genotypes and peptic ulcer in Iranian population: a systematic review and meta-analysis.',\n",
       " 'The cellular origins of cancer with particular reference to the gastrointestinal tract.',\n",
       " 'Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis.',\n",
       " 'Identification of critical genes in gastric cancer to predict prognosis using bioinformatics analysis methods.',\n",
       " 'Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China.',\n",
       " 'Comparison of clinicopathologic profiles and prognosis of gastric cancer in the upper, middle and lower third of the stomach: A retrospective cohort study.',\n",
       " 'Clinical Characteristics of Intramucosal Gastric Cancers with Lymphovascular Invasion Resected by Endoscopic Submucosal Dissection.',\n",
       " 'Bariatric Surgery Is Associated with a Recent Temporal Increase in Colorectal Cancer Resections, Most Pronounced in Adults Below 50\\xa0Years of Age.',\n",
       " 'Apc',\n",
       " 'PDQ Cancer Information Summaries',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'StatPearls',\n",
       " 'Premature mortality of gastrointestinal cancer in Iran: trends and projections 2001-2030.',\n",
       " 'An Unpleasant Surprise: Abdominal Presentation of Malignant Mesothelioma.',\n",
       " 'A new exploration of white globe appearance (WGA) in ulcerative lesions.',\n",
       " 'Limb-bud and heart as a novel biomarker for gastric intestinal type adenocarcinoma.',\n",
       " 'Gastric Microbiome Diversities in Gastric Cancer Patients from Europe and Asia Mimic the Human Population Structure and Are Partly Driven by Microbiome Quantitative Trait Loci.',\n",
       " 'Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers.',\n",
       " 'Association of cancer awareness levels with the risk of cancer in rural China: A population-based cohort study.',\n",
       " 'The incidences of metachronous multiple gastric cancer after various types of gastrectomy: analysis of data from a nationwide Japanese survey.',\n",
       " 'Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma.',\n",
       " 'ANP reduced Hedgehog signaling-mediated activation of matrix metalloproteinase-9 in gastric cancer cell line MGC-803.',\n",
       " 'Structural impact due to PPQEE deletion in multiple cancer associated protein - Integrin αV: An In silico exploration.',\n",
       " 'Evaluating the time-dependent predictive accuracy for event-to-time outcome with a cure fraction.',\n",
       " 'Underwater endoscopic mucosal resection for neoplasms in the pyloric ring of the stomach: Four case reports.',\n",
       " 'Responses of gastric epithelial stem cells and their niche to ',\n",
       " 'Immunotherapy in Gastrointestinal Cancers.',\n",
       " 'Giant Ileocecal Inflammatory Fibroid Polyp: Unique Clinical Presentation.',\n",
       " 'Computational Identification of Tumor Suppressor Genes Based on Gene Expression Profiles in Normal and Cancerous Gastrointestinal Tissues.',\n",
       " 'Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer.',\n",
       " 'Clinical Outcomes of Endoscopic Resection for Low-Grade Dysplasia and High-Grade Dysplasia on Gastric Pretreatment Biopsy: Korea ESD Study Group.',\n",
       " 'Gastric Epithelial Polyps: When to Ponder, When to Panic.',\n",
       " '[H. pylori-associated gastritis: diagnostic, treatment and surveillance].',\n",
       " 'Population-Based Analysis of Differences in Gastric Cancer Incidence Among Races and Ethnicities in Individuals Age 50 Years and Older.',\n",
       " 'Efficacy and safety of Kanglaite injection for gastric cancer: A protocol for systematic review and meta-analysis.',\n",
       " 'A systematic review and meta-analysis protocol of clinical characteristics and prognostic significance of mammalian target of rapamycin for gastric cancer patients.',\n",
       " 'Three-decade failure to eradication of refractory Helicobacter pylori infec-tion and recent efforts to eradicate the infection.',\n",
       " 'Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis.',\n",
       " 'Gastric Carcinoma in Young Patients and Its Clinicopathological Characteristics and Prognosis.',\n",
       " 'Networking and Specificity-Changing DNA Methyltransferases in ',\n",
       " 'A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin.',\n",
       " 'The Facts about Food after Cancer Diagnosis: A Systematic Review of Prospective Cohort Studies.',\n",
       " 'Gastric Microbiota in a Low-Helicobacter pylori Prevalence General Population and Their Associations With Gastric Lesions.',\n",
       " 'The Durham Initiative for Stomach Health (DISH): a pilot community-based Helicobacter pylori education and screening study.',\n",
       " \"A case of Barrett's esophageal cancer with gastric mucosa-associated lymphoma.\",\n",
       " 'A retrospective analysis of emergency surgery for cases of acute abdomen during cancer chemotherapy. Case series.',\n",
       " 'Bioinformatic Analysis of Correlation between Immune Infiltration and COVID-19 in Cancer Patients.',\n",
       " 'Upregulation of miR-133a-3p enhances Bufothionine-induced gastric cancer cell death by modulating IGF1R/PI3K/Akt signal pathway mediated ER stress.',\n",
       " 'Hereditary diffuse gastric cancer: updated clinical practice guidelines.',\n",
       " 'Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis.',\n",
       " 'Solitary metastasis to the skin and colon from gastric cancer after curative gastrectomy and chemotherapy: A case report.',\n",
       " 'Risk factors for precancerous lesions of esophageal squamous cell carcinoma in high-risk areas of rural China: A population-based screening study.',\n",
       " 'Effectiveness and safety of adjunctive traditional Chinese medicine therapy for primary liver cancer patients: A protocol for systematic review and meta analysis.',\n",
       " 'A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers.',\n",
       " 'Krukenberg Tumors: Update on Imaging and Clinical Features.',\n",
       " 'Quantitative Visualization of Lanthanum Accumulation in Lanthanum Carbonate-Administered Human Stomach Tissues Using Mass Spectrometry Imaging.',\n",
       " 'Integration of GWAS and eQTL Analysis to Identify Risk Loci and Susceptibility Genes for Gastric Cancer.',\n",
       " 'Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review.',\n",
       " 'Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.',\n",
       " 'Detection of Epstein-Barr Virus DNA in Gastric Biopsies of Pediatric Patients with Dyspepsia.',\n",
       " 'Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.',\n",
       " 'Three-dimensional (3D) visualization provides better outcome than two-dimensional (2D) visualization in single-port laparoscopic distal gastrectomy: a propensity-matched analysis.',\n",
       " '[Effects of desflurane and sevoflurane anesthesia on postoperative recovery after long-term tumor surgery].',\n",
       " '[The developments of cervical gastric-type adenocarcinoma and its spectrum lesions].',\n",
       " 'Increased HOXC6 mRNA expression is a novel biomarker of gastric cancer.',\n",
       " 'The loss of nuclear expression of single-stranded DNA binding protein 2 of gastric adenocarcinoma and its prognostic role: Analysis of molecular subtype.',\n",
       " 'Can aprepitant used for nausea and vomiting be good gastrointestinal complaints?',\n",
       " 'Endoscopic Doppler probe ultrasonography for detecting blood flow at post-endoscopic submucosal dissection ulcers of the stomach.',\n",
       " 'Advances in para-aortic nodal dissection in gastric cancer surgery: A review of research progress over the last decade.',\n",
       " 'Incidence of Stomach and Esophageal Cancers in Mongolia: Data from 2009 to 2018.',\n",
       " 'A Predictive Nomogram for Early Death of Metastatic Gastric Cancer: A Retrospective Study in the SEER Database and China.',\n",
       " 'Chronic atrophic gastritis detection with a convolutional neural network considering stomach regions.',\n",
       " '[Effectiveness of Topical NSAIDs in a Gastric Cancer Patient with Bone Metastasis Pain during Therapy with Opioids and Oral NSAIDs].',\n",
       " 'Years of life lost due to malignant neoplasms of the digestive system in Poland during 10 years of socioeconomic transformation.',\n",
       " 'Progress in cancer mortality, incidence, and survival: a global overview.',\n",
       " 'Gastric Cancer Among American Indian and Alaska Native Populations in the United States, 2005-2016.',\n",
       " 'Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic.',\n",
       " 'Preoperative diagnosis of a gastric extremely well-differentiated adenocarcinoma: A case report.',\n",
       " 'Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma.',\n",
       " 'Immunotherapy improves efficiency of conversion surgery for metastatic gastric cancer: A case report.',\n",
       " 'Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.',\n",
       " 'Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13.',\n",
       " 'Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.',\n",
       " 'Bleeding gastric ulcer from a pulmonary artery 20 years post-oesophagectomy: a common presentation with a rare cause.',\n",
       " 'Is Ross Syndrome a New Type of Synucleinopathy? A Brief Research Report.',\n",
       " 'Multiple Glomus Tumors in the Left Foot of 41-year-old Woman. A Case Report.',\n",
       " 'Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.',\n",
       " 'The Roles of Connexin 26, 32, and 43 as Prognostic Factors for Gastric Cancer.',\n",
       " 'Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer.',\n",
       " 'Clinical and genomic characteristics of mucosal signet-ring cell carcinoma in Helicobacter pylori-uninfected stomach.',\n",
       " '[Accuracy comparision of abdominal enhanced CT and endoscopic ultrasound in the staging of gastric cancer after neoadjuvant chemotherapy: a post hoc analysis of a randomized clinical trial].',\n",
       " 'Assessment of Diet Quality and Adherence to Dietary Guidelines in Gastrointestinal Cancer Survivors: A Cross-Sectional Study.',\n",
       " 'Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis.',\n",
       " 'Subtotal stomach in esophageal reconstruction surgery achieves an anastomotic leakage rate of less than 1%.',\n",
       " 'The effect of the visceral fat area on the predictive accuracy of C-reactive protein for infectious complications after laparoscopy-assisted gastrectomy.',\n",
       " 'Effects of S-1 combined with palliative care on immune function and quality of life of patients with advanced stomach cancer.',\n",
       " 'Molecular Mechanisms Contributing Bacterial Infections to the Incidence of Various Types of Cancer.',\n",
       " 'Can Simple Tests Prior to Endoscopy Predict the OLGA Stage of Gastritis?',\n",
       " 'Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma.',\n",
       " 'Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis.',\n",
       " 'Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes.',\n",
       " 'Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry.',\n",
       " 'Declining prevalence of ',\n",
       " 'Diagnostic, Therapeutic Predictive, and Prognostic Value of Neutrophil Extracellular Traps in Patients With Gastric Adenocarcinoma.',\n",
       " 'Gastrointestinal Pathologies in Patients After Successful Renal Transplantation.',\n",
       " 'Premature mortality due to stomach cancer in Japan: a nationwide analysis from 1980 to 2015.',\n",
       " 'A rare case of gastric squamous-cell carcinoma metastasized from the cervix.',\n",
       " 'Non-coding RNAs in gastric cancer.',\n",
       " 'Study on the Mechanism of Olfactomedin 4-shRNA Plasmid Chitosan Magnetic Nanoparticles in Intestinal Metaplasia of Chronic Atrophic Gastritis.',\n",
       " 'Fruit and Vegetable Intake and Stomach Cancer among Male Adults: A Case-Control Study in Northern Viet Nam.',\n",
       " 'High expression of miR-135b predicts malignant transformation and poor prognosis of gastric cancer.',\n",
       " 'Malakoplakia of the gastrointestinal tract: clinicopathologic analysis of 23 cases.',\n",
       " 'Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model.',\n",
       " \"Primary gastric Hodgkin's lymphoma: A rare coincidence.\",\n",
       " 'Retrospective epidemiological study on stomach cancer in a region of western Algeria: about 394 cases between 2011 and 2015.',\n",
       " 'The prognostic value of gender in gastric gastrointestinal stromal tumors: a propensity score matching analysis.',\n",
       " 'A protocol of systematic review and meta-analysis of narrow band imaging endoscopy in detection of early gastric cancer.',\n",
       " 'Moxibustion for the side effects of surgical therapy and chemotherapy in patients with gastric cancer: A protocol for systematic review and meta-analysis.',\n",
       " 'Polymeric carriers for enhanced delivery of probiotics.',\n",
       " 'Family-based exome sequencing combined with linkage analyses identifies rare susceptibility variants of MUC4 for gastric cancer.',\n",
       " 'Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants.',\n",
       " 'A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area.',\n",
       " '\"Nobody Is Talking About It\": Diné (Navajo) Communities Speak About Stomach Cancer and Helicobacter pylori Infections.',\n",
       " 'Predominant classic circular-stapled double-tract reconstruction after totally laparoscopic proximal gastrectomy: safe, feasible, time-saving anastomoses by technical tie-up.',\n",
       " 'Glomerular Hyperfiltration and Cancer: A Nationwide Population-Based Study.',\n",
       " 'Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.',\n",
       " \"Molecular Dynamics in Esophageal Adenocarcinoma: Who's in Control?\",\n",
       " 'Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after Helicobacter pylori eradication -analysis based on the Kyoto classification.',\n",
       " 'The vicious cycle between ferritinophagy and ROS production triggered EMT inhibition of gastric cancer cells was through p53/AKT/mTor pathway.',\n",
       " 'Primary gastric melanoma in adult population: a systematic review of the literature.',\n",
       " 'Clinical Characteristics and Surgical Management of Gastrointestinal Schwannomas.',\n",
       " 'Potential Prognostic Value and Mechanism of Stromal-Immune Signature in Tumor Microenvironment for Stomach Adenocarcinoma.',\n",
       " 'Prognostic Value and Immune Infiltrates of ABCA8 and FABP4 in Stomach Adenocarcinoma.',\n",
       " 'Primary Isolated Lymphoplasmacytic Lymphoma (LPL) of the Stomach: A Case Report.',\n",
       " 'Techniques and devices for the endoscopic treatment of gastroparesis (with video).',\n",
       " 'Age-Based Trends of Gastric Adenocarcinoma in the United States.',\n",
       " 'Wide Gastric Conduit Increases the Risk of Benign Anastomotic Stricture After Esophagectomy.',\n",
       " '[Prevention of closure point recanalization after uncut Roux-en-Y anastomosis for radical resection of distal gastric cancer].',\n",
       " '[Thinking of the application of membrane anatomy in gastric cancer surgery after neoadjuvant therapy].',\n",
       " '[Mesogastrium theory of D2 lymphadenectomy for advanced gastric cancer: cogitation and skills].',\n",
       " '[Application of membrane anatomy in key technologies during gastric cancer surgery: guidance and compromise].',\n",
       " 'Distal pancreas-coeliac axis resection with preoperative selective embolization of the coeliac axis: a single high-volume centre experience.',\n",
       " 'Environmental and ecological factors of stomach cancer incidence and mortality: a systematic review study on ecological studies.',\n",
       " 'S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.',\n",
       " 'TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?',\n",
       " 'Single-Session Endoscopic Ultrasound-Directed Transgastric ERCP (\"EDGE\") in a Bariatric Patient with Pancreatic Mass and Biliary Obstruction.',\n",
       " 'A microdosing study with ',\n",
       " 'The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.',\n",
       " 'Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?',\n",
       " 'Suppression of FAK by nexrutine inhibits gastric cancer progression.',\n",
       " 'Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.',\n",
       " 'Comparison of outcomes of pedicled jejunal and colonic conduit for esophageal reconstruction.',\n",
       " 'Protective effect of adenosine triphosphate against sunitinib-related skin damage in rats.',\n",
       " '[Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].',\n",
       " 'The role of a\\xa0knowledge based dose-volume histogram predictive model in the optimisation of intensity-modulated proton plans for hepatocellular carcinoma patients : Training and validation of a\\xa0novel commercial system.',\n",
       " 'Stratification of Postsurgical Computed Tomography Surveillance Based on the Extragastric Recurrence of Early Gastric Cancer.',\n",
       " 'Pulmonary microvascular metastases in cervical carcinoma: A case series.',\n",
       " 'Prognostic thirteen-long non-coding RNAs (IncRNAs) could improve the survival prediction of gastric cancer.',\n",
       " 'Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.',\n",
       " 'Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.',\n",
       " 'Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands.',\n",
       " 'Remnant gastric cancer: a neglected group with high potential for immunotherapy.',\n",
       " 'Metastasis From Gastric Signet Ring Cell Adenocarcinoma Presenting as a Rectosigmoid Stricture: A Rare Case.',\n",
       " 'Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST).',\n",
       " '[Case of Asymptomatic Multiple Bone and Bone Marrow Metastases in Gastric Signet-Ring Cell Carcinoma].',\n",
       " '[A Case of Small Cell Carcinoma of Esophagus in Which Long-Term Survival Was Achieved with Multimodal Treatment].',\n",
       " 'Design of an inhibitor of Helicobacter pylori cholesteryl-α-glucoside transferase critical for bacterial colonization.',\n",
       " 'Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.',\n",
       " 'Neck Dissection for Cervical Lymph Node Metastases from Remote Primary Malignancies.',\n",
       " 'Male mammary gland development after apatinib therapy in advanced gastric cancer: A case report.',\n",
       " 'SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors.',\n",
       " \"Why has Japan become the world's most long-lived country: insights from a food and nutrition perspective.\",\n",
       " 'Effects of sulforaphane on the oxidative response, apoptosis, and the transcriptional profile of human stomach mucosa cells in vitro.',\n",
       " 'Association of MUC1 5640G>A and PSCA 5057C>T polymorphisms with the risk of gastric cancer in Northern Iran.',\n",
       " 'Positive Fecal Immunochemical Test Results Are Associated with Increased Risks of Esophageal, Stomach, and Small Intestine Cancers.',\n",
       " 'Working with cancer: A pilot study of work participation among cancer survivors in Western Sydney.',\n",
       " 'Circular RNA expression profile and m6A modification analysis in poorly differentiated adenocarcinoma of the stomach.',\n",
       " 'Preoperative neutrophil-to-lymphocyte ratio combined with serum CEA, CA19-9, CA125 and CA72-4 levels in the clinical pathological staging of gastric cancer-based on propensity score matching.',\n",
       " 'Effective Oral Administration of Antitumorigenic Nanoformulated Titanium Complex.',\n",
       " 'Endoscopic grading of gastric atrophy on risk assessment of gastric neoplasia: A systematic review and meta-analysis.',\n",
       " 'Association Between Night-Shift Work and Cancer Risk: Updated Systematic Review and Meta-Analysis.',\n",
       " 'TGR5-HNF4α axis contributes to bile acid-induced gastric intestinal metaplasia markers expression.',\n",
       " 'Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis.',\n",
       " 'Adenocarcinoma and Neuroendocrine Collision Tumor in a Giant Gastric Hyperplastic Polyp.',\n",
       " 'CT-based multi-organ segmentation using a 3D self-attention U-net network for pancreatic radiotherapy.',\n",
       " 'Bowel wall thickening on computed tomography scan: Inter-observer agreement and correlation with endoscopic findings.',\n",
       " 'Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.',\n",
       " 'Fluoroscopy-Guided Gastrojejunostomy Creation with Lumen-Apposing Metal Stent in a Porcine Model.',\n",
       " 'Colon specific enzyme responsive oligoester crosslinked dextran nanoparticles for controlled release of 5-fluorouracil.',\n",
       " 'Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer.',\n",
       " 'Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting.',\n",
       " 'Association between Charlson comorbidity index and complications of endoscopic resection of gastric neoplasms in elderly patients.',\n",
       " 'ECCParaCorp: a cross-lingual parallel corpus towards cancer education, dissemination and application.',\n",
       " 'Identification of a 14-lncRNA Signature and Construction of a Prognostic Nomogram Predicting Overall Survival of Gastric Cancer.',\n",
       " 'Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT.',\n",
       " '[Gastric Conduit Ulcer Pentration into the Right Middle Lobe after Esophageal Cancer Surgery;Report of a Case].',\n",
       " 'Optimized Ellagic Acid-Ca Pectinate Floating Beads for Gastroprotection against Indomethacin-Induced Gastric Injury in Rats.',\n",
       " 'MicroRNAs in gastric cancer: Biomarkers and therapeutic targets.',\n",
       " 'Eruptive Mucosal and Ungual Melanoma Metastases.',\n",
       " 'Thrombopoietin is associated with a prognosis of gastric adenocarcinoma.',\n",
       " 'Radiation-related health hazards to uranium miners.',\n",
       " 'High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets.',\n",
       " 'Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC).',\n",
       " 'CagA orchestrates eEF1A1 and PKCδ to induce interleukin-6 expression in ',\n",
       " 'In vivo gene delivery mediated by non-viral vectors for cancer therapy.',\n",
       " 'The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study.',\n",
       " 'Response to the letter from Dr J. Wang.',\n",
       " 'Comparison of laparoscopic surgery and hand-assisted laparoscopic surgery in esophagectomy: A propensity score-matched analysis.',\n",
       " 'Evaluation of three types of reconstruction methods after proximal gastrectomy.',\n",
       " \"Chemopreventive Agent 3,3'-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells.\",\n",
       " 'Hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy for gastric cancer peritoneal carcinomatosis: A protocol for systematic review and meta-analysis of randomized controlled trials.',\n",
       " 'Spontaneous perforation of jejunal gastrointestinal stromal tumor: A case report.',\n",
       " 'Helicobacter pylori eradication for the prevention of gastric neoplasia.',\n",
       " 'New Analysis Framework Incorporating Mixed Mutual Information and Scalable Bayesian Networks for Multimodal High Dimensional Genomic and Epigenomic Cancer Data.',\n",
       " 'Direct Oral Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism in Routine Clinical Practice.',\n",
       " 'Inappropriate data selection and statistical method lead to overestimated mortality for hospitalised HIV/AIDS patients.',\n",
       " 'Risk factors of lymph node metastasis after non-curative endoscopic resection of undifferentiated-type early gastric cancer.',\n",
       " 'Helicobacter pylori gastric infection in patients with laryngeal cancer and chronic laryngitis.',\n",
       " 'The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer.',\n",
       " 'Trends and predictors in all-cause and cause-specific mortality in diabetic and reference populations during 21 years of follow-up.',\n",
       " 'Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial.',\n",
       " 'Should the left gastric artery lymph node be considered as the predictive lymph node for extra-gastric lymph node metastases?',\n",
       " 'Internal hernia of the stomach through the lateral space of the colostomy: a case report.',\n",
       " 'Isolation of Oxyberberine and ',\n",
       " 'PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker.',\n",
       " '[Bioinformatics Analysis and Preliminary Functional Study of Abnormal Expression of Splicing Factors in Gastric Cancer].',\n",
       " 'Impact of OCT4 and Its Related Signaling Pathways on Gastrointestinal Cancers: Focusing on Targeted Therapy.',\n",
       " 'Perforated Ileal GIST Associated with Meckel Diverticulum - A Rare Pathological Entity of Surgical Acute Abdomen.',\n",
       " 'Gender Differences in the Effect of Calcitriol on the Body Disposition and Excretion of Doxorubicin in Mice.',\n",
       " 'Artificial intelligence in gastric cancer: a systematic review.',\n",
       " 'Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.',\n",
       " 'Chinese Cancer Research in 2009-18 and the Disease Burden.',\n",
       " 'A Long-term Survival Case of Pulmonary Tumor Thrombotic Microangiopathy due to Gastric Cancer Confirmed by the Early Diagnosis based on a Transbronchial Lung Biopsy.',\n",
       " 'Risk of primary gastrointestinal cancers following incident non-metastatic breast cancer: a Danish population-based cohort study.',\n",
       " 'Size of the thoracic inlet predicts cervical anastomotic leak after retrosternal reconstruction after esophagectomy for esophageal cancer.',\n",
       " \"A case of Turcot's syndrome type 1 with loss of immunoexpression of MSH6 in colon cancer and liver metastasis due to secondary somatic mutation in coding mononucleotide (C)8 tract: a case report.\",\n",
       " 'Gastric Cancer: Bibliometric Analysis of Epidemiological, Geographical and Socio-Economic Parameters of the Global Research Landscape.',\n",
       " '[Gastroblastoma: report of a case].',\n",
       " '[Metastatic gastrointestinal hepatoid adenocarcinoma of the liver: a high-grade carcinoma that is easily confused with primary hepatocellular carcinoma].',\n",
       " '[Esophageal and esophago-gastric junction cancer\\u2005: management and multimodal treatment].',\n",
       " 'Identification of functional long non-coding RNAs in gastric cancer by bioinformatics analysis.',\n",
       " 'Fluorescence-guided lymphadenectomy in gastric cancer: a prospective western series.',\n",
       " 'Routine panendoscopy in oral squamous cell cancer patients: mandatory or facultative?',\n",
       " 'Increased incidence of metachronous gastric neoplasm after endoscopic resection in patients with synchronous gastric neoplasm.',\n",
       " 'Potentially Bioaccessible Phenolics from Mung Bean and Adzuki Bean Sprouts Enriched with Probiotic-Antioxidant Properties and Effect on the Motility and Survival of AGS Human Gastric Carcinoma Cells.',\n",
       " 'Nutritional and Clinical Factors Affecting Weight and Fat-Free Mass Loss after Gastrectomy in Patients with Gastric Cancer.',\n",
       " 'The gastroprotective potential of silibinin against Helicobacter pylori infection and gastric tumor cells.',\n",
       " 'Prognostic value and association of systemic inflammation for patients with stage IV gastric cancer.',\n",
       " 'Relation of cyclooxygenase-2 expression with premalignant gastric lesions.',\n",
       " 'New germline mutations in non-BRCA genes among breast cancer women of Mongoloid origin.',\n",
       " 'A tumor-associated splice-isoform of ',\n",
       " 'Comparative study between total and subtotal gastrectomy for distal gastric cancer: Meta-analysis of prospective and retrospective studies.',\n",
       " 'A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.',\n",
       " 'Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.',\n",
       " 'The Fear of Cancer from the Standpoint of Oneself, the Opposite Sex and the Fear of Side Effects of Cancer Treatment.',\n",
       " 'Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer.',\n",
       " 'Percutaneous insertion of a jejunal tube via the collapsed blind end of elevated jejunum by a balloon puncturing method assisted by a balloon enteroscope.',\n",
       " '[General and particular issues of etiopathogenesis of peptic ulcer and gastric cancer: current status of the problem].',\n",
       " '[Assessment of external risk factors of hepatocellular cancer development and markers of genetic predisposition to its development in the ethnic group of yakut - men].',\n",
       " 'Ultrasonic Assisted Synthesis of Size-Controlled Cu-Metal-Organic Framework Decorated Graphene Oxide Composite: Sustainable Electrocatalyst for the Trace-Level Determination of Nitrite in Environmental Water Samples.',\n",
       " 'Advantages of Restoring miR-205-3p Expression for Better Prognosis of Gastric Cancer via Prevention of Epithelial-mesenchymal Transition.',\n",
       " 'Contrasting Prognostic Effects of Tumor-Infiltrating Lymphocyte Density in Cardia and Non-cardia Gastric Adenocarcinomas.',\n",
       " 'Advantages of Distal Subtotal Gastrectomy over Total Gastrectomy in the Quality of Life of Long-Term Gastric Cancer Survivors.',\n",
       " 'Evaluation of Submucosal or Lymphovascular Invasion Detection Rates in Early Gastric Cancer Based on Pathology Section Interval.',\n",
       " 'LETM1 Promotes Gastric Cancer Cell Proliferation, Migration, and Invasion via the PI3K/Akt Signaling Pathway.',\n",
       " 'Preoperative endoscopic tattooing using India ink to determine the resection margins during totally laparoscopic distal gastrectomy for gastric cancer.',\n",
       " 'Decreased hypertension in non-obese non-diabetic gastric cancer patients after gastrectomy.',\n",
       " \"A 3'-tRNA-derived fragment enhances cell proliferation, migration and invasion in gastric cancer by targeting FBXO47.\",\n",
       " 'Age-Period-Cohort Analysis of the Sex Differences in Cancer Mortality Rates in Japan from 1995 to 2015.',\n",
       " 'The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study.',\n",
       " 'A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients.',\n",
       " 'Cumulative evidence of relationships between multiple variants in 8q24 region and cancer incidence.',\n",
       " 'High expression of ghrelin and obestatin prepropeptide in tumor tissues predicted adverse overall survival in gastric carcinoma patients.',\n",
       " 'FB-15 inhibits MGC-803 cells growth by regulating energy metabolism.',\n",
       " 'Dietary walnut as food factor to rescue from NSAID-induced gastrointestinal mucosal damages.',\n",
       " 'Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.',\n",
       " 'Lenvatinib and pembrolizumab in advanced gastric cancer.',\n",
       " 'Generation of 3D human gastrointestinal organoids: principle and applications.',\n",
       " 'Zinc: The Wonder Drug for the Treatment of Carcinomas.',\n",
       " 'Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.',\n",
       " 'Fragment-based Discovery of Potential Anticancer Lead: Computational and in Vitro Studies.',\n",
       " 'Diet Quality and Upper Gastrointestinal Cancers Risk: A Meta-Analysis and Critical Assessment of Evidence Quality.',\n",
       " 'Is Proximal Gastric Cancer A Different Entity From Distal Gastric Cancer? Anatomical Site Distribution Of Signet Ring Cell Carcinoma And Its Association With Helicobacter Pylori Infection.',\n",
       " '',\n",
       " 'LncRNA HOTAIR promotes the growth and metastasis of gastric cancer by sponging miR-1277-5p and upregulating COL5A1.',\n",
       " 'Gastric xanthelasma may be a warning sign of intestinal metaplasia: A cross‑sectional study.',\n",
       " 'Chemotherapy-induced necrotising tumour lysis and perforation of a huge gastric cancer simulating emphysematous pancreatitis.',\n",
       " 'Exploring TCGA database for identification of potential prognostic genes in stomach adenocarcinoma.',\n",
       " 'Clinicopathological Characteristics and Prognostic Factors of Patients with Gastric Cancer Accompanying Neuroendocrine Differentiation (NEDGC).',\n",
       " 'Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study.',\n",
       " '[Indocyanine green-guided lymphadenectomy during laparoscopic gastrectomy].',\n",
       " 'Industrial pollution and mortality from digestive cancers at the small area level in a Spanish industrialized province.',\n",
       " '[The clinical value of totally laparoscopic stomach-partitioning gastrojejunostomy for malignant gastric outlet obstruction].',\n",
       " '[Analysis of survival and prognosis of Siewert Ⅱ/Ⅲ esophagogastric junction adenocarcinoma patients with non-operative acute upper gastrointestinal hemorrhage].',\n",
       " 'Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma.',\n",
       " 'Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience',\n",
       " 'Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.',\n",
       " '[A calcium-sensing receptor polymorphism at E942K promotes the proliferation of gastric cancer cells via Ca',\n",
       " 'Trends of robotic assisted surgery for thyroid, colorectal, stomach and hepatopancreaticobiliary cancer-10 year Korea trend investigation.',\n",
       " 'Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.',\n",
       " 'Loss of NFKB1 Results in Expression of Tumor Necrosis Factor and Activation of Signal Transducer and Activator of Transcription 1 to Promote Gastric Tumorigenesis in Mice.',\n",
       " 'The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study.',\n",
       " 'Efficacy and safety of paclitaxel with or without targeted therapy as second-line therapy in advanced gastric cancer: A meta-analysis.',\n",
       " 'Propofol-based total intravenous anesthesia improves survival compared to desflurane anesthesia in gastric cancer surgery: A retrospective analysis.',\n",
       " 'A comprehensive evaluation of single nucleotide polymorphisms associated with gastric cancer risk: A protocol for systematic review and network meta-analysis.',\n",
       " 'An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes.',\n",
       " 'Identification of Functional Interactome of Gastric Cancer Cells with ',\n",
       " 'Laparoscopic Resection of a Left Upper Quadrant Mass Leading to a Surprise Diagnosis.',\n",
       " 'Downregulation of CLCA4 expression is associated with the development and progression of colorectal cancer.',\n",
       " 'The impact of armed conflict on cancer among civilian populations in low- and middle-income countries: a systematic review.',\n",
       " '[Identification of gastric cancer high-risk by serum tests -current status and issues].',\n",
       " '[Endoscopic screening for gastric cancer].',\n",
       " '[X-ray screening for gastric cancer].',\n",
       " '[Current status and future prospects of gastric cancer screening in Japan].',\n",
       " \"Non-Hodgkin's Lymphoma of the Anterior Maxilla Mimicking a Chronic Apical Abscess.\",\n",
       " 'Efficacy of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasia in a Large Cohort in North America.',\n",
       " 'Epstein-Barr virus negative smooth muscle neoplasm of the stomach in a young woman.',\n",
       " 'CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway.',\n",
       " 'Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study.',\n",
       " 'FAM83H and SCRIB stabilize β-catenin and stimulate progression of gastric carcinoma.',\n",
       " 'Toona sinensis modulates autophagy and cytokines in lipopolysaccharide-induced RAW 264.7 macrophages.',\n",
       " 'Epidemiology of liver metastases.',\n",
       " 'Types of occult cancer in stroke and the relation to smoking.',\n",
       " 'Surgical oncology in patients aged 80 years and older is associated with increased postoperative morbidity and mortality: A systematic review and meta-analysis of literature over 25 years.',\n",
       " 'Transient and Persistent Gastric Microbiome: Adherence of Bacteria in Gastric Cancer and Dyspeptic Patient Biopsies after Washing.',\n",
       " 'Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.',\n",
       " 'Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer.',\n",
       " 'A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy.',\n",
       " 'Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma.',\n",
       " 'Total Laparoscopic Uncut Roux-en-Y for Radical Distal Gastrectomy: An Interim Analysis of a Randomized, Controlled, Clinical Trial.',\n",
       " 'A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology.',\n",
       " 'Adenocarcinoma arising from a heterotopic pancreas in the first portion of the duodenum: a case report.',\n",
       " 'Multiple Gastric Polyps Improved After Treatment for Ulcerative Colitis.',\n",
       " 'Cancer cells with high-metastatic potential promote a glycolytic shift in activated fibroblasts.',\n",
       " 'Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder.',\n",
       " 'Recent cancer incidence trends and short-term predictions in Golestan, Iran 2004-2025.',\n",
       " 'Variation in cancer survival between hospital districts and within them in Finland.',\n",
       " 'Systematic Characterization of the Expression and Prognostic Values of Formin-Like Gene Family in Gastric Cancer.',\n",
       " 'Lymph Node Metastasis and Recurrences from Esophageal Squamous Cell Carcinoma in Patients with Previous Gastrectomy.',\n",
       " 'Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer.',\n",
       " 'Immunocytochemistry on scrape cellblock: An aid in the diagnosis of metastatic neoplasm with unknown primary: A series of four cases.',\n",
       " 'Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study.',\n",
       " 'Superior Antitumor Efficacy of IFN-α2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer.',\n",
       " 'Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to ',\n",
       " 'Epidemiology of Signet Ring Cell Adenocarcinomas.',\n",
       " '[Gastrointestinal tumors in older patients].',\n",
       " 'Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study.',\n",
       " 'A nomogram for prediction of stage III/IV gastric cancer outcome after surgery: A multicenter population-based study.',\n",
       " 'A slowly-growing solitary skip lymph nodule of occult gastric cancer above the neck of pancreas: a case report.',\n",
       " 'Rewired functional regulatory networks among miRNA isoforms (isomiRs) from let-7 and miR-10 gene families in cancer.',\n",
       " 'Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.',\n",
       " '[A Case of Remnant Gastric Cancer Occurring 12 Years after Surgery That Was Successfully Treated with Radiation Therapy].',\n",
       " '[A Thoracic Aortic Dissection Case during Treatment with Ramucirumab plus Nab-Paclitaxel].',\n",
       " '[Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].',\n",
       " '',\n",
       " 'Mental Disorders and Suicide Risk among Cancer Patients: A Nationwide Cohort Study.',\n",
       " 'Coordinate expression loss of ',\n",
       " 'Endoscopic ',\n",
       " 'The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.',\n",
       " 'Trends in the Incidence of Stomach Cancer in Golestan Province, a High-risk Area in Northern Iran, 2004-2016.',\n",
       " '[Effect of exosome-derived miR-223 from macrophages on the metastasis of gastric cancer cells].',\n",
       " 'Preoperative Staging of Gastric Cancer Using Computed Tomography and Its Correlation with Histopathology with Emphasis on Multi-planar Reformations and Virtual Gastroscopy.',\n",
       " 'Functional genetic variants in centrosome-related genes CEP72 and YWHAG confer susceptibility to gastric cancer.',\n",
       " 'Mining topoisomerase isoforms in gastric cancer.',\n",
       " 'Complete Genome Sequences of Leclercia sp. W6 and W17 Isolated from a Gastric Cancer Patient.',\n",
       " 'Metastatic clear cell endometrial carcinoma: an unusual cause of a common clinical presentation.',\n",
       " '[Study of epidemiological clinical and pathological characteristics of gastric adenocarcinoma in a Moroccan population].',\n",
       " 'The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery.',\n",
       " 'Epstein-Barr virus-encoded miR-BART11 promotes tumor-associated macrophage-induced epithelial-mesenchymal transition via targeting FOXP1 in gastric cancer.',\n",
       " 'Laparoscopy-assisted pylorus-preserving gastrectomy versus laparoscopy-assisted distal gastrectomy for early gastric cancer in perioperative outcomes: A meta-analysis.',\n",
       " 'Combined Analysis of Intragastric Malignant Exfoliation and Ca 72.4 Concentration in Stomach Adenocarcinoma: The \"GL1 Ca 72.4\" Parameter.',\n",
       " 'A safe and effective surgical navigation technique in laparoscopic radical gastrectomy: Indocyanine green-mediated near-infrared fluorescent imaging.',\n",
       " 'Fruits and vegetables intake and gastric cancer risk: A pooled analysis within the Stomach cancer Pooling Project.',\n",
       " 'Normal and Abnormal Postoperative Imaging Findings after Gastric Oncologic and Bariatric Surgery.',\n",
       " 'To Study the\\xa0Anti-cancer Effects of Shigella Flexneri in AspC-1 Pancreatic Cancer Cell Line in Approach to Bax and bcl-2 Genes.',\n",
       " 'Clinicopathological features of early gastric cancers arising in ',\n",
       " 'Gastrectomy with D2 Lymphadenectomy for Carcinoma of the Stomach in a Stand-alone Cancer Centre in Rural India.',\n",
       " 'Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.',\n",
       " 'Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing.',\n",
       " 'Histopathologic Analysis of Signet-ring Cell Carcinoma In Situ in Patients With Hereditary Diffuse Gastric Cancer.',\n",
       " 'Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.',\n",
       " '',\n",
       " 'Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.',\n",
       " 'Clinical Outcome in Patients with Carcinoma of the Esophagogastric Junction Treated with Neoadjuvant Radiochemotherapy or Perioperative Chemotherapy: A Two-Center Retrospective Analysis.',\n",
       " \"[Vasculotoxicity of Chemotherapy: Assessment оf Endothelial Dysfunction Biomarkers' Levels in Gastric Cancer Patients].\",\n",
       " 'Multiple gastrointestinal metastasis after endoscopic submucosal dissection for poorly differentiated gastric adenocarcinoma.',\n",
       " 'Epstein-Barr virus-associated gastric cancer: disease that requires special approach.',\n",
       " 'Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA.',\n",
       " 'Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy.',\n",
       " 'Over- and Under-sampling Approach for Extremely Imbalanced and Small Minority Data Problem in Health Record Analysis.',\n",
       " \"Information-Stressors and Cancer Patients' Quality of Life: Responses to Deviant Information-Stressors Due to Pre-Postoperative Stage Discordance.\",\n",
       " 'Comparison of Postoperative Quality of Life among Three Different Reconstruction Methods After Proximal Gastrectomy: Insights From the PGSAS Study.',\n",
       " 'Different clinicopathologic features and prognostic significance of signet ring cell histology in early and locally advanced gastric cancer patients.',\n",
       " 'Non-flap hand-sewn esophagogastrostomy as a simple anti-reflux procedure in laparoscopic proximal gastrectomy for gastric cancer.',\n",
       " 'Genetic variations associated with telomere length affect the risk of gastric carcinoma.',\n",
       " 'Chinese patent medicine (Jinlong Capsule) for gastric cancer: Protocol for a systematic review and meta-analysis.',\n",
       " 'The prognostic and diagnostic values of MicroRNA-10b in gastric cancer: A comprehensive study based on meta-analysis and TCGA database.',\n",
       " 'Effect of high-quality nursing intervention on the psychological disorder in patients with gastric cancer during perioperative period: A protocol of systematic review and meta-analysis.',\n",
       " 'Germline SDHB-inactivating mutation in gastric spindle cell sarcoma.',\n",
       " \"Utilizing artificial intelligence in endoscopy: a clinician's guide.\",\n",
       " 'Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.',\n",
       " 'The Relationship between Annual Airborne Pollen Levels and Occurrence of All Cancers, and Lung, Stomach, Colorectal, Pancreatic and Breast Cancers: A Retrospective Study from the National Registry Database of Cancer Incidence in Japan, 1975-2015.',\n",
       " 'Gallstone Disease and Microbiome.',\n",
       " 'Mining the role of RECQL5 in gastric cancer and seeking potential regulatory network by bioinformatics analysis.',\n",
       " 'Impact of enhanced recovery after surgery on postoperative neutrophil-lymphocyte ratio in patients with colorectal cancer.',\n",
       " 'Internal hernia of the stomach associated with colostomy after laparoscopic surgery for rectal cancer: a case report.',\n",
       " 'Comparison of S-1-cisplatin every 5\\xa0weeks with capecitabine-cisplatin every 3\\xa0weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.',\n",
       " 'Colonic varices treated with embolization after pancreatoduodenectomy with portal vein resection: a case report.',\n",
       " 'Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review.',\n",
       " 'Inclusion of Limited Amounts of Extruded Legumes Plus Cereal Mixes in Normocaloric or Obesogenic Diets for Rats: Effects on Lipid Profile.',\n",
       " 'Absorption and Tissue Distribution of Siphonaxanthin from Green Algae.',\n",
       " 'Zanthoxylum nitidum (Roxb.) DC: Traditional uses, phytochemistry, pharmacological activities and toxicology.',\n",
       " 'Laparoscopic sentinel node navigation surgery versus laparoscopic gastrectomy with lymph node dissection for early gastric cancer: short-term outcomes of a multicentre randomized controlled trial (SENORITA).',\n",
       " 'Lung metastasis from gastric cancer presenting as diffuse ground-glass opacities.',\n",
       " '[Network pharmacology research and experimental validation of \"Coptidis Rhizoma-Pinelliae Rhizoma\" in treating gastric carcinoma].',\n",
       " 'Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas.',\n",
       " 'Impact of truncal vagotomy on complicated peptic ulcer after distal gastrectomy with reconstruction by jejunal pouch interposition.',\n",
       " 'Minimally Invasive Ivor-Lewis Esophagectomy for Esophageal Cancer After Gastric Bypass.',\n",
       " 'Hydro-MDCT for Gastric Adenocarcinoma Staging. A Comparative Study With Surgical and Histopathological Findings for Selecting Patients for Echo-endoscopy.',\n",
       " 'EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway ',\n",
       " 'Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells.',\n",
       " 'Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression.',\n",
       " 'Oncological Safety of Ultrasonically Activated Surgical Devices During Gastric Cancer Surgery.',\n",
       " 'Signet ring cells in carcinomatous lymphangitis due to gastric adenocarcinoma.',\n",
       " 'SCDb: an integrated database of stomach cancer.',\n",
       " 'Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis.',\n",
       " 'A Rare Case of Well-Differentiated Neuroendocrine Tumor Arising From a Jejunal Pancreatic Heterotopia.',\n",
       " 'Mechanism of genistein combined with changes in CaSR activity on gastric cancer cells.',\n",
       " '[The value of spectral CT-based radiomics in preoperative prediction of lymph node metastasis of advanced gastric cancer].',\n",
       " '[The 478 th case: multiple myalgia with intramuscular nodules].',\n",
       " 'Targeting Wnt Signaling for the Treatment of Gastric Cancer.',\n",
       " 'TLR2, TLR4 and TLR10 Shape the Cytokine and Chemokine Release of ',\n",
       " 'TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.',\n",
       " 'A multifunctional DNA polymerase I involves in the maturation of Okazaki fragments during the lagging-strand DNA synthesis in Helicobacter\\xa0pylori.',\n",
       " '[A Case of Subcutaneous Scrotal Metastasis from Primary Gastric Cancer].',\n",
       " 'Development and validation of an endoscopic submucosal dissection video assessment tool.',\n",
       " 'Propensity score-matched comparison of short- and long-term outcomes between surgery and endoscopic submucosal dissection (ESD) for intestinal type early gastric cancer (EGC) of the middle and lower third of the stomach: a European tertiary referral center experience.',\n",
       " '[Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].',\n",
       " 'Long-term outcomes of endoscopic submucosal dissection versus surgery for treating early gastric cancer of undifferentiated-type.',\n",
       " 'Evaluation of predictive role of carcinoembryonic antigen and salivary mRNA biomarkers in gastric cancer detection.',\n",
       " 'Exploratory study of clinical effectiveness and safety of TJ-116 bukuryoingohangekobokuto for anxiety and postoperative water brash in esophageal cancer patients (TJ116E).',\n",
       " 'Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report.',\n",
       " 'The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer.',\n",
       " 'The start of gastrectomy at different time-of-day influences postoperative outcomes.',\n",
       " 'Clinical outcomes after multiple self-expandable metallic stent placement using stent-in-stent technique for malignant gastric outlet obstruction.',\n",
       " 'Nobiletin Inhibits Helicobacterium pylori Infection-Induced Gastric Carcinogenic Signaling by Blocking Inflammation, Apoptosis, and Mitogen-Activated Protein Kinase Events in Gastric Epithelial-1 Cells.',\n",
       " 'Hepatitis B virus infection and the risk of cancer among the Chinese population.',\n",
       " 'Expression and Significance of MyD88 in Patients With Gastric Cardia Cancer in a High-Incidence Area of China.',\n",
       " 'Gastric schwannoma.',\n",
       " 'Optical Biopsy of the Upper GI Tract Using Fluorescence Lifetime and Spectra.',\n",
       " 'Optimal proximal resection margin distance for gastrectomy in advanced gastric cancer.',\n",
       " 'Trends in cancer incidence in Uruguay: 2002 -2015.',\n",
       " '[Effects of ginsenoside Rg5 on cell cycle and invasion of gastric cancer].',\n",
       " 'Anti-microbial and anti-inflammatory effects of Cheonwangbosim-dan against ',\n",
       " 'A case of simultaneous superficial hypopharyngeal and superficial esophageal cancers treated by endoscopic resection.',\n",
       " 'Mucosa microbiome of gastric lesions: Fungi and bacteria interactions.',\n",
       " 'Luteolin-loading of Her-2-poly (lactic-co-glycolic acid) nanoparticles and proliferative inhibition of gastric cancer cells via targeted regulation of forkhead box protein O1.',\n",
       " 'Para-aortic lymph node tracing and dissection in advanced gastric cancer: Effectiveness of carbon nanoparticles injection through the no. 12b lymph node.',\n",
       " 'Experimental study on radiation damage of',\n",
       " 'Population Registry of Esophageal and Stomach Tumours in Ontario (PRESTO): protocol for a multicentre clinical and pathological database including 25 000 patients.',\n",
       " 'Identification of salivary volatile organic compounds as potential markers of stomach and colorectal cancer: A pilot study.',\n",
       " 'Qualitative analysis of cancer telephone consultations: Differences in the counseling needs of Japanese men and women.',\n",
       " 'Resveratrol suppresses gastric cancer cell proliferation and survival through inhibition of PIM-1 kinase activity.',\n",
       " 'The Hepatic Left Lateral Segment Inverting Method Offering a Wider Operative Field of View During Laparoscopic Proximal Gastrectomy.',\n",
       " 'Ancestry-specific predisposing germline variants in cancer.',\n",
       " 'A sequentially metastatic gastric and jejunal cancer originating from colon cancer: A case report.',\n",
       " 'Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.',\n",
       " 'Interaction between ACOT7 and LncRNA NMRAL2P via Methylation Regulates Gastric Cancer Progression.',\n",
       " 'Age-specific incidence rates of stomach cancer in the world.',\n",
       " 'A case of gastric adenocarcinoma considered to originate from a sporadic fundic gland polyp in a Helicobacter pylori-uninfected stomach.',\n",
       " 'Splenic artery pseudoaneurysm following chemotherapy in a patient with pancreatic cancer: a case report.',\n",
       " 'Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19.',\n",
       " 'Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.',\n",
       " 'Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.',\n",
       " 'WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.',\n",
       " 'Charactering tumor microenvironment reveals stromal-related transcription factors promote tumor carcinogenesis in gastric cancer.',\n",
       " 'Selective Release of Doxorubicin from Cucurbit[8]uril Stabilized Gold Supra-Pyramid Host at pH of Small Intestine.',\n",
       " 'Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer.',\n",
       " 'Disadvantages for non-Hispanic whites in gastric carcinoma survival in Florida.',\n",
       " 'Cancer mortality risk, fine particulate air pollution, and smoking in a large, representative cohort of US adults.',\n",
       " 'Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database.',\n",
       " 'Two Time Point Analysis of the Change in Risk and Aging Factors for Major Cancers: A 10-Year Longitudinal Study in China.',\n",
       " 'Near-infrared fluorescent clip guided gastrectomy: Report of 2 cases (Case reports).',\n",
       " 'Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany.',\n",
       " 'Consensus Statement on Proton Therapy in Mesothelioma.',\n",
       " 'The overall and sex- and age-group specific incidence rates of cancer in people with schizophrenia: a population-based cohort study.',\n",
       " 'FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.',\n",
       " 'Large gastric hyperplastic polyps: to resect or not to resect, that is the question!',\n",
       " 'Family History of Gastric Cancer and Helicobacter pylori Treatment. Reply.',\n",
       " 'Family History of Gastric Cancer and Helicobacter pylori Treatment.',\n",
       " 'Family History of Gastric Cancer and Helicobacter pylori Treatment.',\n",
       " 'Family History of Gastric Cancer and Helicobacter pylori Treatment.',\n",
       " '[The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.]',\n",
       " 'Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells.',\n",
       " '[Effect of schistosomiasis japonica on the development of gastric and colorectal cancer].',\n",
       " \"Protective Effects of Myricetin on Benzo[a]pyrene-Induced 8-Hydroxy-2'-Deoxyguanosine and BPDE-DNA Adduct.\",\n",
       " '68Ga-FAPI PET/CT Detects Gastric Signet-Ring Cell Carcinoma in a Patient Previously Treated for Prostate Cancer.',\n",
       " 'Progress in cancer mortality, incidence, and survival: a global overview.',\n",
       " 'Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer.',\n",
       " 'Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis.',\n",
       " 'External Airborne-agent Exposure Increase Risk of Digestive Tract Cancer.',\n",
       " 'The Helicobacter pylori Cag Type IV Secretion System.',\n",
       " 'CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer.',\n",
       " 'NOVEL USE OF FLUORESCEIN DYE IN DETECTION OF ORAL DYSPLASIA AND ORAL CANCER.',\n",
       " 'Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells.',\n",
       " 'Downregulation of PHF19 inhibits cell growth and migration in gastric cancer.',\n",
       " 'The role of gastric microbiota in gastric cancer.',\n",
       " 'Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.',\n",
       " 'Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer.',\n",
       " 'CircFOXO3 functions as a molecular sponge for miR-143-3p to promote the progression of gastric carcinoma via upregulating USP44.',\n",
       " 'MicroRNA a small magic bullet for gastric cancer.',\n",
       " 'Familial Adenomatous Polyposis in Dogs: Hereditary Gastrointestinal Polyposis in Jack Russell Terriers with Germline APC Mutations.',\n",
       " \"Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply.\",\n",
       " ...]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "col_title = articlesPD['title'].tolist()\n",
    "col_title"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "No title No link No citation count\n",
      "No title No link No citation count\n",
      "No title No link No citation count\n",
      "No title No link No citation count\n",
      "No title No link No citation count\n",
      "No title No link No citation count\n",
      "No title No link No citation count\n",
      "No title No link No citation count\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup as bs\n",
    "\n",
    "queries = ['Role for migratory wild birds in the global spread of avian influenza H5N8',\n",
    "         'Uncoupling conformational states from activity in an allosteric enzyme',\n",
    "         'Technological Analysis of the World’s Earliest Shamanic Costume: A Multi-Scalar, Experimental Study of a Red Deer Headdress from the Early Holocene Site of Star Carr, North Yorkshire, UK',\n",
    "         'Oxidative potential of PM 2.5  during Atlanta rush hour: Measurements of in-vehicle dithiothreitol (DTT) activity',\n",
    "         'Primary Prevention of CVD','Growth and Deposition of Au Nanoclusters on Polymer-wrapped Graphene and Their Oxygen Reduction Activity',\n",
    "         'Relations of Preschoolers Visual-Motor and Object Manipulation Skills With Executive Function and Social Behavior',\n",
    "         'We Know Who Likes Us, but Not Who Competes Against Us']\n",
    "\n",
    "with requests.Session() as s:\n",
    "    for query in queries:\n",
    "        url = 'https://scholar.google.com/scholar?q=' + query + '&ie=UTF-8&oe=UTF-8&hl=en&btnG=Search'\n",
    "        r = s.get(url)\n",
    "        soup = bs(r.content, 'lxml') # or 'html.parser'\n",
    "        title = soup.select_one('h3.gs_rt a').text if soup.select_one('h3.gs_rt a') is not None else 'No title'\n",
    "        link = soup.select_one('h3.gs_rt a')['href'] if title != 'No title' else 'No link'\n",
    "        citations = soup.select_one('a:contains(\"Cited by\")').text if soup.select_one('a:contains(\"Cited by\")') is not None else 'No citation count'\n",
    "        print(title, link, citations) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
